0001140859-22-000098.txt : 20221122 0001140859-22-000098.hdr.sgml : 20221122 20221122155405 ACCESSION NUMBER: 0001140859-22-000098 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 112 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221122 DATE AS OF CHANGE: 20221122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMERISOURCEBERGEN CORP CENTRAL INDEX KEY: 0001140859 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 233079390 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16671 FILM NUMBER: 221410171 BUSINESS ADDRESS: STREET 1: 1 WEST FIRST AVENUE CITY: CONSHOHOCKEN STATE: PA ZIP: 19428 BUSINESS PHONE: 6107277000 MAIL ADDRESS: STREET 1: 1 WEST FIRST AVENUE CITY: CONSHOHOCKEN STATE: PA ZIP: 19428 10-K 1 abc-20220930.htm 10-K abc-20220930
00011408592022FYfalsehttp://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Memberhttp://fasb.org/us-gaap/2022#AccountingStandardsUpdate201613Memberhttp://fasb.org/us-gaap/2022#NonoperatingIncomeExpense0.5http://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent00011408592021-10-012022-09-3000011408592022-03-31iso4217:USD00011408592022-10-31xbrli:shares00011408592022-09-3000011408592021-09-30iso4217:USDxbrli:shares00011408592020-10-012021-09-3000011408592019-10-012020-09-300001140859us-gaap:CommonStockMember2019-09-300001140859us-gaap:AdditionalPaidInCapitalMember2019-09-300001140859us-gaap:RetainedEarningsMember2019-09-300001140859us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-300001140859us-gaap:TreasuryStockMember2019-09-300001140859us-gaap:NoncontrollingInterestMember2019-09-3000011408592019-09-3000011408592018-10-012019-09-300001140859srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2019-09-300001140859us-gaap:NoncontrollingInterestMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-09-300001140859srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-09-300001140859us-gaap:RetainedEarningsMember2019-10-012020-09-300001140859us-gaap:NoncontrollingInterestMember2019-10-012020-09-300001140859us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-10-012020-09-300001140859us-gaap:CommonStockMember2019-10-012020-09-300001140859us-gaap:AdditionalPaidInCapitalMember2019-10-012020-09-300001140859us-gaap:TreasuryStockMember2019-10-012020-09-300001140859us-gaap:CommonStockMember2020-09-300001140859us-gaap:AdditionalPaidInCapitalMember2020-09-300001140859us-gaap:RetainedEarningsMember2020-09-300001140859us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001140859us-gaap:TreasuryStockMember2020-09-300001140859us-gaap:NoncontrollingInterestMember2020-09-3000011408592020-09-300001140859srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2020-09-300001140859us-gaap:NoncontrollingInterestMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-09-300001140859srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-09-300001140859us-gaap:RetainedEarningsMember2020-10-012021-09-300001140859us-gaap:NoncontrollingInterestMember2020-10-012021-09-300001140859us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-10-012021-09-300001140859us-gaap:CommonStockMember2020-10-012021-09-300001140859us-gaap:AdditionalPaidInCapitalMember2020-10-012021-09-300001140859us-gaap:TreasuryStockMember2020-10-012021-09-300001140859us-gaap:CommonStockMember2021-09-300001140859us-gaap:AdditionalPaidInCapitalMember2021-09-300001140859us-gaap:RetainedEarningsMember2021-09-300001140859us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001140859us-gaap:TreasuryStockMember2021-09-300001140859us-gaap:NoncontrollingInterestMember2021-09-300001140859us-gaap:RetainedEarningsMember2021-10-012022-09-300001140859us-gaap:NoncontrollingInterestMember2021-10-012022-09-300001140859us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-10-012022-09-300001140859us-gaap:CommonStockMember2021-10-012022-09-300001140859us-gaap:AdditionalPaidInCapitalMember2021-10-012022-09-300001140859us-gaap:TreasuryStockMember2021-10-012022-09-300001140859us-gaap:CommonStockMember2022-09-300001140859us-gaap:AdditionalPaidInCapitalMember2022-09-300001140859us-gaap:RetainedEarningsMember2022-09-300001140859us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001140859us-gaap:TreasuryStockMember2022-09-300001140859us-gaap:NoncontrollingInterestMember2022-09-30abc:segment0001140859us-gaap:AccountingStandardsUpdate201613Member2020-10-010001140859us-gaap:AccountingStandardsUpdate201613Member2020-10-012020-10-010001140859us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2022-09-300001140859us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2021-09-300001140859us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2020-09-300001140859us-gaap:OtherNoncurrentAssetsMember2022-09-300001140859us-gaap:OtherNoncurrentAssetsMember2021-09-300001140859us-gaap:OtherNoncurrentAssetsMember2020-09-300001140859us-gaap:SalesRevenueNetMemberabc:WalgreensBootsAllianceIncMemberus-gaap:CustomerConcentrationRiskMember2021-10-012022-09-30xbrli:pure0001140859abc:WalgreensBootsAllianceIncMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2021-10-012022-09-300001140859us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberabc:ExpressScriptsIncMember2021-10-012022-09-300001140859us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberabc:ExpressScriptsIncMember2021-10-012022-09-300001140859us-gaap:CostOfSalesMember2021-10-012022-09-300001140859abc:OtherIncomeLossNetMember2021-10-012022-09-300001140859abc:PharmediumHealthcareHoldingsIncMember2019-10-012020-09-300001140859srt:MinimumMemberus-gaap:BuildingAndBuildingImprovementsMember2021-10-012022-09-300001140859us-gaap:BuildingAndBuildingImprovementsMembersrt:MaximumMember2021-10-012022-09-300001140859us-gaap:MachineryAndEquipmentMembersrt:MinimumMember2021-10-012022-09-300001140859us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2021-10-012022-09-300001140859us-gaap:SoftwareAndSoftwareDevelopmentCostsMembersrt:MinimumMember2021-10-012022-09-300001140859us-gaap:SoftwareAndSoftwareDevelopmentCostsMembersrt:MaximumMember2021-10-012022-09-300001140859us-gaap:LandMember2022-09-300001140859us-gaap:LandMember2021-09-300001140859us-gaap:BuildingAndBuildingImprovementsMember2022-09-300001140859us-gaap:BuildingAndBuildingImprovementsMember2021-09-300001140859us-gaap:MachineryAndEquipmentMember2022-09-300001140859us-gaap:MachineryAndEquipmentMember2021-09-300001140859us-gaap:ShippingAndHandlingMember2021-10-012022-09-300001140859us-gaap:ShippingAndHandlingMember2020-10-012021-09-300001140859us-gaap:ShippingAndHandlingMember2019-10-012020-09-300001140859abc:WalgreensBootsAllianceIncAllianceHealthcareMember2021-06-012021-06-010001140859abc:WalgreensBootsAllianceIncAllianceHealthcareMember2021-06-010001140859abc:WalgreensBootsAllianceIncAllianceHealthcareMember2022-09-300001140859abc:WalgreensBootsAllianceIncAllianceHealthcareMember2021-10-012022-09-300001140859abc:WalgreensBootsAllianceIncAllianceHealthcareMember2022-06-012022-06-010001140859us-gaap:CustomerRelationshipsMemberabc:WalgreensBootsAllianceIncAllianceHealthcareMember2021-06-012021-06-010001140859abc:WalgreensBootsAllianceIncAllianceHealthcareMemberus-gaap:TradeNamesMember2021-06-012021-06-010001140859abc:WalgreensBootsAllianceIncAllianceHealthcareAllianceHealthcareEgyptMember2021-06-010001140859us-gaap:DiscontinuedOperationsHeldforsaleMember2021-07-012021-09-30abc:subsidiary0001140859us-gaap:DiscontinuedOperationsHeldforsaleMemberabc:USHealthcareSolutionsMember2021-10-012022-09-300001140859abc:InternationalHealthcareSolutionsMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2021-10-012022-09-300001140859us-gaap:DiscontinuedOperationsHeldforsaleMemberabc:USHealthcareSolutionsMember2022-09-300001140859us-gaap:DiscontinuedOperationsHeldforsaleMemberabc:USHealthcareSolutionsMember2022-07-012022-09-300001140859us-gaap:DiscontinuedOperationsHeldforsaleMemberabc:USHealthcareSolutionsMember2020-10-012021-09-300001140859us-gaap:DiscontinuedOperationsHeldforsaleMember2022-09-300001140859us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-09-300001140859us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-09-300001140859us-gaap:VariableInterestEntityPrimaryBeneficiaryMemberabc:ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member2020-08-012020-08-310001140859us-gaap:VariableInterestEntityPrimaryBeneficiaryMemberabc:ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Memberabc:RetailBusinessMember2020-08-012020-08-310001140859us-gaap:HerMajestysRevenueAndCustomsHMRCMemberus-gaap:ForeignCountryMember2020-10-012021-09-300001140859us-gaap:ForeignCountryMemberus-gaap:SwissFederalTaxAdministrationFTAMember2020-10-012021-09-300001140859us-gaap:ForeignCountryMemberus-gaap:SwissFederalTaxAdministrationFTAMember2019-10-012020-09-300001140859abc:PharmediumHealthcareHoldingsIncMember2020-10-012021-09-300001140859abc:PharmediumHealthcareHoldingsIncMember2022-09-300001140859us-gaap:SwissFederalTaxAdministrationFTAMember2019-10-012020-09-300001140859us-gaap:SwissFederalTaxAdministrationFTAMember2021-09-300001140859abc:SwissTaxReformMemberus-gaap:SwissFederalTaxAdministrationFTAMember2021-09-300001140859abc:OpioidLawsuitsandInvestigationsMember2021-10-012022-09-300001140859abc:OpioidLawsuitsandInvestigationsMember2020-10-012021-09-300001140859abc:OpioidLawsuitsandInvestigationsMember2019-10-012020-09-300001140859us-gaap:DomesticCountryMember2022-09-300001140859us-gaap:DomesticCountryMembersrt:MaximumMember2021-10-012022-09-300001140859us-gaap:StateAndLocalJurisdictionMember2022-09-300001140859us-gaap:ForeignCountryMember2022-09-300001140859us-gaap:ForeignCountryMemberabc:AlternativeMinimumTaxMember2022-09-300001140859abc:USHealthcareSolutionsMember2020-09-300001140859abc:InternationalHealthcareSolutionsMember2020-09-300001140859abc:USHealthcareSolutionsMember2020-10-012021-09-300001140859abc:InternationalHealthcareSolutionsMember2020-10-012021-09-300001140859abc:USHealthcareSolutionsMember2021-09-300001140859abc:InternationalHealthcareSolutionsMember2021-09-300001140859abc:USHealthcareSolutionsMember2021-10-012022-09-300001140859abc:InternationalHealthcareSolutionsMember2021-10-012022-09-300001140859abc:USHealthcareSolutionsMember2022-09-300001140859abc:InternationalHealthcareSolutionsMember2022-09-3000011408592021-07-012021-07-010001140859us-gaap:TradeNamesMember2022-09-300001140859us-gaap:TradeNamesMember2021-09-300001140859us-gaap:CustomerRelationshipsMember2021-09-302021-09-300001140859us-gaap:CustomerRelationshipsMember2022-09-300001140859us-gaap:CustomerRelationshipsMember2021-09-300001140859abc:TradeNamesAndOtherMember2021-09-302021-09-300001140859abc:TradeNamesAndOtherMember2022-09-300001140859abc:TradeNamesAndOtherMember2021-09-300001140859abc:RevolvingCreditNoteMember2022-09-300001140859abc:RevolvingCreditNoteMember2021-09-300001140859abc:MoneyMarketFacilityMember2022-09-300001140859abc:MoneyMarketFacilityMember2021-09-300001140859abc:ReceivablesSecuritizationFacilityMember2022-09-300001140859abc:ReceivablesSecuritizationFacilityMember2021-09-300001140859abc:TermLoanDueJune2023Member2022-09-300001140859abc:TermLoanDueJune2023Member2021-09-300001140859abc:OverdraftFacilityMember2022-09-30iso4217:GBP0001140859abc:OverdraftFacilityMember2021-09-300001140859abc:MultiCurrencyRevolvingCreditFacilityMember2022-09-300001140859abc:MultiCurrencyRevolvingCreditFacilityMember2021-09-300001140859abc:SeniorNotesDue2023Member2022-09-300001140859abc:SeniorNotesDue2023Member2021-09-300001140859abc:SeniorNotesDue2024Member2022-09-300001140859abc:SeniorNotesDue2024Member2021-09-300001140859abc:SeniorNotesDue2025Member2022-09-300001140859abc:SeniorNotesDue2025Member2021-09-300001140859abc:SeniorNotesDue2027Member2022-09-300001140859abc:SeniorNotesDue2027Member2021-09-300001140859abc:SeniorNotesDue2030Member2022-09-300001140859abc:SeniorNotesDue2030Memberus-gaap:NotesPayableToBanksMember2020-05-310001140859abc:SeniorNotesDue2030Member2021-09-300001140859abc:SeniorNotesDue2031Member2022-09-300001140859abc:SeniorNotesDue2031Member2021-09-300001140859abc:SeniorNotesDue2045Member2022-09-300001140859abc:SeniorNotesDue2045Member2021-09-300001140859abc:SeniorNotesDue2047Member2022-09-300001140859abc:SeniorNotesDue2047Member2021-09-300001140859abc:AllianceHealthcareDebtMember2022-09-300001140859abc:AllianceHealthcareDebtMember2021-09-300001140859abc:NonrecourseDebtMember2022-09-300001140859abc:NonrecourseDebtMember2021-09-300001140859abc:RevolvingCreditNoteMembersrt:ParentCompanyMember2022-09-300001140859abc:RevolvingCreditNoteMembersrt:ParentCompanyMember2021-09-300001140859srt:MinimumMemberabc:SOFREURIBORCDORRFRMemberabc:MultiCurrencyRevolvingCreditFacilityMember2021-10-012022-09-300001140859abc:SOFREURIBORCDORRFRMemberabc:MultiCurrencyRevolvingCreditFacilityMembersrt:MaximumMember2021-10-012022-09-300001140859abc:SOFREURIBORCDORRFRMemberabc:MultiCurrencyRevolvingCreditFacilityMember2021-10-012022-09-300001140859srt:MinimumMemberabc:AlternateBaseRateAndCanadianPrimeRateCdorRateMemberabc:MultiCurrencyRevolvingCreditFacilityMember2021-10-012022-09-300001140859abc:AlternateBaseRateAndCanadianPrimeRateCdorRateMemberabc:MultiCurrencyRevolvingCreditFacilityMembersrt:MaximumMember2021-10-012022-09-300001140859srt:MinimumMemberabc:MultiCurrencyRevolvingCreditFacilityMember2021-10-012022-09-300001140859abc:MultiCurrencyRevolvingCreditFacilityMembersrt:MaximumMember2021-10-012022-09-300001140859abc:MultiCurrencyRevolvingCreditFacilityMember2021-10-012022-09-300001140859us-gaap:CommercialPaperMember2022-09-300001140859us-gaap:CommercialPaperMember2021-10-012022-09-300001140859us-gaap:CommercialPaperMember2021-09-300001140859abc:OverdraftFacilityMember2021-01-310001140859abc:OverdraftFacilityMember2021-02-280001140859abc:TermLoanAgreementOctober2018Member2020-10-310001140859abc:TermLoanDueFebruary2021Member2021-02-280001140859abc:TermLoanDueFebruary2021Member2021-04-300001140859abc:TermLoanDueFebruary2021Member2021-06-300001140859abc:TermLoanDueFebruary2021Member2021-09-012021-09-300001140859abc:TermLoanDueFebruary2021Member2022-03-012022-03-310001140859abc:SeniorNotesDue2021Memberus-gaap:NotesPayableToBanksMember2020-05-310001140859abc:SeniorNotesDue2021Memberus-gaap:NotesPayableToBanksMember2020-05-012020-05-310001140859us-gaap:NotesPayableToBanksMemberabc:SeniorNotesDue2023Member2021-03-310001140859abc:SeniorNotesDue2031Memberus-gaap:NotesPayableToBanksMember2021-03-310001140859abc:SeniorNotesDue2023Member2021-10-012022-09-300001140859abc:WalgreensBootsAllianceIncAllianceHealthcareAllianceHealthcareEgyptMember2022-09-300001140859abc:WalgreensBootsAllianceIncAllianceHealthcareAllianceHealthcareEgyptMember2021-09-30abc:vote0001140859us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-09-300001140859us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-09-300001140859us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300001140859us-gaap:AccumulatedTranslationAdjustmentMember2021-09-300001140859abc:AccumulatedOtherAdjustmentsAttributabletoParentMember2022-09-300001140859abc:AccumulatedOtherAdjustmentsAttributabletoParentMember2021-09-300001140859abc:October2018ShareRepurchaseProgramMember2018-10-310001140859abc:October2018ShareRepurchaseProgramMember2018-10-012019-09-300001140859abc:October2018ShareRepurchaseProgramMember2019-10-012020-09-300001140859abc:October2018ShareRepurchaseProgramMember2020-10-012021-09-300001140859abc:May2020ShareRepurchaseProgramMember2020-05-310001140859abc:May2020ShareRepurchaseProgramMember2020-10-012021-09-300001140859abc:May2020ShareRepurchaseProgramMember2021-10-012022-09-300001140859abc:May2022ShareRepurchaseProgramMember2022-05-310001140859abc:May2022ShareRepurchaseProgramMember2021-10-012022-09-300001140859abc:May2022ShareRepurchaseProgramMember2022-09-300001140859us-gaap:SubsequentEventMemberabc:May2022ShareRepurchaseProgramMember2022-10-012022-10-310001140859us-gaap:SubsequentEventMemberabc:May2022ShareRepurchaseProgramMember2022-11-012022-11-220001140859us-gaap:InvestorMemberabc:AmerisourceBergenMemberabc:WalgreensBootsAllianceIncAllianceHealthcareMember2022-09-300001140859us-gaap:InvestorMemberabc:WalgreensBootsAllianceIncAllianceHealthcareMember2021-10-012022-09-300001140859us-gaap:InvestorMemberabc:WalgreensBootsAllianceIncAllianceHealthcareMember2020-10-012021-09-300001140859us-gaap:InvestorMemberabc:WalgreensBootsAllianceIncAllianceHealthcareMember2019-10-012020-09-300001140859us-gaap:InvestorMemberabc:WalgreensBootsAllianceIncAllianceHealthcareMember2022-09-300001140859us-gaap:InvestorMemberabc:WalgreensBootsAllianceIncAllianceHealthcareMember2021-09-300001140859abc:EmployeeContributionFirstThreePercentOfSalaryMember2021-10-012022-09-300001140859abc:EmployeeContributionAdditionalTwoPercentOfSalaryMember2021-10-012022-09-300001140859abc:A2022OmnibusIncentivePlanMember2022-09-300001140859us-gaap:EmployeeStockOptionMember2021-10-012022-09-300001140859abc:NonEmployeeMember2021-10-012022-09-300001140859abc:GrantedPriorToFiscal2021Memberus-gaap:RestrictedStockUnitsRSUMember2021-10-012022-09-300001140859us-gaap:RestrictedStockUnitsRSUMemberabc:GrantedInFiscal2022Member2021-10-012022-09-300001140859us-gaap:RestrictedStockUnitsRSUMember2021-10-012022-09-300001140859us-gaap:RestrictedStockUnitsRSUMember2020-10-012021-09-300001140859us-gaap:RestrictedStockUnitsRSUMember2019-10-012020-09-300001140859us-gaap:RestrictedStockUnitsRSUMember2021-09-300001140859us-gaap:RestrictedStockUnitsRSUMember2022-09-300001140859us-gaap:PerformanceSharesMember2021-10-012022-09-300001140859srt:MinimumMemberus-gaap:PerformanceSharesMember2021-10-012022-09-300001140859us-gaap:PerformanceSharesMembersrt:MaximumMember2021-10-012022-09-300001140859us-gaap:PerformanceSharesMember2020-10-012021-09-300001140859us-gaap:PerformanceSharesMember2019-10-012020-09-300001140859us-gaap:PerformanceSharesMember2021-09-300001140859us-gaap:PerformanceSharesMember2022-09-3000011408592020-10-010001140859abc:MultidistrictLitigationAndOtherRelatedStateCourtLitigationMemberus-gaap:PendingLitigationMemberabc:ThreeLargestNationalDistributorsMember2020-01-31abc:claim0001140859abc:MultidistrictLitigationAndOtherRelatedStateCourtLitigationMemberus-gaap:SettledLitigationMemberabc:ThreeLargestNationalDistributorsMember2021-10-012022-09-30abc:state0001140859abc:MultidistrictLitigationAndOtherRelatedStateCourtLitigationMemberus-gaap:SettledLitigationMember2021-10-012022-09-300001140859abc:OpioidLawsuitsandInvestigationsMember2021-07-012021-09-300001140859abc:OpioidLawsuitsandInvestigationsMember2022-09-300001140859abc:OpioidLawsuitsandInvestigationsMember2021-09-300001140859abc:HumanHealthMemberabc:USHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300001140859abc:HumanHealthMemberabc:USHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300001140859abc:HumanHealthMemberabc:USHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-10-012022-09-300001140859abc:AnimalHealthMemberabc:USHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300001140859abc:AnimalHealthMemberabc:USHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300001140859abc:AnimalHealthMemberabc:USHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-10-012022-09-300001140859abc:USHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300001140859abc:USHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300001140859abc:USHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-10-012022-09-300001140859abc:InternationalHealthcareSolutionsMemberabc:AllianceHealthcareMemberus-gaap:OperatingSegmentsMember2021-10-012022-09-300001140859abc:InternationalHealthcareSolutionsMemberabc:AllianceHealthcareMemberus-gaap:OperatingSegmentsMember2020-10-012021-09-300001140859abc:InternationalHealthcareSolutionsMemberabc:AllianceHealthcareMemberus-gaap:OperatingSegmentsMember2019-10-012020-09-300001140859abc:InternationalHealthcareSolutionsMemberabc:OtherHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-10-012022-09-300001140859abc:InternationalHealthcareSolutionsMemberabc:OtherHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-10-012021-09-300001140859abc:InternationalHealthcareSolutionsMemberabc:OtherHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2019-10-012020-09-300001140859abc:InternationalHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-10-012022-09-300001140859abc:InternationalHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-10-012021-09-300001140859abc:InternationalHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2019-10-012020-09-300001140859us-gaap:IntersegmentEliminationMember2021-10-012022-09-300001140859us-gaap:IntersegmentEliminationMember2020-10-012021-09-300001140859us-gaap:IntersegmentEliminationMember2019-10-012020-09-300001140859abc:USHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-10-012021-09-300001140859abc:USHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2019-10-012020-09-300001140859us-gaap:OperatingSegmentsMember2021-10-012022-09-300001140859us-gaap:OperatingSegmentsMember2020-10-012021-09-300001140859us-gaap:OperatingSegmentsMember2019-10-012020-09-300001140859us-gaap:MaterialReconcilingItemsMember2021-10-012022-09-300001140859us-gaap:MaterialReconcilingItemsMember2020-10-012021-09-300001140859us-gaap:MaterialReconcilingItemsMember2019-10-012020-09-300001140859abc:USHealthcareSolutionsMember2019-10-012020-09-300001140859abc:InternationalHealthcareSolutionsMember2019-10-012020-09-300001140859us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:MoneyMarketFundsMember2022-09-300001140859us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:MoneyMarketFundsMember2021-09-300001140859us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-09-300001140859us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-09-300001140859us-gaap:CarryingReportedAmountFairValueDisclosureMember2021-09-300001140859us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-09-300001140859us-gaap:SubsequentEventMember2022-11-012022-11-220001140859abc:AllowanceForReturnsAndDoubtfulAccountsCurrentMember2021-09-300001140859abc:AllowanceForReturnsAndDoubtfulAccountsCurrentMember2021-10-012022-09-300001140859abc:AllowanceForReturnsAndDoubtfulAccountsCurrentMember2022-09-300001140859abc:AllowanceForReturnsAndDoubtfulAccountsCurrentMember2020-09-300001140859abc:AllowanceForReturnsAndDoubtfulAccountsCurrentMember2020-10-012021-09-300001140859abc:AllowanceForReturnsAndDoubtfulAccountsCurrentMember2019-09-300001140859abc:AllowanceForReturnsAndDoubtfulAccountsCurrentMember2019-10-012020-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K

☑   ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED September 30, 2022

☐    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM ___________ TO___________

Commission file number 1-16671
AMERISOURCEBERGEN CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 23-3079390
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
1 West First AvenueConshohocken,PA 19428-1800
(Address of principal executive offices) (Zip Code)
(610) 727-7000
(Registrant’s telephone number, including area code)
Securities Registered Pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of exchange on which registered
Common stockABCNew York Stock Exchange(NYSE)
_________________________________________________
Indicate by check mark if the registrant is a well-known seasoned issuer (as defined in Rule 405 of the Securities Act). Yes þ No o
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes o No þ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act:
Large accelerated filer þ  Accelerated filer o  Non-accelerated filer o  Smaller reporting company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered public accounting firm that prepared or issued its audit report.☑ 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes ☐ No þ
The aggregate market value of voting stock held by non-affiliates of the registrant on March 31, 2022 based upon the closing price of such stock on the New York Stock Exchange on March 31, 2022 was $18,539,939,166.
The number of shares of common stock of AmerisourceBergen Corporation outstanding as of October 31, 2022 was 205,668,628.
Documents Incorporated by Reference
    Portions of the following document are incorporated by reference in the Part of this report indicated below:
    Part III — Registrant's Proxy Statement for the 2023 Annual Meeting of Stockholders.

TABLE OF CONTENTS
Item Page
 
 
 
 

PART I

ITEM 1.    BUSINESS
As used herein, the terms "Company," "AmerisourceBergen," "we," "us," or "our" refer to AmerisourceBergen Corporation, a Delaware corporation.
AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health. More specifically, we distribute a comprehensive offering of brand-name, specialty brand-name, and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers located in the United States and select global markets, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, physician practices, medical and dialysis clinics, veterinarians, and other customers. Additionally, we furnish healthcare providers and pharmaceutical manufacturers with an assortment of related services, including data analytics, outcomes research, reimbursement and pharmaceutical consulting services, niche premium logistics services, inventory management, pharmacy automation, pharmacy management, and packaging solutions.
Industry Overview
Pharmaceutical sales in the United States, as recently estimated by IQVIA, an independent third-party provider of information to the pharmaceutical and healthcare industry, are expected to grow at a compound annual growth rate of approximately 4.5% from 2021 through 2026, and the growth rate is dependent, in part, on pharmaceutical manufacturer price increases. In addition to general economic conditions, factors that impact the growth of the pharmaceutical industry in the United States and other industry trends include:
Aging Population. The number of individuals aged 65 and over in the United States is expected to exceed 66 million by 2026 and is the most rapidly growing segment of the population. This age group suffers from more chronic illnesses and disabilities than the rest of the population and accounts for a substantial portion of total healthcare expenditures in the United States.
Introduction of New Pharmaceuticals. Traditional research and development, as well as the advent of new research, production, and delivery methods, such as biotechnology and gene therapy, continue to generate new pharmaceuticals and delivery methods that are more effective in treating diseases. We believe ongoing research and development expenditures by the leading pharmaceutical manufacturers will contribute to continued growth of the industry. In particular, we believe ongoing research and development of biotechnology and other specialty pharmaceutical drugs will provide opportunities for the continued growth of our specialty pharmaceuticals business.
Increased Use of Generic and Biosimilar Pharmaceuticals. A number of patents for widely used brand-name pharmaceutical products will continue to expire during the next several years. In addition, increased emphasis by managed care and other third-party payors on utilization of generics and biosimilars has accelerated their growth. We consider the increase in generic and biosimilar usage a favorable trend because generic and biosimilar pharmaceuticals have historically provided us with a greater gross profit margin opportunity than brand-name products, although their lower prices reduce revenue growth. Generic pharmaceuticals currently account for approximately 90% of the prescription volume in the United States.
Increased Use of Drug Therapies. In response to rising healthcare costs, governmental and private payors have adopted cost containment measures that encourage the use of efficient drug therapies to prevent or treat diseases. While national attention has been focused on the overall increase in aggregate healthcare costs, we believe drug therapy has had a beneficial impact on healthcare costs by reducing expensive surgeries and prolonged hospital stays. Pharmaceuticals currently account for approximately 10% of overall healthcare costs. Pharmaceutical manufacturers' continued emphasis on research and development is expected to result in the continuing introduction of cost-effective drug therapies and new uses for existing drug therapies.
Legislative Developments. In 2010, the federal government enacted major health reform legislation designed to expand access to health insurance, which increased the number of people in the United States who are eligible to be reimbursed for all or a portion of prescription drug costs. The health reform law provides for sweeping changes to Medicare and Medicaid policies (including drug reimbursement policies), expanded disclosure requirements regarding financial arrangements within the healthcare industry, enhanced enforcement authority to prevent fraud and abuse, and new taxes and fees on pharmaceutical and medical device manufacturers. Subsequent legislation and rules promulgated by government agencies have made additional changes to federal drug payment policies. These policies and other legislative developments (including potential revisions to or
1
repeal of any portions of the health reform legislation) may affect our businesses directly and/or indirectly (see Government Regulation and the risk factor titled Legal, regulatory, and legislative changes with respect to reimbursement, pricing, and contracting may adversely affect our business and results of operations, including through declining reimbursement rates for further details).
COVID-19 Pandemic. In March 2020, the World Health Organization ("WHO") declared a global pandemic attributable to the outbreak and continued spread of COVID-19. In connection with the mitigation and containment procedures recommended by the WHO and imposed by federal, state, and local governmental authorities, we implemented measures designed to keep our employees safe and address business continuity issues at our distribution centers and other locations. We continue to evaluate and plan for the potential effects of any disruption and the related impacts on our revenue, results of operations, and cash flows. These items include, but are not limited to, the financial condition of our customers and the realization of accounts receivable, changes in availability and demand for our products and services, changes in operating costs, and delays related to current and future projects. While our operational and financial performance may be significantly impacted by COVID-19, it is not possible for us to predict the duration or magnitude of the outbreak and whether it could have a material adverse impact on the Company's financial position, results of operations, or cash flows (see Risk Factor - We face risks related to health epidemics and pandemics, and the ongoing spread of COVID-19 has had adverse effects on our business).
Other economic conditions and certain risk factors could adversely affect our business and prospects (see Item 1A. Risk Factors).
The Company
We serve our customers (healthcare providers and pharmaceutical and biotech manufacturers) through a geographically diverse network of distribution service centers and other operations in the United States and select global markets. In our pharmaceutical distribution businesses, we are typically the primary supplier of pharmaceutical and related products to our healthcare provider customers. We offer a broad range of services to our customers designed to enhance the efficiency and effectiveness of their operations, which allow them to improve the delivery of healthcare to patients and to lower overall costs in the pharmaceutical supply channel.
Strategy
Our business strategy is focused on the global pharmaceutical supply channel where we provide distribution and value-added services to healthcare providers (primarily pharmacies, health systems, medical and dialysis clinics, physicians, and veterinarians) and pharmaceutical manufacturers to improve channel efficiencies and patient outcomes. Our strategy is one of driving executional excellence in our core distributions solutions business in the U.S. and Internationally, while also investing in higher margin, high growth adjacencies where we provide solutions to pharmaceutical manufacturers to support the clinical development and commercialization of their therapies and support providers in driving efficiency and effectiveness of their operations. Implementing this disciplined and focused strategy in a seamless and unified way has allowed us to significantly expand our business. We are well positioned to grow revenue and increase operating income through the execution of the following key elements of our business strategy:
•Optimize and Grow U.S. Healthcare Solutions Businesses. We are well positioned in size and market breadth to continue to grow our U.S. Healthcare Solutions businesses as we invest to improve our operating and capital efficiencies. Our U.S. human health distribution businesses, including specialty pharmaceuticals, anchors our growth and position in the pharmaceutical supply channel as we provide superior distribution services and deliver value-added solutions, which improve the efficiency and competitiveness of both healthcare providers and pharmaceutical manufacturers, thus allowing the pharmaceutical supply channel to better deliver healthcare to patients.
We are a leader in distribution and services to community oncologists and have leading positions in other physician-administered products. We distribute plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products. We are well positioned to service and support biotechnology therapies, including biosimilars, expected to be coming to market in the near future.
We have introduced strategies to enhance our position in the generic marketplace, including our generic product private label program based in Ireland. We source generics globally, offer a value-added generic formulary program to our healthcare provider customers, and monitor our customers' compliance with our generics program. We also provide data and other valuable services to our manufacturer customers.
We offer value-added services and solutions to assist healthcare providers and pharmaceutical manufacturers to improve their efficiency and their patient outcomes. Services for manufacturers include: assistance with rapid new
2
product launches, promotional and marketing services to accelerate product sales, product data reporting, market access and health economics consulting, patient support programs, and logistical support.
Our provider solutions include: our Good Neighbor Pharmacy® program, which enables independent community pharmacies to compete more effectively through pharmaceutical benefit and merchandising programs; Elevate Provider Network®, our managed care network, which connects our retail pharmacy customers to payor plans throughout the country and is one of the largest in the United States; generic product purchasing and private label services; hospital pharmacy consulting designed to improve operational efficiencies; and packaging solutions for institutional and retail healthcare providers. We also offer services that optimize patient access and provide purchasing power to providers.
We believe we have one of the lowest operating cost structures among all pharmaceutical distributors. Our robust distribution facility network includes a national distribution center in Columbus, OH, which offers pharmaceutical manufacturers a single shipping destination. We continue to seek opportunities to achieve increased productivity and operating income gains as we invest in and continue to implement warehouse automation technology, adopt "best practices" in warehousing activities, and increase operating leverage by increasing volume per full-service distribution facility. We continue to seek opportunities to expand our offerings in our human health distribution businesses.
Our animal health business sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. It also offers its customers a variety of value-added services, including its e-commerce platform, technology management systems, pharmacy fulfillment, inventory management system, equipment procurement consultation, special order fulfillment, and educational seminars, which we believe closely integrate the animal health business with its customers' day-to-day operations and provide them with meaningful incentives to remain customers.
Our consulting service businesses help global pharmaceutical and biotechnology manufacturers commercialize their products. We believe we are one of the largest providers of reimbursement services that assist pharmaceutical companies in supporting access to branded drugs. We also provide outcomes research, contract field staffing, patient assistance and copay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical companies.
•Optimize and Grow Our International Healthcare Solutions Businesses. We are well positioned in size and market breadth to continue to grow our International Healthcare Solutions businesses as we invest to improve our operating and capital efficiencies. The International Healthcare Solutions reportable segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. The International Healthcare Solutions reportable segment distributes pharmaceuticals, other healthcare products, and related services to healthcare providers, including pharmacies, doctors, health centers and hospitals primarily in Europe. It also is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. The Canada business drives innovative partnerships with manufacturers, providers, and pharmacies to improve product access and efficiency throughout the healthcare supply chain.
•Acquisitions. In order to grow our core strategic offerings and to enter related markets, we have acquired and invested in businesses and will continue to consider additional acquisitions and investments.
In September 2022, we entered into a definitive agreement to acquire PharmaLex Holding GmbH (“PharmaLex”), a leading provider of specialized services for the life sciences industry, for €1.28 billion in cash, subject to customary adjustments. PharmaLex's services include regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality management and compliance. The acquisition will advance our role as a partner of choice for biopharmaceutical manufacturers by enhancing our global portfolio of solutions to support manufacturer partners across the pharmaceutical development and commercialization journey. PharmaLex will be a component of our International Healthcare Solutions reportable segment. The acquisition is expected to close by March 2023 and is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals.
•Divestitures. In order to allow us to concentrate on our strategic focus areas, we have divested certain non-core businesses and may, from time to time, consider additional divestitures.
We completed the sales of non-core subsidiaries in the fiscal year ended September 30, 2022 and received total proceeds $272.6 million, subject to final working capital adjustments.
3
Operations
Operating Structure. We are organized geographically based upon the products and services we provide to our customers. Our operations are comprised of two reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions. U.S. Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable segment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. International Healthcare Solutions consists of Alliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). Profarma had previously been included in the Pharmaceutical Distribution Services reportable segment.
U.S. Healthcare Solutions Segment
The U.S. Healthcare Solutions reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The U.S. Healthcare Solutions reportable segment also provides pharmaceutical distribution (including plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. Additionally, the U.S. Healthcare Solutions reportable segment provides data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The U.S. Healthcare Solutions reportable segment also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of retail and institutional healthcare providers. It also provides a full suite of integrated manufacturer services that ranges from clinical trial support to product post-approval and commercialization support. Additionally, it delivers packaging solutions to institutional and retail healthcare providers. Through its animal health business, the U.S. Healthcare Solutions reportable segment sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. Our animal health business also offers demand-creating sales force services to manufacturers.
International Healthcare Solutions
The International Healthcare Solutions reportable segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. The International Healthcare Solutions reportable segment distributes pharmaceuticals, other healthcare products, and related services to healthcare providers, including pharmacies, doctors, health centers and hospitals primarily in Europe. It also is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. In Canada, the business drives innovative partnerships with manufacturers, providers, and pharmacies to improve product access and efficiency throughout the healthcare supply chain.
Sales and Marketing. The majority of U.S. Healthcare Solutions' sales force is led nationally, with geographic focus and specialized by either healthcare provider type or size. Customer service representatives are centralized in order to respond to customer needs in a timely and effective manner. U.S. Healthcare Solutions also has support professionals focused on its various technologies and service offerings. U.S. Healthcare Solutions' sales teams also serve national account customers through close coordination with local distribution centers and ensure that our customers are receiving service offerings that meet their needs. Our International Healthcare Solutions' businesses each have independent sales forces that specialize in their respective product and service offerings. In addition, we have an enterprise-wide marketing team that coordinates branding and all other marketing activities across the Company.
Customers. We have a diverse customer base that includes institutional and retail healthcare providers as well as pharmaceutical manufacturers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies, and providers of pharmacy services to such facilities, physicians, and physician group practices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies, pharmacy departments of supermarkets and mass merchandisers, and veterinarians. We are typically the primary source of supply for our healthcare provider customers. Our manufacturer customers include branded, generic, and biotechnology manufacturers of prescription pharmaceuticals, as well as over-the-counter product and health and beauty aid manufacturers. In addition, we offer a broad range of value-added solutions designed to enhance the operating efficiencies and competitive positions of our customers, thereby allowing them to improve the delivery of healthcare to patients and consumers.
Our two largest customers, Walgreens Boots Alliance, Inc. ("WBA") and Express Scripts, Inc. ("Express Scripts"), accounted for approximately 27% and approximately 13%, respectively, of revenue in the fiscal year ended September 30, 2022. Our top 10 customers, including governmental agencies and group purchasing organizations ("GPO"), represented
4
approximately 66% of revenue in the fiscal year ended September 30, 2022. The loss of any major customer or GPO relationship could adversely affect future revenue and results of operations. Additionally, from time to time, significant contracts may be terminated in accordance with their terms or extended, renewed, or replaced prior to their expiration dates. If those contracts are not renewed, or are extended, renewed, or replaced at less favorable terms, they may negatively impact our revenue, results of operations, and cash flows.
Suppliers. We obtain pharmaceutical and other products from manufacturers, none of which accounted for 10% or more of our purchases in the fiscal year ended September 30, 2022. The loss of a supplier could adversely affect our business if alternate sources of supply are unavailable since we are committed to be the primary source of pharmaceutical products for a majority of our customers. We believe that our relationships with our suppliers are strong. The 10 largest suppliers in fiscal year ended September 30, 2022 accounted for approximately 46% of our purchases.
Information Systems. The U.S. Healthcare Solutions operating segment’s distribution facilities in the United States primarily operate under a single enterprise resource planning (“ERP”) system. U.S. Healthcare Solutions’ ERP system provides for, among other things, electronic order entry by customers, invoice preparation and purchasing, and inventory tracking. Our International Healthcare Solutions operating segment operates the majority of its businesses on their own operating systems. We continue to make investments to enhance and upgrade the operating systems utilized by our International Healthcare Solutions operating segments, including, but not limited to, Alliance Healthcare. We also continue to invest in cybersecurity capabilities as a key priority.
Additionally, we are improving our entity-wide infrastructure environment to drive efficiency, capabilities, and speed to market.
We will continue to invest in advanced information systems and automated warehouse technology. For example, in an effort to comply with future pedigree and other supply chain custody requirements (see Risk Factor - Increasing governmental efforts to regulate the pharmaceutical supply channel may increase our costs and reduce our profitability), we expect to continue to make significant investments in our secure supply chain information systems.
U.S. Healthcare Solutions has made significant investments in its electronic ordering systems. U.S. Healthcare Solutions’ systems are intended to strengthen customer relationships by helping customers to reduce operating costs, and by providing them a platform for a number of basic and value-added services, including product demand data, inventory replenishment, single-source billing, third-party claims processing, real-time price and incentive updates, and price labels.
U.S. Healthcare Solutions processes a substantial portion of its purchase orders, invoices, and payments electronically, and it continues to make substantial investments to expand its electronic interface with its suppliers. U.S. Healthcare Solutions has warehouse operating systems, which are used to manage the majority of its transactional volume. The warehouse operating systems have improved U.S. Healthcare Solutions’ productivity and operating leverage.
Competition
We face a highly competitive global environment in the distribution of pharmaceuticals and related healthcare services. Our largest competitors are McKesson Corporation ("McKesson"), Cardinal Health, Inc. ("Cardinal"), and UPS Logistics, among others. Our U.S. human health distribution businesses compete with both McKesson and Cardinal, as well as national generic distributors and regional distributors within pharmaceutical distribution. In addition, we compete with manufacturers who sell directly to customers, chain drugstores who manage their own warehousing, specialty distributors, and packaging and healthcare technology companies. Our consulting businesses, World Courier, MWI, and Alliance Healthcare also face competition from a variety of businesses. In all areas, competitive factors include price, product offerings, value-added service programs, service and delivery, credit terms, and customer support.
Intellectual Property
We use a number of trademarks and service marks. All of the principal trademarks and service marks used in the course of our business have been registered in the United States and, in some cases, in foreign jurisdictions, or are the subject of pending applications for registration.
We have developed or acquired various proprietary products, processes, software, and other intellectual property that are used either to facilitate the conduct of our business or that are made available as products or services to customers. We generally seek to protect such intellectual property through a combination of trade secret, patent and copyright laws, and through confidentiality and other contractually imposed protections.
We hold patents and have patent applications pending that relate to certain of our products, particularly our automated pharmacy dispensing equipment, our medication and supply dispensing equipment, certain warehousing equipment, and some
5
of our proprietary packaging solutions. We seek patent protection for our proprietary intellectual property from time to time as appropriate.
Although we believe that our patents or other proprietary products and processes do not infringe upon the intellectual property rights of any third parties, third parties may assert infringement claims against us from time to time.
Human Capital Resources
Our ability to succeed in the global marketplace directly depends on attracting and retaining a talented and skilled workforce. We aspire to accelerate business results by fostering a diverse and an inclusive workplace, where all members of our global talent are supported and inspired to perform at their full potential and contribute to our success as their authentic selves.
Workforce
As of September 30, 2022, we had approximately 44,000 employees, of which approximately 39,000 were full-time employees and approximately 39% were U.S.-based employees.
Approximately 28% of our employees are covered by collective bargaining agreements, nearly all of whom are employees located outside of the United States.
We encourage and embrace different cultures and backgrounds, as we recognize the value of employing a workforce of unique and varying viewpoints and experiences. Individuals who self-identify as female make up the majority of AmerisourceBergen’s global workforce and Executive Management Committee, at 51% and 57%, respectively. Additionally, 50% of our U.S. workforce are individuals who self-identify as ethnically and/or racially diverse. We currently have two directors who self-identify as ethnically and/or racially diverse, and we currently have three directors who self-identify as female. In addition, the Company announced the election of a new female director, effective January 1, 2023.
Talent Development
We consider employee development to be a strategic priority. We support employee growth and advancement by offering a variety of benefits to eligible full-time employees including, among others:
•Leadership and professional development programs and resources;
•Leadership and executive coaching;
•Tuition reimbursement;
•Opportunities to volunteer and participate in mentorship and support programs such as our Employee Resource Groups (“ERGs”);
•Recognition for excellence, such as our annual Pursuit of Purpose awards and True Blue associate recognition program; and
•Personalized learning and skill-building programs offered through our global learning experience platform.
Importantly, we continue to make meaningful investments in supporting and building our talent and enhancing our culture. In fiscal 2022, we conducted an Employee Experience survey across the Company as a means to gauge employee satisfaction and identify areas in which we can enhance and improve employee experience. This survey also included a Global Inclusion Index that was comprised of questions designed to measure inclusion across the organization. The Employee Experience Survey is the foundation for our new employee listening strategy to ensure employee voices are heard and valued in shaping our Company’s culture.
We introduced our leadership model, which emphasizes people, collaboration, innovation, and purpose, to our team members in fiscal 2021 through a series of experiential learning programs. In fiscal year 2022, we continued to embed the Leadership Competency Model into our enterprise learning programs, talent processes, succession planning and leadership development. The ultimate goal of our leadership competency model is to help us unlock the full potential of our people and build the new skills and behaviors we need to achieve our enterprise strategy.
Our overarching goal is to provide our team members with clear pathways for career development, access to programs and benefits that allow them to live fuller, healthier lives, and opportunities to participate in their communities in ways that are meaningful to them and inspire and celebrate their individuality. Our talent development programs are designed to help provide a supportive and engaging work environment where team members can excel, while remaining authentic and empowered to share their unique perspectives and experiences.
6
Diversity, Equity, and Inclusion (“DEI”)
At AmerisourceBergen, we are committed to fostering a global workplace that values diversity, equity, and inclusion by creating pathways for every team member to thrive, making a positive impact on our communities, and continuously enhancing our transparency and accountability.
Our long-term DEI strategy is focused on four critical dimensions—people, culture, progress, and community—and is grounded in deep organizational insights, our people data, and industry research and benchmarks. In pursuit of this strategy, in 2022, we:
•Refreshed the membership and mission of AmerisourceBergen’s DEI Global Council (the “DEI Council”) by expanding the membership of the DEI Council to include the Chair of each ERG and revising the DEI Council’s mission to specifically include identifying and amplifying areas of opportunity to advance our global diversity, equity, and inclusion strategy.
•Published a dedicated DEI Summary Report on the Company’s website that highlights content from our Environmental, Social and Governance report, as a means to underscore our commitment to DEI, build trust and accountability through enhanced transparency, and monitor progress on our DEI goals.
•Conducted the first Employee Experience Survey to, among other things, measure inclusion in our global culture.
•Launched a Global Inclusion campaign, which includes a robust communication plan and action-oriented learning assets to empower our team members and inform inclusive leadership.
In addition to the foregoing, we offered a number of DEI programs and initiatives in fiscal 2022, including celebrating global inclusion in partnership with our ERGs by holding two global events: International Women’s Day in March and Pride Month in June.
We are proud that our DEI efforts continue to be recognized. The Human Rights Campaign awarded the Company a perfect score of 100% on its Corporate Equality Index for the fifth consecutive year and also listed us as one of the “Best Places to Work for LGBTQ+ Equality.”
Competitive Compensation and Benefits
We are committed to ensuring equal opportunity and pay equity. We have implemented processes that are designed to drive equitable pay decisions and eliminate unexplained pay inequities. To further support this, AmerisourceBergen has a cross-functional team of leaders from the Global Compensation, Legal, and Human Resource departments that is responsible for researching best practices, reviewing pay practices, working with external resources to analyze current pay equity, and working with senior leaders to implement changes. As a result of these efforts, we have:
•Modified promotional salary increase guidelines to help eliminate pay gaps;
•Removed questions about pay history in the recruiting and interviewing processes of external candidates;
•Adopted the practices of administering annual merit increases based on both performance and base pay within the pay range and making promotional salary increases based on market competitiveness and internal equity; and
•Implemented annual assessments that identify potential pay gaps, with the goal of developing a plan to correct any identified pay gaps that are inexplicable.
Our comprehensive benefit and compensation package offers the following to all eligible full-time team members:
•Medical, dental, and vision care, life insurance and other income protection, a retirement plan with Company match, and a discounted employee stock purchase program;
•An employee assistance program with free counseling sessions and unlimited digital mental health support, tuition assistance (including scholarships for dependents), medical coverage for same and opposite gender domestic partners, and holidays and paid time off;
•Infertility coverage and family building counseling services, as well as reimbursement for adoption expenses;
•Counseling and education guidance benefits to support the needs of team members and dependents with developmental and cognitive challenges; and
7
•Effective January 1, 2023, a minimum of twelve weeks of paid parental leave following birth, adoption, or surrogacy for both parents.
We offer postpartum support and return-to-work assistance, including on-site lactation rooms and flexible work arrangements, such as flex hours. For nursing moms who travel for work, we offer a service to ship breast milk back to their homes. We also offer back-up child and elder care, plus discounts on services, such as childcare, saving for college, and tutoring. Beginning in 2023, we will offer two weeks of paid caregiver leave to care for a family member who has a serious health condition.
We also believe it is important to invest in the health and wellness of our team members. Our myWellbeing program focuses on the physical, emotional, financial, and social aspects of wellness. Team members can earn points towards a reduction in health insurance premium costs by completing activities, such as monthly challenges, financial training, and getting preventive exams and screenings. We also offer diabetes, weight management, and musculoskeletal programs for team members and their dependents. To help team members navigate the often-confusing healthcare system, we provide a navigation and advocacy service to assist in finding the right care, obtaining a medical second opinion, and understanding confusing medical bills.
In fiscal 2022, when we initiated our return-to-office protocol, we adopted WorkSmart, a principled work-from-home flexibility program for those team members whose work does not require them to be at one of our physical locations. WorkSmart is based our philosophy and approach to employee satisfaction and provides team members flexibility in how and where work is completed.
Safety and COVID-19
We are committed to the safety and wellbeing of our team members. In addition to utilizing a peer-to-peer safety program, we regularly convene our company leaders to review and evaluate safety data and issue operational excellence scorecards. Distribution center team members receive training on proper safety procedures and incentive opportunities, with safety performance tracked and shared across the organization.
In connection with prioritizing safety, we continue to follow clinical and regulatory guidance as it relates to the COVID-19 pandemic. We continuously monitor guidance on COVID-19 safety and look for ways to enhance our safety protocols.
To further support our team members during the COVID-19 pandemic, we enhanced our benefit offerings (which are discussed above) to provide greater access to mental health telemedicine, additional paid time off for those needing to self-quarantine or care for a family member, and access to mindfulness videos and other wellness resources. Additionally, team members whose household income was impacted, such as by a spouse experiencing job loss, were offered financial support through the AmerisourceBergen Associate Assistance Fund.
Government Regulation
We are subject to extensive oversight by United States, United Kingdom and European Union governmental entities and we are subject to, and affected by, a variety of laws, regulations, and policies.
The U.S. Drug Enforcement Administration (“DEA”), the U.S. Food and Drug Administration (“FDA”), the U.S. Department of Justice, and various other federal and state authorities regulate the purchase, storage, and/or distribution of pharmaceutical products, including controlled substances. Wholesale distributors of controlled substances must hold valid DEA licenses, meet various security and operating standards, and comply with regulations governing the sale, marketing, packaging, holding, and distribution of controlled substances.
We and our customers are subject to fraud and abuse laws, including the federal anti-kickback statute and False Claims Act. The anti-kickback statute prohibits persons from soliciting, offering, receiving, or paying any remuneration in order to induce the purchasing, leasing, or ordering, induce a referral to purchase, lease, or order, or arrange for or recommend purchasing, leasing, or ordering items or services that are in any way paid for by Medicare, Medicaid, or other federal healthcare programs. The False Claims Act prohibits knowingly submitting, or causing the submission, of false or fraudulent claims for payment to the government and authorizes treble damages and substantial civil penalties in the case of violations. The fraud and abuse laws and regulations are broad in scope and are subject to frequent and varied interpretation.
In recent years, some states have passed or proposed laws and regulations that are intended to protect the safety of the pharmaceutical supply channel. These laws and regulations are designed to prevent the introduction of counterfeit, diverted, adulterated, or mislabeled pharmaceuticals into the distribution system. At the federal level, the supply chain security legislation known as the Drug Quality and Security Act (“DQSA”) became law in 2013. Title II of the DQSA, known as the Drug Supply Chain Security Act (“DSCSA”), establishes federal traceability standards requiring drugs to be labeled and tracked at the lot
8
level, preempts state drug pedigree requirements, and requires all supply-chain stakeholders to participate in an electronic, interoperable prescription drug traceability system. The DSCSA also establishes requirements for drug wholesale distributors and third-party logistics providers, including licensing requirements applicable in states that had not previously licensed third-party logistics providers. The FDA, and eventually all comparable state agencies, will promulgate implementing regulations governing wholesale distributor and third-party logistics providers. There can be no assurance that we are fully compliant with DQSA requirements, or with additional related state regulatory and licensing requirements, and any failure to comply may result in suspension or delay of certain operations and additional costs to bring our operations into compliance. These and other requirements will continue to increase the cost of our operations.
The regulation of public and private health insurance and benefit programs can also affect our business, and scrutiny of the healthcare delivery and reimbursement systems in the United States, including those related to the importation and reimportation of certain drugs from foreign markets, can be expected to continue at both the state and federal levels. This process may result in additional legislation and/or regulation governing the production, delivery, or pricing of pharmaceutical products and other healthcare services. In addition, changes in the interpretations of existing regulations may result in significant additional compliance costs or the discontinuation of our ability to continue to operate certain of our distribution centers, which may have a material adverse effect on our financial condition and results of operations.
Any future reductions in Medicare or Medicaid reimbursement rates could negatively impact our customers' businesses and their ability to continue to purchase drugs from us. We cannot predict what additional initiatives, if any, will be adopted, when they may be adopted, or what impact they may have on us.
We are subject to various federal, state, and local environmental laws, including with respect to the sale, transportation, storage, handling, and disposal of hazardous or potentially hazardous substances, as well as laws relating to safe working conditions and laboratory practices.
The costs, burdens, and/or impacts of complying with federal and state regulations could be significant and the failure to comply with any such legal requirements could have a significant impact on our results of operations and financial condition.
See “Risk Factors” for a discussion of additional legal and regulatory developments, as well as enforcement actions or other litigation that may arise out of our failure to adequately comply with applicable laws and regulations that may negatively affect our results of operations and financial condition.
Health Information and Privacy Practices
The Health Information Portability and Accountability Act of 1996 (“HIPAA”) and its implementing regulations set forth privacy and security standards designed to protect the privacy of and provide for the security of protected health information, as defined under the HIPAA regulations. Some of our businesses collect, maintain, and/or access protected health information and are subject to the HIPAA regulations. Our operations, depending on their location, may also be subject to state or foreign regulations affecting personal data protection and the manner in which information services or products are provided. Significant criminal and civil penalties may be imposed for violation of HIPAA standards and other such laws. We have a HIPAA compliance program to facilitate our ongoing efforts to comply with the HIPAA regulations.
The Health Information Technology for Economic and Clinical Health Act (“HITECH Act”) strengthened federal privacy and security provisions governing protected health information. Among other things, the HITECH Act expanded certain aspects of the HIPAA privacy and security rules, imposed new notification requirements related to health data security breaches, broadened the rights of the U.S. Department of Health and Human Services (“HHS”) to enforce HIPAA, and directed HHS to publish more specific security standards. In January 2013, the Office for Civil Rights of HHS published the HIPAA omnibus final rule (“HIPAA Final Rule”), which amended certain aspects of the HIPAA privacy, security, and enforcement rules pursuant to the HITECH Act, extending certain HIPAA obligations to business associates and their subcontractors. Certain components of our business act as “business associates” within the meaning of HIPAA and are subject to these additional obligations under the HIPAA Final Rule.
Some of our businesses collect, maintain, and/or access other personal information (including sensitive personal information) that is subject to federal and state laws protecting such information, in addition to the requirements of HIPAA, the HITECH Act, and the implementing regulations. Personal information is also highly regulated in many other countries in which we operate and many of these laws place restrictions on the transfer of personal information to other jurisdictions. As such regulations continue to evolve, we must comply with applicable privacy and security requirements of these countries, including but not limited to those in the European Union and the United Kingdom. Most notably certain aspects of our business are subject to the European Union’s General Data Protection Regulation (“GDPR”) which became effective on May 25, 2018, the UK GDPR and the UK Data Protection Act of 2018, the California Consumer Protection Act (“CCPA”), which became effective on January 1, 2020, and Brazil’s General Data Protection Law (Lei Geral de Proteção de Dados Pessoais) – Law No. 13,709/208 (“LGPD”) which became effective in August 2020. On November 3, 2020, the California Privacy Rights Act of
9
2020 (“CPRA”), which amends the CCPA and adds new privacy protections that will become effective on January 1, 2023, was enacted through a ballot initiative. Similarly, Virginia (the Virginia Consumer Data Protection Act, effective on January 1, 2023), Colorado (the Colorado Privacy Act, effective on July 1, 2023), Connecticut (the Connecticut Data Privacy Act, effective on July 1, 2023), and Utah (the Utah Consumer Privacy Act, effective December 31, 2023) have also enacted similarly situated data protection laws. Other states and countries continue to enact similar legislation. We have implemented a privacy and information security compliance program to facilitate our ongoing efforts to comply with the applicable privacy laws and regulations. There can be no assurances that compliance with these requirements will not impose new costs on our business.
Available Information
For more information about us, visit our website at www.amerisourcebergen.com. The contents of the website are not part of this Form 10-K. Our electronic filings with the Securities and Exchange Commission (including all Forms 10-K, 10-Q, and 8-K, and any amendments to these reports) are available free of charge through our website at investor.amerisourcebergen.com immediately after we electronically file with or furnish them to the Securities and Exchange Commission and may also be viewed using their website at www.sec.gov.
10
ITEM 1A.    RISK FACTORS
The following discussion describes certain risk factors that we believe could affect our business and prospects. These risk factors are in addition to those set forth elsewhere in this report. Our business operations could also be affected by additional factors that are not presently known to us or that we currently consider not to be material. The reader should not consider this list to be a complete statement of all risks and uncertainties.
Business and Operational Risks
Our revenue, results of operations, and cash flows may suffer upon the loss, or renewal at less favorable terms, of a significant customer or group purchasing organization.
WBA accounted for approximately 27% of our revenue in the fiscal year ended September 30, 2022. Express Scripts accounted for approximately 13% of our revenue in the fiscal year ended September 30, 2022. Our top ten customers, including governmental agencies, represented approximately 66% of revenue in the fiscal year ended September 30, 2022. We have distributor relationships with GPOs in multiple distribution segments. We may lose a significant customer or GPO relationship if any existing contract with such customer or GPO expires without being extended, renewed, renegotiated or replaced or is terminated by the customer or GPO prior to expiration, to the extent such early termination is permitted by the contract. A number of our contracts with significant customers or GPOs are typically subject to expiration each year and we may lose any of these customers or GPO relationships if we are unable to extend, renew, renegotiate or replace the contracts. The loss of any significant customer or GPO relationship could adversely affect our revenue, results of operations, and cash flows. Additionally, from time to time, significant contracts may be renewed or modified prior to their expiration date in furtherance of our strategic objectives. If those contracts are renewed or modified at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.
The anticipated ongoing strategic and financial benefits of our relationship with WBA may not be realized.
In June 2021, we extended to 2029 our distribution agreement under which we distribute drugs to Walgreens pharmacies and our generics purchasing services arrangement under which Walgreens Boots Alliance Development GmbH (“WBAD”) provides a variety of services, including negotiating acquisition pricing with generic manufacturers on our behalf. This reflected our continued expectation that partnering strategically with WBA will result in various benefits including continued cost savings and initiatives designed to create incremental growth and efficiencies in sourcing, logistics and distribution. We also entered into a distribution agreement pursuant to which we will supply branded and generic pharmaceutical products to WBA’s Boots UK Ltd. subsidiary through 2031. The processes needed to achieve and maintain these initiatives and benefits are complex, costly, and time-consuming. Achieving the anticipated benefits from the arrangements on an ongoing basis is subject to a number of significant challenges and uncertainties, including: the potential inability to realize and/or delays in realizing potential benefits resulting from participation in our generics purchasing services arrangement with WBAD, including improved generic drug pricing and terms, improved service fees from generic manufacturers, cost savings, innovations, or other benefits due to its inability to negotiate successfully with generic manufacturers or otherwise to perform as expected; the potential disruption of our plans and operations as a result of the extension of the duration of our distribution agreement for Walgreens pharmacies and our generics purchasing services agreement with WBAD and the respective terms thereunder, including any disruption of our cash flow and ability to return value to our stockholders in accordance with our past practices and any reduction in our operational, strategic or financial flexibility; potential changes in supplier relationships and terms; unexpected or unforeseen costs, fees, expenses and charges incurred by us related to the transaction or the overall strategic relationship; changes in the economic terms under which we distribute pharmaceuticals to Walgreens pharmacies in the United States or to pharmacies operated by Boots UK Ltd. in the United Kingdom, including changes necessitated by changing market conditions or other unforeseen developments that may arise during the term of either distribution agreement, to the extent that any such changes are not offset by other financial benefits that we are able to obtain through collaboration in other aspects of our strategic relationship with WBA; and any potential issues that could impede our ability to continue to work collaboratively with WBA in an efficient and effective manner in furtherance of the anticipated strategic and financial benefits of the relationship.
In addition, WBA has the right, but not the obligation, under the transactions contemplated by the Framework Agreement dated March 18, 2013 and the Amended and Restated AmerisourceBergen Shareholders Agreement dated June 1, 2021, as further amended on August 2, 2022 (the “Shareholders Agreement”), to make certain additional investments in our common stock. WBA also has the right to sell any of the shares of our common stock that it has acquired so long as WBA has held the shares beyond the requisite dates specified in the Shareholders Agreement, subject to certain restrictions on the number of shares that may be sold at any given time. For example, in November 2022, WBA sold 13.2 million shares of our common stock. Any sales of common stock by WBA could adversely affect prevailing market prices of our common stock. We could also encounter unforeseen costs, circumstances, or issues with respect to the transactions and collaboration we anticipate pursuing with WBA. Many of these potential circumstances are outside of our control and any of them could result in increased
11
costs, decreased revenue, decreased benefits and the diversion of management time and attention. If we are unable to achieve any of our objectives, the expected future benefits may not be realized fully or may take longer to realize than expected, which could have a material adverse impact on our business, financial condition, and results of operations.
A disruption in our distribution or generic purchasing services arrangements with WBA could adversely affect our business and financial results.
We are the primary distributor of pharmaceutical products for WBA in the United States and the United Kingdom. If our operations are seriously disrupted for any reason deemed within our control, we may have an obligation to pay or credit WBA for failure to supply products. In addition, upon the expiration or termination of our distribution agreement for Walgreens pharmacies, our distribution agreement with Boots UK Ltd. or our generics purchasing services arrangement with WBAD, there can be no assurance that we or WBA will be willing to renew, on terms favorable to us or at all.
Our generic pharmaceutical program has also benefited from the generics purchasing services arrangement with WBAD. If the operations of WBA are seriously disrupted for any reason, whether by the COVID-19 pandemic, natural disaster, labor disruption, regulatory or governmental action, or otherwise, it could adversely affect our business and our sales and profitability. Moreover, if the economic benefits we are able to obtain through the generics purchasing services arrangement with WBA decline due to changes in market conditions or other changes impacting the fees and rebates that generic manufacturers make available through the arrangement, our margins and results of operations could also be adversely affected.
In addition, our business may be adversely affected by any operational, financial, or regulatory difficulties that WBA experiences, including any disruptions of certain of its existing distribution facilities or retail pharmacies resulting from ongoing inspections by the DEA and/or state regulatory agencies and possible revocation of the controlled substance registrations for those facilities and pharmacies.
Our results of operations and financial condition may be adversely affected if we undertake acquisitions of or investments in businesses that do not perform as we expect or that are difficult for us to integrate.
As part of our strategy we seek to pursue acquisitions of and investments in other companies. At any particular time, we may be in various stages of assessment, discussion, and negotiation with regard to one or more potential acquisitions or investments, not all of which will be consummated. We make public disclosure of pending and completed acquisitions when appropriate and required by applicable securities laws and regulations. On June 1, 2021, we completed our acquisition of Alliance Healthcare from WBA for $5,596.7 million in net cash, $229.1 million of the our common stock, and $6.1 million of other equity consideration (see Note 2 of the Notes to Consolidated Financial Statements). On September 12, 2022, we announced our intent to acquire PharmaLex Holding GmbH (“PharmaLex”) for €1,280 million in cash, subject to certain customary adjustments. The PharmaLex transaction is expected to close by March 2023 and is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals. Alliance Healthcare and PharmaLex operate in the United Kingdom, Germany, a number of other countries in the European Union, and in select other markets. We may find that our ability to integrate and control Alliance Healthcare and PharmaLex is more difficult, time consuming or costly than expected, especially in certain countries where our investment is not wholly-owned, such as our 50%-owned Alliance Healthcare Egypt subsidiary. Each of Alliance Healthcare and PharmaLex may fail to achieve its expected future financial and operating performance and results and the acquisitions may have the effect of disrupting relationships with employees, suppliers, and other business partners.
Acquisitions involve numerous risks and uncertainties and may be of businesses or in regions in which we lack operational or market experience. Acquired companies may have business practices that we are not accustomed to or have unique terms and conditions with their business partners. As a result of the acquisition of Alliance Healthcare and other future acquisitions, including PharmaLex, our results of operations and financial condition may be adversely affected by a number of factors, including: regulatory or compliance issues that could arise; changes in regulations and laws; the failure of the acquired businesses to achieve the results we have projected in either the near or long term; the assumption of unknown liabilities, including litigation risks; the fair value of assets acquired and liabilities assumed not being properly estimated; the difficulties of imposing adequate financial and operating controls on the acquired companies and their management and the potential liabilities that might arise pending the imposition of adequate controls; the difficulties in the integration of the operations, technologies, services and products of the acquired companies; and the failure to achieve the strategic objectives of these acquisitions. Our businesses operate in a number of jurisdictions, including Egypt and other locations, that have a higher business, operating and regulatory risk profile than the United States and European Union jurisdictions. Such risks may include risks of violation of United States, United Kingdom and other anti-corruption, anti-bribery and international trade laws. Our results of operations and financial condition may be adversely affected if we are not able to effectively put in place effective financial controls and compliance policies to safeguard against such risks as part of our integration of businesses, including Alliance Healthcare.
12
Our business and results of operations may be adversely affected if we fail to manage and complete divestitures.
We regularly evaluate our portfolio to determine whether an asset or business may no longer help us meet our objectives. When we decide to sell assets or a business, we may encounter difficulty finding buyers or alternative exit strategies, which could delay the achievement of our strategic objectives. Further, divestitures may be delayed due to failure to obtain required approvals on a timely basis, if at all, from governmental authorities, or may become more difficult to execute due to conditions placed upon approval that could, among other things, delay or prevent us from completing a transaction, or otherwise restrict our ability to realize the expected financial or strategic goals of a transaction. The impact of a divestiture on our results of operations could also be greater than anticipated.
Our results of operations and our financial condition may be adversely affected by our global operations.
We conduct operations in over 50 countries, which subjects us to various risks inherent in global operations. We may conduct business in additional foreign jurisdictions in the future, which may carry operational risks in addition to the risks of acquisition described above. At any particular time, our global operations may be affected by local changes in laws, regulations, and political and economic environments, including inflation, recession, currency volatility, and competition, as well as business and operational decisions made by joint venture partners. For example, during fiscal 2022, Turkey became a “highly inflationary economy,” as defined under U.S. GAAP, which impacted our consolidated financial statements.
Furthermore, geopolitical dynamics caused by political, economic, social or other conditions in foreign countries and regions may impact our business and results of operations. During fiscal 2022, we have experienced increased costs, including for fuel, and it is possible that we could experience supply disruptions or shortages if tariffs or other protective measures are enacted. Significantly higher and sustained rates of inflation, with subsequent increases in operational costs, could have a material adverse effect on our business, financial position and results of operations. The continued threat of terrorism and heightened security and military action in response thereto, or any other current or future acts of terrorism, war (such as the ongoing Russia and Ukraine war), and other events (such as economic sanctions and trade restrictions, including those related to the on-going Russia and Ukraine war) may cause further disruptions to the economies of the United States and other countries and create further uncertainties or could otherwise negatively impact our business, operating results, and financial condition.
Changes or uncertainty in U.S. policies or policies in other countries and regions in which we do business, including any changes or uncertainty with respect to U.S. or international trade policies or tariffs, also can disrupt our global operations, as well as our customers and suppliers, in a particular location and may require us to spend more money to source certain products or materials that we purchase. Any of these factors could adversely affect our business, financial position, and results of operations.
We might be adversely impacted by fluctuations in foreign currency exchange rates.
We conduct our business in various currencies, including the U.S. Dollar, the Euro, the U.K. Pound Sterling, the Turkish Lira, the Egyptian Pound, the Brazilian Real, and the Canadian Dollar. Changes in foreign currency exchange rates could reduce our revenues, increase our costs or otherwise adversely affect our financial results reported in U.S. dollars. We may from time to time enter into foreign currency contracts, foreign currency borrowings or other techniques intended to hedge a portion of our foreign currency exchange rate risks. These hedging activities may not completely offset the adverse financial effects of unfavorable movements in foreign currency exchange rates during the time the hedges are in place. Any of these risks might have an adverse impact on our business operations and our financial position, results of operations, or cash flows.
We might be adversely impacted by the January 2020 withdrawal of the United Kingdom from the European Union.
We have continued to expand our operations in the United Kingdom and the European Union and face risks associated with the uncertainty and potential disruptions associated with the United Kingdom's withdrawal from the European Union (“Brexit”). We continue to believe Brexit could adversely affect political, regulatory, economic or market conditions and contribute to instability in global political institutions, regulatory agencies and financial markets. For example, we might experience volatility in exchange rates and interest rates and changes in laws regulating our United Kingdom operations as well as sourcing disruptions and associated pricing volatility. Customers might reduce purchases due to the uncertainty caused by Brexit. Any of these risks might have a materially adverse impact on our business operations and our financial position or results of operations. Similar future trade disruptions or disputes could have a negative impact on our operations in the United Kingdom and European Union and other parts of the world.
We are subject to operational and logistical risks that might not be covered by insurance.
We have distribution centers and facilities located in the United States, the United Kingdom, the European Union and throughout the world. Our business exposes us to risks that are inherent in the distribution of pharmaceuticals and the provision
13
of related services, including cold chain storage and shipping. The volume of cold chain storage and shipping has increased in part due to the COVID-19 pandemic and the requirements for distribution of COVID-19 vaccines and certain treatments. We expect this trend to continue. Although we seek to maintain adequate insurance coverage, coverage on acceptable terms might be unavailable, coverage might not cover our losses, coverage might be significantly more costly or may require large deductibles.
Additionally, we seek to maintain coverage for risks associated with cybersecurity, but such insurance has become increasingly difficult to secure and, in some cases, policies may not provide adequate coverage for possible losses. Uninsured losses or operational losses that result from large deductible payments under commercial insurance coverage might have an adverse impact on our business operations and our financial position or results of operations.
We might be unable to successfully recruit and retain qualified employees.
Our ability to attract, engage, develop and retain qualified and experienced employees, including key executives and other talent, is essential for us to meet our objectives. We compete with many other businesses to attract and retain employees. Competition among potential employers might result in increased salaries, benefits or other employee-related costs, or in our failure to recruit and retain employees. We may experience sudden loss of key personnel due to a variety of causes, such as illness, and must adequately plan for succession of key management roles. Employees might not successfully transition into new roles. Any of these risks might have a materially adverse impact on our business operations and our financial position or results of operations.
Additionally, approximately 28% of our employees are covered by collective bargaining agreements, nearly all of whom are employees located outside of the United States. We believe that our relationship with our employees is good but if any of our employees in locations that are unionized should engage in strikes or other such bargaining tactics in connection with the negotiation of new collective bargaining agreements upon the expiration of any existing collective bargaining agreements, such tactics could be disruptive to our operations and adversely affect our results of operations.
Industry and Economic Risks
Our results of operations could be adversely impacted by manufacturer pricing changes.
Our contractual arrangements with pharmaceutical manufacturers for the purchase of brand pharmaceutical products in the United States generally use wholesale acquisition cost (“WAC”) as the reference price. We sell brand pharmaceutical products to many of our customers using WAC as the reference price and to other customers based on their negotiated contract price. If manufacturers change their pricing policies or practices with regard to WAC or if prices charged by manufacturers do not align with prices negotiated to be paid by our customers, and we are unable to negotiate alternative ways to be compensated by manufacturers or customers for the value of our services, our results of operations could be adversely affected. Additionally, there are a number of U.S. government policy initiatives being considered which, if enacted, could directly or indirectly regulate or impact WAC prices. If such initiatives are passed or finalized and we are unable to negotiate equitable changes with our suppliers and/or customers, our results of operations could be adversely impacted.
The pharmaceutical products that we purchase are also subject to price inflation and deflation. Additionally, certain distribution service agreements that we have entered into with brand and generic pharmaceutical manufacturers have a price appreciation component to them. As a result, our gross profit from brand-name and generic pharmaceuticals continues to be subject to fluctuation based upon the timing and extent of manufacturer price increases, which we do not control. If the frequency or rate of brand and generic pharmaceutical price increases slows, whether due to regulatory mandates, the implementation of legislative proposals, policy initiatives or voluntary manufacturer actions, our results of operations could be adversely affected. In addition, generic pharmaceuticals are also subject to price deflation. If the frequency or rate of generic pharmaceutical price deflation accelerates, the negative impact on our results of operations will be greater.
Competition and industry consolidation may erode our profit.
As described in greater detail in the “Competition” section, the industries in which we operate are highly competitive. In addition, the healthcare industry continues to experience increasing consolidation, including through the formation of strategic alliances among pharmaceutical manufacturers, retail pharmacies, healthcare providers and health insurers, which may create further competitive pressures on our pharmaceutical distribution business. Continued consolidation within the healthcare industry could adversely affect our results of operations, to the extent we experience reduced negotiating power or possible customer losses.
14
Our revenue and results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant customer.
Most of our customers buy pharmaceuticals and other products and services from us on credit. Credit is made available to customers based upon our assessment and analysis of creditworthiness. Although we often try to obtain a security interest in assets and other arrangements intended to protect our credit exposure, we generally are either subordinated to the position of the primary lenders to our customers or substantially unsecured. Volatility of the capital and credit markets, general economic conditions, and regulatory changes, including changes in reimbursement, may adversely affect the solvency or creditworthiness of our customers. The COVID-19 pandemic has increased volatility of the capital and credit markets and has led to a general worsening of economic conditions, which has put financial pressure on many of our customers and may threaten certain customers’ ability to maintain liquidity sufficient to repay their obligations to us as they become due. The bankruptcy, insolvency, or other credit failure of any customer that has a substantial amount owed to us could have a material adverse effect on our operating revenue and results of operations. As of September 30, 2022, our two largest trade receivable balances due from customers represented approximately 38% and 7% of accounts receivable, net.
Our results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant supplier.
Our relationships with pharmaceutical suppliers give rise to substantial amounts that are due to us from the suppliers, including amounts owed to us for returned goods or defective goods, chargebacks, and amounts due to us for services provided to the suppliers. Volatility of the capital and credit markets, general economic conditions, pending litigation, and regulatory changes may adversely affect the solvency or creditworthiness of our suppliers. The bankruptcy, insolvency, or other credit failure of any supplier at a time when the supplier has a substantial account payable balance due to us could have a material adverse effect on our results of operations. Furthermore, the bankruptcy, insolvency or other credit failure of a significant supplier could have an adverse effect on the supply or availability of products which may cause supply chain disruptions and increases in the price of substitutes or alternatives.
Our stock price and our ability to access credit markets may be adversely affected by financial market volatility and disruption or a downgrade in our credit ratings.
If the capital and credit markets experience significant disruption and volatility in the future, there can be no assurance that we will not experience downward movement in our stock price without regard to our financial condition or results of operations or an adverse effect, which may be material, on our ability to access credit. Although we believe that our operating cash flow and existing credit arrangements give us the ability to meet our financing needs, there can be no assurance that disruption and volatility will not increase our costs of borrowing, impair our liquidity, or adversely impact our business.
Additionally, rating agencies continually review the ratings they have assigned to us and our outstanding debt securities. To maintain our ratings, we are required to meet certain financial performance ratios. Liabilities related to litigation or any significant related settlements, an increase in our debt or a decline in our earnings could result in downgrades in our credit ratings. Actual or anticipated changes or downgrades in our credit ratings, including any announcement that our ratings are under review for a downgrade or have been assigned a negative outlook, could limit our access to public debt markets, limit the institutions willing to provide credit to us, result in more restrictive financial and other covenants in our public and private debt, and would likely increase our overall borrowing costs and adversely affect our earnings.
Declining economic conditions could adversely affect our results of operations and financial condition.
Our operations and performance depend on economic conditions in the United States and other countries or regions where we do business. Deterioration in general economic conditions, whether due to COVID-19 or otherwise, could adversely affect the amount of prescriptions that are filled and the amount of pharmaceutical products purchased by consumers and, therefore, could reduce purchases by our customers, which would negatively affect our revenue growth and cause a decrease in our profitability. Negative trends in the general economy, including interest rate fluctuations, financial market volatility, or credit market disruptions, may also affect our customers' ability to obtain credit to finance their businesses on acceptable terms and reduce discretionary spending on health products. Reduced purchases by our customers or changes in payment terms could adversely affect our revenue growth and cause a decrease in our cash flows from operations. Bankruptcies or similar events affecting our customers may cause us to incur bad debt expense at levels higher than historically experienced. Declining economic conditions or increases in inflation may also increase our costs. If the economic conditions in the United States or in the countries or regions where we do business deteriorate, our results of operations or financial condition could be adversely affected.
15
Litigation and Regulatory Risks
Increasing governmental efforts to regulate the pharmaceutical supply channel may increase our costs and reduce our profitability.
The healthcare industry in the United States, as well as in the other countries and regions in which we do business, is highly regulated at many levels of government. There have been increasing efforts in the United States by Congress and state and federal agencies, including state boards of pharmacy, departments of health, the FDA, DEA, and TSA, and by similar regulators in the United Kingdom, the European Union, and other countries, to regulate the pharmaceutical supply chain. Regulation of pharmaceutical distribution is intended to prevent diversion and the introduction of counterfeit, adulterated, and/or mislabeled drugs into the pharmaceutical distribution system, as well as provide assurance over the integrity of products traversing the supply chain. Consequently, we are subject to the risk of changes in various laws, which include operating, record keeping, and security standards of the DEA, the FDA, various state boards of pharmacy and comparable agencies. In recent years, some governments have passed or proposed laws and regulations that are intended to protect the safety and security of the supply channel but that also may substantially increase the costs and burden of pharmaceutical distribution.
At the federal level, in the United States, the DSCSA establishes national traceability standards requiring drugs to be labeled and tracked at the bottle level, preempts state drug pedigree requirements, and requires all supply-chain stakeholders to participate in an electronic, interoperable prescription drug traceability system by November 2023. The DSCSA also establishes requirements for drug wholesale distributors and third-party logistics providers, including licensing requirements applicable in states that had not previously licensed third-party logistics providers. The FDA, and eventually all comparable state agencies, will promulgate implementing regulations governing wholesale distributor and third-party logistics providers. Most recently, on February 4, 2022, the FDA issued a proposed rule, which, when finalized, will establish the national standards for the licensure of wholesale drug distributors and third-party logistics providers.
Failure to comply with the DQSA requirements or with additional similar governmental regulatory and licensing requirements may result in suspension or delay of certain operations and additional costs to bring our facilities into compliance. Our international operations may also be subject to local regulations containing record-keeping and other obligations related to our distribution operations in those locations. For example, in 2019, the safety features of the Falsified Medicines Directive became operational in EU member states, which consists of placing a unique identifier (a two-dimensional barcode) and an anti-tampering device on the outer packaging of medicines. Pedigree tracking laws increase our compliance burden and our pharmaceutical distribution costs and could have an adverse impact on our financial position or results of operations.
As discussed in the risk factor below about public concern over the abuse of opioid medications, certain governmental and regulatory agencies, as well as state and local jurisdictions, are focused on the abuse of opioid medications in the United States. In addition to conducting investigations and participating in litigation related to the misuse of prescription opioid medications, federal, state and local governmental and regulatory agencies are considering legislation and regulatory measures to limit opioid prescriptions and more closely monitor product distribution, prescribing, and dispensing of these drugs.
Complying with the DQSA requirements, including the DSCSA requirements, and other chain of custody and pharmaceutical distribution requirements, including follow-on actions related to current public concern over the abuse of opioid medications, could result in suspension or delays in our production and distribution activities which may increase our costs and could otherwise adversely affect our results of operations.
Legal, regulatory, and legislative changes with respect to reimbursement, pricing, and contracting may adversely affect our business and results of operations, including through declining reimbursement rates.
Both our business and our customers' businesses may be adversely affected by laws and regulations reducing reimbursement rates for pharmaceuticals and/or medical treatments or services, changing the methodology by which reimbursement levels are determined, or regulating pricing, contracting, and discounting practices with respect to medical products and services. Additionally, on occasion, price increases and pricing practices with respect to certain brand and generic pharmaceuticals have been the subject of governmental inquiries, national, federal and state investigations and private litigation. Any law or regulation impacting pharmaceutical pricing or reimbursement, such as pricing controls or indexing models at a national, federal or state level, could adversely affect our operations.
In the European Union, many governments provide or subsidize healthcare to consumers and regulate pharmaceutical prices, patient eligibility and reimbursement levels in order to control government healthcare system costs. In most EU member states, for example, the government regulates pricing of a new pharmaceutical product at launch often through direct price controls, international price comparisons, controlling profits and/or reference pricing. Some European governments have implemented or are considering austerity measures to reduce healthcare spending such as volume discounts, cost caps, cost sharing for increases in excess of prior year costs for individual products or aggregated market level spending, outcome-based pricing schemes and free products for a portion of the expected therapy period. All of these measures exert pressure on the
16
pricing and reimbursement levels for pharmaceuticals and may cause our customers to purchase fewer of our products and services or influence us to reduce prices.
In the United States, federal insurance and healthcare reform legislation known as the Affordable Care Act (“ACA”) became law in March 2010, and included numerous reforms broadening healthcare access and affecting Medicare and Medicaid reimbursement, pricing, and contracting for prescription drugs, including changes to the Medicaid rebate statute. We cannot predict the impact that any efforts to change or repeal any provisions of the ACA may have on the ACA or other healthcare legislation and regulation.
Subsequent legislation has made additional changes to federal drug payment policies, including the Bipartisan Budget Act of 2018, which increased the Medicaid rebate due with respect to line extensions of single source or innovator multiple source oral solid dosage form drugs. The federal government and state governments could take other actions in the future that impact Medicaid reimbursement and rebate amounts or the cost of drugs. Any reduction in the Medicaid reimbursement rates to our customers may indirectly impact the prices that we can charge our customers for multiple source pharmaceuticals and cause corresponding declines in our profitability. There can be no assurance that recent or future changes in Medicaid prescription drug reimbursement policies will not have an adverse impact on our business. Unless we are able to successfully advocate to prevent or mitigate the impact of these legislative and regulatory changes, these changes in reimbursement and related reporting requirements could adversely affect our results of operations.
More recently, on August 16, 2022, President Biden signed into law the Inflation Reduction Act (“IRA”), an omnibus budget law which contains significant reforms affecting prescription drug pricing and reimbursement. These reforms include: (i) manufacturer inflation rebates on drugs covered under Medicare Part B and Medicare Part D, to the extent such products’ prices increase faster than the rate of consumer price inflation, beginning in the fourth quarter of 2022 for Part D drugs and the first quarter of 2023 for Part B drugs; (ii) limits on Medicare Part B and Part D patients’ cost sharing for insulin, beginning in 2023; (iii) Medicare Part D benefit redesign beginning in 2024, including replacement of the “coverage gap discounts” that pharmaceutical manufacturers currently pay with new mandatory manufacturer discounts applicable during all phases of the Part D benefit after satisfaction of the deductible, beginning in 2025; and (iv) federal price negotiation of “maximum fair prices” for certain “selected” high-expenditure drugs under Medicare Parts D and B, applicable beginning in 2026 for Part D drugs and 2028 for Part B drugs, under which maximum fair prices must be made available to pharmacies, physicians, and other entities dispensing or providing drugs covered under Medicare Parts D and B. Although the primary effects of the IRA reforms will be felt by manufacturers, these changes may impact our customer pricing structures, our manufacturer distribution relationships and revenue, our customers' billing processes and reimbursement amounts, and drug prices more generally (including outside of the Medicare context). Among other issues, the mechanisms by which maximum fair prices will be made available to pharmacies, physicians and other purchasers of selected drugs, and our associated role and responsibilities, remain to be determined. More broadly, the law contains reimbursement and pricing incentives designed to promote biosimilar introduction and competition which may affect our customers’ selection of products. Each of these considerations, as well as other issues that may arise in connection with the implementation of the IRA, may adversely affect our operations and profitability.
Our businesses also sell specialty and other drugs to physicians, hospitals, community oncology practices and other providers that are reimbursed under Part B of the Medicare program. The Centers for Medicare & Medicaid Services (“CMS”) published a final rule in November 2017 that reduces Medicare outpatient hospital reimbursement for separately payable drugs (other than vaccines) purchased through the 340B drug discount program from average sales price (“ASP”) plus 6% to ASP minus 22.5% (with certain exceptions), effective January 2018. Subsequently, CMS issued proposed rules for later years containing similar reductions in hospital outpatient payments for 340B drugs. In June 2022, the United States Supreme Court ruled in American Hospital Association v. Becerra that CMS’s final rule was inconsistent with the Medicare statute and was therefore invalid. Following the Supreme Court’s decision, CMS published a proposed rule for the calendar year 2023 hospital outpatient payment system, which did not propose a specific “refund” mechanism to implement reimbursement provisions consistent with the Supreme Court’s decision but advised the public that the final rule is likely to include such a mechanism and solicited comments on particular approaches. While the Court’s decision (if fully implemented by CMS) removes the reimbursement restrictions for 340B products affecting our customers and indirectly the company, there can be no assurance that recent or future rules established by CMS will not have an adverse impact on our business.
Further, even where a government does not affirmatively change drug price regulation standards, other parties in the drug manufacturing and distribution system may change their interpretation or approach to implementing or complying with those standards, in a manner that may adversely affect our business. For example, the 340B drug discount program requires manufacturers to provide discounts on outpatient drugs to “covered entity” safety net providers, and previous Health Resources and Services Administration (“HRSA”) guidance has allowed covered entities to dispense 340B discounted drugs through arrangements with multiple “contract pharmacies.” Recently, several manufacturers have announced initiatives that may inhibit or limit covered entities’ ability to use any, or multiple, contract pharmacies, may place conditions on the use of contract
17
pharmacies, or direct us not to honor 340B discounted pricing requests on orders to be shipped to contract pharmacies (or may not honor chargebacks where such discounts are extended to contract pharmacies). Since these manufacturer policies were first announced, both manufacturers and covered entities have filed lawsuits against HRSA regarding the contract pharmacy policy, which are currently pending, in several federal district and appellate courts, and HRSA has also advised certain manufacturers that it was referring their policies to the Office of Inspector General of the Department of Health and Human Services for potential civil money penalty enforcement proceedings. We cannot predict the outcome of these proceedings. Our customers include covered entities and organizations with significant participation as contract pharmacies, and the unavailability of 340B discounts through contract pharmacy arrangements may adversely affect such customers and, therefore, could adversely affect our business.
The federal government may adopt measures in the future that would further reduce Medicare and/or Medicaid spending or impose additional requirements on healthcare entities. Any future reductions in Medicare reimbursement rates or modifications to Medicare drug pricing regulations such as ASP calculations, or the extension of IRA pricing reforms to commercial health plans, could negatively impact our customers' businesses and their ability to continue to purchase such drugs from us, or could indirectly affect the structure of our relationships with manufacturers and our customers. At this time, we can provide no assurances that future Medicare, Medicaid or other insurance payment or policy changes, if adopted, would not have a material adverse effect on our business.
Finally, federal and state governments may adopt policies affecting drug pricing and contracting practices outside of the context of federal programs such as Medicare and Medicaid, which may adversely affect our business. For example, several states have adopted laws that require drug manufacturers to provide advance notice of certain price increases and to report information relating to those price increases, while others have taken legislative or administrative action to establish prescription drug affordability boards or multi-payer purchasing pools to reduce the cost of prescription drugs. On July 31, 2019, the Department of Health and Human Services announced a “Safe Importation Action Plan” that outlines two potential pathways to allow importation of certain drugs from foreign markets. Following this framework, the FDA proposed a draft rule in December 2019 that would allow importation of certain lower-cost prescription drugs from Canada, and in September 2020 the rulemaking was finalized by the FDA along with an industry guidance document. Under the rule, states or certain other non-federal governmental entities would be able to submit importation program proposals to the FDA for review and authorization of two-year programs (with the opportunity to extend for two more years). The new rule became effective on November 30, 2020, although its implementation has been delayed and its impact is uncertain, in part because lawsuits have been filed challenging the government’s authority to promulgate it. Further, authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. Despite the ongoing litigation, on July 9, 2021, President Biden signed an Executive Order pertaining to drug pricing that directs the Commissioner of the FDA to work with states and Indian Tribes to facilitate the commercial importation of certain prescription drugs from Canada. In March 2022, FDA met with representatives from Colorado, Florida, Maine, New Mexico and Vermont to provide assistance in developing importation proposals. If implemented, importation of drugs from Canada may materially and adversely affect our business. The regulatory and market implications of the final rule and guidance are unknown at this time. Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation under certain circumstances. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for products and adversely affect our future revenues and prospects for profitability.
There can be no assurances that future changes to drug reimbursement policies, drug pricing and contracting practices outside of federal healthcare programs, or to government drug price regulation programs such as the Medicaid rebate, ASP, or 340B program will not have an adverse impact on our business.
If we fail to comply with laws and regulations in respect of healthcare fraud and abuse, we could suffer penalties or be required to make significant changes to our operations.
We are subject to extensive and frequently changing laws and regulations relating to healthcare fraud and abuse. The U.S. federal government continues to strengthen its scrutiny of practices potentially involving healthcare fraud affecting Medicare, Medicaid and other government healthcare programs. Our relationships with healthcare providers and pharmaceutical manufacturers subject our business to laws and regulations on fraud and abuse which, among other things, (i) prohibit persons from soliciting, offering, receiving or paying any remuneration in order to induce the referral of a patient for treatment or the ordering or purchasing of items or services that are in any way paid for by Medicare, Medicaid or other government-sponsored healthcare programs and (ii) impose a number of restrictions upon referring physicians and providers of designated health services under Medicare and Medicaid programs. Legislative provisions relating to healthcare fraud and abuse give federal enforcement personnel substantially increased funding, powers and remedies to pursue suspected fraud and abuse, and these enforcement authorities were further expanded by the ACA. Many states have enacted similar statutes which are not necessarily limited to items and services for which payment is made by federal healthcare programs. While we believe that we are in compliance with applicable laws and regulations, many of the regulations applicable to us, including those relating to certain
18
incentives offered in connection with sales of pharmaceutical products and related services, are vague or indefinite, and have not been interpreted by the courts. They may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our operations. If we fail to comply with applicable laws and regulations, we could be subject to administrative, civil and criminal penalties, including the loss of licenses or our ability to participate in Medicare, Medicaid, and other federal, state, or governmental healthcare programs.
Our business, results of operations, and cash flows could be adversely affected by legal proceedings.
Due to the nature of our operations, which we conduct through a variety of businesses, including the distribution of pharmaceuticals, the dispensing of healthcare products, and the provision of services to the pharmaceutical industry, each of our businesses may cause us to become involved in government investigations, legal disputes or proceedings. These investigations, disputes or proceedings have involved or may involve healthcare fraud and abuse, the False Claims Act, antitrust, class action, commercial, employment, environmental, intellectual property, licensing, public disclosures and various other claims, including claims related to opioid medications as discussed in the risk factor below.
Litigation is inherently unpredictable and the unfavorable outcome of legal proceedings could adversely affect our results of operations or financial condition. Litigation is costly, time-consuming, and disruptive to ordinary business operations. The defense and resolution of these current and future proceedings could have a material adverse effect on our results of operations and financial condition. Violations of various laws, including with respect to the marketing, sale, purchase, and dispensing of pharmaceutical products and the provision of services to the pharmaceutical industry, can result in criminal, civil, and administrative liability for which there can be significant financial damages, criminal and civil penalties, and possible exclusion from participation in federal and state health programs. Any settlement, judgment or fine could materially adversely affect our results of operations.
Statutory and/or regulatory violations could also form the basis for qui tam complaints. The qui tam provisions of the federal and various state civil False Claims Acts authorize a private person, known as a relator, to file civil actions under these statutes on behalf of the federal and state governments. Under False Claims Acts, the filing of a qui tam complaint by a relator imposes obligations on government authorities to investigate the allegations and determine whether or not to intervene in the action. Such cases may involve allegations around the marketing, sale, purchase, and/or dispensing of brand and/or generic pharmaceutical products or the provision of services to the pharmaceutical industry. Such complaints are filed under seal and remain sealed until the applicable court orders otherwise. Our business and results of operations could be adversely affected if qui tam complaints are filed against us for alleged violations of any health laws and regulations and damages arising from resultant false claims, if the litigation proceeds whether or not government authorities decide to intervene in any such matters, and/or if we are found liable for all or any portion of violations alleged in any such matters.
In fiscal 2018, we resolved potential civil claims and administrative action by entering into, among other things, a Corporate Integrity Agreement with the Office of Inspector General of the U.S. Department of Health and Human Services. The Corporate Integrity Agreement has a five-year term. Failure to comply with obligations under the Corporate Integrity Agreement could lead to monetary or other penalties.
Opioid-related legal proceedings and the comprehensive settlement agreement that we have entered into could adversely impact our cash flows or results of operations.
On July 21, 2021, we announced that AmerisourceBergen and the two other national pharmaceutical distributors had negotiated a comprehensive proposed settlement agreement that would result in the resolution of a substantial majority of opioid lawsuits filed by state and local governmental entities (the “Settlement Agreement”). On April 2, 2022, the Settlement Agreement became effective, and as of September 30, 2022, it included 48 of 49 eligible states (the “Settling States”), as well as 99% by population of the eligible political subdivisions in the Settling States. Pursuant to the Settlement Agreement and related agreements with Settling States, we will pay up to approximately $6.4 billion over 18 years and comply with other requirements, including establishment of a clearinghouse that will consolidate data from all three national distributors. The Settlement Agreement does not contemplate participation by any non-governmental or non-political entities or individuals. Our estimated liability related to the State of Alabama (with whom we have not reached a settlement agreement), as well as other opioid-related litigation for which we have reached settlements agreements, is approximately $0.4 billion.
Net of $0.8 billion of payments made through September 30, 2022,we have a $6.0 billion liability on our Consolidated Balance Sheet as of September 30, 2022 for litigation relating to the Settlement Agreement, as well as other opioid-related litigation. We currently estimate that $528.7 million will be paid prior to September 30, 2023, which is recorded in Accrued Expenses and Other on our Consolidated Balance Sheet. The remaining long-term liability of $5.5 billion is recorded in Accrued Litigation Liability on our Consolidated Balance Sheet. While we have accrued an estimated liability for opioid litigation, we are unable to estimate the range of possible loss associated with the matters that are not included in the settlement accrual. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the
19
assessment is highly subjective and requires judgments about future events, and the amount of ultimate loss may differ materially from the amount accrued to date. Until such time as otherwise resolved, we will continue to litigate and prepare for trial and to vigorously defend ourself in all such matters. Since these matters are still developing, we are unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief that may affect our operations, which could have a material adverse effect on our business, results of operations, and cash flows and could result in a lower than historical level of capital available for deployment, including a lower level of capital returned to stockholders. Further details on the Settlement Agreement and opioid litigation are provided in Note 13 of the Notes to Consolidated Financial Statements.
Public concern over the abuse of opioid medications, including increased legal and regulatory action, could negatively affect our business.
Certain governmental and regulatory agencies, as well as state and local jurisdictions, are focused on the abuse of opioid medications in the United States. Federal, state and local governmental and regulatory agencies are conducting investigations of us and others in the pharmaceutical supply chain, including pharmaceutical manufacturers, national retail pharmacy chains, independent pharmacies, prescribers, and other pharmaceutical wholesale distributors, regarding the manufacture, dispensing, and distribution of opioid medications. In addition, a significant number of lawsuits have been filed against us, other pharmaceutical wholesale distributors, and others in the pharmaceutical supply chain by state and local governmental entities and other plaintiffs for claims related to the Company’s distribution of opioid medications. The lawsuits against us and other pharmaceutical wholesale distributors allege, among other claims, that we failed to provide effective controls and procedures to guard against the diversion of controlled substances, acted negligently by distributing controlled substances to pharmacies that serve individuals who abuse controlled substances, and failed to report suspicious orders of controlled substances in accordance with regulations. Additional governmental and regulatory entities have indicated an intent to sue and may conduct investigations of us in the future, and lawsuits could be brought against the Company by other plaintiffs under other theories related to opioid abuse. We are deeply committed to diversion control efforts, have sophisticated systems to identify orders placed warranting further review to determine if they are suspicious (including through the use of data analytics), and engage in due diligence and ongoing monitoring of customers. In addition to the claims brought by states and other local governmental entities, we are also being sued by private plaintiffs, such as unions, other health and welfare funds, hospital systems, third party payors, other healthcare providers and individuals alleging personal injury for the same activities, and continue to be named as a defendant in additional lawsuits.
In April 2022, the Settlement Agreement described above, which settles the vast majority of opioid-related lawsuits filed against us by state and local governmental entities, became effective. The Settlement Agreement includes a cash component, pursuant to which we will pay up to approximately $6.4 billion, the majority of which we expect to be paid over 18 years. The Settlement Agreement also includes injunctive relief terms relating to distributors’ controlled substance anti-diversion programs, including with respect to: (i) governance; (ii) independence and training of the personnel operating controlled substances monitoring programs; (iii) due diligence for new and existing customers; (iv) ordering limits for certain products; and (v) suspicious order monitoring. A monitor will oversee compliance with these provisions for a period of five years. In addition, the distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting, which the distributors will fund for ten years. It is possible that the implementation and maintenance of the required changes to distributors’ controlled substance anti-diversion programs may result in unforeseen costs or operational challenges which could have an adverse impact on our results of operations or performance.
Legislative, regulatory or industry measures to address the misuse of prescription opioid medications may also affect our business in ways that we are not be able to predict. Certain jurisdictions have enacted, and others are considering, legislation that could require entities to pay an assessment or tax on the sale or distribution of opioid medications in those states. If additional state or local jurisdictions enact legislation that taxes or assesses the sale or distribution of opioid medications and we are not able to mitigate the impact on our business through operational changes or commercial arrangements where permitted, such legislation in the aggregate may have a material adverse effect on the Company’s results of operations, cash flows, or financial condition.
Ongoing unfavorable publicity regarding the abuse or misuse of prescription opioid pain medications and the role of wholesale distributors in the supply chain of such prescription medications, as well as the continued proliferation of the opioid lawsuits, investigations, regulations and legislative actions, and unfavorable publicity in relation to those lawsuits could continue to have a material adverse effect on our reputation or results of operations.
Tax legislation or challenges to our tax positions could adversely affect our results of operations and financial condition.
We are subject to tax laws and regulations of the U.S. federal, state and local governments, and various foreign jurisdictions. From time to time, various legislative initiatives may be proposed that could adversely affect our tax positions and/or our tax liabilities. In August 2022, the U.S. Inflation Reduction Act of 2022 was signed into law. This law, among other
20
things, provides for a corporate alternative minimum tax on adjusted financial statement income and an excise tax on corporate stock repurchases. We are continuing to evaluate the impact this new law may have on our financial position and results of operations. In addition, there are several proposed changes to U.S. and non-U.S. tax legislation, which if enacted, could have a negative impact on our effective tax rate. Foreign governments may enact tax laws that could result in further changes to global taxation that could materially affect our financial position and results of operations. In addition, we are subject to the continuous examination of our income tax returns by the U.S. Internal Revenue Service and other tax authorities. We regularly assess the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of our provision for income taxes. These examinations may result in unforeseen tax-related liabilities, which may harm our future financial results.
An increasing number of states and foreign jurisdictions have adopted laws or administrative practices, that impose new taxes on all or a portion of gross revenue or other similar amounts or impose additional obligations to collect transaction taxes such as sales, consumption, value added, or similar taxes. We may not have sufficient lead time to build systems and processes to collect these taxes properly, or at all. Failure to comply with such laws or administrative practices, or a successful assertion by such states or foreign jurisdictions requiring us to collect taxes where we do not, could result in material tax liabilities, including for past sales, as well as penalties and interest.
There can be no assurance that our effective tax rate or tax payments will not be adversely affected by legislation resulting from these initiatives both within the United States and other foreign jurisdictions in which we operate. In addition, tax laws and regulations are extremely complex and subject to varying interpretations. While we believe that our historical tax positions are consistent with applicable laws, regulations, and existing precedent, there can be no assurance that our tax positions will not be challenged by relevant tax authorities or that we would be successful in any such challenge.
Due to the potential for changes to tax laws and regulations or changes to the interpretation thereof, the ambiguity of tax laws and regulations, the subjectivity of factual interpretations, the complexity of our business and intercompany arrangements, uncertainties regarding the geographic mix of earnings in any particular period, and other factors, material adjustments to our tax estimates may impact our provision for income taxes and our earnings per share, as well as our cash flows.
Violations of anti-bribery, anti-corruption, and/or international trade laws to which we are subject could have a material adverse effect on our business, financial position, and results of operations.
We are subject to laws concerning our business operations and marketing activities in foreign countries where we conduct business. For example, we are subject to the U.S. Foreign Corrupt Practices Act (the “FCPA”), U.S. export control and trade sanction laws, and similar anti-corruption and international trade laws in certain foreign countries, such as the U.K. Bribery Act, any violation of which could create substantial liability for us and also cause a loss of reputation in the market. We may also have substantial liability if a third party acting on our behalf or on the behalf of our subsidiaries (including our joint venture partners) is in violation of these laws. The FCPA generally prohibits U.S. companies and their officers, directors, employees, and intermediaries from making improper payments to foreign officials for the purpose of obtaining or retaining business abroad or otherwise obtaining favorable treatment. The FCPA also requires that U.S. public companies maintain books and records that fairly and accurately reflect transactions and maintain an adequate system of internal accounting controls. If we are found to have violated the FCPA, we may face sanctions including civil and criminal fines, disgorgement of profits, and suspension or debarment of our ability to contract with government agencies or receive export licenses. We have business operations in many countries worldwide, including business operations in Egypt (through our 50%-owned Alliance Healthcare Egypt subsidiary) as well as Brazil and Turkey, and other countries that are considered to have business environments with higher risk of conduct that could give rise to potential violations and liabilities. From time to time, we may face audits or investigations by one or more domestic or foreign government agencies relating to our international business activities, compliance with which could be costly and time-consuming, and could divert our management and key personnel from our business operations. An adverse outcome under any such investigation or audit could subject us to fines or other penalties, which could adversely affect our business, financial position, and results of operations.
Our actual or perceived failure to adequately protect personal data could result in claims of liability against us, damage our reputation or otherwise materially harm our business.
Given the nature of our business, we, together with third parties acting on our behalf, receive, collect, process, use, and retain sensitive and confidential customer and employee data, in addition to proprietary business information. Some of our third-party service providers, such as identity verification and payment processing providers, also regularly have access to customer data. Additionally, we maintain other confidential, proprietary, or otherwise sensitive information relating to our business and from third parties.
Global privacy, cybersecurity and data protection-related laws and regulations are evolving, extensive, and complex. Compliance with these laws and regulations is difficult and costly. The interpretation and application of these laws in some
21
instances is uncertain, and our legal and regulatory obligations are subject to frequent changes. We are required to comply with increasingly complex and changing data privacy regulations both in the United States and beyond that regulate the collection, use, security, processing, and transfer of personal data, including particularly the transfer of personal data between or among countries. Many of these regulations also grant rights to individuals. Many foreign data privacy regulations (including, without limitation, GDPR in the European Union, UK GDPR, Brazil’s General Data Protection Law, LGPD, and the Personal Information Protection and Electronic Documents Act in Canada) and certain state laws and regulations (including California’s CCPA and recently enacted consumer privacy laws in Colorado, Connecticut, Utah, and Virginia) impose requirements beyond those enacted under United States federal law including, in some instances, private rights of action. For example, the EU GDPR imposes more stringent data protection requirements, including a broader scope of protected data, restrictions on cross-border transfers of personal data and more onerous breach reporting requirements, and the EU GDPR imposes greater penalties for non-compliance than the federal data protection laws in the United States. Other states and countries continue to enact similar legislation. We are also required to comply with expanding and increasingly complex cybersecurity regulations in the United States and abroad with respect to reporting adverse events and additional requirements for avoiding or responding to an adverse event. We may also face audits or investigations by domestic or foreign government agencies relating to our compliance with these regulations. An adverse outcome under any such investigation or audit could subject us to fines or other penalties. We also have contractual obligations to our customers related to the protection of personal data and compliance with privacy laws. The foregoing or other circumstances related to our collection, use, and transfer of personal data could cause a loss of reputation in the market and/or adversely affect our business and financial position.
Other Risks
The loss or disruption of information systems could disrupt our operations and have a material adverse effect on our business.
Our businesses rely on sophisticated information systems to obtain, rapidly process, analyze, and manage data to facilitate the purchase and distribution of thousands of inventory items from numerous distribution centers; to receive, process, and ship orders on a timely basis; to account for other product and service transactions with customers; to manage the accurate billing and collections for thousands of customers; and to process payments to suppliers. We continue to make substantial investments in data centers and information systems, including, but not limited to, those relating to our acquisition of Alliance Healthcare. To the extent our information systems are not successfully implemented or fail, or to the extent there are data center interruptions or outages, our business and results of operations may be materially adversely affected. Our business and results of operations may also be adversely affected if a third-party service provider does not perform satisfactorily, or if the information systems are interrupted or damaged by unforeseen events, including due to the actions of third parties.
Information security risks have generally increased in recent years because of the proliferation of cloud-based infrastructure and other services, new technologies, and the increased sophistication and activities of perpetrators of cyber-attacks. Security incidents such as ransomware attacks are becoming increasingly prevalent and severe, as well as increasingly difficult to detect. These risks have increased with the growth of our business, including as we integrate the information systems of acquired businesses, such as Alliance Healthcare, into our enterprise.
In addition, security incidents may require that we expend substantial additional resources related to the security of information systems and disrupt our businesses. We, and our third-party service providers, may experience cyberattacks aimed at disrupting services. Security breaches can also occur as a result of non-technical issues, including intentional or inadvertent actions by our employees, third-party service providers or their personnel or other parties. A failure, interruption, or breach of our operational or information security systems, or those of our third-party service providers, as a result of cyber-attacks or information security breaches could disrupt our business, result in the disclosure or misuse of confidential or proprietary information or personal data, damage our reputation, cause loss of customers or revenue, increase our costs, result in litigation and/or regulatory action, and/or cause other losses, any of which might have a materially adverse impact on our business operations and our financial position or results of operations. As a result, cyber security and the continued development and enhancement of the controls and processes designed to protect our systems, computers, software, data, and networks from attack, damage, or unauthorized access remain a priority for us. Although we believe that we have robust information security procedures, controls and other safeguards in place, as cyber threats continue to evolve, we may be required to expend additional resources to continue to enhance our information security measures and/or to investigate and remediate information security vulnerabilities.
Our failure to protect our reputation could have a material adverse effect on our business and operations.
We believe that maintaining and enhancing our reputation is critical to our ability to expand and retain our customer base, strategic partnerships and other key relationships. Any negative publicity about us or the industry in which we operate we offer may adversely impact our business and operations. Furthermore, failure to comply with ethical, social, product, labor, health and safety, accounting, or environmental standards could also jeopardize our reputation and potentially lead to various
22
adverse actions, including litigation. Negative claims or publicity, including those made on social media, also could adversely affect our reputation and business, regardless of whether such claims are accurate.
Our reputation may also depend on the success of our environmental, social and governance (“ESG”) initiatives, inclusive of sustainability, social impact and corporate responsibility, which require company-wide coordination and alignment. Risks associated with these initiatives include increased focus on ESG targets, goals and disclosure, including by governmental and nongovernmental organizations, increased costs associated with sustainability efforts, and compliance with laws and regulations. All of the foregoing could expose us to market, operational and execution costs or risks. Any ESG or sustainability metrics that we currently or may in the future disclose, whether based on the standards we set for ourselves or those set by others, may influence our reputation and the value of our brands. There is also increased focus, including by investors, customers, and other stakeholders, on ESG matters, including the use of materials, climate change, waste generation, supply chain, human capital, health equity and worker safety. Our reputation could be damaged if we do not, or are perceived to not, act responsibly with respect to sustainability matters, which could also have a material adverse effect on our business, results of operations, financial position, and cash flows.
We face risks related to health epidemics and pandemics, and the ongoing COVID-19 pandemic has had adverse effects on our business.
We face risks related to health epidemics and pandemics, including risks related to any responses thereto by the federal, state or foreign governments as well as customers and suppliers. The COVID-19 pandemic has adversely affected our operations, supply chains and distribution network, and we have experienced and expect to continue to experience unpredictable reductions in supply and demand for certain of our products and services. Further, it is possible that the manufacturers that produce the products that we distribute may experience delays or shutdowns due to COVID-19, such as from disruptions in their supply chains or in a suspension of production at their own facilities. Accordingly, we expect the impacts of the ongoing COVID-19 pandemic to adversely affect the supply of products and/or potentially disrupt our ability to deliver products to customers. The implementation of any government-mandated vaccination or testing mandates may impact our ability to retain current employees and attract new employees. Any extended disruption in our ability to service our customers could have a material adverse effect on our revenue, results of operations, and cash flows.
Our management of the impact of COVID-19 has and will continue to require significant investment of time from our management and employees, as well as resources across our global enterprise. This may cause us to divert or delay the application of our resources toward new initiatives or investments, which may adversely impact our future results of operations. In addition, issues relating to the COVID-19 pandemic may result in legal claims or litigation against us. We also face risks related to a downturn in our customers’ respective businesses, including the operations of retail pharmacy and health systems customers due to COVID-19. An economic slowdown or recession related to COVID-19 may affect our customers’ ability to obtain credit to finance their business on acceptable terms, which could, in turn, result in reduced spending.
The extent to which the COVID-19 pandemic continues to impact our results of operations and financial condition will depend on future developments that are highly uncertain and cannot be predicted, including the resurgence of COVID-19 and its variants in regions recovering from the impacts of the pandemic, the effectiveness of COVID-19 vaccines and the speed at which populations are vaccinated around the globe, the impact of COVID-19 on economic activity and regulatory actions taken to contain the impact of COVID-19 on public health and the global economy. We have implemented measures designed to keep our employees safe and have protocols in place to address business continuity issues at our distribution centers and other locations, but a widespread or sustained outbreak of COVID-19 at one or more locations could disrupt our ability to service our customers or attract and retain the necessary workforce. The impact of COVID-19 may also exacerbate other risks discussed in this Risk Factors section, any of which could have a material effect on us.
Our goodwill, indefinite-lived intangible assets, or long-lived assets may become impaired, which may require us to record a further significant charge to earnings in accordance with generally accepted accounting principles.
U.S. generally accepted accounting principles (“GAAP”) require us to test our goodwill and indefinite-lived intangible assets for impairment on an annual basis, or more frequently if indicators for potential impairment exist. Indicators that are considered include significant changes in performance relative to expected operating results, significant negative industry or economic trends, including rising interest rates, or a significant decline in our stock price and/or market capitalization for a sustained period of time. In addition, we periodically review our intangible and long-lived assets for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. Factors that may be considered a change in circumstances indicating that the carrying value of our long-lived assets may not be recoverable include slower growth rates, the loss of a significant customer, or divestiture of a business or asset for below its carrying value. The testing required by GAAP involves estimates and judgments by management.
23
For example, as a result of a prolonged decline in Profarma’s stock price, we performed an impairment assessment over our Profarma reporting unit as of June 30, 2022. As a result of the June 30, 2022 interim test, we recorded a $75.9 million impairment to goodwill in fiscal 2022. We may be required to record a significant charge to earnings in our consolidated financial statements during the period in which any impairment of our goodwill, indefinite-lived intangible assets, or long-lived assets is determined. Any such charge could have a material adverse impact on our results of operations.
Natural disasters or other unexpected events, including those related to climate change, may disrupt our operations, adversely affect our results of operations and financial condition, and may not be covered by insurance.
We continue to focus on strategies and systems, such as reducing greenhouse gas emissions and packaging waste, to address climate change. However, we face climate and environmental risks and the occurrence of one or more unexpected events, including fires, tornadoes, tsunamis, hurricanes, earthquakes, drought, storms, sea level rise, floods, and other severe hazards or accidents in the United States, the United Kingdom, the European Union or in other countries or regions in which we operate could adversely affect our operations and financial performance. Extreme weather, natural disasters, power outages, or other unexpected events could result in physical damage to and complete or partial closure of one or more of distribution centers or outsourcing facilities, temporary or long-term disruption in the supply of products, delay in the delivery of products to our distribution centers, and/or disruption of our ability to deliver products to customers. Current or future insurance arrangements may not provide protection for costs that may arise from such events, particularly if such events are catastrophic in nature or occur in combination. Further, the long-term effects of climate change on general economic conditions and the pharmaceutical distribution industry in particular are unclear, and changes in the supply, demand, or available sources of energy and the regulatory and other costs associated with energy production and delivery may affect the availability or cost of goods and services, including natural resources, necessary to run our businesses. Any long-term disruption in our ability to service our customers from one or more distribution centers or outsourcing facilities could have a material adverse effect on our operations.
ITEM 1B.    UNRESOLVED STAFF COMMENTS
None.
ITEM 2.    PROPERTIES
As of September 30, 2022, we conducted our business from office and operating facilities at owned and leased locations throughout the United States (including Puerto Rico) and select global markets. We lease a facility in Conshohocken, Pennsylvania for our corporate headquarters.
U.S. Healthcare Solutions’ human health distribution businesses have a robust distribution facility network in the United States. Significant leased facilities are located in Puerto Rico plus the following states: Arizona, Colorado, Florida, Georgia, Hawaii, Indiana, Kentucky, Minnesota, Mississippi, New York, North Carolina, Utah, and Washington. Owned facilities are located in the following states: Alabama, California, Illinois, Massachusetts, Michigan, Missouri, Ohio, Pennsylvania, Texas, and Virginia.
As of September 30, 2022, our animal health business operations were conducted in the United States and in the United Kingdom. Leased facilities are located in California, Colorado, Florida, Idaho, Indiana, Kansas, Massachusetts, Minnesota, North Carolina, Pennsylvania, Texas, Washington, and internationally in the United Kingdom. Significant owned facilities are located in Alabama, Idaho, Texas, and Virginia and internationally in the United Kingdom. Its headquarters is located in Idaho.
As of September 30, 2022, the International Healthcare Solutions distribution operations were conducted in the Czech Republic, Egypt, France, Lithuania, Netherlands, Norway, Romania, Spain, Turkey, and the United Kingdom. Its global specialty transportation and logistics operating facilities are located in over 50 countries. The International Healthcare Solutions businesses have leased and owned properties.
We consider our operating and office properties to be in satisfactory condition.
ITEM 3.    LEGAL PROCEEDINGS
Legal proceedings in which we are involved are discussed in Note 13 (Legal Matters and Contingencies) of the Notes to Consolidated Financial Statements appearing in this Annual Report on Form 10-K.
ITEM 4.    MINE SAFETY DISCLOSURES
Not applicable.
24
INFORMATION ABOUT OUR EXECUTIVE OFFICERS
The following is a list of our executive officers and their ages and positions as of November 15, 2022.
NameAgeCurrent Position with the Company
Steven H. Collis61Chairman, President, and Chief Executive Officer
Silvana Battaglia55Executive Vice President and Chief Human Resources Officer
Elizabeth S. Campbell48Executive Vice President and Chief Legal Officer
Gina K. Clark65Executive Vice President and Chief Communications & Administration Officer
James F. Cleary59Executive Vice President and Chief Financial Officer
Leslie E. Donato53Executive Vice President and Chief Strategy Officer
Robert P. Mauch55Executive Vice President and Chief Operating Officer
Unless indicated to the contrary, the business experience summaries provided below for our executive officers describe positions held by the named individuals during the last five years.
Mr. Collis has been President and Chief Executive Officer of the Company since July 2011 and Chairman since March 2016. From November 2010 to July 2011, he served as President and Chief Operating Officer. He served as Executive Vice President and President of AmerisourceBergen Drug Corporation from September 2009 to November 2010. He was Executive Vice President and President of AmerisourceBergen Specialty Group from September 2007 to September 2009 and was Senior Vice President of the Company and President of AmerisourceBergen Specialty Group from August 2001 to September 2007. Mr. Collis has been employed by the Company or one of its predecessors for over 25 years.
Ms. Battaglia has been Executive Vice President and Chief Human Resources Officer since January 2019. Prior to joining the Company, she worked at Aramark as Senior Vice President of Global Compensation, Benefits, and Labor Relations from August 2017 to December 2018 and as Senior Vice President, Global Field Human Resources from May 2011 to August 2017. She also previously worked for Day & Zimmerman and Merck Corporation.
Ms. Campbell was named Executive Vice President and Chief Legal Officer in September 2021. She served as Senior Vice President and Deputy General Counsel from June 2020 to August 2021. Prior to that, Ms. Campbell served in a variety of roles within the Company’s legal department with increased responsibility, including serving as Chief Litigator and Chief Compliance Counsel. Ms. Campbell has been employed by the Company for 12 years.
Ms. Clark has been Executive Vice President since November 2014 and became Chief Communication & Administration Officer in June 2017. She served as Chief Marketing Officer from November 2014 to June 2017. Ms. Clark was named Senior Vice President and Chief Marketing Officer in June 2011. She previously served as Senior Vice President of Marketing and Business Development for AmerisourceBergen Specialty Group from January 2007 to June 2011. Prior to joining the Company, she worked in executive leadership roles at Premier Inc. and HealthSouth, including Senior Vice President of Marketing and Alliance Relations, Group Vice President of Relationship Management, and Senior Vice President of Managed Care and National Contracting.
Mr. Cleary has been Executive Vice President since March 2015 and became Chief Financial Officer in November 2018. He served as Group President, Global Commercialization Services & Animal Health from June 2017 to November 2018. He previously served as President, MWI Animal Health from March 2015 to June 2017. Prior to joining the Company, he was President and Chief Executive Officer of MWI Veterinary Supply, Inc. from June 2002.
Ms. Donato has been Executive Vice President and Chief Strategy Officer since July 2019. Prior to joining the Company, she held various leadership roles at Bayer from May 2009 to May 2019, including Vice President of Strategy, Pharmaceuticals Division, Vice President of Strategy, Bayer Healthcare US, and Vice President & General Manager of Neurology & Hematology. She also worked for McKinsey & Company where she was a Partner in the Healthcare Practice.
Mr. Mauch has been Executive Vice President since February 2015 and became Chief Operating Officer effective October 2022. He served as Group President from February 2019 to September 2022. He served as Group President, Pharmaceutical Distribution & Strategic Global Sourcing from June 2017 to February 2019. He served as President, AmerisourceBergen Drug Corporation from February 2015 to June 2017. Mr. Mauch served as Senior Vice President Chief Operating Officer, AmerisourceBergen Drug Corporation from March 2014 to February 2015. He was Senior Vice President, Operations, AmerisourceBergen Drug Corporation from April 2012 to March 2014. He was Senior Vice President of Sales and Marketing, AmerisourceBergen Drug Corporation from April 2011 to April 2012. He was Senior Vice President, Alternate
25
Care Sales and Marketing, AmerisourceBergen Drug Corporation from May 2010 to April 2011. Mr. Mauch has been employed by the Company or one of its predecessors for over 25 years.
PART II
ITEM 5.    MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
The Company's common stock is traded on the New York Stock Exchange under the trading symbol "ABC." As of October 31, 2022, there were 2,246 record holders of the Company's common stock.
Our board of directors approved the following quarterly dividend increases:
Dividend Increases
 Per Share 
DateNew RateOld Rate% Increase
January 2020$0.420$0.4005%
November 2020$0.440$0.4205%
November 2021$0.460$0.4405%
November 2022$0.485$0.4605%
Computershare is the Company's transfer agent. Computershare can be reached at (mail) AmerisourceBergen Corporation c/o Computershare, P.O. Box 50500, Louisville, KY 40233-500; (telephone): Domestic 1-800-522-6645, International 1-201-680-6578, and (internet) www.computershare.com/investor.
26
ISSUER PURCHASES OF EQUITY SECURITIES
The following sets forth the total number of shares purchased, the average price paid per share, the total number of shares purchased as part of publicly announced programs, and the approximate dollar value of shares that may yet be purchased under the programs during each month during the quarter ended September 30, 2022.

PeriodTotal Number
of Shares
Purchased		Average
Price
Paid Per
Share		Total Number of
Shares Purchased
as Part of Publicly
Announced
Programs		Approximate
Dollar Value of
Shares that May
Yet Be Purchased
Under the
Programs
July 1 to July 31667,394 $141.99 650,000 $1,121,012,207 
August 1 to August 31156,456 142.58 155,600 $1,098,826,425 
September 1 to September 30998,988 137.81 997,676 $961,344,059 
Total1,822,8381,803,276  
________________________________________________
(a)In May 2020, the Company's board of directors authorized a share repurchase program allowing the Company to purchase up to $500 million of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2022, the Company purchased 3.3 million shares of its common stock for a total of $473.4 million to complete its authorization under this program.
(b)In May 2022, the Company's board of directors authorized a new share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2022, the Company purchased 0.3 million shares of its common stock for a total of $38.7 million, which included $28.4 million of September 2022 purchases that cash settle in October 2022. As of September 30, 2022, the Company had $961.3 million of availability remaining under this program. In October 2022, under this program, the Company purchased 0.6 million shares of its common stock for $78.8 million. In November 2022, under this program, the Company purchased 3.2 million shares of its common stock from WBA for $500.0 million.
(c)Employees surrendered 305,266 shares during the fiscal year ended September 30, 2022 to meet minimum tax-withholding obligations upon vesting of restricted stock.
27
STOCK PERFORMANCE GRAPH
This graph depicts the Company's five-year cumulative total stockholder returns relative to the performance of the Standard and Poor's 500 Composite Stock Index, the S&P Health Care Index, and an index of peer companies selected by the Company from the market close on September 30, 2017 to September 30, 2022. The graph assumes $100 invested at the closing price of the common stock of the Company and of each of the other indices on the New York Stock Exchange on September 30, 2017. The points on the graph represent fiscal year-end index levels based upon the last trading day in each fiscal year. The Peer Group index (which is weighted on the basis of market capitalization) consists of the following companies engaged primarily in wholesale pharmaceutical distribution and related services: McKesson Corporation and Cardinal Health, Inc.abc-20220930_g1.gif

September 30,
201720182019202020212022
AmerisourceBergen Corporation$100.00 $113.40 $103.16 $123.64 $154.80 $177.67 
S&P 500$100.00 $117.91 $122.93 $141.55 $184.02 $155.55 
S&P Health Care$100.00 $118.35 $114.13 $137.08 $168.00 $162.34 
Peer Group$100.00 $85.72 $85.10 $91.71 $115.22 $186.11 
* $100 invested on September 30, 2017 in stock or index, including reinvestment of dividends.







28
ITEM 6.    [RESERVED]
Cautionary Note Regarding Forward-Looking Statements
Certain of the statements contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Words such as “aim,” “anticipate,” “believe,” “can,” “continue,” “could,”, “estimate,” "expect," “intend,” “may,” “might,” “on track,” “opportunity,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “sustain,” “synergy,” “target,” “will,” “would” and similar expressions may identify are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.
Forward-looking statements in this Annual Report on Form 10-K may include, for example, statements about the following:
•The effect of and uncertainties related to the ongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic;
•our ability to achieve and maintain profitability in the future;
•our ability to respond to general economic conditions, including elevated levels of inflation;
•our ability to manage our growth effectively and our expectations regarding the development and expansion of our business;
•the impact on our business of the regulatory environment and complexities with compliance;
•unfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;
•competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;
•changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals;
•increasing governmental regulations regarding the pharmaceutical supply channel;
•continued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances;
•continued prosecution or suit by federal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder derivative lawsuits;
•increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs;
•failure to comply with the Corporate Integrity Agreement;
•the outcome of any legal or governmental proceedings that may be instituted against us, including material adverse resolution of pending legal proceedings;
•the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers;
•changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;
•the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or that their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex;
•unexpected costs, charges or expenses resulting from the acquisition of PharmaLex;
•the integration of the Alliance Healthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected;
•the Company's, Alliance Healthcare's, or PharmaLex's failure to achieve expected or targeted future financial and operating performance and results;
•the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with employees, suppliers and other business partners;
•the acquisition of businesses, including the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the
29
inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period;
•risks associated with the strategic, long-term relationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;
•managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;
•our ability to respond to financial market volatility and disruption;
•changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions;
•the loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19;
•financial and other impacts of COVID-19 on our operations or business continuity;
•changes to the customer or supplier mix;
•malfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated with cybersecurity;
•risks generally associated with data privacy regulation and the international transfer of personal data;
•financial and other impacts of macroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications;
•natural disasters or other unexpected events, such as additional pandemics, that affect the Company’s operations;
•the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;
•the Company's ability to manage and complete divestitures;
•the disruption of the Company’s cash flow and ability to return value to its stockholders in accordance with its past practices;
•interest rate and foreign currency exchange rate fluctuations;
•declining economic conditions and increases in inflation in the United States and abroad; and
•other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company’s business generally.
These forward-looking statements are based on information available as of the date of this Annual Report on Form 10-K and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. You should not place undue reliance on these forward-looking statements.












30

ITEM 7.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Overview
The following discussion should be read in conjunction with the Consolidated Financial Statements and notes thereto contained herein.
We are one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.
We are organized geographically based upon the products and services we provide to our customers. At the beginning of fiscal 2022, we re-aligned our reporting structure under two reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions. U.S. Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable segment (excluding Profarma Distribuidora de Produtos Farmacêuticos S.A.("Profarma")), MWI Animal Health ("MWI"), Xcenda, Lash Group, and ICS 3PL. International Healthcare Solutions consists of Alliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). Profarma had previously been included in the Pharmaceutical Distribution Services reportable segment. Our previously reported segment results have been revised to conform to our re-aligned reporting structure.
U.S. Healthcare Solutions Segment
The U.S. Healthcare Solutions reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The U.S. Healthcare Solutions reportable segment also provides pharmaceutical distribution (including plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. Additionally, the U.S. Healthcare Solutions reportable segment provides data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The U.S. Healthcare Solutions reportable segment also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of retail and institutional healthcare providers. It also provides a full suite of integrated manufacturer services that ranges from clinical trial support to product post-approval and commercialization support. Additionally, it delivers packaging solutions to institutional and retail healthcare providers. Through its animal health business, the U.S. Healthcare Solutions reportable segment sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. It also offers demand-creating sales force services to manufacturers.
International Healthcare Solutions Segment
The International Healthcare Solutions reportable segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. The International Healthcare Solutions reportable segment distributes pharmaceuticals, other healthcare products, and related services to healthcare providers, including pharmacies, doctors, health centers and hospitals primarily in Europe. It also is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. In Canada, the business drives innovative partnerships with manufacturers, providers, and pharmacies to improve product access and efficiency throughout the healthcare supply chain.






31
Recent Development
PharmaLex Acquisition
In September 2022, we entered into a definitive agreement to acquire PharmaLex Holding GmbH ("PharmaLex"), a leading provider of specialized services for the life sciences industry, for €1.28 billion in cash, subject to customary adjustments. PharmaLex's services include regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality management and compliance. The acquisition will advance our role as a partner of choice for biopharmaceutical manufacturers by enhancing our global portfolio of solutions to support manufacturer partners across the pharmaceutical development and commercialization journey. PharmaLex will be a component of our International Healthcare Solutions reportable segment. The acquisition is expected to close by March 2023 and is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals.
Executive Summary
This executive summary provides highlights from the results of operations that follow:
•Revenue increased by $24.6 billion, or 11.5%, from the prior fiscal year, primarily due to our June 2021 acquisition of Alliance Healthcare and revenue growth in our U.S. Healthcare Solutions segment. Revenue in International Healthcare Solutions increased by $15.0 billion, or 129.8%, from the prior fiscal year primarily due to the June 2021 acquisition of Alliance Healthcare. The U.S. Healthcare Solutions segment grew its revenue $9.6 billion, or 4.8%, from the prior fiscal year primarily due to overall market growth principally driven by unit volume growth and increased sales to specialty physician practices, offset in part by a decline in sales of COVID-19 treatments (primarily commercial treatments);
•Total gross profit increased by $1,353.1 million, or 19.5%, from the prior fiscal year. Gross profit was favorably impacted by increases in gross profit in International Healthcare Solutions of $1,404.7 million, or 91.1%, and U.S. Healthcare Solutions of $425.8 million, or 8.5%, from the prior fiscal year. Gross profit in International Healthcare Solutions increased from the prior fiscal year primarily due to the June 2021 acquisition of Alliance Healthcare. U.S. Healthcare Solutions' gross profit increased from the prior fiscal year primarily due to overall revenue growth and fees earned relating to the distribution of government-owned COVID-19 treatments. These increases were offset in part by last-in, first-out ("LIFO") expense in comparison to a LIFO credit in the prior year, decreases in gains from antitrust litigation settlements, and the Turkey highly inflationary economy's unfavorable impact on the current fiscal year;
•Total operating expenses increased by $1,341.0 million, or 29.2%, from the prior fiscal year primarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization expense primarily due to the June 2021 acquisition of Alliance Healthcare, as well as a $75.9 million goodwill impairment of our Profarma reporting unit, offset in part by lower expense accruals related to opioid litigation settlements in the current fiscal year;
•Total segment operating income increased by $515.2 million, or 19.5%, from the prior fiscal year primarily due to the June 2021 acquisition of Alliance Healthcare and 8.8% operating income growth in the U.S. Healthcare Solutions segment; and
•Our effective tax rates were 23.7% and 30.5% for the fiscal years ended September 30, 2022 and 2021, respectively. The effective tax rate in the fiscal year ended September 30, 2022 was higher than the U.S. statutory rate primarily due to U.S. state income taxes, offset in part by the benefit of non-U.S. income taxed at rates lower than the U.S. statutory rate. Our effective tax rate in the fiscal year ended September 30, 2021 was higher than the current year tax rate primarily due to UK and Swiss tax reforms (see Note 4 of the Notes to Consolidated Financial Statements).


32
Results of Operations
Fiscal Year Ended September 30, 2022 compared to the Fiscal Year Ended September 30, 2021
Revenue
 Fiscal Year Ended
September 30,
(dollars in thousands)20222021Change
U.S. Healthcare Solutions
Human Health207,284,444 197,777,128 4.8%
Animal Health4,815,758 4,684,417 2.8%
Total U.S. Healthcare Solutions212,100,202 202,461,545 4.8%
International Healthcare Solutions
Alliance Healthcare21,890,402 7,373,365 196.9%
Other Healthcare Solutions4,601,271 4,156,264 10.7%
Total International Solutions26,491,673 11,529,629 129.8%
Intersegment eliminations(4,869)(2,331)
Revenue$238,587,006 $213,988,843 11.5%
Our future revenue growth will continue to be affected by various factors, such as industry growth trends, including drug utilization, the introduction of new, innovative brand therapies, the likely increase in the number of generic drugs and biosimilars that will be available over the next few years as a result of the expiration of certain drug patents held by brand-name pharmaceutical manufacturers and the rate of conversion from brand products to those generic drugs and biosimilars, price inflation and price deflation, general economic conditions in the United States and Europe, competition within the industry, customer consolidation, changes in pharmaceutical manufacturer pricing and distribution policies and practices, increased downward pressure on government and other third-party reimbursement rates to our customers, changes in government rules and regulations, foreign currency conversion rates, and the impact of the COVID-19 pandemic.
Revenue increased by 11.5% from the prior fiscal year primarily due to our June 2021 acquisition of Alliance Healthcare and the revenue growth of our U.S. Healthcare Solutions segment.
The U.S. Healthcare Solutions segment grew its revenue by $9.6 billion, or 4.8%, from the prior fiscal year, primarily due to overall market growth principally driven by unit volume growth and increased sales to specialty physician practices, offset in part by a decline in sales of COVID-19 treatments (primarily commercial treatments).
More specifically, the increase in the U.S. Healthcare Solutions segment revenue was largely attributable to the following (in billions):
Increased sales to specialty physician practices$2.9
Decreased sales of COVID-19 treatments($2.0)
Increased sales to other customers$8.7
The continued decline of sales relating to COVID-19 treatments and fees earned from the distribution of government-owned COVID-19 treatments could adversely impact our results of operations.
Revenue in International Healthcare Solutions increased by $15.0 billion, or 129.8%, from the prior fiscal year primarily due to the June 2021 acquisition of Alliance Healthcare.
A number of our contracts with customers, including group purchasing organizations, are typically subject to expiration each year. We may lose a significant customer if an existing contract with such customer expires without being extended, renewed, or replaced. During the fiscal year ended September 30, 2022, no significant contracts expired. In January 2022, we extended our agreement with Express Scripts through September 2026. Over the next twelve months, there are no significant contracts scheduled to expire. Additionally, from time to time, significant contracts may be terminated in accordance with their terms or extended, renewed, or replaced prior to their expiration dates. If those contracts are extended, renewed, or replaced at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.
33
Gross Profit
 Fiscal Year Ended
September 30,
(dollars in thousands)20222021Change
U.S. Healthcare Solutions$5,454,735 $5,028,950 8.5%
International Healthcare Solutions2,947,190 1,542,456 91.1%
Intersegment eliminations(189)— 
Gains from antitrust litigation settlements1,835 168,794  
LIFO (expense) credit(67,171)203,028  
Turkey highly inflationary impact(40,033)— 
Gross profit$8,296,367 $6,943,228 19.5%
Gross profit increased by $1,353.1 million, or 19.5%, from the prior fiscal year. Gross profit in the current fiscal year was favorably impacted by increases in gross profit in International Healthcare Solutions and U.S. Healthcare Solutions. These increases were offset in part by LIFO expense in comparison to a LIFO credit in the prior year, decreases in gains from antitrust litigation settlements, and the Turkey highly inflationary economy's unfavorable impact on the current fiscal year.
U.S. Healthcare Solutions gross profit increased by $425.8 million, or 8.5%, from the prior fiscal year due to overall revenue growth and fees earned from the distribution of government-owned COVID-19 treatments. As a percentage of revenue, U.S. Healthcare Solutions gross profit margin of 2.57% in the current fiscal year increased 9 basis points compared to the prior fiscal year primarily due to fees earned from the distribution of government-owned COVID-19 treatments.
Gross profit in International Healthcare Solutions increased $1,404.7 million, or 91.1%, from the prior fiscal year primarily due to the June 2021 acquisition of Alliance Healthcare.
We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $1.8 million and $168.8 million in the fiscal years ended September 30, 2022 and 2021, respectively. The gains were recorded as reductions to Cost of Goods Sold (see Note 14 of the Notes to Consolidated Financial Statements).
Our cost of goods sold includes a LIFO provision that is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict. Changes to any of the above factors may have a material impact to our annual LIFO provision. The LIFO expense in the current fiscal year was primarily due to lower generic pharmaceutical deflation and inventory product mix.
We recognized an expense of $40.0 million in the fiscal year ended September 30, 2022 in Cost of Goods Sold related to the impact of Turkey highly inflationary accounting (see Note 1 of the Notes to Consolidated Financial Statements).
Operating Expenses
 Fiscal Year Ended
September 30,
(dollars in thousands)20222021Change
Distribution, selling, and administrative$4,848,962 $3,594,251 34.9%
Depreciation and amortization693,895 505,172 37.4%
Litigation and opioid-related expenses123,191 272,623  
Acquisition, integration, and restructuring expenses183,059 199,288 
Goodwill impairment75,936 6,373 
Impairment of assets4,946 11,324 
Total operating expenses$5,929,989 $4,589,031 29.2%
Distribution, selling, and administrative expenses increased by $1,254.7 million, or 34.9%, from the prior fiscal year. The increase from the prior fiscal year was primarily due to the June 2021 acquisition of Alliance Healthcare. As a percentage of revenue, distribution, selling, and administrative expenses were 2.03% in the current fiscal year and represents a 35-basis point increase compared to the prior fiscal year primarily due to the June 2021 acquisition of Alliance Healthcare.
Depreciation expense increased 18.3% from the prior fiscal year primarily due to depreciation of property and equipment originating from the June 2021 acquisition of Alliance Healthcare. Amortization expense increased 72.3% from the prior fiscal year primarily due to amortization of intangible assets originating from the June 2021 acquisition of Alliance Healthcare.
34
Litigation and opioid-related expenses in the fiscal year ended September 30, 2022 included a $36.6 million accrual related to opioid litigation settlements and $86.6 million of legal fees in connection with opioid lawsuits and investigations. Litigation and opioid-related expenses in the fiscal year ended September 30, 2021 included a $147.7 million accrual related to opioid litigation settlements and $124.9 million of legal fees in connection with opioid lawsuits and investigations.
Acquisition, integration, and restructuring expenses in the fiscal year ended September 30, 2022 included $119.6 million of acquisition-related deal and integration costs primarily related to the integration of Alliance Healthcare, $35.5 million of severance and other restructuring initiatives primarily related to the write down of assets in connection with our office optimization plan, and $28.0 million related to our business transformation efforts. Acquisition, integration, and restructuring expenses in the fiscal year ended September 30, 2021 included $117.0 million of acquisition-related deal and integration costs primarily related to the June 2021 acquisition of Alliance Healthcare, $46.1 million of severance and other restructuring initiatives primarily related to the disposal of assets in connection with our office optimization plan, and $36.3 million related to our business transformation efforts.
We recorded goodwill impairments of $75.9 million and $6.4 million in our Profarma reporting unit in the fiscal years ended September 30, 2022 and 2021, respectively (see Note 5 of the Notes to Consolidated Financial Statements).
Operating Income
 Fiscal Year Ended
September 30,
(dollars in thousands)20222021Change
U.S. Healthcare Solutions$2,456,972 $2,257,918 8.8%
International Healthcare Solutions706,458 390,286 81.0%
Total segment operating income3,163,430 2,648,204 19.5%
Gains from antitrust litigation settlements1,835 168,794  
LIFO (expense) credit(67,171)203,028  
Turkey highly inflationary impact(40,033)— 
Acquisition-related intangibles amortization(304,551)(176,221)
Litigation and opioid-related expenses(123,191)(272,623)
Acquisition, integration, and restructuring expenses(183,059)(199,288)
Goodwill impairment(75,936)(6,373)
Impairment of assets(4,946)(11,324)
Operating income$2,366,378 $2,354,197 0.5%
Segment operating income is evaluated before gains from antitrust litigation settlements; LIFO (expense) credit; Turkey highly inflationary impact; acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses; goodwill impairment; and impairment of assets.
U.S. Healthcare Solutions operating income increased $199.1 million, or 8.8%, from the prior fiscal year primarily due to the increase in gross profit, as noted above, and was offset in part by an increase in operating expenses. As a percentage of revenue, U.S. Healthcare Solutions operating income margin was 1.16% and represented an increase of 4 basis points compared to the prior fiscal year. The increase from the prior year fiscal year was primarily due to fees earned from the distribution of government-owned COVID-19 treatments.
Operating income in International Healthcare Solutions increased by $316.2 million, or 81.0%, from the prior fiscal year primarily due to the June 2021 acquisition of Alliance Healthcare.
Other Income, Net
We recognized a gain of $56.2 million from the sale of non-core businesses, a $14.4 million foreign currency loss on the remeasurement of deferred tax assets relating to Swiss tax reform, an $11.9 million expense related to the impact of Turkey highly inflationary accounting, and a $4.8 million gain on the remeasurement of an equity investment in the fiscal year ended September 30, 2022.
We recorded a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable related to a start-up venture, and a $3.4 million foreign currency loss on the remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.
35
Interest Expense, Net
Interest expense, net and the respective weighted average interest rates were as follows:
Fiscal Year Ended September 30,
 20222021
(dollars in thousands)AmountWeighted Average
Interest Rate		AmountWeighted Average
Interest Rate
Interest expense$231,982 2.69%$182,544 2.62%
Interest income(21,309)1.08%(8,470)0.28%
Interest expense, net$210,673  $174,074  
Interest expense, net increased $36.6 million, or 21.0%, from the prior fiscal year due to the issuance of our $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior notes in March 2021, and the $500 million variable-rate term loan that was issued in June 2021, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare, and the incremental interest expense associated with Alliance Healthcare's debt in certain countries, offset in part by the increase in interest income. The increase in interest income was primarily due to higher investment interest rates, offset in part by lower average invested cash balances. The increase in interest expense as a result of the above-mentioned debt issuances was offset in part by repayments of $250 million in September 2021 and again in March 2022 on the above-mentioned $500 million variable-rate term loan, and payments of $500 million in June 2022 and $350 million in September 2022 on the above-mentioned $1,525 million of 0.737% senior notes.
Our interest expense in future periods may vary significantly depending upon changes in net borrowings, interest rates, amendments to our current borrowing facilities, and strategic decisions to deploy our invested cash.
Income Tax Expense
    Our effective tax rates were 23.7% and 30.5% in the fiscal years ended September 30, 2022 and 2021, respectively. Our effective tax rate in the fiscal year ended September 30, 2022 was higher than the U.S. statutory rate primarily due to U.S. state income taxes, offset in part by the benefit of non-U.S. income taxed at rates lower than the U.S. statutory rate. Our effective tax rate in the fiscal year ended September 30, 2021 was higher than the current year tax rate primarily due to UK and Swiss tax reforms (see Note 4 of the Notes to Consolidated Financial Statements).
Fiscal Year Ended September 30, 2021 compared to the Fiscal Year Ended September 30, 2020
Revenue
Fiscal Year Ended
September 30,
(dollars in thousands)20212020Change
U.S. Healthcare Solutions:
Human Health$197,777,128 $182,171,487 8.6%
Animal Health4,684,417 4,216,462 11.1%
Total U.S. Healthcare Solutions202,461,545 186,387,949 8.6%
International Healthcare Solutions:
Alliance Healthcare7,373,365 — 
Other Healthcare Solutions4,156,264 3,508,106 18.5%
Total International Healthcare Solutions11,529,629 3,508,106 228.7%
Intersegment eliminations(2,331)(2,129)
Revenue$213,988,843 $189,893,926 12.7%
Revenue increased by 12.7% from the prior fiscal year primarily due to the revenue growth of our U.S. Healthcare Solutions segment and our June 2021 acquisition of Alliance Healthcare.
The U.S. Healthcare Solutions segment grew its revenue by $16.1 billion, or 8.6%, from the prior fiscal year, primarily due to increased sales of specialty products (which generally have higher selling prices) including COVID-19 treatments, overall market growth principally driven by unit volume growth, and growth in our animal health business.

36
More specifically, the increase in the U.S. Healthcare Solutions segment revenue was largely attributable to the following (in billions):
Increased sales to Walgreens, our largest customer$1.8
Increased sales to specialty physician practices$2.3
Increased sales of COVID-19 treatments$3.2
Increased sales to other customers$8.8
Revenue in International Healthcare Solutions increased by $8.0 billion, or 228.7%, from the prior fiscal year primarily due to the June 2021 acquisition of Alliance Healthcare and due to growth in our Canadian business and our specialty transportation and logistics business.
Gross Profit
Fiscal Year Ended
September 30
(dollars in thousands)20212020Change
U.S. Healthcare Solutions$5,028,950 $4,504,040 11.7%
International Healthcare Solutions1,542,456 713,546 116.2%
Gains from antitrust litigation settlements168,794 9,076 
LIFO credit (expense)203,028 (7,422)
PharMEDium remediation costs— (7,135)
PharMEDium shutdown costs— (5,421)
New York State Opioid Stewardship Act— (14,800)
Gross profit$6,943,228 $5,191,884 33.7%
Gross profit increased by $1,751.3 million, or 33.7%, from the prior fiscal year. Gross profit in fiscal 2021 was favorably impacted by increases in gross profit in U.S. Healthcare Solutions and International Healthcare Solutions, a LIFO credit in the current year period in comparison to a LIFO expense in the prior year period, and an increase in gains from antitrust litigation settlements.
U.S. Healthcare Solutions gross profit increased by $524.9 million, or 11.7%, from the prior fiscal year due to revenue growth, including an increase in specialty product sales. As a percentage of revenue, U.S. Healthcare Solutions' gross profit margin of 2.48% in fiscal 2021 increased 6 basis points compared to the prior fiscal year primarily due to an increase in specialty product sales, including COVID-19 treatments.
Gross profit in International Healthcare Solutions increased by $828.9 million, or 116.2%, from the prior fiscal year primarily due to the June 2021 acquisition of Alliance Healthcare and revenue growth in our specialty transportation and logistics business. As a percentage of revenue, gross profit margin in International Healthcare Solutions of 13.38% in fiscal 2021 decreased from 20.34% in the prior fiscal year. The decline in gross profit margin in fiscal 2021 was primarily due to the June 2021 acquisition of Alliance Healthcare, which has a lower gross profit margin than the other operating segments within International Healthcare Solutions.
We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $168.8 million and $9.1 million in the fiscal years ended September 30, 2021 and 2020, respectively. The gains were recorded as reductions to Cost of Goods Sold (see Note 14 of the Notes to Consolidated Financial Statements).
In the prior fiscal year, we incurred remediation costs in connection with the suspended production activities at PharMEDium. We also incurred shutdown costs in connection with permanently exiting the PharMEDium compounding business.
New York State ("NYS") enacted the Opioid Stewardship Act ("OSA"), which went into effect on July 1, 2018. The OSA established an annual $100 million Opioid Stewardship Fund (the "Fund") and required manufacturers, distributors, and importers licensed in NYS to ratably source the Fund. The ratable share of the assessment for each licensee was to be based upon opioids sold or distributed to or within NYS. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York. In September 2020, the United States Court of Appeals for the Second Circuit reversed the District Court’s decision, and, as a result, we accrued $14.8 million in the fiscal year ended September 30, 2020 related to our ratable share of the assessment.

37
Operating Expenses
Fiscal Year Ended
September 30,
(dollars in thousands)20212020Change
Distribution, selling, and administrative$3,594,251 $2,767,217 29.9%
Depreciation and amortization505,172391,06229.2%
Litigation and opioid-related expenses272,623 6,722,346 
Acquisition, integration, and restructuring expenses199,288 84,961 
Goodwill impairment6,373—
Impairment of assets11,324361,652
Total operating expenses$4,589,031 $10,327,238 (55.6)%
Distribution, selling, and administrative expenses increased by $827.0 million, or 29.9%, from the prior fiscal year. The increase from the prior fiscal year was primarily due to the June 2021 acquisition of Alliance Healthcare and an increase in payroll-related operating costs to support current and future revenue growth. As a percentage of revenue, distribution, selling, and administrative expenses were 1.68% in the current fiscal year and represents a 22-basis point increase compared to the prior fiscal year. The increase in distribution, selling, and administrative expenses as a percentage of revenue was primarily due to the June 2021 acquisition of Alliance Healthcare.
Depreciation expense increased 16.6% from the prior fiscal year primarily due to depreciation of property and equipment originating from the June 2021 acquisition of Alliance Healthcare. Amortization expense increased 60.9% from the prior fiscal year primarily due to amortization of intangible assets originating from the June 2021 acquisition of Alliance Healthcare.
Litigation and opioid-related expenses in the fiscal year ended September 30, 2021 included a $147.7 million accrual related to opioid litigation settlements and $124.9 million of legal fees in connection with opioid lawsuits and investigations. Litigation and opioid-related expenses in the fiscal year ended September 30, 2020 included a $6.6 billion legal accrual and $115.4 million of legal fees in connection with opioid lawsuits and investigations.
Acquisition, integration, and restructuring expenses in the fiscal year ended September 30, 2021 included $117.0 million of acquisition-related deal and integration costs primarily related to the June 2021 acquisition of Alliance Healthcare, $46.1 million of severance and other restructuring initiatives primarily related to the disposal of assets in connection with our office optimization plan, and $36.3 million related to our business transformation efforts. Acquisition, integration, and restructuring expenses in the fiscal year ended September 30, 2020 included $38.0 million related to our business transformation efforts, $34.4 million of severance costs primarily related to position eliminations resulting from our decision to permanently exit the PharMEDium compounding business, and $12.6 million of acquisition-related deal and integration costs and other restructuring initiatives.
We recorded a goodwill impairment of $6.4 million in our Profarma reporting unit in the fiscal year ended September 30, 2021 in connection with our fiscal 2021 annual impairment test (see Note 5 of the Notes to Consolidated Financial Statements).
We recorded a $361.7 million impairment of PharMEDium's assets in Impairment of Assets in the fiscal year ended September 30, 2020 (see Note 1 of the Notes to Consolidated Financial Statements).







38
Operating Income (Loss)
Fiscal Year Ended
September 30,
(dollars in thousands)20212020Change
U.S. Healthcare Solutions$2,257,918 $2,020,067 11.8%
International Healthcare Solutions390,286 184,380 111.7%
Total segment operating income2,648,204 2,204,447 20.1%
Gains from antitrust litigation settlements168,794 9,076 
LIFO credit (expense)203,028 (7,422)
Acquisition-related intangibles amortization(176,221)(110,478)
Litigation and opioid-related expenses(272,623)(6,722,346)
Acquisition, integration, and restructuring expenses
(199,288)(84,961)
Goodwill impairment(6,373)— 
Impairment of assets(11,324)(361,652)
PharMEDium remediation costs— (16,165)
PharMEDium shutdown costs— (43,206)
New York State Opioid Stewardship Act— (14,800)
Contingent consideration adjustment— 12,153 
Operating income (loss)$2,354,197 $(5,135,354)145.8%
Segment operating income is evaluated before gains from antitrust litigation settlements; LIFO credit (expense); acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses; goodwill impairment; impairment of assets; PharMEDium remediation costs; PharMEDium shutdown costs; New York State Opioid Stewardship Act; and contingent consideration adjustment.
U.S. Healthcare Solutions operating income increased by $237.9 million, or 11.8%, from the prior fiscal year primarily due to the increase in gross profit, as noted above, and was offset in part by an increase in operating expenses. As a percentage of revenue, U.S. Healthcare Solutions operating income margin was 1.12% and represented an increase of 4 basis points compared to the prior fiscal year. The increase from the prior year fiscal year was primarily due to the increase in specialty product sales, including COVID-19 treatments.
Operating income in International Healthcare Solutions increased by $205.9 million, or 111.7%, from the prior fiscal year primarily due to the June 2021 acquisition of Alliance Healthcare and an increase in operating income at World Courier.
One of our non-wholly-owned subsidiaries, Profarma, which we consolidate based on certain governance rights (see Note 3 of the Notes to Consolidated Financial Statements), adjusted its previous estimate of contingent consideration in the prior fiscal year related to the purchase price of one of its prior business acquisitions.
Other Income, Net
We recorded a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable related to a start-up venture, and a $3.4 million foreign currency loss on the remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal year ended September 30, 2021.
Interest Expense, Net
Interest expense, net and the respective weighted average interest rates were as follows:
Fiscal Year Ended September 30,
20212020
(dollars in thousands)AmountWeighted Average
Interest Rate		AmountWeighted Average
Interest Rate
Interest expense$182,544 2.62%$158,522 3.42%
Interest income(8,470)0.28%(20,639)0.69%
Interest expense, net$174,074 $137,883 
39
Interest expense, net increased by $36.2 million, or 26.2%, from the prior fiscal year due to the issuance of our $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior notes in March 2021, and the $500 million variable-rate term loan that was issued in June 2021, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare, the incremental interest expense associated with Alliance Healthcare's debt in certain countries, and the decrease in interest income resulting from a decrease in investment interest rates. The increase in interest expense as a result of the above-mentioned debt issuances was offset in part by a lower weighted-average borrowing interest rate and the repayment of our $400 million October 2018 term loan upon its maturity in October 2020.
Income Tax Expense (Benefit)
Our effective tax rates were 30.5% and 35.8% in the fiscal years ended September 30, 2021 and 2020, respectively. Our effective tax rate in the fiscal year ended September 30, 2021 was higher than the U.S. statutory rate due to U.K. Tax Reform (see Note 4 of the Notes to Consolidated Financial Statements). Our effective tax rate in the fiscal year ended September 30, 2020 was higher than the U.S. statutory rate due to our operating loss, the tax benefits associated with our decision to permanently exit the PharMEDium compounding business, Swiss Tax Reform, the CARES Act, and other discrete items and offset in part by the tax impact of the portion of the opioid legal accrual that is not expected to be tax deductible.
Net Income (Loss) Attributable to AmerisourceBergen Corporation and Diluted Earnings Per Share
Net income attributable to AmerisourceBergen and diluted earnings per share were significantly lower in fiscal 2020 due to the legal accrual recognized in connection with opioid lawsuits.
Critical Accounting Policies and Estimates
Critical accounting policies are those policies that involve accounting estimates and assumptions that can have a material impact on our financial position and results of operations and require the use of complex and subjective estimates based upon past experience and management's judgment. Actual results may differ from these estimates due to uncertainties inherent in such estimates. Below are those policies applied in preparing our financial statements that management believes are the most dependent upon the application of estimates and assumptions. For a complete list of significant accounting policies, see Note 1 of the Notes to Consolidated Financial Statements.
Allowances for Returns and Credit Losses
Trade receivables are primarily comprised of amounts owed to us for our pharmaceutical distribution and services activities and are presented net of an allowance for customer sales returns and an allowance for credit losses. Our customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit. We record an accrual for estimated customer sales returns at the time of sale to the customer based upon historical customer return trends. The allowance for returns as of September 30, 2022 and 2021 was $1,532.1 million and $1,271.6 million, respectively.
We evaluate our receivables for risk of loss by grouping our receivables with similar risk characteristics. Expected losses are determined based on a combination of historical loss trends, current economic conditions, and forward-looking risk factors. Changes in these factors, among others, may lead to adjustments in our allowance for credit losses. The calculation of the required allowance requires judgment by management as to the impact of those and other factors on the ultimate realization of our trade receivables. Each of our business units performs ongoing credit evaluations of its customers' financial condition and maintains reserves for expected credit losses and specific credit problems when they arise. We write off balances against the reserves when collectability is deemed remote. Each business unit performs formal, documented reviews of the allowance at least quarterly, and our largest business units perform such reviews monthly. There were no significant changes to this process during the fiscal years ended September 30, 2022, 2021, and 2020, and bad debt expense was computed in a consistent manner during these periods. The bad debt expense for any period presented is equal to the changes in the period end allowance for credit losses, net of write-offs, recoveries, and other adjustments.
Bad debt expense for the fiscal years ended September 30, 2022, 2021 and 2020 was $26.1 million, $12.1 million, and $11.9 million respectively. An increase or decrease of 0.1% in the 2022 allowance as a percentage of trade receivables would result in an increase or decrease in the provision on accounts receivable of approximately $18.5 million. The allowance for credit losses was $94.7 million and $85.1 million as of September 30, 2022 and 2021, respectively.
Schedule II of this Form 10-K sets forth a rollforward of allowances for returns and credit losses.
40
Business Combinations
The assets acquired and liabilities assumed upon the acquisition or consolidation of a business are recorded at fair value, with the residual of the purchase price allocated to goodwill. We engage third-party appraisal firms to assist management in determining the fair values of certain assets acquired and liabilities assumed. Such valuations require management to make significant judgments, estimates, and assumptions, especially with respect to intangible assets. Management makes estimates of fair value based upon assumptions it believes to be reasonable. These estimates are based upon historical experience and information obtained from the management of the acquired companies and are inherently uncertain. Critical estimates in valuing certain of the intangible assets include, but are not limited to: discount rates and expected future cash flows from and economic lives of customer relationships, trade names, existing technology, and other intangible assets. Unanticipated events and circumstances may occur, which may affect the accuracy or validity of such assumptions or estimates.
Goodwill and Other Intangible Assets
Goodwill arises from acquisitions or consolidations of specific operating companies and is assigned to the reporting unit in which a particular operating company resides. We identify our reporting units based upon our management reporting structure, beginning with our operating segments. We aggregate two or more components within an operating segment that have similar economic characteristics. We evaluate whether the components within our operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment. We announced a strategic reorganization of our business and began reporting externally under the new structure as of October 1, 2021. As of September 30, 2022, our reporting units include Pharmaceutical Distribution Services, U.S. Consulting Services, MWI, Alliance Healthcare, Innomar, World Courier, and Profarma.
Goodwill and other intangible assets with indefinite lives, such as certain trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. For the purpose of these impairment tests, we can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite-lived intangible assets, respectively. Such qualitative factors can include, among others, industry and market conditions, overall financial performance, and relevant entity-specific events. If we conclude based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis. We elected to perform a quantitative impairment assessment of goodwill and indefinite-lived intangible assets in fiscal 2022. We elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in fiscal 2021, with the exception of our testing of goodwill in the AmerisourceBergen Consulting Services (the sum of U.S. Consulting Services and Innomar reporting units, under our prior reporting structure) and Profarma reporting units. We elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in fiscal 2020, with the exception of our testing of goodwill and indefinite-lived intangibles in the MWI and Profarma reporting units.
The quantitative goodwill impairment test requires us to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit. If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized. If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.
When performing a quantitative impairment assessment, we utilize an income-based approach to value our reporting units, with the exception of the Profarma reporting unit, the fair value of which is based upon its publicly-traded stock price, plus an estimated control premium. The income-based approach relies on a discounted cash flow analysis, which considers forecasted cash flows discounted at an appropriate discount rate, to determine the fair value of each reporting unit. We generally believe that market participants would use a discounted cash flow analysis to determine the fair value of our reporting units in a sale transaction. The annual goodwill impairment test requires us to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon our long-range plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both debt and equity, including a risk premium. While we use the best available information to prepare our forecasted cash flows and discount rate assumptions, actual future cash flows and/or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, our overall methodology and the population of assumptions used have remained unchanged.
The quantitative impairment test for indefinite-lived intangibles other than goodwill (certain trademarks and trade names) consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset as of
41
the impairment testing date. We estimate the fair value of its indefinite-lived intangibles using the relief from royalty method. We believe the relief from royalty method is a widely used valuation technique for such assets. The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.
We completed our required annual impairment tests relating to goodwill and indefinite-lived intangible assets in the fiscal years ended September 30, 2022, 2021, and 2020. We recorded goodwill impairments of $75.9 million and $6.4 million in our Profarma reporting unit in connection with our fiscal 2022 and 2021 impairment tests, respectively (see Note 5 of the Notes to Consolidated Financial Statements). No goodwill impairments were recorded in the fiscal years ended September 30, 2020, and no indefinite-lived intangible asset impairments were recorded in the fiscal years ended September 30, 2022, 2021, or 2020.
Finite-lived intangible assets are amortized using the straight-line method over the estimated useful lives of the assets. We perform a recoverability assessment of our long-lived assets when impairment indicators are present.
We recorded impairments of intangible and tangible assets totaling $361.7 million in the fiscal year ended September 30, 2020 in connection with the permanent shutdown of our compounding business.
Income Taxes
Our income tax expense, deferred tax assets and liabilities, and uncertain tax positions reflect management's assessment of estimated future taxes to be paid on items in the financial statements. Deferred income taxes arise from temporary differences between financial reporting and tax reporting bases of assets and liabilities, as well as net operating loss and tax credit carryforwards for tax purposes.
We have established a valuation allowance against certain deferred tax assets for which the ultimate realization of future benefits is uncertain. Expiring carryforwards and the required valuation allowances are adjusted annually. After application of the valuation allowances described above, we anticipate that no limitations will apply with respect to utilization of any of the other deferred income tax assets described above.
We prepare and file tax returns based upon our interpretation of tax laws and regulations and record estimates based upon these judgments and interpretations. In the normal course of business, our tax returns are subject to examination by various taxing authorities. Such examinations may result in future tax and interest assessments by these taxing authorities. Inherent uncertainties exist in estimates of tax contingencies due to changes in tax law resulting from legislation, regulation, and/or as concluded through the various jurisdictions' tax court systems. Significant judgment is exercised in applying complex tax laws and regulations across multiple global jurisdictions where we conduct our operations. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based upon the technical merits of the position.
We believe that our estimates for the valuation allowances against deferred tax assets and the amount of benefits recognized in our financial statements for uncertain tax positions are appropriate based upon current facts and circumstances. However, others applying reasonable judgment to the same facts and circumstances could develop a different estimate and the amount ultimately paid upon resolution of issues raised may differ from the amounts accrued.
The significant assumptions and estimates described in the preceding paragraphs are important contributors to the ultimate effective tax rate in each year. If any of our assumptions or estimates were to change, an increase or decrease in our effective tax rate by 1% on income before income taxes would have caused income tax expense to change by $21.8 million in the fiscal year ended September 30, 2022.
For a complete discussion of the tax impact of UK Tax Reform, Swiss Tax Reform, the legal accrual related to opioid litigation, the CARES Act, and the PharMEDium worthless stock deduction, refer to Note 4 of the Notes to Consolidated Financial Statements.
Inventories
Inventories are stated at the lower of cost or market. Cost for approximately 66% of our inventories as of September 30, 2022 and 2021 has been determined using the LIFO method. If we had used the first-in, first-out method of inventory valuation, which approximates current replacement cost, inventories would have been approximately $1,383.4 million and $1,316.2 million higher than the amounts reported as of September 30, 2022 and 2021, respectively. We recorded LIFO expense of $67.2 million and $7.4 million in the fiscal years ended September 30, 2022 and 2020, respectively. We recorded a LIFO credit of $203.0 million in the fiscal year ended September 30, 2021. The annual LIFO provision is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory
42
quantities, and product mix, many of which are difficult to predict. Changes to any of the above factors can have a material impact to our annual LIFO provision.
Loss Contingencies
In the ordinary course of business, we become involved in lawsuits, administrative proceedings, government subpoenas, government investigations, stockholder demands, and other disputes, including antitrust, commercial, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought in some matters, and some matters may require years to resolve. We record a liability when it is both probable that a loss has been incurred and the amount can be reasonably estimated. We also perform an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued. If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, we provide disclosure of the loss contingency and whether a reasonable estimate of the loss or the range of the loss can made in the footnotes to our financial statements. We review all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made. Among the loss contingencies we considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 13 of the Notes to Consolidated Financial Statements.
Liquidity and Capital Resources
Our operating results have generated cash flows, which, together with availability under our debt agreements and credit terms from suppliers, have provided sufficient capital resources to finance working capital and cash operating requirements, and to fund capital expenditures, acquisitions, repayment of debt, the payment of interest on outstanding debt, dividends, and purchases of shares of our common stock.
 Our primary ongoing cash requirements will be to finance working capital, fund the repayment of debt, fund the payment of interest on debt, fund the payment of dividends, fund purchases of our common stock, finance acquisitions, and fund capital expenditures and routine growth and expansion through new business opportunities. Future cash flows from operations and borrowings are expected to be sufficient to fund our ongoing cash requirements, including the opioid litigation payments that will be made over 18 years (see below).
Cash Flows
As of September 30, 2022 and 2021, our cash and cash equivalents held by foreign subsidiaries were $688.4 million and $725.4 million, respectively. We have the ability to repatriate the majority of our cash and cash equivalents held by our foreign subsidiaries without incurring significant additional taxes upon repatriation.
We have increased seasonal needs related to our inventory build during the December and March quarters that, depending on our cash balance, may require the use of our credit facilities to fund short-term capital needs. Our cash balances in the fiscal years ended September 30, 2022 and 2021 were supplemented by intra-period credit facility borrowings to cover short-term working capital needs. The largest amount of intra-period borrowings under our revolving and securitization credit facilities that was outstanding at any one time during the fiscal years ended September 30, 2022 and 2021 was $590.0 million and $637.7 million, respectively. We had $4,435.9 million, $4,730.5 million, and $117.4 million of cumulative intra-period borrowings that were repaid under our credit facilities during the fiscal years ended September 30, 2022, 2021, and 2020, respectively.
During the fiscal years ended September 30, 2022 and 2021, our operating activities provided cash of $2,703.1 million and $2,666.6 million, respectively. Cash provided by operations in the fiscal year ended September 30, 2022 was principally the result of the following:
•An increase in accounts payable of $3,320.7 million primarily due to the increase in our inventory balances and the timing of scheduled payments to our suppliers;
•Net income of $1,666.5 million;
•Positive non-cash items of $1,176.2 million, which is primarily comprised of depreciation expense of $390.6 million, amortization expense of $319.2 million, and the provision for deferred income taxes of $196.2 million, offset in part by:
◦An increase in accounts receivable of $1,659.5 million primarily due to an increase in sales and the timing of scheduled payments from our customers;
◦An increase in inventories of $665.4 million to support the increase in business volume;
43
◦A decrease in long-term accrued litigation liability of $500.2 million due to opioid litigation settlement payments;
◦A decrease in accrued expenses of $457.2 million; and
◦A decrease in income taxes payable and other liabilities of $330.1 million.
During the fiscal years ended September 30, 2021 and 2020, our operating activities provided cash of $2,666.6 million and $2,207.0 million, respectively. Cash provided by operations in the fiscal year ended September 30, 2021 was principally the result of the following:
•An increase in accounts payable of $2,049.2 million primarily driven by the increase in inventories and the timing of scheduled payments to our suppliers;
•Net income of $1,544.6 million;
•Net positive non-cash items totaling $754.7 million, which is primarily comprised of the provision for deferred income taxes of $334.9 million, depreciation expense of $326.7 million, amortization expense of $188.1 million, and a LIFO credit of $203.0 million, offset in part by:
◦An increase in inventories of $1,116.3 million to support the increase in business volume; and
◦An increase in accounts receivable of $930.1 million primarily due to our revenue growth and the timing of payments from our customers.
We use days sales outstanding, days inventory on hand, and days payable outstanding to evaluate our working capital performance. The below financial metrics are calculated based upon a quarterly average and can be impacted by the timing of cash receipts and disbursements, which can vary significantly depending upon the day of the week in which the month ends.
 Fiscal Year Ended September 30,
 202220212020
Days sales outstanding27.726.224.7
Days inventory on hand28.328.628.7
Days payable outstanding60.058.357.6
Our cash flows from operating activities can vary significantly from period to period based upon fluctuations in our period-end working capital account balances. Additionally, any changes to payment terms with a significant customer or manufacturer supplier could have a material impact to our cash flows from operations. The acquisition of Alliance Healthcare increased our days sales outstanding and days payable outstanding as it has longer payment terms with customers and manufacturers. Operating cash flows during the fiscal year ended September 30, 2022 included $219.8 million of interest payments and $244.4 million of income tax payments, net of refunds. Operating cash flows during the fiscal year ended September 30, 2021 included $170.9 million of interest payments and $93.5 million of income tax payments, net of refunds. Operating cash flows during the fiscal year ended September 30, 2020 included $150.7 million of interest payments and $139.4 million of income tax payments, net of refunds.
Capital expenditures in the fiscal years ended September 30, 2022, 2021, and 2020 were $496.3 million, $438.2 million, and $369.7 million, respectively. Significant capital expenditures in fiscal 2022 included investments in various technology initiatives, including technology initiatives at Alliance Healthcare. Significant capital expenditures in fiscal 2021 and 2020 included costs associated with facility expansions, and various technology initiatives, including costs related to enhancing and upgrading our primary information technology operating systems.
We currently expect to spend approximately $500 million for capital expenditures during fiscal 2023. Larger 2023 capital expenditures will include investments relating to various technology initiatives, including technology investments at Alliance Healthcare and those required to comply with new regulatory requirements.
In addition to capital expenditures, net cash used in investing activities in the fiscal year ended September 30, 2022 included $133.8 million of cash to acquire companies, including $60.0 million that was paid to settle accrued consideration related to the Alliance Healthcare acquisition (see Note 2 of the Notes to Consolidated Financial Statements), and was offset in part by $272.6 million in proceeds from the sale of non-core businesses.
In addition to capital expenditures, net cash used in investing activities in the fiscal year ended 2021 included $5,563.0 million of cash to acquire companies, which principally related to the June 2021 acquisition of Alliance Healthcare, net of cash acquired, and $162.6 million for equity investments.
Net cash used in financing activities in the fiscal year ended September 30, 2022 principally resulted from an $850 million repayment of our 0.737% senior notes that mature in 2023, the repayment of our $250 million term loan, $391.7 million in cash dividends paid on our common stock, and $483.7 million in purchases of our common stock.
44
Net cash provided by financing activities in the fiscal year ended September 30, 2021 principally resulted from the issuance of senior notes and the February 2021 Term Loan (see above) and $198.8 million of exercises of stock options, offset in part by $650 million of repayments of our term loans, $366.6 million in cash dividends paid on our common stock, and $82.2 million in purchases of our common stock.
Net cash used in financing activities in the fiscal year ended September 30, 2020 principally related to $420.4 million in purchases of our common stock and $343.6 million in cash dividends paid on our common stock.
Debt and Credit Facility Availability
The following illustrates our debt structure as of September 30, 2022, including availability under the multi-currency revolving credit facility, the receivables securitization facility, the revolving credit note, the money market facility, Alliance Healthcare debt, and the overdraft facility:
(in thousands)Outstanding
Balance		Additional
Availability
Fixed-Rate Debt:  
0.737% senior notes due 2023$672,736 $— 
$500,000, 3.400% senior notes due 2024499,195 — 
$500,000, 3.250% senior notes due 2025498,347 — 
$750,000, 3.450% senior notes due 2027745,622 — 
$500,000, 2.800% senior notes due 2030495,348 — 
$1,000,000, 2.700% senior notes due 2031990,480 — 
$500,000, 4.250% senior notes due 2045495,162 — 
$500,000, 4.300% senior notes due 2047493,288 — 
Nonrecourse debt66,539 — 
Total fixed-rate debt4,956,717 — 
Variable-Rate Debt:  
Revolving credit note— 75,000 
Money market facility— 100,000 
Receivables securitization facility due 2025350,000 1,100,000 
Overdraft facility due 2024 (£10,000)— 11,169 
Multi-currency revolving credit facility due 2027— 2,400,000 
Alliance Healthcare debt336,886 109,624 
Nonrecourse debt59,230 — 
Total variable-rate debt746,116 3,795,793 
Total debt$5,702,833 $3,795,793 
In May 2020, we issued $500 million of 2.80% senior notes due May 15, 2030 (the "2030 Notes"). The 2030 Notes were sold at 99.71% of the principal amount and have an effective yield of 2.81%. Interest on the 2030 Notes is payable semi-annually in arrears and commenced on November 15, 2020.
We used the proceeds from the 2030 Notes to finance the early retirement of the $500 million of 3.50% senior notes that were due in 2021 and made a $21.4 million prepayment premium in connection with this early retirement.
In March 2021, we issued $1,525 million of 0.737% senior notes due March 15, 2023 (the "2023 Notes"). The 2023 Notes were sold at 100.00% of the principal amount. Interest on the 2023 Notes is payable semi-annually in arrears, commencing on September 15, 2021. In March 2021, we issued $1,000 million of 2.700% senior notes due March 15, 2031 (the "2031 Notes"). The 2031 Notes were sold at 99.79% of the principal amount and have an effective yield of 2.706%. Interest on the 2031 Notes is payable semi-annually in arrears and commenced on September 15, 2021. The 2023 Notes and 2031 Notes rank pari passu to our other senior notes, the Multi-Currency Revolving Credit Facility, the Revolving Credit Note, the Overdraft Facility, and the Money Market Facility. We used the proceeds from the 2023 Notes and 2031 Notes to finance a portion of the June 2021 Alliance Healthcare acquisition.
In fiscal 2022, we elected to repay $850 million of the 2023 Notes due in March 2023.
In addition to the 2023 Notes, the 2030 Notes, and the 2031 Notes, we have $500 million of 3.40% senior notes due May 15, 2024, $500 million of 3.25% senior notes due March 1, 2025, $750 million of 3.45% senior notes due December 15, 2027, $500 million of 4.25% senior notes due March 1, 2045, and $500 million of 4.300% senior notes due December 15, 2047 (collectively, the "Notes"). Interest on the Notes is payable semiannually in arrears.
45
We have a $2.4 billion multi-currency senior unsecured revolving credit facility ("Multi-Currency Revolving Credit Facility"), which was scheduled to expire in November 2026, with a syndicate of lenders. In October 2022, we amended and restated the Multi-Currency Revolving Credit Facility to extend the expiration to October 2027 and to make changes to effect a transition from the LIBOR interest rate benchmark to Term SOFR. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based upon our debt rating and ranges from 80.5 basis points to 122.5 basis points over SOFR/EURIBOR/CDOR/RFR, as applicable (101.5 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee as of September 30, 2022) and from 0 basis points to 22.5 basis points over the alternate base rate and Canadian prime rate, as applicable. We pay facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based upon our debt rating, ranging from 7 basis points to 15 basis points, annually, of the total commitment (11 basis points as of September 30, 2022). We may choose to repay or reduce our commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which we were compliant as of September 30, 2022.
We have a commercial paper program whereby we may from time to time issue short-term promissory notes in an aggregate amount of up to $2.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase our borrowing capacity as it is fully backed by our Multi-Currency Revolving Credit Facility. There were no borrowings outstanding under our commercial paper program as of September 30, 2022 and 2021.
We have a $1,450 million receivables securitization facility ("Receivables Securitization Facility"), which was scheduled to expire in November 2024. In October 2022, we amended the Receivables Securitization Facility ("Receivables Amendment") to extend the expiration for an additional one year until October 2025. In addition, the Receivables Amendment made changes to (i) substitute Term SOFR for LIBOR as a benchmark and establish procedures to choose a new benchmark if Term SOFR becomes unavailable, (ii) provide for the return of erroneous payments, if any, by purchasers, (iii) update provisions regarding compliance with sanctions and anti-money laundering laws, and (iv) implement certain other technical amendments. We have available to us an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters. Interest rates are based upon prevailing market rates for short-term commercial paper or 30-day Term SOFR plus a program fee. We pay a customary unused fee at prevailing market rates, annually, to maintain the availability under the Receivables Securitization Facility.
In connection with the Receivables Securitization Facility, AmerisourceBergen Drug Corporation and a specialty distribution subsidiary sell on a revolving basis certain accounts receivable to Amerisource Receivables Financial Corporation, a wholly-owned special purpose entity, which in turn sells a percentage ownership interest in the receivables to financial institutions and commercial paper conduits sponsored by financial institutions. AmerisourceBergen Drug Corporation is the servicer of the accounts receivable under the Receivables Securitization Facility. As sold receivables are collected, additional receivables may be sold up to the maximum amount available under the facility. We use the facility as a financing vehicle because it generally offers an attractive interest rate relative to other financing sources. We securitize our trade accounts, which are generally non-interest bearing, in transactions that are accounted for as borrowings. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of September 30, 2022.
We have an uncommitted, unsecured line of credit available to us pursuant to a revolving credit note ("Revolving Credit Note"). The Revolving Credit Note provides us with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million. The Revolving Credit Note may be decreased or terminated by the bank or us at any time without prior notice. We also have a £10 million uncommitted U.K. overdraft facility ("Overdraft Facility"), which expires in February 2024, to fund short-term normal trading cycle fluctuations related to our MWI Animal Health business. We have an uncommitted, unsecured line of credit available to us pursuant to a money market credit agreement ("Money Market Facility"). The Money Market Facility provides us with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $100 million. The Money Market Facility may be decreased or terminated by the bank or us at any time without prior notice.
Our $400 million Term Loan matured and was repaid in October 2020.
In February 2021, we entered into a $1.0 billion variable-rate term loan (“February 2021 Term Loan”), which was available to be drawn on the closing date of the acquisition of Alliance Healthcare. In April 2021, we reduced our commitment under the February 2021 Term Loan to $500 million. In June 2021, we borrowed $500 million under the February 2021 Term Loan to finance a portion of the June 2021 Alliance Healthcare acquisition. We elected to make principal payments of $250 million in September 2021 and again in March 2022 to repay the loan that was scheduled to mature in 2023.
46
Alliance Healthcare debt is comprised of uncommitted revolving credit facilities in various currencies with various rates. A majority of the outstanding borrowings were held in Egypt (which is 50% owned) as of September 30, 2022 and 2021. These facilities are used to fund its working capital needs.
Nonrecourse debt is comprised of short-term and long-term debt belonging to the Brazil subsidiaries and is repaid solely from the Brazil subsidiaries' cash flows and such debt agreements provide that the repayment of the loans (and interest thereon) is secured solely by the capital stock, physical assets, contracts, and cash flows of the Brazil subsidiaries.
Share Purchase Programs and Dividends
    In October 2018, our board of directors authorized a share repurchase program allowing us to purchase up to $1.0 billion of our shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2019, we purchased $538.9 million of our common stock under this program, which included $14.8 million of September 2019 purchases that cash settled in October 2019. During the fiscal year ended September 30, 2020, we purchased $405.6 million of our common stock, which excluded $14.8 million of September 2019 purchases that cash settled in October 2019. During the fiscal year ended September 30, 2021, we purchased $55.5 million of our common stock to complete our authorization under this program.
In May 2020, our board of directors authorized a share repurchase program allowing us to purchase up to $500 million of our outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2021, we purchased $26.6 million of our common stock. During the fiscal year ended September 30, 2022, we purchased $473.4 million of our common stock to complete our authorization under this program.
In May 2022, the Company's board of directors authorized a new share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2022, we purchased $38.7 million of our common stock, which included $28.4 million of September 2022 purchases that cash settled in October 2022. As of September 30, 2022, we had $961.3 million of availability remaining under this program. In October 2022, under this program, we purchased 0.6 million shares of our common stock for $78.8 million. In November 2022, under this program, we purchased 3.2 million shares of our common stock from WBA for $500.0 million.
Our board of directors approved the following quarterly dividend increases:
Dividend Increases
 Per Share 
DateNew RateOld Rate% Increase
January 2020$0.420$0.4005%
November 2020$0.440$0.4205%
November 2021$0.460$0.4405%
November 2022$0.485$0.4605%
We anticipate that we will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of our board of directors and will depend upon our future earnings, financial condition, capital requirements, and other factors.
Commitments and Obligations
As discussed in Note 13 of the Notes to Consolidated Financial Statements, on July 21, 2021, it was announced that we and the two other national pharmaceutical distributors had negotiated a comprehensive opioid settlement agreement. The comprehensive settlement agreement became effective on April 2, 2022, and as of September 30, 2022, it included 48 of 49 eligible states (the “Settling States”) as well as 99% by population of the eligible political subdivisions in the Settling States. Pursuant to the comprehensive settlement agreement and related agreements with Settling States, we will pay up to approximately $6.4 billion over 18 years. Our estimated liability related to the State of Alabama (with whom we have not reached a settlement agreement), as well as other opioid-related litigation for which we have reached settlement agreements is approximately $0.4 billion. Net of $0.8 billion of payments made through September 30, 2022, we have a $6.0 billion liability on our Consolidated Balance Sheet as of September 30, 2022 for litigation relating to our comprehensive opioid settlement as well as other opioid-related litigation. The payment of the aforementioned litigation liability has not and is not expected to have an impact on our ability to pay dividends.
47
The following is a summary of our contractual obligations for future principal and interest payments on our debt, minimum rental payments on our noncancellable operating leases, and minimum payments on our other commitments as of September 30, 2022:
Payments Due by Period (in thousands)Debt, Including Interest PaymentsOperating
Leases		Other CommitmentsTotal
Within 1 year$1,245,995 $192,031 $123,771 $1,561,797 
1-3 years1,688,379 333,213 137,111 2,158,703 
4-5 years235,886 257,090 57,788 550,764 
After 5 years4,215,090 456,276 — 4,671,366 
Total$7,385,350 $1,238,610 $318,670 $8,942,630 
    The 2017 Tax Act required a one-time transition tax to be recognized on historical foreign earnings and profits. We expect to pay $157.1 million, net of overpayments and tax credits, related to this transition tax, as of September 30, 2022, which is payable in installments over a six-year period that commenced in January 2021. The transition tax commitment is included in "Other Commitments" in the above table.
Our liability for uncertain tax positions was $553.2 million (including interest and penalties) as of September 30, 2022. This liability represents an estimate of tax positions that we have taken in our tax returns which may ultimately not be sustained upon examination by taxing authorities. Since the amount and timing of any future cash settlements cannot be predicted with reasonable certainty, the estimated liability has been excluded from the above contractual obligations table. Our liability for uncertain tax positions as of September 30, 2022 primarily includes an uncertain tax benefit related to the $6.8 billion legal accrual for litigation related to the distribution of prescription opioid pain medications, as disclosed in Note 13 of the Notes to Consolidated Financial Statements.
Market Risk
We have exposure to foreign currency and exchange rate risk from our non-U.S. operations. Our largest exposure to foreign exchange rates exists primarily with the U.K. Pound Sterling, the Euro, the Turkish Lira, the Egyptian Pound, the Brazilian Real, and the Canadian Dollar. During the quarter ended March 31, 2022, Turkey became a highly inflationary economy, as defined under U.S. GAAP (see Note 1 of the Notes to Consolidated Financial Statements). Also, with the June 2021 acquisition of Alliance Healthcare, our foreign currency and exchange rate risk increased; therefore, we now use forward contracts to hedge against the foreign currency exchange rate impact on certain intercompany receivable and payable balances. We may use derivative instruments to hedge our foreign currency exposure, but not for speculative or trading purposes. Revenue from our foreign operations during the fiscal year ended September 30, 2022 was approximately 11% of our consolidated revenue.
We have market risk exposure to interest rate fluctuations relating to our debt. We manage interest rate risk by using a combination of fixed-rate and variable-rate debt. The amount of variable-rate debt fluctuates during the year based on our working capital requirements. We had $746.1 million of variable-rate debt outstanding as of September 30, 2022. We periodically evaluate financial instruments to manage our exposure to fixed and variable interest rates. However, there are no assurances that such instruments will be available in the combinations we want and/or on terms acceptable to us. There were no such financial instruments in effect as of September 30, 2022.
We also have market risk exposure to interest rate fluctuations relating to our cash and cash equivalents. We had $3,388.2 million in cash and cash equivalents as of September 30, 2022. The unfavorable impact of a hypothetical decrease in interest rates on cash and cash equivalents would be partially offset by the favorable impact of such a decrease on variable-rate debt. For every $100 million of cash invested that is in excess of variable-rate debt, a 10-basis point decrease in interest rates would increase our annual net interest expense by $0.1 million. 
Deterioration of general economic conditions, among other factors, could adversely affect the number of prescriptions that are filled and the amount of pharmaceutical products purchased by consumers and, therefore, could reduce purchases by our customers. In addition, volatility in financial markets may also negatively impact our customers' ability to obtain credit to finance their businesses on acceptable terms. Reduced purchases by our customers or changes in the ability of our customers to remit payments to us could adversely affect our revenue growth, our profitability, and our cash flow from operations.
Recent elevated levels of inflation in the global and U.S. economies have not had a significant impact on our results of operations. If elevated levels of inflation persist or increase, our operations and financial results could be adversely affected, particularly in certain global markets.
48
We have risks from other geopolitical trends and events, such as the Russia-Ukraine war. Although the long-term implications of Russia’s invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in fiscal 2022 has not been material.
ITEM 7A.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Company's most significant market risks are the effects of changing interest rates, foreign currency risk, and the changes in the price of the Company's common stock. See discussion under the heading "Market Risk," which is incorporated by reference herein.
49
ITEM 8.    FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
50
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and the Board of Directors of AmerisourceBergen Corporation

Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of AmerisourceBergen Corporation and subsidiaries (the Company) as of September 30, 2022 and 2021, the related consolidated statements of operations, comprehensive income, stockholders’ equity, and cash flows for each of the three years in the period ended September 30, 2022, and the related notes and financial statement schedule listed in the Index at Item 15(a) (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at September 30, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended September 30, 2022, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of September 30, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated November 22, 2022 expressed an unqualified opinion thereon.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
Legal Matters and Contingencies - Opioid Lawsuits
Description of the MatterAs discussed in Note 13 of the consolidated financial statements, the Company is involved in a significant number of lawsuits with counties, municipalities, and other governmental entities in a majority of U.S. states and Puerto Rico, as well as numerous states and tribes relating to the distribution of prescription opioid pain medications (“opioid litigation”). The Company recognizes a liability for those legal contingencies for which it is probable that a liability has been incurred at the date of the consolidated financial statements and the amount is reasonably estimable. The Company has recognized a $6.0 billion liability related to the opioid litigation as of September 30, 2022 and has disclosed that it is unable to estimate the range of possible loss in excess of the amount accrued. In connection with this liability, the Company recognized a related income tax benefit, which reflects an unrecognized tax benefit resulting from uncertainty in the amount that is more likely than not to be deductible for U.S. federal and state income tax purposes. The Company used significant judgment in measuring the amount of income tax benefit that may ultimately be deductible for U.S. federal and state purposes.

51
Auditing management’s determination of the measurement of the opioid litigation liability and disclosures is highly subjective and requires significant judgment. For instance, auditing management’s judgments related to the opioid litigation is challenging due to the significant judgment applied in determining the magnitude of the liability and whether a range of possible loss in excess of the amount accrued is reasonably estimable, based upon the proposed or final settlement agreements. In addition, auditing management's estimate of the amount of income tax benefit related to the Company's uncertain tax position is challenging because the evaluation of the technical merits of income tax benefits that qualify for a deduction related to the opioid litigation requires significant judgment.
How We Addressed the Matter in Our Audit
We tested the Company’s internal controls that address the risks of material misstatement related to the completeness, presentation and disclosure of the opioid litigation liability and related uncertain tax position. This included testing controls related to the Company’s process for identification, recognition, completeness and disclosure of the opioid litigation and testing controls related to the Company’s process to assess the technical merits of its tax position, including the Company’s assessment as to the amount of benefit that is more likely than not to be realized upon ultimate settlement with taxing authorities. For example, we tested controls over management’s review of the assessment of the completeness of the opioid litigation liability and whether a range of possible loss in excess of the amount accrued is reasonably estimable to determine the accuracy of the opioid litigation liability and the related financial statement footnote disclosures.
To test the Company’s opioid litigation liability, our substantive audit procedures included, among others, testing the measurement of the opioid litigation contingencies by inspecting the proposed or final settlement agreements and agreeing key terms to management’s reserve calculation and assumptions, as well as vouching payments made during the year. We inspected responses to inquiry letters sent to both internal and external legal counsel, held discussions with internal general counsel and external legal counsel to confirm our understanding of any settlement discussions, and obtained written representations from executives of the Company. In addition, we evaluated the adequacy of the Company’s financial statement disclosures.
We involved our tax subject matter professionals in assessing the technical merits and measurement of the Company’s tax position related to the opioid litigation liability. We examined the Company’s analysis and evaluated the underlying facts upon which the tax position was based. We used our knowledge of historical settlement activity to evaluate the Company’s measurement of the uncertain tax position associated with the opioid litigation. This included evaluating third-party evidence obtained from the Company’s external income tax advisors. We also evaluated the adequacy of the Company’s financial statement disclosures and obtained written representations from executives of the Company related to this income tax matter.
52
Other Legal Matters and Contingencies
Description of the MatterAs discussed in Note 13 of the consolidated financial statements, in addition to the opioid litigation addressed above, the Company is involved in government subpoenas, derivative actions, and other disputes. The Company recognizes a liability for those legal contingencies for which it is probable that a liability has been incurred at the date of the consolidated financial statements and the amount is reasonably estimable. The Company also performs an assessment of the materiality of legal contingencies where a loss is either reasonably possible or it is reasonably possible that an exposure to loss exists in excess of the amount accrued. If it is reasonably possible that such a loss or an additional loss may have been incurred and the effect on the consolidated financial statements is material, the Company discloses the nature of the loss contingency and an estimate of the possible loss or range of loss or a statement that such an estimate cannot be made within the notes to the consolidated financial statements.
Auditing management’s determination of whether a loss for a legal contingency is probable and reasonably estimable, reasonably possible or remote, and the related measurement and disclosures, is highly subjective and requires significant judgment. For instance, auditing management’s judgments was challenging due to the significant judgment applied in determining the likelihood of resolution of the matters through settlement or litigation.
How We Addressed the Matter in Our AuditWe tested the Company’s internal controls that address the risks of material misstatement related to the completeness, valuation, presentation and disclosure of legal contingencies. This included testing controls related to the Company’s process for identification, recognition, measurement and disclosure of legal contingencies. For example, we tested controls over management’s review of the assessment of the probability of occurrence of a loss and whether the loss was reasonably estimable to determine the completeness and accuracy of legal contingencies and the related financial statement footnote disclosures. We also tested controls over management’s assessment of the likelihood of the resolution of the matters through settlement or litigation.
To test the Company’s legal contingencies, our substantive audit procedures included, among others, testing the completeness of the legal contingencies subject to evaluation by the Company and evaluating the Company’s analysis of its assessment of the probability of outcome for each material legal contingency, including the Company’s assessment as to whether a loss is reasonably estimable or if the Company is unable to estimate the range of loss, through inspection of responses to inquiry letters sent to both internal and external legal counsel, discussions with internal general counsel and external legal counsel to confirm our understanding of the allegations, and obtaining written representations from executives of the Company. In addition, we evaluated the adequacy of the Company’s financial statement disclosures.






 /s/ Ernst & Young LLP
 

We have served as the Company's auditor since 1985.
Philadelphia, Pennsylvania
November 22, 2022
53
AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
September 30,
(in thousands, except share and per share data)20222021
ASSETS  
Current assets:  
Cash and cash equivalents$3,388,189 $2,547,142 
Accounts receivable, less allowances for returns and credit losses:
2022 — $1,626,729; 2021 — $1,356,684
18,452,675 18,167,175 
Inventories15,556,394 15,368,352 
Right to recover assets1,532,061 1,271,557 
Income tax receivable
172,568 221,875 
Prepaid expenses and other487,871 853,600 
Assets held for sale— 372,908 
Total current assets39,589,758 38,802,609 
Property and equipment, net2,135,003 2,162,961 
Goodwill8,503,886 9,030,531 
Other intangible assets4,332,737 5,256,927 
Deferred income taxes237,571 290,791 
Other assets1,761,661 1,793,986 
TOTAL ASSETS$56,560,616 $57,337,805 
LIABILITIES AND STOCKHOLDERS' EQUITY   
Current liabilities:  
Accounts payable$40,192,890 $38,009,954 
Accrued expenses and other2,214,592 2,856,405 
Short-term debt1,070,473 300,213 
Liabilities held for sale— 192,069 
Total current liabilities43,477,955 41,358,641 
Long-term debt4,632,360 6,383,711 
Accrued income taxes320,274 281,070 
Deferred income taxes1,620,413 1,685,296 
Other liabilities976,583 1,082,723 
Accrued litigation liability
5,461,758 5,961,953 
Commitments and contingencies (Note 13)
Stockholders' equity:  
Common stock, $0.01 par value — authorized, issued, and outstanding:
2022 — 600,000,000 shares, 292,700,490 shares and 206,203,817 shares;
2021 — 600,000,000 shares, 290,722,533 shares and 208,089,298 shares
2,927 2,907 
Additional paid-in capital5,658,733 5,465,104 
Retained earnings2,977,646 1,670,513 
Accumulated other comprehensive loss(1,830,970)(445,442)
Treasury stock, at cost: 2022 — 86,496,673 shares; 2021 — 82,633,235 shares
(7,019,895)(6,469,728)
Total AmerisourceBergen Corporation stockholders' (deficit) equity(211,559)223,354 
Noncontrolling interests282,832 361,057 
Total stockholders' equity71,273 584,411 
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $56,560,616 $57,337,805 
See notes to consolidated financial statements.
54
AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
 Fiscal Year Ended September 30,
(in thousands, except per share data)202220212020
Revenue$238,587,006 $213,988,843 $189,893,926 
Cost of goods sold230,290,639 207,045,615 184,702,042 
Gross profit8,296,367 6,943,228 5,191,884 
Operating expenses:   
Distribution, selling, and administrative4,848,962 3,594,251 2,767,217 
Depreciation386,595 326,824 280,187 
Amortization307,300 178,348 110,875 
Litigation and opioid-related expenses123,191 272,623 6,722,346 
Acquisition, integration, and restructuring expenses183,059 199,288 84,961 
Goodwill impairment75,936 6,373 — 
Impairment of assets4,946 11,324 361,652 
Operating income (loss)2,366,378 2,354,197 (5,135,354)
Other income, net(27,352)(41,736)(1,581)
Interest expense, net210,673 174,074 137,883 
Loss on early retirement of debt— — 22,175 
Income (loss) before income taxes2,183,057 2,221,859 (5,293,831)
Income tax expense (benefit) 516,517 677,251 (1,894,273)
Net income (loss)1,666,540 1,544,608 (3,399,558)
Net loss (income) attributable to noncontrolling interests32,280 (4,676)(9,158)
Net income (loss) attributable to AmerisourceBergen Corporation$1,698,820 $1,539,932 $(3,408,716)
Earnings per share:   
Basic$8.15 $7.48 $(16.65)
Diluted$8.04 $7.39 $(16.65)
Weighted average common shares outstanding:   
Basic208,472 205,919 204,783 
Diluted211,210 208,465 204,783 
See notes to consolidated financial statements.

55
AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
 Fiscal Year Ended September 30,
(in thousands)202220212020
Net income (loss)$1,666,540 $1,544,608 $(3,399,558)
Other comprehensive loss:   
Foreign currency translation adjustments(1,426,741)(334,522)(7,872)
Other, net4,910 10 (1,074)
Total other comprehensive loss(1,421,831)(334,512)(8,946)
Total comprehensive income (loss)244,709 1,210,096 (3,408,504)
Comprehensive loss (income) attributable to noncontrolling interests68,583 (6,776)2,923 
Comprehensive income (loss) income attributable to AmerisourceBergen Corporation$313,292 $1,203,320 $(3,405,581)
See notes to consolidated financial statements.
56
AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(in thousands, except per share data)Common
Stock		Additional
Paid-in
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss		Treasury
Stock		Non-controlling InterestTotal
September 30, 2019$2,853 $4,850,142 $4,235,491 $(111,965)$(6,097,604)$114,289 $2,993,206 
Adoption of lease accounting standard
— — 35,138 — — — 35,138 
Net (loss) income— — (3,408,716)— — 9,158 (3,399,558)
Other comprehensive income (loss)— — — 3,135 — (12,081)(8,946)
Cash dividends, $1.66 per share
— — (343,578)— — — (343,578)
Exercises of stock options21 159,512 — — — — 159,533 
Share-based compensation expense— 74,411 — — — — 74,411 
Purchases of common stock— — — — (405,692)— (405,692)
Profarma retail equity offering— (1,567)— — — 67,922 66,355 
Employee tax withholdings related to restricted share vesting
— — — — (9,787)— (9,787)
Other, net4 (722)— — — — (718)
September 30, 20202,878 5,081,776 518,335 (108,830)(6,513,083)179,288 (839,636)
Adoption of ASC 326, net of tax (Note 1)
— — (21,106)— — (2,988)(24,094)
Net income— — 1,539,932 — — 4,676 1,544,608 
Other comprehensive (loss) income— — — (336,612)— 2,100 (334,512)
Cash dividends, $1.76 per share
— — (366,648)— — — (366,648)
Exercises of stock options23 198,727 — — — — 198,750 
Share-based compensation expense— 99,594 — — — — 99,594 
Purchases of common stock— — — — (82,150)— (82,150)
Employee tax withholdings related to restricted share vesting
— — — — (23,547)— (23,547)
Equity consideration issued for acquisition of Alliance Healthcare (Note 2)— 86,089 — — 149,052 — 235,141 
Acquisition of Alliance Healthcare (Note 2)— — — — — 178,264 178,264 
Other, net6 (1,082)— — — (283)(1,359)
September 30, 20212,907 5,465,104 1,670,513 (445,442)(6,469,728)361,057 584,411 
Net income (loss)— — 1,698,820 — — (32,280)1,666,540 
Other comprehensive loss— — — (1,385,528)— (36,303)(1,421,831)
Cash dividends, $1.84 per share
— — (391,687)— — — (391,687)
Exercises of stock options10 93,902 — — — — 93,912 
Share-based compensation expense— 93,400 — — — — 93,400 
Purchases of common stock— — — — (512,091)— (512,091)
Employee tax withholdings related to restricted share vesting
— — — — (38,076)— (38,076)
Sale of business— — — — — (3,544)(3,544)
Other, net10 6,327 — — — (6,098)239 
September 30, 2022$2,927 $5,658,733 $2,977,646 $(1,830,970)$(7,019,895)$282,832 $71,273 
See notes to consolidated financial statements.
57
AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOW
 Fiscal Year Ended September 30,
(in thousands)202220212020
OPERATING ACTIVITIES   
Net income (loss)$1,666,540 $1,544,608 $(3,399,558)
Adjustments to reconcile net income (loss) to net cash provided by operating activities: 
Depreciation, including amounts charged to cost of goods sold390,643 326,713 290,744 
Amortization, including amounts charged to interest expense319,192 188,073 117,269 
Provision for credit losses26,053 12,101 11,912 
Provision (benefit) for deferred income taxes196,184 334,866 (1,544,971)
Share-based compensation expense93,400 99,594 74,411 
LIFO expense (credit)67,171 (203,028)7,422 
Impairment of assets, including goodwill80,882 31,697 361,652 
Gain on sale of businesses(56,228)— — 
Turkey highly inflationary impact51,966 — — 
Gain on remeasurement of equity investment(4,834)(64,721)— 
Loss on early retirement of debt— — 22,175 
Other, net11,781 29,361 (3,044)
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures:   
Accounts receivable(1,659,525)(930,078)(1,628,991)
Inventories(665,370)(1,116,344)(1,621,143)
Income tax receivable49,307 266,552 (482,569)
Prepaid expenses and other assets102,708 141,057 28,050 
Accounts payable3,320,725 2,049,167 3,300,832 
Accrued expenses(457,233)372,078 524,021 
Income taxes payable and other liabilities(330,079)(178,120)(50,115)
Long-term accrued litigation liability(500,195)(236,990)6,198,943 
NET CASH PROVIDED BY OPERATING ACTIVITIES2,703,088 2,666,586 2,207,040 
INVESTING ACTIVITIES   
Capital expenditures(496,318)(438,217)(369,677)
Cost of acquired companies, net of cash acquired(133,814)(5,563,040)— 
Cost of equity investments(18,491)(162,620)(56,080)
Proceeds from sale of property and equipment6,302 14,439 36,364 
Proceeds from sale of businesses272,586 — — 
Other, net1,298 7,861 9,522 
NET CASH USED IN INVESTING ACTIVITIES(368,437)(6,141,577)(379,871)
FINANCING ACTIVITIES   
Senior notes and other loan borrowings155,189 3,166,980 599,480 
Senior notes and other loan repayments(1,238,954)(835,313)(598,452)
Borrowings under revolving and securitization credit facilities4,832,605 4,968,815 116,946 
Repayments under revolving and securitization credit facilities(4,671,943)(5,083,930)(149,980)
Payment of premium on early retirement of debt— — (21,448)
Purchases of common stock(483,704)(82,150)(420,449)
Exercises of stock options93,912 198,750 159,533 
Cash dividends on common stock(391,687)(366,648)(343,578)
Profarma retail equity offering— — 66,355 
Tax withholdings related to restricted share vesting(38,076)(23,547)(9,787)
Other, net(10,122)9,892 (2,237)
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES(1,752,780)1,952,849 (603,617)
EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH(57,850)(3,725)— 
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, INCLUDING CASH CLASSIFIED WITHIN ASSETS HELD FOR SALE524,021 (1,525,867)1,223,552 
LESS: INCREASE IN CASH CLASSIFIED WITHIN ASSETS HELD FOR SALE(610)(1,751)— 
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS523,411 (1,527,618)1,223,552 
Cash, cash equivalents, and restricted cash at beginning of year3,070,128 4,597,746 3,374,194 
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT END OF YEAR$3,593,539 $3,070,128 $4,597,746 
See notes to consolidated financial statements.
58
AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2022

Note 1. Summary of Significant Accounting Policies
AmerisourceBergen Corporation and its subsidiaries, including less-than-wholly-owned subsidiaries in which AmerisourceBergen Corporation has a controlling financial interest (the "Company"), is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company delivers innovative programs and services designed to improve the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.
The Company undertook a strategic evaluation of its reporting structure to reflect its expanded international presence as a result of the June 2021 acquisition of Alliance Healthcare. As a result, at the beginning of fiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions. U.S. Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable segment (excluding Profarma Distribuidora de Produtos Farmacêuticos S.A. ("Profarma")), MWI Animal Health ("MWI"), Xcenda, Lash Group, and ICS 3PL. International Healthcare Solutions consists of Alliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). Profarma had previously been included in the Pharmaceutical Distribution Services reportable segment. The Company’s prior period segment disclosures have been revised to reflect this change in reportable segments.
Basis of Presentation
The accompanying financial statements present the consolidated financial position, results of operations, and cash flows of the Company as of the dates and for the periods indicated. All significant intercompany accounts and transactions have been eliminated in consolidation.
The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts due to uncertainties inherent in such estimates. Management periodically evaluates estimates used in the preparation of the financial statements for continued reasonableness.
Recently Adopted Accounting Pronouncements
In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectibility of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. ASU 2016-13 was effective for annual reporting periods beginning after December 15, 2019, including interim periods within those fiscal years, and a modified retrospective approach was required, with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance was effective.
The Company adopted ASU 2016-13 as of October 1, 2020. In connection with the adoption of ASU 2016-13, the Company recognized a $21.1 million, net of tax of $6.1 million, cumulative adjustment to retained earnings.
For the Company's credit loss policy, refer to the "Concentrations of Credit Risk and Allowance for Credit Losses" section of Note 1.
In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes" ("ASU 2019-12"). ASU 2019-12 removes certain exceptions to the general principles in Accounting Standards Codification ("ASC") 740 in order to reduce the cost and complexity of its application. ASU 2019-12 was effective for annual reporting periods beginning after December 15, 2020, including interim periods within those fiscal years, with certain amendments applied on a modified retrospective basis, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption, and others prospectively.
The Company adopted ASU No. 2019-12 as of October 1, 2021. The adoption of ASU No. 2019-12 had no impact on the Company's financial statements.
59
Recently Issued Accounting Pronouncements Not Yet Adopted
As of September 30, 2022, there were no recently issued accounting standards that may have a material impact on the Company's financial position, results of operations, or cash flows upon their adoption.
Business Combinations
The assets acquired and liabilities assumed from an acquired business are recorded at fair value, with the residual of the purchase price recorded as goodwill. The results of operations of an acquired businesses are included in the Company's operating results from the date of acquisition.
Cash, Cash Equivalents, and Restricted Cash
The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value.
The Company is required to maintain certain cash deposits with banks mainly consisting of deposits restricted under contractual agency agreements and cash restricted by law and other obligations, including opioid-related legal settlements.
The following represents a reconciliation of cash and cash equivalents in the Consolidated Balance Sheets to cash, cash equivalents, and restricted cash in the Consolidated Statements of Cash Flows:
September 30,
(amounts in thousands)202220212020
Cash and cash equivalents$3,388,189 $2,547,142 $4,597,746 
Restricted cash (included in Prepaid Expenses and Other)144,980 462,986 — 
Restricted cash (included in Other Assets)60,370 60,000 — 
Cash, cash equivalents, and restricted cash$3,593,539 $3,070,128 $4,597,746 
Concentrations of Credit Risk and Allowance for Credit Losses
    The Company sells its inventories to a large number of customers in the healthcare industry that include institutional and retail healthcare providers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies and providers of pharmacy services to such facilities, and physician offices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies, pharmacy departments of supermarkets and mass merchandisers, and veterinarians. The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry.
The Company's trade accounts receivables are exposed to credit risk. Revenue from the various agreements and arrangements with the Company's largest customer in the fiscal year ended September 30, 2022, Walgreens Boots Alliance, Inc. ("WBA"), accounted for approximately 27% of revenue and represented approximately 38% of accounts receivable, net of incentives, as of September 30, 2022. Express Scripts, Inc., the Company's second largest customer in the fiscal year ended September 30, 2022, accounted for approximately 13% of revenue and represented approximately 7% of accounts receivable as of September 30, 2022. The Company generally does not require collateral for trade receivables. The Company evaluates its receivables for risk of loss by grouping its receivables with similar risk characteristics. Expected losses are determined based on a combination of historical loss trends, current economic conditions, and forward-looking risk factors. Changes in these factors, among others, may lead to adjustments in the Company's allowance for credit losses. The calculation of the required allowance requires judgment by Company management as to the impact of those and other factors on the ultimate realization of its trade receivables. Each of the Company's business units performs ongoing credit evaluations of its customers' financial condition and maintains reserves for expected credit losses for specific credit problems when they arise. There were no significant changes to this process during the fiscal years ended September 30, 2022, 2021, and 2020, and bad debt expense was computed in a consistent manner during these periods.
The Company maintains cash, cash equivalents, and restricted cash with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and, therefore, bear minimal credit risk. The Company seeks to mitigate such risks by monitoring the risk profiles of these counterparties. The Company also seeks to mitigate risk by monitoring the investment strategy of money market accounts in which it is invested, which are classified as cash equivalents.
60
Contingencies
Loss Contingencies: In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, stockholder demands, and other disputes, including antitrust, commercial, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a liability when it is both probable that a loss has been incurred and the amount can be reasonably estimated. The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued. If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, the Company provides disclosure of the loss contingency in the notes to its financial statements. The Company reviews all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made. Among the loss contingencies that the Company considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 13.
Gain Contingencies: The Company records gain contingencies when they are realized. Gains from antitrust litigation settlements are realized upon the receipt of cash and recorded as a reduction to cost of goods sold because they represent a recovery of amounts historically paid to manufacturers to originally acquire the pharmaceuticals that were the subject of the antitrust litigation settlements (see Note 14).
Derivative Financial Instruments
The Company utilizes derivative financial instruments to manage exposures to foreign currency. The Company records all derivative financial instruments on the balance sheet at fair value and complies with established criteria for designation and effectiveness of hedging relationships. The Company's policy prohibits it from entering into derivative financial instruments for speculative or trading purposes.
Foreign Currency
When the functional currency of the Company's foreign operations is the applicable local currency, assets and liabilities are translated into U.S. dollars using the current exchange rates in effect at the balance sheet date, while revenues and expenses are translated at the weighted average exchange rates for the period. The resulting asset and liability translation adjustments are recorded as a component of Accumulated Other Comprehensive Loss within Stockholders' Equity.
During the quarter ended March 31, 2022, Turkey became a highly inflationary economy, as defined under U.S. GAAP. As a result, effective April 1, 2022, and until such time as the applicable economy is no longer considered highly inflationary, Turkish Lira-denominated assets and liabilities are remeasured using the Company's reporting currency in accordance with ASC 830, "Foreign Currency Matters." Turkish Lira denominated monetary assets and liabilities (primarily cash, accounts receivables, and accounts payables) are remeasured at each balance sheet date using the currency exchange rate then in effect, with currency remeasurement gains and losses recognized in Other Income in the Statement of Operations. Turkish Lira-denominated nonmonetary assets and liabilities (primarily inventories, goodwill, and other intangible assets) are translated at the currency exchange rate in effect prior to highly inflation accounting commencement or at the exchange rate in effect at their date of acquisition if subsequent to April 1, 2022. As such, nonmonetary assets and liabilities retain a higher historical basis when currencies are devalued. This higher historical basis results in incremental expense being recognized when nonmonetary assets are consumed (i.e., sale of inventory). During the fiscal year ended September 30, 2022, the Company recorded an incremental expense of $40.0 million in Cost of Goods Sold related to the consumption of inventory and an expense of $11.9 million within Other Income related to the currency remeasurement of monetary assets and liabilities.
Goodwill and Other Intangible Assets
Goodwill arises from acquisitions or consolidations of specific operating companies and is assigned to the reporting unit in which a particular operating company resides. The Company identifies its reporting units based upon the Company's management reporting structure, beginning with its operating segments. The Company aggregates two or more components within an operating segment that have similar economic characteristics. The Company evaluates whether the components within its operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment. The Company announced a strategic reorganization of its business and began reporting externally under the new structure as of October 1, 2021. As of September 30, 2022, the Company’s reporting units include Pharmaceutical Distribution Services, U.S. Consulting Services, MWI, Alliance Healthcare, Innomar, World Courier, and Profarma.
61
Goodwill and other intangible assets with indefinite lives, such as certain trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. For the purpose of these impairment tests, the Company can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite-lived intangible assets, respectively. Such qualitative factors can include, among others, industry and market conditions, overall financial performance, and relevant entity-specific events. If the Company concludes based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis. The Company elected to perform a quantitative impairment assessment of goodwill and indefinite-lived intangible assets in fiscal 2022. The Company elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in fiscal 2021, with the exception of its testing of goodwill in the AmerisourceBergen Consulting Services (the sum of U.S. Consulting Service and Innomar reporting units, under the Company’s prior reporting structure) and Profarma reporting units. The Company elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in fiscal 2020, with the exception of its testing of goodwill and indefinite-lived intangibles in the MWI and Profarma reporting units.
The quantitative goodwill impairment test requires the Company to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit. If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized. If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.
When performing a quantitative impairment assessment, the Company utilizes an income-based approach to value its reporting units, with the exception of the Profarma reporting unit, the fair value of which is based upon its publicly-traded stock price, plus an estimated control premium. The income-based approach relies on a discounted cash flow analysis, which considers forecasted cash flows discounted at an appropriate discount rate, to determine the fair value of each reporting unit. The Company generally believes that market participants would use a discounted cash flow analysis to determine the fair value of the Company's reporting units in a sale transaction. The annual goodwill impairment test requires the Company to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon the Company's long-range plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both debt and equity, including a risk premium. While the Company uses the best available information to prepare its forecasted cash flows and discount rate assumptions, actual future cash flows and/or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, the Company's overall methodology and the population of assumptions used have remained unchanged.
The quantitative impairment test for indefinite-lived intangibles other than goodwill (certain trademarks and trade names) consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date. The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method. The Company believes the relief from royalty method is a widely used valuation technique for such assets. The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.
The Company completed its required annual impairment tests relating to goodwill and indefinite-lived intangible assets in the fiscal years ended September 30, 2022, 2021, and 2020. The Company recorded goodwill impairments of $75.9 million and $6.4 million in its Profarma reporting unit in connection with its fiscal 2022 and 2021 impairment tests (see Note 5), respectively. No goodwill impairments were recorded in the fiscal years ended September 30, 2020, and no indefinite-lived intangible asset impairments were recorded in the fiscal years ended September 30, 2022, 2021, or 2020.
Finite-lived intangible assets are amortized using the straight-line method over the estimated useful lives of the assets. The Company performs a recoverability assessment of its long-lived assets when impairment indicators are present.
The Company recorded impairments of intangible and tangible assets totaling $361.7 million in the fiscal year ended September 30, 2020 in connection with the permanent shutdown of its compounding business.
62
Held for Sale
Assets and liabilities to be disposed of by sale ("disposal groups") are reclassified into assets and liabilities held for sale on the Company's Consolidated Balance Sheet. The reclassification occurs when an agreement to sell exists, or management has committed to a plan to sell the assets within one year. Disposal groups are measured at the lower of carrying value or fair value less costs to sell and are not depreciated or amortized. When the net realizable value of a disposal group increases during a period, a gain can be recognized to the extent that it does not increase the value of the disposal group beyond its original carrying value when the disposal group was reclassified as held for sale. The fair value of a disposal group, less any costs to sell, is assessed each reporting period it remains classified as held for sale and any remeasurement to the lower of carrying value or fair value less costs to sell is reported as an adjustment to the carrying value of the disposal group.
Income Taxes
The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities (commonly known as the asset and liability method). In assessing the need to establish a valuation allowance on deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.
The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including settlements with tax authorities or resolutions of any related appeals or litigation processes, based upon the technical merits of the position. Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based upon the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination.
Inventories
Inventories are stated at the lower of cost or market. Cost for approximately 66% of the Company's inventories as of September 30, 2022 and 2021 has been determined using the last-in, first-out ("LIFO") method. If the Company had used the first-in, first-out method of inventory valuation, which approximates current replacement cost, inventories would have been approximately $1,383.4 million and $1,316.2 million higher than the amounts reported as of September 30, 2022 and 2021, respectively. The Company recorded LIFO expense of $67.2 million and $7.4 million in the fiscal years ended September 30, 2022 and 2020, respectively, and a LIFO credit of $203.0 million in the fiscal year ended September 30, 2021. The annual LIFO provision is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict. Changes to any of the above factors can have a material impact to the Company's annual LIFO provision.
Investments
The Company first evaluates its investments in accordance with the variable interest model to determine whether it has a controlling financial interest in an investment. This evaluation is made as of the date on which the Company makes its initial investment, and subsequent evaluations are made if the structure of the investment changes. If it has determined that an investment is a variable interest entity ("VIE"), the Company evaluates whether the VIE is required to be consolidated. When the Company holds rights that give it the power to direct the activities of an entity that most significantly impact the entity's economic performance, combined with the obligation to absorb an entity's losses and the right to receive benefits, the Company consolidates a VIE. If it is determined that an investment is not a VIE, the Company then evaluates its investments under the voting interest model and generally consolidates investments in which it holds an ownership interest of greater than 50%. When the Company consolidates less-than-wholly-owned subsidiaries, it presents its noncontrolling interest in its consolidated financial statements.
    For equity securities without a readily determinable fair value, the Company uses the fair value measurement alternative and measures the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which the Company can exercise significant influence but does not control, it uses the equity method of accounting. The Company's share of earnings and losses of its investments is recorded in Other Income in the Consolidated Statements of Operations. The Company monitors its investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions.
63
Leases
At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the facts and circumstances present. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. At the lease commencement date, operating and finance lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable and, as such, the Company uses its incremental borrowing rate to discount the lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term in a similar economic environment. Certain adjustments to the right-of-use ("ROU") asset may be required for items such as incentives received. The Company does not recognize on the balance sheet leases with terms of one year or less.
    The Company has operating leases that are primarily comprised of buildings, office equipment, distribution center equipment, and vehicles. Some of the Company's leases include options to extend or early terminate the lease, which are included in the lease term when it is reasonably certain to exercise and there is a significant economic incentive to exercise that option. Certain lease agreements contain provisions for future rent increases. Lease payments included in the measurement of the lease liability comprise fixed payments. The Company combines lease and non-lease components as a single component. Operating lease cost is recognized over the expected lease term on a straight-line basis and is recorded in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations. Variable lease payments, which are primarily comprised of maintenance, taxes, and other payments based on usage, are recognized when the expense is incurred. The Company's leases do not contain residual value guarantees.
Manufacturer Incentives
The Company considers fees and other incentives received from its suppliers relating to the purchase and distribution of inventory to represent product discounts, and, as a result, they are recognized within cost of goods sold upon the sale of the related inventory.
Property and Equipment
Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 40 years for buildings and improvements and from 3 to 10 years for machinery, equipment, and other. The costs of repairs and maintenance are charged to expense as incurred.
The Company capitalizes project costs relating to computer software developed or obtained for internal use when the activities related to the project reach the application development stage. Costs that are associated with preliminary stage activities, training, maintenance, and all other post-implementation stage activities are expensed as they are incurred. Software development costs are depreciated using the straight-line method over the estimated useful lives, which range from 3 to 10 years.
The following table summarizes the Company's property and equipment balances for the periods indicated:
September 30,
(in thousands)20222021
Property and equipment, at cost:
Land$122,426 $129,944 
Buildings and improvements840,852 838,615 
Machinery, equipment, and other3,424,070 3,113,132 
Total property and equipment4,387,348 4,081,691 
Less accumulated depreciation(2,252,345)(1,918,730)
Property and equipment, net$2,135,003 $2,162,961 
Revenue Recognition
The Company's revenues are primarily generated from the distribution of pharmaceutical products. The Company also generates revenues from global commercialization services, which include clinical trial support, post-approval and commercialization support, and global specialty transportation and logistics for the biopharmaceutical industry. See Note 15 for the Company's disaggregated revenue.
The Company recognizes revenue related to the distribution of products at a point in time when title and control transfers to customers and there is no further obligation to provide services related to such products. Service revenue is recognized over the period that services are provided to the customer. The Company is generally the principal in a transaction;
64
therefore, revenue is primarily recorded on a gross basis. When the Company is the principal in a transaction, it has determined that it controls the ability to direct the use of the product or service prior to the transfer to a customer, it is primarily responsible for fulfilling the promise to provide the product or service to its customer, it has discretion in establishing pricing, and it controls the relationship with the customer. Revenue is recognized at the amount of consideration expected to be received. For the distribution business, revenue is primarily generated from a contract related to a confirmed purchase order with a customer in a distribution arrangement and is net of estimated sales returns and allowances, other customer incentives, and sales tax.
When the Company is the agent in a transaction, the fee received from a manufacturer customer is recognized within revenue as the service is performed.
The Company's customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit. The Company records an accrual for estimated customer sales returns at the time of sale to the customer based upon historical return trends. As of September 30, 2022 and 2021, the Company's accrual for estimated customer sales returns was $1,532.1 million and $1,271.6 million, respectively.
Share-Based Compensation
    The Company accounts for the compensation cost of all share-based payments at fair value. The fair value of restricted stock units and performance stock units is based upon the grant date market price of the Company’s common stock. The Company estimated the fair value of options granted in fiscal 2020 using a binomial option pricing model.
    Share-based compensation expense is recognized over the requisite service period within Distribution, Selling, and Administrative in the Consolidated Statements of Operations to correspond with the same line item as the cash compensation paid to employees. Compensation expense associated with nonvested performance stock units is dependent upon the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued.
    The income tax effects of awards are recognized when the awards vest or are settled and are recognized in Income Tax Expense in the Company’s Consolidated Statements of Operations.
Shipping and Handling Costs
Shipping and handling costs include all costs to warehouse, pick, pack, and deliver inventory to customers. These costs, which were $1,040.8 million, $809.3 million, and $665.3 million for the fiscal years ended September 30, 2022, 2021, and 2020, respectively, are included in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations.
Supplier Reserves
The Company establishes reserves against amounts due from its suppliers relating to various price and rebate incentives, including deductions or billings taken against payments otherwise due to them from the Company. These reserve estimates are established based upon the judgment of Company management after carefully considering the status of current outstanding claims, historical experience with the suppliers, the specific incentive programs, and any other pertinent information available to the Company. The Company evaluates the amounts due from its suppliers on a continual basis and adjusts the reserve estimates when appropriate based upon changes in factual circumstances. The ultimate outcome of any outstanding claim may be different than the Company's estimate.
65
Note 2. Acquisition and Assets and Liabilities Held for Sale
Acquisition
On June 1, 2021, the Company acquired a majority of Walgreens Boots Alliance, Inc.'s ("WBA") Alliance Healthcare businesses ("Alliance Healthcare") for $6,662.0 million in cash, $229.1 million of the Company's common stock (2 million shares at the Company's June 1, 2021 opening stock price of $114.54 per share), and $6.1 million of other equity consideration. The net cash payment was $5,596.7 million, as the Company acquired $922.0 million of cash and cash equivalents and $143.3 million of restricted cash. The shares issued were from the Company's treasury stock on a first-in, first-out basis and were originally purchased for $149.1 million. In the fiscal year ended September 30, 2022, the Company's previous estimate of $96.9 million of accrued consideration was settled for $60.0 million, which resulted in a $36.9 million reduction to Goodwill. The $60.0 million cash payment is included in the total $6,662.0 million cash consideration. The Company funded the cash purchase price through a combination of cash on hand and new debt financing. The acquisition expands the Company's reach and solutions in pharmaceutical distribution and adds to the Company's depth and breadth of global manufacturer services.
The Company completed the purchase price allocation as of June 1, 2022 and recorded purchase accounting adjustments that reduced working capital account balances by $102.7 million, increased the corresponding deferred tax assets by $63.0 million, and decreased other assets by $13.3 million, which resulted in a $53.0 million increase to Goodwill. There were no measurement period adjustments recorded to the previously-reported opening balance sheet that would have had a material impact on the Company's previously-reported results of operations had those adjustments been recorded in the previous reporting periods. The final purchase price has been allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values at the date of the acquisition in the table that follows:
66
(in thousands)
Consideration
Cash$6,662,020 
Equity (2 million shares of AmerisourceBergen Corporation common stock)
229,080 
Other equity consideration6,061 
Fair value of total consideration$6,897,161 
Recognized amounts of identifiable assets acquired and liabilities assumed
Cash and cash equivalents$921,995 
Accounts receivable3,628,056 
Inventories1,647,330 
Prepaid expenses and other355,030 
Property and equipment634,220 
Goodwill2,496,338 
Other intangible assets3,735,000 
Deferred income taxes33,922 
Other assets534,393 
Total assets acquired13,986,284 
Accounts payable(4,618,807)
Accrued expenses and other(765,463)
Short-term debt(353,420)
Deferred income taxes(760,937)
Other liabilities(405,332)
Total liabilities assumed(6,903,959)
Net assets acquired7,082,325 
Noncontrolling interest(185,164)
Equity consideration(235,141)
Cash acquired, including restricted cash of $143,308 included in Prepaid Expenses and Other
(1,065,303)
Net cash paid$5,596,717 
The estimated fair value of the intangible assets acquired of $3.7 billion and the estimated useful lives are as follows:
(in thousands, except useful lives)Fair ValueWeighted-Average Useful Life
Customer relationships$3,327,000 18
Trade names408,000 11
Total$3,735,000 
Goodwill resulting from this acquisition is not expected to be deductible for income tax purposes.
The fair value of the $185.2 million noncontrolling interest in Alliance Healthcare Egypt, a 50%-owned subsidiary, was estimated by applying income and market-based approaches. This fair value measurement is based on inputs that are not observable in the market and; therefore, represents a fair value measurement categorized within Level 3 of the fair value hierarchy.
The Company incurred $90.9 million of acquisition-related costs in connection with this acquisition. These costs are included in Acquisition, Integration, and Restructuring Expenses in the Company's Statements of Operations for the twelve months ended September 30, 2021.
67
See Part I. Other Information-Item 1A. Risk Factors of this Annual Report on Form 10-K for additional risk factors related to our strategic transactions with WBA.
Assets and Liabilities Held for Sale
The Company entered into agreements in the fourth quarter of fiscal 2021 to sell two of its non-core subsidiaries. In connection with entering into these agreements, the Company concluded that both disposal groups met the held for sale criteria and classified their assets and liabilities as held for sale as of September 30, 2021. One disposal group was included within the U.S. Healthcare Solutions reportable segment and the other disposal group was included within International Healthcare Solutions reportable segment.
In connection with the held for sale classification, the Company recorded a total loss of $16.3 million on the remeasurement of the disposal group held for sale in the U.S. Healthcare Solutions reportable segment to fair value less cost to sell, $4.9 million of which was recorded in Impairment of Assets on its Consolidated Statement of Operations in the fiscal year ended September 30, 2022. The Company previously recorded a loss of $11.3 million in fiscal year ended September 30, 2021. The Company completed the sales of the disposal groups in the fiscal year ended September 30, 2022 and received total proceeds of $267.6 million, subject to final working capital adjustments. In connection with the sales of these disposal groups, the Company recorded a gain of $52.6 million, which is included in Other Income, Net in the Company's Consolidated Statements of Operations.
Total assets and liabilities of the combined disposal groups held for sale on the September 30, 2021 Consolidated Balance Sheet are comprised of the following:
(in thousands)
Cash and cash equivalents$1,751 
Accounts receivable, less allowance for credit losses182,077 
Inventories123,424 
Prepaid expenses and other11,258 
Property and equipment3,084 
Goodwill31,903 
Other intangible assets22,923 
Other assets7,812 
Loss on the remeasurement of a disposal group held for sale to fair value less cost to sell(11,324)
    Total assets held for sale$372,908 
Accounts payable$173,104 
Accrued expenses and other7,234 
Short-term debt4,225 
Long-term debt50 
Deferred income taxes5,857 
Other liabilities1,599 
    Total liabilities held for sale$192,069 
68
Note 3. Variable Interest Entity
The Company has substantial governance rights that allow it to direct the activities that significantly impact Profarma’s economic performance. As such, the Company consolidates the operating results of Profarma in its consolidated financial statements. The Company is not obligated to provide future financial support to Profarma.
The following assets and liabilities of Profarma are included in the Company's Consolidated Balance Sheet for the periods indicated:
(in thousands)September 30,
2022		September 30,
2021
Cash and cash equivalents$23,144 $33,699 
Accounts receivables, net192,930 148,485 
Inventories207,858 168,229 
Prepaid expenses and other63,982 62,545 
Property and equipment, net35,554 31,920 
Goodwill— 75,936 
Other intangible assets66,568 70,840 
Other long-term assets71,327 74,177 
Total assets$661,363 $665,831 
Accounts payable$215,515 $162,768 
Accrued expenses and other47,952 38,477 
Short-term debt60,851 64,215 
Long-term debt64,918 52,613 
Deferred income taxes25,801 37,041 
Other long-term liabilities52,417 57,945 
Total liabilities$467,454 $413,059 
Profarma's assets can only be used to settle its obligations, and its creditors do not have recourse to the general credit of the Company.
Profarma Retail Equity Offering
In August 2020, Profarma received $66.4 million through an equity offering of its retail business. The equity offering decreased Profarma's voting ownership interest in the retail business from 100% to 53.5%. Profarma continues to consolidate the operating results of the retail business in its consolidated financial statements.
69
Note 4. Income Taxes
The following table summarizes the Company's income (loss) before income taxes for the periods indicated:
 Fiscal Year Ended September 30,
(in thousands)202220212020
Domestic$1,351,696 $1,495,899 $(5,961,269)
Foreign831,361 725,960 667,438 
Total$2,183,057 $2,221,859 $(5,293,831)
The components of the Company's consolidated income tax expense (benefit) are summarized in the following table for the periods indicated:
 Fiscal Year Ended September 30,
(in thousands)202220212020
Current provision (benefit):   
Federal$126,969 $184,375 $(473,751)
State and local39,282 30,659 30,236 
Foreign154,082 127,351 94,213 
Total current provision (benefit)320,333 342,385 (349,302)
Deferred provision (benefit):   
Federal150,328 111,428 (914,613)
State and local31,129 47,516 (264,409)
Foreign14,727 175,922 (365,949)
Total deferred provision (benefit)196,184 334,866 (1,544,971)
Provision (benefit) for income taxes$516,517 $677,251 $(1,894,273)
A reconciliation of the statutory U.S. federal income tax rate to the Company's consolidated effective income tax rate is as follows for the periods indicated:
 Fiscal Year Ended September 30,
 202220212020
Statutory U.S. federal income tax rate21.0%21.0%21.0%
State and local income tax rate, net of federal tax benefit2.52.8(0.5)
Tax effect of foreign operations(1.9)(0.5)1.0
Litigation settlements and accruals (see Note 13)
0.40.8(6.2)
Tax law changes 1
—7.36.8
PharMEDium worthless stock deduction—(1.1)12.4
CARES Act——1.2
Other, net1.70.20.1
Effective income tax rate23.7%30.5%35.8%
1 Tax law changes include 5.7% related to UK Tax Reform and 1.6% related to Swiss Tax Reform in fiscal 2021 and 6.8% in fiscal 2020 related to Swiss Tax Reform.
United Kingdom Tax Reform
The United Kingdom ("UK") government delivered a Spring Budget in March 2021 that set out a plan to provide continuing support for jobs and businesses as the UK recovers from the COVID-19 pandemic. The UK government Finance Act 2021 includes a provision to increase the corporate tax rate from 19% to 25% beginning on April 1, 2023. As a result, the Company recognized a deferred tax expense of $127.6 million to increase its deferred tax liabilities for the change in the tax rate in the fiscal year ended September 30, 2021.

70
The Coronavirus Aid, Relief, and Economic Security Act
    The Coronavirus Aid, Relief, and Economic Security ("CARES") Act became law on March 27, 2020. The CARES Act was a response to the market volatility and instability resulting from the coronavirus pandemic and included provisions to support businesses in the form of loans, grants, and tax changes, among other types of relief that were not previously available under the U.S. Tax Cuts and Jobs Act of 2017 (the "2017 Tax Act"). The CARES Act provided the Company relief through adjustments to net operating loss rules and the acceleration of available refunds for alternative minimum tax credit carryforwards.
PharMEDium
    The Company decided in January 2020 to shut down and permanently exit its compounding business. Following the decision to exit PharMEDium and in connection with the permanent shutdown of this business, PharMEDium underwent a voluntary change in tax status, which resulted in the Company recognizing a worthless stock ordinary income tax deduction of approximately $2.4 billion and, in turn, yielded a tax benefit of approximately $655 million. The estimated tax benefit was higher than it would have been prior to the enactment of the CARES Act as the net operating losses resulting from the worthless stock deduction could now be carried back to years with higher statutory tax rates.
In addition to the PharMEDium worthless stock deduction, the Company recognized other discrete tax benefits primarily resulting from the CARES Act. In the aggregate, the Company recognized discrete tax benefits of $720.6 million in the fiscal year ended September 30, 2020.
The Company's September 30, 2022 Consolidated Balance Sheet includes a current income tax receivable balance of $172.6 million primarily resulting from the recognition of the above discrete tax benefits.
Swiss Tax Reform
In August 2020, the Canton of Bern enacted tax reforms to comply with requirements imposed by earlier Swiss federal tax reforms, which were retroactively effective as of January 1, 2020. A key provision of the Swiss federal tax reforms was the elimination of cantonal preferential tax regimes, which had the effect of increasing overall tax rates on Swiss income. To phase in the tax rate increase, the canton of Bern granted a tax ruling to the Company that effectively reduces the Company's Swiss tax rate for a period of 10 years.
As a result of the aforementioned Swiss tax law change and ruling, the Company recorded a deferred tax asset in the fiscal year ended September 30, 2020 that is expected to be realized over the following 10 years. As of September 30, 2022, the deferred tax asset of $446.6 million was reduced by a $234.0 million valuation allowance for the amount that more likely than not will not be realized.
In November 2020, the Canton of Bern approved its Budget 2021, which called for lowering its corporate income tax rate applicable to the Company’s Swiss operations effective October 1, 2020. As a result, the Company recognized a deferred tax expense to reduce its Swiss deferred tax asset for the change in tax rate.
Opioid Legal Accrual
In the fiscal years ended September 30, 2022, 2021, and 2020 the Company recorded accruals related to the opioid litigation settlements of $36.6 million, $147.7 million, and $6.6 billion, respectively (see Note 13). The Company's September 30, 2022 Consolidated Balance Sheet includes a net deferred tax asset of $981.6 million in connection with the total expense accrued.




71
Deferred income taxes reflect the future tax consequences of differences between the tax bases of assets and liabilities and their financial reporting amounts. Significant components of the Company's deferred tax liabilities (assets) are as follows:
 September 30,
(in thousands)20222021
Inventories$1,471,064 $1,388,913 
Property and equipment149,896 167,974 
Goodwill and other intangible assets1,184,477 1,409,296 
Right-of-use assets219,616 249,920 
Other61,148 57,450 
Gross deferred tax liabilities3,086,201 3,273,553 
Net operating loss and tax credit carryforwards(426,651)(389,724)
Allowance for credit losses(67,788)(27,569)
Accrued expenses(24,435)(13,411)
Accrued litigation liability(981,627)(1,082,845)
Employee and retiree benefits(22,682)(26,196)
Goodwill and other intangible assets(446,605)(488,235)
Lease liabilities(241,469)(263,278)
Share-based compensation(33,933)(37,466)
Other(75,428)(88,855)
Gross deferred tax assets(2,320,618)(2,417,579)
Valuation allowance for deferred tax assets617,259 538,531 
Deferred tax assets, net of valuation allowance(1,703,359)(1,879,048)
Net deferred tax liabilities$1,382,842 $1,394,505 
As of September 30, 2022, the Company had $2.6 million of potential tax benefits from federal net operating loss carryforwards, which expire in 15 years, $136.0 million of potential tax benefits from state net operating loss carryforwards and $297.2 million of potential tax benefits from foreign net operating loss carryforwards, which have varying expiration dates. The Company had $6.0 million of state tax credit carryforwards and $3.1 million in foreign alternative minimum tax credit carryforwards.
The Company assesses the available positive and negative evidence to determine whether deferred tax assets are more likely than not to be realized. As a result of this assessment, valuation allowances have been recorded on certain deferred tax assets. For the fiscal year ended September 30, 2022 and 2021, the Company increased the valuation allowance on deferred tax assets by $78.7 million and $126.9 million, respectively. The increase in the valuation allowance in the fiscal year ended September 30, 2022 was primarily due to the increase in the valuation allowance against foreign net operating loss carryforwards. The increase in the valuation allowance in the fiscal year ended September 30, 2021 was primarily due to the valuation allowance established in connection with purchase accounting associated with Alliance Healthcare acquisition.
In the fiscal years ended September 30, 2022, 2021, and 2020 tax benefits of $13.4 million, $8.2 million and $3.9 million, respectively, related to the exercise of employee stock options and lapses of restricted stock units were recorded in Income Tax Expense (Benefit) in the Company's Consolidated Statements of Operations. The tax benefits recognized in the fiscal years ended September 30, 2022, 2021, and 2020 are not necessarily indicative of amounts that may arise in future periods.
Income tax payments, net of refunds, were $244.4 million, $93.5 million, and $139.4 million in the fiscal years ended September 30, 2022, 2021, and 2020, respectively.
Cumulative undistributed earnings of international subsidiaries were $3.7 billion as of September 30, 2022, $2.1 billion of which is considered permanently reinvested. It is not practicable to estimate the taxes that would be due if such earnings were to be repatriated in the future.
The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various states and foreign jurisdictions. The Company is currently undergoing a U.S. federal income tax audit for fiscal years 2019 and 2018 and certain state and local income tax audits for various years. With few exceptions, the Company is no longer subject to U.S. federal tax
72
examinations for years before 2018, and state and local, or foreign income tax examinations by tax authorities for years before 2019. The Company believes it has adequate tax reserves to cover potential federal, state or foreign tax exposures.
As of September 30, 2022 and 2021, the Company had unrecognized tax benefits, defined as the aggregate tax effect of differences between tax return positions and the benefits recognized in the Company's financial statements, of $553.2 million and $522.8 million, respectively ($479.6 million and $467.9 million, net of federal tax benefit, respectively). If recognized in the fiscal years ended September 30, 2022 and 2021, $461.4 million and $449.7 million, respectively, of these benefits would have reduced income tax expense and the effective tax rate. As of September 30, 2022 and 2021, included in the unrecognized tax benefits are $26.7 million and $22.4 million of interest and penalties, respectively, which the Company records in Income Tax Expense (Benefit) in the Company's Consolidated Statements of Operations.
A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, for the periods indicated is as follows:
Fiscal Year Ended September 30,
(in thousands)202220212020
Unrecognized tax benefits at beginning of period$500,399 $478,351 $105,657 
Additions of tax positions of the current year21,074 20,515 385,797 
Additions to tax positions of the prior years5,073 17,022 5,599 
Reductions of tax positions of the prior years— — (6,480)
Expiration of statutes of limitations(24)(15,489)(12,222)
Unrecognized tax benefits at end of period$526,522 $500,399 $478,351 
Included in the additions of unrecognized tax benefits in the fiscal year ended September 30, 2020 is $371.5 million for an unrecognized tax benefit related to the $6.6 billion legal accrual for litigation related to the global opioid settlement, as well as other opioid-related litigation, as disclosed in Note 13. The Company has applied significant judgment in estimating the amount of the opioid settlements that will be deductible for U.S. federal and state purposes. In estimating the amount that would be deductible, the Company considered prior U.S. tax case law, the amount and character of the damages sought in litigation, and other relevant factors. During the next 12 months, it is reasonably possible that tax audit resolutions and the expiration of statutes of limitations could result in a reduction of unrecognized tax benefits by approximately $21.2 million.
Note 5. Goodwill and Other Intangible Assets
In connection with the change in the Company's reporting structure that is discussed in Note 1, the Company reallocated goodwill among the impacted reporting units using a relative fair value approach and assessed impairment before and after goodwill was reallocated. The following is a summary of the changes in the carrying value of goodwill, by reportable segment, for the fiscal years ended September 30, 2022 and 2021:
(in thousands)U.S. Healthcare SolutionsInternational Healthcare SolutionsTotal
Goodwill as of September 30, 2020 (as revised)$6,267,502 $439,217 $6,706,719 
Goodwill recognized in connection with acquisitions (Note 2)19,076 2,469,152 2,488,228 
Goodwill impairment— (6,373)(6,373)
Goodwill reclassified to assets held for sale (Note 2)(27,223)(4,680)(31,903)
Foreign currency translation1,019 (127,159)(126,140)
Goodwill as of September 30, 2021 (as revised)6,260,374 2,770,157 9,030,531 
Purchase accounting adjustments— 27,186 27,186 
Goodwill recognized in connection with acquisition26,143 — 26,143 
Goodwill derecognized in connection with disposal(1,224)— (1,224)
Goodwill impairment— (75,936)(75,936)
Foreign currency translation(5,053)(497,761)(502,814)
Goodwill as of September 30, 2022$6,280,240 $2,223,646 $8,503,886 
In connection with the Company's annual goodwill impairment test as of July 1, 2021, the Company recorded a goodwill impairment of $6.4 million in its Profarma reporting unit. The fair value of the reporting unit was determined based upon Profarma's publicly-traded stock price, plus an estimated control premium. This represents a level 2 nonrecurring fair value measurement.
73
As a result of a prolonged decline in Profarma’s stock price, the Company performed an impairment assessment over the Profarma reporting unit as of June 30, 2022 and recorded a goodwill impairment of $75.9 million in the fiscal year ended September 30, 2022. The Company determined the fair value of the Profarma reporting unit based upon Profarma’s publicly-traded stock price, plus an estimated control premium. This represents a level 2 nonrecurring fair value measurement.
In connection with the Profarma impairment assessment, the Company first performed a recoverability assessment of Profarma’s long-lived assets by comparing the undiscounted cash flows to the carrying value of the Profarma asset group, and it was determined to be recoverable. However, the forecasted undiscounted cash flows used to perform the recoverability assessment are inherently uncertain and include assumptions that could differ from actual results in future periods.
The following is a summary of other intangible assets:
 September 30, 2022September 30, 2021
(dollars in thousands)Weighted Average Remaining Useful LifeGross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount		Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount
Indefinite-lived trade names$667,932 $— $667,932 $668,119 $— $668,119 
Finite-lived:
Customer relationships15 years4,226,547 (931,961)3,294,586 4,838,549 (718,750)4,119,799 
Trade names and other11 years542,346 (172,127)370,219 609,050 (140,041)469,009 
Total other intangible assets$5,436,825 $(1,104,088)$4,332,737 $6,115,718 $(858,791)$5,256,927 
The decreases in the gross amounts of finite-lived intangible assets since September 30, 2021 were primarily due to foreign currency translation.
Amortization expense for finite-lived intangible assets was $307.3 million, $178.3 million, and $110.9 million in the fiscal years ended September 30, 2022, 2021, and 2020, respectively. Amortization expense for finite-lived intangible assets is estimated to be $275.5 million in fiscal 2023, $274.3 million in fiscal 2024, $273.3 million in fiscal 2025, $268.9 million in fiscal 2026, $264.2 million in 2027, and $2,308.6 million thereafter.
74
Note 6. Debt
Debt consisted of the following:
 September 30,
(in thousands)20222021
Revolving credit note$— $— 
Money market facility— — 
Receivables securitization facility due 2025350,000 350,000 
Term loan due June 2023— 249,640 
Overdraft facility due 2024 (£10,000)
— — 
Multi-currency revolving credit facility due 2027— — 
0.737% senior notes due 2023
672,736 1,518,223 
$500,000, 3.400% senior notes due 2024
499,195 498,714 
$500,000, 3.250% senior notes due 2025
498,347 497,669 
$750,000, 3.450% senior notes due 2027
745,622 744,781 
$500,000, 2.800% senior notes due 2030
495,348 494,738 
$1,000,000, 2.700% senior notes due 2031
990,480 989,366 
$500,000, 4.250% senior notes due 2045
495,162 494,946 
$500,000, 4.300% senior notes due 2047
493,288 493,021 
Alliance Healthcare debt336,886 235,998 
Nonrecourse debt125,769 116,828 
Total debt5,702,833 6,683,924 
Less AmerisourceBergen Corporation current portion672,736 — 
Less Alliance Healthcare current portion336,886 235,998 
Less nonrecourse current portion60,851 64,215 
Total, net of current portion$4,632,360 $6,383,711 
Multi-Currency Revolving Credit Facility
The Company has a $2.4 billion multi-currency senior unsecured revolving credit facility ("Multi-Currency Revolving Credit Facility") with a syndicate of lenders, which was scheduled to expire in November 2026. In October 2022, the Company amended the Multi-currecy Revolving Credit Facility to extend the expiration to October 2027 and to make certain changes to effect a transition from the LIBOR interest rate benchmark to Term SOFR. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based upon the Company's debt rating and ranges from 80.5 basis points to 122.5 basis points over SOFR/EURIBOR/CDOR/RFR, as applicable (101.5 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee as of September 30, 2022) and from 0 basis points to 22.5 basis points over the alternate base rate and Canadian prime rate, as applicable. The Company pays facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on its debt rating, ranging from 7 basis points to 15 basis points, annually, of the total commitment (11 basis points as of September 30, 2022). The Company may choose to repay or reduce its commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which the Company was compliant as of September 30, 2022.
Commercial Paper Program
The Company has a commercial paper program whereby it may from time to time issue short-term promissory notes in an aggregate amount of up to $2.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase the Company's borrowing capacity as it is fully backed by the Company's Multi-Currency Revolving Credit Facility. There were no borrowings outstanding under the commercial paper program as of September 30, 2022 and 2021.
75
Receivables Securitization Facility
The Company has a $1,450 million receivables securitization facility ("Receivables Securitization Facility"), which was scheduled to expire in November 2024. In October 2022, the Company amended the Receivables Securitization Facility (the “Receivables Amendment”) to extend the expiration for an additional one year to October 2025. In addition, the Receivables Amendment made certain changes to (i) substitute Term SOFR for LIBOR as a benchmark and establish procedures to choose a new benchmark if Term SOFR becomes unavailable, (ii) provide for the return of erroneous payments, if any, by purchasers, (iii) update provisions regarding compliance with sanctions and anti-money laundering laws, and (iv) implement certain other technical amendments. The Company has available to it an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters. Interest rates are based on prevailing market rates for short-term commercial paper or 30-day Term SOFR, plus a program fee. The Company pays a customary unused fee at prevailing market rates, annually, to maintain the availability under the Receivables Securitization Facility.
In connection with the Receivables Securitization Facility, AmerisourceBergen Drug Corporation and a specialty distribution subsidiary sell on a revolving basis certain accounts receivable to Amerisource Receivables Financial Corporation, a wholly-owned special purpose entity, which in turn sells a percentage ownership interest in the receivables to financial institutions and commercial paper conduits sponsored by financial institutions. AmerisourceBergen Drug Corporation is the servicer of the accounts receivable under the Receivables Securitization Facility. As sold receivables are collected, additional receivables may be sold up to the maximum amount available under the facility. The facility is a financing vehicle utilized by the Company because it generally offers an attractive interest rate relative to other financing sources. The Company securitizes its trade accounts, which are generally non-interest bearing, in transactions that are accounted for as borrowings. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of September 30, 2022.
Revolving Credit Note, Overdraft Facility, and Money Market Facility
The Company has an uncommitted, unsecured line of credit available to it pursuant to a revolving credit note ("Revolving Credit Note"). The Revolving Credit Note provides the Company with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million. The Revolving Credit Note may be decreased or terminated by the bank or the Company at any time without prior notice. The Company also has an uncommitted U.K. overdraft facility ("Overdraft Facility") to fund short-term normal trading cycle fluctuations related to its MWI Animal Health business. In February 2021, the Company extended the Overdraft Facility to February 2024 and reduced the borrowing capacity from £30 million to £10 million. The Company has an uncommitted, unsecured line of credit available to it pursuant to a money market credit agreement ("Money Market Facility"). The Money Market Facility provides the Company with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $100 million. The Money Market Facility may be decreased or terminated by the bank or the Company at any time without prior notice.
Term Loans
The Company's $400 million October 2018 Term Loan matured and was repaid in October 2020.
In February 2021, the Company entered into a $1.0 billion variable-rate term loan (“February 2021 Term Loan”), which was available to be drawn on the closing date of the acquisition of Alliance Healthcare. In April 2021, the Company reduced its commitment under the February 2021 Term Loan to $500 million. In June 2021, the Company borrowed $500 million under the February 2021 Term Loan to finance a portion of the June 2021 Alliance Healthcare acquisition. The Company elected to make principal payments of $250 million in September 2021 and again in March 2022 to repay the loan that was scheduled to mature in 2023.
Senior Notes
In May 2020, the Company issued $500 million of 2.80% senior notes due May 15, 2030 (the "2030 Notes"). The 2030 Notes were sold at 99.71% of the principal amount and have an effective yield of 2.81%. Interest on the 2030 Notes is payable semi-annually in arrears, commencing on November 15, 2020. The 2030 Notes rank pari passu to the Company's other senior notes, the Multi-Currency Revolving Credit Facility, the Revolving Credit Note, the Overdraft Facility, and the Money Market Facility.
The Company used the proceeds from the 2030 Notes to finance the early retirement of the $500 million of 3.50% senior notes that were due in 2021 and made a $21.4 million prepayment premium in connection with this early retirement.
76
In March 2021, the Company issued $1,525 million of 0.737% senior notes due March 15, 2023 (the "2023 Notes"). The 2023 Notes were sold at 100.00% of the principal amount. Interest on the 2023 Notes is payable semi-annually in arrears, commencing on September 15, 2021. In March 2021, the Company issued $1,000 million of 2.700% senior notes due March 15, 2031 (the "2031 Notes"). The 2031 Notes were sold at 99.79% of the principal amount and have an effective yield of 2.706%. Interest on the 2031 Notes is payable semi-annually in arrears and commenced on September 15, 2021. The 2023 Notes and 2031 Notes rank pari passu to the Company's other senior notes, the Multi-Currency Revolving Credit Facility, the Revolving Credit Note, the Overdraft Facility, and the Money Market Facility. The Company used the proceeds from the 2023 Notes and the 2031 Notes to finance a portion of the June 2021 Alliance Healthcare acquisition.
In the fiscal year ended September 30, 2022, the Company elected to repay $850 million of 2023 Notes due in March 2023.
The senior notes discussed above and also illustrated in the above debt table are collectively referred to as the "Notes." Interest on the Notes is payable semiannually in arrears. Most of the Notes were sold at small discounts to the principal amounts and, therefore, have effective yields that are greater than the stated interest rates in the table above. Costs incurred in connection with the issuance of the Notes were deferred and are being amortized over the terms of the Notes. The indentures governing the Notes contain restrictions and covenants, which include limitations on additional indebtedness; distributions to stockholders; the repurchase of stock and the making of other restricted payments; issuance of preferred stock; creation of certain liens; transactions with subsidiaries and other affiliates; and certain corporate acts such as mergers, consolidations, and the sale of substantially all assets. An additional covenant requires compliance with a financial leverage ratio test. The Company was compliant with all covenants as of September 30, 2022.
Alliance Healthcare Debt
Alliance Healthcare debt is comprised of uncommitted revolving credit facilities in various currencies with various rates. A majority of the outstanding borrowings were held in Egypt (which is 50% owned) as of September 30, 2022 and 2021. These facilities are used to fund its working capital needs.
Nonrecourse Debt
    Nonrecourse debt is comprised of short-term and long-term debt belonging to the Brazil subsidiaries and is repaid solely from the Brazil subsidiaries' cash flows and such debt agreements provide that the repayment of the loans (and interest thereon) is secured solely by the capital stock, physical assets, contracts, and cash flows of the Brazil subsidiaries.
Other Information
Scheduled future principal payments of debt are $1,071.8 million in fiscal 2023, $526.3 million in fiscal 2024, $873.2 million in fiscal 2025, $12.1 million in fiscal 2026, $2.7 million in fiscal 2027, and $3,252.6 million thereafter.
Interest paid on the above indebtedness during the fiscal years ended September 30, 2022, 2021, and 2020 was $219.8 million, $170.9 million, and $150.7 million, respectively.
Total amortization of financing fees and the accretion of original issue discounts, which are recorded as components of Interest Expense, Net on the Consolidated Statements of Operations, were $11.9 million, $9.7 million, and $6.4 million, for the fiscal years ended September 30, 2022, 2021, and 2020, respectively.
Note 7. Stockholders' Equity and Weighted Average Common Shares Outstanding
The authorized capital stock of the Company consists of 600,000,000 shares of common stock, par value $0.01 per share (the "common stock"), and 10,000,000 shares of preferred stock, par value $0.01 per share (the "preferred stock").
The holders of the Company's common stock are entitled to one vote per share and have the exclusive right to vote for the board of directors and for all other purposes as provided by law. Subject to the rights of holders of the Company's preferred stock, holders of common stock are entitled to receive ratably on a per share basis such dividends and other distributions in cash, stock, or property of the Company as may be declared by the board of directors from time to time out of the legally available assets or funds of the Company. The opioid litigation accrual discussed in Note 13 has not and is not expected to impact the Company's ability to pay dividends.
77
The following illustrates the components of Accumulated Other Comprehensive Loss, net of income taxes:
 September 30,
(in thousands)20222021
Pension and postretirement adjustments$(9,038)$(5,750)
Foreign currency translation(1,820,292)(439,692)
Other(1,640)— 
Total accumulated other comprehensive loss$(1,830,970)$(445,442)
The increase in total accumulated other comprehensive loss from foreign currency translation primarily relates to the translation of the Company's Alliance Healthcare business' goodwill and intangible assets balances.
In October 2018, the Company's board of directors authorized a share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2019, the Company purchased 6.7 million shares of its common stock for a total of $538.9 million under this program, which included $14.8 million of September 2019 purchases that cash settled in October 2019. During the fiscal year ended September 30, 2020, the Company purchased 4.9 million shares of its common stock for a total of $405.6 million, which excluded $14.8 million of September 2019 purchases that cash settled in October 2019. During the fiscal year ended September 30, 2021, the Company purchased 0.6 million shares of its common stock for a total of $55.5 million to complete its authorization under this program.
In May 2020, the Company's board of directors authorized a share repurchase program allowing the Company to purchase up to $500 million of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2021, the Company purchased 0.3 million shares of its common stock for $26.6 million. During the fiscal year ended September 30, 2022, the Company purchased 3.3 million shares of its common stock for $473.4 million to complete its authorization under this program.
In May 2022, the Company's board of directors authorized a new share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2022, the Company purchased 0.3 million shares of its common stock for a total of $38.7 million, which included $28.4 million of September 2022 purchases that cash settled in October 2022. As of September 30, 2022, the Company had $961.3 million of availability remaining under this program. In October 2022, under this program, the Company purchased 0.6 million shares of its common stock for $78.8 million. In November 2022, under this program, the Company purchased 3.2 million shares of its common stock from WBA for $500.0 million.
Common Shares Outstanding
Basic earnings per share is computed by dividing net income attributable to AmerisourceBergen Corporation by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed by dividing net income attributable to AmerisourceBergen Corporation by the weighted average number of shares of common stock outstanding, plus the dilutive effect of stock options and restricted stock units during the periods presented.
The following illustrates the components of diluted weighted average shares outstanding:
 Fiscal Year Ended September 30,
(in thousands)202220212020
Weighted average common shares outstanding - basic208,472 205,919 204,783 
Effect of dilutive securities - stock options and restricted stock units
2,738 2,546 — 
Weighted average common shares outstanding - diluted211,210 208,465 204,783 
The potentially dilutive stock options and restricted stock units that were antidilutive were 0.1 million for the fiscal years ended September 30, 2022 and 2021 and 4.2 million for the fiscal year ended September 30, 2020.
78
Note 8. Related Party Transactions
WBA continues to own more than 10% of the Company's outstanding common stock and is, therefore, considered a related party. The Company operates under various agreements and arrangements with WBA, including a pharmaceutical distribution agreement pursuant to which the Company distributes pharmaceutical products to WBA and an agreement that provides the Company the ability to access favorable economic pricing and generic products through a generic purchasing services arrangement with Walgreens Boots Alliance Development GmbH (both through 2029) as well as a distribution agreement pursuant to which it will supplies branded and generic pharmaceutical products to WBA’s Boots UK Ltd. subsidiary (through 2031).
Revenue from the various agreements and arrangements with WBA was $64.1 billion, $65.5 billion, and $63.1 billion in the fiscal years ended September 30, 2022, 2021, and 2020, respectively. The Company's receivable from WBA, net of incentives, was $7.0 billion as of September 30, 2022 and 2021.
Note 9. Retirement and Other Benefit Plans
The Company sponsors various retirement benefit plans and a deferred compensation plan covering eligible employees.
The Compensation and Succession Planning Committee ("Compensation Committee") of the Company's board of directors has delegated the administration of the Company's retirement and other benefit plans to its Benefits Committee, an internal committee, comprised of senior finance, human resources, and legal executives. The Benefits Committee is responsible for the investment options under the Company's savings plans, as well as performance of the investment advisers and plan administrators.
Retirement Benefit Plans
The Company sponsors the AmerisourceBergen Employee Investment Plan (the "Plan"), which is a defined contribution 401(k) plan covering salaried and certain hourly employees. Eligible participants may contribute to the plan from 1% to 50% of their regular compensation before taxes. The Company contributes $1.00 for each $1.00 invested by the participant up to the first 3% of the participant's salary and $0.50 for each additional $1.00 invested by the participant of up to an additional 2% of salary. An additional discretionary contribution, in an amount not to exceed the limits established by the Internal Revenue Code ("IRC"), may also be made depending upon the Company's performance. Based on the Company's performance in fiscal 2022, 2021, and 2020, the Company recognized expenses for discretionary contributions to the Plan in the fiscal years ended September 30, 2022, 2021, and 2020. All contributions are invested at the direction of the employee in one or more funds. All contributions vest immediately except for the discretionary contributions made by the Company, which vest in full after five years of credited service.
The Company's international businesses sponsor various country-specific retirement plans.
Costs of above retirement benefit plans charged to expense for the fiscal years ended September 30, 2022, 2021, and 2020 were $90.1 million, $62.3 million, and $45.9 million, respectively.
The Company also sponsors the AmerisourceBergen Corporation Benefit Restoration Plan. This unfunded plan provides benefits to selected key management, including each of the Company's executive officers. This plan provides eligible participants with an annual amount equal to 4% of the participant's total cash compensation to the extent that his or her compensation exceeds the annual compensation limit established by Section 401(a) (17) of the IRC.
Deferred Compensation Plan
The Company sponsors the AmerisourceBergen Corporation 2001 Deferred Compensation Plan. This unfunded plan allows eligible officers, directors, and key management employees to defer a portion of their annual compensation. The amount deferred may be allocated by the employee among a selection of mutual funds. The Company's liability relating to its deferred compensation plan as of September 30, 2022 and 2021 was $31.7 million and $38.1 million, respectively.
79
Note 10. Share-Based Compensation
The Company's stockholders approved the AmerisourceBergen Corporation 2022 Omnibus Incentive Plan (the "2022 Plan"). As of September 30, 2022, there were 25.4 million shares available to be granted for employee and non-employee director stock restricted stock units, performance stock units, and stock options under the 2022 Plan.
Stock Options
The Company's employee stock option plans provide for the granting of incentive and nonqualified stock options to acquire shares of common stock to employees at a price not less than the fair market value of the common stock on the dates options are granted. Option terms and vesting periods are determined at the date of grant by the Compensation Committee of the board of directors. Employee stock options generally vest ratably, in equal amounts, over a four-year service period and expire in seven years. The Company's non-employee director stock option plans provide for the granting of nonqualified stock options to acquire shares of common stock to non-employee directors at the fair market value of the common stock on the date of the grant. Non-employee director stock options vest ratably, in equal amounts, over a three-year service period and expire in ten years.
The estimated fair value of options granted is expensed on a straight-line basis over the requisite service periods of the awards and are net of estimated forfeitures. The Company estimates the fair values of option grants using a binomial option pricing model. Expected volatilities are based upon the historical volatility of the Company's common stock and other factors, such as implied market volatility. The Company uses historical exercise data, taking into consideration the optionees' ages at grant date, to estimate the terms for which the options are expected to be outstanding. The risk-free rates during the terms of such options are based upon the U.S. Treasury yield curve in effect at the time of grant.
The Company did not grant any stock options to employees in fiscal 2022 and 2021, and it does not expect to grant any stock options in fiscal 2023. The weighted average fair values of the options granted during the fiscal year ended September 30, 2020 was $16.61. The following weighted average assumptions were used to estimate the fair values of options granted:
 2020
Risk-free interest rate1.66%
Expected dividend yield1.86%
Volatility of common stock28.17%
Expected life of the options3.79 years
During the fiscal years ended September 30, 2022, 2021, and 2020, the Company recognized stock option expense of $2.2 million, $4.6 million and $13.0 million, respectively.
A summary of the Company's stock option activity and related information for its option plans for the fiscal year ended September 30, 2022 is presented below:
(in thousands, except exercise price and contractual term)OptionsWeighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Term		Aggregate
Intrinsic
Value
Outstanding as of September 30, 20213,138 $843 years$109,772 
Exercised(1,189)$86  
Forfeited(17)$89  
Outstanding as of September 30, 20221,932 $833 years$100,496 
Exercisable as of September 30, 20221,521 $822 years$81,000 
Expected to vest after September 30, 2022407 $884 years$19,283 
The intrinsic value of stock options exercised during the fiscal years ended September 30, 2022, 2021, and 2020 was $60.3 million, $58.7 million, and $42.6 million, respectively.
80
A summary of the status of the Company's nonvested options as of September 30, 2022 and changes during the fiscal year ended September 30, 2022 is presented below:
(in thousands, except grant date fair value)OptionsWeighted
Average
Grant Date
Fair Value
Nonvested as of September 30, 20211,046 $17
Vested(617)$16
Forfeited(17)$18
Nonvested as of September 30, 2022412 $18
During the fiscal years ended September 30, 2022, 2021, and 2020, the total fair values of options vested were $10.0 million, $15.5 million, and $21.3 million, respectively. Expected future compensation expense relating to the 0.4 million nonvested options outstanding as of September 30, 2022 is $0.4 million, which will be recognized through November 2023.
Restricted Stock Units
Restricted stock units granted prior to fiscal 2021 vest in full after three years. The majority of the restricted stock units granted beginning in fiscal 2021 and thereafter vest ratably over a three-year period. The estimated fair value of restricted stock units under the Company's restricted stock unit plans is determined by the product of the number of shares granted and the closing grant date market price of the Company's common stock. The estimated fair value of restricted stock units is expensed on a straight-line basis over the requisite service period, net of estimated forfeitures. During the fiscal years ended September 30, 2022, 2021, and 2020, the Company recognized restricted stock unit expense of $71.3 million, $55.8 million, and $39.8 million, respectively.
A summary of the status of the Company's nonvested restricted stock units as of September 30, 2022 and changes during the fiscal year ended September 30, 2022 are presented below:
(in thousands, except grant date fair value)Restricted
Stock Units		Weighted
Average
Grant Date
Fair Value
Nonvested as of September 30, 20211,838 $98
Granted726 $127
Vested(592)$98
Forfeited(166)$106
Nonvested as of September 30, 20221,806 $108
During the fiscal years ended September 30, 2022, 2021, and 2020, the total fair values of restricted stock units vested were $58.1 million, $31.1 million, and $26.4 million, respectively. Expected future compensation expense relating to the 1.8 million restricted stock units outstanding as of September 30, 2022 is $71.2 million, which will be recognized over a weighted average period of 1.1 years.
Performance Stock Units
Performance stock units are granted to certain executive employees under the Plan and represent common stock potentially issuable in the future. Performance stock units vest at the end of a three-year performance period based upon achievement of specific performance goals. Based upon the extent to which the targets are achieved, vested shares may range from 0% to 200% of the target award amount. The fair value of performance stock units is determined by the grant date market price of the Company's common stock. Compensation expense associated with nonvested performance stock units is recognized over the requisite service period and is dependent on the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued. During the fiscal years ended September 30, 2022, 2021, and 2020, the Company recognized performance stock expense of $19.7 million, $38.9 million, and $21.5 million, respectively.
81
A summary of the status of the Company's nonvested performance stock units as of September 30, 2022 and changes during the fiscal year ended September 30, 2022 is presented below (based upon target award amounts).
(in thousands, except grant date fair value)Performance
Stock
Units		Weighted
Average
Grant Date
Fair Value
Nonvested as of September 30, 2021296 $98
Granted131 $126
Vested(148)$86
Forfeited(2)$117
Nonvested as of September 30, 2022277 $117
Shares that vested over the three-year performance period ended September 30, 2022 were distributed to employees in November 2022.
Note 11. Leases
The Company has long-term leases for facilities and equipment. In the normal course of business, leases are generally renewed or replaced by other leases. Certain leases include escalation clauses.
The following illustrates the components of lease cost for the periods presented:
Fiscal Year Ended September 30,
(in thousands)202220212020
Operating lease cost$220,935 $161,054 $118,144 
Short-term lease cost11,257 5,901 4,632 
Variable lease cost25,108 14,208 17,814 
Total lease cost$257,300 $181,163 $140,590 
The following summarizes balance sheet information related to operating leases:
September 30,
(in thousands, except for lease term and discount rate)20222021
Right of use assets
Other assets$944,974 $1,067,175 
Lease liabilities
Accrued expenses and other$158,184 $175,352 
Other long-term liabilities864,288 946,155 
Total lease liabilities$1,022,472 $1,121,507 
Weighted-average remaining lease term8.37 years8.75 years
Weighted-average discount rate3.22%2.86%
82
Other cash flow information related to operating leases is as follows:
Fiscal Year Ended September 30,
(in thousands)202220212020
Cash paid for amounts included in the measurement of lease liabilities
Operating lease cash payments$214,793 $148,385 $115,028 
Right-of-use assets obtained in exchange for lease liabilities
New operating leases$179,214 $770,858 $61,779 
Leases recognized upon adoption of ASC 842
$— $— $526,281 
Future minimum rental payments under noncancellable operating leases were as follows:
Payments Due by Fiscal Year (in thousands)As of
September 30, 2022
2023$192,031 
2024176,635 
2025156,578 
2026136,788 
2027120,302 
Thereafter456,276 
Total future undiscounted lease payments1,238,610 
Less: Future payments for leases that have not yet commenced 1
(19,141)
Less: Imputed interest(196,997)
Total lease liabilities$1,022,472 
1 The Company has certain leases that it has executed of which it does not control the underlying assets; therefore, liabilities and ROU assets related to these leases were not recorded on the Company's Consolidated Balance Sheet as of September 30, 2022.
Note 12. Acquisition, Integration, and Restructuring Expenses
The following illustrates the expenses incurred by the Company relating to Acquisition, Integration, and Restructuring Expenses for the periods indicated:
Fiscal Year Ended September 30,
 (in thousands)202220212020
Acquisition-related deal and integration$119,561 $116,969 $15,958 
Employee severance12,681 13,705 34,401 
Business transformation efforts27,990 36,255 37,961 
Other restructuring initiatives22,827 32,359 (3,359)
Total$183,059 $199,288 $84,961 
Acquisition-related deal and integration expenses in the fiscal year ended September 30, 2022 primarily related to costs associated with the integration of Alliance Healthcare. Acquisition-related deal and integration expenses in the fiscal year ended September 30, 2021 primarily related to the June 2021 acquisition of Alliance Healthcare.
Employee severance in the fiscal year ended September 30, 2022 included costs primarily related to restructuring activities within certain businesses in the U.S. Healthcare Solutions reportable segment. Employee severance in the fiscal year ended September 30, 2021 included costs primarily related to restructuring activities primarily within one business unit in the International Healthcare Solutions reportable segment. Employee severance in the fiscal year ended September 30, 2020 included costs primarily related to position eliminations resulting from the Company's decision to permanently exit the PharMEDium compounding business.    
83
Business transformation efforts in the fiscal years ended September 30, 2022, 2021, and 2020 were primarily related to costs associated with reorganizing the Company to further align the organization to its customers' needs. The majority of these costs were related to services provided by third-party consultants, including certain technology initiatives.
Other restructuring initiatives in the fiscal year ended September 30, 2022 and 2021 primarily related to the write down and disposal of assets, respectively, related to the Company's office optimization plan. Other restructuring initiatives in the fiscal year ended September 30, 2020 included a $19.1 million gain on the sale of property.
Note 13. Legal Matters and Contingencies
In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, stockholder demands, and other disputes, including antitrust, commercial, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.
For those matters for which the Company has not recognized a liability, the Company cannot predict the outcome of their impact on the Company as uncertainty remains with regard to whether such matters will proceed to trial, whether settlements will be reached, and the amount and terms of any such settlements. Outcomes may include settlements in significant amounts that are not currently estimable, limitations on the Company’s conduct, the imposition of corporate integrity agreement obligations, consent decrees, and/or other civil and criminal penalties. From time to time, the Company is also involved in disputes with its customers, which the Company generally seeks to resolve through commercial negotiations. If negotiations are unsuccessful, the parties may litigate the dispute or otherwise attempt to settle the matter.
With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company’s results of operations or cash flows for that period or on the Company's financial condition.
Opioid Lawsuits and Investigations
A significant number of counties, municipalities, and other governmental entities in a majority of U.S. states and Puerto Rico, as well as numerous states and tribes, filed lawsuits in various federal, state and other courts against pharmaceutical wholesale distributors (including the Company and certain subsidiaries, such as AmerisourceBergen Drug Corporation (“ABDC”) and H.D. Smith), pharmaceutical manufacturers, retail pharmacy chains, medical practices, and physicians relating to the distribution of prescription opioid pain medications.
An initial group of cases was consolidated for Multidistrict Litigation (“MDL”) proceedings before the United States District Court for the Northern District of Ohio (the “Court”) in December 2017. In April 2018, the Court issued an order creating a litigation track, which included dispositive motion practice, discovery, and trials in certain bellwether jurisdictions. In November 2019 and January 2020, the Court filed Suggestions of Remand with the Judicial Panel on Multidistrict Litigation that identified four cases filed against the Company for potential transfer from the MDL back to federal courts in California, Oklahoma, and West Virginia for the completion of discovery, motion practice, and trial. All four cases were remanded to those federal district courts. Trial in the two consolidated cases in West Virginia commenced in May 2021 and concluded in July 2021. On July 4, 2022, the court entered judgment in favor of the defendants, including the Company. The plaintiffs filed an appeal of the court’s decision on August 2, 2022. The Oklahoma case, in which the plaintiff was the Cherokee Nation, was resolved through a settlement with the Cherokee Nation, as announced on September 28, 2021. The California case, in which the plaintiff was the City and County of San Francisco, was resolved pursuant to the comprehensive settlement described below, and all claims against the Company have been dismissed in both cases.
On July 21, 2021, the Company announced that it and the two other national pharmaceutical distributors had negotiated a comprehensive settlement agreement that, if all conditions were satisfied, would result in the resolution of a substantial majority of opioid lawsuits filed by state and local governmental entities. The comprehensive settlement agreement became effective on April 2, 2022 and as of September 30, 2022, it included 48 of 49 eligible states (the “Settling States”) as well as 99% by population of the eligible political subdivisions in the Settling States. Pursuant to the comprehensive settlement agreement and related agreements with Settling States, the Company will pay up to approximately $6.4 billion over 18 years and comply with other requirements, including establishment of a clearinghouse that will consolidate data from all three national distributors. The exact payment amount will depend on several factors, including the extent to which states take action to foreclose opioid lawsuits by subdivisions (e.g., laws barring opioid lawsuits by subdivisions). West Virginia and its
84
subdivisions and Native American tribes are not a part of the comprehensive settlement agreement and the Company has reached separate agreements with these groups.
On July 22, 2022, the State of Alabama sought and was subsequently granted leave to amend its complaint in a pending state court action against another distributor in order to add the Company as a party. The amended Complaint was filed on July 25, 2022.
The Company recorded accruals related to opioid litigation of $36.6 million, $147.7 million, and $6.6 billion in the fiscal years ended September 30, 2022, 2021, and 2020 in Litigation and Opioid-Related Expenses in its Consolidated Statements of Operations. The Company’s accrued litigation liability related to the comprehensive settlement, including an estimate for the State of Alabama (with whom the Company has not reached a settlement agreement), as well as other opioid-related litigation for which it has reached settlement agreements, as described above, was $6.0 billion as of September 30, 2022 and $6.7 billion as of September 30, 2021. The Company currently estimates that $528.7 million will be paid prior to September 30, 2023, which is recorded in Accrued Expenses and Other on the Company’s Consolidated Balance Sheet. The remaining long-term liability of $5.5 billion is recorded in Accrued Litigation Liability on the Company’s Consolidated Balance Sheet. While the Company has accrued its estimated liability for opioid litigation, it is unable to estimate the range of possible loss associated with the matters that are not included in the settlement accrual. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. The Company regularly reviews opioid litigation matters to determine whether its accrual is adequate. The amount of ultimate loss may differ materially from the amount accrued to date. Until such time as otherwise resolved, the Company will continue to litigate and prepare for trial and to vigorously defend itself in all such matters. Since these matters are still developing, the Company is unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief that may affect the Company’s operations.
Other lawsuits regarding the distribution of prescription opioid pain medications have been filed by: third-party payors and similar entities; hospitals; hospital groups; and individuals, including cases styled as putative class actions. These lawsuits, which have been and continue to be filed in federal, state, and other courts, generally allege violations of controlled substance laws and various other statutes as well as common law claims, including negligence, public nuisance, and unjust enrichment, and seek equitable relief and monetary damages. Motion practice and active discovery are ongoing in many of these cases. Ongoing and additional litigation is anticipated in cases filed by subdivisions that are not participating in the global settlement agreement, as well as in cases filed by non-governmental or non-political entities, including hospitals, third-party payors, and individuals, among others. Certain cases related to opioids filed in various state courts have trial dates scheduled in January 2023 and later, although all such dates are subject to change. The Company is vigorously defending itself in the pending lawsuits and intends to vigorously defend itself against any threatened lawsuits or enforcement proceedings.
Since July 2017, the Company has received subpoenas from several U.S. Attorney’s Offices, including grand jury subpoenas from the U.S. Attorney’s Office for the District of New Jersey (“USAO-NJ”) and the U.S. Attorney’s Office for the Eastern District of New York (“USAO-EDNY”). Those subpoenas request the production of a broad range of documents pertaining to the Company’s distribution of controlled substances through its various subsidiaries, including ABDC, and its diversion control programs. The Company has produced documents in response to the subpoenas and continues to engage in discussions with the various U.S. Attorney’s Offices, including the Health Care and Government Fraud Unit of the Criminal Division of the USAO-NJ, the U.S. Department of Justice Consumer Protection Branch and the U.S. Drug Enforcement Administration, in an attempt to resolve these matters.
Shareholder Securities Litigation
On October 11, 2019, Teamsters Local 443 Health Services & Insurance Plan, St. Paul Electrical Construction Pension Plan, St. Paul Electrical Construction Workers Supplemental Pension Plan (2014 Restatement), Retirement Medical Funding Plan for the St. Paul Electrical Workers, and San Antonio Fire & Police Pension Fund filed a complaint for a purported derivative action in the Delaware Court of Chancery against the Company and certain of its current and former officers and directors (collectively, “Defendants”). The complaint alleges that the Defendants breached their fiduciary duties by failing to oversee the compliance by certain of the Company’s subsidiaries (including the Company’s former subsidiary Medical Initiatives, Inc. (“MII”)) with federal regulations, allegedly resulting in the payment of fines and penalties in connection with the settlements with the USAO-EDNY in fiscal 2017 and 2018 that resolved claims arising from MII’s pre-filled syringe program. In December 2019, Defendants filed a motion to dismiss the complaint. After briefing and oral argument, on August 24, 2020 the Delaware Court of Chancery denied Defendants’ motion to dismiss. On September 24, 2020, the Board of Directors of the Company established a Special Litigation Committee to conduct an investigation concerning the plaintiffs’ allegations, and on November 10, 2020, the Delaware Court of Chancery granted the Special Litigation Committee’s motion to stay the litigation pending its investigation. On September 22, 2021, the Special Litigation Committee filed its report under seal and moved to dismiss the case. The Special Litigation Committee’s motion to dismiss the case is pending.
85
On July 17, 2020, CCAR Investments, Inc. filed a complaint for a purported derivative action in the United States District Court for the District of Delaware against the Company and certain of its current and former officers and directors (“CCAR Defendants”). The complaint allegedclaims for breach of fiduciary duty, corporate waste and unjust enrichment allegedly arising from the Board's oversight of the Company’s controlled substance diversion control programs and violation of Section 14(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). On August 14, 2020, the CCAR Defendants answered the complaint and filed a motion for judgment on the pleadings. On October 29, 2020 the parties filed a stipulation permitting CCAR Investments, Inc. to file an amended complaint on or before November 20, 2020. On December 4, 2020, the parties filed a stipulation tolling the deadline for CCAR Investments, Inc. to file an amended complaint pending the Company’s production of certain documents to CCAR Investments, Inc. The Company’s production was completed on January 29, 2021. On May 2, 2022, the Court entered a stipulation that the case will be dismissed without prejudice upon the Company providing notice to stockholders through the filing of a Current Report on Form 8-K and subsequent notification to the Court of such filing. On May 6, 2022, the Company provided notice to stockholders through the filing of a Current Report on Form 8-K that the case would be dismissed and gave notice to the Court of the Form 8-K filing.
On December 30, 2021, Lebanon County Employees’ Retirement Fund and Teamsters Local 443 Health Services & Insurance Plan filed a complaint for a purported derivative action in the Delaware Court of Chancery against the Company and certain of its current officers and directors. The complaint alleges claims for breach of fiduciary duty allegedly arising from the Board’s and certain officers’ oversight of the Company’s controlled substance diversion control programs. The defendants moved to dismiss the complaint on March 29, 2022. The motion is pending.
Subpoenas, Ongoing Investigations, and Other Contingencies
From time to time, the Company receives subpoenas or requests for information from various government agencies relating to the Company’s business or to the business of a customer, supplier, or other industry participant. The Company’s responses often require time and effort and can result in considerable costs being incurred. Most of these matters are resolved without incident; however, such subpoenas or requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the healthcare industry, as well as to substantial settlements.
In January 2017, U.S. Bioservices Corporation (“U.S. Bio”), a former subsidiary of the Company, received a subpoena for information from the USAO-EDNY relating to its activities in connection with billing for products and making returns of potential overpayments to government payers. A filed qui tam complaint related to the investigation was unsealed in April 2019 and the relator filed an amended complaint under seal in the U.S. District Court for the Eastern District of New York. In December 2019, the government filed a notice that it was declining to intervene. The court ordered that the relator’s complaint against the Company and other defendants, including AmerisourceBergen Specialty Group, LLC, be unsealed. The relator’s complaint alleged violations of the federal False Claims Act and the false claims acts of various states. The relator filed a second amended complaint, removing one state false claims act count. The Company filed a motion to dismiss the second amended complaint and all briefing on the motion was filed with the court on October 9, 2020.
In December 2019, Reliable Pharmacy, together with other retail pharmacies and North Sunflower Medical Center, filed a civil antitrust complaint against multiple generic drug manufacturers, and also included claims against ABDC and H.D. Smith (collectively, the “Company” for this matter description), and other drug distributors and industry participants. The case is filed as a putative class action and plaintiffs purport to represent a class of drug purchasers including other retail pharmacies and healthcare providers. The case has been consolidated for multidistrict litigation proceedings before the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that the Company and others in the industry participated in a conspiracy to fix prices, allocate markets and rig bids regarding generic drugs. In March 2020, the plaintiffs filed a further amended complaint. On July 15, 2020, the Company and other industry participants filed a motion to dismiss the complaint. On May 25, 2022, the Court granted the motion to dismiss without prejudice. On July 1, 2022, the plaintiffs filed an amended complaint, again including claims against the Company and other drug distributors and industry participants. On August 21, 2022, the Company and other industry participants filed a motion to dismiss the amended complaint.
On March 3, 2022, the United States Attorney’s Office for the Western District of Virginia notified the Company of the existence of a criminal investigation into MWI Veterinary Supply Co., the Company’s animal health subsidiary, in connection with grand jury subpoenas to which MWI previously responded relating to compliance with state and federal regulatory requirements governing wholesale shipments of animal health products to customers in certain states. The Company is cooperating with the investigation.
86
Note 14. Litigation Settlements
Antitrust Settlements
Numerous lawsuits have been filed against certain brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. These lawsuits are generally brought as class actions. The Company has not been a named a plaintiff in any of these lawsuits, but has been a member of the direct purchasers’ class (i.e., those purchasers who purchase directly from these pharmaceutical manufacturers). None of the lawsuits has gone to trial, but some have settled in the past with the Company receiving proceeds from the settlement funds. During the fiscal years ended September 30, 2022, 2021, and 2020, the Company recognized gains relating to these lawsuits of $1.8 million, $168.8 million, and $9.1 million, respectively. These gains, which are net of attorney fees and estimated payments due to other parties, were recorded as reductions to cost of goods sold in the Company’s Consolidated Statements of Operations.
Note 15. Business Segment Information
The Company is organized geographically based upon the products and services it provides to its customers. The Company’s reporting structure is comprised of two reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions. U.S. Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable segment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. International Healthcare Solutions consists of Alliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). Profarma had previously been included in the Pharmaceutical Distribution Services reportable segment. The Company's previously reported segment results have been revised to conform to its realigned reporting structure.
The chief operating decision maker ("CODM") of the Company is the Chairman, President & Chief Executive Officer of the Company, whose function is to allocate resources to, and assess the performance of, the Company's operating segments. The CODM does not review assets by operating segment for the purpose of assessing performance or allocating resources.
The U.S. Healthcare Solutions reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The U.S. Healthcare Solutions reportable segment also provides pharmaceutical distribution (including plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. Additionally, the U.S. Healthcare Solutions reportable segment provides data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The U.S. Healthcare Solutions reportable segment also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of retail and institutional healthcare providers. It also provides a full suite of integrated manufacturer services that ranges from clinical trial support to product post-approval and commercialization support. Additionally, it delivers packaging solutions to institutional and retail healthcare providers. Through its animal health business, the U.S. Healthcare Solutions reportable segment sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. It also offers demand-creating sales force services to manufacturers.
The International Healthcare Solutions reportable segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. The International Healthcare Solutions reportable segment distributes pharmaceuticals, other healthcare products, and related services to healthcare providers, including pharmacies, doctors, health centers and hospitals primarily in Europe. It also is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. In Canada, the business drives innovative partnerships with manufacturers, providers, and pharmacies to improve product access and efficiency throughout the healthcare supply chain.
87
The following illustrates reportable and operating segment disaggregated revenue as required by ASC 606, "Revenue from Contracts with Customers," for the periods indicated:
 Fiscal Year Ended September 30,
(in thousands)202220212020
U.S. Healthcare Solutions
Human Health$207,284,444 $197,777,128 $182,171,487 
Animal Health4,815,758 4,684,417 4,216,462 
Total U.S. Healthcare Solutions212,100,202 202,461,545 186,387,949 
International Healthcare Solutions
Alliance Healthcare21,890,402 7,373,365 — 
Other Healthcare Solutions4,601,271 4,156,264 3,508,106 
Total International Healthcare Solutions26,491,673 11,529,629 3,508,106 
Intersegment eliminations(4,869)(2,331)(2,129)
Revenue$238,587,006 $213,988,843 $189,893,926 
The following illustrates reportable segment operating income information for the periods indicated:
 Fiscal Year Ended September 30,
(in thousands)202220212020
U.S. Healthcare Solutions$2,456,972 $2,257,918 $2,020,067 
International Healthcare Solutions706,458 390,286 184,380 
Total segment operating income$3,163,430 $2,648,204 $2,204,447 
The following reconciles total segment operating income to income (loss) before income taxes for the periods indicated:
 Fiscal Year Ended September 30,
(in thousands)202220212020
Total segment operating income$3,163,430 $2,648,204 $2,204,447 
Gains from antitrust litigation settlements1,835 168,794 9,076 
LIFO (expense) credit(67,171)203,028 (7,422)
Turkey highly inflationary impact(40,033)— — 
Acquisition-related intangibles amortization(304,551)(176,221)(110,478)
Litigation and opioid-related expenses(123,191)(272,623)(6,722,346)
Acquisition, integration, and restructuring expenses(183,059)(199,288)(84,961)
Goodwill impairment(75,936)(6,373)— 
Impairment of assets(4,946)(11,324)(361,652)
PharMEDium remediation costs— — (16,165)
PharMEDium shutdown costs— — (43,206)
New York State Opioid Stewardship Act— — (14,800)
Contingent consideration adjustment— — 12,153 
Operating income (loss)2,366,378 2,354,197 (5,135,354)
Other income(27,352)(41,736)(1,581)
Interest expense, net210,673 174,074 137,883 
Loss on early retirement of debt— — 22,175 
Income (loss) before income taxes$2,183,057 $2,221,859 $(5,293,831)
Segment operating income is evaluated by the CODM of the Company and excludes gains from antitrust litigation settlements; LIFO (expense) credit; Turkey highly inflationary impact; acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses; goodwill impairment; impairment of assets;
88
PharMEDium remediation costs; PharMEDium shutdown costs; New York State Opioid Stewardship Act; and contingent consideration adjustment. All corporate office expenses are allocated to the operating segment level.
    The Company recognized a net gain of $56.2 million from sale of non-core businesses, an expense related to the impact of Turkey highly inflationary accounting of $11.9 million, a foreign currency loss of $14.4 million on the remeasurement of deferred tax assets relating to Swiss tax reform, and a $4.8 million gain on the remeasurement of an equity investment in Other Income in the Consolidated Statements of Operations in the fiscal year ended September 30, 2022. The Company recorded a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable related to a start-up venture, and a foreign currency loss of $3.4 million on the remeasurement of deferred tax assets relating to Swiss tax reform in Other Income in the Consolidated Statements of Operations in the fiscal year ended September 30, 2021.
    The following illustrates depreciation and amortization by reportable segment for the periods indicated:
Fiscal Year Ended September 30,
(in thousands)202220212020
U.S. Healthcare Solutions$274,554 $266,575 $253,687 
International Healthcare Solutions114,790 62,376 26,897 
Acquisition-related intangibles amortization304,551 176,221 110,478 
Total depreciation and amortization$693,895 $505,172 $391,062 
                
Depreciation and amortization includes depreciation and amortization of property and equipment and intangible assets, but excludes amortization of deferred financing costs and other debt-related items, which are included in interest expense, net.
The following illustrates capital expenditures by reportable segment for the periods indicated:
Fiscal Year Ended September 30,
(in thousands)202220212020
U.S. Healthcare Solutions$295,406 $310,525 $316,249 
International Healthcare Solutions200,912 127,692 53,428 
Total capital expenditures$496,318 $438,217 $369,677 
Note 16. Fair Value of Financial Instruments
The recorded amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable as of September 30, 2022 and 2021 approximate fair value based upon the relatively short-term nature of these financial instruments. Within Cash and Cash Equivalents, the Company had $1,602.0 million and $671.0 million of investments in money market accounts as of September 30, 2022 and 2021, respectively. The fair value of the money market accounts was determined based upon unadjusted quoted prices in active markets for identical assets, otherwise known as Level 1 inputs.
The recorded amount of long-term debt (see Note 6) and the corresponding fair value as of September 30, 2022 were $4,632.4 million and $4,130.3 million, respectively. The recorded amount of long-term debt and the corresponding fair value as of September 30, 2021 were $6,383.8 million and $6,761.6 million, respectively. The fair value of long-term debt was determined based upon inputs other than quoted prices, otherwise known as Level 2 inputs.
Note 17. Subsequent Event
In November 2022, the Company's board of directors increased the quarterly dividend paid on common stock by 5% and declared a regular quarterly cash dividend of $0.485 per share, payable on November 28, 2022 to shareholders of record on November 14, 2022.






89
ITEM 9.    CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
ITEM 9A.    CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
The Company maintains disclosure controls and procedures that are intended to ensure that information required to be disclosed in the Company's reports submitted under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. These controls and procedures also are intended to ensure that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.
The Company's Chief Executive Officer and Chief Financial Officer, with the participation of other members of the Company's management, have evaluated the effectiveness of the Company's disclosure controls and procedures (as such term is defined in Rules 13a — 15(e) and 15d — 15(e) under the Exchange Act) and have concluded that the Company's disclosure controls and procedures were effective for their intended purposes as of the end of the period covered by this report.
Changes in Internal Control over Financial Reporting
There were no changes during the fiscal quarter ended September 30, 2022 in the Company's internal control over financial reporting that materially affected, or are reasonably likely to materially affect, those controls.
MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING
The management of AmerisourceBergen Corporation ("AmerisourceBergen" or the "Company") is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended. AmerisourceBergen's internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The Company's internal control over financial reporting includes those policies and procedures that:
(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and
(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.
Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
AmerisourceBergen's management assessed the effectiveness of AmerisourceBergen's internal control over financial reporting as of September 30, 2022. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control — Integrated Framework (2013). Based on management's assessment and those criteria, management has concluded that AmerisourceBergen's internal control over financial reporting was effective as of September 30, 2022.
AmerisourceBergen's independent registered public accounting firm, Ernst & Young LLP, has issued an attestation report on the effectiveness of AmerisourceBergen's internal control over financial reporting. This report is set forth below.
90
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and the Board of Directors of AmerisourceBergen Corporation
Opinion on Internal Control over Financial Reporting
We have audited AmerisourceBergen Corporation and subsidiaries’ internal control over financial reporting as of September 30, 2022, based on criteria established in Internal Control— Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, AmerisourceBergen Corporation and subsidiaries (the Company) maintained, in all material respects, effective internal control over financial reporting as of September 30, 2022, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2022 consolidated financial statements of the Company and our report dated November 22, 2022 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ Ernst & Young LLP
Philadelphia, Pennsylvania
November 22, 2022
91
ITEM 9B.    OTHER INFORMATION
None.
ITEM 9C.    DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
Not applicable.
PART III

ITEM 10.    DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Information appearing in our Notice of Annual Meeting of Stockholders and Proxy Statement for the 2023 Annual Meeting of Stockholders (the "2023 Proxy Statement"), including information appearing under "Proxy Statement Highlights," "Corporate Governance and Related Matters," and "Audit Committee Matters" is incorporated herein by reference. We will file the 2023 Proxy Statement with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the close of the fiscal year.
Information with respect to Executive Officers of the Company appears in Part I of this report.
We adopted a Code of Ethics for Designated Senior Officers that applies to our Chief Executive Officer, Chief Financial Officer, and Corporate Controller. A copy of this Code of Ethics is posted on our Internet website, which is investor.amerisourcebergen.com. Any amendment to, or waiver from, any provision of this Code of Ethics will be posted on our Internet website.
ITEM 11.    EXECUTIVE COMPENSATION
Information contained in the 2023 Proxy Statement, including information appearing under "Corporate Governance and Related Matters" and "Executive Compensation and Related Matters" in the 2023 Proxy Statement, is incorporated herein by reference.
ITEM 12.    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
Information contained in the 2023 Proxy Statement, including information appearing under "Beneficial Ownership of Common Stock" and "Equity Compensation Plan Information" in the 2023 Proxy Statement, is incorporated herein by reference.
ITEM 13.    CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
Information contained in the 2023 Proxy Statement, including information appearing under "Corporate Governance and Related Matters" and "Related Person Transactions" in the 2023 Proxy Statement, is incorporated herein by reference.
ITEM 14.    PRINCIPAL ACCOUNTANT FEES AND SERVICES
Information contained in the 2023 Proxy Statement, including information appearing under "Audit Committee Matters" in the 2023 Proxy Statement, is incorporated herein by reference.
92
PART IV

ITEM 15.    EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(a) (1) and (2) List of Financial Statements and Schedules.
Financial Statements: The following consolidated financial statements are submitted in response to Item 15(a)(1):
All other schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission are not required under the related instructions or are inapplicable and, therefore, have been omitted.


















93
(a) (3) List of Exhibits.
Exhibit
Number		Description
2.1
3.1
3.2
4.1
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
4.10
4.11
4.12
4.13
4.14
94
Exhibit
Number		Description
4.15
4.16
4.17
4.18
10.1
10.2
10.3
‡10.4
‡10.5
‡10.6
‡10.7
‡10.8
‡10.9
‡10.10
‡10.11
‡10.12
‡10.13
‡10.14
‡10.15
‡10.16
95
Exhibit
Number		Description
‡10.17
‡10.18
‡10.19
‡10.20
‡10.21
‡10.22
‡10.23
‡10.24
‡10.25
‡10.26
‡10.27
10.28
10.29
10.30
10.31
10.32
10.33
10.34
96
Exhibit
Number		Description
10.35
10.36
10.37
10.38
10.39
10.40
10.41
10.42
10.43
10.44
10.45
10.46
97
Exhibit
Number		Description
10.47
10.48
10.49
10.50
10.51
10.52
10.53
10.54
10.55
10.56
21
23
31.1
31.2
32
101Financial statements from the Annual Report on Form 10-K of AmerisourceBergen Corporation for the fiscal year ended September 30, 2022, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Comprehensive Income, (iv) the Consolidated Statements of Changes in Stockholders' Equity, (v) the Consolidated Statements of Cash Flows, and (vi) the Notes to Consolidated Financial Statements.
104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).
__________________________________________________________
‡    Each marked exhibit is a management contract or a compensatory plan, contract or arrangement in which a director or executive officer of the Registrant participates or has participated.
ITEM 16.    FORM 10-K SUMMARY

    Not applicable.

98
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
  AMERISOURCEBERGEN CORPORATION
Date: November 22, 2022 By: 
/s/ STEVEN H. COLLIS
Steven H. Collis
Chairman, President and Chief Executive Officer
 Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below as of November 22, 2022 by the following persons on behalf of the Registrant and in the capacities indicated.

Signature Title
   
/s/ STEVEN H. COLLIS___________________________
Steven H. Collis
 Chairman, President and Chief Executive Officer
(Principal Executive Officer)
/s/ JAMES F. CLEARY____________________________
James F. Cleary
 Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
/s/ LAZARUS KRIKORIAN________________________
Lazarus Krikorian
 Senior Vice President and Chief Accounting Officer
(Principal Accounting Officer)
/s/ ORNELLA BARRA____________________________
Ornella Barra
 Director
/s/ D. MARK DURCAN____________________________
D. Mark Durcan
 Director
/s/ RICHARD W. GOCHNAUER____________________
Richard W. Gochnauer
 Director
/s/ LON R. GREENBERG__________________________
Lon R. Greenberg
 Director
99
Signature Title
/s/ JANE E. HENNEY, M.D.________________________
Jane E. Henney, M.D.
 Lead Independent Director
/s/ KATHLEEN W. HYLE__________________________
Kathleen W. Hyle
 Director
/s/ LORENCE H. KIM, M.D._______________________
Lorence H. Kim, M.D.
Director
/s/ MICHAEL J. LONG____________________________
Michael J. Long
Director
/s/ HENRY W. MCGEE____________________________
Henry W. McGee
 Director
/s/ DENNIS M. NALLY____________________________
Dennis M. Nally
Director
100
AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS
(In thousands)Balance at
Beginning
of Period		Charged to
Costs and
Expenses (1)		Deductions (2)Balance at
End of
Period
Year Ended September 30, 2022    
Allowances for returns and credit losses$1,356,684 $5,124,081 $(4,854,036)$1,626,729 
Year Ended September 30, 2021    
Allowances for returns and credit losses$1,417,308 $3,906,776 $(3,967,400)$1,356,684 
Year Ended September 30, 2020    
Allowances for returns and credit losses$1,223,887 $4,019,830 $(3,826,409)$1,417,308 
__________________________________________________________

(1)Represents the provision for returns and credit losses.
(2)Represents reductions to the returns allowance and accounts receivable written off during year, net of recoveries.


101
 EX-10.23 2 exhibit1023-rsuawardtoempl.htm EX-10.23 Document
Exhibit 10.23
U.S.

AMERISOURCEBERGEN CORPORATION
RESTRICTED STOCK UNIT AWARD TO EMPLOYEE
Participant:               Participant Name
Number of
Restricted Stock Units Granted:      Number of Shares Granted
Date of Grant:                Grant Date
Vesting Date:         [•]
RECITALS
This Restricted Stock Unit Award (the “Award Agreement”) is made by AmerisourceBergen Corporation, a Delaware corporation (the “Company”), pursuant to the AmerisourceBergen Corporation 2022 Omnibus Incentive Plan (the “Plan”).
WHEREAS, the Company has agreed to grant to the Participant Restricted Stock Units, subject to certain restrictions and on the terms and conditions contained in this Award Agreement.
NOW, THEREFORE, in consideration of the foregoing and the premises contained herein and intending to be legally bound hereby:
1.Definitions. Unless otherwise defined herein, capitalized terms used in this Award Agreement shall have the meanings ascribed to them in the Plan. As used herein:
(a)“Award” means an award of Restricted Stock Units hereby granted.
(b)“Date of Grant” means the date on which the Company awarded the Restricted Stock Units to the Participant pursuant to the Plan.
(c)“Disability” means the Participant is eligible to receive long-term disability benefits under the Company’s long-term disability plan.
(d)“Qualifying Change in Control” means a Change in Control that is a “change in the ownership or effective control” or a “ change in the ownership of a substantial portion of the assets” within the meaning of Treasury Regulation 1.409A-3(i)(5).
(e)“Restricted Stock Units” means the Restricted Stock Units which are the subject of the Award hereby granted.
(f)“Retirement” means any termination of employment, other than by the Company (or a Parent or Subsidiary) for Cause, after reaching age fifty-five (55), where the Participant’s age plus years of continuous employment with the Company and/or its Parent or Subsidiaries equals at least sixty-five (65).
(g)“Shares” mean shares of the Company’s Common Stock.
(h)“Taxes” means the federal, state and local income and employment taxes required to be withheld in connection with the vesting and issuance of the Shares (or other amounts or property) under the Award.


(i)“Vesting Period” means, with respect to each Restricted Stock Unit, the period beginning on the Date of Grant and ending on the third anniversary thereof.
2.Grant of Restricted Stock Units. Subject to the terms and conditions set forth herein and in the Plan, the Company hereby grants to the Participant the Restricted Stock Units. Each Restricted Stock Unit represents an unfunded unsecured right of the Participant, upon vesting of the Restricted Stock Unit, to receive one Share.
3.Vesting. Subject to the terms and conditions set forth herein and in the Plan, the Restricted Stock Units shall vest [•] (each, a “Vesting Date”), provided the Participant has remained in Service from the Date of Grant through the applicable Vesting Date.
Notwithstanding the foregoing,
(a)if the Participant ceases to be in Service during the Vesting Period as a result of the Participant’s death or Disability, the Restricted Stock Units shall become one hundred percent (100%) vested as of the date of such cessation of Service;
(b)if the Participant’s Service terminates during the Vesting Period due to the Participant’s Retirement, then the Restricted Stock Units shall continue to vest as if the Participant had continued in Service through each Vesting Date; provided, however, that (i) if the
Participant’s Service terminates due to the Participant’s Retirement prior to the date of a Change in Control that occurs after the Date of Grant, the Restricted Stock Units shall become one hundred percent (100%) vested as of the date of the Change in Control; and (ii) if the Participant’s Service terminates due to the Participant’s Retirement after the date of a Change in Control that occurs after the Date of Grant, the Restricted Stock Units to the extent outstanding shall become one hundred percent (100%) vested as of the date of such cessation of Service; and
(c)if upon or within two (2) years following a Change in Control that occurs after the Date of Grant, the Participant’s Service as an employee is involuntarily terminated by the Company (or successor thereto, or a Parent or Subsidiary), other than for Cause, the Restricted Stock Units to the extent outstanding shall become one hundred percent (100%) vested as of the date of such cessation of Service.
4.Forfeiture of Restricted Stock Units. If at any time the Participant ceases Service for any reason other than death, Disability or Retirement during the Vesting Period, the Restricted Stock Units shall be forfeited by the Participant and deemed canceled by the Company and the Participant shall thereupon cease to have any right or be entitled to receive any Shares under those forfeited Restrict Stock Units.
5.Rights of Participant. The Participant shall not have the rights of a stockholder of the Company with respect the Shares represented by the Restricted Stock Units, including, without limitation, the right to vote the Shares represented by the Restricted Stock Units, unless and until such Shares have been delivered to the Participant in accordance with Section 9.
6.Dividend Equivalents. The Participant shall not receive cash dividends on the Restricted Stock Units, but instead shall, with respect to each Restricted Stock Unit, be entitled to a cash payment from the Company determined on each cash dividend payment date with respect to the Shares with a record date occurring at any time following the Date of Grant but prior to the date that the Shares represented by the Restricted Stock Units are delivered to the Participant in accordance with Section 9. Such cash payment shall be equal to the dividend that would have been paid on the Share represented by each Restricted Stock Unit had the Share been issued and outstanding and entitled to the dividend. Cash payments for each cash dividend payment date with respect to the Shares with a record date occurring prior to the date that the Shares represented by the Restricted Stock Units vest and are delivered to the Participant in accordance with Section 9 shall be accrued until such delivery date and paid to the Participant at the same time delivery of the Shares represented by the Restricted Stock Units is made to the Participant in accordance with Section 9, subject to applicable withholding. However, no such dividend equivalent payments shall be paid if the Participant does not vest in the Restricted Stock Units.
2

7.Notices. Any notice to the Company provided for in this instrument shall be addressed to the Compensation Committee c/o Chief Human Resources Officer at 1 West First Avenue Conshohocken, PA 19428, and any notice to the Participant shall be addressed to such Participant at the current address or electronic mail address shown on the records of the Company (or Parent or Subsidiary), or to such other address or electronic mail address as the Participant may designate to the Company in writing. Any notice shall be delivered by hand, sent by overnight courier or telecopy or enclosed in a properly sealed envelope addressed as stated above, registered and deposited, postage prepaid, in a post office regularly maintained by the United States Postal Service, or, if to the Participant, delivered via electronic mail (provided written confirmation of the transmission is obtained).
8.Securities Laws, etc. The Administrator may from time to time impose any conditions on the Restricted Stock Units, and the Shares represented by the Restricted Stock Units, as it deems necessary or advisable to ensure that the Plan and this Award satisfy the conditions of Rule 16b-3, and that such Shares are issued and resold in compliance with the Securities Act of 1933, as amended. The Company may require that the Participant represent that the Participant is holding the Shares for the Participant's own account and not with a view to or for sale in connection with any distribution of the Shares, or such other representation as the Administrator deems appropriate.
9.Delivery of Shares.
(a)Notwithstanding any provision of this Award Agreement or the Plan to the contrary (other than Sections 11, 14(b) and 14(c) hereof and Section 14 of the Plan), the Shares represented by the Restricted Stock Units (or such other consideration as permitted by Section 18(b) of the Plan) that have become nonforfeitable shall only be delivered to or on behalf of the Participant (in certificate or electronic form) on the earliest of:
(i)the applicable Vesting Date;
(ii)the date that the Participant’s Service ceases due to the Participant’s death or Disability;
(iii)if the Participant’s Service as an employee is involuntarily terminated by the Company (or successor thereto, or Parent or Subsidiary), other than for Cause, upon or within two (2) years following a Change in Control that constitutes a Qualifying Change in Control, the date of such termination;
(iv)the date of a Change in Control that occurs after the Date of Grant if such Change in Control constitutes a Qualifying Change in Control and if the Participant’s Service has terminated by reason of Retirement prior to the date of such Change in Control; or
(v)if the Participant’s Service has not terminated by reason of Retirement prior to a Change in Control that occurs after the Date of Grant, as of the earliest of (A) the date that the Participant’s Service terminates on account of Retirement if such termination occurs upon or within two (2) years following a Change in Control that constitutes a Qualifying Change in Control, (B) the date that the Restricted Stock Units become vested pursuant to Section 18(a) of the Plan or (C) the date that the Administrator exercises its discretion to vest and deliver such Shares (or other consideration) to the Participant pursuant to Section 18(b) of the Plan, consistent with Code Section 409A.

(b)The Shares will be delivered without payment from the Participant and without any legend or restrictions, except for such restrictions as may be imposed by the Administrator, in its sole judgment, under Section 8, provided that no certificates for Shares will be delivered to the Participant until appropriate arrangements have been made with the Company for the withholding of any Taxes which may be due with respect to such Shares. The Company may condition delivery of certificates for Shares upon the prior receipt from the Participant of any undertakings which it may determine are required to ensure that the certificates are being issued in compliance with federal and state securities laws.
3

(c)The right to payment of any fractional Shares shall be satisfied in cash, measured by the product of the fractional amount times the Fair Market Value of a Share on the Vesting Date (or the date that the cessation of the Participant’s Service due to the Participant’s death or Disability or other date on which the Restricted Stock Units become vested under Section 3, if earlier) determined by the Administrator.
10.Withholding Taxes.
(a)The issuance of the Shares shall be subject to the collection of all applicable Taxes. The Taxes may be paid in one or both of the following forms:
(vi)delivery of a check to the Company in the amount of such Taxes, or
(vii)through a Share withholding procedure approved by the Administrator pursuant to which the Company will withhold, at the time of such issuance, a portion of the Shares with a Fair Market Value (measured as of the applicable issuance date) equal to the amount of those Taxes.
Unless the Participant delivers a check to the Company in the amount of the Taxes, the Company will withhold Shares in accordance with Section 10(a)(ii) to cover the Taxes.

(b)Notwithstanding the foregoing provisions of this Section 10, the employee portion of the federal, state and local employment taxes required to be withheld by the Company in connection with the vesting (or deemed vesting by reason of the Participant being or becoming eligible for Retirement) of the Shares or any other amounts hereunder (the “Employment Taxes”) shall in all events be collected from the Participant in connection with vesting of the Restricted Stock Units. The provisions of this Section 10(b) shall be applicable only to the extent necessary to comply with the applicable tax withholding requirements of Code Section 3121(v).
(c)The Company shall collect the Taxes with respect to each non-Share distribution (including a dividend-equivalent payment) by withholding a portion of that distribution equal to the amount of the applicable Taxes, with the cash portion of the distribution to be the first portion so withheld.
11.Special Forfeiture and Repayment Rules.
(a)The Participant hereby acknowledges and agrees that this Award is subject to the Company’s Compensation Recoupment Policy, the Financial Recoupment Policy of the Company’s Corporate Integrity Agreement, to the extent applicable, and any other applicable clawback, recoupment or similar policy that the Board or Compensation Committee may adopt at any time (each, a “Policy”) and acknowledges and agrees that the Restricted Stock Units (and related dividend equivalents) hereunder granted, the Shares issued or to be issued and/or amounts paid or to be paid hereunder and/or amounts received with respect to any sale of such Shares, shall be subject to potential cancellation, recoupment, rescission, payback or other action in accordance with the terms of such Policy and this Agreement. The Participant agrees and consents to the Company’s application, implementation and enforcement of (i) any such Policy established by the Company that may apply to the Participant and (ii) any provision of applicable law relating to cancellation, rescission, payback or recoupment of compensation, and expressly agrees that the Company may take such actions as are necessary to effectuate such Policy or applicable law without further consent or action being required by the Participant.
(b)Accordingly, in addition to any remedies set forth in the applicable Policy, in the event that a covered event or other triggering event (as described in the applicable Policy) with respect to a Participant occurs, or the Participant’s breach of any of the Restrictive Covenants set forth in Attachment A hereto (each, a “Triggering Event”), and unless the Administrator or its delegate determines otherwise, then:
(i)any of the Restricted Stock Units (and related dividend equivalents) that remain unvested as of the date the Administrator or its delegate determines that the
4

Participant has experienced a Triggering Event, and any Restricted Stock Units (or related dividend equivalents) that have so vested but the Shares represented by such Restricted Stock Units (or related dividend equivalents) have not yet been delivered in accordance with Section 9, shall be immediately and automatically forfeited; and
(ii)if the Restricted Stock Units have vested and the Shares represented by such
Restricted Stock Units (and related dividend equivalents) have been delivered to the Participant in accordance with Section 9 within the twelve (12)-month period immediately prior to the date of the acts or omissions that gave rise to such Triggering Event or anytime thereafter, within ten (10) days of receiving written notice from the Company that a Triggering Event has occurred, the Participant shall deliver to the Company a number of unrestricted Shares equal to the number of Shares and any cash delivered to the Participant in respect of the Restricted Stock Units (and related dividend equivalents) during such period; provided that if, at the time delivery of the Shares by the Participant is required, the Participant cannot deliver a number of unrestricted Shares equal to the number of Shares delivered to the Participant in respect of the Restricted Stock Units during such period, in addition to the delivery of the number of unrestricted Shares by the Participant at such time, the Participant shall be required to pay to the Company an amount equal to the product of the number of such Shares delivered to the Participant in respect of the Restricted Stock Units during such period (less the number of Shares contemporaneously delivered by the Participant to the Company), multiplied by the Fair Market Value of one Share as of the date the Restricted Stock Units became vested.
(c)The Administrator shall determine in its sole discretion whether a Triggering Event has occurred with respect to the Participant.
(d)The Participant hereby acknowledges and agrees that the restrictions contained herein, including, but not limited to, the Restrictive Covenants set forth in Attachment A hereto, are being made for the benefit of the Company in consideration of the Participant’s receipt of the Award. The Participant further acknowledges that the receipt of the Award is a voluntary action on the part of the Participant and that the Company is unwilling to provide the Award to the Participant without including the restrictions contained in the Plan.
(e)The Participant hereby consents to a deduction from, and set-off against, any amounts owed to the Participant by the Company or its affiliates from time to time (including, but not limited to, amounts owed to the Participant as wages, severance payments or other fringe benefits) to the extent of the amounts owed to the Company by the Participant under this Award Agreement.
(f)The Special Forfeiture and Repayment Rules provisions of this Award Agreement and the Plan are in addition to, not in lieu of, any other obligation and/or restriction that the Participant may have with respect to the Company, whether by operation of law, contract, or otherwise, including, without limitation, any non-competition and non-solicitation obligations contained in an employment agreement entered into by and between the Participant and the Company or any of its affiliates.
12.Transferability. The Restricted Stock Units (and the underlying Shares (and related dividend equivalents)) may not be assigned, alienated, pledged, attached, sold or otherwise transferred or encumbered by the Participant other than by will or by the laws of descent and distribution, and any purported assignment, alienation, pledge, attachment, sale, transfer or encumbrance not permitted by this Section 12 shall be void and unenforceable. However, any Shares (and related dividend equivalents) which vest hereunder but otherwise remain unissued at the time of the Participant’s death, shall be issued to the Participant’s designated beneficiary or beneficiaries of this Award or in the absence of such designated beneficiaries, pursuant to the provisions of the Participant’s will or laws of descent and distribution.
5

13.Restrictive Covenants and Other Attachments. The Participant hereby agrees to the Restrictive Covenants set forth in Attachment A hereto and acknowledges and agrees to the provisions of Attachment B hereto.
14.Section 409A.
(a)It is the intention of the parties that the provisions of this Award Agreement shall, to the maximum extent possible, be exempt from Code Section 409A. Accordingly, to the extent there is any ambiguity as to whether one or more provisions of this Award Agreement would otherwise contravene
the requirements or limitations of Code Section 409A and the Treasury Regulations applicable thereunder, then those provisions shall be interpreted and applied in a manner that does not result in a violation of the requirements or limitations of Code Section 409A and the Treasury Regulations thereunder.
(b)However, to the extent this Award Agreement should be deemed to create a deferred compensation arrangement subject to the requirements of Code Section 409A, then no Shares or other amounts which become issuable or distributable under this Award Agreement by reason of the Participant’s cessation of Service shall actually be issued or distributed to the Participant until the date of the Participant’s separation from service within the meaning of Treasury Regulation 1.409A-1(h) or as soon thereafter as administratively practicable, but in no event later the fifteenth (15th) day of the third (3rd)calendar month following the date of such separation from service, unless a delayed commencement date is otherwise required pursuant to Section 14(c).
(c)No Shares or other amounts which become issuable or distributable under this Award Agreement by reason of the Participant’s separation from service shall actually be issued or distributed to the Participant prior to the earlier of (i) the first day of the seventh (7th) month following the date of such separation from service or (ii) the date of the Participant’s death, if the Participant is deemed at the time of such separation from service to be a specified employee under Treasury Regulation 1.409A-1(i), as determined by the Administrator in accordance with consistent and uniform standards applied to all other Code Section 409A arrangements of the Company, and such delayed commencement is otherwise required in order to avoid a prohibited distribution under Code Section 409A(a)(2). The deferred Shares or other distributable amount shall be issued or distributed in a lump sum on the first day of the seventh (7th) month following the date of the Participant’s separation from service or, if earlier, the first day of the month immediately following the date the Company receives proof of the Participant’s death. In no event shall the Participant have the right to determine the calendar year in which any such issuance or distribution is to occur.
15.Miscellaneous.
(a)The Award granted hereunder shall not confer upon the Participant any right to continue in
Service and shall not interfere in any way with the right of the Company (or any Parent or
Subsidiary) to terminate the Participant’s Service at any time. The right of the Company (or any Parent or Subsidiary) to terminate at will the Participant’s Service at any time for any reason is specifically reserved.
(b)The Award granted hereunder is subject to the approval of the Plan by the shareholders of the Company to the extent that such approval (i) is required pursuant to the rules and regulations of the New York Stock Exchange, or (ii) is required to satisfy the conditions of Rule 16b-3.
(c)The Participant acknowledges that the Company has not advised the Participant regarding the Participant’s tax liability in connection with the grant or vesting of the Restricted Stock Units
(and related dividend equivalents) or the delivery of the Shares represented by the Restricted Stock Units (and related dividend equivalents). The Participant is not relying on any statements or representations of the Company or any of its agents in regard to such liability. The Participant understands that the Participant (and not the Company) shall be responsible for the Participant’s
6

own tax liability that may arise as a result of the transactions contemplated by this Award Agreement.
(d)The validity, performance, construction and effect of this Award shall be governed by and determined in accordance with the law of the State of Delaware, without giving effect to conflicts of laws principles thereof.
(e)Except to the extent otherwise provided in this Award Agreement, the provisions of this Award Agreement shall inure to the benefit of, and be binding upon, the Company and its successors and assigns and the Participant, the Participant’s assigns, the legal representatives, heirs and legatees of the Participant’s estate and any beneficiaries of the Award designated by the Participant.
(f)This Award Agreement shall not in any way affect the right of the Company to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.
(g)The Participant has received a copy of the Plan, a copy of which is attached hereto, has been provided with the opportunity to read the Plan and is familiar with the terms and provisions thereof and hereby accepts this Award subject to all of the terms and provisions of this Award Agreement and the Plan, including, without limitation, the Special Forfeiture and Repayment Rule provisions of the Plan. The Participant hereby acknowledges the receipt of the prospectus for the Plan, a copy of which is attached hereto. All decisions or interpretations of the Administrator upon any questions arising under the Plan or this Award Agreement shall be binding, conclusive and final.
16.GRANT ACCEPTANCE. YOU MUST ACCEPT THE TERMS OF THIS AWARD AGREEMENT WITHIN A TIME PERIOD SPECIFIED BY THE COMPANY FOLLOWING RECEIPT IN ACCORDANCE WITH THE PROCEDURES SPECIFIED BY THE COMPANY. IF YOU DO NOT ACCEPT THE TERMS AS INSTRUCTED, THIS AWARD AGREEMENT WILL AUTOMATICALLY, WITHOUT FURTHER ACTION OF THE COMPANY OR THE ADMINISTRATOR, TERMINATE AND THE AWARD WILL BE FORFEITED.

ACCEPTANCE OF THIS AWARD AGREEMENT CONSTITUTES YOUR CONSENT TO ANY ACTION TAKEN UNDER THE PLAN AND THIS AWARD AGREEMENT AND YOUR AGREEMENT TO BE BOUND BY THE COVENANTS AND AGREEMENTS CONTAINED IN ATTACHMENT A AND ATTACHMENT B HERETO. YOU SHOULD READ ATTACHMENT A AND ATTACHMENT B CAREFULLY BEFORE DECIDING WHETHER TO ACCEPT THIS AWARD. YOU HAVE THE RIGHT TO CONSULT WITH COUNSEL PRIOR TO ACCEPTING THIS AWARD. IF YOU DECIDE NOT TO ACCEPT THIS AWARD, YOU WILL FORFEIT THE AWARD AND THE RESTRICTIVE COVENANTS SET FORTH IN ATTACHMENT A AND ATTACHMENT B HERETO WILL NOT APPLY. HOWEVER, YOU WILL CONTINUE TO BE SUBJECT TO ANY RESTRICTIVE COVENANTS WITH RESPECT TO PRIOR OR SUBSEQUENT EQUITY GRANTS AND ANY OTHER RESTRICTIVE COVENANT AGREEMENTS BETWEEN YOU AND THE COMPANY. THERE WILL BE NO OTHER CONSEQUENCES AS A RESULT OF YOUR DECISION NOT TO ACCEPT AWARD.
IN WITNESS WHEREOF, the Company has caused its duly authorized officer to execute this Award Agreement
effective as of the Date of Grant.
AMERISOURCEBERGEN CORPORATION

Elizabeth Campbell
Executive Vice President
Chief Legal Officer

7
 EX-10.24 3 exhibit1024-psuawardtoempl.htm EX-10.24 Document
Exhibit 10.24
U.S.


AMERISOURCEBERGEN CORPORATION
PERFORMANCE SHARE AWARD TO EMPLOYEE

Participant:    #ParticipantName#

Target Number
of Performance Shares:    #QuantityGranted#

Date of Grant:    #GrantDate#

Vesting Date:    #Vesting Date#


RECITALS

This Performance Share Award (the “Award Agreement”) is made by AmerisourceBergen Corporation, a Delaware corporation (the “Company”), pursuant to the AmerisourceBergen Corporation 2022 Omnibus Incentive Plan (the “Plan”).

WHEREAS, the Company has agreed to grant to the Participant a performance share award, subject to certain restrictions and on the terms and conditions contained in this Award Agreement.

NOW, THEREFORE, in consideration of the foregoing and the premises contained herein and intending to be legally bound hereby:

1.Definitions. Unless otherwise defined herein, capitalized terms used in this Award Agreement shall have the meanings ascribed to them in the Plan. As used herein:

a)“Award” means the performance share award hereby granted.

b)“Date of Grant” means the date on which the Company granted the Award to the Participant pursuant to the Plan.

c)“Disability” means the Participant is eligible to receive long-term disability benefits under the Company’s long-term disability plan.

d)“Performance Criteria” means the performance criteria established by the Compensation Committee and as set forth in Schedule 1 hereto.

e)“Performance Period” means the period beginning on [•] and ending on [•].

f)“Retirement” means any termination of employment, other than by the Company (or a Parent or Subsidiary) for Cause, after reaching age fifty-five (55), where the Participant’s age plus years of continuous employment with the Company and/or its Parent or Subsidiaries equals at least sixty-five (65).

g)“Settlement Date” means no later than [•].

h)“Shares” mean shares of the Company’s Common Stock.

i)“Taxes” means the federal, state and local income and employment taxes required to be withheld in connection with the vesting and issuance of the Shares (or other amounts or property) under the Award.

2.Grant of Performance Shares. Subject to the terms and conditions set forth herein and in the Plan, the Company hereby grants to the Participant an Award authorizing the Participant to receive a number of Shares based on the extent to which the applicable vesting criteria are satisfied. The initial number of Shares that shall be used to
1


determine the Participant’s rights pursuant to this Award is the “Target Number of Performance Shares.” The Target Number of Performance Shares shall be used solely to calculate the maximum number of Shares that may be issued to the Participant under this Award Agreement (“Performance-Qualified Shares”).

The number of Performance-Qualified Shares to which the Participant may become entitled shall be calculated by multiplying the designated Target Number of Performance Shares by a percentage ranging from zero (0%) to [•] percent ([•]%) based on the attained level of Company performance for the Performance Period as set forth in Schedule 1 hereto. The number of Performance-Qualified Shares may exceed [•]percent ([•]%) of the Target Number of Performance Shares, based on actual performance in accordance with Schedule 1 hereto.

Notwithstanding the foregoing, (i) in the event of a Change in Control during the Performance Period, the number of Performance-Qualified Shares issuable under this Award shall be determined as set forth in Section 4 below and (ii) in the event the Participant’s Service ceases prior to the Vesting Date by reason of death or Disability, the number of Performance-Qualified Shares used to determine the number of Shares issuable under Section 3(b)(ii) shall be based on the actual level of Performance Criteria attainment through the most recently completed calendar quarter prior to the date of death or Disability (or the Performance-Qualified Shares determined in accordance with Section 4 if a Change in Control occurs prior to the date of death or Disability).

3.Vesting. Subject to the terms and conditions set forth herein and in the Plan, the actual number of Shares that may vest and become issuable pursuant to the Award shall be determined pursuant to a two-step process: (i) first there shall be calculated the maximum number of Performance-Qualified Shares in which the Participant can vest based upon the level at which the Performance Criteria are actually attained and (ii) then the number of Shares resulting from the clause (i) calculation in which the Participant shall actually vest shall be determined on the basis of his or her completion of the applicable Service-vesting provisions set forth below. Accordingly, the vesting of the Shares shall be calculated as follows:

a)Performance Vesting: Within sixty (60) days following the completion of the Performance Period (or any earlier applicable determination date), the Compensation Committee shall, on the basis of the level at which the Performance Criteria have been attained, determine the applicable number of Performance-Qualified Shares in accordance with the provisions of Section 2.

b)Service Vesting: The Performance-Qualified Shares so determined represent the maximum number of Shares in which the Participant can vest hereunder. The actual number of Shares in which the Participant shall vest shall be determined as follows:

i.If the Participant continues in Service from the Date of Grant through the Vesting Date, the Participant shall vest in all of the Performance-Qualified Shares;

ii.If the Participant ceases to be in Service prior to the Vesting Date but after [•] by reason of death or Disability, then the Participant shall, upon such cessation of Service, vest in a number of Shares determined by multiplying (x) the applicable number of Performance-Qualified Shares, (determined in accordance with the last paragraph of Section 2 above) , by (y) a fraction, the numerator of which is the number of days of actual Service completed by the Participant during Performance Period, and the denominator of which is one thousand ninety-five (1,095);

iii.If the Participant’s Service terminates during the Performance Period due to the Participant’s Retirement, then the Participant shall vest in the maximum number of Performance-Qualified Shares in which the Participant would have vested if the Participant had continued in Service through the Vesting Date;

iv.If upon or within two (2) years following a Change in Control that occurs after the Date of Grant, the Participant’s Service as an employee is involuntarily terminated by the Company (or successor thereto, or a Parent or Subsidiary), other than for Cause, then the Performance-Qualified Shares (as determined pursuant to Section 4) to the extent outstanding shall become one hundred percent (100%) vested as of the date of such cessation of Service;

v.If the Participant ceases to be in Service prior to the Vesting Date but after [•]as a result of termination of the Participant’s employment by the Company without Cause (other than a
2


termination described in Section 3(b)(iv)), then the Participant shall vest in a portion of the Performance-Qualified Shares determined by multiplying (x) the maximum number of Performance-Qualified Shares in which the Participant would have vested had the Participant continued in Service through the Vesting Date by (y) a fraction, the numerator of which is the number of days in the Performance Period up to the date of such termination, and the denominator of which is one thousand ninety-five (1,095). Notwithstanding any other provision of this Award Agreement, any vesting of Shares pursuant to this Section 3(b)(v) is conditioned upon the Participant’s execution during the applicable release review period, and non- revocation, of a written release (in such form reasonably prescribed by the Company or in substantially the form attached to an employment agreement entered into by and between the Participant and the Company or any of its affiliates) of any and all claims against the Company and all related parties; and

vi.If the Participant’s Service ceases for any other reason prior to the completion of the Performance Period, then the Participant shall not vest in any of the Performance-Qualified Shares, and all of the Participant’s right, title and interest in and to the Shares subject to this Award shall immediately terminate.

4.Change in Control. In the event a Change in Control occurs during the Performance Period: (A) the Performance Period shall be deemed to end on the last day of the calendar quarter ending prior to the Change in Control; and (B) the Performance-Qualified Shares shall be based on the extent to which the Performance Criteria were achieved for such abbreviated period as determined and certified by the Compensation Committee.

5.Rights of Participant. The Participant shall not have the rights of a stockholder of the Company with respect the Shares represented by the Award, including, without limitation, the right to vote the Shares represented by the Award, unless and until such Shares have been delivered to the Participant in accordance with Section 9.

6.Dividend Equivalents. The Participant shall not receive cash dividends on the Shares subject to the Award, but instead shall, with respect to each Share, be entitled to a cash payment from the Company determined on each cash dividend payment date with respect to the Shares with a record date occurring at any time following the Date of Grant but prior to the date that the Shares represented by the Award are delivered to the Participant in accordance with Section 9. Such cash payment shall be equal to the dividend that would have been paid on the Shares actually delivered to the Participant had the Shares been issued and outstanding and entitled to the dividend. Cash payments for each cash dividend payment date with respect to the Shares with a record date occurring prior to the date that the Shares represented by the Award vest and are delivered to the Participant in accordance with Section 9 shall be accrued until such delivery date and paid to the Participant at the same time delivery of the Shares is made to the Participant in accordance with Section 9, subject to applicable withholding. However, no such dividend equivalent payments shall be paid if the Participant does not vest in the Shares.

7.Notices. Any notice to the Company provided for in this instrument shall be addressed to the Compensation Committee c/o Chief Human Resources Officer at 1 West First Avenue Conshohocken, PA 19428, and any notice to the Participant shall be addressed to such Participant at the current address or electronic mail address shown on the records of the Company (or Parent or Subsidiary), or to such other address or electronic mail address as the Participant may designate to the Company in writing. Any notice shall be delivered by hand, sent by overnight courier or telecopy or enclosed in a properly sealed envelope addressed as stated above, registered and deposited, postage prepaid, in a post office regularly maintained by the United States Postal Service, or, if to the Participant, delivered via electronic mail (provided written confirmation of the transmission is obtained).

8.Securities Laws, etc. The Administrator may from time to time impose any conditions on the Award, and the Shares represented by the Award, as it deems necessary or advisable to ensure that the Plan and this Award satisfy the conditions of Rule 16b-3, and that such Shares are issued and resold in compliance with the Securities Act of 1933, as amended. The Company may require that the Participant represent that the Participant is holding the Shares for the Participant's own account and not with a view to or for sale in connection with any distribution of the Shares, or such other representation as the Administrator deems appropriate.

9.Delivery of Shares.

a)Notwithstanding any provision of this Award Agreement or the Plan to the contrary (other than Sections 12, 15(b) and 15(c) hereof and Section 14 of the Plan), the Shares (or such other consideration as
3


permitted by Section 18(b) of the Plan) issuable under this Award that have vested and become issuable shall be delivered to or on behalf of the Participant (in certificate or electronic form) (i) after the Vesting Date but no later than the Settlement Date or (ii) if earlier, within sixty (60) days following the date that the Participant’s Service terminates pursuant to Section 3(b)(ii) or Section 3(b)(iv).

b)The Shares will be delivered without payment from the Participant and without any legend or restrictions, except for such restrictions as may be imposed by the Administrator, in its sole judgment, under Section 8, provided that no certificates for Shares will be delivered to the Participant until appropriate arrangements have been made with the Company for the withholding of any Taxes which may be due with respect to such Shares. The Company may condition delivery of certificates for Shares upon the prior receipt from the Participant of any undertakings which it may determine are required to ensure that the certificates are being issued in compliance with federal and state securities laws.

c)The right to payment of any fractional Shares shall be satisfied in cash, measured by the product of the fractional amount times the Fair Market Value of a Share on the date that the Shares are delivered pursuant to this Section 9, as determined by the Administrator.

10.Withholding Taxes.

a)The issuance of the Shares shall be subject to the collection of all applicable Taxes. The Taxes may be paid in one or both of the following forms:

i.delivery of a check to the Company in the amount of such Taxes, or

ii.through a Share withholding procedure approved by the Administrator pursuant to which the Company will withhold, at the time of such issuance, a portion of the Shares with a Fair Market Value (measured as of the applicable issuance date) equal to the amount of those Taxes.

Unless the Participant delivers a check to the Company in the amount of the Taxes, the Company will withhold Shares in accordance with Section 10(a)(ii) to cover the Taxes.

b)Notwithstanding the foregoing provisions of this Section 10, the employee portion of the federal, state and local employment taxes required to be withheld by the Company in connection with the vesting (or deemed vesting by reason of the Participant being or becoming eligible for Retirement) of the Shares or any other amounts hereunder (the “Employment Taxes”) shall in all events be collected from the Participant in connection with vesting of the Performance-Qualified Shares. The provisions of this Section 10(b) shall be applicable only to the extent necessary to comply with the applicable tax withholding requirements of Code Section 3121(v).
c)The Company shall collect the Taxes with respect to each non-Share distribution (including a dividend- equivalent payment) by withholding a portion of that distribution equal to the amount of the applicable Taxes, with the cash portion of the distribution to be the first portion so withheld.

11.[Holding Requirements. Fifty percent (50%) of the Shares issued to the Participant under this Award on or after the Vesting Date, net of any Shares withheld for Taxes, must be held by the Participant for [two years – CEO] [one year – Other Named Executive Officers] following the Vesting Date (the “Holding Period”) and may not be assigned, transferred, pledged or otherwise disposed of by the Participant, other than by will or the laws of descent and distribution, during the Holding Period. However, if a Change in Control occurs, the holding requirement of this Section 11 shall lapse as of the date of the Change in Control. Notwithstanding the foregoing, if the Participant’s Service terminates pursuant to Section 3(b)(ii), the holding requirement of this Section 11 shall not apply. Additionally, if the holding requirement of this Section 11 has been imposed on the Participant’s Shares in accordance with this Section 11 and the Participant dies or becomes Disabled before the end of the Holding Period, then the Holding Period shall lapse as of the date of the Participant’s death or Disability.]

12.Special Forfeiture and Repayment Rules.

a)The Participant hereby acknowledges and agrees that this Award is subject to the Company’s Compensation Recoupment Policy, the Financial Recoupment Policy of the Company’s Corporate Integrity Agreement, to the extent applicable, and any other applicable clawback, recoupment or similar
4


policy that the Board or Compensation Committee may adopt at any time (each, a “Policy”), and acknowledges and agrees that the Performance-Qualified Shares (and related dividend equivalents) hereunder granted, the Shares issued or to be issued and/or amounts paid or to be paid hereunder and/or amounts received with respect to any sale of such Shares, shall be subject to potential cancellation, recoupment, rescission, payback or other action in accordance with the terms of such Policy and this Agreement. The Participant agrees and consents to the Company’s application, implementation and enforcement of (i) any such Policy established by the Company that may apply to the Participant and (ii) any provision of applicable law relating to cancellation, rescission, payback or recoupment of compensation, and expressly agrees that the Company may take such actions as are necessary to effectuate such Policy or applicable law without further consent or action being required by the Participant.

b)Accordingly, in addition to any remedies set forth in the applicable Policy, in the event that a covered event or other triggering event (as described in the applicable Policy) with respect to a Participant occurs, or the Participant’s breach of any of the Restrictive Covenants set forth in Attachment A hereto, occurs (each, a “Triggering Event”), and unless the Administrator or its delegate determines otherwise, then:

i.any portion of the Award (and related dividend equivalents) that remain unvested as of the date the Compensation Committee or its delegate determines that the Participant has experienced a Triggering Event, and any portion of the Award (or related dividend equivalents) that has so vested but the Shares represented by such vested portion (or related dividend equivalents) have not yet been delivered in accordance with Section 9, shall be immediately and automatically forfeited; and

ii.if the Award has vested and the Shares represented by such vested Award (and related dividend equivalents) have been delivered to the Participant in accordance with Section 9 within the twelve (12)-month period immediately prior to the date of the acts or omissions that gave rise to such Triggering Event or anytime thereafter, within ten (10) days of receiving written notice from the Company that a Triggering Event has occurred, the Participant shall deliver to the Company a number of unrestricted Shares equal to the number of Shares and any cash delivered to the Participant in respect of the Award (and related dividend equivalents) during such period; provided that if, at the time delivery of the Shares by the Participant is required, the Participant cannot deliver a number of unrestricted Shares equal to the number of Shares delivered to the Participant in respect of the Award during such period, in addition to the delivery of the number of unrestricted Shares by the Participant at such time, the Participant shall be required to pay to the Company an amount equal to the product of the number of such Shares delivered to the Participant in respect of the Award during such period (less the number of Shares contemporaneously delivered by the Participant to the Company), multiplied by the Fair Market Value of one Share as of the date the Award became vested.

c)The Administrator shall determine in its sole discretion whether a Triggering Event has occurred with respect to the Participant.

d)The Participant hereby acknowledges and agrees that the restrictions contained herein, including, but not limited to, the Restrictive Covenants set forth in Attachment A hereto, are being made for the benefit of the Company in consideration of the Participant’s receipt of the Award. The Participant further acknowledges that the receipt of the Award is a voluntary action on the part of the Participant and that the Company is unwilling to provide the Award to the Participant without including the restrictions contained in the Plan.

e)The Participant hereby consents to a deduction from, and set-off against, any amounts owed to the Participant by the Company or its affiliates from time to time (including, but not limited to, amounts owed to the Participant as wages, severance payments or other fringe benefits) to the extent of the amounts owed to the Company by the Participant under this Award Agreement.

f)The Special Forfeiture and Repayment Rules provisions of this Award Agreement and the Plan are in addition to, not in lieu of, any other obligation and/or restriction that the Participant may have with respect to the Company, whether by operation of law, contract, or otherwise, including, without limitation, any
5


non-competition and non-solicitation obligations contained in an employment agreement entered into by and between the Participant and the Company or any of its affiliates.

13.Transferability. The Award (and the underlying Shares (and related dividend equivalents)) may not be assigned, alienated, pledged, attached, sold or otherwise transferred or encumbered by the Participant other than by will or by the laws of descent and distribution, and any purported assignment, alienation, pledge, attachment, sale, transfer or encumbrance not permitted by this Section 13 shall be void and unenforceable. However, any Shares (and related dividend equivalents) which vest hereunder but otherwise remain unissued at the time of the Participant’s death, shall be issued to the Participant’s designated beneficiary or beneficiaries of this Award or in the absence of such designated beneficiaries, pursuant to the provisions of the Participant’s will or laws of descent and distribution.

14.Restrictive Covenants and Other Attachments. The Participant hereby agrees to the Restrictive Covenants set forth in Attachment A hereto and acknowledges and agrees to the provisions of Attachment B hereto.

15.Section 409A.

a)It is the intention of the parties that the provisions of this Award Agreement shall, to the maximum extent possible, be exempt from Code Section 409A. Accordingly, to the extent there is any ambiguity as to whether one or more provisions of this Award Agreement would otherwise contravene the requirements or limitations of Code Section 409A and the Treasury Regulations applicable thereunder, then those provisions shall be interpreted and applied in a manner that does not result in a violation of the requirements or limitations of Code Section 409A and the Treasury Regulations thereunder.

b)However, to the extent this Award Agreement should be deemed to create a deferred compensation arrangement subject to the requirements of Code Section 409A, then no Shares or other amounts which become issuable or distributable under this Award Agreement by reason of the Participant’s cessation of Service shall actually be issued or distributed to the Participant until the date of the Participant’s separation from service within the meaning of Treasury Regulation 1.409A-1(h) or as soon thereafter as administratively practicable, but in no event later the fifteenth (15th) day of the third (3rd)calendar month following the date of such separation from service, unless a delayed commencement date is otherwise required pursuant to Section 15(c).

c)No Shares or other amounts which become issuable or distributable under this Award Agreement by reason of the Participant’s separation from service shall actually be issued or distributed to the Participant prior to the earlier of (i) the first day of the seventh (7th) month following the date of such separation from service or (ii) the date of the Participant’s death, if the Participant is deemed at the time of such separation from service to be a specified employee under Treasury Regulation 1.409A-1(i), as determined by the Administrator in accordance with consistent and uniform standards applied to all other Code Section 409A arrangements of the Company, and such delayed commencement is otherwise required in order to avoid a prohibited distribution under Code Section 409A(a)(2). The deferred Shares or other distributable amount shall be issued or distributed in a lump sum on the first day of the seventh (7th) month following the date of the Participant’s separation from service or, if earlier, the first day of the month immediately following the date the Company receives proof of the Participant’s death. In no event shall the Participant have the right to determine the calendar year in which any such issuance or distribution is to occur.

16.Miscellaneous.

a)The Award granted hereunder shall not confer upon the Participant any right to continue in Service and shall not interfere in any way with the right of the Company (or any Parent or Subsidiary) to terminate the Participant’s Service at any time. The right of the Company (or any Parent or Subsidiary) to terminate at will the Participant’s Service at any time for any reason is specifically reserved.

b)The Award granted hereunder is subject to the approval of the Plan by the shareholders of the Company to the extent that such approval (i) is required pursuant to the rules and regulations of the New York Stock Exchange, or (ii) is required to satisfy the conditions of Rule 16b-3.
c)The Participant acknowledges that the Company has not advised the Participant regarding the Participant’s tax liability in connection with the grant or vesting of the Award (and related dividend equivalents) or the
6


delivery of the Shares represented by the Award (and related dividend equivalents). The Participant is not relying on any statements or representations of the Company or any of its agents in regard to such liability. The Participant understands that the Participant (and not the Company) shall be responsible for the Participant’s own tax liability that may arise as a result of the transactions contemplated by this Award Agreement.

d)The validity, performance, construction and effect of this Award shall be governed by and determined in accordance with the law of the State of Delaware, without giving effect to conflicts of laws principles thereof.

e)Except to the extent otherwise provided in this Award Agreement, the provisions of this Award Agreement shall inure to the benefit of, and be binding upon, the Company and its successors and assigns and the Participant, the Participant’s assigns, the legal representatives, heirs and legatees of the Participant’s estate and any beneficiaries of the Award designated by the Participant.

f)This Award Agreement shall not in any way affect the right of the Company to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.

g)The Participant has received a copy of the Plan, a copy of which is attached hereto, has been provided with the opportunity to read the Plan and is familiar with the terms and provisions thereof and hereby accepts this Award subject to all of the terms and provisions of this Award Agreement and the Plan, including, without limitation, the Special Forfeiture and Repayment Rule provisions of the Plan. The Participant hereby acknowledges the receipt of the prospectus for the Plan, a copy of which is attached hereto. All decisions or interpretations of the Administrator upon any questions arising under the Plan or this Award Agreement shall be binding, conclusive and final.

17.GRANT ACCEPTANCE. YOU MUST ACCEPT THE TERMS OF THIS AWARD AGREEMENT WITHIN A TIME PERIOD SPECIFIED BY THE COMPANY FOLLOWING RECEIPT IN ACCORDANCE WITH THE PROCEDURES SPECIFIED BY THE COMPANY. IF YOU DO NOT ACCEPT THE TERMS AS INSTRUCTED, THIS AWARD AGREEMENT WILL AUTOMATICALLY, WITHOUT FURTHER ACTION BY THE COMPANY OR THE ADMINISTRATOR, TERMINATE AND THE AWARD WILL BE FORFEITED.

ACCEPTANCE OF THIS AWARD AGREEMENT CONSTITUTES YOUR CONSENT TO ANY ACTION TAKEN UNDER THE PLAN AND THIS AWARD AGREEMENT AND YOUR AGREEMENT TO BE BOUND BY THE COVENANTS AND AGREEMENTS CONTAINED IN ATTACHMENT A AND ATTACHMENT B HERETO. YOU SHOULD READ ATTACHMENT A AND ATTACHMENT B CAREFULLY BEFORE DECIDING WHETHER TO ACCEPT THIS AWARD. YOU HAVE THE RIGHT TO CONSULT WITH COUNSEL PRIOR TO ACCEPTING THIS AWARD. IF YOU DECIDE NOT TO ACCEPT THIS AWARD, YOU WILL FORFEIT THE AWARD AND THE RESTRICTIVE COVENANTS SET FORTH IN ATTACHMENT A AND ATTACHMENT B HERETO WILL NOT APPLY. HOWEVER, YOU WILL CONTINUE TO BE SUBJECT TO ANY RESTRICTIVE COVENANTS WITH RESPECT TO PRIOR OR SUBSEQUENT EQUITY GRANTS AND ANY OTHER RESTRICTIVE COVENANT AGREEMENTS BETWEEN YOU AND THE COMPANY. THERE WILL BE NO OTHER CONSEQUENCES AS A RESULT OF YOUR DECISION NOT TO ACCEPT AWARD.

IN WITNESS WHEREOF, the Company has caused its duly authorized officer to execute this Award Agreement effective as of the Date of Grant.

AMERISOURCEBERGEN CORPORATION


Elizabeth Campbell
Executive Vice President
Chief Legal Officer

7


SCHEDULE 1

Performance Criteria
FY[•]_ – FY[•]_ Performance Goals
Performance Period: [•]– [•]

Metric

Weighting

Baseline
Threshold
Target
Maximum
Goal
Payout/
Modifier
Goal
Payout/ Modifier
Payout
Goal
Payout/
Modifier Payout

























Notes:


8
 EX-21 4 exhibit21202210-k.htm EX-21 Document

Exhibit 21


SUBSIDIARIES OF THE REGISTRANT

The following is a list of significant subsidiaries of the Registrant:
Subsidiary
Jurisdiction of Incorporation
AB Singapore Investments Pte LtdSingapore
AB UK Holdings LtdUK
Amerisource Receivables Financial Corporation
Delaware
AmerisourceBergen Drug Corporation
Delaware
AmerisourceBergen Global Holdings GmbHSwitzerland
AmerisourceBergen Global Manufacturer Services GmbHSwitzerland
AmerisourceBergen Group GmbHSwitzerland
AmerisourceBergen International B.V.Netherlands
AmerisourceBergen International Holdings Inc.Delaware
AmerisourceBergen Luxembourg S.a.r.L.Luxembourg
AmerisourceBergen Services CorporationDelaware
AmerisourceBergen Sourcing, LLCDelaware
AmerisourceBergen Specialty Group, LLCDelaware
ASD Specialty Healthcare, LLCCalifornia
BPL Group, LLCDelaware
BPLH Ireland Unlimited CompanyIreland
International Physician Networks, L.L.C.Delaware
World Courier Group S.à r.l.Luxembourg


 EX-23 5 exhibit23-9302022.htm EX-23 Document

Exhibit 23

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:
a.Registration Statement (Form S-8 No. 333-86012) pertaining to the AmerisourceBergen Employee Investment Plan,
b.Registration Statements (Form S-8 Nos. 333-88230, 333-110431, and 333-140470) pertaining to the AmerisourceBergen Corporation 2002 Management Stock Incentive Plan, as amended,
c.Registration Statement (Form S-8 No. 333-101042) pertaining to the AmerisourceBergen Corporation 2001 Deferred Compensation Plan and the AmerisourceBergen Corporation 2001 Restricted Stock Plan,
d.Registration Statement (Form S-8 No. 333-101043) pertaining to the AmerisourceBergen Corporation 2001 Non-Employee Directors' Stock Option Plan,
e.Registration Statement (Form S-8 No. 333-159924) pertaining to the AmerisourceBergen Corporation Management Incentive Plan,
f.Registration Statement (Form S-8 No. 333-173982) pertaining to the AmerisourceBergen Corporation 2011 Employee Stock Purchase Plan,
g.Registration Statement (Form S-8 No. 333-194325) pertaining to the AmerisourceBergen Corporation Omnibus Incentive Plan,
h.Registration Statement (Form S-8 No. 333-264076) pertaining to the AmerisourceBergen Corporation 2022 Omnibus Incentive Plan, and
i.Registration Statement (Form S-3 No. 333-261306) of AmerisourceBergen Corporation;
of our reports dated November 22, 2022, with respect to the consolidated financial statements and schedule of AmerisourceBergen Corporation and subsidiaries and the effectiveness of internal control over financial reporting of AmerisourceBergen Corporation and subsidiaries included in this Annual Report (Form 10-K) of AmerisourceBergen Corporation and subsidiaries for the year ended September 30, 2022.


/s/ Ernst & Young LLP

Philadelphia, Pennsylvania
November 22, 2022


 EX-31.1 6 exhibit311-9302022.htm EX-31.1 Document

Exhibit 31.1

Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer

I, Steven H. Collis, certify that:

1. I have reviewed this Annual Report on Form 10-K (the "Report") of AmerisourceBergen Corporation (the "Registrant");

2. Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;

3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this Report;

4. The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and

(d) Disclosed in this Report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of Registrant's board of directors:

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.
 
/s/ Steven H. Collis
Steven H. Collis
Chairman, President and Chief Executive Officer
Date: November 22, 2022




EX-31.2 7 exhibit312-9302022.htm EX-31.2 Document

Exhibit 31.2

Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer

I, James F. Cleary, certify that:

1. I have reviewed this Annual Report on Form 10-K (the "Report") of AmerisourceBergen Corporation (the "Registrant");

2. Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;

3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this Report;

4. The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and

(d) Disclosed in this Report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of Registrant's board of directors:

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.
 
/s/ James F. Cleary
James F. Cleary
Executive Vice President and Chief Financial Officer
Date: November 22, 2022


EX-32 8 exhibit32-9302022.htm EX-32 Document

Exhibit 32

Section 1350 Certification of Chief Executive Officer

In connection with the Annual Report of AmerisourceBergen Corporation (the "Company") on Form 10-K for the fiscal year ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Steven H. Collis, Chairman, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

             (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
/s/ Steven H. Collis
Steven H. Collis
Chairman, President and Chief Executive Officer
November 22, 2022

Section 1350 Certification of Chief Financial Officer

In connection with the Annual Report of AmerisourceBergen Corporation (the "Company") on Form 10-K for the fiscal year ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, James F. Cleary, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
/s/ James F. Cleary
James F. Cleary
Executive Vice President and Chief Financial Officer
November 22, 2022

A signed original of this written statement required by Section 906 has been provided to AmerisourceBergen Corporation and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended.


 EX-101.SCH 9 abc-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOW link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Acquisition and Assets and Liabilities Held for Sale link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Variable Interest Entity link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Retirement and Other Benefit Plans link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Acquisition, Integration, and Restructuring Expenses link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Legal Matters and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Litigation Settlements link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Business Segment Information link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Acquisition and Assets and Liabilities Held for Sale (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Variable Interest Entity (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Acquisition, Integration, and Restructuring Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Business Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Summary of Significant Accounting Policies - Recently Adopted Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Summary of Significant Accounting Policies - Schedule of Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Summary of Significant Accounting Policies - Foreign Currency (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Summary of Significant Accounting Policies - Merchandise Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Summary of Significant Accounting Policies - Shipping and Handling Costs (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Acquisition and Assets and Liabilities Held for Sale - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Acquisition and Assets and Liabilities Held for Sale - Assets And Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Acquisition and Assets and Liabilities Held for Sale - Fair Value Of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Acquisition and Assets and Liabilities Held for Sale - Assets and Liabilities Held for Sale (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Variable Interest Entity - Schedule of Assets and Liabilities of Profarma (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Variable Interest Entity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Income Taxes - Domestic and Foreign Income From Continuing Operations Before Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Income Taxes - Income Tax Expense (Benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Income Taxes - Significant Components of Deferred Tax Liabilities (Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - Goodwill and Other Intangible Assets - Changes in Carrying Value of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - Goodwill and Other Intangible Assets - Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - Goodwill and Other Intangible Assets - Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - Debt - Debt Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 0000066 - Disclosure - Debt - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000067 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000068 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 0000069 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Diluted Weighted Average Shares Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 0000070 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 0000071 - Disclosure - Retirement and Other Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 0000072 - Disclosure - Share-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000073 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 0000074 - Disclosure - Share-Based Compensation - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 0000075 - Disclosure - Share-Based Compensation - Nonvested Options (Details) link:presentationLink link:calculationLink link:definitionLink 0000076 - Disclosure - Share-Based Compensation - Nonvested Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 0000077 - Disclosure - Share-Based Compensation - Nonvested Performance Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 0000078 - Disclosure - Leases - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 0000079 - Disclosure - Leases - Summary of Balance Sheet Information Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 0000080 - Disclosure - Leases - Other Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000081 - Disclosure - Leases - Future Minimum Rental Payments Under Noncancelable Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 0000081 - Disclosure - Leases - Future Minimum Rental Payments Under Noncancelable Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 0000082 - Disclosure - Acquisition, Integration, and Restructuring Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 0000083 - Disclosure - Legal Matters and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 0000084 - Disclosure - Litigation Settlements (Details) link:presentationLink link:calculationLink link:definitionLink 0000085 - Disclosure - Business Segment Information - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000086 - Disclosure - Business Segment Information - Segment Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 0000087 - Disclosure - Business Segment Information - Segment Operating Income (Details) link:presentationLink link:calculationLink link:definitionLink 0000088 - Disclosure - Business Segment Information - Reconciliation of Segment Operating Income to Income From Continuing Operations (Details) link:presentationLink link:calculationLink link:definitionLink 0000089 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 0000090 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 0000091 - Disclosure - SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 abc-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 abc-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 abc-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Business Acquisition [Axis] Business Acquisition [Axis] Other, net Other Comprehensive Income, Other, Net of Tax Foreign Current Foreign Tax Expense (Benefit) Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Number of pending claims Loss Contingency, Pending Claims, Number Related Party Transactions [Abstract] Related Party Transactions [Abstract] Provision for credit losses Accounts Receivable, Credit Loss Expense (Reversal) Deferred income taxes Deferred Income Tax Assets, Net Granted beginning in fiscal 2022 Granted In Fiscal 2022 [Member] Granted In Fiscal 2022 Deferred compensation liability Deferred Compensation Arrangement with Individual, Recorded Liability Other assets Disposal Group, Including Discontinued Operation, Other Assets, Current Deferred provision (benefit): Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Debt Instrument [Axis] Debt Instrument [Axis] Schedule of Other Intangible Assets - Indefinite-lived Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Property and equipment, at cost Property, Plant and Equipment, Gross Cash dividends on common stock Payments of Ordinary Dividends, Common Stock $500,000, 3.250% senior notes due 2025 Senior Notes Due 2025 [Member] Represents the 3.25% senior notes due March 1, 2025. Alternative minimum tax credit carryforwards Alternative Minimum Tax [Member] Represents information pertaining to alternative minimum tax. Financial Instrument [Domain] Financial Instruments [Domain] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Restrictions on Cash and Cash Equivalents [Table] Restrictions on Cash and Cash Equivalents [Table] Variable rate spread Debt Instrument, Basis Spread on Variable Rate Depreciation, including amounts charged to cost of goods sold Depreciation Acquisition, integration, and restructuring expenses Total Acquisition, integration, and restructuring expenses Business Combination, Acquisition, Integration, And Restructuring Expenses Business Combination, Acquisition, Integration, And Restructuring Expenses Exercised (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Interest rate Debt Instrument, Interest Rate, Stated Percentage Legal Matters and Contingencies Legal Matters and Contingencies [Text Block] Additional paid-in capital Additional Paid in Capital, Common Stock Equity issued (shares) Stock Issued During Period, Shares, Acquisitions Other, net Other Noncash Income (Expense) Employee contribution, first 3% of salary Employee Contribution First Three Percent Of Salary [Member] Represents the information pertaining to the employee contribution up to the first three percent of the salary. State and local Current State and Local Tax Expense (Benefit) Decreased other assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Assets Alliance Healthcare Egypt Walgreens Boots Alliance, Inc. Alliance Healthcare, Alliance Healthcare Egypt [Member] Walgreens Boots Alliance, Inc. Alliance Healthcare, Alliance Healthcare Egypt Cash and cash equivalents Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents Antidilutive securities excluded from computation of diluted earnings per share (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Share Repurchase Program [Domain] Share Repurchase Program [Domain] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Other, net Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Ownership [Axis] Ownership [Axis] Unrecognized tax benefits Additions of tax positions of the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Deferred income taxes Disposal Group, Including Discontinued Operation, Deferred Revenue, Current Schedule of Reconciliation Amount Of Unrecognized Tax Benefits, Excluding Interest and Penalties Summary of Income Tax Contingencies [Table Text Block] Related Party [Domain] Related Party [Domain] Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Forfeited (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Valuation Allowance by Deferred Tax Asset [Axis] Valuation Allowance by Deferred Tax Asset [Axis] Other Healthcare Solutions Other Healthcare Solutions [Member] Other Healthcare Solutions Entity Address, State or Province Entity Address, State or Province Settled Business Combination, Contingent Consideration, Payment Business Combination, Contingent Consideration, Payment Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Award Type [Axis] Award Type [Axis] Aggregate Intrinsic Value Aggregate Intrinsic Value No definition available Accrued expenses and other Operating Lease, Liability, Current SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Proceeds from sale of businesses Proceeds from Divestiture of Businesses PharMEDium Healthcare Holdings, Inc Pharmedium Healthcare Holdings Inc [Member] Represents information pertaining to PharMEDium Healthcare Holdings, Inc. May 2020 Share Repurchase Program May 2020 Share Repurchase Program [Member] May 2020 Share Repurchase Program [Member] Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Long-term debt Total, net of current portion Long-Term Debt, Excluding Current Maturities Total liabilities Liabilities Weighted-average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Purchase accounting adjustments Goodwill, Purchase Accounting Adjustments INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Current estimate recorded in accrued expenses and other Loss Contingency, Accrual, Current Current provision (benefit): Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Document Type Document Type Ownership percentage before equity offering Sale of Stock, Percentage of Ownership before Transaction Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Estimated useful lives Property, Plant and Equipment, Useful Life Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Employee severance Severance Costs Nonvested, beginning of period (usd per share) Nonvested, end of period (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Provision (benefit) for deferred income taxes Total deferred provision (benefit) Deferred tax benefit Deferred Income Tax Expense (Benefit) Property and equipment Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current Equity consideration Business Combination, Consideration Transferred, Equity Interests Issued and Issuable and Other Business Combination, Consideration Transferred, Equity Interests Issued and Issuable and Other Net assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net UK Her Majesty's Revenue and Customs (HMRC) [Member] Accounts payable Disposal Group, Including Discontinued Operation, Accounts Payable, Current Debt Disclosure [Abstract] Debt Disclosure [Abstract] Right of use assets Operating Lease, Right-of-Use Assets [Abstract] Operating Lease, Right-of-Use Assets [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Accrued expenses and other Accrued Liabilities, Current Less nonrecourse current portion Long-Term Debt, Current Maturities Fair Value Finite-Lived Intangible Assets Acquired NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities PharMEDium remediation costs Remediation Costs Remediation Costs Accounting Policies [Abstract] Accounting Policies [Abstract] Variable lease cost Variable Lease, Cost Gain on sale of businesses Gain (loss) on disposition of business Gain (Loss) on Disposition of Business Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other Prepaid Expense and Other Assets, Current Right to recover assets Contract with Customer, Asset, before Allowance for Credit Loss, Current Tax effect of foreign operations Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Customer [Axis] Customer [Axis] Schedule of Weighted Average Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Deferred compensation, annual benefit, percent of compensation, Benefit Restoration Plan Deferred Compensation Arrangement with Individual, Annual Distributions Represents the percentage of the annual amount of the participant's base salary and bonus incentive by which the compensation exceeds the annual compensation limit established by the provisions of the Internal Revenue Code. Settling States Loss Contingency, Claims Settled, Number Related Party Transaction [Line Items] Related Party Transaction [Line Items] Schedule of Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Weighted average period over which expected future compensation expense relating to restricted shares outstanding will be recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Schedule of Other Intangible Assets - Finite-lived Schedule of Finite-Lived Intangible Assets [Table Text Block] Purchase price in cash Cash Payments to Acquire Businesses, Gross Auditor Information [Abstract] Auditor Information Gross profit Gross Profit Entity Registrant Name Entity Registrant Name Shares repurchased, cash settled Treasury Stock, Value, Acquired, Cost Method, Settlements Treasury Stock, Value, Acquired, Cost Method, Settlements Subsequent Events Subsequent Events [Text Block] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Accrued litigation liability Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies PharMEDium shutdown costs Business Shutdown Costs Business Shutdown Costs Retirement and Other Benefit Plans Retirement Benefits [Text Block] Reduced tax rate for a period (in years) Reduced Tax Rate, Period Reduced Tax Rate, Period Net operating loss carryforwards, term (in years) Operating Loss Carryforwards, Term Term operating loss carryforwards. Leases [Abstract] Subsegments [Axis] Subsegments [Axis] Total stockholders' equity Balance, beginning of period Balance, end of period Cumulative adjustment to retained earnings Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Minimum Minimum [Member] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Four Ownership percentage after equity offering Sale of Stock, Percentage of Ownership after Transaction $500,000, 3.5% senior notes due 2021 Senior Notes Due 2021 [Member] Comprehensive loss (income) attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Foreign Deferred Foreign Income Tax Expense (Benefit) Derivative Financial Instruments Derivatives, Policy [Policy Text Block] Granted (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Borrowings under revolving and securitization credit facilities Proceeds from Lines of Credit Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Use of Estimates Use of Estimates, Policy [Policy Text Block] Acquisition and Assets and Liabilities Held for Sale Business Combination Disclosure [Text Block] Accounts payable Increase (Decrease) in Accounts Payable Schedule of Variable Interest Entities [Table] Schedule of Variable Interest Entities [Table] Concentration percentage Concentration Risk, Percentage Accrued expenses and other Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current Income Taxes Income Tax Disclosure [Text Block] Revenue from related party Revenue from Related Parties Gross Carrying Amount Intangible Assets, Gross (Excluding Goodwill) Long-term debt Disposal Group, Including Discontinued Operation, Long-term Debt, Current Disposal Group, Including Discontinued Operation, Long-term Debt, Current Basic (usd per share) Earnings Per Share, Basic Service period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Total fair values of restricted shares vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Effective Income Tax Rate Reconciliation [Table] Effective Income Tax Rate Reconciliation [Table] Effective Income Tax Rate Reconciliation [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Long-term accrued litigation liability Increase (Decrease) in Accrued Estimated Litigation Liability Increase (Decrease) in Accrued Estimated Litigation Liability Restrictions on Cash and Cash Equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Ownership [Domain] Ownership [Domain] Entity Interactive Data Current Entity Interactive Data Current Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Prepaid Expenses and Other Prepaid Expenses and Other Current Assets [Member] Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures: Increase (Decrease) in Operating Capital [Abstract] Money market accounts Money Market Funds [Member] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] Litigation Status [Domain] Litigation Status [Domain] Purchases of common stock Payments for Repurchase of Common Stock Scheduled future principal payments, thereafter Long-Term Debt, Maturity, after Year Five Income Taxes Income Tax, Policy [Policy Text Block] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Senior notes and other loan repayments Repayments of Other Long-Term Debt Goodwill reclassified to assets held for sale Goodwill, Transfers Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Increased in the deferred tax assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Assets Current assets: Assets, Current [Abstract] Lease liabilities Operating Lease, Liability [Abstract] Less: Future payments for leases that have not yet commenced Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Goodwill Disposal Group, Including Discontinued Operation, Goodwill, Current Retained earnings Retained Earnings (Accumulated Deficit) Profarma Distribuidora de Produtos Farmaceuticos S.A. Profarma Distribuidora de Produtos Farmaceuticos S.A. [Member] Profarma Distribuidora de Produtos Farmaceuticos S.A. Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Allowance for credit losses Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss Exercisable, end of period (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Related Party Transactions Related Party Transactions Disclosure [Text Block] Amortization of financing fees and accretion of original issue discounts Debt Related Commitment Fees and Debt Issuance Costs Shipping and Handling Costs Shipping and Handling Costs [Policy Text Block] Shipping and Handling Costs [Policy Text Block] Document Fiscal Year Focus Document Fiscal Year Focus OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Total proceeds Disposal Group, Including Discontinued Operation, Consideration Three Largest National Distributors Three Largest National Distributors [Member] Three Largest National Distributors Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] LESS: INCREASE IN CASH CLASSIFIED WITHIN ASSETS HELD FOR SALE Disposal Group, Including Discontinued Operation, Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Disposal Group, Including Discontinued Operation, Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Loss Contingencies [Table] Loss Contingencies [Table] Total current provision (benefit) Current Income Tax Expense (Benefit) Held for Sale Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Retail Business Retail Business [Member] Retail Business Legal settlement term (in years) Legal Settlement Payment Term Legal Settlement Payment Term Inventories Increase (Decrease) in Inventories Litigation Status [Axis] Litigation Status [Axis] Share-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Receivable from related party Accounts Receivable, Related Parties Common stock, outstanding (shares) Common Stock, Shares, Outstanding Goodwill Goodwill Beginning balance Ending balance Goodwill Defined Contribution Plan Tranches [Domain] Defined Contribution Plan Tranches [Domain] [Domain] for Defined Contribution Plan Tranches [Axis] Treasury stock (shares) Treasury Stock, Shares Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Acquisition of Alliance Healthcare (Note 2) Noncontrolling Interest, Increase from Subsidiary Equity Issuance Income tax expense (benefit) Provision (benefit) for income taxes Income Tax Expense (Benefit) Valuation allowance for deferred tax assets Deferred Tax Assets, Valuation Allowance Deferred income taxes Deferred Income Tax Liabilities, Net Entity Public Float Entity Public Float Balance Sheet Location [Domain] Balance Sheet Location [Domain] Alliance Healthcare debt Alliance Healthcare Debt [Member] Alliance Healthcare Debt Cost of goods sold Cost of Goods and Services Sold Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Loss Contingencies [Line Items] Loss Contingencies [Line Items] Accounts receivables Accounts Receivable [Member] Dividend increase percentage Dividend Increase Percentage Dividend increase percentage. Common stock, $0.01 par value — authorized, issued, and outstanding: 2022 — 600,000,000 shares, 292,700,490 shares and 206,203,817 shares; 2021 — 600,000,000 shares, 290,722,533 shares and 208,089,298 shares Common Stock, Value, Issued Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Held for sale Discontinued Operations, Held-for-sale [Member] Nonrecourse debt Non-recourse Debt [Member] Non-recourse Debt [Member] Contingencies Commitments and Contingencies, Policy [Policy Text Block] Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Express Scripts, Inc. Express Scripts, Inc. [Member] Express Scripts, Inc. Cash, cash equivalents, and restricted cash at beginning of year CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT END OF YEAR Cash, cash equivalents, and restricted cash Cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Current liabilities: Liabilities, Current [Abstract] Multidistrict Litigation and Other Related State Court Litigation Multidistrict Litigation and Other Related State Court Litigation [Member] Multidistrict Litigation and Other Related State Court Litigation Exercises of stock options Proceeds from Stock Options Exercised Expected to vest after end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Alternate base rate and Canadian prime rate Alternate Base Rate And Canadian Prime Rate Cdor Rate [Member] Alternate base rate and Canadian prime rate. Employer matching contribution, percent of salary Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Income Statement Location [Domain] Income Statement Location [Domain] Amendment Flag Amendment Flag Weighted Average Remaining Useful Life Finite-Lived Intangible Asset, Useful Life Operating lease cost Operating Lease, Cost SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] Total other comprehensive loss Other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax Swiss Swiss Federal Tax Administration (FTA) [Member] Goodwill recognized in connection with acquisition Goodwill, Acquired During Period Total liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Deferred income taxes Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Other assets Other long-term assets Other Assets, Noncurrent Goodwill and Other Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Exercisable, end of period (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Other Accumulated Other Adjustments Attributable to Parent [Member] Accumulated Other Adjustments Attributable to Parent [Member] Total depreciation and amortization Depreciation, Depletion and Amortization Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Counterparty Name [Axis] Counterparty Name [Axis] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Operating lease cash payments Operating Lease, Payments Repayments of debt Repayments of Long-Term Debt Employee options Share-Based Payment Arrangement, Option [Member] WBA Alliance Healthcare Walgreens Boots Alliance, Inc. Alliance Healthcare [Member] Walgreens Boots Alliance, Inc. Alliance Healthcare Treasury stock, at cost: 2022 — 86,496,673 shares; 2021 — 82,633,235 shares Treasury Stock, Value Volatility of common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Net gain Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Allowances for returns and credit losses Accounts Receivable, Allowance for Credit Loss, Current Exercises of stock options Stock Issued During Period, Value, Stock Options Exercised Common stock, authorized (shares) Common Stock, Shares Authorized Restricted cash acquired Restricted Cash Acquired from Acquisition Restricted Cash Acquired from Acquisition Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] $500,000, 2.800% senior notes due 2030 Senior Notes Due 2030 [Member] Senior Notes Due 2030 Maximum Maximum [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Intangible Assets Intangible Assets, Net (Excluding Goodwill) [Abstract] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Accrued expenses and other Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Expenses And Other Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Expenses And Other Business Acquisition [Line Items] Business Acquisition [Line Items] Investor Investor [Member] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Manufacturer Incentives Cost of Goods and Service [Policy Text Block] Investments Consolidation, Variable Interest Entity, Policy [Policy Text Block] Supplier Reserves Supplier Reserves Policy [Policy Text Block] Supplier Reserves Policy Short-term debt Amount outstanding Short-Term Debt Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Ownership percentage (more than) Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Class of Treasury Stock [Table] Class of Treasury Stock [Table] Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Subsequent Event [Line Items] Subsequent Event [Line Items] Repayments under revolving and securitization credit facilities Repayments of Lines of Credit Business Segment Information Segment Reporting Disclosure [Text Block] Inventories Deferred Tax Liabilities, Inventory Excess tax benefit from the exercise of stock options and lapses of restricted stock units Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount Net deferred tax liabilities Deferred Tax Liabilities, Net LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Fair value Estimate of Fair Value Measurement [Member] Weighted average common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Other liabilities Disposal Group, Including Discontinued Operation, Other Liabilities, Current Inventories Inventories Inventory, Net Accounts payable Accounts Payable, Current Income Tax Authority [Axis] Income Tax Authority [Axis] Profarma retail equity offering Proceeds from Issuance of Common Stock Basic (shares) Weighted average common shares outstanding - basic (shares) Weighted Average Number of Shares Outstanding, Basic Schedule of Assets and Liabilities of Profarma Schedule of Variable Interest Entities [Table Text Block] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Total liability accrual Loss Contingency Accrual Defined Contribution Plan Tranches [Axis] Defined Contribution Plan Tranches [Axis] Defined Contribution Plan Tranches [Axis] Minimum allowed employee contributions, percent of salary Defined Contribution Plan, Minimum Annual Contributions Per Employee, Percent Defined Contribution Plan, Minimum Annual Contributions Per Employee, Percent Stock option expense Stock or Unit Option Plan Expense Accounts receivables, net Accounts Receivable, after Allowance for Credit Loss Allowances for returns and doubtful accounts Allowance For Returns And Doubtful Accounts, Current [Member] Allowance For Returns And Doubtful Accounts, Current Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Employer matching contribution, percent of match Defined Contribution Plan, Employer Matching Contribution, Percent of Match Short-term debt Debt, Current Pending Litigation Pending Litigation [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Leases Lessee, Leases [Policy Text Block] Employee tax withholdings related to restricted share vesting Employee Tax Withholdings Related to Restricted Share Vesting Withholdings Related to Restricted Share Vesting Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Share-Based Compensation Share-Based Payment Arrangement [Text Block] Depreciation Depreciation, Nonproduction Non-controlling Interest Noncontrolling Interest [Member] Goodwill derecognized in connection with disposal Goodwill, Written off Related to Sale of Business Unit Award Date [Axis] Award Date [Axis] Legal accrual Recorded charge Loss Contingency Accrual, Provision Debt instrument, term Debt Instrument, Term Schedule of Significant Components Of Deferred Tax Liabilities (Assets) Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Related Party [Axis] Related Party [Axis] Goodwill [Roll Forward] Goodwill [Roll Forward] Land Land [Member] Effect of dilutive securities - stock options and restricted stock units (shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Disposal Group Name [Domain] Disposal Group Name [Domain] Cost of acquired companies, net of cash acquired Net cash paid Payments to Acquire Businesses, Net of Cash Acquired Level 2 Fair Value, Inputs, Level 2 [Member] Goodwill expected to be deductible Business Acquisition, Goodwill, Expected Tax Deductible Amount Current Fiscal Year End Date Current Fiscal Year End Date Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Other intangible assets Net Carrying Amount Intangible Assets, Net (Excluding Goodwill) Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term No definition available Gain on the sale of a facility Gain (Loss) on Disposition of Property Plant Equipment Share-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Customer Customer Concentration Risk [Member] Accrued income taxes Accrued Income Taxes, Noncurrent Accounts payable Accounts Payable Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Expiration period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period October 2018 Share Repurchase Program October 2018 Share Repurchase Program [Member] October 2018 Share Repurchase Program [Member] Accounts receivable, less allowance for credit losses Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Income Tax Authority [Domain] Income Tax Authority [Domain] Other, net Proceeds from (Payments for) Other Financing Activities Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] PharMEDium worthless stock deduction Effective Income Tax Rate Reconciliation, Deduction, Worthless Stock, Percent Effective Income Tax Rate Reconciliation, Deduction, Worthless Stock, Percent Valuation allowance - increase (decrease) Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Expected to vest after end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Equity [Abstract] Equity [Abstract] Subsequent Event [Table] Subsequent Event [Table] Vested (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract] Entity Tax Identification Number Entity Tax Identification Number Schedule of Nonvested Options Schedule of Nonvested Share Activity [Table Text Block] Consolidated Entities [Domain] Consolidated Entities [Domain] Discretionary contributions, vesting period (in years) Defined Contribution Plan, Employer Discretionary Contribution, Vesting Period Defined Contribution Plan, Employer Discretionary Contribution, Vesting Period Schedule of Reconciliation of Effective Income Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Litigation and opioid-related expenses Litigation Settlement, Expense INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Schedule of Employee Severance, Litigation, and Other Charges Restructuring and Related Costs [Table Text Block] Other intangible assets Other Intangible Assets, Net Entity Central Index Key Entity Central Index Key Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Fair value of total consideration Business Combination, Consideration Transferred Entity [Domain] Entity [Domain] City Area Code City Area Code ASSETS Assets [Abstract] Leases Commitments Disclosure [Text Block] Notes Payable to Banks Notes Payable to Banks [Member] Scheduled future principal payments, in fiscal 2022 Long-Term Debt, Maturity, Year One Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Deferred tax expense Deferred Tax Liabilities, Deferred Expense Cost of equity investments Payments to Acquire Equity Method Investments CARES Act Effective Income Tax Rate Reconciliation, CARES Act, Percent Effective Income Tax Rate Reconciliation, CARES Act, Percent Weighted average fair values of options granted (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Variable Rate [Axis] Variable Rate [Axis] Other liabilities Other long-term liabilities Other Liabilities, Noncurrent Capital expenditures Total capital expenditures Payments to Acquire Property, Plant, and Equipment Other intangible assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Oher Intangible Assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Oher Intangible Assets 2022 Finite-Lived Intangible Asset, Expected Amortization, Year One New operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Customer [Domain] Customer [Domain] Increase (decrease) in stockholders' equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Total future undiscounted lease payments Lessee, Operating Lease, Liability, to be Paid Net income (loss) Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Profarma Variable Interest Entity, Primary Beneficiary [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Scheduled future principal payments, in fiscal 2023 Long-Term Debt, Maturity, Year Two Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Business Combinations Business Combinations Policy [Policy Text Block] Effective Income Tax Rate Reconciliation [Line Items] Effective Income Tax Rate Reconciliation [Line Items] Effective Income Tax Rate Reconciliation [Line Items] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Prepaid expenses and other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Deductions SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Loss contingency, damages awarded, value Loss Contingency, Damages Awarded, Value Software development costs Software and Software Development Costs [Member] Unrecognized tax benefits, including interest and penalties, net of federal benefit Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued, Net of Federal Benefit Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued, Net of Federal Benefit Acquisition-related intangibles amortization Acquisition-related intangibles amortization Other Depreciation and Amortization Other, net Payments for (Proceeds from) Other Investing Activities Statistical Measurement [Domain] Statistical Measurement [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Senior notes and other loan borrowings Proceeds from Issuance of Debt Accrual for estimated customer sales returns Accrual for Estimated Customer Sales Returns No definition available. Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Expiration of statutes of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Short-term debt Disposal Group, Including Discontinued Operation, Short-term Debt, Current Disposal Group, Including Discontinued Operation, Short-term Debt, Current U.S. Federal Domestic Tax Authority [Member] EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Non-employee options Non Employee [Member] Represents information pertaining to compensation granted to Non-employee director. Purchases of common stock Repurchase of common stock Treasury Stock, Value, Acquired, Cost Method 2022 Omnibus 2022 Omnibus Incentive Plan [Member] 2022 Omnibus Incentive Plan Net income (loss) attributable to AmerisourceBergen Corporation Net Income (Loss) Attributable to Parent Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Axis] $1,000,000, 2.700% senior notes due 2031 Senior Notes Due 2031 [Member] Senior Notes Due 2031 Vesting percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage LIFO expense (credit) LIFO (expense) credit Inventory, LIFO Reserve, Period Charge Litigation settlements and accruals (see Note 13) Effective Income Tax Rate Reconciliation, Tax Settlement, Percent Finite-Lived Finite-Lived Intangible Assets, Net [Abstract] Term Loan Agreement October 2018 Term Loan Agreement October 2018 [Member] Term Loan Agreement October 2018 [Member] Goodwill and other intangible assets Deferred Tax Liabilities, Goodwill and Intangible Assets Goodwill [Line Items] Goodwill [Line Items] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Level 1 Fair Value, Inputs, Level 1 [Member] Schedule of Components of Diluted Weighted Average Shares Outstanding Schedule of Weighted Average Number of Shares [Table Text Block] Multi-currency revolving credit facility due 2027 Multi Currency Revolving Credit Facility [Member] Percentage of principal amount Debt Instrument, Issuance Price, Percentage Debt Instrument, Issuance Price, Percentage New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] NET CASH PROVIDED BY OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities Schedule of Nonvested Restricted Shares Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Worthless stock ordinary income tax deduction Effective Income Tax Rate Reconciliation, Disposition of Business, Amount 0.737% senior notes due 2023 Senior Notes Due 2023 [Member] Senior Notes Due 2023 Right-of-use assets obtained in exchange for lease liabilities Right-of-Use Asset Obtained in Exchange for Lease Liabilities [Abstract] Right-of-Use Asset Obtained in Exchange for Lease Liabilities [Abstract] Maximum allowed employee contributions, percent of salary Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Forfeited (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Document Annual Report Document Annual Report Legal Entity [Axis] Legal Entity [Axis] Ownership percentage Business Acquisition, Percentage of Voting Interests Acquired Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Profarma retail equity offering Stock Issued During Period, Value, New Issues Number of votes per share Common Stock, Voting Rights, Vote Per Share Common Stock, Voting Rights, Vote Per Share Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Restricted Stock Units Performance Stock Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Revolving credit note Revolving Credit Note [Member] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Segments [Axis] Segments [Axis] Debt Debt Disclosure [Text Block] Entity Shell Company Entity Shell Company Accrued expenses Increase (Decrease) in Accrued Liabilities Reductions of tax positions of the prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Other restructuring initiatives Other Restructuring Costs Inventories Disposal Group, Including Discontinued Operation, Inventory, Current Concentration Risk [Table] Concentration Risk [Table] 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Financial Instrument [Axis] Financial Instrument [Axis] Scheduled future principal payments, in fiscal 2024 Long-Term Debt, Maturity, Year Three Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Consolidation Items [Domain] Consolidation Items [Domain] Subsequent Event Subsequent Event [Member] Revenue Revenue Benchmark [Member] Document Period End Date Document Period End Date Swiss federal tax reforms Swiss Tax Reform [Member] Swiss Tax Reform Expected to vest after end of period (usd per share) Options Expected to Vest Weighted Average Exercise Price No definition available. Schedule of Components of Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] TOTAL ASSETS Assets Schedule of Summarized Balance Sheet Information Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee Earnings per share: Earnings Per Share [Abstract] Performance stock units Performance Shares [Member] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Five Exercised (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Long-term debt Long-Term Debt, Fair Value Authorized amount under share repurchase program Stock Repurchase Program, Authorized Amount Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Segments [Domain] Segments [Domain] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Other Deferred Tax Liabilities, Other INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, INCLUDING CASH CLASSIFIED WITHIN ASSETS HELD FOR SALE Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect And Disposal Group, Including Discontinue Operation Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect And Disposal Group, Including Discontinue Operation Total comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Total fair values of options vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Award Type [Domain] Award Type [Domain] Loss on early retirement of debt Loss on early retirement of debt Gain (Loss) on Extinguishment of Debt Concentrations of Credit Risk and Allowance for Credit Losses Receivable [Policy Text Block] Income tax receivable Net current income tax receivable Income Taxes Receivable, Current Lease liabilities Deferred Tax Assets, Lease Liabilities Deferred Tax Assets, Lease Liabilities Term loan due June 2023 Term Loan Due June 2023 [Member] Term Loan Due June 2023 Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Accrued litigation liability Estimated Litigation Liability, Noncurrent WBA Walgreens Boots Alliance Inc. [Member] Walgreens Boots Alliance Inc. Business transformation efforts Business Transformation Efforts Business Transformation Efforts Foreign currency translation Goodwill, Foreign Currency Translation Gain (Loss) Foreign currency translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Customer relationships Customer Relationships [Member] Entity Address, City or Town Entity Address, City or Town Sale of business Noncontrolling Interest, Decrease from Deconsolidation Operating expenses: Operating Expenses [Abstract] Excess cost of inventories over LIFO, if used FIFO Excess of Replacement or Current Costs over Stated LIFO Value Intersegment eliminations Intersegment Eliminations [Member] Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Auditor Name Auditor Name Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Turkey highly inflationary impact Financing Receivable, Impairment Charges Financing Receivable, Impairment Charges Share price (in usd per share) Share Price International Healthcare Solutions International Healthcare Solutions [Member] International Healthcare Solutions Potential tax benefits from net operating loss carryforwards Operating Loss Carryforwards Other (Income) Loss, Net Other (Income) Loss, Net [Member] Other (Income) Loss, Net Number Of Subsidiaries Number Of Subsidiaries Number Of Subsidiaries Additions to tax positions of the prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Disposal Group Classification [Axis] Disposal Group Classification [Axis] Variable Interest Entity Variable Interest Entity Disclosure [Text Block] Restricted stock units Restricted Stock Units (RSUs) [Member] Other intangible assets Disposal Group, Including Discontinued Operation, Intangible Assets, Current Shipping and Handling [Table] Shipping and Handling [Table] Shipping and Handling [Table] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Parent Company Parent Company [Member] Subsequent Events [Abstract] Subsequent Events [Abstract] Revenue Revenues Animal Health Animal Health [Member] MWI Animal Health [Member] Opioid Lawsuits and Investigations Opioid Lawsuits and Investigations [Member] Opioid Lawsuits and Investigations [Member] Payment of premium on early retirement of debt Payment of premium on early retirement of debt Payment for Debt Extinguishment or Debt Prepayment Cost State and local Deferred State and Local Income Tax Expense (Benefit) Percentage of inventories, cost determined using LIFO Percentage of LIFO Inventory Amortization Amortization expense Amortization of Intangible Assets Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Schedule of Changes in the Carrying Value of Goodwill Schedule of Goodwill [Table Text Block] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Pension and postretirement adjustments Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Inventories Inventory, Policy [Policy Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Treasury Stock Treasury Stock [Member] Total AmerisourceBergen Corporation stockholders' (deficit) equity Total accumulated other comprehensive loss Stockholders' Equity Attributable to Parent Tax credit carryforwards Tax Credit Carryforward, Amount Forfeited (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Alliance Healthcare Alliance Healthcare [Member] Alliance Healthcare Other Deferred Tax Assets, Other Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Deferred Tax Asset [Domain] Deferred Tax Asset [Domain] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Three Award Date [Domain] Award Date [Domain] Scheduled future principal payments, in fiscal 2026 Long-Term Debt, Maturity, Year Five Retained Earnings Retained Earnings [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Expected future compensation expense relating to nonvested options outstanding Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Cash dividends Dividends, Common Stock, Cash Gains from antitrust litigation settlements Gain (Loss) Related to Litigation Settlement Cares act, tax benefit Income Tax Expense (Benefit), CARES Act Income Tax Expense (Benefit), CARES Act Total lease cost Lease, Cost Common Stock Common Stock [Member] Reportable segments Number of Reportable Segments Schedule of Lease Cost Lease, Cost [Table Text Block] Shares available for grant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Accrued consideration Business Combination, Contingent Consideration, Liability Revenue Recognition Revenue [Policy Text Block] Statement [Table] Statement [Table] Schedule of Assets and Liabilities Held for Sale Disposal Groups, Including Discontinued Operations [Table Text Block] Vested (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Effective yield percentage Debt Instrument, Interest Rate, Effective Percentage Equity consideration issued for acquisition of Alliance Healthcare (Note 2) Stock Issued During Period, Value, Acquisitions Loss on write-down Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down Schedule of Nonvested Performance Stock Units Schedule of Nonvested Performance-Based Units Activity [Table Text Block] Overdraft facility due 2024 (£10,000) Overdraft Facility [Member] Refers to overdraft facility. Other long-term liabilities Operating Lease, Liability, Noncurrent Defined contribution plans expense Defined Contribution Plan, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Repurchase of common stock (shares) Treasury Stock, Shares, Acquired Indefinite-lived intangibles Indefinite-Lived Intangible Assets (Excluding Goodwill) Disposal Group Name [Axis] Disposal Group Name [Axis] Accounts receivable, less allowances for returns and credit losses: 2022 — $1,626,729; 2021 — $1,356,684 Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Other equity consideration Business Combination, Consideration Transferred, Other Litigation Case [Domain] Litigation Case [Domain] Interest expense, net Interest Income (Expense), Nonoperating, Net Schedule of Fair Value of the Intangible Assets Acquired Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Shipping and Handling [Line Items] Shipping and Handling [Line Items] [Line Items] for Shipping and Handling [Table] Statement [Line Items] Statement [Line Items] Litigation Settlement [Abstract] Litigation Settlement [Abstract] Nonvested shares outstanding (shares) Nonvested, beginning of period (shares) Nonvested, end of period (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Restricted Cash and Cash Equivalents Items [Line Items] Restricted Cash and Cash Equivalents Items [Line Items] Other income, net Other income Nonoperating Income (Expense) Variable Rate [Domain] Variable Rate [Domain] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Distribution, selling, and administrative Selling, General and Administrative Expense Contingent consideration adjustment Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Other assets Operating Lease, Right-of-Use Asset Accumulated Other Comprehensive Loss Total accumulated other comprehensive loss AOCI Attributable to Parent [Member] Auditor Firm ID Auditor Firm ID Income taxes payable and other liabilities Increase (Decrease) in Income Taxes Payable And Other Liabilities Increase (Decrease) in Income Taxes Payable And Other Liabilities Document Transition Report Document Transition Report Foreign Foreign Tax Authority [Member] Local Phone Number Local Phone Number Schedule of Stock Options Share-Based Payment Arrangement, Option, Activity [Table Text Block] Operating income (loss) Operating income Total segment operating income Operating Income (Loss) Shipping and Handling Shipping and Handling [Member] Gain on remeasurement of equity investment Gain on revaluation of equity investment Equity Investment, Remeasurement Gain (Loss) Equity Investment, Remeasurement Gain (Loss) Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accrued expenses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities State State and Local Jurisdiction [Member] Accrued expenses and other Accrued Liabilities and Other Liabilities Interim Period, Costs Not Allocable [Domain] Interim Period, Costs Not Allocable [Domain] Tax benefit Discontinued Operation, Tax Effect of Discontinued Operation Settlement percent of population Loss Contingency, Claims Settled, Percent Loss Contingency, Claims Settled, Percent Granted prior to fiscal 2021 Granted Prior to Fiscal 2021 [Member] Granted Prior to Fiscal 2021 Adjustments to reconcile net income (loss) to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Goodwill and Other Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Preferred stock, par value (usd per share) Preferred Stock, Par or Stated Value Per Share 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) Additional Paid-in Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Stockholders' Equity and Weighted Average Common Shares Outstanding Stockholders' Equity and Weighted Average Common Shares Outstanding [Text Block] Stockholders' Equity and Weighted Average Common Shares Outstanding Intrinsic value of stock option exercises Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Diluted (shares) Weighted average common shares outstanding - diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Accumulated loss on the remeasurement Disposal Group, Not Discontinued Operation, Accumulated Loss (Gain) on Write-down Disposal Group, Not Discontinued Operation, Accumulated Loss (Gain) on Write-down Expected life of the options Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Buildings and improvements Building and Building Improvements [Member] Cash dividends (usd per share) Common Stock, Dividends, Per Share, Cash Paid ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag $500,000, 4.250% senior notes due 2045 Senior Notes Due2045 [Member] Represents the 4.25% senior notes due March 1, 2045. Carrying amount Reported Value Measurement [Member] Granted (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Operating segments Operating Segments [Member] Deferred income taxes Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Short-term lease cost Short-Term Lease, Cost Preferred stock, authorized (shares) Preferred Stock, Shares Authorized Net loss (income) attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Litigation Settlements Commitments and Contingencies Disclosure [Text Block] Common stock, issued (shares) Common Stock, Shares, Issued Liabilities held for sale Total liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities, Current Concentration Risk [Line Items] Concentration Risk [Line Items] Foreign currency loss Foreign Currency Transaction Gain (Loss), before Tax Acquisition related costs Acquisition-related deal and integration Business Combination, Acquisition Related Costs NET CASH USED IN INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities Principal amount Debt Instrument, Face Amount Employee and retiree benefits Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits Cash acquired, including restricted cash of $143,308 included in Prepaid Expenses and Other Cash And Restricted Cash Acquired From Acquisition Cash And Restricted Cash Acquired From Acquisition Comprehensive income (loss) income attributable to AmerisourceBergen Corporation Comprehensive Income (Loss), Net of Tax, Attributable to Parent New York State Opioid Stewardship Act New York State Opioid Stewardship Act Expense New York State Opioid Stewardship Act Expense Litigation Case [Axis] Litigation Case [Axis] Schedule of Assets [Table] Schedule of Impaired Long-Lived Assets Held and Used [Table] Impairment of assets, including goodwill Impairment of Long-Lived Assets to be Disposed of Entity Current Reporting Status Entity Current Reporting Status Net operating loss and tax credit carryforwards Deferred Tax Assets, Net Operating Loss and Tax Credit Carryforwards Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards and net operating loss. Impairment of assets Tangible Asset Impairment Charges Prepaid expenses and other Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current Statutory U.S. federal income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Treasury stock reissued Stock Issued During Period, Value, Treasury Stock Reissued Charged to costs and expenses SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Schedule of Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Potential increase in receivables securitization facility Line of Credit Facility, Accordion Feature, Increase Limit Line of Credit Facility, Accordion Feature, Increase Limit Outstanding, beginning of period (shares) Outstanding, end of period (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number State and local income tax rate, net of federal tax benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Other, net Stockholders' Equity, Other Cash paid for amounts included in the measurement of lease liabilities Lease Cash Flow [Abstract] Lease Cash Flow [Abstract] Components of Deferred Tax Assets and Liabilities [Abstract] Components of Deferred Tax Assets and Liabilities [Abstract] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Property and equipment, net Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Forfeited (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Long-term debt Total debt Long-Term Debt Balance Sheet Location [Axis] Balance Sheet Location [Axis] Acquisition, Integration, and Restructuring Expenses Restructuring and Related Activities Disclosure [Text Block] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Unrecognized tax benefits, including interest and penalties Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Turkey highly inflationary impact Inflationary Accounting Impact Inflationary Accounting Impact Cash, Cash Equivalents, and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Stock purchased with the participant's compensation allocated to stock credits (in shares) Deferred Compensation Arrangement with Individual, Discretionary Shares Per Each Full Share Deferred Compensation Arrangement with Individual, Discretionary Shares Per Each Full Share Total current assets Assets, Current Income tax payments, net of refunds Income Taxes Paid, Net Settled Litigation Settled Litigation [Member] Entity Small Business Entity Small Business Measurement Basis [Axis] Measurement Basis [Axis] Quarterly cash dividend declared (usd per share) Common Stock, Dividends, Per Share, Declared Net Carrying Amount Finite-Lived Intangible Assets, Net Restricted cash Restricted Cash Income tax receivable Increase (Decrease) in Income Taxes Receivable Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Expected future compensation expense relating to restricted shares outstanding Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] $500,000, 3.400% senior notes due 2024 Senior Notes Due 2024 [Member] Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Consolidated Entities [Axis] Consolidated Entities [Axis] Debt Instrument [Line Items] Debt Instrument [Line Items] Business Combination and Asset Acquisition [Abstract] Total lease liabilities Operating Lease, Liability Balance at beginning of period Balance at end of period Allowance for doubtful accounts for long-term accounts receivable SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] $500,000, 4.300% senior notes due 2047 Senior Notes Due2047 [Member] Senior Notes Due2047 [Member] 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Two Subsegments [Domain] Subsegments [Domain] Schedule of Operating Income Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block] May 2022 Share Repurchase Program May 2022 Share Repurchase Program [Member] May 2022 Share Repurchase Program Litigation and opioid-related expenses Restructuring Charges Scheduled future principal payments, in fiscal 2025 Long-Term Debt, Maturity, Year Four Auditor Location Auditor Location Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] AmerisourceBergen AmerisourceBergen [Member] AmerisourceBergen [Member] Entity Filer Category Entity Filer Category Federal Current Federal Tax Expense (Benefit) Turkey highly inflationary impact Amount Recognized in Income Due to Inflationary Accounting Assets Held and Used [Line Items] Impaired Long-Lived Assets Held and Used [Line Items] Stock expense Share-Based Payment Arrangement, Expense Commitments and contingencies (Note 13) Commitments and Contingencies Security Exchange Name Security Exchange Name Outstanding, beginning of period (usd per share) Outstanding, end of period (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted-Average Useful Life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Schedule of Segments Revenue Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Assets held for sale Total assets held for sale Disposal Group, Including Discontinued Operation, Assets, Current Segment reconciling items Segment Reconciling Items [Member] Other liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Receivables securitization facility due 2025 Receivables Securitization Facility [Member] Equity issued Equity (2 million shares of AmerisourceBergen Corporation common stock) Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Prepaid expenses and other Prepaid Expense and Other Assets Cover [Abstract] Cover [Abstract] Entity Voluntary Filers Entity Voluntary Filers Goodwill impairment Goodwill impairment Goodwill impairment Goodwill, Impairment Loss Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Undistributed earnings of international subsidiaries Undistributed Earnings of Foreign Subsidiaries Acquired cash and cash equivalents Cash Acquired from Acquisition Segment Reporting [Abstract] Segment Reporting [Abstract] Nonvested, beginning of period (usd per share) Nonvested, end of period (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Working capital adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Working Capital Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Working Capital Tax withholdings related to restricted share vesting Payment, Tax Withholding, Share-Based Payment Arrangement TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Availability remaining under program Stock Repurchase Program, Remaining Authorized Repurchase Amount Deferred tax asset Goodwill and other intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Gross deferred tax assets Deferred Tax Assets, Gross U.S. Healthcare Solutions U.S. Healthcare Solutions [Member] U.S. Healthcare Solutions Schedule of Domestic and Foreign Income from Continuing Operations before Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Noncontrolling interest Noncontrolling interest Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Schedule of Reconciliation of Total Segment Operating Income to Income from Continuing Operations before Income Taxes Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Unrecognized tax benefits, interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Diluted (usd per share) Earnings Per Share, Diluted Proceeds from sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Ownership percentage Noncontrolling Interest, Ownership Percentage by Parent ASU 2016-13 Accounting Standards Update 2016-13 [Member] Consolidation Items [Axis] Consolidation Items [Axis] Vested (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Term Loan Due February 2021 Term Loan Due February 2021 [Member] Term Loan Due February 2021 Unrecognized tax benefits at beginning of period Unrecognized tax benefits at end of period Unrecognized Tax Benefits Deferred tax assets, net of valuation allowance Deferred Tax Assets, Net of Valuation Allowance $750,000, 3.450% senior notes due 2027 Senior Notes Due 2027 [Member] Senior Notes Due2027 [Member] Money market facility Money Market Facility [Member] Money Market Facility Share Repurchase Program [Axis] Share Repurchase Program [Axis] Employee contribution, additional 2% of salary Employee Contribution Additional Two Percent Of Salary [Member] Represents the information pertaining to the employee contribution by additional two percentage of the salary. Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Facility fee Line of Credit Facility, Commitment Fee Percentage Adoption ASC Cumulative Effect, Period of Adoption, Adjustment [Member] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Amortization, including amounts charged to interest expense Amortization Schedule of Future Minimum Renal Payments, Operating Leases Lessee, Operating Lease, Liability, Maturity [Table Text Block] Reduction of unrecognized tax benefits reasonably possible Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Entity Address, Address Line One Entity Address, Address Line One Cumulative adjustment to retained earnings, tax Income Tax Effects Allocated Directly to Equity, Cumulative Effect of Change in Accounting Principle Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Tax law changes Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Trade names Trade name Trade Names [Member] Equity Securities Equity Method Investments [Policy Text Block] Vested (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Schedule of Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Machinery, equipment, and other Machinery and Equipment [Member] Right-of-use assets Deferred Tax Liabilities, Leasing Arrangements Other Assets Other Noncurrent Assets [Member] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Gross deferred tax liabilities Deferred Tax Liabilities, Gross Nature of Expense [Axis] Nature of Expense [Axis] SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Commercial paper Commercial Paper [Member] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Five Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Expected to vest after end of period (shares) Options Expected to Vest No definition available. Accounting Standards Update [Domain] Accounting Standards Update [Domain] Trade names and other Trade Names And Other [Member] Represents trade names and other. Impairment loss Impairment of Intangible Assets (Excluding Goodwill) Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Retirement Benefits [Abstract] Retirement Benefits [Abstract] SOFR / EURIBOR / CDOR / RFR SOFR/EURIBOR/CDOR/RFR [Member] SOFR/EURIBOR/CDOR/RFR Nonvested options outstanding (shares) Nonvested, beginning of period (shares) Nonvested, end of period (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Short-term debt Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Short Term Debt Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Short Term Debt FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Human Health Human Health [Member] Human Health Permanently reinvested cumulative undistributed earnings Undistributed Earnings of Foreign Subsidiaries Permanently Reinvested Undistributed Earnings of Foreign Subsidiaries Permanently Reinvested Disposal Group Classification [Domain] Disposal Group Classification [Domain] Impairment of assets, including goodwill Impairment of assets Asset Impairment Charges Forfeited (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value Cost of Sales Cost of Sales [Member] Accounting Standards Update [Extensible List] Accounting Standards Update [Extensible Enumeration] Accounting Standards Update 2016-02 [Member] EX-101.PRE 13 abc-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 abc-20220930_g1.gif begin 644 abc-20220930_g1.gif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end XML 15 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover - USD ($)
 12 Months Ended
Sep. 30, 2022
Oct. 31, 2022
Mar. 31, 2022
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Sep. 30, 2022    
Current Fiscal Year End Date --09-30    
Document Transition Report false    
Entity File Number 1-16671    
Entity Registrant Name AMERISOURCEBERGEN CORP    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 23-3079390    
Entity Address, Address Line One 1 West First Avenue    
Entity Address, City or Town Conshohocken,    
Entity Address, State or Province PA    
Entity Address, Postal Zip Code 19428-1800    
City Area Code 610    
Local Phone Number 727-7000    
Title of 12(b) Security Common stock    
Trading Symbol ABC    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 18,539,939,166
Entity Common Stock, Shares Outstanding   205,668,628  
Documents Incorporated by Reference Portions of the following document are incorporated by reference in the Part of this report indicated below:    Part III — Registrant's Proxy Statement for the 2023 Annual Meeting of Stockholders.    
Entity Central Index Key 0001140859    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Amendment Flag false    

XML 16 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Audit Information
 12 Months Ended
Sep. 30, 2022
Auditor Information [Abstract]  
Auditor Name Ernst & Young LLP
Auditor Location Philadelphia, Pennsylvania
Auditor Firm ID 42
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Sep. 30, 2021
Current assets:    
Cash and cash equivalents $ 3,388,189 $ 2,547,142
Accounts receivable, less allowances for returns and credit losses: 2022 — $1,626,729; 2021 — $1,356,684 18,452,675 18,167,175
Inventories 15,556,394 15,368,352
Right to recover assets 1,532,061 1,271,557
Income tax receivable 172,568 221,875
Prepaid expenses and other 487,871 853,600
Assets held for sale 0 372,908
Total current assets 39,589,758 38,802,609
Property and equipment, net 2,135,003 2,162,961
Goodwill 8,503,886 9,030,531
Other intangible assets 4,332,737 5,256,927
Deferred income taxes 237,571 290,791
Other assets 1,761,661 1,793,986
TOTAL ASSETS 56,560,616 57,337,805
Current liabilities:    
Accounts payable 40,192,890 38,009,954
Accrued expenses and other 2,214,592 2,856,405
Short-term debt 1,070,473 300,213
Liabilities held for sale 0 192,069
Total current liabilities 43,477,955 41,358,641
Long-term debt 4,632,360 6,383,711
Accrued income taxes 320,274 281,070
Deferred income taxes 1,620,413 1,685,296
Other liabilities 976,583 1,082,723
Accrued litigation liability 5,461,758 5,961,953
Commitments and contingencies (Note 13)
Stockholders' equity:    
Common stock, $0.01 par value — authorized, issued, and outstanding: 2022 — 600,000,000 shares, 292,700,490 shares and 206,203,817 shares; 2021 — 600,000,000 shares, 290,722,533 shares and 208,089,298 shares 2,927 2,907
Additional paid-in capital 5,658,733 5,465,104
Retained earnings 2,977,646 1,670,513
Accumulated other comprehensive loss (1,830,970) (445,442)
Treasury stock, at cost: 2022 — 86,496,673 shares; 2021 — 82,633,235 shares (7,019,895) (6,469,728)
Total AmerisourceBergen Corporation stockholders' (deficit) equity (211,559) 223,354
Noncontrolling interests 282,832 361,057
Total stockholders' equity 71,273 584,411
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 56,560,616 $ 57,337,805
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2022
Sep. 30, 2021
Statement of Financial Position [Abstract]    
Allowances for returns and credit losses $ 1,626,729 $ 1,356,684
Common stock, par value (usd per share) $ 0.01 $ 0.01
Common stock, authorized (shares) 600,000,000 600,000,000
Common stock, issued (shares) 292,700,490 290,722,533
Common stock, outstanding (shares) 206,203,817 208,089,298
Treasury stock (shares) 86,496,673 82,633,235
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]      
Revenue $ 238,587,006,000 $ 213,988,843,000 $ 189,893,926,000
Cost of goods sold 230,290,639,000 207,045,615,000 184,702,042,000
Gross profit 8,296,367,000 6,943,228,000 5,191,884,000
Operating expenses:      
Distribution, selling, and administrative 4,848,962,000 3,594,251,000 2,767,217,000
Depreciation 386,595,000 326,824,000 280,187,000
Amortization 307,300,000 178,348,000 110,875,000
Litigation and opioid-related expenses 123,191,000 272,623,000 6,722,346,000
Acquisition, integration, and restructuring expenses 183,059,000 199,288,000 84,961,000
Goodwill impairment 75,936,000 6,373,000 0
Impairment of assets 4,946,000 11,324,000 361,652,000
Operating income (loss) 2,366,378,000 2,354,197,000 (5,135,354,000)
Other income, net (27,352,000) (41,736,000) (1,581,000)
Interest expense, net 210,673,000 174,074,000 137,883,000
Loss on early retirement of debt 0 0 22,175,000
Income (loss) before income taxes 2,183,057,000 2,221,859,000 (5,293,831,000)
Income tax expense (benefit) 516,517,000 677,251,000 (1,894,273,000)
Net income (loss) 1,666,540,000 1,544,608,000 (3,399,558,000)
Net loss (income) attributable to noncontrolling interests 32,280,000 (4,676,000) (9,158,000)
Net income (loss) attributable to AmerisourceBergen Corporation $ 1,698,820,000 $ 1,539,932,000 $ (3,408,716,000)
Earnings per share:      
Basic (usd per share) $ 8.15 $ 7.48 $ (16.65)
Diluted (usd per share) $ 8.04 $ 7.39 $ (16.65)
Weighted average common shares outstanding:      
Basic (shares) 208,472 205,919 204,783
Diluted (shares) 211,210 208,465 204,783
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Statement of Comprehensive Income [Abstract]      
Net income (loss) $ 1,666,540 $ 1,544,608 $ (3,399,558)
Other comprehensive loss:      
Foreign currency translation adjustments (1,426,741) (334,522) (7,872)
Other, net 4,910 10 (1,074)
Total other comprehensive loss (1,421,831) (334,512) (8,946)
Total comprehensive income (loss) 244,709 1,210,096 (3,408,504)
Comprehensive loss (income) attributable to noncontrolling interests 68,583 (6,776) 2,923
Comprehensive income (loss) income attributable to AmerisourceBergen Corporation $ 313,292 $ 1,203,320 $ (3,405,581)
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Adoption ASC
Common Stock
Additional Paid-in Capital
Retained Earnings
Retained Earnings
Adoption ASC
Accumulated Other Comprehensive Loss
Treasury Stock
Non-controlling Interest
Non-controlling Interest
Adoption ASC
Balance, beginning of period at Sep. 30, 2019 $ 2,993,206 $ 35,138 $ 2,853 $ 4,850,142 $ 4,235,491 $ 35,138 $ (111,965) $ (6,097,604) $ 114,289 $ 0
Increase (decrease) in stockholders' equity                    
Net income (loss) (3,399,558)       (3,408,716)       9,158  
Other comprehensive (loss) income (8,946)           3,135   (12,081)  
Cash dividends (343,578)       (343,578)          
Exercises of stock options 159,533   21 159,512            
Share-based compensation expense 74,411     74,411            
Purchases of common stock (405,692)             (405,692)    
Profarma retail equity offering 66,355     (1,567)         67,922  
Employee tax withholdings related to restricted share vesting (9,787)             (9,787)    
Other, net (718)   4 (722)            
Balance, end of period at Sep. 30, 2020 $ (839,636) $ (24,094) 2,878 5,081,776 518,335 $ (21,106) (108,830) (6,513,083) 179,288 $ (2,988)
Increase (decrease) in stockholders' equity                    
Accounting Standards Update [Extensible List] ASU 2016-13                  
Net income (loss) $ 1,544,608       1,539,932       4,676  
Other comprehensive (loss) income (334,512)           (336,612)   2,100  
Cash dividends (366,648)       (366,648)          
Exercises of stock options 198,750   23 198,727            
Share-based compensation expense 99,594     99,594            
Purchases of common stock (82,150)             (82,150)    
Employee tax withholdings related to restricted share vesting (23,547)             (23,547)    
Equity consideration issued for acquisition of Alliance Healthcare (Note 2) 235,141     86,089       149,052    
Acquisition of Alliance Healthcare (Note 2) 178,264               178,264  
Other, net (1,359)   6 (1,082)         (283)  
Balance, end of period at Sep. 30, 2021 584,411   2,907 5,465,104 1,670,513   (445,442) (6,469,728) 361,057  
Increase (decrease) in stockholders' equity                    
Net income (loss) 1,666,540       1,698,820       (32,280)  
Other comprehensive (loss) income (1,421,831)           (1,385,528)   (36,303)  
Cash dividends (391,687)       (391,687)          
Exercises of stock options 93,912   10 93,902            
Share-based compensation expense 93,400     93,400            
Purchases of common stock (512,091)             (512,091)    
Employee tax withholdings related to restricted share vesting (38,076)             (38,076)    
Sale of business (3,544)               (3,544)  
Other, net 239   10 6,327         (6,098)  
Balance, end of period at Sep. 30, 2022 $ 71,273   $ 2,927 $ 5,658,733 $ 2,977,646   $ (1,830,970) $ (7,019,895) $ 282,832  
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Statement of Stockholders' Equity [Abstract]      
Accounting Standards Update [Extensible List]     ASU 2016-13
Cash dividends (usd per share) $ 1.84 $ 1.76 $ 1.66
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF CASH FLOW - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
OPERATING ACTIVITIES      
Net income (loss) $ 1,666,540 $ 1,544,608 $ (3,399,558)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:      
Depreciation, including amounts charged to cost of goods sold 390,643 326,713 290,744
Amortization, including amounts charged to interest expense 319,192 188,073 117,269
Provision for credit losses 26,053 12,101 11,912
Provision (benefit) for deferred income taxes 196,184 334,866 (1,544,971)
Share-based compensation expense 93,400 99,594 74,411
LIFO expense (credit) 67,171 (203,028) 7,422
Impairment of assets, including goodwill 80,882 31,697 361,652
Gain on sale of businesses (56,228) 0 0
Turkey highly inflationary impact 51,966 0 0
Gain on remeasurement of equity investment (4,834) (64,721) 0
Loss on early retirement of debt 0 0 22,175
Other, net 11,781 29,361 (3,044)
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures:      
Accounts receivable (1,659,525) (930,078) (1,628,991)
Inventories (665,370) (1,116,344) (1,621,143)
Income tax receivable 49,307 266,552 (482,569)
Prepaid expenses and other assets 102,708 141,057 28,050
Accounts payable 3,320,725 2,049,167 3,300,832
Accrued expenses (457,233) 372,078 524,021
Income taxes payable and other liabilities (330,079) (178,120) (50,115)
Long-term accrued litigation liability (500,195) (236,990) 6,198,943
NET CASH PROVIDED BY OPERATING ACTIVITIES 2,703,088 2,666,586 2,207,040
INVESTING ACTIVITIES      
Capital expenditures (496,318) (438,217) (369,677)
Cost of acquired companies, net of cash acquired (133,814) (5,563,040) 0
Cost of equity investments (18,491) (162,620) (56,080)
Proceeds from sale of property and equipment 6,302 14,439 36,364
Proceeds from sale of businesses 272,586 0 0
Other, net 1,298 7,861 9,522
NET CASH USED IN INVESTING ACTIVITIES (368,437) (6,141,577) (379,871)
FINANCING ACTIVITIES      
Senior notes and other loan borrowings 155,189 3,166,980 599,480
Senior notes and other loan repayments (1,238,954) (835,313) (598,452)
Borrowings under revolving and securitization credit facilities 4,832,605 4,968,815 116,946
Repayments under revolving and securitization credit facilities (4,671,943) (5,083,930) (149,980)
Payment of premium on early retirement of debt 0 0 (21,448)
Purchases of common stock (483,704) (82,150) (420,449)
Exercises of stock options 93,912 198,750 159,533
Cash dividends on common stock (391,687) (366,648) (343,578)
Profarma retail equity offering 0 0 66,355
Tax withholdings related to restricted share vesting (38,076) (23,547) (9,787)
Other, net (10,122) 9,892 (2,237)
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES (1,752,780) 1,952,849 (603,617)
EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH (57,850) (3,725) 0
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, INCLUDING CASH CLASSIFIED WITHIN ASSETS HELD FOR SALE 524,021 (1,525,867) 1,223,552
LESS: INCREASE IN CASH CLASSIFIED WITHIN ASSETS HELD FOR SALE (610) (1,751) 0
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 523,411 (1,527,618) 1,223,552
Cash, cash equivalents, and restricted cash at beginning of year 3,070,128 4,597,746 3,374,194
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT END OF YEAR $ 3,593,539 $ 3,070,128 $ 4,597,746
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies
 12 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
AmerisourceBergen Corporation and its subsidiaries, including less-than-wholly-owned subsidiaries in which AmerisourceBergen Corporation has a controlling financial interest (the "Company"), is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company delivers innovative programs and services designed to improve the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.
The Company undertook a strategic evaluation of its reporting structure to reflect its expanded international presence as a result of the June 2021 acquisition of Alliance Healthcare. As a result, at the beginning of fiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions. U.S. Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable segment (excluding Profarma Distribuidora de Produtos Farmacêuticos S.A. ("Profarma")), MWI Animal Health ("MWI"), Xcenda, Lash Group, and ICS 3PL. International Healthcare Solutions consists of Alliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). Profarma had previously been included in the Pharmaceutical Distribution Services reportable segment. The Company’s prior period segment disclosures have been revised to reflect this change in reportable segments.
Basis of Presentation
The accompanying financial statements present the consolidated financial position, results of operations, and cash flows of the Company as of the dates and for the periods indicated. All significant intercompany accounts and transactions have been eliminated in consolidation.
The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts due to uncertainties inherent in such estimates. Management periodically evaluates estimates used in the preparation of the financial statements for continued reasonableness.
Recently Adopted Accounting Pronouncements
In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectibility of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. ASU 2016-13 was effective for annual reporting periods beginning after December 15, 2019, including interim periods within those fiscal years, and a modified retrospective approach was required, with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance was effective.
The Company adopted ASU 2016-13 as of October 1, 2020. In connection with the adoption of ASU 2016-13, the Company recognized a $21.1 million, net of tax of $6.1 million, cumulative adjustment to retained earnings.
For the Company's credit loss policy, refer to the "Concentrations of Credit Risk and Allowance for Credit Losses" section of Note 1.
In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes" ("ASU 2019-12"). ASU 2019-12 removes certain exceptions to the general principles in Accounting Standards Codification ("ASC") 740 in order to reduce the cost and complexity of its application. ASU 2019-12 was effective for annual reporting periods beginning after December 15, 2020, including interim periods within those fiscal years, with certain amendments applied on a modified retrospective basis, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption, and others prospectively.
The Company adopted ASU No. 2019-12 as of October 1, 2021. The adoption of ASU No. 2019-12 had no impact on the Company's financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted
As of September 30, 2022, there were no recently issued accounting standards that may have a material impact on the Company's financial position, results of operations, or cash flows upon their adoption.
Business Combinations
The assets acquired and liabilities assumed from an acquired business are recorded at fair value, with the residual of the purchase price recorded as goodwill. The results of operations of an acquired businesses are included in the Company's operating results from the date of acquisition.
Cash, Cash Equivalents, and Restricted Cash
The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value.
The Company is required to maintain certain cash deposits with banks mainly consisting of deposits restricted under contractual agency agreements and cash restricted by law and other obligations, including opioid-related legal settlements.
The following represents a reconciliation of cash and cash equivalents in the Consolidated Balance Sheets to cash, cash equivalents, and restricted cash in the Consolidated Statements of Cash Flows:
September 30,
(amounts in thousands)202220212020
Cash and cash equivalents$3,388,189 $2,547,142 $4,597,746 
Restricted cash (included in Prepaid Expenses and Other)144,980 462,986 — 
Restricted cash (included in Other Assets)60,370 60,000 — 
Cash, cash equivalents, and restricted cash$3,593,539 $3,070,128 $4,597,746 
Concentrations of Credit Risk and Allowance for Credit Losses
    The Company sells its inventories to a large number of customers in the healthcare industry that include institutional and retail healthcare providers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies and providers of pharmacy services to such facilities, and physician offices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies, pharmacy departments of supermarkets and mass merchandisers, and veterinarians. The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry.
The Company's trade accounts receivables are exposed to credit risk. Revenue from the various agreements and arrangements with the Company's largest customer in the fiscal year ended September 30, 2022, Walgreens Boots Alliance, Inc. ("WBA"), accounted for approximately 27% of revenue and represented approximately 38% of accounts receivable, net of incentives, as of September 30, 2022. Express Scripts, Inc., the Company's second largest customer in the fiscal year ended September 30, 2022, accounted for approximately 13% of revenue and represented approximately 7% of accounts receivable as of September 30, 2022. The Company generally does not require collateral for trade receivables. The Company evaluates its receivables for risk of loss by grouping its receivables with similar risk characteristics. Expected losses are determined based on a combination of historical loss trends, current economic conditions, and forward-looking risk factors. Changes in these factors, among others, may lead to adjustments in the Company's allowance for credit losses. The calculation of the required allowance requires judgment by Company management as to the impact of those and other factors on the ultimate realization of its trade receivables. Each of the Company's business units performs ongoing credit evaluations of its customers' financial condition and maintains reserves for expected credit losses for specific credit problems when they arise. There were no significant changes to this process during the fiscal years ended September 30, 2022, 2021, and 2020, and bad debt expense was computed in a consistent manner during these periods.
The Company maintains cash, cash equivalents, and restricted cash with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and, therefore, bear minimal credit risk. The Company seeks to mitigate such risks by monitoring the risk profiles of these counterparties. The Company also seeks to mitigate risk by monitoring the investment strategy of money market accounts in which it is invested, which are classified as cash equivalents.
Contingencies
Loss Contingencies: In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, stockholder demands, and other disputes, including antitrust, commercial, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a liability when it is both probable that a loss has been incurred and the amount can be reasonably estimated. The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued. If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, the Company provides disclosure of the loss contingency in the notes to its financial statements. The Company reviews all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made. Among the loss contingencies that the Company considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 13.
Gain Contingencies: The Company records gain contingencies when they are realized. Gains from antitrust litigation settlements are realized upon the receipt of cash and recorded as a reduction to cost of goods sold because they represent a recovery of amounts historically paid to manufacturers to originally acquire the pharmaceuticals that were the subject of the antitrust litigation settlements (see Note 14).
Derivative Financial Instruments
The Company utilizes derivative financial instruments to manage exposures to foreign currency. The Company records all derivative financial instruments on the balance sheet at fair value and complies with established criteria for designation and effectiveness of hedging relationships. The Company's policy prohibits it from entering into derivative financial instruments for speculative or trading purposes.
Foreign Currency
When the functional currency of the Company's foreign operations is the applicable local currency, assets and liabilities are translated into U.S. dollars using the current exchange rates in effect at the balance sheet date, while revenues and expenses are translated at the weighted average exchange rates for the period. The resulting asset and liability translation adjustments are recorded as a component of Accumulated Other Comprehensive Loss within Stockholders' Equity.
During the quarter ended March 31, 2022, Turkey became a highly inflationary economy, as defined under U.S. GAAP. As a result, effective April 1, 2022, and until such time as the applicable economy is no longer considered highly inflationary, Turkish Lira-denominated assets and liabilities are remeasured using the Company's reporting currency in accordance with ASC 830, "Foreign Currency Matters." Turkish Lira denominated monetary assets and liabilities (primarily cash, accounts receivables, and accounts payables) are remeasured at each balance sheet date using the currency exchange rate then in effect, with currency remeasurement gains and losses recognized in Other Income in the Statement of Operations. Turkish Lira-denominated nonmonetary assets and liabilities (primarily inventories, goodwill, and other intangible assets) are translated at the currency exchange rate in effect prior to highly inflation accounting commencement or at the exchange rate in effect at their date of acquisition if subsequent to April 1, 2022. As such, nonmonetary assets and liabilities retain a higher historical basis when currencies are devalued. This higher historical basis results in incremental expense being recognized when nonmonetary assets are consumed (i.e., sale of inventory). During the fiscal year ended September 30, 2022, the Company recorded an incremental expense of $40.0 million in Cost of Goods Sold related to the consumption of inventory and an expense of $11.9 million within Other Income related to the currency remeasurement of monetary assets and liabilities.
Goodwill and Other Intangible Assets
Goodwill arises from acquisitions or consolidations of specific operating companies and is assigned to the reporting unit in which a particular operating company resides. The Company identifies its reporting units based upon the Company's management reporting structure, beginning with its operating segments. The Company aggregates two or more components within an operating segment that have similar economic characteristics. The Company evaluates whether the components within its operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment. The Company announced a strategic reorganization of its business and began reporting externally under the new structure as of October 1, 2021. As of September 30, 2022, the Company’s reporting units include Pharmaceutical Distribution Services, U.S. Consulting Services, MWI, Alliance Healthcare, Innomar, World Courier, and Profarma.
Goodwill and other intangible assets with indefinite lives, such as certain trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. For the purpose of these impairment tests, the Company can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite-lived intangible assets, respectively. Such qualitative factors can include, among others, industry and market conditions, overall financial performance, and relevant entity-specific events. If the Company concludes based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis. The Company elected to perform a quantitative impairment assessment of goodwill and indefinite-lived intangible assets in fiscal 2022. The Company elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in fiscal 2021, with the exception of its testing of goodwill in the AmerisourceBergen Consulting Services (the sum of U.S. Consulting Service and Innomar reporting units, under the Company’s prior reporting structure) and Profarma reporting units. The Company elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in fiscal 2020, with the exception of its testing of goodwill and indefinite-lived intangibles in the MWI and Profarma reporting units.
The quantitative goodwill impairment test requires the Company to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit. If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized. If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.
When performing a quantitative impairment assessment, the Company utilizes an income-based approach to value its reporting units, with the exception of the Profarma reporting unit, the fair value of which is based upon its publicly-traded stock price, plus an estimated control premium. The income-based approach relies on a discounted cash flow analysis, which considers forecasted cash flows discounted at an appropriate discount rate, to determine the fair value of each reporting unit. The Company generally believes that market participants would use a discounted cash flow analysis to determine the fair value of the Company's reporting units in a sale transaction. The annual goodwill impairment test requires the Company to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon the Company's long-range plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both debt and equity, including a risk premium. While the Company uses the best available information to prepare its forecasted cash flows and discount rate assumptions, actual future cash flows and/or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, the Company's overall methodology and the population of assumptions used have remained unchanged.
The quantitative impairment test for indefinite-lived intangibles other than goodwill (certain trademarks and trade names) consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date. The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method. The Company believes the relief from royalty method is a widely used valuation technique for such assets. The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.
The Company completed its required annual impairment tests relating to goodwill and indefinite-lived intangible assets in the fiscal years ended September 30, 2022, 2021, and 2020. The Company recorded goodwill impairments of $75.9 million and $6.4 million in its Profarma reporting unit in connection with its fiscal 2022 and 2021 impairment tests (see Note 5), respectively. No goodwill impairments were recorded in the fiscal years ended September 30, 2020, and no indefinite-lived intangible asset impairments were recorded in the fiscal years ended September 30, 2022, 2021, or 2020.
Finite-lived intangible assets are amortized using the straight-line method over the estimated useful lives of the assets. The Company performs a recoverability assessment of its long-lived assets when impairment indicators are present.
The Company recorded impairments of intangible and tangible assets totaling $361.7 million in the fiscal year ended September 30, 2020 in connection with the permanent shutdown of its compounding business.
Held for Sale
Assets and liabilities to be disposed of by sale ("disposal groups") are reclassified into assets and liabilities held for sale on the Company's Consolidated Balance Sheet. The reclassification occurs when an agreement to sell exists, or management has committed to a plan to sell the assets within one year. Disposal groups are measured at the lower of carrying value or fair value less costs to sell and are not depreciated or amortized. When the net realizable value of a disposal group increases during a period, a gain can be recognized to the extent that it does not increase the value of the disposal group beyond its original carrying value when the disposal group was reclassified as held for sale. The fair value of a disposal group, less any costs to sell, is assessed each reporting period it remains classified as held for sale and any remeasurement to the lower of carrying value or fair value less costs to sell is reported as an adjustment to the carrying value of the disposal group.
Income Taxes
The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities (commonly known as the asset and liability method). In assessing the need to establish a valuation allowance on deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.
The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including settlements with tax authorities or resolutions of any related appeals or litigation processes, based upon the technical merits of the position. Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based upon the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination.
Inventories
Inventories are stated at the lower of cost or market. Cost for approximately 66% of the Company's inventories as of September 30, 2022 and 2021 has been determined using the last-in, first-out ("LIFO") method. If the Company had used the first-in, first-out method of inventory valuation, which approximates current replacement cost, inventories would have been approximately $1,383.4 million and $1,316.2 million higher than the amounts reported as of September 30, 2022 and 2021, respectively. The Company recorded LIFO expense of $67.2 million and $7.4 million in the fiscal years ended September 30, 2022 and 2020, respectively, and a LIFO credit of $203.0 million in the fiscal year ended September 30, 2021. The annual LIFO provision is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict. Changes to any of the above factors can have a material impact to the Company's annual LIFO provision.
Investments
The Company first evaluates its investments in accordance with the variable interest model to determine whether it has a controlling financial interest in an investment. This evaluation is made as of the date on which the Company makes its initial investment, and subsequent evaluations are made if the structure of the investment changes. If it has determined that an investment is a variable interest entity ("VIE"), the Company evaluates whether the VIE is required to be consolidated. When the Company holds rights that give it the power to direct the activities of an entity that most significantly impact the entity's economic performance, combined with the obligation to absorb an entity's losses and the right to receive benefits, the Company consolidates a VIE. If it is determined that an investment is not a VIE, the Company then evaluates its investments under the voting interest model and generally consolidates investments in which it holds an ownership interest of greater than 50%. When the Company consolidates less-than-wholly-owned subsidiaries, it presents its noncontrolling interest in its consolidated financial statements.
    For equity securities without a readily determinable fair value, the Company uses the fair value measurement alternative and measures the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which the Company can exercise significant influence but does not control, it uses the equity method of accounting. The Company's share of earnings and losses of its investments is recorded in Other Income in the Consolidated Statements of Operations. The Company monitors its investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions.
Leases
At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the facts and circumstances present. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. At the lease commencement date, operating and finance lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable and, as such, the Company uses its incremental borrowing rate to discount the lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term in a similar economic environment. Certain adjustments to the right-of-use ("ROU") asset may be required for items such as incentives received. The Company does not recognize on the balance sheet leases with terms of one year or less.
    The Company has operating leases that are primarily comprised of buildings, office equipment, distribution center equipment, and vehicles. Some of the Company's leases include options to extend or early terminate the lease, which are included in the lease term when it is reasonably certain to exercise and there is a significant economic incentive to exercise that option. Certain lease agreements contain provisions for future rent increases. Lease payments included in the measurement of the lease liability comprise fixed payments. The Company combines lease and non-lease components as a single component. Operating lease cost is recognized over the expected lease term on a straight-line basis and is recorded in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations. Variable lease payments, which are primarily comprised of maintenance, taxes, and other payments based on usage, are recognized when the expense is incurred. The Company's leases do not contain residual value guarantees.
Manufacturer Incentives
The Company considers fees and other incentives received from its suppliers relating to the purchase and distribution of inventory to represent product discounts, and, as a result, they are recognized within cost of goods sold upon the sale of the related inventory.
Property and Equipment
Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 40 years for buildings and improvements and from 3 to 10 years for machinery, equipment, and other. The costs of repairs and maintenance are charged to expense as incurred.
The Company capitalizes project costs relating to computer software developed or obtained for internal use when the activities related to the project reach the application development stage. Costs that are associated with preliminary stage activities, training, maintenance, and all other post-implementation stage activities are expensed as they are incurred. Software development costs are depreciated using the straight-line method over the estimated useful lives, which range from 3 to 10 years.
The following table summarizes the Company's property and equipment balances for the periods indicated:
September 30,
(in thousands)20222021
Property and equipment, at cost:
Land$122,426 $129,944 
Buildings and improvements840,852 838,615 
Machinery, equipment, and other3,424,070 3,113,132 
Total property and equipment4,387,348 4,081,691 
Less accumulated depreciation(2,252,345)(1,918,730)
Property and equipment, net$2,135,003 $2,162,961 
Revenue Recognition
The Company's revenues are primarily generated from the distribution of pharmaceutical products. The Company also generates revenues from global commercialization services, which include clinical trial support, post-approval and commercialization support, and global specialty transportation and logistics for the biopharmaceutical industry. See Note 15 for the Company's disaggregated revenue.
The Company recognizes revenue related to the distribution of products at a point in time when title and control transfers to customers and there is no further obligation to provide services related to such products. Service revenue is recognized over the period that services are provided to the customer. The Company is generally the principal in a transaction;
therefore, revenue is primarily recorded on a gross basis. When the Company is the principal in a transaction, it has determined that it controls the ability to direct the use of the product or service prior to the transfer to a customer, it is primarily responsible for fulfilling the promise to provide the product or service to its customer, it has discretion in establishing pricing, and it controls the relationship with the customer. Revenue is recognized at the amount of consideration expected to be received. For the distribution business, revenue is primarily generated from a contract related to a confirmed purchase order with a customer in a distribution arrangement and is net of estimated sales returns and allowances, other customer incentives, and sales tax.
When the Company is the agent in a transaction, the fee received from a manufacturer customer is recognized within revenue as the service is performed.
The Company's customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit. The Company records an accrual for estimated customer sales returns at the time of sale to the customer based upon historical return trends. As of September 30, 2022 and 2021, the Company's accrual for estimated customer sales returns was $1,532.1 million and $1,271.6 million, respectively.
Share-Based Compensation
    The Company accounts for the compensation cost of all share-based payments at fair value. The fair value of restricted stock units and performance stock units is based upon the grant date market price of the Company’s common stock. The Company estimated the fair value of options granted in fiscal 2020 using a binomial option pricing model.
    Share-based compensation expense is recognized over the requisite service period within Distribution, Selling, and Administrative in the Consolidated Statements of Operations to correspond with the same line item as the cash compensation paid to employees. Compensation expense associated with nonvested performance stock units is dependent upon the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued.
    The income tax effects of awards are recognized when the awards vest or are settled and are recognized in Income Tax Expense in the Company’s Consolidated Statements of Operations.
Shipping and Handling Costs
Shipping and handling costs include all costs to warehouse, pick, pack, and deliver inventory to customers. These costs, which were $1,040.8 million, $809.3 million, and $665.3 million for the fiscal years ended September 30, 2022, 2021, and 2020, respectively, are included in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations.
Supplier Reserves
The Company establishes reserves against amounts due from its suppliers relating to various price and rebate incentives, including deductions or billings taken against payments otherwise due to them from the Company. These reserve estimates are established based upon the judgment of Company management after carefully considering the status of current outstanding claims, historical experience with the suppliers, the specific incentive programs, and any other pertinent information available to the Company. The Company evaluates the amounts due from its suppliers on a continual basis and adjusts the reserve estimates when appropriate based upon changes in factual circumstances. The ultimate outcome of any outstanding claim may be different than the Company's estimate.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisition and Assets and Liabilities Held for Sale
 12 Months Ended
Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Acquisition and Assets and Liabilities Held for Sale Acquisition and Assets and Liabilities Held for Sale
Acquisition
On June 1, 2021, the Company acquired a majority of Walgreens Boots Alliance, Inc.'s ("WBA") Alliance Healthcare businesses ("Alliance Healthcare") for $6,662.0 million in cash, $229.1 million of the Company's common stock (2 million shares at the Company's June 1, 2021 opening stock price of $114.54 per share), and $6.1 million of other equity consideration. The net cash payment was $5,596.7 million, as the Company acquired $922.0 million of cash and cash equivalents and $143.3 million of restricted cash. The shares issued were from the Company's treasury stock on a first-in, first-out basis and were originally purchased for $149.1 million. In the fiscal year ended September 30, 2022, the Company's previous estimate of $96.9 million of accrued consideration was settled for $60.0 million, which resulted in a $36.9 million reduction to Goodwill. The $60.0 million cash payment is included in the total $6,662.0 million cash consideration. The Company funded the cash purchase price through a combination of cash on hand and new debt financing. The acquisition expands the Company's reach and solutions in pharmaceutical distribution and adds to the Company's depth and breadth of global manufacturer services.
The Company completed the purchase price allocation as of June 1, 2022 and recorded purchase accounting adjustments that reduced working capital account balances by $102.7 million, increased the corresponding deferred tax assets by $63.0 million, and decreased other assets by $13.3 million, which resulted in a $53.0 million increase to Goodwill. There were no measurement period adjustments recorded to the previously-reported opening balance sheet that would have had a material impact on the Company's previously-reported results of operations had those adjustments been recorded in the previous reporting periods. The final purchase price has been allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values at the date of the acquisition in the table that follows:
(in thousands)
Consideration
Cash$6,662,020 
Equity (2 million shares of AmerisourceBergen Corporation common stock)
229,080 
Other equity consideration6,061 
Fair value of total consideration$6,897,161 
Recognized amounts of identifiable assets acquired and liabilities assumed
Cash and cash equivalents$921,995 
Accounts receivable3,628,056 
Inventories1,647,330 
Prepaid expenses and other355,030 
Property and equipment634,220 
Goodwill2,496,338 
Other intangible assets3,735,000 
Deferred income taxes33,922 
Other assets534,393 
Total assets acquired13,986,284 
Accounts payable(4,618,807)
Accrued expenses and other(765,463)
Short-term debt(353,420)
Deferred income taxes(760,937)
Other liabilities(405,332)
Total liabilities assumed(6,903,959)
Net assets acquired7,082,325 
Noncontrolling interest(185,164)
Equity consideration(235,141)
Cash acquired, including restricted cash of $143,308 included in Prepaid Expenses and Other
(1,065,303)
Net cash paid$5,596,717 
The estimated fair value of the intangible assets acquired of $3.7 billion and the estimated useful lives are as follows:
(in thousands, except useful lives)Fair ValueWeighted-Average Useful Life
Customer relationships$3,327,000 18
Trade names408,000 11
Total$3,735,000 
Goodwill resulting from this acquisition is not expected to be deductible for income tax purposes.
The fair value of the $185.2 million noncontrolling interest in Alliance Healthcare Egypt, a 50%-owned subsidiary, was estimated by applying income and market-based approaches. This fair value measurement is based on inputs that are not observable in the market and; therefore, represents a fair value measurement categorized within Level 3 of the fair value hierarchy.
The Company incurred $90.9 million of acquisition-related costs in connection with this acquisition. These costs are included in Acquisition, Integration, and Restructuring Expenses in the Company's Statements of Operations for the twelve months ended September 30, 2021.
See Part I. Other Information-Item 1A. Risk Factors of this Annual Report on Form 10-K for additional risk factors related to our strategic transactions with WBA.
Assets and Liabilities Held for Sale
The Company entered into agreements in the fourth quarter of fiscal 2021 to sell two of its non-core subsidiaries. In connection with entering into these agreements, the Company concluded that both disposal groups met the held for sale criteria and classified their assets and liabilities as held for sale as of September 30, 2021. One disposal group was included within the U.S. Healthcare Solutions reportable segment and the other disposal group was included within International Healthcare Solutions reportable segment.
In connection with the held for sale classification, the Company recorded a total loss of $16.3 million on the remeasurement of the disposal group held for sale in the U.S. Healthcare Solutions reportable segment to fair value less cost to sell, $4.9 million of which was recorded in Impairment of Assets on its Consolidated Statement of Operations in the fiscal year ended September 30, 2022. The Company previously recorded a loss of $11.3 million in fiscal year ended September 30, 2021. The Company completed the sales of the disposal groups in the fiscal year ended September 30, 2022 and received total proceeds of $267.6 million, subject to final working capital adjustments. In connection with the sales of these disposal groups, the Company recorded a gain of $52.6 million, which is included in Other Income, Net in the Company's Consolidated Statements of Operations.
Total assets and liabilities of the combined disposal groups held for sale on the September 30, 2021 Consolidated Balance Sheet are comprised of the following:
(in thousands)
Cash and cash equivalents$1,751 
Accounts receivable, less allowance for credit losses182,077 
Inventories123,424 
Prepaid expenses and other11,258 
Property and equipment3,084 
Goodwill31,903 
Other intangible assets22,923 
Other assets7,812 
Loss on the remeasurement of a disposal group held for sale to fair value less cost to sell(11,324)
    Total assets held for sale$372,908 
Accounts payable$173,104 
Accrued expenses and other7,234 
Short-term debt4,225 
Long-term debt50 
Deferred income taxes5,857 
Other liabilities1,599 
    Total liabilities held for sale$192,069 
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Variable Interest Entity
 12 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Variable Interest Entity Variable Interest Entity
The Company has substantial governance rights that allow it to direct the activities that significantly impact Profarma’s economic performance. As such, the Company consolidates the operating results of Profarma in its consolidated financial statements. The Company is not obligated to provide future financial support to Profarma.
The following assets and liabilities of Profarma are included in the Company's Consolidated Balance Sheet for the periods indicated:
(in thousands)September 30,
2022		September 30,
2021
Cash and cash equivalents$23,144 $33,699 
Accounts receivables, net192,930 148,485 
Inventories207,858 168,229 
Prepaid expenses and other63,982 62,545 
Property and equipment, net35,554 31,920 
Goodwill— 75,936 
Other intangible assets66,568 70,840 
Other long-term assets71,327 74,177 
Total assets$661,363 $665,831 
Accounts payable$215,515 $162,768 
Accrued expenses and other47,952 38,477 
Short-term debt60,851 64,215 
Long-term debt64,918 52,613 
Deferred income taxes25,801 37,041 
Other long-term liabilities52,417 57,945 
Total liabilities$467,454 $413,059 
Profarma's assets can only be used to settle its obligations, and its creditors do not have recourse to the general credit of the Company.
Profarma Retail Equity Offering
In August 2020, Profarma received $66.4 million through an equity offering of its retail business. The equity offering decreased Profarma's voting ownership interest in the retail business from 100% to 53.5%. Profarma continues to consolidate the operating results of the retail business in its consolidated financial statements.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes
 12 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The following table summarizes the Company's income (loss) before income taxes for the periods indicated:
 Fiscal Year Ended September 30,
(in thousands)202220212020
Domestic$1,351,696 $1,495,899 $(5,961,269)
Foreign831,361 725,960 667,438 
Total$2,183,057 $2,221,859 $(5,293,831)
The components of the Company's consolidated income tax expense (benefit) are summarized in the following table for the periods indicated:
 Fiscal Year Ended September 30,
(in thousands)202220212020
Current provision (benefit):   
Federal$126,969 $184,375 $(473,751)
State and local39,282 30,659 30,236 
Foreign154,082 127,351 94,213 
Total current provision (benefit)320,333 342,385 (349,302)
Deferred provision (benefit):   
Federal150,328 111,428 (914,613)
State and local31,129 47,516 (264,409)
Foreign14,727 175,922 (365,949)
Total deferred provision (benefit)196,184 334,866 (1,544,971)
Provision (benefit) for income taxes$516,517 $677,251 $(1,894,273)
A reconciliation of the statutory U.S. federal income tax rate to the Company's consolidated effective income tax rate is as follows for the periods indicated:
 Fiscal Year Ended September 30,
 202220212020
Statutory U.S. federal income tax rate21.0%21.0%21.0%
State and local income tax rate, net of federal tax benefit2.52.8(0.5)
Tax effect of foreign operations(1.9)(0.5)1.0
Litigation settlements and accruals (see Note 13)
0.40.8(6.2)
Tax law changes 1
—7.36.8
PharMEDium worthless stock deduction—(1.1)12.4
CARES Act——1.2
Other, net1.70.20.1
Effective income tax rate23.7%30.5%35.8%
1 Tax law changes include 5.7% related to UK Tax Reform and 1.6% related to Swiss Tax Reform in fiscal 2021 and 6.8% in fiscal 2020 related to Swiss Tax Reform.
United Kingdom Tax Reform
The United Kingdom ("UK") government delivered a Spring Budget in March 2021 that set out a plan to provide continuing support for jobs and businesses as the UK recovers from the COVID-19 pandemic. The UK government Finance Act 2021 includes a provision to increase the corporate tax rate from 19% to 25% beginning on April 1, 2023. As a result, the Company recognized a deferred tax expense of $127.6 million to increase its deferred tax liabilities for the change in the tax rate in the fiscal year ended September 30, 2021.
The Coronavirus Aid, Relief, and Economic Security Act
    The Coronavirus Aid, Relief, and Economic Security ("CARES") Act became law on March 27, 2020. The CARES Act was a response to the market volatility and instability resulting from the coronavirus pandemic and included provisions to support businesses in the form of loans, grants, and tax changes, among other types of relief that were not previously available under the U.S. Tax Cuts and Jobs Act of 2017 (the "2017 Tax Act"). The CARES Act provided the Company relief through adjustments to net operating loss rules and the acceleration of available refunds for alternative minimum tax credit carryforwards.
PharMEDium
    The Company decided in January 2020 to shut down and permanently exit its compounding business. Following the decision to exit PharMEDium and in connection with the permanent shutdown of this business, PharMEDium underwent a voluntary change in tax status, which resulted in the Company recognizing a worthless stock ordinary income tax deduction of approximately $2.4 billion and, in turn, yielded a tax benefit of approximately $655 million. The estimated tax benefit was higher than it would have been prior to the enactment of the CARES Act as the net operating losses resulting from the worthless stock deduction could now be carried back to years with higher statutory tax rates.
In addition to the PharMEDium worthless stock deduction, the Company recognized other discrete tax benefits primarily resulting from the CARES Act. In the aggregate, the Company recognized discrete tax benefits of $720.6 million in the fiscal year ended September 30, 2020.
The Company's September 30, 2022 Consolidated Balance Sheet includes a current income tax receivable balance of $172.6 million primarily resulting from the recognition of the above discrete tax benefits.
Swiss Tax Reform
In August 2020, the Canton of Bern enacted tax reforms to comply with requirements imposed by earlier Swiss federal tax reforms, which were retroactively effective as of January 1, 2020. A key provision of the Swiss federal tax reforms was the elimination of cantonal preferential tax regimes, which had the effect of increasing overall tax rates on Swiss income. To phase in the tax rate increase, the canton of Bern granted a tax ruling to the Company that effectively reduces the Company's Swiss tax rate for a period of 10 years.
As a result of the aforementioned Swiss tax law change and ruling, the Company recorded a deferred tax asset in the fiscal year ended September 30, 2020 that is expected to be realized over the following 10 years. As of September 30, 2022, the deferred tax asset of $446.6 million was reduced by a $234.0 million valuation allowance for the amount that more likely than not will not be realized.
In November 2020, the Canton of Bern approved its Budget 2021, which called for lowering its corporate income tax rate applicable to the Company’s Swiss operations effective October 1, 2020. As a result, the Company recognized a deferred tax expense to reduce its Swiss deferred tax asset for the change in tax rate.
Opioid Legal Accrual
In the fiscal years ended September 30, 2022, 2021, and 2020 the Company recorded accruals related to the opioid litigation settlements of $36.6 million, $147.7 million, and $6.6 billion, respectively (see Note 13). The Company's September 30, 2022 Consolidated Balance Sheet includes a net deferred tax asset of $981.6 million in connection with the total expense accrued.
Deferred income taxes reflect the future tax consequences of differences between the tax bases of assets and liabilities and their financial reporting amounts. Significant components of the Company's deferred tax liabilities (assets) are as follows:
 September 30,
(in thousands)20222021
Inventories$1,471,064 $1,388,913 
Property and equipment149,896 167,974 
Goodwill and other intangible assets1,184,477 1,409,296 
Right-of-use assets219,616 249,920 
Other61,148 57,450 
Gross deferred tax liabilities3,086,201 3,273,553 
Net operating loss and tax credit carryforwards(426,651)(389,724)
Allowance for credit losses(67,788)(27,569)
Accrued expenses(24,435)(13,411)
Accrued litigation liability(981,627)(1,082,845)
Employee and retiree benefits(22,682)(26,196)
Goodwill and other intangible assets(446,605)(488,235)
Lease liabilities(241,469)(263,278)
Share-based compensation(33,933)(37,466)
Other(75,428)(88,855)
Gross deferred tax assets(2,320,618)(2,417,579)
Valuation allowance for deferred tax assets617,259 538,531 
Deferred tax assets, net of valuation allowance(1,703,359)(1,879,048)
Net deferred tax liabilities$1,382,842 $1,394,505 
As of September 30, 2022, the Company had $2.6 million of potential tax benefits from federal net operating loss carryforwards, which expire in 15 years, $136.0 million of potential tax benefits from state net operating loss carryforwards and $297.2 million of potential tax benefits from foreign net operating loss carryforwards, which have varying expiration dates. The Company had $6.0 million of state tax credit carryforwards and $3.1 million in foreign alternative minimum tax credit carryforwards.
The Company assesses the available positive and negative evidence to determine whether deferred tax assets are more likely than not to be realized. As a result of this assessment, valuation allowances have been recorded on certain deferred tax assets. For the fiscal year ended September 30, 2022 and 2021, the Company increased the valuation allowance on deferred tax assets by $78.7 million and $126.9 million, respectively. The increase in the valuation allowance in the fiscal year ended September 30, 2022 was primarily due to the increase in the valuation allowance against foreign net operating loss carryforwards. The increase in the valuation allowance in the fiscal year ended September 30, 2021 was primarily due to the valuation allowance established in connection with purchase accounting associated with Alliance Healthcare acquisition.
In the fiscal years ended September 30, 2022, 2021, and 2020 tax benefits of $13.4 million, $8.2 million and $3.9 million, respectively, related to the exercise of employee stock options and lapses of restricted stock units were recorded in Income Tax Expense (Benefit) in the Company's Consolidated Statements of Operations. The tax benefits recognized in the fiscal years ended September 30, 2022, 2021, and 2020 are not necessarily indicative of amounts that may arise in future periods.
Income tax payments, net of refunds, were $244.4 million, $93.5 million, and $139.4 million in the fiscal years ended September 30, 2022, 2021, and 2020, respectively.
Cumulative undistributed earnings of international subsidiaries were $3.7 billion as of September 30, 2022, $2.1 billion of which is considered permanently reinvested. It is not practicable to estimate the taxes that would be due if such earnings were to be repatriated in the future.
The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various states and foreign jurisdictions. The Company is currently undergoing a U.S. federal income tax audit for fiscal years 2019 and 2018 and certain state and local income tax audits for various years. With few exceptions, the Company is no longer subject to U.S. federal tax
examinations for years before 2018, and state and local, or foreign income tax examinations by tax authorities for years before 2019. The Company believes it has adequate tax reserves to cover potential federal, state or foreign tax exposures.
As of September 30, 2022 and 2021, the Company had unrecognized tax benefits, defined as the aggregate tax effect of differences between tax return positions and the benefits recognized in the Company's financial statements, of $553.2 million and $522.8 million, respectively ($479.6 million and $467.9 million, net of federal tax benefit, respectively). If recognized in the fiscal years ended September 30, 2022 and 2021, $461.4 million and $449.7 million, respectively, of these benefits would have reduced income tax expense and the effective tax rate. As of September 30, 2022 and 2021, included in the unrecognized tax benefits are $26.7 million and $22.4 million of interest and penalties, respectively, which the Company records in Income Tax Expense (Benefit) in the Company's Consolidated Statements of Operations.
A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, for the periods indicated is as follows:
Fiscal Year Ended September 30,
(in thousands)202220212020
Unrecognized tax benefits at beginning of period$500,399 $478,351 $105,657 
Additions of tax positions of the current year21,074 20,515 385,797 
Additions to tax positions of the prior years5,073 17,022 5,599 
Reductions of tax positions of the prior years— — (6,480)
Expiration of statutes of limitations(24)(15,489)(12,222)
Unrecognized tax benefits at end of period$526,522 $500,399 $478,351 
Included in the additions of unrecognized tax benefits in the fiscal year ended September 30, 2020 is $371.5 million for an unrecognized tax benefit related to the $6.6 billion legal accrual for litigation related to the global opioid settlement, as well as other opioid-related litigation, as disclosed in Note 13. The Company has applied significant judgment in estimating the amount of the opioid settlements that will be deductible for U.S. federal and state purposes. In estimating the amount that would be deductible, the Company considered prior U.S. tax case law, the amount and character of the damages sought in litigation, and other relevant factors. During the next 12 months, it is reasonably possible that tax audit resolutions and the expiration of statutes of limitations could result in a reduction of unrecognized tax benefits by approximately $21.2 million.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill and Other Intangible Assets
 12 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets
In connection with the change in the Company's reporting structure that is discussed in Note 1, the Company reallocated goodwill among the impacted reporting units using a relative fair value approach and assessed impairment before and after goodwill was reallocated. The following is a summary of the changes in the carrying value of goodwill, by reportable segment, for the fiscal years ended September 30, 2022 and 2021:
(in thousands)U.S. Healthcare SolutionsInternational Healthcare SolutionsTotal
Goodwill as of September 30, 2020 (as revised)$6,267,502 $439,217 $6,706,719 
Goodwill recognized in connection with acquisitions (Note 2)19,076 2,469,152 2,488,228 
Goodwill impairment— (6,373)(6,373)
Goodwill reclassified to assets held for sale (Note 2)(27,223)(4,680)(31,903)
Foreign currency translation1,019 (127,159)(126,140)
Goodwill as of September 30, 2021 (as revised)6,260,374 2,770,157 9,030,531 
Purchase accounting adjustments— 27,186 27,186 
Goodwill recognized in connection with acquisition26,143 — 26,143 
Goodwill derecognized in connection with disposal(1,224)— (1,224)
Goodwill impairment— (75,936)(75,936)
Foreign currency translation(5,053)(497,761)(502,814)
Goodwill as of September 30, 2022$6,280,240 $2,223,646 $8,503,886 
In connection with the Company's annual goodwill impairment test as of July 1, 2021, the Company recorded a goodwill impairment of $6.4 million in its Profarma reporting unit. The fair value of the reporting unit was determined based upon Profarma's publicly-traded stock price, plus an estimated control premium. This represents a level 2 nonrecurring fair value measurement.
As a result of a prolonged decline in Profarma’s stock price, the Company performed an impairment assessment over the Profarma reporting unit as of June 30, 2022 and recorded a goodwill impairment of $75.9 million in the fiscal year ended September 30, 2022. The Company determined the fair value of the Profarma reporting unit based upon Profarma’s publicly-traded stock price, plus an estimated control premium. This represents a level 2 nonrecurring fair value measurement.
In connection with the Profarma impairment assessment, the Company first performed a recoverability assessment of Profarma’s long-lived assets by comparing the undiscounted cash flows to the carrying value of the Profarma asset group, and it was determined to be recoverable. However, the forecasted undiscounted cash flows used to perform the recoverability assessment are inherently uncertain and include assumptions that could differ from actual results in future periods.
The following is a summary of other intangible assets:
 September 30, 2022September 30, 2021
(dollars in thousands)Weighted Average Remaining Useful LifeGross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount		Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount
Indefinite-lived trade names$667,932 $— $667,932 $668,119 $— $668,119 
Finite-lived:
Customer relationships15 years4,226,547 (931,961)3,294,586 4,838,549 (718,750)4,119,799 
Trade names and other11 years542,346 (172,127)370,219 609,050 (140,041)469,009 
Total other intangible assets$5,436,825 $(1,104,088)$4,332,737 $6,115,718 $(858,791)$5,256,927 
The decreases in the gross amounts of finite-lived intangible assets since September 30, 2021 were primarily due to foreign currency translation.
Amortization expense for finite-lived intangible assets was $307.3 million, $178.3 million, and $110.9 million in the fiscal years ended September 30, 2022, 2021, and 2020, respectively. Amortization expense for finite-lived intangible assets is estimated to be $275.5 million in fiscal 2023, $274.3 million in fiscal 2024, $273.3 million in fiscal 2025, $268.9 million in fiscal 2026, $264.2 million in 2027, and $2,308.6 million thereafter.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt
 12 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Debt Debt
Debt consisted of the following:
 September 30,
(in thousands)20222021
Revolving credit note$— $— 
Money market facility— — 
Receivables securitization facility due 2025350,000 350,000 
Term loan due June 2023— 249,640 
Overdraft facility due 2024 (£10,000)
— — 
Multi-currency revolving credit facility due 2027— — 
0.737% senior notes due 2023
672,736 1,518,223 
$500,000, 3.400% senior notes due 2024
499,195 498,714 
$500,000, 3.250% senior notes due 2025
498,347 497,669 
$750,000, 3.450% senior notes due 2027
745,622 744,781 
$500,000, 2.800% senior notes due 2030
495,348 494,738 
$1,000,000, 2.700% senior notes due 2031
990,480 989,366 
$500,000, 4.250% senior notes due 2045
495,162 494,946 
$500,000, 4.300% senior notes due 2047
493,288 493,021 
Alliance Healthcare debt336,886 235,998 
Nonrecourse debt125,769 116,828 
Total debt5,702,833 6,683,924 
Less AmerisourceBergen Corporation current portion672,736 — 
Less Alliance Healthcare current portion336,886 235,998 
Less nonrecourse current portion60,851 64,215 
Total, net of current portion$4,632,360 $6,383,711 
Multi-Currency Revolving Credit Facility
The Company has a $2.4 billion multi-currency senior unsecured revolving credit facility ("Multi-Currency Revolving Credit Facility") with a syndicate of lenders, which was scheduled to expire in November 2026. In October 2022, the Company amended the Multi-currecy Revolving Credit Facility to extend the expiration to October 2027 and to make certain changes to effect a transition from the LIBOR interest rate benchmark to Term SOFR. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based upon the Company's debt rating and ranges from 80.5 basis points to 122.5 basis points over SOFR/EURIBOR/CDOR/RFR, as applicable (101.5 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee as of September 30, 2022) and from 0 basis points to 22.5 basis points over the alternate base rate and Canadian prime rate, as applicable. The Company pays facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on its debt rating, ranging from 7 basis points to 15 basis points, annually, of the total commitment (11 basis points as of September 30, 2022). The Company may choose to repay or reduce its commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which the Company was compliant as of September 30, 2022.
Commercial Paper Program
The Company has a commercial paper program whereby it may from time to time issue short-term promissory notes in an aggregate amount of up to $2.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase the Company's borrowing capacity as it is fully backed by the Company's Multi-Currency Revolving Credit Facility. There were no borrowings outstanding under the commercial paper program as of September 30, 2022 and 2021.
Receivables Securitization Facility
The Company has a $1,450 million receivables securitization facility ("Receivables Securitization Facility"), which was scheduled to expire in November 2024. In October 2022, the Company amended the Receivables Securitization Facility (the “Receivables Amendment”) to extend the expiration for an additional one year to October 2025. In addition, the Receivables Amendment made certain changes to (i) substitute Term SOFR for LIBOR as a benchmark and establish procedures to choose a new benchmark if Term SOFR becomes unavailable, (ii) provide for the return of erroneous payments, if any, by purchasers, (iii) update provisions regarding compliance with sanctions and anti-money laundering laws, and (iv) implement certain other technical amendments. The Company has available to it an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters. Interest rates are based on prevailing market rates for short-term commercial paper or 30-day Term SOFR, plus a program fee. The Company pays a customary unused fee at prevailing market rates, annually, to maintain the availability under the Receivables Securitization Facility.
In connection with the Receivables Securitization Facility, AmerisourceBergen Drug Corporation and a specialty distribution subsidiary sell on a revolving basis certain accounts receivable to Amerisource Receivables Financial Corporation, a wholly-owned special purpose entity, which in turn sells a percentage ownership interest in the receivables to financial institutions and commercial paper conduits sponsored by financial institutions. AmerisourceBergen Drug Corporation is the servicer of the accounts receivable under the Receivables Securitization Facility. As sold receivables are collected, additional receivables may be sold up to the maximum amount available under the facility. The facility is a financing vehicle utilized by the Company because it generally offers an attractive interest rate relative to other financing sources. The Company securitizes its trade accounts, which are generally non-interest bearing, in transactions that are accounted for as borrowings. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of September 30, 2022.
Revolving Credit Note, Overdraft Facility, and Money Market Facility
The Company has an uncommitted, unsecured line of credit available to it pursuant to a revolving credit note ("Revolving Credit Note"). The Revolving Credit Note provides the Company with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million. The Revolving Credit Note may be decreased or terminated by the bank or the Company at any time without prior notice. The Company also has an uncommitted U.K. overdraft facility ("Overdraft Facility") to fund short-term normal trading cycle fluctuations related to its MWI Animal Health business. In February 2021, the Company extended the Overdraft Facility to February 2024 and reduced the borrowing capacity from £30 million to £10 million. The Company has an uncommitted, unsecured line of credit available to it pursuant to a money market credit agreement ("Money Market Facility"). The Money Market Facility provides the Company with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $100 million. The Money Market Facility may be decreased or terminated by the bank or the Company at any time without prior notice.
Term Loans
The Company's $400 million October 2018 Term Loan matured and was repaid in October 2020.
In February 2021, the Company entered into a $1.0 billion variable-rate term loan (“February 2021 Term Loan”), which was available to be drawn on the closing date of the acquisition of Alliance Healthcare. In April 2021, the Company reduced its commitment under the February 2021 Term Loan to $500 million. In June 2021, the Company borrowed $500 million under the February 2021 Term Loan to finance a portion of the June 2021 Alliance Healthcare acquisition. The Company elected to make principal payments of $250 million in September 2021 and again in March 2022 to repay the loan that was scheduled to mature in 2023.
Senior Notes
In May 2020, the Company issued $500 million of 2.80% senior notes due May 15, 2030 (the "2030 Notes"). The 2030 Notes were sold at 99.71% of the principal amount and have an effective yield of 2.81%. Interest on the 2030 Notes is payable semi-annually in arrears, commencing on November 15, 2020. The 2030 Notes rank pari passu to the Company's other senior notes, the Multi-Currency Revolving Credit Facility, the Revolving Credit Note, the Overdraft Facility, and the Money Market Facility.
The Company used the proceeds from the 2030 Notes to finance the early retirement of the $500 million of 3.50% senior notes that were due in 2021 and made a $21.4 million prepayment premium in connection with this early retirement.
In March 2021, the Company issued $1,525 million of 0.737% senior notes due March 15, 2023 (the "2023 Notes"). The 2023 Notes were sold at 100.00% of the principal amount. Interest on the 2023 Notes is payable semi-annually in arrears, commencing on September 15, 2021. In March 2021, the Company issued $1,000 million of 2.700% senior notes due March 15, 2031 (the "2031 Notes"). The 2031 Notes were sold at 99.79% of the principal amount and have an effective yield of 2.706%. Interest on the 2031 Notes is payable semi-annually in arrears and commenced on September 15, 2021. The 2023 Notes and 2031 Notes rank pari passu to the Company's other senior notes, the Multi-Currency Revolving Credit Facility, the Revolving Credit Note, the Overdraft Facility, and the Money Market Facility. The Company used the proceeds from the 2023 Notes and the 2031 Notes to finance a portion of the June 2021 Alliance Healthcare acquisition.
In the fiscal year ended September 30, 2022, the Company elected to repay $850 million of 2023 Notes due in March 2023.
The senior notes discussed above and also illustrated in the above debt table are collectively referred to as the "Notes." Interest on the Notes is payable semiannually in arrears. Most of the Notes were sold at small discounts to the principal amounts and, therefore, have effective yields that are greater than the stated interest rates in the table above. Costs incurred in connection with the issuance of the Notes were deferred and are being amortized over the terms of the Notes. The indentures governing the Notes contain restrictions and covenants, which include limitations on additional indebtedness; distributions to stockholders; the repurchase of stock and the making of other restricted payments; issuance of preferred stock; creation of certain liens; transactions with subsidiaries and other affiliates; and certain corporate acts such as mergers, consolidations, and the sale of substantially all assets. An additional covenant requires compliance with a financial leverage ratio test. The Company was compliant with all covenants as of September 30, 2022.
Alliance Healthcare Debt
Alliance Healthcare debt is comprised of uncommitted revolving credit facilities in various currencies with various rates. A majority of the outstanding borrowings were held in Egypt (which is 50% owned) as of September 30, 2022 and 2021. These facilities are used to fund its working capital needs.
Nonrecourse Debt
    Nonrecourse debt is comprised of short-term and long-term debt belonging to the Brazil subsidiaries and is repaid solely from the Brazil subsidiaries' cash flows and such debt agreements provide that the repayment of the loans (and interest thereon) is secured solely by the capital stock, physical assets, contracts, and cash flows of the Brazil subsidiaries.
Other Information
Scheduled future principal payments of debt are $1,071.8 million in fiscal 2023, $526.3 million in fiscal 2024, $873.2 million in fiscal 2025, $12.1 million in fiscal 2026, $2.7 million in fiscal 2027, and $3,252.6 million thereafter.
Interest paid on the above indebtedness during the fiscal years ended September 30, 2022, 2021, and 2020 was $219.8 million, $170.9 million, and $150.7 million, respectively.
Total amortization of financing fees and the accretion of original issue discounts, which are recorded as components of Interest Expense, Net on the Consolidated Statements of Operations, were $11.9 million, $9.7 million, and $6.4 million, for the fiscal years ended September 30, 2022, 2021, and 2020, respectively.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity and Weighted Average Common Shares Outstanding
 12 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Stockholders' Equity and Weighted Average Common Shares Outstanding Stockholders' Equity and Weighted Average Common Shares Outstanding
The authorized capital stock of the Company consists of 600,000,000 shares of common stock, par value $0.01 per share (the "common stock"), and 10,000,000 shares of preferred stock, par value $0.01 per share (the "preferred stock").
The holders of the Company's common stock are entitled to one vote per share and have the exclusive right to vote for the board of directors and for all other purposes as provided by law. Subject to the rights of holders of the Company's preferred stock, holders of common stock are entitled to receive ratably on a per share basis such dividends and other distributions in cash, stock, or property of the Company as may be declared by the board of directors from time to time out of the legally available assets or funds of the Company. The opioid litigation accrual discussed in Note 13 has not and is not expected to impact the Company's ability to pay dividends.
The following illustrates the components of Accumulated Other Comprehensive Loss, net of income taxes:
 September 30,
(in thousands)20222021
Pension and postretirement adjustments$(9,038)$(5,750)
Foreign currency translation(1,820,292)(439,692)
Other(1,640)— 
Total accumulated other comprehensive loss$(1,830,970)$(445,442)
The increase in total accumulated other comprehensive loss from foreign currency translation primarily relates to the translation of the Company's Alliance Healthcare business' goodwill and intangible assets balances.
In October 2018, the Company's board of directors authorized a share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2019, the Company purchased 6.7 million shares of its common stock for a total of $538.9 million under this program, which included $14.8 million of September 2019 purchases that cash settled in October 2019. During the fiscal year ended September 30, 2020, the Company purchased 4.9 million shares of its common stock for a total of $405.6 million, which excluded $14.8 million of September 2019 purchases that cash settled in October 2019. During the fiscal year ended September 30, 2021, the Company purchased 0.6 million shares of its common stock for a total of $55.5 million to complete its authorization under this program.
In May 2020, the Company's board of directors authorized a share repurchase program allowing the Company to purchase up to $500 million of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2021, the Company purchased 0.3 million shares of its common stock for $26.6 million. During the fiscal year ended September 30, 2022, the Company purchased 3.3 million shares of its common stock for $473.4 million to complete its authorization under this program.
In May 2022, the Company's board of directors authorized a new share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2022, the Company purchased 0.3 million shares of its common stock for a total of $38.7 million, which included $28.4 million of September 2022 purchases that cash settled in October 2022. As of September 30, 2022, the Company had $961.3 million of availability remaining under this program. In October 2022, under this program, the Company purchased 0.6 million shares of its common stock for $78.8 million. In November 2022, under this program, the Company purchased 3.2 million shares of its common stock from WBA for $500.0 million.
Common Shares Outstanding
Basic earnings per share is computed by dividing net income attributable to AmerisourceBergen Corporation by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed by dividing net income attributable to AmerisourceBergen Corporation by the weighted average number of shares of common stock outstanding, plus the dilutive effect of stock options and restricted stock units during the periods presented.
The following illustrates the components of diluted weighted average shares outstanding:
 Fiscal Year Ended September 30,
(in thousands)202220212020
Weighted average common shares outstanding - basic208,472 205,919 204,783 
Effect of dilutive securities - stock options and restricted stock units
2,738 2,546 — 
Weighted average common shares outstanding - diluted211,210 208,465 204,783 
The potentially dilutive stock options and restricted stock units that were antidilutive were 0.1 million for the fiscal years ended September 30, 2022 and 2021 and 4.2 million
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions
 12 Months Ended
Sep. 30, 2022
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
WBA continues to own more than 10% of the Company's outstanding common stock and is, therefore, considered a related party. The Company operates under various agreements and arrangements with WBA, including a pharmaceutical distribution agreement pursuant to which the Company distributes pharmaceutical products to WBA and an agreement that provides the Company the ability to access favorable economic pricing and generic products through a generic purchasing services arrangement with Walgreens Boots Alliance Development GmbH (both through 2029) as well as a distribution agreement pursuant to which it will supplies branded and generic pharmaceutical products to WBA’s Boots UK Ltd. subsidiary (through 2031).
Revenue from the various agreements and arrangements with WBA was $64.1 billion, $65.5 billion, and $63.1 billion in the fiscal years ended September 30, 2022, 2021, and 2020, respectively. The Company's receivable from WBA, net of incentives, was $7.0 billion as of September 30, 2022 and 2021.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Retirement and Other Benefit Plans
 12 Months Ended
Sep. 30, 2022
Retirement Benefits [Abstract]  
Retirement and Other Benefit Plans Retirement and Other Benefit Plans
The Company sponsors various retirement benefit plans and a deferred compensation plan covering eligible employees.
The Compensation and Succession Planning Committee ("Compensation Committee") of the Company's board of directors has delegated the administration of the Company's retirement and other benefit plans to its Benefits Committee, an internal committee, comprised of senior finance, human resources, and legal executives. The Benefits Committee is responsible for the investment options under the Company's savings plans, as well as performance of the investment advisers and plan administrators.
Retirement Benefit Plans
The Company sponsors the AmerisourceBergen Employee Investment Plan (the "Plan"), which is a defined contribution 401(k) plan covering salaried and certain hourly employees. Eligible participants may contribute to the plan from 1% to 50% of their regular compensation before taxes. The Company contributes $1.00 for each $1.00 invested by the participant up to the first 3% of the participant's salary and $0.50 for each additional $1.00 invested by the participant of up to an additional 2% of salary. An additional discretionary contribution, in an amount not to exceed the limits established by the Internal Revenue Code ("IRC"), may also be made depending upon the Company's performance. Based on the Company's performance in fiscal 2022, 2021, and 2020, the Company recognized expenses for discretionary contributions to the Plan in the fiscal years ended September 30, 2022, 2021, and 2020. All contributions are invested at the direction of the employee in one or more funds. All contributions vest immediately except for the discretionary contributions made by the Company, which vest in full after five years of credited service.
The Company's international businesses sponsor various country-specific retirement plans.
Costs of above retirement benefit plans charged to expense for the fiscal years ended September 30, 2022, 2021, and 2020 were $90.1 million, $62.3 million, and $45.9 million, respectively.
The Company also sponsors the AmerisourceBergen Corporation Benefit Restoration Plan. This unfunded plan provides benefits to selected key management, including each of the Company's executive officers. This plan provides eligible participants with an annual amount equal to 4% of the participant's total cash compensation to the extent that his or her compensation exceeds the annual compensation limit established by Section 401(a) (17) of the IRC.
Deferred Compensation Plan
The Company sponsors the AmerisourceBergen Corporation 2001 Deferred Compensation Plan. This unfunded plan allows eligible officers, directors, and key management employees to defer a portion of their annual compensation. The amount deferred may be allocated by the employee among a selection of mutual funds. The Company's liability relating to its deferred compensation plan as of September 30, 2022 and 2021 was $31.7 million and $38.1 million, respectively.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation
 12 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation Share-Based Compensation
The Company's stockholders approved the AmerisourceBergen Corporation 2022 Omnibus Incentive Plan (the "2022 Plan"). As of September 30, 2022, there were 25.4 million shares available to be granted for employee and non-employee director stock restricted stock units, performance stock units, and stock options under the 2022 Plan.
Stock Options
The Company's employee stock option plans provide for the granting of incentive and nonqualified stock options to acquire shares of common stock to employees at a price not less than the fair market value of the common stock on the dates options are granted. Option terms and vesting periods are determined at the date of grant by the Compensation Committee of the board of directors. Employee stock options generally vest ratably, in equal amounts, over a four-year service period and expire in seven years. The Company's non-employee director stock option plans provide for the granting of nonqualified stock options to acquire shares of common stock to non-employee directors at the fair market value of the common stock on the date of the grant. Non-employee director stock options vest ratably, in equal amounts, over a three-year service period and expire in ten years.
The estimated fair value of options granted is expensed on a straight-line basis over the requisite service periods of the awards and are net of estimated forfeitures. The Company estimates the fair values of option grants using a binomial option pricing model. Expected volatilities are based upon the historical volatility of the Company's common stock and other factors, such as implied market volatility. The Company uses historical exercise data, taking into consideration the optionees' ages at grant date, to estimate the terms for which the options are expected to be outstanding. The risk-free rates during the terms of such options are based upon the U.S. Treasury yield curve in effect at the time of grant.
The Company did not grant any stock options to employees in fiscal 2022 and 2021, and it does not expect to grant any stock options in fiscal 2023. The weighted average fair values of the options granted during the fiscal year ended September 30, 2020 was $16.61. The following weighted average assumptions were used to estimate the fair values of options granted:
 2020
Risk-free interest rate1.66%
Expected dividend yield1.86%
Volatility of common stock28.17%
Expected life of the options3.79 years
During the fiscal years ended September 30, 2022, 2021, and 2020, the Company recognized stock option expense of $2.2 million, $4.6 million and $13.0 million, respectively.
A summary of the Company's stock option activity and related information for its option plans for the fiscal year ended September 30, 2022 is presented below:
(in thousands, except exercise price and contractual term)OptionsWeighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Term		Aggregate
Intrinsic
Value
Outstanding as of September 30, 20213,138 $843 years$109,772 
Exercised(1,189)$86  
Forfeited(17)$89  
Outstanding as of September 30, 20221,932 $833 years$100,496 
Exercisable as of September 30, 20221,521 $822 years$81,000 
Expected to vest after September 30, 2022407 $884 years$19,283 
The intrinsic value of stock options exercised during the fiscal years ended September 30, 2022, 2021, and 2020 was $60.3 million, $58.7 million, and $42.6 million, respectively.
A summary of the status of the Company's nonvested options as of September 30, 2022 and changes during the fiscal year ended September 30, 2022 is presented below:
(in thousands, except grant date fair value)OptionsWeighted
Average
Grant Date
Fair Value
Nonvested as of September 30, 20211,046 $17
Vested(617)$16
Forfeited(17)$18
Nonvested as of September 30, 2022412 $18
During the fiscal years ended September 30, 2022, 2021, and 2020, the total fair values of options vested were $10.0 million, $15.5 million, and $21.3 million, respectively. Expected future compensation expense relating to the 0.4 million nonvested options outstanding as of September 30, 2022 is $0.4 million, which will be recognized through November 2023.
Restricted Stock Units
Restricted stock units granted prior to fiscal 2021 vest in full after three years. The majority of the restricted stock units granted beginning in fiscal 2021 and thereafter vest ratably over a three-year period. The estimated fair value of restricted stock units under the Company's restricted stock unit plans is determined by the product of the number of shares granted and the closing grant date market price of the Company's common stock. The estimated fair value of restricted stock units is expensed on a straight-line basis over the requisite service period, net of estimated forfeitures. During the fiscal years ended September 30, 2022, 2021, and 2020, the Company recognized restricted stock unit expense of $71.3 million, $55.8 million, and $39.8 million, respectively.
A summary of the status of the Company's nonvested restricted stock units as of September 30, 2022 and changes during the fiscal year ended September 30, 2022 are presented below:
(in thousands, except grant date fair value)Restricted
Stock Units		Weighted
Average
Grant Date
Fair Value
Nonvested as of September 30, 20211,838 $98
Granted726 $127
Vested(592)$98
Forfeited(166)$106
Nonvested as of September 30, 20221,806 $108
During the fiscal years ended September 30, 2022, 2021, and 2020, the total fair values of restricted stock units vested were $58.1 million, $31.1 million, and $26.4 million, respectively. Expected future compensation expense relating to the 1.8 million restricted stock units outstanding as of September 30, 2022 is $71.2 million, which will be recognized over a weighted average period of 1.1 years.
Performance Stock Units
Performance stock units are granted to certain executive employees under the Plan and represent common stock potentially issuable in the future. Performance stock units vest at the end of a three-year performance period based upon achievement of specific performance goals. Based upon the extent to which the targets are achieved, vested shares may range from 0% to 200% of the target award amount. The fair value of performance stock units is determined by the grant date market price of the Company's common stock. Compensation expense associated with nonvested performance stock units is recognized over the requisite service period and is dependent on the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued. During the fiscal years ended September 30, 2022, 2021, and 2020, the Company recognized performance stock expense of $19.7 million, $38.9 million, and $21.5 million, respectively.
A summary of the status of the Company's nonvested performance stock units as of September 30, 2022 and changes during the fiscal year ended September 30, 2022 is presented below (based upon target award amounts).
(in thousands, except grant date fair value)Performance
Stock
Units		Weighted
Average
Grant Date
Fair Value
Nonvested as of September 30, 2021296 $98
Granted131 $126
Vested(148)$86
Forfeited(2)$117
Nonvested as of September 30, 2022277 $117
Shares that vested over the three-year performance period ended September 30, 2022 were distributed to employees in November 2022.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases
 12 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Leases Leases
The Company has long-term leases for facilities and equipment. In the normal course of business, leases are generally renewed or replaced by other leases. Certain leases include escalation clauses.
The following illustrates the components of lease cost for the periods presented:
Fiscal Year Ended September 30,
(in thousands)202220212020
Operating lease cost$220,935 $161,054 $118,144 
Short-term lease cost11,257 5,901 4,632 
Variable lease cost25,108 14,208 17,814 
Total lease cost$257,300 $181,163 $140,590 
The following summarizes balance sheet information related to operating leases:
September 30,
(in thousands, except for lease term and discount rate)20222021
Right of use assets
Other assets$944,974 $1,067,175 
Lease liabilities
Accrued expenses and other$158,184 $175,352 
Other long-term liabilities864,288 946,155 
Total lease liabilities$1,022,472 $1,121,507 
Weighted-average remaining lease term8.37 years8.75 years
Weighted-average discount rate3.22%2.86%
Other cash flow information related to operating leases is as follows:
Fiscal Year Ended September 30,
(in thousands)202220212020
Cash paid for amounts included in the measurement of lease liabilities
Operating lease cash payments$214,793 $148,385 $115,028 
Right-of-use assets obtained in exchange for lease liabilities
New operating leases$179,214 $770,858 $61,779 
Leases recognized upon adoption of ASC 842
$— $— $526,281 
Future minimum rental payments under noncancellable operating leases were as follows:
Payments Due by Fiscal Year (in thousands)As of
September 30, 2022
2023$192,031 
2024176,635 
2025156,578 
2026136,788 
2027120,302 
Thereafter456,276 
Total future undiscounted lease payments1,238,610 
Less: Future payments for leases that have not yet commenced 1
(19,141)
Less: Imputed interest(196,997)
Total lease liabilities$1,022,472 
1 The Company has certain leases that it has executed of which it does not control the underlying assets; therefore, liabilities and ROU assets related to these leases were not recorded on the Company's Consolidated Balance Sheet as of September 30, 2022.
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisition, Integration, and Restructuring Expenses
 12 Months Ended
Sep. 30, 2022
Restructuring and Related Activities [Abstract]  
Acquisition, Integration, and Restructuring Expenses Acquisition, Integration, and Restructuring Expenses
The following illustrates the expenses incurred by the Company relating to Acquisition, Integration, and Restructuring Expenses for the periods indicated:
Fiscal Year Ended September 30,
 (in thousands)202220212020
Acquisition-related deal and integration$119,561 $116,969 $15,958 
Employee severance12,681 13,705 34,401 
Business transformation efforts27,990 36,255 37,961 
Other restructuring initiatives22,827 32,359 (3,359)
Total$183,059 $199,288 $84,961 
Acquisition-related deal and integration expenses in the fiscal year ended September 30, 2022 primarily related to costs associated with the integration of Alliance Healthcare. Acquisition-related deal and integration expenses in the fiscal year ended September 30, 2021 primarily related to the June 2021 acquisition of Alliance Healthcare.
Employee severance in the fiscal year ended September 30, 2022 included costs primarily related to restructuring activities within certain businesses in the U.S. Healthcare Solutions reportable segment. Employee severance in the fiscal year ended September 30, 2021 included costs primarily related to restructuring activities primarily within one business unit in the International Healthcare Solutions reportable segment. Employee severance in the fiscal year ended September 30, 2020 included costs primarily related to position eliminations resulting from the Company's decision to permanently exit the PharMEDium compounding business.    
Business transformation efforts in the fiscal years ended September 30, 2022, 2021, and 2020 were primarily related to costs associated with reorganizing the Company to further align the organization to its customers' needs. The majority of these costs were related to services provided by third-party consultants, including certain technology initiatives.
Other restructuring initiatives in the fiscal year ended September 30, 2022 and 2021 primarily related to the write down and disposal of assets, respectively, related to the Company's office optimization plan. Other restructuring initiatives in the fiscal year ended September 30, 2020 included a $19.1 million gain on the sale of property.
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Legal Matters and Contingencies
 12 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Legal Matters and Contingencies Legal Matters and Contingencies
In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, stockholder demands, and other disputes, including antitrust, commercial, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.
For those matters for which the Company has not recognized a liability, the Company cannot predict the outcome of their impact on the Company as uncertainty remains with regard to whether such matters will proceed to trial, whether settlements will be reached, and the amount and terms of any such settlements. Outcomes may include settlements in significant amounts that are not currently estimable, limitations on the Company’s conduct, the imposition of corporate integrity agreement obligations, consent decrees, and/or other civil and criminal penalties. From time to time, the Company is also involved in disputes with its customers, which the Company generally seeks to resolve through commercial negotiations. If negotiations are unsuccessful, the parties may litigate the dispute or otherwise attempt to settle the matter.
With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company’s results of operations or cash flows for that period or on the Company's financial condition.
Opioid Lawsuits and Investigations
A significant number of counties, municipalities, and other governmental entities in a majority of U.S. states and Puerto Rico, as well as numerous states and tribes, filed lawsuits in various federal, state and other courts against pharmaceutical wholesale distributors (including the Company and certain subsidiaries, such as AmerisourceBergen Drug Corporation (“ABDC”) and H.D. Smith), pharmaceutical manufacturers, retail pharmacy chains, medical practices, and physicians relating to the distribution of prescription opioid pain medications.
An initial group of cases was consolidated for Multidistrict Litigation (“MDL”) proceedings before the United States District Court for the Northern District of Ohio (the “Court”) in December 2017. In April 2018, the Court issued an order creating a litigation track, which included dispositive motion practice, discovery, and trials in certain bellwether jurisdictions. In November 2019 and January 2020, the Court filed Suggestions of Remand with the Judicial Panel on Multidistrict Litigation that identified four cases filed against the Company for potential transfer from the MDL back to federal courts in California, Oklahoma, and West Virginia for the completion of discovery, motion practice, and trial. All four cases were remanded to those federal district courts. Trial in the two consolidated cases in West Virginia commenced in May 2021 and concluded in July 2021. On July 4, 2022, the court entered judgment in favor of the defendants, including the Company. The plaintiffs filed an appeal of the court’s decision on August 2, 2022. The Oklahoma case, in which the plaintiff was the Cherokee Nation, was resolved through a settlement with the Cherokee Nation, as announced on September 28, 2021. The California case, in which the plaintiff was the City and County of San Francisco, was resolved pursuant to the comprehensive settlement described below, and all claims against the Company have been dismissed in both cases.
On July 21, 2021, the Company announced that it and the two other national pharmaceutical distributors had negotiated a comprehensive settlement agreement that, if all conditions were satisfied, would result in the resolution of a substantial majority of opioid lawsuits filed by state and local governmental entities. The comprehensive settlement agreement became effective on April 2, 2022 and as of September 30, 2022, it included 48 of 49 eligible states (the “Settling States”) as well as 99% by population of the eligible political subdivisions in the Settling States. Pursuant to the comprehensive settlement agreement and related agreements with Settling States, the Company will pay up to approximately $6.4 billion over 18 years and comply with other requirements, including establishment of a clearinghouse that will consolidate data from all three national distributors. The exact payment amount will depend on several factors, including the extent to which states take action to foreclose opioid lawsuits by subdivisions (e.g., laws barring opioid lawsuits by subdivisions). West Virginia and its
subdivisions and Native American tribes are not a part of the comprehensive settlement agreement and the Company has reached separate agreements with these groups.
On July 22, 2022, the State of Alabama sought and was subsequently granted leave to amend its complaint in a pending state court action against another distributor in order to add the Company as a party. The amended Complaint was filed on July 25, 2022.
The Company recorded accruals related to opioid litigation of $36.6 million, $147.7 million, and $6.6 billion in the fiscal years ended September 30, 2022, 2021, and 2020 in Litigation and Opioid-Related Expenses in its Consolidated Statements of Operations. The Company’s accrued litigation liability related to the comprehensive settlement, including an estimate for the State of Alabama (with whom the Company has not reached a settlement agreement), as well as other opioid-related litigation for which it has reached settlement agreements, as described above, was $6.0 billion as of September 30, 2022 and $6.7 billion as of September 30, 2021. The Company currently estimates that $528.7 million will be paid prior to September 30, 2023, which is recorded in Accrued Expenses and Other on the Company’s Consolidated Balance Sheet. The remaining long-term liability of $5.5 billion is recorded in Accrued Litigation Liability on the Company’s Consolidated Balance Sheet. While the Company has accrued its estimated liability for opioid litigation, it is unable to estimate the range of possible loss associated with the matters that are not included in the settlement accrual. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. The Company regularly reviews opioid litigation matters to determine whether its accrual is adequate. The amount of ultimate loss may differ materially from the amount accrued to date. Until such time as otherwise resolved, the Company will continue to litigate and prepare for trial and to vigorously defend itself in all such matters. Since these matters are still developing, the Company is unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief that may affect the Company’s operations.
Other lawsuits regarding the distribution of prescription opioid pain medications have been filed by: third-party payors and similar entities; hospitals; hospital groups; and individuals, including cases styled as putative class actions. These lawsuits, which have been and continue to be filed in federal, state, and other courts, generally allege violations of controlled substance laws and various other statutes as well as common law claims, including negligence, public nuisance, and unjust enrichment, and seek equitable relief and monetary damages. Motion practice and active discovery are ongoing in many of these cases. Ongoing and additional litigation is anticipated in cases filed by subdivisions that are not participating in the global settlement agreement, as well as in cases filed by non-governmental or non-political entities, including hospitals, third-party payors, and individuals, among others. Certain cases related to opioids filed in various state courts have trial dates scheduled in January 2023 and later, although all such dates are subject to change. The Company is vigorously defending itself in the pending lawsuits and intends to vigorously defend itself against any threatened lawsuits or enforcement proceedings.
Since July 2017, the Company has received subpoenas from several U.S. Attorney’s Offices, including grand jury subpoenas from the U.S. Attorney’s Office for the District of New Jersey (“USAO-NJ”) and the U.S. Attorney’s Office for the Eastern District of New York (“USAO-EDNY”). Those subpoenas request the production of a broad range of documents pertaining to the Company’s distribution of controlled substances through its various subsidiaries, including ABDC, and its diversion control programs. The Company has produced documents in response to the subpoenas and continues to engage in discussions with the various U.S. Attorney’s Offices, including the Health Care and Government Fraud Unit of the Criminal Division of the USAO-NJ, the U.S. Department of Justice Consumer Protection Branch and the U.S. Drug Enforcement Administration, in an attempt to resolve these matters.
Shareholder Securities Litigation
On October 11, 2019, Teamsters Local 443 Health Services & Insurance Plan, St. Paul Electrical Construction Pension Plan, St. Paul Electrical Construction Workers Supplemental Pension Plan (2014 Restatement), Retirement Medical Funding Plan for the St. Paul Electrical Workers, and San Antonio Fire & Police Pension Fund filed a complaint for a purported derivative action in the Delaware Court of Chancery against the Company and certain of its current and former officers and directors (collectively, “Defendants”). The complaint alleges that the Defendants breached their fiduciary duties by failing to oversee the compliance by certain of the Company’s subsidiaries (including the Company’s former subsidiary Medical Initiatives, Inc. (“MII”)) with federal regulations, allegedly resulting in the payment of fines and penalties in connection with the settlements with the USAO-EDNY in fiscal 2017 and 2018 that resolved claims arising from MII’s pre-filled syringe program. In December 2019, Defendants filed a motion to dismiss the complaint. After briefing and oral argument, on August 24, 2020 the Delaware Court of Chancery denied Defendants’ motion to dismiss. On September 24, 2020, the Board of Directors of the Company established a Special Litigation Committee to conduct an investigation concerning the plaintiffs’ allegations, and on November 10, 2020, the Delaware Court of Chancery granted the Special Litigation Committee’s motion to stay the litigation pending its investigation. On September 22, 2021, the Special Litigation Committee filed its report under seal and moved to dismiss the case. The Special Litigation Committee’s motion to dismiss the case is pending.
On July 17, 2020, CCAR Investments, Inc. filed a complaint for a purported derivative action in the United States District Court for the District of Delaware against the Company and certain of its current and former officers and directors (“CCAR Defendants”). The complaint allegedclaims for breach of fiduciary duty, corporate waste and unjust enrichment allegedly arising from the Board's oversight of the Company’s controlled substance diversion control programs and violation of Section 14(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). On August 14, 2020, the CCAR Defendants answered the complaint and filed a motion for judgment on the pleadings. On October 29, 2020 the parties filed a stipulation permitting CCAR Investments, Inc. to file an amended complaint on or before November 20, 2020. On December 4, 2020, the parties filed a stipulation tolling the deadline for CCAR Investments, Inc. to file an amended complaint pending the Company’s production of certain documents to CCAR Investments, Inc. The Company’s production was completed on January 29, 2021. On May 2, 2022, the Court entered a stipulation that the case will be dismissed without prejudice upon the Company providing notice to stockholders through the filing of a Current Report on Form 8-K and subsequent notification to the Court of such filing. On May 6, 2022, the Company provided notice to stockholders through the filing of a Current Report on Form 8-K that the case would be dismissed and gave notice to the Court of the Form 8-K filing.
On December 30, 2021, Lebanon County Employees’ Retirement Fund and Teamsters Local 443 Health Services & Insurance Plan filed a complaint for a purported derivative action in the Delaware Court of Chancery against the Company and certain of its current officers and directors. The complaint alleges claims for breach of fiduciary duty allegedly arising from the Board’s and certain officers’ oversight of the Company’s controlled substance diversion control programs. The defendants moved to dismiss the complaint on March 29, 2022. The motion is pending.
Subpoenas, Ongoing Investigations, and Other Contingencies
From time to time, the Company receives subpoenas or requests for information from various government agencies relating to the Company’s business or to the business of a customer, supplier, or other industry participant. The Company’s responses often require time and effort and can result in considerable costs being incurred. Most of these matters are resolved without incident; however, such subpoenas or requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the healthcare industry, as well as to substantial settlements.
In January 2017, U.S. Bioservices Corporation (“U.S. Bio”), a former subsidiary of the Company, received a subpoena for information from the USAO-EDNY relating to its activities in connection with billing for products and making returns of potential overpayments to government payers. A filed qui tam complaint related to the investigation was unsealed in April 2019 and the relator filed an amended complaint under seal in the U.S. District Court for the Eastern District of New York. In December 2019, the government filed a notice that it was declining to intervene. The court ordered that the relator’s complaint against the Company and other defendants, including AmerisourceBergen Specialty Group, LLC, be unsealed. The relator’s complaint alleged violations of the federal False Claims Act and the false claims acts of various states. The relator filed a second amended complaint, removing one state false claims act count. The Company filed a motion to dismiss the second amended complaint and all briefing on the motion was filed with the court on October 9, 2020.
In December 2019, Reliable Pharmacy, together with other retail pharmacies and North Sunflower Medical Center, filed a civil antitrust complaint against multiple generic drug manufacturers, and also included claims against ABDC and H.D. Smith (collectively, the “Company” for this matter description), and other drug distributors and industry participants. The case is filed as a putative class action and plaintiffs purport to represent a class of drug purchasers including other retail pharmacies and healthcare providers. The case has been consolidated for multidistrict litigation proceedings before the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that the Company and others in the industry participated in a conspiracy to fix prices, allocate markets and rig bids regarding generic drugs. In March 2020, the plaintiffs filed a further amended complaint. On July 15, 2020, the Company and other industry participants filed a motion to dismiss the complaint. On May 25, 2022, the Court granted the motion to dismiss without prejudice. On July 1, 2022, the plaintiffs filed an amended complaint, again including claims against the Company and other drug distributors and industry participants. On August 21, 2022, the Company and other industry participants filed a motion to dismiss the amended complaint.
On March 3, 2022, the United States Attorney’s Office for the Western District of Virginia notified the Company of the existence of a criminal investigation into MWI Veterinary Supply Co., the Company’s animal health subsidiary, in connection with grand jury subpoenas to which MWI previously responded relating to compliance with state and federal regulatory requirements governing wholesale shipments of animal health products to customers in certain states. The Company is cooperating with the investigation.
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Litigation Settlements
 12 Months Ended
Sep. 30, 2022
Litigation Settlement [Abstract]  
Litigation Settlements Litigation Settlements
Antitrust Settlements
Numerous lawsuits have been filed against certain brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. These lawsuits are generally brought as class actions. The Company has not been a named a plaintiff in any of these lawsuits, but has been a member of the direct purchasers’ class (i.e., those purchasers who purchase directly from these pharmaceutical manufacturers). None of the lawsuits has gone to trial, but some have settled in the past with the Company receiving proceeds from the settlement funds. During the fiscal years ended September 30, 2022, 2021, and 2020, the Company recognized gains relating to these lawsuits of $1.8 million, $168.8 million, and $9.1 million, respectively. These gains, which are net of attorney fees and estimated payments due to other parties, were recorded as reductions to cost of goods sold in the Company’s Consolidated Statements of Operations.
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Segment Information
 12 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Business Segment Information Business Segment Information
The Company is organized geographically based upon the products and services it provides to its customers. The Company’s reporting structure is comprised of two reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions. U.S. Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable segment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. International Healthcare Solutions consists of Alliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). Profarma had previously been included in the Pharmaceutical Distribution Services reportable segment. The Company's previously reported segment results have been revised to conform to its realigned reporting structure.
The chief operating decision maker ("CODM") of the Company is the Chairman, President & Chief Executive Officer of the Company, whose function is to allocate resources to, and assess the performance of, the Company's operating segments. The CODM does not review assets by operating segment for the purpose of assessing performance or allocating resources.
The U.S. Healthcare Solutions reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The U.S. Healthcare Solutions reportable segment also provides pharmaceutical distribution (including plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. Additionally, the U.S. Healthcare Solutions reportable segment provides data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The U.S. Healthcare Solutions reportable segment also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of retail and institutional healthcare providers. It also provides a full suite of integrated manufacturer services that ranges from clinical trial support to product post-approval and commercialization support. Additionally, it delivers packaging solutions to institutional and retail healthcare providers. Through its animal health business, the U.S. Healthcare Solutions reportable segment sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. It also offers demand-creating sales force services to manufacturers.
The International Healthcare Solutions reportable segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. The International Healthcare Solutions reportable segment distributes pharmaceuticals, other healthcare products, and related services to healthcare providers, including pharmacies, doctors, health centers and hospitals primarily in Europe. It also is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. In Canada, the business drives innovative partnerships with manufacturers, providers, and pharmacies to improve product access and efficiency throughout the healthcare supply chain.
The following illustrates reportable and operating segment disaggregated revenue as required by ASC 606, "Revenue from Contracts with Customers," for the periods indicated:
 Fiscal Year Ended September 30,
(in thousands)202220212020
U.S. Healthcare Solutions
Human Health$207,284,444 $197,777,128 $182,171,487 
Animal Health4,815,758 4,684,417 4,216,462 
Total U.S. Healthcare Solutions212,100,202 202,461,545 186,387,949 
International Healthcare Solutions
Alliance Healthcare21,890,402 7,373,365 — 
Other Healthcare Solutions4,601,271 4,156,264 3,508,106 
Total International Healthcare Solutions26,491,673 11,529,629 3,508,106 
Intersegment eliminations(4,869)(2,331)(2,129)
Revenue$238,587,006 $213,988,843 $189,893,926 
The following illustrates reportable segment operating income information for the periods indicated:
 Fiscal Year Ended September 30,
(in thousands)202220212020
U.S. Healthcare Solutions$2,456,972 $2,257,918 $2,020,067 
International Healthcare Solutions706,458 390,286 184,380 
Total segment operating income$3,163,430 $2,648,204 $2,204,447 
The following reconciles total segment operating income to income (loss) before income taxes for the periods indicated:
 Fiscal Year Ended September 30,
(in thousands)202220212020
Total segment operating income$3,163,430 $2,648,204 $2,204,447 
Gains from antitrust litigation settlements1,835 168,794 9,076 
LIFO (expense) credit(67,171)203,028 (7,422)
Turkey highly inflationary impact(40,033)— — 
Acquisition-related intangibles amortization(304,551)(176,221)(110,478)
Litigation and opioid-related expenses(123,191)(272,623)(6,722,346)
Acquisition, integration, and restructuring expenses(183,059)(199,288)(84,961)
Goodwill impairment(75,936)(6,373)— 
Impairment of assets(4,946)(11,324)(361,652)
PharMEDium remediation costs— — (16,165)
PharMEDium shutdown costs— — (43,206)
New York State Opioid Stewardship Act— — (14,800)
Contingent consideration adjustment— — 12,153 
Operating income (loss)2,366,378 2,354,197 (5,135,354)
Other income(27,352)(41,736)(1,581)
Interest expense, net210,673 174,074 137,883 
Loss on early retirement of debt— — 22,175 
Income (loss) before income taxes$2,183,057 $2,221,859 $(5,293,831)
Segment operating income is evaluated by the CODM of the Company and excludes gains from antitrust litigation settlements; LIFO (expense) credit; Turkey highly inflationary impact; acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses; goodwill impairment; impairment of assets;
PharMEDium remediation costs; PharMEDium shutdown costs; New York State Opioid Stewardship Act; and contingent consideration adjustment. All corporate office expenses are allocated to the operating segment level.
    The Company recognized a net gain of $56.2 million from sale of non-core businesses, an expense related to the impact of Turkey highly inflationary accounting of $11.9 million, a foreign currency loss of $14.4 million on the remeasurement of deferred tax assets relating to Swiss tax reform, and a $4.8 million gain on the remeasurement of an equity investment in Other Income in the Consolidated Statements of Operations in the fiscal year ended September 30, 2022. The Company recorded a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable related to a start-up venture, and a foreign currency loss of $3.4 million on the remeasurement of deferred tax assets relating to Swiss tax reform in Other Income in the Consolidated Statements of Operations in the fiscal year ended September 30, 2021.
    The following illustrates depreciation and amortization by reportable segment for the periods indicated:
Fiscal Year Ended September 30,
(in thousands)202220212020
U.S. Healthcare Solutions$274,554 $266,575 $253,687 
International Healthcare Solutions114,790 62,376 26,897 
Acquisition-related intangibles amortization304,551 176,221 110,478 
Total depreciation and amortization$693,895 $505,172 $391,062 
                
Depreciation and amortization includes depreciation and amortization of property and equipment and intangible assets, but excludes amortization of deferred financing costs and other debt-related items, which are included in interest expense, net.
The following illustrates capital expenditures by reportable segment for the periods indicated:
Fiscal Year Ended September 30,
(in thousands)202220212020
U.S. Healthcare Solutions$295,406 $310,525 $316,249 
International Healthcare Solutions200,912 127,692 53,428 
Total capital expenditures$496,318 $438,217 $369,677 
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value of Financial Instruments
 12 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments Fair Value of Financial Instruments
The recorded amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable as of September 30, 2022 and 2021 approximate fair value based upon the relatively short-term nature of these financial instruments. Within Cash and Cash Equivalents, the Company had $1,602.0 million and $671.0 million of investments in money market accounts as of September 30, 2022 and 2021, respectively. The fair value of the money market accounts was determined based upon unadjusted quoted prices in active markets for identical assets, otherwise known as Level 1 inputs.
The recorded amount of long-term debt (see Note 6) and the corresponding fair value as of September 30, 2022 were $4,632.4 million and $4,130.3 million, respectively. The recorded amount of long-term debt and the corresponding fair value as of September 30, 2021 were $6,383.8 million and $6,761.6 million, respectively. The fair value of long-term debt was determined based upon inputs other than quoted prices, otherwise known as Level 2 inputs.
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subsequent Events
 12 Months Ended
Sep. 30, 2022
Subsequent Events [Abstract]  
Subsequent Events Subsequent EventIn November 2022, the Company's board of directors increased the quarterly dividend paid on common stock by 5% and declared a regular quarterly cash dividend of $0.485 per share, payable on November 28, 2022 to shareholders of record on November 14, 2022.
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS
 12 Months Ended
Sep. 30, 2022
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS
SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS
(In thousands)Balance at
Beginning
of Period		Charged to
Costs and
Expenses (1)		Deductions (2)Balance at
End of
Period
Year Ended September 30, 2022    
Allowances for returns and credit losses$1,356,684 $5,124,081 $(4,854,036)$1,626,729 
Year Ended September 30, 2021    
Allowances for returns and credit losses$1,417,308 $3,906,776 $(3,967,400)$1,356,684 
Year Ended September 30, 2020    
Allowances for returns and credit losses$1,223,887 $4,019,830 $(3,826,409)$1,417,308 
__________________________________________________________

(1)Represents the provision for returns and credit losses.
(2)Represents reductions to the returns allowance and accounts receivable written off during year, net of recoveries.
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying financial statements present the consolidated financial position, results of operations, and cash flows of the Company as of the dates and for the periods indicated. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts due to uncertainties inherent in such estimates. Management periodically evaluates estimates used in the preparation of the financial statements for continued reasonableness
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted
Recently Adopted Accounting Pronouncements
In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectibility of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. ASU 2016-13 was effective for annual reporting periods beginning after December 15, 2019, including interim periods within those fiscal years, and a modified retrospective approach was required, with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance was effective.
The Company adopted ASU 2016-13 as of October 1, 2020. In connection with the adoption of ASU 2016-13, the Company recognized a $21.1 million, net of tax of $6.1 million, cumulative adjustment to retained earnings.
For the Company's credit loss policy, refer to the "Concentrations of Credit Risk and Allowance for Credit Losses" section of Note 1.
In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes" ("ASU 2019-12"). ASU 2019-12 removes certain exceptions to the general principles in Accounting Standards Codification ("ASC") 740 in order to reduce the cost and complexity of its application. ASU 2019-12 was effective for annual reporting periods beginning after December 15, 2020, including interim periods within those fiscal years, with certain amendments applied on a modified retrospective basis, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption, and others prospectively.
The Company adopted ASU No. 2019-12 as of October 1, 2021. The adoption of ASU No. 2019-12 had no impact on the Company's financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted
As of September 30, 2022, there were no recently issued accounting standards that may have a material impact on the Company's financial position, results of operations, or cash flows upon their adoption.
Business Combinations
Business Combinations
The assets acquired and liabilities assumed from an acquired business are recorded at fair value, with the residual of the purchase price recorded as goodwill. The results of operations of an acquired businesses are included in the Company's operating results from the date of acquisition.
Cash, Cash Equivalents, and Restricted Cash
Cash, Cash Equivalents, and Restricted Cash
The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value.
The Company is required to maintain certain cash deposits with banks mainly consisting of deposits restricted under contractual agency agreements and cash restricted by law and other obligations, including opioid-related legal settlements.
Concentrations of Credit Risk and Allowance for Credit Losses
Concentrations of Credit Risk and Allowance for Credit Losses
    The Company sells its inventories to a large number of customers in the healthcare industry that include institutional and retail healthcare providers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies and providers of pharmacy services to such facilities, and physician offices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies, pharmacy departments of supermarkets and mass merchandisers, and veterinarians. The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry.
The Company's trade accounts receivables are exposed to credit risk. Revenue from the various agreements and arrangements with the Company's largest customer in the fiscal year ended September 30, 2022, Walgreens Boots Alliance, Inc. ("WBA"), accounted for approximately 27% of revenue and represented approximately 38% of accounts receivable, net of incentives, as of September 30, 2022. Express Scripts, Inc., the Company's second largest customer in the fiscal year ended September 30, 2022, accounted for approximately 13% of revenue and represented approximately 7% of accounts receivable as of September 30, 2022. The Company generally does not require collateral for trade receivables. The Company evaluates its receivables for risk of loss by grouping its receivables with similar risk characteristics. Expected losses are determined based on a combination of historical loss trends, current economic conditions, and forward-looking risk factors. Changes in these factors, among others, may lead to adjustments in the Company's allowance for credit losses. The calculation of the required allowance requires judgment by Company management as to the impact of those and other factors on the ultimate realization of its trade receivables. Each of the Company's business units performs ongoing credit evaluations of its customers' financial condition and maintains reserves for expected credit losses for specific credit problems when they arise. There were no significant changes to this process during the fiscal years ended September 30, 2022, 2021, and 2020, and bad debt expense was computed in a consistent manner during these periods.
The Company maintains cash, cash equivalents, and restricted cash with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and, therefore, bear minimal credit risk. The Company seeks to mitigate such risks by monitoring the risk profiles of these counterparties. The Company also seeks to mitigate risk by monitoring the investment strategy of money market accounts in which it is invested, which are classified as cash equivalents.
Contingencies
Contingencies
Loss Contingencies: In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, stockholder demands, and other disputes, including antitrust, commercial, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a liability when it is both probable that a loss has been incurred and the amount can be reasonably estimated. The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued. If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, the Company provides disclosure of the loss contingency in the notes to its financial statements. The Company reviews all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made. Among the loss contingencies that the Company considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 13.
Gain Contingencies: The Company records gain contingencies when they are realized. Gains from antitrust litigation settlements are realized upon the receipt of cash and recorded as a reduction to cost of goods sold because they represent a recovery of amounts historically paid to manufacturers to originally acquire the pharmaceuticals that were the subject of the antitrust litigation settlements (see Note 14).
Derivative Financial Instruments
Derivative Financial Instruments
The Company utilizes derivative financial instruments to manage exposures to foreign currency. The Company records all derivative financial instruments on the balance sheet at fair value and complies with established criteria for designation and effectiveness of hedging relationships. The Company's policy prohibits it from entering into derivative financial instruments for speculative or trading purposes.
Foreign Currency
Foreign Currency
When the functional currency of the Company's foreign operations is the applicable local currency, assets and liabilities are translated into U.S. dollars using the current exchange rates in effect at the balance sheet date, while revenues and expenses are translated at the weighted average exchange rates for the period. The resulting asset and liability translation adjustments are recorded as a component of Accumulated Other Comprehensive Loss within Stockholders' Equity.
During the quarter ended March 31, 2022, Turkey became a highly inflationary economy, as defined under U.S. GAAP. As a result, effective April 1, 2022, and until such time as the applicable economy is no longer considered highly inflationary, Turkish Lira-denominated assets and liabilities are remeasured using the Company's reporting currency in accordance with ASC 830, "Foreign Currency Matters." Turkish Lira denominated monetary assets and liabilities (primarily cash, accounts receivables, and accounts payables) are remeasured at each balance sheet date using the currency exchange rate then in effect, with currency remeasurement gains and losses recognized in Other Income in the Statement of Operations. Turkish Lira-denominated nonmonetary assets and liabilities (primarily inventories, goodwill, and other intangible assets) are translated at the currency exchange rate in effect prior to highly inflation accounting commencement or at the exchange rate in effect at their date of acquisition if subsequent to April 1, 2022. As such, nonmonetary assets and liabilities retain a higher historical basis when currencies are devalued. This higher historical basis results in incremental expense being recognized when nonmonetary assets are consumed (i.e., sale of inventory). During the fiscal year ended September 30, 2022, the Company recorded an incremental expense of $40.0 million in Cost of Goods Sold related to the consumption of inventory and an expense of $11.9 million within Other Income related to the currency remeasurement of monetary assets and liabilities.
Goodwill and Other Intangible Assets
Goodwill and Other Intangible Assets
Goodwill arises from acquisitions or consolidations of specific operating companies and is assigned to the reporting unit in which a particular operating company resides. The Company identifies its reporting units based upon the Company's management reporting structure, beginning with its operating segments. The Company aggregates two or more components within an operating segment that have similar economic characteristics. The Company evaluates whether the components within its operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment. The Company announced a strategic reorganization of its business and began reporting externally under the new structure as of October 1, 2021. As of September 30, 2022, the Company’s reporting units include Pharmaceutical Distribution Services, U.S. Consulting Services, MWI, Alliance Healthcare, Innomar, World Courier, and Profarma.
Goodwill and other intangible assets with indefinite lives, such as certain trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. For the purpose of these impairment tests, the Company can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite-lived intangible assets, respectively. Such qualitative factors can include, among others, industry and market conditions, overall financial performance, and relevant entity-specific events. If the Company concludes based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis. The Company elected to perform a quantitative impairment assessment of goodwill and indefinite-lived intangible assets in fiscal 2022. The Company elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in fiscal 2021, with the exception of its testing of goodwill in the AmerisourceBergen Consulting Services (the sum of U.S. Consulting Service and Innomar reporting units, under the Company’s prior reporting structure) and Profarma reporting units. The Company elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in fiscal 2020, with the exception of its testing of goodwill and indefinite-lived intangibles in the MWI and Profarma reporting units.
The quantitative goodwill impairment test requires the Company to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit. If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized. If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.
When performing a quantitative impairment assessment, the Company utilizes an income-based approach to value its reporting units, with the exception of the Profarma reporting unit, the fair value of which is based upon its publicly-traded stock price, plus an estimated control premium. The income-based approach relies on a discounted cash flow analysis, which considers forecasted cash flows discounted at an appropriate discount rate, to determine the fair value of each reporting unit. The Company generally believes that market participants would use a discounted cash flow analysis to determine the fair value of the Company's reporting units in a sale transaction. The annual goodwill impairment test requires the Company to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon the Company's long-range plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both debt and equity, including a risk premium. While the Company uses the best available information to prepare its forecasted cash flows and discount rate assumptions, actual future cash flows and/or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, the Company's overall methodology and the population of assumptions used have remained unchanged.
The quantitative impairment test for indefinite-lived intangibles other than goodwill (certain trademarks and trade names) consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date. The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method. The Company believes the relief from royalty method is a widely used valuation technique for such assets. The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.
The Company completed its required annual impairment tests relating to goodwill and indefinite-lived intangible assets in the fiscal years ended September 30, 2022, 2021, and 2020. The Company recorded goodwill impairments of $75.9 million and $6.4 million in its Profarma reporting unit in connection with its fiscal 2022 and 2021 impairment tests (see Note 5), respectively. No goodwill impairments were recorded in the fiscal years ended September 30, 2020, and no indefinite-lived intangible asset impairments were recorded in the fiscal years ended September 30, 2022, 2021, or 2020.
Finite-lived intangible assets are amortized using the straight-line method over the estimated useful lives of the assets. The Company performs a recoverability assessment of its long-lived assets when impairment indicators are present.
The Company recorded impairments of intangible and tangible assets totaling $361.7 million in the fiscal year ended September 30, 2020 in connection with the permanent shutdown of its compounding business.
Held for Sale Held for SaleAssets and liabilities to be disposed of by sale ("disposal groups") are reclassified into assets and liabilities held for sale on the Company's Consolidated Balance Sheet. The reclassification occurs when an agreement to sell exists, or management has committed to a plan to sell the assets within one year. Disposal groups are measured at the lower of carrying value or fair value less costs to sell and are not depreciated or amortized. When the net realizable value of a disposal group increases during a period, a gain can be recognized to the extent that it does not increase the value of the disposal group beyond its original carrying value when the disposal group was reclassified as held for sale. The fair value of a disposal group, less any costs to sell, is assessed each reporting period it remains classified as held for sale and any remeasurement to the lower of carrying value or fair value less costs to sell is reported as an adjustment to the carrying value of the disposal group.
Income Taxes
Income Taxes
The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities (commonly known as the asset and liability method). In assessing the need to establish a valuation allowance on deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.
The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including settlements with tax authorities or resolutions of any related appeals or litigation processes, based upon the technical merits of the position. Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based upon the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination.
Inventories
Inventories
Inventories are stated at the lower of cost or market. Cost for approximately 66% of the Company's inventories as of September 30, 2022 and 2021 has been determined using the last-in, first-out ("LIFO") method. If the Company had used the first-in, first-out method of inventory valuation, which approximates current replacement cost, inventories would have been approximately $1,383.4 million and $1,316.2 million higher than the amounts reported as of September 30, 2022 and 2021, respectively. The Company recorded LIFO expense of $67.2 million and $7.4 million in the fiscal years ended September 30, 2022 and 2020, respectively, and a LIFO credit of $203.0 million in the fiscal year ended September 30, 2021. The annual LIFO provision is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict. Changes to any of the above factors can have a material impact to the Company's annual LIFO provision.
Investments
Investments
The Company first evaluates its investments in accordance with the variable interest model to determine whether it has a controlling financial interest in an investment. This evaluation is made as of the date on which the Company makes its initial investment, and subsequent evaluations are made if the structure of the investment changes. If it has determined that an investment is a variable interest entity ("VIE"), the Company evaluates whether the VIE is required to be consolidated. When the Company holds rights that give it the power to direct the activities of an entity that most significantly impact the entity's economic performance, combined with the obligation to absorb an entity's losses and the right to receive benefits, the Company consolidates a VIE. If it is determined that an investment is not a VIE, the Company then evaluates its investments under the voting interest model and generally consolidates investments in which it holds an ownership interest of greater than 50%. When the Company consolidates less-than-wholly-owned subsidiaries, it presents its noncontrolling interest in its consolidated financial statements.
Equity Securities For equity securities without a readily determinable fair value, the Company uses the fair value measurement alternative and measures the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which the Company can exercise significant influence but does not control, it uses the equity method of accounting. The Company's share of earnings and losses of its investments is recorded in Other Income in the Consolidated Statements of Operations. The Company monitors its investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions.
Leases
Leases
At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the facts and circumstances present. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. At the lease commencement date, operating and finance lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable and, as such, the Company uses its incremental borrowing rate to discount the lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term in a similar economic environment. Certain adjustments to the right-of-use ("ROU") asset may be required for items such as incentives received. The Company does not recognize on the balance sheet leases with terms of one year or less.
    The Company has operating leases that are primarily comprised of buildings, office equipment, distribution center equipment, and vehicles. Some of the Company's leases include options to extend or early terminate the lease, which are included in the lease term when it is reasonably certain to exercise and there is a significant economic incentive to exercise that option. Certain lease agreements contain provisions for future rent increases. Lease payments included in the measurement of the lease liability comprise fixed payments. The Company combines lease and non-lease components as a single component. Operating lease cost is recognized over the expected lease term on a straight-line basis and is recorded in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations. Variable lease payments, which are primarily comprised of maintenance, taxes, and other payments based on usage, are recognized when the expense is incurred. The Company's leases do not contain residual value guarantees.
Manufacturer Incentives
Manufacturer Incentives
The Company considers fees and other incentives received from its suppliers relating to the purchase and distribution of inventory to represent product discounts, and, as a result, they are recognized within cost of goods sold upon the sale of the related inventory.
Property and Equipment
Property and Equipment
Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 40 years for buildings and improvements and from 3 to 10 years for machinery, equipment, and other. The costs of repairs and maintenance are charged to expense as incurred.
The Company capitalizes project costs relating to computer software developed or obtained for internal use when the activities related to the project reach the application development stage. Costs that are associated with preliminary stage activities, training, maintenance, and all other post-implementation stage activities are expensed as they are incurred. Software development costs are depreciated using the straight-line method over the estimated useful lives, which range from 3 to 10 years.
Revenue Recognition
Revenue Recognition
The Company's revenues are primarily generated from the distribution of pharmaceutical products. The Company also generates revenues from global commercialization services, which include clinical trial support, post-approval and commercialization support, and global specialty transportation and logistics for the biopharmaceutical industry. See Note 15 for the Company's disaggregated revenue.
The Company recognizes revenue related to the distribution of products at a point in time when title and control transfers to customers and there is no further obligation to provide services related to such products. Service revenue is recognized over the period that services are provided to the customer. The Company is generally the principal in a transaction;
therefore, revenue is primarily recorded on a gross basis. When the Company is the principal in a transaction, it has determined that it controls the ability to direct the use of the product or service prior to the transfer to a customer, it is primarily responsible for fulfilling the promise to provide the product or service to its customer, it has discretion in establishing pricing, and it controls the relationship with the customer. Revenue is recognized at the amount of consideration expected to be received. For the distribution business, revenue is primarily generated from a contract related to a confirmed purchase order with a customer in a distribution arrangement and is net of estimated sales returns and allowances, other customer incentives, and sales tax.
When the Company is the agent in a transaction, the fee received from a manufacturer customer is recognized within revenue as the service is performed.
The Company's customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit. The Company records an accrual for estimated customer sales returns at the time of sale to the customer based upon historical return trends. As of September 30, 2022 and 2021, the Company's accrual for estimated customer sales returns was $1,532.1 million and $1,271.6 million, respectively.
Share-Based Compensation
Share-Based Compensation
    The Company accounts for the compensation cost of all share-based payments at fair value. The fair value of restricted stock units and performance stock units is based upon the grant date market price of the Company’s common stock. The Company estimated the fair value of options granted in fiscal 2020 using a binomial option pricing model.
    Share-based compensation expense is recognized over the requisite service period within Distribution, Selling, and Administrative in the Consolidated Statements of Operations to correspond with the same line item as the cash compensation paid to employees. Compensation expense associated with nonvested performance stock units is dependent upon the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued.
    The income tax effects of awards are recognized when the awards vest or are settled and are recognized in Income Tax Expense in the Company’s Consolidated Statements of Operations.
Shipping and Handling Costs Shipping and Handling CostsShipping and handling costs include all costs to warehouse, pick, pack, and deliver inventory to customers.
Supplier Reserves
Supplier Reserves
The Company establishes reserves against amounts due from its suppliers relating to various price and rebate incentives, including deductions or billings taken against payments otherwise due to them from the Company. These reserve estimates are established based upon the judgment of Company management after carefully considering the status of current outstanding claims, historical experience with the suppliers, the specific incentive programs, and any other pertinent information available to the Company. The Company evaluates the amounts due from its suppliers on a continual basis and adjusts the reserve estimates when appropriate based upon changes in factual circumstances. The ultimate outcome of any outstanding claim may be different than the Company's estimate.
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Schedule of Cash and Cash Equivalents
The following represents a reconciliation of cash and cash equivalents in the Consolidated Balance Sheets to cash, cash equivalents, and restricted cash in the Consolidated Statements of Cash Flows:
September 30,
(amounts in thousands)202220212020
Cash and cash equivalents$3,388,189 $2,547,142 $4,597,746 
Restricted cash (included in Prepaid Expenses and Other)144,980 462,986 — 
Restricted cash (included in Other Assets)60,370 60,000 — 
Cash, cash equivalents, and restricted cash$3,593,539 $3,070,128 $4,597,746 
Restrictions on Cash and Cash Equivalents
The following represents a reconciliation of cash and cash equivalents in the Consolidated Balance Sheets to cash, cash equivalents, and restricted cash in the Consolidated Statements of Cash Flows:
September 30,
(amounts in thousands)202220212020
Cash and cash equivalents$3,388,189 $2,547,142 $4,597,746 
Restricted cash (included in Prepaid Expenses and Other)144,980 462,986 — 
Restricted cash (included in Other Assets)60,370 60,000 — 
Cash, cash equivalents, and restricted cash$3,593,539 $3,070,128 $4,597,746 
Schedule of Property and Equipment
The following table summarizes the Company's property and equipment balances for the periods indicated:
September 30,
(in thousands)20222021
Property and equipment, at cost:
Land$122,426 $129,944 
Buildings and improvements840,852 838,615 
Machinery, equipment, and other3,424,070 3,113,132 
Total property and equipment4,387,348 4,081,691 
Less accumulated depreciation(2,252,345)(1,918,730)
Property and equipment, net$2,135,003 $2,162,961 
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisition and Assets and Liabilities Held for Sale (Tables)
 12 Months Ended
Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Schedule of Assets Acquired and Liabilities Assumed The Company completed the purchase price allocation as of June 1, 2022 and recorded purchase accounting adjustments that reduced working capital account balances by $102.7 million, increased the corresponding deferred tax assets by $63.0 million, and decreased other assets by $13.3 million, which resulted in a $53.0 million increase to Goodwill. There were no measurement period adjustments recorded to the previously-reported opening balance sheet that would have had a material impact on the Company's previously-reported results of operations had those adjustments been recorded in the previous reporting periods. The final purchase price has been allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values at the date of the acquisition in the table that follows:
(in thousands)
Consideration
Cash$6,662,020 
Equity (2 million shares of AmerisourceBergen Corporation common stock)
229,080 
Other equity consideration6,061 
Fair value of total consideration$6,897,161 
Recognized amounts of identifiable assets acquired and liabilities assumed
Cash and cash equivalents$921,995 
Accounts receivable3,628,056 
Inventories1,647,330 
Prepaid expenses and other355,030 
Property and equipment634,220 
Goodwill2,496,338 
Other intangible assets3,735,000 
Deferred income taxes33,922 
Other assets534,393 
Total assets acquired13,986,284 
Accounts payable(4,618,807)
Accrued expenses and other(765,463)
Short-term debt(353,420)
Deferred income taxes(760,937)
Other liabilities(405,332)
Total liabilities assumed(6,903,959)
Net assets acquired7,082,325 
Noncontrolling interest(185,164)
Equity consideration(235,141)
Cash acquired, including restricted cash of $143,308 included in Prepaid Expenses and Other
(1,065,303)
Net cash paid$5,596,717 
Schedule of Fair Value of the Intangible Assets Acquired
The estimated fair value of the intangible assets acquired of $3.7 billion and the estimated useful lives are as follows:
(in thousands, except useful lives)Fair ValueWeighted-Average Useful Life
Customer relationships$3,327,000 18
Trade names408,000 11
Total$3,735,000 
Schedule of Assets and Liabilities Held for Sale
Total assets and liabilities of the combined disposal groups held for sale on the September 30, 2021 Consolidated Balance Sheet are comprised of the following:
(in thousands)
Cash and cash equivalents$1,751 
Accounts receivable, less allowance for credit losses182,077 
Inventories123,424 
Prepaid expenses and other11,258 
Property and equipment3,084 
Goodwill31,903 
Other intangible assets22,923 
Other assets7,812 
Loss on the remeasurement of a disposal group held for sale to fair value less cost to sell(11,324)
    Total assets held for sale$372,908 
Accounts payable$173,104 
Accrued expenses and other7,234 
Short-term debt4,225 
Long-term debt50 
Deferred income taxes5,857 
Other liabilities1,599 
    Total liabilities held for sale$192,069 
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Variable Interest Entity (Tables)
 12 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Assets and Liabilities of Profarma
The following assets and liabilities of Profarma are included in the Company's Consolidated Balance Sheet for the periods indicated:
(in thousands)September 30,
2022		September 30,
2021
Cash and cash equivalents$23,144 $33,699 
Accounts receivables, net192,930 148,485 
Inventories207,858 168,229 
Prepaid expenses and other63,982 62,545 
Property and equipment, net35,554 31,920 
Goodwill— 75,936 
Other intangible assets66,568 70,840 
Other long-term assets71,327 74,177 
Total assets$661,363 $665,831 
Accounts payable$215,515 $162,768 
Accrued expenses and other47,952 38,477 
Short-term debt60,851 64,215 
Long-term debt64,918 52,613 
Deferred income taxes25,801 37,041 
Other long-term liabilities52,417 57,945 
Total liabilities$467,454 $413,059 
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes (Tables)
 12 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Schedule of Domestic and Foreign Income from Continuing Operations before Income Taxes
The following table summarizes the Company's income (loss) before income taxes for the periods indicated:
 Fiscal Year Ended September 30,
(in thousands)202220212020
Domestic$1,351,696 $1,495,899 $(5,961,269)
Foreign831,361 725,960 667,438 
Total$2,183,057 $2,221,859 $(5,293,831)
Schedule of Income Tax Expense (Benefit)
The components of the Company's consolidated income tax expense (benefit) are summarized in the following table for the periods indicated:
 Fiscal Year Ended September 30,
(in thousands)202220212020
Current provision (benefit):   
Federal$126,969 $184,375 $(473,751)
State and local39,282 30,659 30,236 
Foreign154,082 127,351 94,213 
Total current provision (benefit)320,333 342,385 (349,302)
Deferred provision (benefit):   
Federal150,328 111,428 (914,613)
State and local31,129 47,516 (264,409)
Foreign14,727 175,922 (365,949)
Total deferred provision (benefit)196,184 334,866 (1,544,971)
Provision (benefit) for income taxes$516,517 $677,251 $(1,894,273)
Schedule of Reconciliation of Effective Income Tax Rate
A reconciliation of the statutory U.S. federal income tax rate to the Company's consolidated effective income tax rate is as follows for the periods indicated:
 Fiscal Year Ended September 30,
 202220212020
Statutory U.S. federal income tax rate21.0%21.0%21.0%
State and local income tax rate, net of federal tax benefit2.52.8(0.5)
Tax effect of foreign operations(1.9)(0.5)1.0
Litigation settlements and accruals (see Note 13)
0.40.8(6.2)
Tax law changes 1
—7.36.8
PharMEDium worthless stock deduction—(1.1)12.4
CARES Act——1.2
Other, net1.70.20.1
Effective income tax rate23.7%30.5%35.8%
1 Tax law changes include 5.7% related to UK Tax Reform and 1.6% related to Swiss Tax Reform in fiscal 2021 and 6.8% in fiscal 2020 related to Swiss Tax Reform.
Schedule of Significant Components Of Deferred Tax Liabilities (Assets) Significant components of the Company's deferred tax liabilities (assets) are as follows:
 September 30,
(in thousands)20222021
Inventories$1,471,064 $1,388,913 
Property and equipment149,896 167,974 
Goodwill and other intangible assets1,184,477 1,409,296 
Right-of-use assets219,616 249,920 
Other61,148 57,450 
Gross deferred tax liabilities3,086,201 3,273,553 
Net operating loss and tax credit carryforwards(426,651)(389,724)
Allowance for credit losses(67,788)(27,569)
Accrued expenses(24,435)(13,411)
Accrued litigation liability(981,627)(1,082,845)
Employee and retiree benefits(22,682)(26,196)
Goodwill and other intangible assets(446,605)(488,235)
Lease liabilities(241,469)(263,278)
Share-based compensation(33,933)(37,466)
Other(75,428)(88,855)
Gross deferred tax assets(2,320,618)(2,417,579)
Valuation allowance for deferred tax assets617,259 538,531 
Deferred tax assets, net of valuation allowance(1,703,359)(1,879,048)
Net deferred tax liabilities$1,382,842 $1,394,505 
Schedule of Reconciliation Amount Of Unrecognized Tax Benefits, Excluding Interest and Penalties
A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, for the periods indicated is as follows:
Fiscal Year Ended September 30,
(in thousands)202220212020
Unrecognized tax benefits at beginning of period$500,399 $478,351 $105,657 
Additions of tax positions of the current year21,074 20,515 385,797 
Additions to tax positions of the prior years5,073 17,022 5,599 
Reductions of tax positions of the prior years— — (6,480)
Expiration of statutes of limitations(24)(15,489)(12,222)
Unrecognized tax benefits at end of period$526,522 $500,399 $478,351 
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill and Other Intangible Assets (Tables)
 12 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Changes in the Carrying Value of Goodwill September 30, 2022 and 2021:
(in thousands)U.S. Healthcare SolutionsInternational Healthcare SolutionsTotal
Goodwill as of September 30, 2020 (as revised)$6,267,502 $439,217 $6,706,719 
Goodwill recognized in connection with acquisitions (Note 2)19,076 2,469,152 2,488,228 
Goodwill impairment— (6,373)(6,373)
Goodwill reclassified to assets held for sale (Note 2)(27,223)(4,680)(31,903)
Foreign currency translation1,019 (127,159)(126,140)
Goodwill as of September 30, 2021 (as revised)6,260,374 2,770,157 9,030,531 
Purchase accounting adjustments— 27,186 27,186 
Goodwill recognized in connection with acquisition26,143 — 26,143 
Goodwill derecognized in connection with disposal(1,224)— (1,224)
Goodwill impairment— (75,936)(75,936)
Foreign currency translation(5,053)(497,761)(502,814)
Goodwill as of September 30, 2022$6,280,240 $2,223,646 $8,503,886 
Schedule of Other Intangible Assets - Indefinite-lived
The following is a summary of other intangible assets:
 September 30, 2022September 30, 2021
(dollars in thousands)Weighted Average Remaining Useful LifeGross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount		Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount
Indefinite-lived trade names$667,932 $— $667,932 $668,119 $— $668,119 
Finite-lived:
Customer relationships15 years4,226,547 (931,961)3,294,586 4,838,549 (718,750)4,119,799 
Trade names and other11 years542,346 (172,127)370,219 609,050 (140,041)469,009 
Total other intangible assets$5,436,825 $(1,104,088)$4,332,737 $6,115,718 $(858,791)$5,256,927 
Schedule of Other Intangible Assets - Finite-lived
The following is a summary of other intangible assets:
 September 30, 2022September 30, 2021
(dollars in thousands)Weighted Average Remaining Useful LifeGross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount		Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount
Indefinite-lived trade names$667,932 $— $667,932 $668,119 $— $668,119 
Finite-lived:
Customer relationships15 years4,226,547 (931,961)3,294,586 4,838,549 (718,750)4,119,799 
Trade names and other11 years542,346 (172,127)370,219 609,050 (140,041)469,009 
Total other intangible assets$5,436,825 $(1,104,088)$4,332,737 $6,115,718 $(858,791)$5,256,927 
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt (Tables)
 12 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Schedule of Debt Instruments
Debt consisted of the following:
 September 30,
(in thousands)20222021
Revolving credit note$— $— 
Money market facility— — 
Receivables securitization facility due 2025350,000 350,000 
Term loan due June 2023— 249,640 
Overdraft facility due 2024 (£10,000)
— — 
Multi-currency revolving credit facility due 2027— — 
0.737% senior notes due 2023
672,736 1,518,223 
$500,000, 3.400% senior notes due 2024
499,195 498,714 
$500,000, 3.250% senior notes due 2025
498,347 497,669 
$750,000, 3.450% senior notes due 2027
745,622 744,781 
$500,000, 2.800% senior notes due 2030
495,348 494,738 
$1,000,000, 2.700% senior notes due 2031
990,480 989,366 
$500,000, 4.250% senior notes due 2045
495,162 494,946 
$500,000, 4.300% senior notes due 2047
493,288 493,021 
Alliance Healthcare debt336,886 235,998 
Nonrecourse debt125,769 116,828 
Total debt5,702,833 6,683,924 
Less AmerisourceBergen Corporation current portion672,736 — 
Less Alliance Healthcare current portion336,886 235,998 
Less nonrecourse current portion60,851 64,215 
Total, net of current portion$4,632,360 $6,383,711 
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity and Weighted Average Common Shares Outstanding (Tables)
 12 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Schedule of Components of Accumulated Other Comprehensive Loss
The following illustrates the components of Accumulated Other Comprehensive Loss, net of income taxes:
 September 30,
(in thousands)20222021
Pension and postretirement adjustments$(9,038)$(5,750)
Foreign currency translation(1,820,292)(439,692)
Other(1,640)— 
Total accumulated other comprehensive loss$(1,830,970)$(445,442)
Schedule of Components of Diluted Weighted Average Shares Outstanding
The following illustrates the components of diluted weighted average shares outstanding:
 Fiscal Year Ended September 30,
(in thousands)202220212020
Weighted average common shares outstanding - basic208,472 205,919 204,783 
Effect of dilutive securities - stock options and restricted stock units
2,738 2,546 — 
Weighted average common shares outstanding - diluted211,210 208,465 204,783 
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation (Tables)
 12 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Weighted Average Assumptions The following weighted average assumptions were used to estimate the fair values of options granted:
 2020
Risk-free interest rate1.66%
Expected dividend yield1.86%
Volatility of common stock28.17%
Expected life of the options3.79 years
Schedule of Stock Options
A summary of the Company's stock option activity and related information for its option plans for the fiscal year ended September 30, 2022 is presented below:
(in thousands, except exercise price and contractual term)OptionsWeighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Term		Aggregate
Intrinsic
Value
Outstanding as of September 30, 20213,138 $843 years$109,772 
Exercised(1,189)$86  
Forfeited(17)$89  
Outstanding as of September 30, 20221,932 $833 years$100,496 
Exercisable as of September 30, 20221,521 $822 years$81,000 
Expected to vest after September 30, 2022407 $884 years$19,283 
Schedule of Nonvested Options
A summary of the status of the Company's nonvested options as of September 30, 2022 and changes during the fiscal year ended September 30, 2022 is presented below:
(in thousands, except grant date fair value)OptionsWeighted
Average
Grant Date
Fair Value
Nonvested as of September 30, 20211,046 $17
Vested(617)$16
Forfeited(17)$18
Nonvested as of September 30, 2022412 $18
Schedule of Nonvested Restricted Shares
A summary of the status of the Company's nonvested restricted stock units as of September 30, 2022 and changes during the fiscal year ended September 30, 2022 are presented below:
(in thousands, except grant date fair value)Restricted
Stock Units		Weighted
Average
Grant Date
Fair Value
Nonvested as of September 30, 20211,838 $98
Granted726 $127
Vested(592)$98
Forfeited(166)$106
Nonvested as of September 30, 20221,806 $108
Schedule of Nonvested Performance Stock Units
A summary of the status of the Company's nonvested performance stock units as of September 30, 2022 and changes during the fiscal year ended September 30, 2022 is presented below (based upon target award amounts).
(in thousands, except grant date fair value)Performance
Stock
Units		Weighted
Average
Grant Date
Fair Value
Nonvested as of September 30, 2021296 $98
Granted131 $126
Vested(148)$86
Forfeited(2)$117
Nonvested as of September 30, 2022277 $117
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases (Tables)
 12 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Schedule of Lease Cost
The following illustrates the components of lease cost for the periods presented:
Fiscal Year Ended September 30,
(in thousands)202220212020
Operating lease cost$220,935 $161,054 $118,144 
Short-term lease cost11,257 5,901 4,632 
Variable lease cost25,108 14,208 17,814 
Total lease cost$257,300 $181,163 $140,590 
Other cash flow information related to operating leases is as follows:
Fiscal Year Ended September 30,
(in thousands)202220212020
Cash paid for amounts included in the measurement of lease liabilities
Operating lease cash payments$214,793 $148,385 $115,028 
Right-of-use assets obtained in exchange for lease liabilities
New operating leases$179,214 $770,858 $61,779 
Leases recognized upon adoption of ASC 842
$— $— $526,281 
Schedule of Summarized Balance Sheet Information
The following summarizes balance sheet information related to operating leases:
September 30,
(in thousands, except for lease term and discount rate)20222021
Right of use assets
Other assets$944,974 $1,067,175 
Lease liabilities
Accrued expenses and other$158,184 $175,352 
Other long-term liabilities864,288 946,155 
Total lease liabilities$1,022,472 $1,121,507 
Weighted-average remaining lease term8.37 years8.75 years
Weighted-average discount rate3.22%2.86%
Schedule of Future Minimum Renal Payments, Operating Leases
Future minimum rental payments under noncancellable operating leases were as follows:
Payments Due by Fiscal Year (in thousands)As of
September 30, 2022
2023$192,031 
2024176,635 
2025156,578 
2026136,788 
2027120,302 
Thereafter456,276 
Total future undiscounted lease payments1,238,610 
Less: Future payments for leases that have not yet commenced 1
(19,141)
Less: Imputed interest(196,997)
Total lease liabilities$1,022,472 
1 The Company has certain leases that it has executed of which it does not control the underlying assets; therefore, liabilities and ROU assets related to these leases were not recorded on the Company's Consolidated Balance Sheet as of September 30, 2022.
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisition, Integration, and Restructuring Expenses (Tables)
 12 Months Ended
Sep. 30, 2022
Restructuring and Related Activities [Abstract]  
Schedule of Employee Severance, Litigation, and Other Charges
The following illustrates the expenses incurred by the Company relating to Acquisition, Integration, and Restructuring Expenses for the periods indicated:
Fiscal Year Ended September 30,
 (in thousands)202220212020
Acquisition-related deal and integration$119,561 $116,969 $15,958 
Employee severance12,681 13,705 34,401 
Business transformation efforts27,990 36,255 37,961 
Other restructuring initiatives22,827 32,359 (3,359)
Total$183,059 $199,288 $84,961 
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Segment Information (Tables)
 12 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Schedule of Segments Revenue
 Fiscal Year Ended September 30,
(in thousands)202220212020
U.S. Healthcare Solutions
Human Health$207,284,444 $197,777,128 $182,171,487 
Animal Health4,815,758 4,684,417 4,216,462 
Total U.S. Healthcare Solutions212,100,202 202,461,545 186,387,949 
International Healthcare Solutions
Alliance Healthcare21,890,402 7,373,365 — 
Other Healthcare Solutions4,601,271 4,156,264 3,508,106 
Total International Healthcare Solutions26,491,673 11,529,629 3,508,106 
Intersegment eliminations(4,869)(2,331)(2,129)
Revenue$238,587,006 $213,988,843 $189,893,926 
Schedule of Operating Income
The following illustrates reportable segment operating income information for the periods indicated:
 Fiscal Year Ended September 30,
(in thousands)202220212020
U.S. Healthcare Solutions$2,456,972 $2,257,918 $2,020,067 
International Healthcare Solutions706,458 390,286 184,380 
Total segment operating income$3,163,430 $2,648,204 $2,204,447 
The following illustrates depreciation and amortization by reportable segment for the periods indicated:
Fiscal Year Ended September 30,
(in thousands)202220212020
U.S. Healthcare Solutions$274,554 $266,575 $253,687 
International Healthcare Solutions114,790 62,376 26,897 
Acquisition-related intangibles amortization304,551 176,221 110,478 
Total depreciation and amortization$693,895 $505,172 $391,062 
                
The following illustrates capital expenditures by reportable segment for the periods indicated:
Fiscal Year Ended September 30,
(in thousands)202220212020
U.S. Healthcare Solutions$295,406 $310,525 $316,249 
International Healthcare Solutions200,912 127,692 53,428 
Total capital expenditures$496,318 $438,217 $369,677 
Schedule of Reconciliation of Total Segment Operating Income to Income from Continuing Operations before Income Taxes The following reconciles total segment operating income to income (loss) before income taxes for the periods indicated:
 Fiscal Year Ended September 30,
(in thousands)202220212020
Total segment operating income$3,163,430 $2,648,204 $2,204,447 
Gains from antitrust litigation settlements1,835 168,794 9,076 
LIFO (expense) credit(67,171)203,028 (7,422)
Turkey highly inflationary impact(40,033)— — 
Acquisition-related intangibles amortization(304,551)(176,221)(110,478)
Litigation and opioid-related expenses(123,191)(272,623)(6,722,346)
Acquisition, integration, and restructuring expenses(183,059)(199,288)(84,961)
Goodwill impairment(75,936)(6,373)— 
Impairment of assets(4,946)(11,324)(361,652)
PharMEDium remediation costs— — (16,165)
PharMEDium shutdown costs— — (43,206)
New York State Opioid Stewardship Act— — (14,800)
Contingent consideration adjustment— — 12,153 
Operating income (loss)2,366,378 2,354,197 (5,135,354)
Other income(27,352)(41,736)(1,581)
Interest expense, net210,673 174,074 137,883 
Loss on early retirement of debt— — 22,175 
Income (loss) before income taxes$2,183,057 $2,221,859 $(5,293,831)
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies - Recently Adopted Accounting Pronouncements (Details)
$ in Thousands
 12 Months Ended
Oct. 01, 2020
USD ($)
Sep. 30, 2022
USD ($)
segment
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Accounting Policies [Abstract]          
Reportable segments | segment   2      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative adjustment to retained earnings   $ 71,273 $ 584,411 $ (839,636) $ 2,993,206
ASU 2016-13          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative adjustment to retained earnings $ 21,100        
Cumulative adjustment to retained earnings, tax $ 6,100        
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies - Schedule of Restricted Cash (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2019
Restricted Cash and Cash Equivalents Items [Line Items]        
Cash and cash equivalents $ 3,388,189 $ 2,547,142 $ 4,597,746  
Cash, cash equivalents, and restricted cash 3,593,539 3,070,128 4,597,746 $ 3,374,194
Prepaid Expenses and Other        
Restricted Cash and Cash Equivalents Items [Line Items]        
Restricted cash 144,980 462,986 0  
Other Assets        
Restricted Cash and Cash Equivalents Items [Line Items]        
Restricted cash $ 60,370 $ 60,000 $ 0  
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details) - Customer
 12 Months Ended
Sep. 30, 2022
Revenue | WBA  
Concentration Risk [Line Items]  
Concentration percentage 27.00%
Revenue | Express Scripts, Inc.  
Concentration Risk [Line Items]  
Concentration percentage 13.00%
Accounts receivables | WBA  
Concentration Risk [Line Items]  
Concentration percentage 38.00%
Accounts receivables | Express Scripts, Inc.  
Concentration Risk [Line Items]  
Concentration percentage 7.00%
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies - Foreign Currency (Details)
$ in Millions
 12 Months Ended
Sep. 30, 2022
USD ($)
Cost of Sales  
New Accounting Pronouncements or Change in Accounting Principle [Line Items]  
Turkey highly inflationary impact $ 40.0
Other (Income) Loss, Net  
New Accounting Pronouncements or Change in Accounting Principle [Line Items]  
Turkey highly inflationary impact $ 11.9
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets (Details) - USD ($)
 12 Months Ended
Jul. 01, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Assets Held and Used [Line Items]        
Goodwill impairment $ 6,400,000 $ 75,936,000 $ 6,373,000 $ 0
Impairment loss   $ 0 $ 0 0
PharMEDium Healthcare Holdings, Inc        
Assets Held and Used [Line Items]        
Impairment of assets, including goodwill       $ 361,700,000
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies - Merchandise Inventories (Details) - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Accounting Policies [Abstract]      
Percentage of inventories, cost determined using LIFO 66.00% 66.00%  
Excess cost of inventories over LIFO, if used FIFO $ 1,383,400 $ 1,316,200  
LIFO expense (credit) $ 67,171 $ (203,028) $ 7,422
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies - Property and Equipment (Details)
 12 Months Ended
Sep. 30, 2022
Buildings and improvements | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 3 years
Buildings and improvements | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 40 years
Machinery, equipment, and other | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 3 years
Machinery, equipment, and other | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 10 years
Software development costs | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 3 years
Software development costs | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 10 years
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Sep. 30, 2021
Property, Plant and Equipment [Line Items]    
Property and equipment, at cost $ 4,387,348 $ 4,081,691
Less accumulated depreciation (2,252,345) (1,918,730)
Property and equipment, net 2,135,003 2,162,961
Land    
Property, Plant and Equipment [Line Items]    
Property and equipment, at cost 122,426 129,944
Buildings and improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, at cost 840,852 838,615
Machinery, equipment, and other    
Property, Plant and Equipment [Line Items]    
Property and equipment, at cost $ 3,424,070 $ 3,113,132
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Sep. 30, 2021
Accounting Policies [Abstract]    
Accrual for estimated customer sales returns $ 1,532.1 $ 1,271.6
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies - Shipping and Handling Costs (Details) - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Shipping and Handling [Line Items]      
Distribution, selling, and administrative $ 4,848,962 $ 3,594,251 $ 2,767,217
Shipping and Handling      
Shipping and Handling [Line Items]      
Distribution, selling, and administrative $ 1,040,800 $ 809,300 $ 665,300
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisition and Assets and Liabilities Held for Sale - Additional Information (Details)
 3 Months Ended 12 Months Ended
Jun. 01, 2022
USD ($)
Jun. 01, 2021
USD ($)
$ / shares
shares
Sep. 30, 2022
USD ($)
Sep. 30, 2021
subsidiary
Sep. 30, 2022
USD ($)
subsidiary
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Business Acquisition [Line Items]              
Net cash paid         $ 133,814,000 $ 5,563,040,000 $ 0
Purchase accounting adjustments         27,186,000    
Acquisition related costs         $ 119,561,000 116,969,000 $ 15,958,000
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]         Nonoperating Income (Expense)    
U.S. Healthcare Solutions              
Business Acquisition [Line Items]              
Purchase accounting adjustments         $ 0    
International Healthcare Solutions              
Business Acquisition [Line Items]              
Purchase accounting adjustments         27,186,000    
Held for sale              
Business Acquisition [Line Items]              
Number Of Subsidiaries | subsidiary       2      
Accumulated loss on the remeasurement     $ (11,324,000)   $ (11,324,000)    
Held for sale | U.S. Healthcare Solutions              
Business Acquisition [Line Items]              
Number Of Subsidiaries | subsidiary         1    
Accumulated loss on the remeasurement     16,300,000   $ 16,300,000    
Loss on write-down     4,900,000     $ 11,300,000  
Total proceeds     267,600,000   267,600,000    
Net gain         $ 52,600,000    
Held for sale | International Healthcare Solutions              
Business Acquisition [Line Items]              
Number Of Subsidiaries | subsidiary         1    
WBA Alliance Healthcare              
Business Acquisition [Line Items]              
Purchase price in cash   $ 6,662,020,000          
Equity issued   $ 229,080,000          
Equity issued (shares) | shares   2,000,000          
Share price (in usd per share) | $ / shares   $ 114.54          
Other equity consideration   $ 6,061,000          
Net cash paid   5,596,717,000          
Acquired cash and cash equivalents   922,000,000          
Restricted cash acquired   143,308,000          
Treasury stock reissued   149,100,000          
Accrued consideration     $ 96,900,000   $ 96,900,000    
Settled         60,000,000    
Purchase accounting adjustments $ 53,000,000       (36,900,000)    
Working capital adjustments 102,700,000            
Increased in the deferred tax assets 63,000,000            
Decreased other assets $ 13,300,000            
Fair Value   3,735,000,000          
Goodwill expected to be deductible   0          
Noncontrolling interest   $ 185,164,000          
Acquisition related costs         $ 90,900,000    
Alliance Healthcare Egypt              
Business Acquisition [Line Items]              
Ownership percentage   50.00%          
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisition and Assets and Liabilities Held for Sale - Assets And Liabilities (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 01, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]        
Goodwill   $ 8,503,886 $ 9,030,531 $ 6,706,719
Net cash paid   $ 133,814 $ 5,563,040 $ 0
WBA Alliance Healthcare        
Business Acquisition [Line Items]        
Cash $ 6,662,020      
Equity (2 million shares of AmerisourceBergen Corporation common stock) 229,080      
Other equity consideration 6,061      
Fair value of total consideration 6,897,161      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]        
Cash and cash equivalents 921,995      
Accounts receivable 3,628,056      
Inventories 1,647,330      
Prepaid expenses and other 355,030      
Property and equipment 634,220      
Goodwill 2,496,338      
Other intangible assets 3,735,000      
Deferred income taxes 33,922      
Other assets 534,393      
Total assets acquired 13,986,284      
Accounts payable (4,618,807)      
Accrued expenses and other (765,463)      
Short-term debt (353,420)      
Deferred income taxes (760,937)      
Other liabilities (405,332)      
Total liabilities assumed (6,903,959)      
Net assets acquired 7,082,325      
Noncontrolling interest (185,164)      
Equity consideration (235,141)      
Cash acquired, including restricted cash of $143,308 included in Prepaid Expenses and Other (1,065,303)      
Net cash paid $ 5,596,717      
Equity issued (shares) 2,000,000      
Restricted cash acquired $ 143,308      
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisition and Assets and Liabilities Held for Sale - Fair Value Of Intangible Assets (Details) - WBA Alliance Healthcare
$ in Thousands
Jun. 01, 2021
USD ($)
Finite-Lived Intangible Assets [Line Items]  
Fair Value $ 3,735,000
Customer relationships  
Finite-Lived Intangible Assets [Line Items]  
Fair Value $ 3,327,000
Weighted-Average Useful Life 18 years
Trade names  
Finite-Lived Intangible Assets [Line Items]  
Fair Value $ 408,000
Weighted-Average Useful Life 11 years
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisition and Assets and Liabilities Held for Sale - Assets and Liabilities Held for Sale (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Sep. 30, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Total assets held for sale $ 0 $ 372,908
Total liabilities held for sale 0 $ 192,069
Held for sale    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Cash and cash equivalents 1,751  
Accounts receivable, less allowance for credit losses 182,077  
Inventories 123,424  
Prepaid expenses and other 11,258  
Property and equipment 3,084  
Goodwill 31,903  
Other intangible assets 22,923  
Other assets 7,812  
Accumulated loss on the remeasurement (11,324)  
Total assets held for sale 372,908  
Accounts payable 173,104  
Accrued expenses and other 7,234  
Short-term debt 4,225  
Long-term debt 50  
Deferred income taxes 5,857  
Other liabilities 1,599  
Total liabilities held for sale $ 192,069  
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
Variable Interest Entity - Schedule of Assets and Liabilities of Profarma (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2019
Variable Interest Entity [Line Items]        
Cash and cash equivalents $ 3,593,539 $ 3,070,128 $ 4,597,746 $ 3,374,194
Inventories 15,556,394 15,368,352    
Property and equipment, net 2,135,003 2,162,961    
Goodwill 8,503,886 9,030,531 $ 6,706,719  
Other long-term assets 1,761,661 1,793,986    
TOTAL ASSETS 56,560,616 57,337,805    
Long-term debt 5,702,833 6,683,924    
Deferred income taxes 1,620,413 1,685,296    
Other long-term liabilities 976,583 1,082,723    
Profarma        
Variable Interest Entity [Line Items]        
Cash and cash equivalents 23,144 33,699    
Accounts receivables, net 192,930 148,485    
Inventories 207,858 168,229    
Prepaid expenses and other 63,982 62,545    
Property and equipment, net 35,554 31,920    
Goodwill 0 75,936    
Other intangible assets 66,568 70,840    
Other long-term assets 71,327 74,177    
TOTAL ASSETS 661,363 665,831    
Accounts payable 215,515 162,768    
Accrued expenses and other 47,952 38,477    
Short-term debt 60,851 64,215    
Long-term debt 64,918 52,613    
Deferred income taxes 25,801 37,041    
Other long-term liabilities 52,417 57,945    
Total liabilities $ 467,454 $ 413,059    
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
Variable Interest Entity - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Aug. 31, 2020
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Variable Interest Entity [Line Items]        
Profarma retail equity offering   $ 0 $ 0 $ 66,355
Profarma Distribuidora de Produtos Farmaceuticos S.A. | Profarma        
Variable Interest Entity [Line Items]        
Profarma retail equity offering $ 66,400      
Profarma Distribuidora de Produtos Farmaceuticos S.A. | Profarma | Retail Business        
Variable Interest Entity [Line Items]        
Ownership percentage before equity offering 100.00%      
Ownership percentage after equity offering 53.50%      
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes - Domestic and Foreign Income From Continuing Operations Before Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Income Tax Disclosure [Abstract]      
Domestic $ 1,351,696 $ 1,495,899 $ (5,961,269)
Foreign 831,361 725,960 667,438
Income (loss) before income taxes $ 2,183,057 $ 2,221,859 $ (5,293,831)
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Current provision (benefit):      
Federal $ 126,969 $ 184,375 $ (473,751)
State and local 39,282 30,659 30,236
Foreign 154,082 127,351 94,213
Total current provision (benefit) 320,333 342,385 (349,302)
Deferred provision (benefit):      
Federal 150,328 111,428 (914,613)
State and local 31,129 47,516 (264,409)
Foreign 14,727 175,922 (365,949)
Total deferred provision (benefit) 196,184 334,866 (1,544,971)
Provision (benefit) for income taxes $ 516,517 $ 677,251 $ (1,894,273)
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes - Reconciliation of Effective Income Tax Rate (Details)
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Effective Income Tax Rate Reconciliation [Line Items]      
Statutory U.S. federal income tax rate 21.00% 21.00% 21.00%
State and local income tax rate, net of federal tax benefit 2.50% 2.80% (0.50%)
Tax effect of foreign operations (1.90%) (0.50%) 1.00%
Litigation settlements and accruals (see Note 13) 0.40% 0.80% (6.20%)
Tax law changes 0.00% 7.30% 6.80%
PharMEDium worthless stock deduction 0.00% (1.10%) 12.40%
CARES Act 0.00% 0.00% 1.20%
Other, net 1.70% 0.20% 0.10%
Effective income tax rate 23.70% 30.50% 35.80%
Foreign | UK      
Effective Income Tax Rate Reconciliation [Line Items]      
Tax law changes   5.70%  
Foreign | Swiss      
Effective Income Tax Rate Reconciliation [Line Items]      
Tax law changes   1.60% 6.80%
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Operating Loss Carryforwards [Line Items]        
Deferred tax expense $ 127,600   $ 127,600  
Cares act, tax benefit       $ 720,600
Net current income tax receivable 221,875 $ 172,568 221,875  
Deferred tax asset 488,235 446,605 488,235  
Valuation allowance for deferred tax assets 538,531 617,259 538,531  
Deferred tax benefit   (196,184) (334,866) 1,544,971
Valuation allowance - increase (decrease)   78,700 126,900  
Excess tax benefit from the exercise of stock options and lapses of restricted stock units   13,400 8,200 3,900
Income tax payments, net of refunds   244,400 93,500 139,400
Undistributed earnings of international subsidiaries   3,700,000    
Permanently reinvested cumulative undistributed earnings   2,100,000    
Unrecognized tax benefits, including interest and penalties 522,800 553,200 522,800  
Unrecognized tax benefits, including interest and penalties, net of federal benefit 467,900 479,600 467,900  
Unrecognized tax benefits that would impact effective tax rate 449,700 461,400 449,700  
Unrecognized tax benefits, interest and penalties 22,400 26,700 22,400  
Unrecognized tax benefits   21,074 20,515 385,797
Reduction of unrecognized tax benefits reasonably possible   21,200    
Federal        
Operating Loss Carryforwards [Line Items]        
Potential tax benefits from net operating loss carryforwards   $ 2,600    
Federal | Maximum        
Operating Loss Carryforwards [Line Items]        
Net operating loss carryforwards, term (in years)   15 years    
State        
Operating Loss Carryforwards [Line Items]        
Potential tax benefits from net operating loss carryforwards   $ 136,000    
Tax credit carryforwards   6,000    
Foreign        
Operating Loss Carryforwards [Line Items]        
Potential tax benefits from net operating loss carryforwards   297,200    
Foreign | Alternative minimum tax credit carryforwards        
Operating Loss Carryforwards [Line Items]        
Tax credit carryforwards   3,100    
Opioid Lawsuits and Investigations        
Operating Loss Carryforwards [Line Items]        
Legal accrual 147,700 36,600 147,700 6,600,000
Deferred tax benefit   981,600    
Unrecognized tax benefits       $ 371,500
Swiss        
Operating Loss Carryforwards [Line Items]        
Reduced tax rate for a period (in years)       10 years
Deferred tax asset 446,600   446,600  
Swiss | Swiss federal tax reforms        
Operating Loss Carryforwards [Line Items]        
Valuation allowance for deferred tax assets $ 234,000   234,000  
PharMEDium Healthcare Holdings, Inc        
Operating Loss Carryforwards [Line Items]        
Worthless stock ordinary income tax deduction     2,400,000  
Tax benefit     $ 655,000  
Net current income tax receivable   $ 172,600    
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes - Significant Components of Deferred Tax Liabilities (Assets) (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Sep. 30, 2021
Components of Deferred Tax Assets and Liabilities [Abstract]    
Inventories $ 1,471,064 $ 1,388,913
Property and equipment 149,896 167,974
Goodwill and other intangible assets 1,184,477 1,409,296
Right-of-use assets 219,616 249,920
Other 61,148 57,450
Gross deferred tax liabilities 3,086,201 3,273,553
Net operating loss and tax credit carryforwards (426,651) (389,724)
Allowance for credit losses (67,788) (27,569)
Accrued expenses (24,435) (13,411)
Accrued litigation liability (981,627) (1,082,845)
Employee and retiree benefits (22,682) (26,196)
Goodwill and other intangible assets (446,605) (488,235)
Lease liabilities (241,469) (263,278)
Share-based compensation (33,933) (37,466)
Other (75,428) (88,855)
Gross deferred tax assets (2,320,618) (2,417,579)
Valuation allowance for deferred tax assets 617,259 538,531
Deferred tax assets, net of valuation allowance (1,703,359) (1,879,048)
Net deferred tax liabilities $ 1,382,842 $ 1,394,505
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Unrecognized tax benefits at beginning of period $ 500,399 $ 478,351 $ 105,657
Additions of tax positions of the current year 21,074 20,515 385,797
Additions to tax positions of the prior years 5,073 17,022 5,599
Reductions of tax positions of the prior years 0 0 (6,480)
Expiration of statutes of limitations (24) (15,489) (12,222)
Unrecognized tax benefits at end of period $ 526,522 $ 500,399 $ 478,351
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill and Other Intangible Assets - Changes in Carrying Value of Goodwill (Details) - USD ($)
 12 Months Ended
Jul. 01, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Goodwill [Roll Forward]        
Beginning balance   $ 9,030,531,000 $ 6,706,719,000  
Goodwill recognized in connection with acquisition   26,143,000 2,488,228,000  
Goodwill impairment $ (6,400,000) (75,936,000) (6,373,000) $ 0
Goodwill reclassified to assets held for sale     (31,903,000)  
Goodwill derecognized in connection with disposal   (1,224,000)    
Purchase accounting adjustments   27,186,000    
Foreign currency translation   (502,814,000) (126,140,000)  
Ending balance   8,503,886,000 9,030,531,000 6,706,719,000
U.S. Healthcare Solutions        
Goodwill [Roll Forward]        
Beginning balance   6,260,374,000 6,267,502,000  
Goodwill recognized in connection with acquisition   26,143,000 19,076,000  
Goodwill impairment   0 0  
Goodwill reclassified to assets held for sale     (27,223,000)  
Goodwill derecognized in connection with disposal   (1,224,000)    
Purchase accounting adjustments   0    
Foreign currency translation   (5,053,000) 1,019,000  
Ending balance   6,280,240,000 6,260,374,000 6,267,502,000
International Healthcare Solutions        
Goodwill [Roll Forward]        
Beginning balance   2,770,157,000 439,217,000  
Goodwill recognized in connection with acquisition   0 2,469,152,000  
Goodwill impairment   (75,936,000) (6,373,000)  
Goodwill reclassified to assets held for sale     (4,680,000)  
Goodwill derecognized in connection with disposal   0    
Purchase accounting adjustments   27,186,000    
Foreign currency translation   (497,761,000) (127,159,000)  
Ending balance   $ 2,223,646,000 $ 2,770,157,000 $ 439,217,000
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill and Other Intangible Assets - Additional Information (Details) - USD ($)
 12 Months Ended
Jul. 01, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]        
Goodwill impairment $ 6,400,000 $ 75,936,000 $ 6,373,000 $ 0
Amortization expense   307,300,000 $ 178,348,000 $ 110,875,000
2022   275,500,000    
2023   274,300,000    
2024   273,300,000    
2025   268,900,000    
2026   264,200,000    
Thereafter   $ 2,308,600,000    
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill and Other Intangible Assets - Other Intangible Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Sep. 30, 2022
Finite-Lived    
Accumulated Amortization $ (858,791) $ (1,104,088)
Intangible Assets    
Gross Carrying Amount 6,115,718 5,436,825
Net Carrying Amount 5,256,927 4,332,737
Trade name    
Indefinite-lived Intangible Assets [Line Items]    
Indefinite-lived intangibles $ 668,119 667,932
Customer relationships    
Finite-Lived    
Weighted Average Remaining Useful Life 15 years  
Gross Carrying Amount $ 4,838,549 4,226,547
Accumulated Amortization (718,750) (931,961)
Net Carrying Amount $ 4,119,799 3,294,586
Trade names and other    
Finite-Lived    
Weighted Average Remaining Useful Life 11 years  
Gross Carrying Amount $ 609,050 542,346
Accumulated Amortization (140,041) (172,127)
Net Carrying Amount $ 469,009 $ 370,219
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt - Debt Instruments (Details)
Sep. 30, 2022
USD ($)
Sep. 30, 2022
GBP (£)
Sep. 30, 2021
USD ($)
Feb. 28, 2021
GBP (£)
Jan. 31, 2021
GBP (£)
Debt Instrument [Line Items]          
Total debt $ 5,702,833,000   $ 6,683,924,000    
Total, net of current portion 4,632,360,000   6,383,711,000    
Revolving credit note          
Debt Instrument [Line Items]          
Maximum borrowing capacity 75,000,000        
Total debt 0   0    
Revolving credit note | Parent Company          
Debt Instrument [Line Items]          
Less nonrecourse current portion 672,736,000   0    
Money market facility          
Debt Instrument [Line Items]          
Maximum borrowing capacity 100,000,000        
Total debt 0   0    
Receivables securitization facility due 2025          
Debt Instrument [Line Items]          
Maximum borrowing capacity 1,450,000,000        
Total debt 350,000,000   350,000,000    
Term loan due June 2023          
Debt Instrument [Line Items]          
Total debt 0   249,640,000    
Overdraft facility due 2024 (£10,000)          
Debt Instrument [Line Items]          
Maximum borrowing capacity | £   £ 10,000,000   £ 10,000,000 £ 30,000,000
Total debt 0   0    
Multi-currency revolving credit facility due 2027          
Debt Instrument [Line Items]          
Maximum borrowing capacity 2,400,000,000        
Total debt $ 0   0    
0.737% senior notes due 2023          
Debt Instrument [Line Items]          
Interest rate 0.737% 0.737%      
Total debt $ 672,736,000   1,518,223,000    
$500,000, 3.400% senior notes due 2024          
Debt Instrument [Line Items]          
Principal amount $ 500,000,000        
Interest rate 3.40% 3.40%      
Total debt $ 499,195,000   498,714,000    
$500,000, 3.250% senior notes due 2025          
Debt Instrument [Line Items]          
Principal amount $ 500,000,000        
Interest rate 3.25% 3.25%      
Total debt $ 498,347,000   497,669,000    
$750,000, 3.450% senior notes due 2027          
Debt Instrument [Line Items]          
Principal amount $ 750,000,000        
Interest rate 3.45% 3.45%      
Total debt $ 745,622,000   744,781,000    
$500,000, 2.800% senior notes due 2030          
Debt Instrument [Line Items]          
Principal amount 500,000,000        
Total debt 495,348,000   494,738,000    
$1,000,000, 2.700% senior notes due 2031          
Debt Instrument [Line Items]          
Principal amount $ 1,000,000,000        
Interest rate 0.027% 0.027%      
Total debt $ 990,480,000   989,366,000    
$500,000, 4.250% senior notes due 2045          
Debt Instrument [Line Items]          
Principal amount $ 500,000,000        
Interest rate 4.25% 4.25%      
Total debt $ 495,162,000   494,946,000    
$500,000, 4.300% senior notes due 2047          
Debt Instrument [Line Items]          
Principal amount $ 500,000,000        
Interest rate 4.30% 4.30%      
Total debt $ 493,288,000   493,021,000    
Alliance Healthcare debt          
Debt Instrument [Line Items]          
Total debt 336,886,000   235,998,000    
Less nonrecourse current portion 336,886,000   235,998,000    
Nonrecourse debt          
Debt Instrument [Line Items]          
Total debt 125,769,000   116,828,000    
Less nonrecourse current portion $ 60,851,000   $ 64,215,000    
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt - Additional Information (Details)
 1 Months Ended 12 Months Ended
Mar. 31, 2022
USD ($)
Sep. 30, 2021
USD ($)
May 31, 2020
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2022
GBP (£)
Jun. 30, 2021
USD ($)
Apr. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Feb. 28, 2021
USD ($)
Feb. 28, 2021
GBP (£)
Jan. 31, 2021
GBP (£)
Oct. 31, 2020
USD ($)
Debt Instrument [Line Items]                            
Payment of premium on early retirement of debt       $ 0 $ 0 $ 21,448,000                
Scheduled future principal payments, in fiscal 2022       1,071,800,000                    
Scheduled future principal payments, in fiscal 2023       526,300,000                    
Scheduled future principal payments, in fiscal 2024       873,200,000                    
Scheduled future principal payments, in fiscal 2025       12,100,000                    
Scheduled future principal payments, in fiscal 2026       2,700,000                    
Scheduled future principal payments, thereafter       3,252,600,000                    
Interest paid       219,800,000 170,900,000 150,700,000                
Amortization of financing fees and accretion of original issue discounts       $ 11,900,000 $ 9,700,000 $ 6,400,000                
Alliance Healthcare Egypt                            
Debt Instrument [Line Items]                            
Ownership percentage   50.00%   50.00% 50.00%   50.00%              
Multi-currency revolving credit facility due 2027                            
Debt Instrument [Line Items]                            
Maximum borrowing capacity       $ 2,400,000,000                    
Facility fee       0.11%                    
Multi-currency revolving credit facility due 2027 | Minimum                            
Debt Instrument [Line Items]                            
Facility fee       0.07%                    
Multi-currency revolving credit facility due 2027 | Maximum                            
Debt Instrument [Line Items]                            
Facility fee       0.15%                    
Multi-currency revolving credit facility due 2027 | SOFR / EURIBOR / CDOR / RFR                            
Debt Instrument [Line Items]                            
Variable rate spread       1.015%                    
Multi-currency revolving credit facility due 2027 | SOFR / EURIBOR / CDOR / RFR | Minimum                            
Debt Instrument [Line Items]                            
Variable rate spread       0.805%                    
Multi-currency revolving credit facility due 2027 | SOFR / EURIBOR / CDOR / RFR | Maximum                            
Debt Instrument [Line Items]                            
Variable rate spread       1.225%                    
Multi-currency revolving credit facility due 2027 | Alternate base rate and Canadian prime rate | Minimum                            
Debt Instrument [Line Items]                            
Variable rate spread       0.00%                    
Multi-currency revolving credit facility due 2027 | Alternate base rate and Canadian prime rate | Maximum                            
Debt Instrument [Line Items]                            
Variable rate spread       0.225%                    
Commercial paper                            
Debt Instrument [Line Items]                            
Maximum borrowing capacity       $ 2,400,000,000                    
Debt instrument, term       365 days                    
Amount outstanding   $ 0   $ 0 $ 0                  
Receivables securitization facility due 2025                            
Debt Instrument [Line Items]                            
Maximum borrowing capacity       1,450,000,000                    
Potential increase in receivables securitization facility       250,000,000                    
Revolving credit note                            
Debt Instrument [Line Items]                            
Maximum borrowing capacity       75,000,000                    
Overdraft facility due 2024 (£10,000)                            
Debt Instrument [Line Items]                            
Maximum borrowing capacity | £             £ 10,000,000         £ 10,000,000 £ 30,000,000  
Money market facility                            
Debt Instrument [Line Items]                            
Maximum borrowing capacity       100,000,000                    
Term Loan Agreement October 2018                            
Debt Instrument [Line Items]                            
Principal amount                           $ 400,000,000
Term Loan Due February 2021                            
Debt Instrument [Line Items]                            
Maximum borrowing capacity                 $ 500,000,000   $ 1,000,000,000      
Principal amount               $ 500,000,000            
Repayments of debt $ 250,000,000 $ 250,000,000                        
$500,000, 2.800% senior notes due 2030                            
Debt Instrument [Line Items]                            
Principal amount       500,000,000                    
$500,000, 2.800% senior notes due 2030 | Notes Payable to Banks                            
Debt Instrument [Line Items]                            
Principal amount     $ 500,000,000                      
Interest rate     2.80%                      
Percentage of principal amount     0.9971%                      
Effective yield percentage     2.81%                      
$500,000, 3.5% senior notes due 2021 | Notes Payable to Banks                            
Debt Instrument [Line Items]                            
Principal amount     $ 500,000,000                      
Interest rate     3.50%                      
Payment of premium on early retirement of debt     $ 21,400,000                      
0.737% senior notes due 2023                            
Debt Instrument [Line Items]                            
Repayments of debt       $ 850,000,000                    
Interest rate       0.737%     0.737%              
0.737% senior notes due 2023 | Notes Payable to Banks                            
Debt Instrument [Line Items]                            
Principal amount                   $ 1,525,000,000        
Interest rate                   0.737%        
Percentage of principal amount                   100.00%        
$1,000,000, 2.700% senior notes due 2031                            
Debt Instrument [Line Items]                            
Principal amount       $ 1,000,000,000                    
Interest rate       0.027%     0.027%              
$1,000,000, 2.700% senior notes due 2031 | Notes Payable to Banks                            
Debt Instrument [Line Items]                            
Principal amount                   $ 1,000,000,000        
Interest rate                   2.70%        
Percentage of principal amount                   99.79%        
Effective yield percentage                   2.706%        
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity and Weighted Average Common Shares Outstanding - Additional Information (Details)
 1 Months Ended 12 Months Ended
Nov. 22, 2022
USD ($)
shares
Oct. 31, 2022
USD ($)
shares
Sep. 30, 2022
USD ($)
vote
$ / shares
shares
Sep. 30, 2021
USD ($)
$ / shares
shares
Sep. 30, 2020
USD ($)
shares
Sep. 30, 2019
USD ($)
shares
May 31, 2022
USD ($)
May 31, 2020
USD ($)
Oct. 31, 2018
USD ($)
Equity, Class of Treasury Stock [Line Items]                  
Common stock, authorized (shares) | shares     600,000,000 600,000,000          
Common stock, par value (usd per share) | $ / shares     $ 0.01 $ 0.01          
Preferred stock, authorized (shares) | shares     10,000,000            
Preferred stock, par value (usd per share) | $ / shares     $ 0.01            
Number of votes per share | vote     1            
Repurchase of common stock     $ 512,091,000 $ 82,150,000 $ 405,692,000        
Antidilutive securities excluded from computation of diluted earnings per share (shares) | shares     100,000 100,000 4,200,000        
October 2018 Share Repurchase Program                  
Equity, Class of Treasury Stock [Line Items]                  
Authorized amount under share repurchase program                 $ 1,000,000,000
Repurchase of common stock (shares) | shares       600,000 4,900,000 6,700,000      
Repurchase of common stock       $ 55,500,000 $ 405,600,000 $ 538,900,000      
Shares repurchased, cash settled         $ 14,800,000 $ 14,800,000      
May 2020 Share Repurchase Program                  
Equity, Class of Treasury Stock [Line Items]                  
Authorized amount under share repurchase program               $ 500,000,000  
Repurchase of common stock (shares) | shares     3,300,000 300,000          
Repurchase of common stock     $ 473,400,000 $ 26,600,000          
May 2022 Share Repurchase Program                  
Equity, Class of Treasury Stock [Line Items]                  
Authorized amount under share repurchase program             $ 1,000,000,000    
Repurchase of common stock (shares) | shares     300,000            
Repurchase of common stock     $ 38,700,000            
Shares repurchased, cash settled     28,400,000            
Availability remaining under program     $ 961,300,000            
May 2022 Share Repurchase Program | Subsequent Event                  
Equity, Class of Treasury Stock [Line Items]                  
Repurchase of common stock (shares) | shares 3,200,000 600,000              
Repurchase of common stock $ 500,000,000 $ 78,800,000              
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Sep. 30, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Total accumulated other comprehensive loss $ (211,559) $ 223,354
Total accumulated other comprehensive loss    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Total accumulated other comprehensive loss (1,830,970) (445,442)
Pension and postretirement adjustments    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Total accumulated other comprehensive loss (9,038) (5,750)
Foreign currency translation    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Total accumulated other comprehensive loss (1,820,292) (439,692)
Other    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Total accumulated other comprehensive loss $ (1,640) $ 0
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Diluted Weighted Average Shares Outstanding (Details) - shares
shares in Thousands
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Equity [Abstract]      
Weighted average common shares outstanding - basic (shares) 208,472 205,919 204,783
Effect of dilutive securities - stock options and restricted stock units (shares) 2,738 2,546 0
Weighted average common shares outstanding - diluted (shares) 211,210 208,465 204,783
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions (Details) - Investor - USD ($)
$ in Billions
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
AmerisourceBergen | WBA Alliance Healthcare      
Related Party Transaction [Line Items]      
Ownership percentage (more than) 10.00%    
WBA Alliance Healthcare      
Related Party Transaction [Line Items]      
Revenue from related party $ 64.1 $ 65.5 $ 63.1
Receivable from related party $ 7.0 $ 7.0  
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.22.2.2
Retirement and Other Benefit Plans (Details) - USD ($)
$ in Millions
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Defined Benefit Plan Disclosure [Line Items]      
Minimum allowed employee contributions, percent of salary 1.00%    
Maximum allowed employee contributions, percent of salary 50.00%    
Discretionary contributions, vesting period (in years) 5 years    
Defined contribution plans expense $ 90.1 $ 62.3 $ 45.9
Deferred compensation, annual benefit, percent of compensation, Benefit Restoration Plan 4.00%    
Deferred compensation liability $ 31.7 $ 38.1  
Stock purchased with the participant's compensation allocated to stock credits (in shares) 0.5    
Employee contribution, first 3% of salary      
Defined Benefit Plan Disclosure [Line Items]      
Employer matching contribution, percent of match 100.00%    
Employer matching contribution, percent of salary 3.00%    
Employee contribution, additional 2% of salary      
Defined Benefit Plan Disclosure [Line Items]      
Employer matching contribution, percent of match 50.00%    
Employer matching contribution, percent of salary 2.00%    
XML 86 R72.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Additional Information (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted average fair values of options granted (usd per share)     $ 16.61
Stock option expense $ 2.2 $ 4.6 $ 13.0
Intrinsic value of stock option exercises 60.3 58.7 42.6
Total fair values of options vested $ 10.0 $ 15.5 21.3
Nonvested options outstanding (shares) 412 1,046  
Expected future compensation expense relating to nonvested options outstanding $ 0.4    
2022 Omnibus      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares available for grant 25,400    
Employee options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Service period (in years) 4 years    
Vesting period (in years) 4 years    
Expiration period (in years) 7 years    
Non-employee options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Service period (in years) 3 years    
Vesting period (in years) 3 years    
Expiration period (in years) 10 years    
Restricted stock units      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock expense $ 71.3 $ 55.8 39.8
Total fair values of restricted shares vested $ 58.1 $ 31.1 26.4
Nonvested shares outstanding (shares) 1,806 1,838  
Expected future compensation expense relating to restricted shares outstanding $ 71.2    
Weighted average period over which expected future compensation expense relating to restricted shares outstanding will be recognized 1 year 1 month 6 days    
Restricted stock units | Granted prior to fiscal 2021      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period (in years) 3 years    
Restricted stock units | Granted beginning in fiscal 2022      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period (in years) 3 years    
Performance stock units      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period (in years) 3 years    
Stock expense $ 19.7 $ 38.9 $ 21.5
Nonvested shares outstanding (shares) 277 296  
Performance stock units | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting percentage 0.00%    
Performance stock units | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting percentage 200.00%    
XML 87 R73.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Weighted Average Assumptions (Details)
 12 Months Ended
Sep. 30, 2020
Share-Based Payment Arrangement [Abstract]  
Risk-free interest rate 1.66%
Expected dividend yield 1.86%
Volatility of common stock 28.17%
Expected life of the options 3 years 9 months 14 days
XML 88 R74.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Stock Options (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Options    
Outstanding, beginning of period (shares) 3,138  
Exercised (shares) (1,189)  
Forfeited (shares) (17)  
Outstanding, end of period (shares) 1,932 3,138
Exercisable, end of period (shares) 1,521  
Expected to vest after end of period (shares) 407  
Weighted Average Exercise Price    
Outstanding, beginning of period (usd per share) $ 84  
Exercised (usd per share) 86  
Forfeited (usd per share) 89  
Outstanding, end of period (usd per share) 83 $ 84
Exercisable, end of period (usd per share) 82  
Expected to vest after end of period (usd per share) $ 88  
Weighted Average Remaining Contractual Term    
Outstanding 3 years 3 years
Exercisable 2 years  
Expected to vest after end of period 4 years  
Aggregate Intrinsic Value    
Outstanding $ 100,496 $ 109,772
Exercisable 81,000  
Expected to vest after end of period $ 19,283  
XML 89 R75.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Nonvested Options (Details)
shares in Thousands
 12 Months Ended
Sep. 30, 2022
$ / shares
shares
Options  
Nonvested, beginning of period (shares) | shares 1,046
Vested (shares) | shares (617)
Forfeited (shares) | shares (17)
Nonvested, end of period (shares) | shares 412
Weighted Average Grant Date Fair Value  
Nonvested, beginning of period (usd per share) | $ / shares $ 17
Vested (usd per share) | $ / shares 16
Forfeited (usd per share) | $ / shares 18
Nonvested, end of period (usd per share) | $ / shares $ 18
XML 90 R76.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Nonvested Restricted Stock Units (Details) - Restricted stock units
shares in Thousands
 12 Months Ended
Sep. 30, 2022
$ / shares
shares
Restricted Stock Units  
Nonvested, beginning of period (shares) | shares 1,838
Granted (shares) | shares 726
Vested (shares) | shares (592)
Forfeited (shares) | shares (166)
Nonvested, end of period (shares) | shares 1,806
Weighted Average Grant Date Fair Value  
Nonvested, beginning of period (usd per share) | $ / shares $ 98
Granted (usd per share) | $ / shares 127
Vested (usd per share) | $ / shares 98
Forfeited (usd per share) | $ / shares 106
Nonvested, end of period (usd per share) | $ / shares $ 108
XML 91 R77.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Nonvested Performance Stock Units (Details) - Performance stock units
shares in Thousands
 12 Months Ended
Sep. 30, 2022
$ / shares
shares
Performance Stock Units  
Nonvested, beginning of period (shares) | shares 296
Granted (shares) | shares 131
Vested (shares) | shares (148)
Forfeited (shares) | shares (2)
Nonvested, end of period (shares) | shares 277
Weighted Average Grant Date Fair Value  
Nonvested, beginning of period (usd per share) | $ / shares $ 98
Granted (usd per share) | $ / shares 126
Vested (usd per share) | $ / shares 86
Forfeited (usd per share) | $ / shares 117
Nonvested, end of period (usd per share) | $ / shares $ 117
XML 92 R78.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Lease Cost (Details) - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Leases [Abstract]      
Operating lease cost $ 220,935 $ 161,054 $ 118,144
Short-term lease cost 11,257 5,901 4,632
Variable lease cost 25,108 14,208 17,814
Total lease cost $ 257,300 $ 181,163 $ 140,590
XML 93 R79.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Summary of Balance Sheet Information Related to Leases (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Sep. 30, 2021
Oct. 01, 2020
Right of use assets      
Other assets $ 944,974 $ 1,067,175 $ 526,281
Lease liabilities      
Accrued expenses and other 158,184 175,352  
Other long-term liabilities 864,288 946,155  
Total lease liabilities $ 1,022,472 $ 1,121,507  
Weighted-average remaining lease term 8 years 4 months 13 days 8 years 9 months  
Weighted-average discount rate 3.22% 2.86%  
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Accrued Liabilities, Current Accrued Liabilities, Current  
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Other long-term liabilities Other long-term liabilities  
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other long-term assets Other long-term assets Other long-term assets
XML 94 R80.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Other Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Oct. 01, 2020
Cash paid for amounts included in the measurement of lease liabilities        
Operating lease cash payments $ 214,793 $ 148,385 $ 115,028  
Right-of-use assets obtained in exchange for lease liabilities        
New operating leases 179,214 770,858 $ 61,779  
Other assets $ 944,974 $ 1,067,175   $ 526,281
XML 95 R81.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Future Minimum Rental Payments Under Noncancelable Operating Leases (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Sep. 30, 2021
Leases [Abstract]    
2023 $ 192,031  
2024 176,635  
2025 156,578  
2026 136,788  
2027 120,302  
Thereafter 456,276  
Total future undiscounted lease payments 1,238,610  
Less: Future payments for leases that have not yet commenced (19,141)  
Less: Imputed interest (196,997)  
Total lease liabilities $ 1,022,472 $ 1,121,507
XML 96 R82.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisition, Integration, and Restructuring Expenses (Details) - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Restructuring and Related Activities [Abstract]      
Acquisition-related deal and integration $ 119,561 $ 116,969 $ 15,958
Employee severance 12,681 13,705 34,401
Business transformation efforts 27,990 36,255 37,961
Other restructuring initiatives 22,827 32,359 (3,359)
Total $ 183,059 $ 199,288 84,961
Gain on the sale of a facility     $ 19,100
XML 97 R83.htm IDEA: XBRL DOCUMENT v3.22.2.2
Legal Matters and Contingencies (Details)
$ in Thousands
 3 Months Ended 12 Months Ended
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
state
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Jan. 31, 2020
claim
Loss Contingencies [Line Items]          
Accrued litigation liability $ 5,961,953 $ 5,461,758 $ 5,961,953    
Multidistrict Litigation and Other Related State Court Litigation | Settled Litigation          
Loss Contingencies [Line Items]          
Loss contingency, damages awarded, value   $ 6,400,000      
Legal settlement term (in years)   18 years      
Multidistrict Litigation and Other Related State Court Litigation | Three Largest National Distributors | Pending Litigation          
Loss Contingencies [Line Items]          
Number of pending claims | claim         4
Multidistrict Litigation and Other Related State Court Litigation | Three Largest National Distributors | Settled Litigation          
Loss Contingencies [Line Items]          
Settling States | state   48      
Settlement percent of population   99.00%      
Opioid Lawsuits and Investigations          
Loss Contingencies [Line Items]          
Recorded charge 147,700 $ 36,600 147,700 $ 6,600,000  
Total liability accrual $ 6,700,000 6,000,000 $ 6,700,000    
Current estimate recorded in accrued expenses and other   528,700      
Accrued litigation liability   $ 5,500,000      
XML 98 R84.htm IDEA: XBRL DOCUMENT v3.22.2.2
Litigation Settlements (Details) - USD ($)
$ in Millions
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Litigation Settlement [Abstract]      
Gains from antitrust litigation settlements $ 1.8 $ 168.8 $ 9.1
XML 99 R85.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Segment Information - Additional Information (Details)
$ in Thousands
 12 Months Ended
Sep. 30, 2022
USD ($)
segment
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Segment Reporting Information [Line Items]      
Reportable segments | segment 2    
Gain (loss) on disposition of business $ 56,228 $ 0 $ 0
Foreign currency loss 14,400 3,400  
Gain on revaluation of equity investment 4,834 64,721 $ 0
Turkey highly inflationary impact   $ 14,000  
Other (Income) Loss, Net      
Segment Reporting Information [Line Items]      
Turkey highly inflationary impact $ 11,900    
XML 100 R86.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Segment Information - Segment Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Segment Reporting Information [Line Items]          
Revenue     $ 238,587,006 $ 213,988,843 $ 189,893,926
Operating segments | U.S. Healthcare Solutions          
Segment Reporting Information [Line Items]          
Revenue $ 212,100,202 $ 202,461,545 186,387,949    
Operating segments | U.S. Healthcare Solutions | Human Health          
Segment Reporting Information [Line Items]          
Revenue 207,284,444 197,777,128 182,171,487    
Operating segments | U.S. Healthcare Solutions | Animal Health          
Segment Reporting Information [Line Items]          
Revenue $ 4,815,758 $ 4,684,417 4,216,462    
Operating segments | International Healthcare Solutions          
Segment Reporting Information [Line Items]          
Revenue     26,491,673 11,529,629 3,508,106
Operating segments | International Healthcare Solutions | Alliance Healthcare          
Segment Reporting Information [Line Items]          
Revenue     21,890,402 7,373,365 0
Operating segments | International Healthcare Solutions | Other Healthcare Solutions          
Segment Reporting Information [Line Items]          
Revenue     4,601,271 4,156,264 3,508,106
Intersegment eliminations          
Segment Reporting Information [Line Items]          
Revenue     $ (4,869) $ (2,331) $ (2,129)
XML 101 R87.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Segment Information - Segment Operating Income (Details) - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Segment Reporting Information [Line Items]      
Operating income $ 2,366,378 $ 2,354,197 $ (5,135,354)
Total depreciation and amortization 693,895 505,172 391,062
Total capital expenditures 496,318 438,217 369,677
U.S. Healthcare Solutions      
Segment Reporting Information [Line Items]      
Total capital expenditures 295,406 310,525 316,249
International Healthcare Solutions      
Segment Reporting Information [Line Items]      
Total capital expenditures 200,912 127,692 53,428
Operating segments      
Segment Reporting Information [Line Items]      
Operating income 3,163,430 2,648,204 2,204,447
Operating segments | U.S. Healthcare Solutions      
Segment Reporting Information [Line Items]      
Operating income 2,456,972 2,257,918 2,020,067
Total depreciation and amortization 274,554 266,575 253,687
Operating segments | International Healthcare Solutions      
Segment Reporting Information [Line Items]      
Operating income 706,458 390,286 184,380
Total depreciation and amortization 114,790 62,376 26,897
Segment reconciling items      
Segment Reporting Information [Line Items]      
Acquisition-related intangibles amortization $ 304,551 $ 176,221 $ 110,478
XML 102 R88.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Segment Information - Reconciliation of Segment Operating Income to Income From Continuing Operations (Details) - USD ($)
 12 Months Ended
Jul. 01, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Segment Reporting Information [Line Items]        
Total segment operating income   $ 2,366,378,000 $ 2,354,197,000 $ (5,135,354,000)
Gains from antitrust litigation settlements   1,800,000 168,800,000 9,100,000
LIFO (expense) credit   (67,171,000) 203,028,000 (7,422,000)
Acquisition, integration, and restructuring expenses   (183,059,000) (199,288,000) (84,961,000)
Goodwill impairment $ (6,400,000) (75,936,000) (6,373,000) 0
Impairment of assets   (80,882,000) (31,697,000) (361,652,000)
Other income   (27,352,000) (41,736,000) (1,581,000)
Interest expense, net   210,673,000 174,074,000 137,883,000
Loss on early retirement of debt   0 0 22,175,000
Income (loss) before income taxes   2,183,057,000 2,221,859,000 (5,293,831,000)
Operating segments        
Segment Reporting Information [Line Items]        
Total segment operating income   3,163,430,000 2,648,204,000 2,204,447,000
Segment reconciling items        
Segment Reporting Information [Line Items]        
Gains from antitrust litigation settlements   1,835,000 168,794,000 9,076,000
LIFO (expense) credit   (67,171,000) 203,028,000 (7,422,000)
Turkey highly inflationary impact   (40,033,000) 0 0
Acquisition-related intangibles amortization   (304,551,000) (176,221,000) (110,478,000)
Litigation and opioid-related expenses   (123,191,000) (272,623,000) (6,722,346,000)
Goodwill impairment   (75,936,000) (6,373,000) 0
Impairment of assets   (4,946,000) (11,324,000) (361,652,000)
PharMEDium remediation costs   0 0 (16,165,000)
PharMEDium shutdown costs   0 0 (43,206,000)
New York State Opioid Stewardship Act   0 0 (14,800,000)
Contingent consideration adjustment   $ 0 $ 0 $ 12,153,000
XML 103 R89.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value of Financial Instruments (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Sep. 30, 2021
Carrying amount    
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]    
Long-term debt $ 4,632.4 $ 6,383.8
Fair value | Level 1 | Money market accounts    
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]    
Cash and cash equivalents 1,602.0 671.0
Fair value | Level 2    
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]    
Long-term debt $ 4,130.3 $ 6,761.6
XML 104 R90.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subsequent Events (Details)
 1 Months Ended 12 Months Ended
Nov. 22, 2022
$ / shares
Sep. 30, 2022
segment
Subsequent Event [Line Items]    
Reportable segments | segment   2
Subsequent Event    
Subsequent Event [Line Items]    
Dividend increase percentage 5.00%  
Quarterly cash dividend declared (usd per share) | $ / shares $ 0.485  
XML 105 R91.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS (Details) - Allowances for returns and doubtful accounts - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at beginning of period $ 1,356,684 $ 1,417,308 $ 1,223,887
Charged to costs and expenses 5,124,081 3,906,776 4,019,830
Deductions (4,854,036) (3,967,400) (3,826,409)
Balance at end of period 1,626,729 1,356,684 1,417,308
Allowance for doubtful accounts for long-term accounts receivable $ 1,626,729 $ 1,356,684 $ 1,417,308
XML 106 abc-20220930_htm.xml IDEA: XBRL DOCUMENT 0001140859 2021-10-01 2022-09-30 0001140859 2022-03-31 0001140859 2022-10-31 0001140859 2022-09-30 0001140859 2021-09-30 0001140859 2020-10-01 2021-09-30 0001140859 2019-10-01 2020-09-30 0001140859 us-gaap:CommonStockMember 2019-09-30 0001140859 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001140859 us-gaap:RetainedEarningsMember 2019-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001140859 us-gaap:TreasuryStockMember 2019-09-30 0001140859 us-gaap:NoncontrollingInterestMember 2019-09-30 0001140859 2019-09-30 0001140859 2018-10-01 2019-09-30 0001140859 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-09-30 0001140859 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:NoncontrollingInterestMember 2019-09-30 0001140859 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-09-30 0001140859 us-gaap:RetainedEarningsMember 2019-10-01 2020-09-30 0001140859 us-gaap:NoncontrollingInterestMember 2019-10-01 2020-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-10-01 2020-09-30 0001140859 us-gaap:CommonStockMember 2019-10-01 2020-09-30 0001140859 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2020-09-30 0001140859 us-gaap:TreasuryStockMember 2019-10-01 2020-09-30 0001140859 us-gaap:CommonStockMember 2020-09-30 0001140859 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001140859 us-gaap:RetainedEarningsMember 2020-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001140859 us-gaap:TreasuryStockMember 2020-09-30 0001140859 us-gaap:NoncontrollingInterestMember 2020-09-30 0001140859 2020-09-30 0001140859 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2020-09-30 0001140859 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:NoncontrollingInterestMember 2020-09-30 0001140859 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-09-30 0001140859 us-gaap:RetainedEarningsMember 2020-10-01 2021-09-30 0001140859 us-gaap:NoncontrollingInterestMember 2020-10-01 2021-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-10-01 2021-09-30 0001140859 us-gaap:CommonStockMember 2020-10-01 2021-09-30 0001140859 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2021-09-30 0001140859 us-gaap:TreasuryStockMember 2020-10-01 2021-09-30 0001140859 us-gaap:CommonStockMember 2021-09-30 0001140859 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001140859 us-gaap:RetainedEarningsMember 2021-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001140859 us-gaap:TreasuryStockMember 2021-09-30 0001140859 us-gaap:NoncontrollingInterestMember 2021-09-30 0001140859 us-gaap:RetainedEarningsMember 2021-10-01 2022-09-30 0001140859 us-gaap:NoncontrollingInterestMember 2021-10-01 2022-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-01 2022-09-30 0001140859 us-gaap:CommonStockMember 2021-10-01 2022-09-30 0001140859 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2022-09-30 0001140859 us-gaap:TreasuryStockMember 2021-10-01 2022-09-30 0001140859 us-gaap:CommonStockMember 2022-09-30 0001140859 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001140859 us-gaap:RetainedEarningsMember 2022-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001140859 us-gaap:TreasuryStockMember 2022-09-30 0001140859 us-gaap:NoncontrollingInterestMember 2022-09-30 0001140859 us-gaap:AccountingStandardsUpdate201613Member 2020-10-01 0001140859 us-gaap:AccountingStandardsUpdate201613Member 2020-10-01 2020-10-01 0001140859 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2022-09-30 0001140859 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2021-09-30 0001140859 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2020-09-30 0001140859 us-gaap:OtherNoncurrentAssetsMember 2022-09-30 0001140859 us-gaap:OtherNoncurrentAssetsMember 2021-09-30 0001140859 us-gaap:OtherNoncurrentAssetsMember 2020-09-30 0001140859 abc:WalgreensBootsAllianceIncMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-10-01 2022-09-30 0001140859 abc:WalgreensBootsAllianceIncMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-10-01 2022-09-30 0001140859 abc:ExpressScriptsIncMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-10-01 2022-09-30 0001140859 abc:ExpressScriptsIncMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-10-01 2022-09-30 0001140859 us-gaap:CostOfSalesMember 2021-10-01 2022-09-30 0001140859 abc:OtherIncomeLossNetMember 2021-10-01 2022-09-30 0001140859 abc:PharmediumHealthcareHoldingsIncMember 2019-10-01 2020-09-30 0001140859 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2021-10-01 2022-09-30 0001140859 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2021-10-01 2022-09-30 0001140859 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2021-10-01 2022-09-30 0001140859 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2021-10-01 2022-09-30 0001140859 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-10-01 2022-09-30 0001140859 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-10-01 2022-09-30 0001140859 us-gaap:LandMember 2022-09-30 0001140859 us-gaap:LandMember 2021-09-30 0001140859 us-gaap:BuildingAndBuildingImprovementsMember 2022-09-30 0001140859 us-gaap:BuildingAndBuildingImprovementsMember 2021-09-30 0001140859 us-gaap:MachineryAndEquipmentMember 2022-09-30 0001140859 us-gaap:MachineryAndEquipmentMember 2021-09-30 0001140859 us-gaap:ShippingAndHandlingMember 2021-10-01 2022-09-30 0001140859 us-gaap:ShippingAndHandlingMember 2020-10-01 2021-09-30 0001140859 us-gaap:ShippingAndHandlingMember 2019-10-01 2020-09-30 0001140859 abc:WalgreensBootsAllianceIncAllianceHealthcareMember 2021-06-01 2021-06-01 0001140859 abc:WalgreensBootsAllianceIncAllianceHealthcareMember 2021-06-01 0001140859 abc:WalgreensBootsAllianceIncAllianceHealthcareMember 2022-09-30 0001140859 abc:WalgreensBootsAllianceIncAllianceHealthcareMember 2021-10-01 2022-09-30 0001140859 abc:WalgreensBootsAllianceIncAllianceHealthcareMember 2022-06-01 2022-06-01 0001140859 abc:WalgreensBootsAllianceIncAllianceHealthcareMember us-gaap:CustomerRelationshipsMember 2021-06-01 2021-06-01 0001140859 abc:WalgreensBootsAllianceIncAllianceHealthcareMember us-gaap:TradeNamesMember 2021-06-01 2021-06-01 0001140859 abc:WalgreensBootsAllianceIncAllianceHealthcareAllianceHealthcareEgyptMember 2021-06-01 0001140859 us-gaap:DiscontinuedOperationsHeldforsaleMember 2021-07-01 2021-09-30 0001140859 us-gaap:DiscontinuedOperationsHeldforsaleMember abc:USHealthcareSolutionsMember 2021-10-01 2022-09-30 0001140859 us-gaap:DiscontinuedOperationsHeldforsaleMember abc:InternationalHealthcareSolutionsMember 2021-10-01 2022-09-30 0001140859 us-gaap:DiscontinuedOperationsHeldforsaleMember abc:USHealthcareSolutionsMember 2022-09-30 0001140859 us-gaap:DiscontinuedOperationsHeldforsaleMember abc:USHealthcareSolutionsMember 2022-07-01 2022-09-30 0001140859 us-gaap:DiscontinuedOperationsHeldforsaleMember abc:USHealthcareSolutionsMember 2020-10-01 2021-09-30 0001140859 us-gaap:DiscontinuedOperationsHeldforsaleMember 2022-09-30 0001140859 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2022-09-30 0001140859 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2021-09-30 0001140859 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember abc:ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member 2020-08-01 2020-08-31 0001140859 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember abc:RetailBusinessMember abc:ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member 2020-08-01 2020-08-31 0001140859 us-gaap:ForeignCountryMember us-gaap:HerMajestysRevenueAndCustomsHMRCMember 2020-10-01 2021-09-30 0001140859 us-gaap:ForeignCountryMember us-gaap:SwissFederalTaxAdministrationFTAMember 2020-10-01 2021-09-30 0001140859 us-gaap:ForeignCountryMember us-gaap:SwissFederalTaxAdministrationFTAMember 2019-10-01 2020-09-30 0001140859 abc:PharmediumHealthcareHoldingsIncMember 2020-10-01 2021-09-30 0001140859 abc:PharmediumHealthcareHoldingsIncMember 2022-09-30 0001140859 us-gaap:SwissFederalTaxAdministrationFTAMember 2019-10-01 2020-09-30 0001140859 us-gaap:SwissFederalTaxAdministrationFTAMember 2021-09-30 0001140859 us-gaap:SwissFederalTaxAdministrationFTAMember abc:SwissTaxReformMember 2021-09-30 0001140859 abc:OpioidLawsuitsandInvestigationsMember 2021-10-01 2022-09-30 0001140859 abc:OpioidLawsuitsandInvestigationsMember 2020-10-01 2021-09-30 0001140859 abc:OpioidLawsuitsandInvestigationsMember 2019-10-01 2020-09-30 0001140859 us-gaap:DomesticCountryMember 2022-09-30 0001140859 srt:MaximumMember us-gaap:DomesticCountryMember 2021-10-01 2022-09-30 0001140859 us-gaap:StateAndLocalJurisdictionMember 2022-09-30 0001140859 us-gaap:ForeignCountryMember 2022-09-30 0001140859 us-gaap:ForeignCountryMember abc:AlternativeMinimumTaxMember 2022-09-30 0001140859 abc:USHealthcareSolutionsMember 2020-09-30 0001140859 abc:InternationalHealthcareSolutionsMember 2020-09-30 0001140859 abc:USHealthcareSolutionsMember 2020-10-01 2021-09-30 0001140859 abc:InternationalHealthcareSolutionsMember 2020-10-01 2021-09-30 0001140859 abc:USHealthcareSolutionsMember 2021-09-30 0001140859 abc:InternationalHealthcareSolutionsMember 2021-09-30 0001140859 abc:USHealthcareSolutionsMember 2021-10-01 2022-09-30 0001140859 abc:InternationalHealthcareSolutionsMember 2021-10-01 2022-09-30 0001140859 abc:USHealthcareSolutionsMember 2022-09-30 0001140859 abc:InternationalHealthcareSolutionsMember 2022-09-30 0001140859 2021-07-01 2021-07-01 0001140859 us-gaap:TradeNamesMember 2022-09-30 0001140859 us-gaap:TradeNamesMember 2021-09-30 0001140859 us-gaap:CustomerRelationshipsMember 2021-09-30 2021-09-30 0001140859 us-gaap:CustomerRelationshipsMember 2022-09-30 0001140859 us-gaap:CustomerRelationshipsMember 2021-09-30 0001140859 abc:TradeNamesAndOtherMember 2021-09-30 2021-09-30 0001140859 abc:TradeNamesAndOtherMember 2022-09-30 0001140859 abc:TradeNamesAndOtherMember 2021-09-30 0001140859 abc:RevolvingCreditNoteMember 2022-09-30 0001140859 abc:RevolvingCreditNoteMember 2021-09-30 0001140859 abc:MoneyMarketFacilityMember 2022-09-30 0001140859 abc:MoneyMarketFacilityMember 2021-09-30 0001140859 abc:ReceivablesSecuritizationFacilityMember 2022-09-30 0001140859 abc:ReceivablesSecuritizationFacilityMember 2021-09-30 0001140859 abc:TermLoanDueJune2023Member 2022-09-30 0001140859 abc:TermLoanDueJune2023Member 2021-09-30 0001140859 abc:OverdraftFacilityMember 2022-09-30 0001140859 abc:OverdraftFacilityMember 2021-09-30 0001140859 abc:MultiCurrencyRevolvingCreditFacilityMember 2022-09-30 0001140859 abc:MultiCurrencyRevolvingCreditFacilityMember 2021-09-30 0001140859 abc:SeniorNotesDue2023Member 2022-09-30 0001140859 abc:SeniorNotesDue2023Member 2021-09-30 0001140859 abc:SeniorNotesDue2024Member 2022-09-30 0001140859 abc:SeniorNotesDue2024Member 2021-09-30 0001140859 abc:SeniorNotesDue2025Member 2022-09-30 0001140859 abc:SeniorNotesDue2025Member 2021-09-30 0001140859 abc:SeniorNotesDue2027Member 2022-09-30 0001140859 abc:SeniorNotesDue2027Member 2021-09-30 0001140859 abc:SeniorNotesDue2030Member 2022-09-30 0001140859 abc:SeniorNotesDue2030Member us-gaap:NotesPayableToBanksMember 2020-05-31 0001140859 abc:SeniorNotesDue2030Member 2021-09-30 0001140859 abc:SeniorNotesDue2031Member 2022-09-30 0001140859 abc:SeniorNotesDue2031Member 2021-09-30 0001140859 abc:SeniorNotesDue2045Member 2022-09-30 0001140859 abc:SeniorNotesDue2045Member 2021-09-30 0001140859 abc:SeniorNotesDue2047Member 2022-09-30 0001140859 abc:SeniorNotesDue2047Member 2021-09-30 0001140859 abc:AllianceHealthcareDebtMember 2022-09-30 0001140859 abc:AllianceHealthcareDebtMember 2021-09-30 0001140859 abc:NonrecourseDebtMember 2022-09-30 0001140859 abc:NonrecourseDebtMember 2021-09-30 0001140859 srt:ParentCompanyMember abc:RevolvingCreditNoteMember 2022-09-30 0001140859 srt:ParentCompanyMember abc:RevolvingCreditNoteMember 2021-09-30 0001140859 srt:MinimumMember abc:MultiCurrencyRevolvingCreditFacilityMember abc:SOFREURIBORCDORRFRMember 2021-10-01 2022-09-30 0001140859 srt:MaximumMember abc:MultiCurrencyRevolvingCreditFacilityMember abc:SOFREURIBORCDORRFRMember 2021-10-01 2022-09-30 0001140859 abc:MultiCurrencyRevolvingCreditFacilityMember abc:SOFREURIBORCDORRFRMember 2021-10-01 2022-09-30 0001140859 srt:MinimumMember abc:MultiCurrencyRevolvingCreditFacilityMember abc:AlternateBaseRateAndCanadianPrimeRateCdorRateMember 2021-10-01 2022-09-30 0001140859 srt:MaximumMember abc:MultiCurrencyRevolvingCreditFacilityMember abc:AlternateBaseRateAndCanadianPrimeRateCdorRateMember 2021-10-01 2022-09-30 0001140859 srt:MinimumMember abc:MultiCurrencyRevolvingCreditFacilityMember 2021-10-01 2022-09-30 0001140859 srt:MaximumMember abc:MultiCurrencyRevolvingCreditFacilityMember 2021-10-01 2022-09-30 0001140859 abc:MultiCurrencyRevolvingCreditFacilityMember 2021-10-01 2022-09-30 0001140859 us-gaap:CommercialPaperMember 2022-09-30 0001140859 us-gaap:CommercialPaperMember 2021-10-01 2022-09-30 0001140859 us-gaap:CommercialPaperMember 2021-09-30 0001140859 abc:OverdraftFacilityMember 2021-01-31 0001140859 abc:OverdraftFacilityMember 2021-02-28 0001140859 abc:TermLoanAgreementOctober2018Member 2020-10-31 0001140859 abc:TermLoanDueFebruary2021Member 2021-02-28 0001140859 abc:TermLoanDueFebruary2021Member 2021-04-30 0001140859 abc:TermLoanDueFebruary2021Member 2021-06-30 0001140859 abc:TermLoanDueFebruary2021Member 2021-09-01 2021-09-30 0001140859 abc:TermLoanDueFebruary2021Member 2022-03-01 2022-03-31 0001140859 abc:SeniorNotesDue2021Member us-gaap:NotesPayableToBanksMember 2020-05-31 0001140859 abc:SeniorNotesDue2021Member us-gaap:NotesPayableToBanksMember 2020-05-01 2020-05-31 0001140859 abc:SeniorNotesDue2023Member us-gaap:NotesPayableToBanksMember 2021-03-31 0001140859 abc:SeniorNotesDue2031Member us-gaap:NotesPayableToBanksMember 2021-03-31 0001140859 abc:SeniorNotesDue2023Member 2021-10-01 2022-09-30 0001140859 abc:WalgreensBootsAllianceIncAllianceHealthcareAllianceHealthcareEgyptMember 2022-09-30 0001140859 abc:WalgreensBootsAllianceIncAllianceHealthcareAllianceHealthcareEgyptMember 2021-09-30 0001140859 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-09-30 0001140859 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-09-30 0001140859 us-gaap:AccumulatedTranslationAdjustmentMember 2022-09-30 0001140859 us-gaap:AccumulatedTranslationAdjustmentMember 2021-09-30 0001140859 abc:AccumulatedOtherAdjustmentsAttributabletoParentMember 2022-09-30 0001140859 abc:AccumulatedOtherAdjustmentsAttributabletoParentMember 2021-09-30 0001140859 abc:October2018ShareRepurchaseProgramMember 2018-10-31 0001140859 abc:October2018ShareRepurchaseProgramMember 2018-10-01 2019-09-30 0001140859 abc:October2018ShareRepurchaseProgramMember 2019-10-01 2020-09-30 0001140859 abc:October2018ShareRepurchaseProgramMember 2020-10-01 2021-09-30 0001140859 abc:May2020ShareRepurchaseProgramMember 2020-05-31 0001140859 abc:May2020ShareRepurchaseProgramMember 2020-10-01 2021-09-30 0001140859 abc:May2020ShareRepurchaseProgramMember 2021-10-01 2022-09-30 0001140859 abc:May2022ShareRepurchaseProgramMember 2022-05-31 0001140859 abc:May2022ShareRepurchaseProgramMember 2021-10-01 2022-09-30 0001140859 abc:May2022ShareRepurchaseProgramMember 2022-09-30 0001140859 abc:May2022ShareRepurchaseProgramMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-31 0001140859 abc:May2022ShareRepurchaseProgramMember us-gaap:SubsequentEventMember 2022-11-01 2022-11-22 0001140859 abc:AmerisourceBergenMember us-gaap:InvestorMember abc:WalgreensBootsAllianceIncAllianceHealthcareMember 2022-09-30 0001140859 abc:WalgreensBootsAllianceIncAllianceHealthcareMember us-gaap:InvestorMember 2021-10-01 2022-09-30 0001140859 abc:WalgreensBootsAllianceIncAllianceHealthcareMember us-gaap:InvestorMember 2020-10-01 2021-09-30 0001140859 abc:WalgreensBootsAllianceIncAllianceHealthcareMember us-gaap:InvestorMember 2019-10-01 2020-09-30 0001140859 abc:WalgreensBootsAllianceIncAllianceHealthcareMember us-gaap:InvestorMember 2022-09-30 0001140859 abc:WalgreensBootsAllianceIncAllianceHealthcareMember us-gaap:InvestorMember 2021-09-30 0001140859 abc:EmployeeContributionFirstThreePercentOfSalaryMember 2021-10-01 2022-09-30 0001140859 abc:EmployeeContributionAdditionalTwoPercentOfSalaryMember 2021-10-01 2022-09-30 0001140859 abc:A2022OmnibusIncentivePlanMember 2022-09-30 0001140859 us-gaap:EmployeeStockOptionMember 2021-10-01 2022-09-30 0001140859 abc:NonEmployeeMember 2021-10-01 2022-09-30 0001140859 abc:GrantedPriorToFiscal2021Member us-gaap:RestrictedStockUnitsRSUMember 2021-10-01 2022-09-30 0001140859 abc:GrantedInFiscal2022Member us-gaap:RestrictedStockUnitsRSUMember 2021-10-01 2022-09-30 0001140859 us-gaap:RestrictedStockUnitsRSUMember 2021-10-01 2022-09-30 0001140859 us-gaap:RestrictedStockUnitsRSUMember 2020-10-01 2021-09-30 0001140859 us-gaap:RestrictedStockUnitsRSUMember 2019-10-01 2020-09-30 0001140859 us-gaap:RestrictedStockUnitsRSUMember 2021-09-30 0001140859 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0001140859 us-gaap:PerformanceSharesMember 2021-10-01 2022-09-30 0001140859 srt:MinimumMember us-gaap:PerformanceSharesMember 2021-10-01 2022-09-30 0001140859 srt:MaximumMember us-gaap:PerformanceSharesMember 2021-10-01 2022-09-30 0001140859 us-gaap:PerformanceSharesMember 2020-10-01 2021-09-30 0001140859 us-gaap:PerformanceSharesMember 2019-10-01 2020-09-30 0001140859 us-gaap:PerformanceSharesMember 2021-09-30 0001140859 us-gaap:PerformanceSharesMember 2022-09-30 0001140859 2020-10-01 0001140859 abc:MultidistrictLitigationAndOtherRelatedStateCourtLitigationMember us-gaap:PendingLitigationMember abc:ThreeLargestNationalDistributorsMember 2020-01-31 0001140859 abc:MultidistrictLitigationAndOtherRelatedStateCourtLitigationMember us-gaap:SettledLitigationMember abc:ThreeLargestNationalDistributorsMember 2021-10-01 2022-09-30 0001140859 abc:MultidistrictLitigationAndOtherRelatedStateCourtLitigationMember us-gaap:SettledLitigationMember 2021-10-01 2022-09-30 0001140859 abc:OpioidLawsuitsandInvestigationsMember 2021-07-01 2021-09-30 0001140859 abc:OpioidLawsuitsandInvestigationsMember 2022-09-30 0001140859 abc:OpioidLawsuitsandInvestigationsMember 2021-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:USHealthcareSolutionsMember abc:HumanHealthMember 2022-07-01 2022-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:USHealthcareSolutionsMember abc:HumanHealthMember 2021-07-01 2021-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:USHealthcareSolutionsMember abc:HumanHealthMember 2021-10-01 2022-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:USHealthcareSolutionsMember abc:AnimalHealthMember 2022-07-01 2022-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:USHealthcareSolutionsMember abc:AnimalHealthMember 2021-07-01 2021-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:USHealthcareSolutionsMember abc:AnimalHealthMember 2021-10-01 2022-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:USHealthcareSolutionsMember 2022-07-01 2022-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:USHealthcareSolutionsMember 2021-07-01 2021-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:USHealthcareSolutionsMember 2021-10-01 2022-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:InternationalHealthcareSolutionsMember abc:AllianceHealthcareMember 2021-10-01 2022-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:InternationalHealthcareSolutionsMember abc:AllianceHealthcareMember 2020-10-01 2021-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:InternationalHealthcareSolutionsMember abc:AllianceHealthcareMember 2019-10-01 2020-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:InternationalHealthcareSolutionsMember abc:OtherHealthcareSolutionsMember 2021-10-01 2022-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:InternationalHealthcareSolutionsMember abc:OtherHealthcareSolutionsMember 2020-10-01 2021-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:InternationalHealthcareSolutionsMember abc:OtherHealthcareSolutionsMember 2019-10-01 2020-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:InternationalHealthcareSolutionsMember 2021-10-01 2022-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:InternationalHealthcareSolutionsMember 2020-10-01 2021-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:InternationalHealthcareSolutionsMember 2019-10-01 2020-09-30 0001140859 us-gaap:IntersegmentEliminationMember 2021-10-01 2022-09-30 0001140859 us-gaap:IntersegmentEliminationMember 2020-10-01 2021-09-30 0001140859 us-gaap:IntersegmentEliminationMember 2019-10-01 2020-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:USHealthcareSolutionsMember 2020-10-01 2021-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:USHealthcareSolutionsMember 2019-10-01 2020-09-30 0001140859 us-gaap:OperatingSegmentsMember 2021-10-01 2022-09-30 0001140859 us-gaap:OperatingSegmentsMember 2020-10-01 2021-09-30 0001140859 us-gaap:OperatingSegmentsMember 2019-10-01 2020-09-30 0001140859 us-gaap:MaterialReconcilingItemsMember 2021-10-01 2022-09-30 0001140859 us-gaap:MaterialReconcilingItemsMember 2020-10-01 2021-09-30 0001140859 us-gaap:MaterialReconcilingItemsMember 2019-10-01 2020-09-30 0001140859 abc:USHealthcareSolutionsMember 2019-10-01 2020-09-30 0001140859 abc:InternationalHealthcareSolutionsMember 2019-10-01 2020-09-30 0001140859 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MoneyMarketFundsMember 2022-09-30 0001140859 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MoneyMarketFundsMember 2021-09-30 0001140859 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-09-30 0001140859 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-09-30 0001140859 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-09-30 0001140859 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-09-30 0001140859 us-gaap:SubsequentEventMember 2022-11-01 2022-11-22 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsCurrentMember 2021-09-30 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsCurrentMember 2021-10-01 2022-09-30 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsCurrentMember 2022-09-30 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsCurrentMember 2020-09-30 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsCurrentMember 2020-10-01 2021-09-30 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsCurrentMember 2019-09-30 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsCurrentMember 2019-10-01 2020-09-30 iso4217:USD shares iso4217:USD shares abc:segment pure abc:subsidiary iso4217:GBP abc:vote abc:claim abc:state 0001140859 2022 FY false http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201613Member http://fasb.org/us-gaap/2022#NonoperatingIncomeExpense 0.5 http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent 10-K true 2022-09-30 --09-30 false 1-16671 AMERISOURCEBERGEN CORP DE 23-3079390 1 West First Avenue Conshohocken, PA 19428-1800 610 727-7000 Common stock ABC NYSE Yes No Yes Yes Large Accelerated Filer false false true false 18539939166 205668628 Portions of the following document are incorporated by reference in the Part of this report indicated below:    Part III — Registrant's Proxy Statement for the 2023 Annual Meeting of Stockholders. 42 Ernst & Young LLP Philadelphia, Pennsylvania 3388189000 2547142000 1626729000 1356684000 18452675000 18167175000 15556394000 15368352000 1532061000 1271557000 172568000 221875000 487871000 853600000 0 372908000 39589758000 38802609000 2135003000 2162961000 8503886000 9030531000 4332737000 5256927000 237571000 290791000 1761661000 1793986000 56560616000 57337805000 40192890000 38009954000 2214592000 2856405000 1070473000 300213000 0 192069000 43477955000 41358641000 4632360000 6383711000 320274000 281070000 1620413000 1685296000 976583000 1082723000 5461758000 5961953000 0.01 0.01 600000000 292700490 206203817 600000000 290722533 208089298 2927000 2907000 5658733000 5465104000 2977646000 1670513000 -1830970000 -445442000 86496673 82633235 7019895000 6469728000 -211559000 223354000 282832000 361057000 71273000 584411000 56560616000 57337805000 238587006000 213988843000 189893926000 230290639000 207045615000 184702042000 8296367000 6943228000 5191884000 4848962000 3594251000 2767217000 386595000 326824000 280187000 307300000 178348000 110875000 123191000 272623000 6722346000 183059000 199288000 84961000 75936000 6373000 0 4946000 11324000 361652000 2366378000 2354197000 -5135354000 27352000 41736000 1581000 -210673000 -174074000 -137883000 0 0 -22175000 2183057000 2221859000 -5293831000 516517000 677251000 -1894273000 1666540000 1544608000 -3399558000 -32280000 4676000 9158000 1698820000 1539932000 -3408716000 8.15 7.48 -16.65 8.04 7.39 -16.65 208472000 205919000 204783000 211210000 208465000 204783000 1666540000 1544608000 -3399558000 -1426741000 -334522000 -7872000 4910000 10000 -1074000 -1421831000 -334512000 -8946000 244709000 1210096000 -3408504000 -68583000 6776000 -2923000 313292000 1203320000 -3405581000 2853000 4850142000 4235491000 -111965000 -6097604000 114289000 2993206000 35138000 0 35138000 -3408716000 9158000 -3399558000 3135000 -12081000 -8946000 1.66 343578000 343578000 21000 159512000 159533000 74411000 74411000 405692000 405692000 -1567000 67922000 66355000 9787000 9787000 -4000 722000 718000 2878000 5081776000 518335000 -108830000 -6513083000 179288000 -839636000 -21106000 -2988000 -24094000 1539932000 4676000 1544608000 -336612000 2100000 -334512000 1.76 366648000 366648000 23000 198727000 198750000 99594000 99594000 82150000 82150000 23547000 23547000 86089000 149052000 235141000 178264000 178264000 -6000 1082000 283000 1359000 2907000 5465104000 1670513000 -445442000 -6469728000 361057000 584411000 1698820000 -32280000 1666540000 -1385528000 -36303000 -1421831000 1.84 391687000 391687000 10000 93902000 93912000 93400000 93400000 512091000 512091000 38076000 38076000 3544000 3544000 -10000 -6327000 6098000 -239000 2927000 5658733000 2977646000 -1830970000 -7019895000 282832000 71273000 1666540000 1544608000 -3399558000 390643000 326713000 290744000 319192000 188073000 117269000 26053000 12101000 11912000 196184000 334866000 -1544971000 93400000 99594000 74411000 67171000 -203028000 7422000 80882000 31697000 361652000 56228000 0 0 51966000 0 0 4834000 64721000 0 0 0 -22175000 -11781000 -29361000 3044000 1659525000 930078000 1628991000 665370000 1116344000 1621143000 -49307000 -266552000 482569000 -102708000 -141057000 -28050000 3320725000 2049167000 3300832000 -457233000 372078000 524021000 -330079000 -178120000 -50115000 -500195000 -236990000 6198943000 2703088000 2666586000 2207040000 496318000 438217000 369677000 133814000 5563040000 0 18491000 162620000 56080000 6302000 14439000 36364000 272586000 0 0 -1298000 -7861000 -9522000 -368437000 -6141577000 -379871000 155189000 3166980000 599480000 1238954000 835313000 598452000 4832605000 4968815000 116946000 4671943000 5083930000 149980000 0 0 21448000 483704000 82150000 420449000 93912000 198750000 159533000 391687000 366648000 343578000 0 0 66355000 38076000 23547000 9787000 -10122000 9892000 -2237000 -1752780000 1952849000 -603617000 -57850000 -3725000 0 524021000 -1525867000 1223552000 -610000 -1751000 0 523411000 -1527618000 1223552000 3070128000 4597746000 3374194000 3593539000 3070128000 4597746000 Summary of Significant Accounting Policies<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AmerisourceBergen Corporation and its subsidiaries, including less-than-wholly-owned subsidiaries in which AmerisourceBergen Corporation has a controlling financial interest (the "Company"), is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company delivers innovative programs and services designed to improve the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company undertook a strategic evaluation of its reporting structure to reflect its expanded international presence as a result of the June 2021 acquisition of Alliance Healthcare. As a result, at the beginning of fiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions. U.S. Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable segment (excluding Profarma Distribuidora de Produtos Farmacêuticos S.A. ("Profarma")), MWI Animal Health ("MWI"), Xcenda, Lash Group, and ICS 3PL. International Healthcare Solutions consists of Alliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). Profarma had previously been included in the Pharmaceutical Distribution Services reportable segment. The Company’s prior period segment disclosures have been revised to reflect this change in reportable segments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements present the consolidated financial position, results of operations, and cash flows of the Company as of the dates and for the periods indicated. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts due to uncertainties inherent in such estimates. Management periodically evaluates estimates used in the preparation of the financial statements for continued reasonableness.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectibility of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. ASU 2016-13 was effective for annual reporting periods beginning after December 15, 2019, including interim periods within those fiscal years, and a modified retrospective approach was required, with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance was effective. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU 2016-13 as of October 1, 2020. In connection with the adoption of ASU 2016-13, the Company recognized a $21.1 million, net of tax of $6.1 million, cumulative adjustment to retained earnings. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company's credit loss policy, refer to the "Concentrations of Credit Risk and Allowance for Credit Losses" section of Note 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes" ("ASU 2019-12"). ASU 2019-12 removes certain exceptions to the general principles in Accounting Standards Codification ("ASC") 740 in order to reduce the cost and complexity of its application. ASU 2019-12 was effective for annual reporting periods beginning after December 15, 2020, including interim periods within those fiscal years, with certain amendments applied on a modified retrospective basis, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption, and others prospectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU No. 2019-12 as of October 1, 2021. The adoption of ASU No. 2019-12 had no impact on the Company's financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, there were no recently issued accounting standards that may have a material impact on the Company's financial position, results of operations, or cash flows upon their adoption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets acquired and liabilities assumed from an acquired business are recorded at fair value, with the residual of the purchase price recorded as goodwill. The results of operations of an acquired businesses are included in the Company's operating results from the date of acquisition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to maintain certain cash deposits with banks mainly consisting of deposits restricted under contractual agency agreements and cash restricted by law and other obligations, including opioid-related legal settlements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a reconciliation of cash and cash equivalents in the Consolidated Balance Sheets to cash, cash equivalents, and restricted cash in the Consolidated Statements of Cash Flows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(amounts in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,388,189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,597,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in Prepaid Expenses and Other)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in Other Assets)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,593,539 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,070,128 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,597,746 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Allowance for Credit Losses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells its inventories to a large number of customers in the healthcare industry that include institutional and retail healthcare providers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies and providers of pharmacy services to such facilities, and physician offices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies, pharmacy departments of supermarkets and mass merchandisers, and veterinarians. The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's trade accounts receivables are exposed to credit risk. Revenue from the various agreements and arrangements with the Company's largest customer in the fiscal year ended September 30, 2022, Walgreens Boots Alliance, Inc. ("WBA"), accounted for approximately 27% of revenue and represented approximately 38% of accounts receivable, net of incentives, as of September 30, 2022. Express Scripts, Inc., the Company's second largest customer in the fiscal year ended September 30, 2022, accounted for approximately 13% of revenue and represented approximately 7% of accounts receivable as of September 30, 2022. The Company generally does not require collateral for trade receivables. The Company evaluates its receivables for risk of loss by grouping its receivables with similar risk characteristics. Expected losses are determined based on a combination of historical loss trends, current economic conditions, and forward-looking risk factors. Changes in these factors, among others, may lead to adjustments in the Company's allowance for credit losses. The calculation of the required allowance requires judgment by Company management as to the impact of those and other factors on the ultimate realization of its trade receivables. Each of the Company's business units performs ongoing credit evaluations of its customers' financial condition and maintains reserves for expected credit losses for specific credit problems when they arise. There were no significant changes to this process during the fiscal years ended September 30, 2022, 2021, and 2020, and bad debt expense was computed in a consistent manner during these periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains cash, cash equivalents, and restricted cash with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and, therefore, bear minimal credit risk. The Company seeks to mitigate such risks by monitoring the risk profiles of these counterparties. The Company also seeks to mitigate risk by monitoring the investment strategy of money market accounts in which it is invested, which are classified as cash equivalents.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss Contingencies:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, stockholder demands, and other disputes, including antitrust, commercial, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a liability when it is both probable that a loss has been incurred and the amount can be reasonably estimated. The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued. If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, the Company provides disclosure of the loss contingency in the notes to its financial statements. The Company reviews all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made. Among the loss contingencies that the Company considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain Contingencies:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company records gain contingencies when they are realized. Gains from antitrust litigation settlements are realized upon the receipt of cash and recorded as a reduction to cost of goods sold because they represent a recovery of amounts historically paid to manufacturers to originally acquire the pharmaceuticals that were the subject of the antitrust litigation settlements (see Note 14).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes derivative financial instruments to manage exposures to foreign currency. The Company records all derivative financial instruments on the balance sheet at fair value and complies with established criteria for designation and effectiveness of hedging relationships. The Company's policy prohibits it from entering into derivative financial instruments for speculative or trading purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the functional currency of the Company's foreign operations is the applicable local currency, assets and liabilities are translated into U.S. dollars using the current exchange rates in effect at the balance sheet date, while revenues and expenses are translated at the weighted average exchange rates for the period. The resulting asset and liability translation adjustments are recorded as a component of Accumulated Other Comprehensive Loss within Stockholders' Equity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended March 31, 2022, Turkey became a highly inflationary economy, as defined under U.S. GAAP. As a result, effective April 1, 2022, and until such time as the applicable economy is no longer considered highly inflationary, Turkish Lira-denominated assets and liabilities are remeasured using the Company's reporting currency in accordance with ASC 830, "Foreign Currency Matters." Turkish Lira denominated monetary assets and liabilities (primarily cash, accounts receivables, and accounts payables) are remeasured at each balance sheet date using the currency exchange rate then in effect, with currency remeasurement gains and losses recognized in Other Income in the Statement of Operations. Turkish Lira-denominated nonmonetary assets and liabilities (primarily inventories, goodwill, and other intangible assets) are translated at the currency exchange rate in effect prior to highly inflation accounting commencement or at the exchange rate in effect at their date of acquisition if subsequent to April 1, 2022. As such, nonmonetary assets and liabilities retain a higher historical basis when currencies are devalued. This higher historical basis results in incremental expense being recognized when nonmonetary assets are consumed (i.e., sale of inventory). During the fiscal year ended September 30, 2022, the Company recorded an incremental expense of $40.0 million in Cost of Goods Sold related to the consumption of inventory and an expense of $11.9 million within Other Income related to the currency remeasurement of monetary assets and liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill arises from acquisitions or consolidations of specific operating companies and is assigned to the reporting unit in which a particular operating company resides. The Company identifies its reporting units based upon the Company's management reporting structure, beginning with its operating segments. The Company aggregates two or more components within an operating segment that have similar economic characteristics. The Company evaluates whether the components within its operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment. The Company announced a strategic reorganization of its business and began reporting externally under the new structure as of October 1, 2021. As of September 30, 2022, the Company’s reporting units include Pharmaceutical Distribution Services, U.S. Consulting Services, MWI, Alliance Healthcare, Innomar, World Courier, and Profarma.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and other intangible assets with indefinite lives, such as certain trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. For the purpose of these impairment tests, the Company can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite-lived intangible assets, respectively. Such qualitative factors can include, among others, industry and market conditions, overall financial performance, and relevant entity-specific events. If the Company concludes based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis. The Company elected to perform a quantitative impairment assessment of goodwill and indefinite-lived intangible assets in fiscal 2022. The Company elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in fiscal 2021, with the exception of its testing of goodwill in the AmerisourceBergen Consulting Services (the sum of U.S. Consulting Service and Innomar reporting units, under the Company’s prior reporting structure) and Profarma reporting units. The Company elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in fiscal 2020, with the exception of its testing of goodwill and indefinite-lived intangibles in the MWI and Profarma reporting units.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative goodwill impairment test requires the Company to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit. If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized. If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performing a quantitative impairment assessment, the Company utilizes an income-based approach to value its reporting units, with the exception of the Profarma reporting unit, the fair value of which is based upon its publicly-traded stock price, plus an estimated control premium. The income-based approach relies on a discounted cash flow analysis, which considers forecasted cash flows discounted at an appropriate discount rate, to determine the fair value of each reporting unit. The Company generally believes that market participants would use a discounted cash flow analysis to determine the fair value of the Company's reporting units in a sale transaction. The annual goodwill impairment test requires the Company to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon the Company's long-range plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both debt and equity, including a risk premium. While the Company uses the best available information to prepare its forecasted cash flows and discount rate assumptions, actual future cash flows and/or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, the Company's overall methodology and the population of assumptions used have remained unchanged.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative impairment test for indefinite-lived intangibles other than goodwill (certain trademarks and trade names) consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date. The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method. The Company believes the relief from royalty method is a widely used valuation technique for such assets. The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed its required annual impairment tests relating to goodwill and indefinite-lived intangible assets in the fiscal years ended September 30, 2022, 2021, and 2020. The Company recorded goodwill impairments of $75.9 million and $6.4 million in its Profarma reporting unit in connection with its fiscal 2022 and 2021 impairment tests (see Note 5), respectively. No goodwill impairments were recorded in the fiscal years ended September 30, 2020, and no indefinite-lived intangible asset impairments were recorded in the fiscal years ended September 30, 2022, 2021, or 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangible assets are amortized using the straight-line method over the estimated useful lives of the assets. The Company performs a recoverability assessment of its long-lived assets when impairment indicators are present.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded impairments of intangible and tangible assets totaling $361.7 million in the fiscal year ended September 30, 2020 in connection with the permanent shutdown of its compounding business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Held for Sale</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities to be disposed of by sale ("disposal groups") are reclassified into assets and liabilities held for sale on the Company's Consolidated Balance Sheet. The reclassification occurs when an agreement to sell exists, or management has committed to a plan to sell the assets within one year. Disposal groups are measured at the lower of carrying value or fair value less costs to sell and are not depreciated or amortized. When the net realizable value of a disposal group increases during a period, a gain can be recognized to the extent that it does not increase the value of the disposal group beyond its original carrying value when the disposal group was reclassified as held for sale. The fair value of a disposal group, less any costs to sell, is assessed each reporting period it remains classified as held for sale and any remeasurement to the lower of carrying value or fair value less costs to sell is reported as an adjustment to the carrying value of the disposal group. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities (commonly known as the asset and liability method). In assessing the need to establish a valuation allowance on deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including settlements with tax authorities or resolutions of any related appeals or litigation processes, based upon the technical merits of the position. Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based upon the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or market. Cost for approximately 66% of the Company's inventories as of September 30, 2022 and 2021 has been determined using the last-in, first-out ("LIFO") method. If the Company had used the first-in, first-out method of inventory valuation, which approximates current replacement cost, inventories would have been approximately $1,383.4 million and $1,316.2 million higher than the amounts reported as of September 30, 2022 and 2021, respectively. The Company recorded LIFO expense of $67.2 million and $7.4 million in the fiscal years ended September 30, 2022 and 2020, respectively, and a LIFO credit of $203.0 million in the fiscal year ended September 30, 2021. The annual LIFO provision is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict. Changes to any of the above factors can have a material impact to the Company's annual LIFO provision.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company first evaluates its investments in accordance with the variable interest model to determine whether it has a controlling financial interest in an investment. This evaluation is made as of the date on which the Company makes its initial investment, and subsequent evaluations are made if the structure of the investment changes. If it has determined that an investment is a variable interest entity ("VIE"), the Company evaluates whether the VIE is required to be consolidated. When the Company holds rights that give it the power to direct the activities of an entity that most significantly impact the entity's economic performance, combined with the obligation to absorb an entity's losses and the right to receive benefits, the Company consolidates a VIE. If it is determined that an investment is not a VIE, the Company then evaluates its investments under the voting interest model and generally consolidates investments in which it holds an ownership interest of greater than 50%. When the Company consolidates less-than-wholly-owned subsidiaries, it presents its noncontrolling interest in its consolidated financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    For equity securities without a readily determinable fair value, the Company uses the fair value measurement alternative and measures the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which the Company can exercise significant influence but does not control, it uses the equity method of accounting. The Company's share of earnings and losses of its investments is recorded in Other Income in the Consolidated Statements of Operations. The Company monitors its investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the facts and circumstances present. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. At the lease commencement date, operating and finance lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable and, as such, the Company uses its incremental borrowing rate to discount the lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term in a similar economic environment. Certain adjustments to the right-of-use ("ROU") asset may be required for items such as incentives received. The Company does not recognize on the balance sheet leases with terms of one year or less. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company has operating leases that are primarily comprised of buildings, office equipment, distribution center equipment, and vehicles. Some of the Company's leases include options to extend or early terminate the lease, which are included in the lease term when it is reasonably certain to exercise and there is a significant economic incentive to exercise that option. Certain lease agreements contain provisions for future rent increases. Lease payments included in the measurement of the lease liability comprise fixed payments. The Company combines lease and non-lease components as a single component. Operating lease cost is recognized over the expected lease term on a straight-line basis and is recorded in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations. Variable lease payments, which are primarily comprised of maintenance, taxes, and other payments based on usage, are recognized when the expense is incurred. The Company's leases do not contain residual value guarantees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturer Incentives</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers fees and other incentives received from its suppliers relating to the purchase and distribution of inventory to represent product discounts, and, as a result, they are recognized within cost of goods sold upon the sale of the related inventory.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 40 years for buildings and improvements and from 3 to 10 years for machinery, equipment, and other. The costs of repairs and maintenance are charged to expense as incurred.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes project costs relating to computer software developed or obtained for internal use when the activities related to the project reach the application development stage. Costs that are associated with preliminary stage activities, training, maintenance, and all other post-implementation stage activities are expensed as they are incurred. Software development costs are depreciated using the straight-line method over the estimated useful lives, which range from 3 to 10 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's property and equipment balances for the periods indicated:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, at cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,426 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,944 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840,852 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838,615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery, equipment, and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,424,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,113,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387,348 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,081,691 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,252,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,918,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,135,003 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,162,961 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues are primarily generated from the distribution of pharmaceutical products. The Company also generates revenues from global commercialization services, which include clinical trial support, post-approval and commercialization support, and global specialty transportation and logistics for the biopharmaceutical industry. See Note 15 for the Company's disaggregated revenue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue related to the distribution of products at a point in time when title and control transfers to customers and there is no further obligation to provide services related to such products. Service revenue is recognized over the period that services are provided to the customer. The Company is generally the principal in a transaction; </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therefore, revenue is primarily recorded on a gross basis. When the Company is the principal in a transaction, it has determined that it controls the ability to direct the use of the product or service prior to the transfer to a customer, it is primarily responsible for fulfilling the promise to provide the product or service to its customer, it has discretion in establishing pricing, and it controls the relationship with the customer. Revenue is recognized at the amount of consideration expected to be received. For the distribution business, revenue is primarily generated from a contract related to a confirmed purchase order with a customer in a distribution arrangement and is net of estimated sales returns and allowances, other customer incentives, and sales tax.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company is the agent in a transaction, the fee received from a manufacturer customer is recognized within revenue as the service is performed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit. The Company records an accrual for estimated customer sales returns at the time of sale to the customer based upon historical return trends. As of September 30, 2022 and 2021, the Company's accrual for estimated customer sales returns was $1,532.1 million and $1,271.6 million, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company accounts for the compensation cost of all share-based payments at fair value. The fair value of restricted stock units and performance stock units is based upon the grant date market price of the Company’s common stock. The Company estimated the fair value of options granted in fiscal 2020 using a binomial option pricing model. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Share-based compensation expense is recognized over the requisite service period within Distribution, Selling, and Administrative in the Consolidated Statements of Operations to correspond with the same line item as the cash compensation paid to employees. Compensation expense associated with nonvested performance stock units is dependent upon the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The income tax effects of awards are recognized when the awards vest or are settled and are recognized in Income Tax Expense in the Company’s Consolidated Statements of Operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs include all costs to warehouse, pick, pack, and deliver inventory to customers. These costs, which were $1,040.8 million, $809.3 million, and $665.3 million for the fiscal years ended September 30, 2022, 2021, and 2020, respectively, are included in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supplier Reserves</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company establishes reserves against amounts due from its suppliers relating to various price and rebate incentives, including deductions or billings taken against payments otherwise due to them from the Company. These reserve estimates are established based upon the judgment of Company management after carefully considering the status of current outstanding claims, historical experience with the suppliers, the specific incentive programs, and any other pertinent information available to the Company. The Company evaluates the amounts due from its suppliers on a continual basis and adjusts the reserve estimates when appropriate based upon changes in factual circumstances. The ultimate outcome of any outstanding claim may be different than the Company's estimate.</span></div> 2 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements present the consolidated financial position, results of operations, and cash flows of the Company as of the dates and for the periods indicated. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div> The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts due to uncertainties inherent in such estimates. Management periodically evaluates estimates used in the preparation of the financial statements for continued reasonableness <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectibility of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. ASU 2016-13 was effective for annual reporting periods beginning after December 15, 2019, including interim periods within those fiscal years, and a modified retrospective approach was required, with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance was effective. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU 2016-13 as of October 1, 2020. In connection with the adoption of ASU 2016-13, the Company recognized a $21.1 million, net of tax of $6.1 million, cumulative adjustment to retained earnings. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company's credit loss policy, refer to the "Concentrations of Credit Risk and Allowance for Credit Losses" section of Note 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes" ("ASU 2019-12"). ASU 2019-12 removes certain exceptions to the general principles in Accounting Standards Codification ("ASC") 740 in order to reduce the cost and complexity of its application. ASU 2019-12 was effective for annual reporting periods beginning after December 15, 2020, including interim periods within those fiscal years, with certain amendments applied on a modified retrospective basis, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption, and others prospectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU No. 2019-12 as of October 1, 2021. The adoption of ASU No. 2019-12 had no impact on the Company's financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, there were no recently issued accounting standards that may have a material impact on the Company's financial position, results of operations, or cash flows upon their adoption.</span></div> 21100000 6100000 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets acquired and liabilities assumed from an acquired business are recorded at fair value, with the residual of the purchase price recorded as goodwill. The results of operations of an acquired businesses are included in the Company's operating results from the date of acquisition.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to maintain certain cash deposits with banks mainly consisting of deposits restricted under contractual agency agreements and cash restricted by law and other obligations, including opioid-related legal settlements.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a reconciliation of cash and cash equivalents in the Consolidated Balance Sheets to cash, cash equivalents, and restricted cash in the Consolidated Statements of Cash Flows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(amounts in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,388,189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,597,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in Prepaid Expenses and Other)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in Other Assets)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,593,539 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,070,128 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,597,746 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a reconciliation of cash and cash equivalents in the Consolidated Balance Sheets to cash, cash equivalents, and restricted cash in the Consolidated Statements of Cash Flows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(amounts in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,388,189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,597,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in Prepaid Expenses and Other)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (included in Other Assets)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,593,539 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,070,128 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,597,746 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3388189000 2547142000 4597746000 144980000 462986000 0 60370000 60000000 0 3593539000 3070128000 4597746000 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Allowance for Credit Losses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells its inventories to a large number of customers in the healthcare industry that include institutional and retail healthcare providers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies and providers of pharmacy services to such facilities, and physician offices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies, pharmacy departments of supermarkets and mass merchandisers, and veterinarians. The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's trade accounts receivables are exposed to credit risk. Revenue from the various agreements and arrangements with the Company's largest customer in the fiscal year ended September 30, 2022, Walgreens Boots Alliance, Inc. ("WBA"), accounted for approximately 27% of revenue and represented approximately 38% of accounts receivable, net of incentives, as of September 30, 2022. Express Scripts, Inc., the Company's second largest customer in the fiscal year ended September 30, 2022, accounted for approximately 13% of revenue and represented approximately 7% of accounts receivable as of September 30, 2022. The Company generally does not require collateral for trade receivables. The Company evaluates its receivables for risk of loss by grouping its receivables with similar risk characteristics. Expected losses are determined based on a combination of historical loss trends, current economic conditions, and forward-looking risk factors. Changes in these factors, among others, may lead to adjustments in the Company's allowance for credit losses. The calculation of the required allowance requires judgment by Company management as to the impact of those and other factors on the ultimate realization of its trade receivables. Each of the Company's business units performs ongoing credit evaluations of its customers' financial condition and maintains reserves for expected credit losses for specific credit problems when they arise. There were no significant changes to this process during the fiscal years ended September 30, 2022, 2021, and 2020, and bad debt expense was computed in a consistent manner during these periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains cash, cash equivalents, and restricted cash with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and, therefore, bear minimal credit risk. The Company seeks to mitigate such risks by monitoring the risk profiles of these counterparties. The Company also seeks to mitigate risk by monitoring the investment strategy of money market accounts in which it is invested, which are classified as cash equivalents.</span></div> 0.27 0.38 0.13 0.07 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss Contingencies:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, stockholder demands, and other disputes, including antitrust, commercial, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a liability when it is both probable that a loss has been incurred and the amount can be reasonably estimated. The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued. If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, the Company provides disclosure of the loss contingency in the notes to its financial statements. The Company reviews all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made. Among the loss contingencies that the Company considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain Contingencies:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company records gain contingencies when they are realized. Gains from antitrust litigation settlements are realized upon the receipt of cash and recorded as a reduction to cost of goods sold because they represent a recovery of amounts historically paid to manufacturers to originally acquire the pharmaceuticals that were the subject of the antitrust litigation settlements (see Note 14).</span></div> <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes derivative financial instruments to manage exposures to foreign currency. The Company records all derivative financial instruments on the balance sheet at fair value and complies with established criteria for designation and effectiveness of hedging relationships. The Company's policy prohibits it from entering into derivative financial instruments for speculative or trading purposes.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the functional currency of the Company's foreign operations is the applicable local currency, assets and liabilities are translated into U.S. dollars using the current exchange rates in effect at the balance sheet date, while revenues and expenses are translated at the weighted average exchange rates for the period. The resulting asset and liability translation adjustments are recorded as a component of Accumulated Other Comprehensive Loss within Stockholders' Equity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended March 31, 2022, Turkey became a highly inflationary economy, as defined under U.S. GAAP. As a result, effective April 1, 2022, and until such time as the applicable economy is no longer considered highly inflationary, Turkish Lira-denominated assets and liabilities are remeasured using the Company's reporting currency in accordance with ASC 830, "Foreign Currency Matters." Turkish Lira denominated monetary assets and liabilities (primarily cash, accounts receivables, and accounts payables) are remeasured at each balance sheet date using the currency exchange rate then in effect, with currency remeasurement gains and losses recognized in Other Income in the Statement of Operations. Turkish Lira-denominated nonmonetary assets and liabilities (primarily inventories, goodwill, and other intangible assets) are translated at the currency exchange rate in effect prior to highly inflation accounting commencement or at the exchange rate in effect at their date of acquisition if subsequent to April 1, 2022. As such, nonmonetary assets and liabilities retain a higher historical basis when currencies are devalued. This higher historical basis results in incremental expense being recognized when nonmonetary assets are consumed (i.e., sale of inventory). During the fiscal year ended September 30, 2022, the Company recorded an incremental expense of $40.0 million in Cost of Goods Sold related to the consumption of inventory and an expense of $11.9 million within Other Income related to the currency remeasurement of monetary assets and liabilities.</span></div> 40000000 11900000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill arises from acquisitions or consolidations of specific operating companies and is assigned to the reporting unit in which a particular operating company resides. The Company identifies its reporting units based upon the Company's management reporting structure, beginning with its operating segments. The Company aggregates two or more components within an operating segment that have similar economic characteristics. The Company evaluates whether the components within its operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment. The Company announced a strategic reorganization of its business and began reporting externally under the new structure as of October 1, 2021. As of September 30, 2022, the Company’s reporting units include Pharmaceutical Distribution Services, U.S. Consulting Services, MWI, Alliance Healthcare, Innomar, World Courier, and Profarma.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and other intangible assets with indefinite lives, such as certain trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. For the purpose of these impairment tests, the Company can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite-lived intangible assets, respectively. Such qualitative factors can include, among others, industry and market conditions, overall financial performance, and relevant entity-specific events. If the Company concludes based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis. The Company elected to perform a quantitative impairment assessment of goodwill and indefinite-lived intangible assets in fiscal 2022. The Company elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in fiscal 2021, with the exception of its testing of goodwill in the AmerisourceBergen Consulting Services (the sum of U.S. Consulting Service and Innomar reporting units, under the Company’s prior reporting structure) and Profarma reporting units. The Company elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in fiscal 2020, with the exception of its testing of goodwill and indefinite-lived intangibles in the MWI and Profarma reporting units.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative goodwill impairment test requires the Company to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit. If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized. If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performing a quantitative impairment assessment, the Company utilizes an income-based approach to value its reporting units, with the exception of the Profarma reporting unit, the fair value of which is based upon its publicly-traded stock price, plus an estimated control premium. The income-based approach relies on a discounted cash flow analysis, which considers forecasted cash flows discounted at an appropriate discount rate, to determine the fair value of each reporting unit. The Company generally believes that market participants would use a discounted cash flow analysis to determine the fair value of the Company's reporting units in a sale transaction. The annual goodwill impairment test requires the Company to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon the Company's long-range plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both debt and equity, including a risk premium. While the Company uses the best available information to prepare its forecasted cash flows and discount rate assumptions, actual future cash flows and/or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, the Company's overall methodology and the population of assumptions used have remained unchanged.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative impairment test for indefinite-lived intangibles other than goodwill (certain trademarks and trade names) consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date. The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method. The Company believes the relief from royalty method is a widely used valuation technique for such assets. The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed its required annual impairment tests relating to goodwill and indefinite-lived intangible assets in the fiscal years ended September 30, 2022, 2021, and 2020. The Company recorded goodwill impairments of $75.9 million and $6.4 million in its Profarma reporting unit in connection with its fiscal 2022 and 2021 impairment tests (see Note 5), respectively. No goodwill impairments were recorded in the fiscal years ended September 30, 2020, and no indefinite-lived intangible asset impairments were recorded in the fiscal years ended September 30, 2022, 2021, or 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangible assets are amortized using the straight-line method over the estimated useful lives of the assets. The Company performs a recoverability assessment of its long-lived assets when impairment indicators are present.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded impairments of intangible and tangible assets totaling $361.7 million in the fiscal year ended September 30, 2020 in connection with the permanent shutdown of its compounding business.</span></div> 75900000 6400000 0 0 0 0 361700000 Held for SaleAssets and liabilities to be disposed of by sale ("disposal groups") are reclassified into assets and liabilities held for sale on the Company's Consolidated Balance Sheet. The reclassification occurs when an agreement to sell exists, or management has committed to a plan to sell the assets within one year. Disposal groups are measured at the lower of carrying value or fair value less costs to sell and are not depreciated or amortized. When the net realizable value of a disposal group increases during a period, a gain can be recognized to the extent that it does not increase the value of the disposal group beyond its original carrying value when the disposal group was reclassified as held for sale. The fair value of a disposal group, less any costs to sell, is assessed each reporting period it remains classified as held for sale and any remeasurement to the lower of carrying value or fair value less costs to sell is reported as an adjustment to the carrying value of the disposal group. <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities (commonly known as the asset and liability method). In assessing the need to establish a valuation allowance on deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including settlements with tax authorities or resolutions of any related appeals or litigation processes, based upon the technical merits of the position. Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based upon the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or market. Cost for approximately 66% of the Company's inventories as of September 30, 2022 and 2021 has been determined using the last-in, first-out ("LIFO") method. If the Company had used the first-in, first-out method of inventory valuation, which approximates current replacement cost, inventories would have been approximately $1,383.4 million and $1,316.2 million higher than the amounts reported as of September 30, 2022 and 2021, respectively. The Company recorded LIFO expense of $67.2 million and $7.4 million in the fiscal years ended September 30, 2022 and 2020, respectively, and a LIFO credit of $203.0 million in the fiscal year ended September 30, 2021. The annual LIFO provision is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict. Changes to any of the above factors can have a material impact to the Company's annual LIFO provision.</span></div> 0.66 0.66 1383400000 1316200000 67200000 7400000 -203000000 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company first evaluates its investments in accordance with the variable interest model to determine whether it has a controlling financial interest in an investment. This evaluation is made as of the date on which the Company makes its initial investment, and subsequent evaluations are made if the structure of the investment changes. If it has determined that an investment is a variable interest entity ("VIE"), the Company evaluates whether the VIE is required to be consolidated. When the Company holds rights that give it the power to direct the activities of an entity that most significantly impact the entity's economic performance, combined with the obligation to absorb an entity's losses and the right to receive benefits, the Company consolidates a VIE. If it is determined that an investment is not a VIE, the Company then evaluates its investments under the voting interest model and generally consolidates investments in which it holds an ownership interest of greater than 50%. When the Company consolidates less-than-wholly-owned subsidiaries, it presents its noncontrolling interest in its consolidated financial statements.</span></div> For equity securities without a readily determinable fair value, the Company uses the fair value measurement alternative and measures the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which the Company can exercise significant influence but does not control, it uses the equity method of accounting. The Company's share of earnings and losses of its investments is recorded in Other Income in the Consolidated Statements of Operations. The Company monitors its investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions. <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the facts and circumstances present. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. At the lease commencement date, operating and finance lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable and, as such, the Company uses its incremental borrowing rate to discount the lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term in a similar economic environment. Certain adjustments to the right-of-use ("ROU") asset may be required for items such as incentives received. The Company does not recognize on the balance sheet leases with terms of one year or less. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company has operating leases that are primarily comprised of buildings, office equipment, distribution center equipment, and vehicles. Some of the Company's leases include options to extend or early terminate the lease, which are included in the lease term when it is reasonably certain to exercise and there is a significant economic incentive to exercise that option. Certain lease agreements contain provisions for future rent increases. Lease payments included in the measurement of the lease liability comprise fixed payments. The Company combines lease and non-lease components as a single component. Operating lease cost is recognized over the expected lease term on a straight-line basis and is recorded in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations. Variable lease payments, which are primarily comprised of maintenance, taxes, and other payments based on usage, are recognized when the expense is incurred. The Company's leases do not contain residual value guarantees.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturer Incentives</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers fees and other incentives received from its suppliers relating to the purchase and distribution of inventory to represent product discounts, and, as a result, they are recognized within cost of goods sold upon the sale of the related inventory.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 40 years for buildings and improvements and from 3 to 10 years for machinery, equipment, and other. The costs of repairs and maintenance are charged to expense as incurred.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes project costs relating to computer software developed or obtained for internal use when the activities related to the project reach the application development stage. Costs that are associated with preliminary stage activities, training, maintenance, and all other post-implementation stage activities are expensed as they are incurred. Software development costs are depreciated using the straight-line method over the estimated useful lives, which range from 3 to 10 years.</span></div> P3Y P40Y P3Y P10Y P3Y P10Y <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's property and equipment balances for the periods indicated:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, at cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,426 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,944 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840,852 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838,615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery, equipment, and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,424,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,113,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387,348 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,081,691 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,252,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,918,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,135,003 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,162,961 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 122426000 129944000 840852000 838615000 3424070000 3113132000 4387348000 4081691000 2252345000 1918730000 2135003000 2162961000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues are primarily generated from the distribution of pharmaceutical products. The Company also generates revenues from global commercialization services, which include clinical trial support, post-approval and commercialization support, and global specialty transportation and logistics for the biopharmaceutical industry. See Note 15 for the Company's disaggregated revenue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue related to the distribution of products at a point in time when title and control transfers to customers and there is no further obligation to provide services related to such products. Service revenue is recognized over the period that services are provided to the customer. The Company is generally the principal in a transaction; </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therefore, revenue is primarily recorded on a gross basis. When the Company is the principal in a transaction, it has determined that it controls the ability to direct the use of the product or service prior to the transfer to a customer, it is primarily responsible for fulfilling the promise to provide the product or service to its customer, it has discretion in establishing pricing, and it controls the relationship with the customer. Revenue is recognized at the amount of consideration expected to be received. For the distribution business, revenue is primarily generated from a contract related to a confirmed purchase order with a customer in a distribution arrangement and is net of estimated sales returns and allowances, other customer incentives, and sales tax.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company is the agent in a transaction, the fee received from a manufacturer customer is recognized within revenue as the service is performed.</span></div>The Company's customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit. The Company records an accrual for estimated customer sales returns at the time of sale to the customer based upon historical return trends. As of September 30, 2022 and 2021, the Company's accrual for estimated customer sales returns was $1,532.1 million and $1,271.6 million, respectively. 1532100000 1271600000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company accounts for the compensation cost of all share-based payments at fair value. The fair value of restricted stock units and performance stock units is based upon the grant date market price of the Company’s common stock. The Company estimated the fair value of options granted in fiscal 2020 using a binomial option pricing model. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Share-based compensation expense is recognized over the requisite service period within Distribution, Selling, and Administrative in the Consolidated Statements of Operations to correspond with the same line item as the cash compensation paid to employees. Compensation expense associated with nonvested performance stock units is dependent upon the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The income tax effects of awards are recognized when the awards vest or are settled and are recognized in Income Tax Expense in the Company’s Consolidated Statements of Operations.</span></div> Shipping and Handling CostsShipping and handling costs include all costs to warehouse, pick, pack, and deliver inventory to customers. 1040800000 809300000 665300000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supplier Reserves</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company establishes reserves against amounts due from its suppliers relating to various price and rebate incentives, including deductions or billings taken against payments otherwise due to them from the Company. These reserve estimates are established based upon the judgment of Company management after carefully considering the status of current outstanding claims, historical experience with the suppliers, the specific incentive programs, and any other pertinent information available to the Company. The Company evaluates the amounts due from its suppliers on a continual basis and adjusts the reserve estimates when appropriate based upon changes in factual circumstances. The ultimate outcome of any outstanding claim may be different than the Company's estimate.</span></div> Acquisition and Assets and Liabilities Held for Sale<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2021, the Company acquired a majority of Walgreens Boots Alliance, Inc.'s ("WBA") Alliance Healthcare businesses ("Alliance Healthcare") for $6,662.0 million in cash, $229.1 million of the Company's common stock (2 million shares at the Company's June 1, 2021 opening stock price of $114.54 per share), and $6.1 million of other equity consideration. The net cash payment was $5,596.7 million, as the Company acquired $922.0 million of cash and cash equivalents and $143.3 million of restricted cash. The shares issued were from the Company's treasury stock on a first-in, first-out basis and were originally purchased for $149.1 million. In the fiscal year ended September 30, 2022, the Company's previous estimate of $96.9 million of accrued consideration was settled for $60.0 million, which resulted in a $36.9 million reduction to Goodwill. The $60.0 million cash payment is included in the total $6,662.0 million cash consideration. The Company funded the cash purchase price through a combination of cash on hand and new debt financing. The acquisition expands the Company's reach and solutions in pharmaceutical distribution and adds to the Company's depth and breadth of global manufacturer services.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed the purchase price allocation as of June 1, 2022 and recorded purchase accounting adjustments that reduced working capital account balances by $102.7 million, increased the corresponding deferred tax assets by $63.0 million, and decreased other assets by $13.3 million, which resulted in a $53.0 million increase to Goodwill. There were no measurement period adjustments recorded to the previously-reported opening balance sheet that would have had a material impact on the Company's previously-reported results of operations had those adjustments been recorded in the previous reporting periods. The final purchase price has been allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values at the date of the acquisition in the table that follows: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,662,020 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity (2 million shares of AmerisourceBergen Corporation common stock)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,080 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equity consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,061 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,897,161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recognized amounts of identifiable assets acquired and liabilities assumed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,628,056 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,647,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,030 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634,220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,496,338 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,735,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,922 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,393 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,986,284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,618,807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(765,463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(353,420)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(760,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(405,332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,903,959)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,082,325 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired, including restricted cash of $143,308 included in Prepaid Expenses and Other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,065,303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,596,717 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the intangible assets acquired of $3.7 billion and the estimated useful lives are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except useful lives)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,327,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,735,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill resulting from this acquisition is not expected to be deductible for income tax purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the $185.2 million noncontrolling interest in Alliance Healthcare Egypt, a 50%-owned subsidiary, was estimated by applying income and market-based approaches. This fair value measurement is based on inputs that are not observable in the market and; therefore, represents a fair value measurement categorized within Level 3 of the fair value hierarchy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $90.9 million of acquisition-related costs in connection with this acquisition. These costs are included in Acquisition, Integration, and Restructuring Expenses in the Company's Statements of Operations for the twelve months ended September 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part I. Other Information-Item 1A. Risk Factors of this Annual Report on Form 10-K for additional risk factors related to our strategic transactions with WBA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Held for Sale</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into agreements in the fourth quarter of fiscal 2021 to sell two of its non-core subsidiaries. In connection with entering into these agreements, the Company concluded that both disposal groups met the held for sale criteria and classified their assets and liabilities as held for sale as of September 30, 2021. One disposal group was included within the U.S. Healthcare Solutions reportable segment and the other disposal group was included within International Healthcare Solutions reportable segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the held for sale classification, the Company recorded a total loss of $16.3 million on the remeasurement of the disposal group held for sale in the U.S. Healthcare Solutions reportable segment to fair value less cost to sell, $4.9 million of which was recorded in Impairment of Assets on its Consolidated Statement of Operations in the fiscal year ended September 30, 2022. The Company previously recorded a loss of $11.3 million in fiscal year ended September 30, 2021. The Company completed the sales of the disposal groups in the fiscal year ended September 30, 2022 and received total proceeds of $267.6 million, subject to final working capital adjustments. In connection with the sales of these disposal groups, the Company recorded a gain of $52.6 million, which is included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwMDYxNDRhZjY2ZTQwMzZiMDA4Yzk3MGQyNWQ0YjJlL3NlYzo0MDA2MTQ0YWY2NmU0MDM2YjAwOGM5NzBkMjVkNGIyZV84OC9mcmFnOjVhODdlZWE2NTVmZDRkNGE4ODFhZTYyNTIxMDliYTQ2L3RleHRyZWdpb246NWE4N2VlYTY1NWZkNGQ0YTg4MWFlNjI1MjEwOWJhNDZfNzE0NjgyNTU5Njg0Nw_6a0562a2-293e-4ca4-a89e-392da961abcb">Other Income, Net</span> in the Company's Consolidated Statements of Operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets and liabilities of the combined disposal groups held for sale on the September 30, 2021 Consolidated Balance Sheet are comprised of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, less allowance for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,424 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,903 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on the remeasurement of a disposal group held for sale to fair value less cost to sell</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Total assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,908 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Total liabilities held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,069 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6662000000 229100000 2000000 114.54 6100000 5596700000 922000000 143300000 149100000 96900000 60000000 -36900000 60000000 6662000000 The Company completed the purchase price allocation as of June 1, 2022 and recorded purchase accounting adjustments that reduced working capital account balances by $102.7 million, increased the corresponding deferred tax assets by $63.0 million, and decreased other assets by $13.3 million, which resulted in a $53.0 million increase to Goodwill. There were no measurement period adjustments recorded to the previously-reported opening balance sheet that would have had a material impact on the Company's previously-reported results of operations had those adjustments been recorded in the previous reporting periods. The final purchase price has been allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values at the date of the acquisition in the table that follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,662,020 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity (2 million shares of AmerisourceBergen Corporation common stock)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,080 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equity consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,061 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,897,161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recognized amounts of identifiable assets acquired and liabilities assumed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,628,056 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,647,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,030 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634,220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,496,338 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,735,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,922 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,393 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,986,284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,618,807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(765,463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(353,420)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(760,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(405,332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,903,959)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,082,325 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired, including restricted cash of $143,308 included in Prepaid Expenses and Other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,065,303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,596,717 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -102700000 63000000 -13300000 53000000 6662020000 2000000 229080000 6061000 6897161000 921995000 3628056000 1647330000 355030000 634220000 2496338000 3735000000 33922000 534393000 13986284000 4618807000 765463000 353420000 760937000 405332000 6903959000 7082325000 185164000 235141000 143308000 1065303000 5596717000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the intangible assets acquired of $3.7 billion and the estimated useful lives are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except useful lives)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,327,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,735,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div> 3700000000 3327000000 P18Y 408000000 P11Y 3735000000 0 185200000 0.50 90900000 2 1 1 16300000 4900000 11300000 267600000 52600000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets and liabilities of the combined disposal groups held for sale on the September 30, 2021 Consolidated Balance Sheet are comprised of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, less allowance for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,424 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,903 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on the remeasurement of a disposal group held for sale to fair value less cost to sell</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Total assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,908 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Total liabilities held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,069 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1751000 182077000 123424000 11258000 3084000 31903000 22923000 7812000 -11324000 372908000 173104000 7234000 4225000 50000 5857000 1599000 192069000 Variable Interest Entity<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has substantial governance rights that allow it to direct the activities that significantly impact Profarma’s economic performance. As such, the Company consolidates the operating results of Profarma in its consolidated financial statements. The Company is not obligated to provide future financial support to Profarma. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assets and liabilities of Profarma are included in the Company's Consolidated Balance Sheet for the periods indicated:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:73.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,699 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivables, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,930 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,982 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,554 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,920 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,936 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,363 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665,831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,515 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,768 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,851 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,613 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,041 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467,454 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,059 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Profarma's assets can only be used to settle its obligations, and its creditors do not have recourse to the general credit of the Company. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Profarma Retail Equity Offering</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Profarma received $66.4 million through an equity offering of its retail business. The equity offering decreased Profarma's voting ownership interest in the retail business from 100% to 53.5%. Profarma continues to consolidate the operating results of the retail business in its consolidated financial statements.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assets and liabilities of Profarma are included in the Company's Consolidated Balance Sheet for the periods indicated:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:73.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,699 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivables, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,930 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,982 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,554 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,920 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,936 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,363 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665,831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,515 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,768 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,851 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,613 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,041 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467,454 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,059 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 23144000 33699000 192930000 148485000 207858000 168229000 63982000 62545000 35554000 31920000 0 75936000 66568000 70840000 71327000 74177000 661363000 665831000 215515000 162768000 47952000 38477000 60851000 64215000 64918000 52613000 25801000 37041000 52417000 57945000 467454000 413059000 66400000 1 0.535 Income Taxes<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's income (loss) before income taxes for the periods indicated:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351,696 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495,899 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,961,269)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831,361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725,960 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,183,057 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221,859 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,293,831)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's consolidated income tax expense (benefit) are summarized in the following table for the periods indicated:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision (benefit):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,969 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(473,751)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,659 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision (benefit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,333 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,385 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349,302)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred provision (benefit):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,328 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(914,613)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,516 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264,409)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,727 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,922 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365,949)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred provision (benefit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,184 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,866 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,544,971)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (benefit) for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,517 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677,251 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,894,273)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory U.S. federal income tax rate to the Company's consolidated effective income tax rate is as follows for the periods indicated:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory U.S. federal income tax rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local income tax rate, net of federal tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax effect of foreign operations</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation settlements and accruals (see Note 13)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax law changes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharMEDium worthless stock deduction</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARES Act</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.8%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Tax law changes include 5.7% related to UK Tax Reform and 1.6% related to Swiss Tax Reform in fiscal 2021 and 6.8% in fiscal 2020 related to Swiss Tax Reform.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">United Kingdom Tax Reform</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United Kingdom ("UK") government delivered a Spring Budget in March 2021 that set out a plan to provide continuing support for jobs and businesses as the UK recovers from the COVID-19 pandemic. The UK government Finance Act 2021 includes a provision to increase the corporate tax rate from 19% to 25% beginning on April 1, 2023. As a result, the Company recognized a deferred tax expense of $127.6 million to increase its deferred tax liabilities for the change in the tax rate in the fiscal year ended September 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Coronavirus Aid, Relief, and Economic Security Act</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Coronavirus Aid, Relief, and Economic Security ("CARES") Act became law on March 27, 2020. The CARES Act was a response to the market volatility and instability resulting from the coronavirus pandemic and included provisions to support businesses in the form of loans, grants, and tax changes, among other types of relief that were not previously available under the U.S. Tax Cuts and Jobs Act of 2017 (the "2017 Tax Act"). The CARES Act provided the Company relief through adjustments to net operating loss rules and the acceleration of available refunds for alternative minimum tax credit carryforwards.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PharMEDium</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company decided in January 2020 to shut down and permanently exit its compounding business. Following the decision to exit PharMEDium and in connection with the permanent shutdown of this business, PharMEDium underwent a voluntary change in tax status, which resulted in the Company recognizing a worthless stock ordinary income tax deduction of approximately $2.4 billion and, in turn, yielded a tax benefit of approximately $655 million. The estimated tax benefit was higher than it would have been prior to the enactment of the CARES Act as the net operating losses resulting from the worthless stock deduction could now be carried back to years with higher statutory tax rates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the PharMEDium worthless stock deduction, the Company recognized other discrete tax benefits primarily resulting from the CARES Act. In the aggregate, the Company recognized discrete tax benefits of $720.6 million in the fiscal year ended September 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's September 30, 2022 Consolidated Balance Sheet includes a current income tax receivable balance of $172.6 million primarily resulting from the recognition of the above discrete tax benefits.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Swiss Tax Reform</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Canton of Bern enacted tax reforms to comply with requirements imposed by earlier Swiss federal tax reforms, which were retroactively effective as of January 1, 2020. A key provision of the Swiss federal tax reforms was the elimination of cantonal preferential tax regimes, which had the effect of increasing overall tax rates on Swiss income. To phase in the tax rate increase, the canton of Bern granted a tax ruling to the Company that effectively reduces the Company's Swiss tax rate for a period of 10 years. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result of the aforementioned Swiss tax law change and ruling, the Company recorded a deferred tax asset in the fiscal year ended September 30, 2020 that is expected to be realized over the following 10 years. As of September 30, 2022, the deferred tax asset of $446.6 million was reduced by a $234.0 million valuation allowance for the amount that more likely than not will not be realized. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Canton of Bern approved its Budget 2021, which called for lowering its corporate income tax rate applicable to the Company’s Swiss operations effective October 1, 2020. As a result, the Company recognized a deferred tax expense to reduce its Swiss deferred tax asset for the change in tax rate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opioid Legal Accrual</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal years ended September 30, 2022, 2021, and 2020 the Company recorded accruals related to the opioid litigation settlements of $36.6 million, $147.7 million, and $6.6 billion, respectively (see Note 13). The Company's September 30, 2022 Consolidated Balance Sheet includes a net deferred tax asset of $981.6 million in connection with the total expense accrued.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the future tax consequences of differences between the tax bases of assets and liabilities and their financial reporting amounts. Significant components of the Company's deferred tax liabilities (assets) are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471,064 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388,913 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,896 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409,296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,616 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,086,201 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,273,553 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and tax credit carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(389,724)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,788)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,569)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,435)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,411)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(981,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,082,845)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee and retiree benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,682)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(446,605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(488,235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263,278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,933)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,466)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,320,618)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,417,579)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,703,359)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,879,048)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,382,842 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394,505 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company had $2.6 million of potential tax benefits from federal net operating loss carryforwards, which expire in 15 years, $136.0 million of potential tax benefits from state net operating loss carryforwards and $297.2 million of potential tax benefits from foreign net operating loss carryforwards, which have varying expiration dates. The Company had $6.0 million of state tax credit carryforwards and $3.1 million in foreign alternative minimum tax credit carryforwards. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the available positive and negative evidence to determine whether deferred tax assets are more likely than not to be realized. As a result of this assessment, valuation allowances have been recorded on certain deferred tax assets. For the fiscal year ended September 30, 2022 and 2021, the Company increased the valuation allowance on deferred tax assets by $78.7 million and $126.9 million, respectively. The increase in the valuation allowance in the fiscal year ended September 30, 2022 was primarily due to the increase in the valuation allowance against foreign net operating loss carryforwards. The increase in the valuation allowance in the fiscal year ended September 30, 2021 was primarily due to the valuation allowance established in connection with purchase accounting associated with Alliance Healthcare acquisition. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal years ended September 30, 2022, 2021, and 2020 tax benefits of $13.4 million, $8.2 million and $3.9 million, respectively, related to the exercise of employee stock options and lapses of restricted stock units were recorded in Income Tax Expense (Benefit) in the Company's Consolidated Statements of Operations. The tax benefits recognized in the fiscal years ended September 30, 2022, 2021, and 2020 are not necessarily indicative of amounts that may arise in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax payments, net of refunds, were $244.4 million, $93.5 million, and $139.4 million in the fiscal years ended September 30, 2022, 2021, and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative undistributed earnings of international subsidiaries were $3.7 billion as of September 30, 2022, $2.1 billion of which is considered permanently reinvested. It is not practicable to estimate the taxes that would be due if such earnings were to be repatriated in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various states and foreign jurisdictions. The Company is currently undergoing a U.S. federal income tax audit for fiscal years 2019 and 2018 and certain state and local income tax audits for various years. With few exceptions, the Company is no longer subject to U.S. federal tax </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">examinations for years before 2018, and state and local, or foreign income tax examinations by tax authorities for years before 2019. The Company believes it has adequate tax reserves to cover potential federal, state or foreign tax exposures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and 2021, the Company had unrecognized tax benefits, defined as the aggregate tax effect of differences between tax return positions and the benefits recognized in the Company's financial statements, of $553.2 million and $522.8 million, respectively ($479.6 million and $467.9 million, net of federal tax benefit, respectively). If recognized in the fiscal years ended September 30, 2022 and 2021, $461.4 million and $449.7 million, respectively, of these benefits would have reduced income tax expense and the effective tax rate. As of September 30, 2022 and 2021, included in the unrecognized tax benefits are $26.7 million and $22.4 million of interest and penalties, respectively, which the Company records in Income Tax Expense (Benefit) in the Company's Consolidated Statements of Operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, for the periods indicated is as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,351 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,657 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions of tax positions of the current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,074 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to tax positions of the prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,073 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,022 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions of tax positions of the prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,480)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration of statutes of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,489)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526,522 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,399 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,351 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the additions of unrecognized tax benefits in the fiscal year ended September 30, 2020 is $371.5 million for an unrecognized tax benefit related to the $6.6 billion legal accrual for litigation related to the global opioid settlement, as well as other opioid-related litigation, as disclosed in Note 13. The Company has applied significant judgment in estimating the amount of the opioid settlements that will be deductible for U.S. federal and state purposes. In estimating the amount that would be deductible, the Company considered prior U.S. tax case law, the amount and character of the damages sought in litigation, and other relevant factors. During the next 12 months, it is reasonably possible that tax audit resolutions and the expiration of statutes of limitations could result in a reduction of unrecognized tax benefits by approximately $21.2 million.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's income (loss) before income taxes for the periods indicated:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351,696 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495,899 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,961,269)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831,361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725,960 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,183,057 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221,859 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,293,831)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1351696000 1495899000 -5961269000 831361000 725960000 667438000 2183057000 2221859000 -5293831000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's consolidated income tax expense (benefit) are summarized in the following table for the periods indicated:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision (benefit):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,969 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(473,751)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,659 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision (benefit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,333 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,385 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349,302)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred provision (benefit):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,328 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(914,613)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,516 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264,409)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,727 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,922 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365,949)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred provision (benefit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,184 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,866 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,544,971)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (benefit) for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,517 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677,251 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,894,273)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 126969000 184375000 -473751000 39282000 30659000 30236000 154082000 127351000 94213000 320333000 342385000 -349302000 150328000 111428000 -914613000 31129000 47516000 -264409000 14727000 175922000 -365949000 196184000 334866000 -1544971000 516517000 677251000 -1894273000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory U.S. federal income tax rate to the Company's consolidated effective income tax rate is as follows for the periods indicated:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory U.S. federal income tax rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local income tax rate, net of federal tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax effect of foreign operations</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation settlements and accruals (see Note 13)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax law changes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharMEDium worthless stock deduction</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARES Act</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.8%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Tax law changes include 5.7% related to UK Tax Reform and 1.6% related to Swiss Tax Reform in fiscal 2021 and 6.8% in fiscal 2020 related to Swiss Tax Reform.</span></div></td></tr></table></div> 0.210 0.210 0.210 0.025 0.028 -0.005 -0.019 -0.005 0.010 0.004 0.008 -0.062 0 0.073 0.068 0 -0.011 0.124 0 0 0.012 0.017 0.002 0.001 0.237 0.305 0.358 0.057 0.016 0.068 127600000 2400000000 -655000000 -720600000 172600000 P10Y P10Y 446600000 234000000 36600000 147700000 6600000000 -981600000 Significant components of the Company's deferred tax liabilities (assets) are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471,064 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388,913 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,896 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,184,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409,296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,616 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,086,201 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,273,553 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and tax credit carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(389,724)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,788)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,569)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,435)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,411)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(981,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,082,845)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee and retiree benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,682)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(446,605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(488,235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263,278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,933)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,466)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,320,618)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,417,579)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,703,359)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,879,048)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,382,842 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394,505 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1471064000 1388913000 149896000 167974000 1184477000 1409296000 219616000 249920000 61148000 57450000 3086201000 3273553000 426651000 389724000 67788000 27569000 24435000 13411000 981627000 1082845000 22682000 26196000 446605000 488235000 241469000 263278000 33933000 37466000 75428000 88855000 2320618000 2417579000 617259000 538531000 1703359000 1879048000 1382842000 1394505000 2600000 P15Y 136000000 297200000 6000000 3100000 78700000 126900000 -13400000 -8200000 -3900000 244400000 93500000 139400000 3700000000 2100000000 553200000 522800000 479600000 467900000 461400000 449700000 26700000 22400000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, for the periods indicated is as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,351 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,657 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions of tax positions of the current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,074 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to tax positions of the prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,073 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,022 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions of tax positions of the prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,480)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiration of statutes of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,489)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526,522 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,399 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,351 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 500399000 478351000 105657000 21074000 20515000 385797000 5073000 17022000 5599000 0 0 6480000 24000 15489000 12222000 526522000 500399000 478351000 371500000 6600000000 21200000 Goodwill and Other Intangible Assets<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the change in the Company's reporting structure that is discussed in Note 1, the Company reallocated goodwill among the impacted reporting units using a relative fair value approach and assessed impairment before and after goodwill was reallocated. The following is a summary of the changes in the carrying value of goodwill, by reportable segment, for the fiscal years ended September 30, 2022 and 2021:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Healthcare Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International Healthcare Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as of September 30, 2020 (as revised)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,267,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439,217 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,706,719 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill recognized in connection with acquisitions (Note 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,469,152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale (Note 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,903)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127,159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as of September 30, 2021 (as revised)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,260,374 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,770,157 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,030,531 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill recognized in connection with acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill derecognized in connection with disposal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,936)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,936)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(497,761)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(502,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as of September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,280,240 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,223,646 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,503,886 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company's annual goodwill impairment test as of July 1, 2021, the Company recorded a goodwill impairment of $6.4 million in its Profarma reporting unit. The fair value of the reporting unit was determined based upon Profarma's publicly-traded stock price, plus an estimated control premium. This represents a level 2 nonrecurring fair value measurement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of a prolonged decline in Profarma’s stock price, the Company performed an impairment assessment over the Profarma reporting unit as of June 30, 2022 and recorded a goodwill impairment of $75.9 million in the fiscal year ended September 30, 2022. The Company determined the fair value of the Profarma reporting unit based upon Profarma’s publicly-traded stock price, plus an estimated control premium. This represents a level 2 nonrecurring fair value measurement. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Profarma impairment assessment, the Company first performed a recoverability assessment of Profarma’s long-lived assets by comparing the undiscounted cash flows to the carrying value of the Profarma asset group, and it was determined to be recoverable. However, the forecasted undiscounted cash flows used to perform the recoverability assessment are inherently uncertain and include assumptions that could differ from actual results in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other intangible assets:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:22.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived trade names</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668,119 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668,119 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,226,547 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(931,961)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,294,586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,838,549 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(718,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,119,799 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172,127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,041)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,009 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,436,825 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,104,088)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,332,737 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,115,718 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(858,791)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,256,927 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decreases in the gross amounts of finite-lived intangible assets since September 30, 2021 were primarily due to foreign currency translation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for finite-lived intangible assets was $307.3 million, $178.3 million, and $110.9 million in the fiscal years ended September 30, 2022, 2021, and 2020, respectively. Amortization expense for finite-lived intangible assets is estimated to be $275.5 million in fiscal 2023, $274.3 million in fiscal 2024, $273.3 million in fiscal 2025, $268.9 million in fiscal 2026, $264.2 million in 2027, and $2,308.6 million thereafter.</span></div> September 30, 2022 and 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Healthcare Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International Healthcare Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as of September 30, 2020 (as revised)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,267,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439,217 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,706,719 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill recognized in connection with acquisitions (Note 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,469,152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale (Note 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,903)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127,159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as of September 30, 2021 (as revised)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,260,374 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,770,157 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,030,531 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill recognized in connection with acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill derecognized in connection with disposal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,936)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,936)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(497,761)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(502,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as of September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,280,240 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,223,646 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,503,886 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 6267502000 439217000 6706719000 19076000 2469152000 2488228000 0 6373000 6373000 -27223000 -4680000 -31903000 1019000 -127159000 -126140000 6260374000 2770157000 9030531000 0 27186000 27186000 26143000 0 26143000 1224000 0 1224000 0 75936000 75936000 -5053000 -497761000 -502814000 6280240000 2223646000 8503886000 6400000 75900000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other intangible assets:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:22.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived trade names</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668,119 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668,119 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,226,547 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(931,961)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,294,586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,838,549 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(718,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,119,799 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172,127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,041)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,009 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,436,825 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,104,088)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,332,737 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,115,718 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(858,791)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,256,927 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of other intangible assets:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:22.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived trade names</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668,119 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668,119 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,226,547 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(931,961)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,294,586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,838,549 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(718,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,119,799 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172,127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609,050 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,041)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,009 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,436,825 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,104,088)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,332,737 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,115,718 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(858,791)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,256,927 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 667932000 667932000 668119000 668119000 P15Y 4226547000 931961000 3294586000 4838549000 718750000 4119799000 P11Y 542346000 172127000 370219000 609050000 140041000 469009000 5436825000 1104088000 4332737000 6115718000 858791000 5256927000 307300000 178300000 110900000 275500000 274300000 273300000 268900000 264200000 2308600000 Debt<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consisted of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving credit note</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables securitization facility due 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan due June 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Overdraft facility due 2024 (£10,000)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-currency revolving credit facility due 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.737% senior notes due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672,736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500,000, 3.400% senior notes due 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500,000, 3.250% senior notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497,669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750,000, 3.450% senior notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745,622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744,781 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500,000, 2.800% senior notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,348 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,738 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,000,000, 2.700% senior notes due 2031</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989,366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500,000, 4.250% senior notes due 2045</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,946 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500,000, 4.300% senior notes due 2047</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance Healthcare debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonrecourse debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,769 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,702,833 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,683,924 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less AmerisourceBergen Corporation current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672,736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less Alliance Healthcare current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less nonrecourse current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,632,360 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,383,711 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Multi-Currency Revolving Credit Facility</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a $2.4 billion multi-currency senior unsecured revolving credit facility ("Multi-Currency Revolving Credit Facility") with a syndicate of lenders, which was scheduled to expire in November 2026. In October 2022, the Company amended the Multi-currecy Revolving Credit Facility to extend the expiration to October 2027 and to make certain changes to effect a transition from the LIBOR interest rate benchmark to Term SOFR. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based upon the Company's debt rating and ranges from 80.5 basis points to 122.5 basis points over SOFR/EURIBOR/CDOR/RFR, as applicable (101.5 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee as of September 30, 2022) and from 0 basis points to 22.5 basis points over the alternate base rate and Canadian prime rate, as applicable. The Company pays facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on its debt rating, ranging from 7 basis points to 15 basis points, annually, of the total commitment (11 basis points as of September 30, 2022). The Company may choose to repay or reduce its commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which the Company was compliant as of September 30, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial Paper Program</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a commercial paper program whereby it may from time to time issue short-term promissory notes in an aggregate amount of up to $2.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase the Company's borrowing capacity as it is fully backed by the Company's Multi-Currency Revolving Credit Facility. There were no borrowings outstanding under the commercial paper program as of September 30, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables Securitization Facility</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a $1,450 million receivables securitization facility ("Receivables Securitization Facility"), which was scheduled to expire in November 2024. In October 2022, the Company amended the Receivables Securitization Facility (the “Receivables Amendment”) to extend the expiration for an additional one year to October 2025. In addition, the Receivables Amendment made certain changes to (i) substitute Term SOFR for LIBOR as a benchmark and establish procedures to choose a new benchmark if Term SOFR becomes unavailable, (ii) provide for the return of erroneous payments, if any, by purchasers, (iii) update provisions regarding compliance with sanctions and anti-money laundering laws, and (iv) implement certain other technical amendments. The Company has available to it an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters. Interest rates are based on prevailing market rates for short-term commercial paper or 30-day Term SOFR, plus a program fee. The Company pays a customary unused fee at prevailing market rates, annually, to maintain the availability under the Receivables Securitization Facility. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Receivables Securitization Facility, AmerisourceBergen Drug Corporation and a specialty distribution subsidiary sell on a revolving basis certain accounts receivable to Amerisource Receivables Financial Corporation, a wholly-owned special purpose entity, which in turn sells a percentage ownership interest in the receivables to financial institutions and commercial paper conduits sponsored by financial institutions. AmerisourceBergen Drug Corporation is the servicer of the accounts receivable under the Receivables Securitization Facility. As sold receivables are collected, additional receivables may be sold up to the maximum amount available under the facility. The facility is a financing vehicle utilized by the Company because it generally offers an attractive interest rate relative to other financing sources. The Company securitizes its trade accounts, which are generally non-interest bearing, in transactions that are accounted for as borrowings. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of September 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Note, Overdraft Facility, and Money Market Facility</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an uncommitted, unsecured line of credit available to it pursuant to a revolving credit note ("Revolving Credit Note"). The Revolving Credit Note provides the Company with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million. The Revolving Credit Note may be decreased or terminated by the bank or the Company at any time without prior notice. The Company also has an uncommitted U.K. overdraft facility ("Overdraft Facility") to fund short-term normal trading cycle fluctuations related to its MWI Animal Health business. In February 2021, the Company extended the Overdraft Facility to February 2024 and reduced the borrowing capacity from £30 million to £10 million. The Company has an uncommitted, unsecured line of credit available to it pursuant to a money market credit agreement ("Money Market Facility"). The Money Market Facility provides the Company with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $100 million. The Money Market Facility may be decreased or terminated by the bank or the Company at any time without prior notice.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term Loans</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's $400 million October 2018 Term Loan matured and was repaid in October 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company entered into a $1.0 billion variable-rate term loan (“February 2021 Term Loan”), which was available to be drawn on the closing date of the acquisition of Alliance Healthcare. In April 2021, the Company reduced its commitment under the February 2021 Term Loan to $500 million. In June 2021, the Company borrowed $500 million under the February 2021 Term Loan to finance a portion of the June 2021 Alliance Healthcare acquisition. The Company elected to make principal payments of $250 million in September 2021 and again in March 2022 to repay the loan that was scheduled to mature in 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company issued $500 million of 2.80% senior notes due May 15, 2030 (the "2030 Notes"). The 2030 Notes were sold at 99.71% of the principal amount and have an effective yield of 2.81%. Interest on the 2030 Notes is payable semi-annually in arrears, commencing on November 15, 2020. The 2030 Notes rank pari passu to the Company's other senior notes, the Multi-Currency Revolving Credit Facility, the Revolving Credit Note, the Overdraft Facility, and the Money Market Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the proceeds from the 2030 Notes to finance the early retirement of the $500 million of 3.50% senior notes that were due in 2021 and made a $21.4 million prepayment premium in connection with this early retirement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company issued $1,525 million of 0.737% senior notes due March 15, 2023 (the "2023 Notes"). The 2023 Notes were sold at 100.00% of the principal amount. Interest on the 2023 Notes is payable semi-annually in arrears, commencing on September 15, 2021. In March 2021, the Company issued $1,000 million of 2.700% senior notes due March 15, 2031 (the "2031 Notes"). The 2031 Notes were sold at 99.79% of the principal amount and have an effective yield of 2.706%. Interest on the 2031 Notes is payable semi-annually in arrears and commenced on September 15, 2021. The 2023 Notes and 2031 Notes rank pari passu to the Company's other senior notes, the Multi-Currency Revolving Credit Facility, the Revolving Credit Note, the Overdraft Facility, and the Money Market Facility. The Company used the proceeds from the 2023 Notes and the 2031 Notes to finance a portion of the June 2021 Alliance Healthcare acquisition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal year ended September 30, 2022, the Company elected to repay $850 million of 2023 Notes due in March 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The senior notes discussed above and also illustrated in the above debt table are collectively referred to as the "Notes." Interest on the Notes is payable semiannually in arrears. Most of the Notes were sold at small discounts to the principal amounts and, therefore, have effective yields that are greater than the stated interest rates in the table above. Costs incurred in connection with the issuance of the Notes were deferred and are being amortized over the terms of the Notes. The indentures governing the Notes contain restrictions and covenants, which include limitations on additional indebtedness; distributions to stockholders; the repurchase of stock and the making of other restricted payments; issuance of preferred stock; creation of certain liens; transactions with subsidiaries and other affiliates; and certain corporate acts such as mergers, consolidations, and the sale of substantially all assets. An additional covenant requires compliance with a financial leverage ratio test. The Company was compliant with all covenants as of September 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alliance Healthcare Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alliance Healthcare debt is comprised of uncommitted revolving credit facilities in various currencies with various rates. A majority of the outstanding borrowings were held in Egypt (which is 50% owned) as of September 30, 2022 and 2021. These facilities are used to fund its working capital needs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonrecourse Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Nonrecourse debt is comprised of short-term and long-term debt belonging to the Brazil subsidiaries and is repaid solely from the Brazil subsidiaries' cash flows and such debt agreements provide that the repayment of the loans (and interest thereon) is secured solely by the capital stock, physical assets, contracts, and cash flows of the Brazil subsidiaries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled future principal payments of debt are $1,071.8 million in fiscal 2023, $526.3 million in fiscal 2024, $873.2 million in fiscal 2025, $12.1 million in fiscal 2026, $2.7 million in fiscal 2027, and $3,252.6 million thereafter. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest paid on the above indebtedness during the fiscal years ended September 30, 2022, 2021, and 2020 was $219.8 million, $170.9 million, and $150.7 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of financing fees and the accretion of original issue discounts, which are recorded as components of Interest Expense, Net on the Consolidated Statements of Operations, were $11.9 million, $9.7 million, and $6.4 million, for the fiscal years ended September 30, 2022, 2021, and 2020, respectively.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consisted of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving credit note</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables securitization facility due 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan due June 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Overdraft facility due 2024 (£10,000)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-currency revolving credit facility due 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.737% senior notes due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672,736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500,000, 3.400% senior notes due 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500,000, 3.250% senior notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497,669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750,000, 3.450% senior notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745,622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744,781 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500,000, 2.800% senior notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,348 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,738 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,000,000, 2.700% senior notes due 2031</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989,366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500,000, 4.250% senior notes due 2045</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,946 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500,000, 4.300% senior notes due 2047</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance Healthcare debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonrecourse debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,769 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,702,833 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,683,924 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less AmerisourceBergen Corporation current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672,736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less Alliance Healthcare current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less nonrecourse current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,632,360 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,383,711 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div> 0 0 0 0 350000000 350000000 0 249640000 10000000 0 0 0 0 0.00737 672736000 1518223000 500000000 0.03400 499195000 498714000 500000000 0.03250 498347000 497669000 750000000 0.03450 745622000 744781000 500000000 0.02800 495348000 494738000 1000000000 0.0002700 990480000 989366000 500000000 0.04250 495162000 494946000 500000000 0.04300 493288000 493021000 336886000 235998000 125769000 116828000 5702833000 6683924000 672736000 0 336886000 235998000 60851000 64215000 4632360000 6383711000 2400000000 0.00805 0.01225 0.01015 0 0.00225 0.0007 0.0015 0.0011 2400000000 P365D 0 0 1450000000 250000000 75000000 30000000 10000000 100000000 400000000 1000000000 500000000 500000000 250000000 250000000 500000000 0.0280 0.009971 0.0281 500000000 0.0350 21400000 1525000000 0.00737 1.0000 1000000000 0.02700 0.9979 0.02706 850000000 0.50 0.50 1071800000 526300000 873200000 12100000 2700000 3252600000 219800000 170900000 150700000 11900000 9700000 6400000 Stockholders' Equity and Weighted Average Common Shares Outstanding<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authorized capital stock of the Company consists of 600,000,000 shares of common stock, par value $0.01 per share (the "common stock"), and 10,000,000 shares of preferred stock, par value $0.01 per share (the "preferred stock").</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the Company's common stock are entitled to one vote per share and have the exclusive right to vote for the board of directors and for all other purposes as provided by law. Subject to the rights of holders of the Company's preferred stock, holders of common stock are entitled to receive ratably on a per share basis such dividends and other distributions in cash, stock, or property of the Company as may be declared by the board of directors from time to time out of the legally available assets or funds of the Company. The opioid litigation accrual discussed in Note 13 has not and is not expected to impact the Company's ability to pay dividends.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following illustrates the components of Accumulated Other Comprehensive Loss, net of income taxes:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,038)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,750)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,820,292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,640)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,830,970)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(445,442)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in total accumulated other comprehensive loss from foreign currency translation primarily relates to the translation of the Company's Alliance Healthcare business' goodwill and intangible assets balances.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company's board of directors authorized a share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2019, the Company purchased 6.7 million shares of its common stock for a total of $538.9 million under this program, which included $14.8 million of September 2019 purchases that cash settled in October 2019. During the fiscal year ended September 30, 2020, the Company purchased 4.9 million shares of its common stock for a total of $405.6 million, which excluded $14.8 million of September 2019 purchases that cash settled in October 2019. During the fiscal year ended September 30, 2021, the Company purchased 0.6 million shares of its common stock for a total of $55.5 million to complete its authorization under this program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company's board of directors authorized a share repurchase program allowing the Company to purchase up to $500 million of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2021, the Company purchased 0.3 million shares of its common stock for $26.6 million. During the fiscal year ended September 30, 2022, the Company purchased 3.3 million shares of its common stock for $473.4 million to complete its authorization under this program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company's board of directors authorized a new share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2022, the Company purchased 0.3 million shares of its common stock for a total of $38.7 million, which included $28.4 million of September 2022 purchases that cash settled in October 2022. As of September 30, 2022, the Company had $961.3 million of availability remaining under this program. In October 2022, under this program, the Company purchased 0.6 million shares of its common stock for $78.8 million. In November 2022, under this program, the Company purchased 3.2 million shares of its common stock from WBA for $500.0 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Shares Outstanding</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income attributable to AmerisourceBergen Corporation by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed by dividing net income attributable to AmerisourceBergen Corporation by the weighted average number of shares of common stock outstanding, plus the dilutive effect of stock options and restricted stock units during the periods presented.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following illustrates the components of diluted weighted average shares outstanding:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,472 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,919 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,783 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities - stock options and restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,738 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,210 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,465 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,783 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The potentially dilutive stock options and restricted stock units that were antidilutive were 0.1 million for the fiscal years ended September 30, 2022 and 2021 and 4.2 million 600000000 0.01 10000000 0.01 1 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following illustrates the components of Accumulated Other Comprehensive Loss, net of income taxes:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,038)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,750)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,820,292)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,640)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,830,970)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(445,442)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div> -9038000 -5750000 -1820292000 -439692000 -1640000 0 -1830970000 -445442000 1000000000 6700000 538900000 14800000 4900000 405600000 14800000 600000 55500000 500000000 300000 26600000 3300000 473400000 1000000000 300000 38700000 28400000 961300000 600000 78800000 3200000 500000000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following illustrates the components of diluted weighted average shares outstanding:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,472 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,919 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,783 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities - stock options and restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,738 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,210 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,465 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,783 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 208472000 205919000 204783000 2738000 2546000 0 211210000 208465000 204783000 100000 100000 4200000 Related Party Transactions<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WBA continues to own more than 10% of the Company's outstanding common stock and is, therefore, considered a related party. The Company operates under various agreements and arrangements with WBA, including a pharmaceutical distribution agreement pursuant to which the Company distributes pharmaceutical products to WBA and an agreement that provides the Company the ability to access favorable economic pricing and generic products through a generic purchasing services arrangement with Walgreens Boots Alliance Development GmbH (both through 2029) as well as a distribution agreement pursuant to which it will supplies branded and generic pharmaceutical products to WBA’s Boots UK Ltd. subsidiary (through 2031). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the various agreements and arrangements with WBA was $64.1 billion, $65.5 billion, and $63.1 billion in the fiscal years ended September 30, 2022, 2021, and 2020, respectively. The Company's receivable from WBA, net of incentives, was $7.0 billion as of September 30, 2022 and 2021.</span></div> 0.10 64100000000 65500000000 63100000000 7000000000 7000000000 Retirement and Other Benefit Plans<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors various retirement benefit plans and a deferred compensation plan covering eligible employees. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation and Succession Planning Committee ("Compensation Committee") of the Company's board of directors has delegated the administration of the Company's retirement and other benefit plans to its Benefits Committee, an internal committee, comprised of senior finance, human resources, and legal executives. The Benefits Committee is responsible for the investment options under the Company's savings plans, as well as performance of the investment advisers and plan administrators.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Retirement Benefit Plans</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors the AmerisourceBergen Employee Investment Plan (the "Plan"), which is a defined contribution 401(k) plan covering salaried and certain hourly employees. Eligible participants may contribute to the plan from 1% to 50% of their regular compensation before taxes. The Company contributes $1.00 for each $1.00 invested by the participant up to the first 3% of the participant's salary and $0.50 for each additional $1.00 invested by the participant of up to an additional 2% of salary. An additional discretionary contribution, in an amount not to exceed the limits established by the Internal Revenue Code ("IRC"), may also be made depending upon the Company's performance. Based on the Company's performance in fiscal 2022, 2021, and 2020, the Company recognized expenses for discretionary contributions to the Plan in the fiscal years ended September 30, 2022, 2021, and 2020. All contributions are invested at the direction of the employee in one or more funds. All contributions vest immediately except for the discretionary contributions made by the Company, which vest in full after five years of credited service. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's international businesses sponsor various country-specific retirement plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of above retirement benefit plans charged to expense for the fiscal years ended September 30, 2022, 2021, and 2020 were $90.1 million, $62.3 million, and $45.9 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also sponsors the AmerisourceBergen Corporation Benefit Restoration Plan. This unfunded plan provides benefits to selected key management, including each of the Company's executive officers. This plan provides eligible participants with an annual amount equal to 4% of the participant's total cash compensation to the extent that his or her compensation exceeds the annual compensation limit established by Section 401(a) (17) of the IRC.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Compensation Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors the AmerisourceBergen Corporation 2001 Deferred Compensation Plan. This unfunded plan allows eligible officers, directors, and key management employees to defer a portion of their annual compensation. The amount deferred may be allocated by the employee among a selection of mutual funds. The Company's liability relating to its deferred compensation plan as of September 30, 2022 and 2021 was $31.7 million and $38.1 million, respectively.</span></div> 0.01 0.50 1.00 0.03 0.50 0.02 P5Y 90100000 62300000 45900000 0.04 31700000 38100000 Share-Based Compensation<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's stockholders approved the AmerisourceBergen Corporation 2022 Omnibus Incentive Plan (the "2022 Plan"). As of September 30, 2022, there were 25.4 million shares available to be granted for employee and non-employee director stock restricted stock units, performance stock units, and stock options under the 2022 Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's employee stock option plans provide for the granting of incentive and nonqualified stock options to acquire shares of common stock to employees at a price not less than the fair market value of the common stock on the dates options are granted. Option terms and vesting periods are determined at the date of grant by the Compensation Committee of the board of directors. Employee stock options generally vest ratably, in equal amounts, over a four-year service period and expire in seven years. The Company's non-employee director stock option plans provide for the granting of nonqualified stock options to acquire shares of common stock to non-employee directors at the fair market value of the common stock on the date of the grant. Non-employee director stock options vest ratably, in equal amounts, over a three-year service period and expire in ten years. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of options granted is expensed on a straight-line basis over the requisite service periods of the awards and are net of estimated forfeitures. The Company estimates the fair values of option grants using a binomial option pricing model. Expected volatilities are based upon the historical volatility of the Company's common stock and other factors, such as implied market volatility. The Company uses historical exercise data, taking into consideration the optionees' ages at grant date, to estimate the terms for which the options are expected to be outstanding. The risk-free rates during the terms of such options are based upon the U.S. Treasury yield curve in effect at the time of grant. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not grant any stock options to employees in fiscal 2022 and 2021, and it does not expect to grant any stock options in fiscal 2023. The weighted average fair values of the options granted during the fiscal year ended September 30, 2020 was $16.61. The following weighted average assumptions were used to estimate the fair values of options granted:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.649%"><tr><td style="width:1.0%"/><td style="width:77.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.663%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.626%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.66%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.86%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.17%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of the options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.79 years</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal years ended September 30, 2022, 2021, and 2020, the Company recognized stock option expense of $2.2 million, $4.6 million and $13.0 million, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company's stock option activity and related information for its option plans for the fiscal year ended September 30, 2022 is presented below:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except exercise price and contractual term)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,138 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,772 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$86</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$89</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,932 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,496 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,521 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$82</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest after September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$88</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,283 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value of stock options exercised during the fiscal years ended September 30, 2022, 2021, and 2020 was $60.3 million, $58.7 million, and $42.6 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company's nonvested options as of September 30, 2022 and changes during the fiscal year ended September 30, 2022 is presented below:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.391%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except grant date fair value)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested as of September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$18</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested as of September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$18</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal years ended September 30, 2022, 2021, and 2020, the total fair values of options vested were $10.0 million, $15.5 million, and $21.3 million, respectively. Expected future compensation expense relating to the 0.4 million nonvested options outstanding as of September 30, 2022 is $0.4 million, which will be recognized through November 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units granted prior to fiscal 2021 vest in full after three years. The majority of the restricted stock units granted beginning in fiscal 2021 and thereafter vest ratably over a three-year period. The estimated fair value of restricted stock units under the Company's restricted stock unit plans is determined by the product of the number of shares granted and the closing grant date market price of the Company's common stock. The estimated fair value of restricted stock units is expensed on a straight-line basis over the requisite service period, net of estimated forfeitures. During the fiscal years ended September 30, 2022, 2021, and 2020, the Company recognized restricted stock unit expense of $71.3 million, $55.8 million, and $39.8 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company's nonvested restricted stock units as of September 30, 2022 and changes during the fiscal year ended September 30, 2022 are presented below:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.391%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except grant date fair value)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested as of September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,838 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$98</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$127</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$98</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$106</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested as of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$108</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal years ended September 30, 2022, 2021, and 2020, the total fair values of restricted stock units vested were $58.1 million, $31.1 million, and $26.4 million, respectively. Expected future compensation expense relating to the 1.8 million restricted stock units outstanding as of September 30, 2022 is $71.2 million, which will be recognized over a weighted average period of 1.1 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Stock Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock units are granted to certain executive employees under the Plan and represent common stock potentially issuable in the future. Performance stock units vest at the end of a three-year performance period based upon achievement of specific performance goals. Based upon the extent to which the targets are achieved, vested shares may range from 0% to 200% of the target award amount. The fair value of performance stock units is determined by the grant date market price of the Company's common stock. Compensation expense associated with nonvested performance stock units is recognized over the requisite service period and is dependent on the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued. During the fiscal years ended September 30, 2022, 2021, and 2020, the Company recognized performance stock expense of $19.7 million, $38.9 million, and $21.5 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company's nonvested performance stock units as of September 30, 2022 and changes during the fiscal year ended September 30, 2022 is presented below (based upon target award amounts).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.391%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except grant date fair value)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Stock<br/>Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested as of September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$98</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$126</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$86</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$117</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested as of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$117</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares that vested over the three-year performance period ended September 30, 2022 were distributed to employees in November 2022.</span></div> 25400000 P4Y P4Y P7Y P3Y P3Y P10Y 16.61 The following weighted average assumptions were used to estimate the fair values of options granted:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.649%"><tr><td style="width:1.0%"/><td style="width:77.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.663%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.626%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.66%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.86%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.17%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of the options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.79 years</span></td></tr></table> 0.0166 0.0186 0.2817 P3Y9M14D 2200000 4600000 13000000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company's stock option activity and related information for its option plans for the fiscal year ended September 30, 2022 is presented below:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except exercise price and contractual term)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,138 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,772 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$86</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$89</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,932 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,496 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,521 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$82</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest after September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$88</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,283 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3138000 84 P3Y 109772000 1189000 86 17000 89 1932000 83 P3Y 100496000 1521000 82 P2Y 81000000 407000 88 P4Y 19283000 60300000 58700000 42600000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company's nonvested options as of September 30, 2022 and changes during the fiscal year ended September 30, 2022 is presented below:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.391%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except grant date fair value)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested as of September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$18</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested as of September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$18</span></td></tr></table></div> 1046000 17 617000 16 17000 18 412000 18 10000000 15500000 21300000 400000 400000 P3Y P3Y 71300000 55800000 39800000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company's nonvested restricted stock units as of September 30, 2022 and changes during the fiscal year ended September 30, 2022 are presented below:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.391%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except grant date fair value)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested as of September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,838 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$98</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$127</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$98</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$106</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested as of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$108</span></td></tr></table></div> 1838000 98 726000 127 592000 98 166000 106 1806000 108 58100000 31100000 26400000 1800000 71200000 P1Y1M6D P3Y 0 2 19700000 38900000 21500000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company's nonvested performance stock units as of September 30, 2022 and changes during the fiscal year ended September 30, 2022 is presented below (based upon target award amounts).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.391%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except grant date fair value)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Stock<br/>Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested as of September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$98</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$126</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$86</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$117</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested as of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$117</span></td></tr></table></div> 296000 98 131000 126 148000 86 2000 117 277000 117 P3Y Leases<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has long-term leases for facilities and equipment. In the normal course of business, leases are generally renewed or replaced by other leases. Certain leases include escalation clauses. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following illustrates the components of lease cost for the periods presented:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.181%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,935 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,054 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,901 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,814 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,300 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,163 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,590 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes balance sheet information related to operating leases:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:62.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.506%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except for lease term and discount rate)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right of use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwMDYxNDRhZjY2ZTQwMzZiMDA4Yzk3MGQyNWQ0YjJlL3NlYzo0MDA2MTQ0YWY2NmU0MDM2YjAwOGM5NzBkMjVkNGIyZV8xMjEvZnJhZzo2ZTIwNmNkODY2NTQ0YmQ0OGQwYmQxNDE4NGRkOGNiMS90YWJsZTo0NjY0MDIxMzNmYzM0YTdjOGE2YmFjNDlkODBmODA2Ny90YWJsZXJhbmdlOjQ2NjQwMjEzM2ZjMzRhN2M4YTZiYWM0OWQ4MGY4MDY3XzMtMC0xLTEtODMxMDQ_3efbf3f6-d611-4929-8bf8-3206ae75660a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwMDYxNDRhZjY2ZTQwMzZiMDA4Yzk3MGQyNWQ0YjJlL3NlYzo0MDA2MTQ0YWY2NmU0MDM2YjAwOGM5NzBkMjVkNGIyZV8xMjEvZnJhZzo2ZTIwNmNkODY2NTQ0YmQ0OGQwYmQxNDE4NGRkOGNiMS90YWJsZTo0NjY0MDIxMzNmYzM0YTdjOGE2YmFjNDlkODBmODA2Ny90YWJsZXJhbmdlOjQ2NjQwMjEzM2ZjMzRhN2M4YTZiYWM0OWQ4MGY4MDY3XzMtMC0xLTEtODMxMDQ_7b5e9313-bf61-470d-89c8-f37d8007b301"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwMDYxNDRhZjY2ZTQwMzZiMDA4Yzk3MGQyNWQ0YjJlL3NlYzo0MDA2MTQ0YWY2NmU0MDM2YjAwOGM5NzBkMjVkNGIyZV8xMjEvZnJhZzo2ZTIwNmNkODY2NTQ0YmQ0OGQwYmQxNDE4NGRkOGNiMS90YWJsZTo0NjY0MDIxMzNmYzM0YTdjOGE2YmFjNDlkODBmODA2Ny90YWJsZXJhbmdlOjQ2NjQwMjEzM2ZjMzRhN2M4YTZiYWM0OWQ4MGY4MDY3XzMtMC0xLTEtODMxMDQ_9c69fed1-ecd0-42bf-b90e-9dd30f577cde">Other assets</span></span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwMDYxNDRhZjY2ZTQwMzZiMDA4Yzk3MGQyNWQ0YjJlL3NlYzo0MDA2MTQ0YWY2NmU0MDM2YjAwOGM5NzBkMjVkNGIyZV8xMjEvZnJhZzo2ZTIwNmNkODY2NTQ0YmQ0OGQwYmQxNDE4NGRkOGNiMS90YWJsZTo0NjY0MDIxMzNmYzM0YTdjOGE2YmFjNDlkODBmODA2Ny90YWJsZXJhbmdlOjQ2NjQwMjEzM2ZjMzRhN2M4YTZiYWM0OWQ4MGY4MDY3XzYtMC0xLTEtODMxMDQ_52617ee2-6a16-44f4-990f-18bd427c34b0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwMDYxNDRhZjY2ZTQwMzZiMDA4Yzk3MGQyNWQ0YjJlL3NlYzo0MDA2MTQ0YWY2NmU0MDM2YjAwOGM5NzBkMjVkNGIyZV8xMjEvZnJhZzo2ZTIwNmNkODY2NTQ0YmQ0OGQwYmQxNDE4NGRkOGNiMS90YWJsZTo0NjY0MDIxMzNmYzM0YTdjOGE2YmFjNDlkODBmODA2Ny90YWJsZXJhbmdlOjQ2NjQwMjEzM2ZjMzRhN2M4YTZiYWM0OWQ4MGY4MDY3XzYtMC0xLTEtODMxMDQ_6c9f0fd7-965d-4e8b-aeba-b0b71bced200">Accrued expenses and other</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwMDYxNDRhZjY2ZTQwMzZiMDA4Yzk3MGQyNWQ0YjJlL3NlYzo0MDA2MTQ0YWY2NmU0MDM2YjAwOGM5NzBkMjVkNGIyZV8xMjEvZnJhZzo2ZTIwNmNkODY2NTQ0YmQ0OGQwYmQxNDE4NGRkOGNiMS90YWJsZTo0NjY0MDIxMzNmYzM0YTdjOGE2YmFjNDlkODBmODA2Ny90YWJsZXJhbmdlOjQ2NjQwMjEzM2ZjMzRhN2M4YTZiYWM0OWQ4MGY4MDY3XzctMC0xLTEtODMxMDQ_faf86f04-d935-4913-9c1f-8d0821d6839c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwMDYxNDRhZjY2ZTQwMzZiMDA4Yzk3MGQyNWQ0YjJlL3NlYzo0MDA2MTQ0YWY2NmU0MDM2YjAwOGM5NzBkMjVkNGIyZV8xMjEvZnJhZzo2ZTIwNmNkODY2NTQ0YmQ0OGQwYmQxNDE4NGRkOGNiMS90YWJsZTo0NjY0MDIxMzNmYzM0YTdjOGE2YmFjNDlkODBmODA2Ny90YWJsZXJhbmdlOjQ2NjQwMjEzM2ZjMzRhN2M4YTZiYWM0OWQ4MGY4MDY3XzctMC0xLTEtODMxMDQ_fbc33cc0-74e9-4586-a294-d85bc847189d">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022,472 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121,507 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.37 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.75 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.22%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.86%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other cash flow information related to operating leases is as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.302%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cash payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,028 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases recognized upon adoption of ASC 842</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526,281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under noncancellable operating leases were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments Due by Fiscal Year (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of <br/>September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,031 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,578 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,788 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total future undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238,610 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Future payments for leases that have not yet commenced </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196,997)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022,472 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> The Company has certain leases that it has executed of which it does not control the underlying assets; therefore, liabilities and ROU assets related to these leases were not recorded on the Company's Consolidated Balance Sheet as of September 30, 2022. </span></div></td></tr></table></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following illustrates the components of lease cost for the periods presented:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.179%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.181%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,935 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,054 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,901 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,814 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,300 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,163 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,590 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other cash flow information related to operating leases is as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.302%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cash payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,028 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases recognized upon adoption of ASC 842</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526,281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 220935000 161054000 118144000 11257000 5901000 4632000 25108000 14208000 17814000 257300000 181163000 140590000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes balance sheet information related to operating leases:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:62.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.506%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except for lease term and discount rate)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right of use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwMDYxNDRhZjY2ZTQwMzZiMDA4Yzk3MGQyNWQ0YjJlL3NlYzo0MDA2MTQ0YWY2NmU0MDM2YjAwOGM5NzBkMjVkNGIyZV8xMjEvZnJhZzo2ZTIwNmNkODY2NTQ0YmQ0OGQwYmQxNDE4NGRkOGNiMS90YWJsZTo0NjY0MDIxMzNmYzM0YTdjOGE2YmFjNDlkODBmODA2Ny90YWJsZXJhbmdlOjQ2NjQwMjEzM2ZjMzRhN2M4YTZiYWM0OWQ4MGY4MDY3XzMtMC0xLTEtODMxMDQ_3efbf3f6-d611-4929-8bf8-3206ae75660a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwMDYxNDRhZjY2ZTQwMzZiMDA4Yzk3MGQyNWQ0YjJlL3NlYzo0MDA2MTQ0YWY2NmU0MDM2YjAwOGM5NzBkMjVkNGIyZV8xMjEvZnJhZzo2ZTIwNmNkODY2NTQ0YmQ0OGQwYmQxNDE4NGRkOGNiMS90YWJsZTo0NjY0MDIxMzNmYzM0YTdjOGE2YmFjNDlkODBmODA2Ny90YWJsZXJhbmdlOjQ2NjQwMjEzM2ZjMzRhN2M4YTZiYWM0OWQ4MGY4MDY3XzMtMC0xLTEtODMxMDQ_7b5e9313-bf61-470d-89c8-f37d8007b301"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwMDYxNDRhZjY2ZTQwMzZiMDA4Yzk3MGQyNWQ0YjJlL3NlYzo0MDA2MTQ0YWY2NmU0MDM2YjAwOGM5NzBkMjVkNGIyZV8xMjEvZnJhZzo2ZTIwNmNkODY2NTQ0YmQ0OGQwYmQxNDE4NGRkOGNiMS90YWJsZTo0NjY0MDIxMzNmYzM0YTdjOGE2YmFjNDlkODBmODA2Ny90YWJsZXJhbmdlOjQ2NjQwMjEzM2ZjMzRhN2M4YTZiYWM0OWQ4MGY4MDY3XzMtMC0xLTEtODMxMDQ_9c69fed1-ecd0-42bf-b90e-9dd30f577cde">Other assets</span></span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwMDYxNDRhZjY2ZTQwMzZiMDA4Yzk3MGQyNWQ0YjJlL3NlYzo0MDA2MTQ0YWY2NmU0MDM2YjAwOGM5NzBkMjVkNGIyZV8xMjEvZnJhZzo2ZTIwNmNkODY2NTQ0YmQ0OGQwYmQxNDE4NGRkOGNiMS90YWJsZTo0NjY0MDIxMzNmYzM0YTdjOGE2YmFjNDlkODBmODA2Ny90YWJsZXJhbmdlOjQ2NjQwMjEzM2ZjMzRhN2M4YTZiYWM0OWQ4MGY4MDY3XzYtMC0xLTEtODMxMDQ_52617ee2-6a16-44f4-990f-18bd427c34b0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwMDYxNDRhZjY2ZTQwMzZiMDA4Yzk3MGQyNWQ0YjJlL3NlYzo0MDA2MTQ0YWY2NmU0MDM2YjAwOGM5NzBkMjVkNGIyZV8xMjEvZnJhZzo2ZTIwNmNkODY2NTQ0YmQ0OGQwYmQxNDE4NGRkOGNiMS90YWJsZTo0NjY0MDIxMzNmYzM0YTdjOGE2YmFjNDlkODBmODA2Ny90YWJsZXJhbmdlOjQ2NjQwMjEzM2ZjMzRhN2M4YTZiYWM0OWQ4MGY4MDY3XzYtMC0xLTEtODMxMDQ_6c9f0fd7-965d-4e8b-aeba-b0b71bced200">Accrued expenses and other</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwMDYxNDRhZjY2ZTQwMzZiMDA4Yzk3MGQyNWQ0YjJlL3NlYzo0MDA2MTQ0YWY2NmU0MDM2YjAwOGM5NzBkMjVkNGIyZV8xMjEvZnJhZzo2ZTIwNmNkODY2NTQ0YmQ0OGQwYmQxNDE4NGRkOGNiMS90YWJsZTo0NjY0MDIxMzNmYzM0YTdjOGE2YmFjNDlkODBmODA2Ny90YWJsZXJhbmdlOjQ2NjQwMjEzM2ZjMzRhN2M4YTZiYWM0OWQ4MGY4MDY3XzctMC0xLTEtODMxMDQ_faf86f04-d935-4913-9c1f-8d0821d6839c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwMDYxNDRhZjY2ZTQwMzZiMDA4Yzk3MGQyNWQ0YjJlL3NlYzo0MDA2MTQ0YWY2NmU0MDM2YjAwOGM5NzBkMjVkNGIyZV8xMjEvZnJhZzo2ZTIwNmNkODY2NTQ0YmQ0OGQwYmQxNDE4NGRkOGNiMS90YWJsZTo0NjY0MDIxMzNmYzM0YTdjOGE2YmFjNDlkODBmODA2Ny90YWJsZXJhbmdlOjQ2NjQwMjEzM2ZjMzRhN2M4YTZiYWM0OWQ4MGY4MDY3XzctMC0xLTEtODMxMDQ_fbc33cc0-74e9-4586-a294-d85bc847189d">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022,472 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121,507 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.37 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.75 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.22%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.86%</span></td></tr></table></div> 944974000 1067175000 158184000 175352000 864288000 946155000 1022472000 1121507000 P8Y4M13D P8Y9M 0.0322 0.0286 214793000 148385000 115028000 179214000 770858000 61779000 526281000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental payments under noncancellable operating leases were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments Due by Fiscal Year (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of <br/>September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,031 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,578 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,788 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total future undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238,610 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Future payments for leases that have not yet commenced </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196,997)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022,472 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> The Company has certain leases that it has executed of which it does not control the underlying assets; therefore, liabilities and ROU assets related to these leases were not recorded on the Company's Consolidated Balance Sheet as of September 30, 2022. </span></div></td></tr></table></div> 192031000 176635000 156578000 136788000 120302000 456276000 1238610000 19141000 196997000 1022472000 Acquisition, Integration, and Restructuring Expenses<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following illustrates the expenses incurred by the Company relating to Acquisition, Integration, and Restructuring Expenses for the periods indicated:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related deal and integration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,561 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,969 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee severance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,705 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,401 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business transformation efforts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,961 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other restructuring initiatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,827 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,059 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,288 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,961 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related deal and integration expenses in the fiscal year ended September 30, 2022 primarily related to costs associated with the integration of Alliance Healthcare. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related deal and integration expenses in the fiscal year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2021 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily related to the June 2021 acquisition of Alliance Healthcare.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee severance in the fiscal year ended September 30, 2022 included costs primarily related to restructuring activities within certain businesses in the U.S. Healthcare Solutions reportable segment. Employee severance in the fiscal year ended September 30, 2021 included costs primarily related to restructuring activities primarily within one business unit in the International Healthcare Solutions reportable segment. Employee severance in the fiscal year ended September 30, 2020 included costs primarily related to position eliminations resulting from the Company's decision to permanently exit the PharMEDium compounding business.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business transformation efforts in the fiscal years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2022, 2021, and 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were primarily related to costs associated with reorganizing the Company to further align the organization to its customers' needs. The majority of these costs were related to services provided by third-party consultants, including certain technology initiatives.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other restructuring initiatives in the fiscal year ended September 30, 2022 and 2021 primarily related to the write down and disposal of assets, respectively, related to the Company's office optimization plan. Other restructuring initiatives in the fiscal year ended September 30, 2020 included a $19.1 million gain on the sale of property.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following illustrates the expenses incurred by the Company relating to Acquisition, Integration, and Restructuring Expenses for the periods indicated:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related deal and integration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,561 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,969 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee severance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,705 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,401 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business transformation efforts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,961 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other restructuring initiatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,827 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,059 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,288 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,961 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 119561000 116969000 15958000 12681000 13705000 34401000 27990000 36255000 37961000 22827000 32359000 -3359000 183059000 199288000 84961000 19100000 Legal Matters and Contingencies<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, stockholder demands, and other disputes, including antitrust, commercial, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:38.25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For those matters for which the Company has not recognized a liability, the Company cannot predict the outcome of their impact on the Company as uncertainty remains with regard to whether such matters will proceed to trial, whether settlements will be reached, and the amount and terms of any such settlements. Outcomes may include settlements in significant amounts that are not currently estimable, limitations on the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s conduct, the imposition of corporate integrity agreement obligations, consent decrees, and/or other civil and criminal penalties. From time to time, the Company is also involved in disputes with its customers, which the Company generally seeks to resolve through commercial negotiations. If negotiations are unsuccessful, the parties may litigate the dispute or otherwise attempt to settle the matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s results of operations or cash flows for that period or on the Company's financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant number of counties, municipalities, and other governmental entities in a majority of U.S. states and Puerto Rico, as well as numerous states and tribes, filed lawsuits in various federal, state and other courts against pharmaceutical wholesale distributors (including the Company and certain subsidiaries, such as AmerisourceBergen Drug Corporation (“ABDC”) and H.D. Smith), pharmaceutical manufacturers, retail pharmacy chains, medical practices, and physicians relating to the distribution of prescription opioid pain medications. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An initial group of cases was consolidated for Multidistrict Litigation (“MDL”) proceedings before the United States District Court for the Northern District of Ohio (the “Court”) in December 2017. In April 2018, the Court issued an order creating a litigation track, which included dispositive motion practice, discovery, and trials in certain bellwether jurisdictions. In November 2019 and January 2020, the Court filed Suggestions of Remand with the Judicial Panel on Multidistrict Litigation that identified four cases filed against the Company for potential transfer from the MDL back to federal courts in California, Oklahoma, and West Virginia for the completion of discovery, motion practice, and trial. All </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">four</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases were remanded to those federal district courts. Trial in the two consolidated cases in West Virginia commenced in May 2021 and concluded in July 2021. On July 4, 2022, the court entered judgment in favor of the defendants, including the Company. The plaintiffs filed an appeal of the court’s decision on August 2, 2022. The Oklahoma case, in which the plaintiff was the Cherokee Nation, was resolved through a settlement with the Cherokee Nation, as announced on September 28, 2021. The California case, in which the plaintiff was the City and County of San Francisco, was resolved pursuant to the comprehensive settlement described below, and all claims against the Company have been dismissed in both cases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 21, 2021, the Company announced that it and the two other national pharmaceutical distributors had negotiated a comprehensive settlement agreement that, if all conditions were satisfied, would result in the resolution of a substantial majority of opioid lawsuits filed by state and local governmental entities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The comprehensive settlement agreement became effective on April 2, 2022 and as of September 30, 2022, it included 48 of 49</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> eligible states (the “Settling States”) as well as 99% by</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> population of the eligible political subdivisions in the Settling States. Pursuant to the comprehensive settlement agreement and related agreements with Settling States, the Company will pay up to approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.4 billion o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ver 18 years and comply with other requirements, including establishment of a clearinghouse that will consolidate data from all three national distributors. The exact payment amount will depend on several factors, including the extent to which states take action to foreclose opioid lawsuits by subdivisions (e.g., laws barring opioid lawsuits by subdivisions). West Virginia and its </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subdivisions and Native American tribes are not a part of the comprehensive settlement agreement and the Company has reached separate agreements with these groups.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 22, 2022, the State of Alabama sought and was subsequently granted leave to amend its complaint in a pending state court action against another distributor in order to add the Company as a party. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amended Complaint was filed on July 25, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded accruals related to opioid litigation of $36.6 million, $147.7 million, and $6.6 billion in the fiscal years ended September 30, 2022, 2021, and 2020 in Litigation and Opioid-Related Expenses in its Consolidated Statements of Operations. The Company’s accrued litigation liability related to the comprehensive settlement, including an estimate for the State of Alabama (with whom the Company has not reached a settlement agreement), as well as other opioid-related litigation for which it has reached settlement agreements, as described above, was $6.0 billion as of September 30, 2022 and $6.7 billion as of September 30, 2021. The Company currently estimates that $528.7 million will be paid prior to September 30, 2023, which is recorded in Accrued Expenses and Other on the Company’s Consolidated Balance Sheet. The remaining long-term liability of $5.5 billion </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is recorded in Accrued Litigation Liability on the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Consolidated Balance Sheet. While the Company has accrued its estimated liability for opioid litigation, it is unable to estimate the range of possible loss associated with the matters that are not included in the settlement accrual. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. The Company regularly reviews opioid litigation matters to determine whether its accrual is adequate. The amount of ultimate loss may differ materially from the amount accrued to date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time as otherwise resolved, the Company will continue to litigate and prepare for trial and to vigorously defend itself in all such matters. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since these matters are still developing, the Company is unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief that may affect the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other lawsuits regarding the distribution of prescription opioid pain medications have been filed by: third-party payors and similar entities; hospitals; hospital groups; and individuals, including cases styled as putative class actions. These lawsuits, which have been and continue to be filed in federal, state, and other courts, generally allege violations of controlled substance laws and various other statutes as well as common law claims, including negligence, public nuisance, and unjust enrichment, and seek equitable relief and monetary damages. Motion practice and active discovery are ongoing in many of these cases.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Ongoing and additional litigation is anticipated in cases filed by subdivisions that are not participating in the global settlement agreement, as well as in cases filed by non-governmental or non-political entities, including hospitals, third-party payors, and individuals, among others. Certain cases related to opioids filed in various state courts have trial dates scheduled in January 2023 and later, although all such dates are subject to change. The Company is vigorously defending itself in the pending lawsuits and intends to vigorously defend itself against any threatened lawsuits or enforcement proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since July 2017, the Company has received subpoenas from several U.S. Attorney</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Offices, including grand jury subpoenas from the U.S. Attorney</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Office for the District of New Jersey (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USAO-NJ”) and the U.S. Attorney</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Office for the Eastern District of New York (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USAO-EDNY”). Those subpoenas request the production of a broad range of documents pertaining to the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s distribution of controlled substances through its various subsidiaries, including ABDC, and its diversion control programs. The Company has produced documents in response to the subpoenas and continues to engage in discussions with the various U.S. Attorney’s Offices, including the Health Care and Government Fraud Unit of the Criminal Division of the USAO-NJ, the U.S. Department of Justice Consumer Protection Branch and the U.S. Drug Enforcement Administration, in an attempt to resolve these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shareholder Securities Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 11, 2019, Teamsters Local 443 Health Services &amp; Insurance Plan, St. Paul Electrical Construction Pension Plan, St. Paul Electrical Construction Workers Supplemental Pension Plan (2014 Restatement), Retirement Medical Funding Plan for the St. Paul Electrical Workers, and San Antonio Fire &amp; Police Pension Fund filed a complaint for a purported derivative action in the Delaware Court of Chancery against the Company and certain of its current and former officers and directors (collectively, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defendants”). The complaint alleges that the Defendants breached their fiduciary duties by failing to oversee the compliance by certain of the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s subsidiaries (including the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s former subsidiary Medical Initiatives, Inc. (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MII”)) with federal regulations, allegedly resulting in the payment of fines and penalties in connection with the settlements with the USAO-EDNY in fiscal 2017 and 2018 that resolved claims arising from MII</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s pre-filled syringe program. In December 2019, Defendants filed a motion to dismiss the complaint. After briefing and oral argument, on August 24, 2020 the Delaware Court of Chancery denied Defendants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> motion to dismiss. On September 24, 2020, the Board of Directors of the Company established a Special Litigation Committee to conduct an investigation concerning the plaintiffs’ allegations, and on November 10, 2020, the Delaware Court of Chancery granted the Special Litigation Committee’s motion to stay the litigation pending its investigation. On September 22, 2021, the Special Litigation Committee filed its report under seal and moved to dismiss the case. The Special Litigation Committee’s motion to dismiss the case is pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 17, 2020, CCAR Investments, Inc. filed a complaint for a purported derivative action in the United States District Court for the District of Delaware against the Company and certain of its current and former officers and directors (“CCAR Defendants”). The complaint allegedclaims for breach of fiduciary duty, corporate waste and unjust enrichment allegedly arising from the Board's oversight of the Company’s controlled substance diversion control programs and violation of Section 14(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). On August 14, 2020, the CCAR Defendants answered the complaint and filed a motion for judgment on the pleadings. On October 29, 2020 the parties filed a stipulation permitting CCAR Investments, Inc. to file an amended complaint on or before November 20, 2020. On December 4, 2020, the parties filed a stipulation tolling the deadline for CCAR Investments, Inc. to file an amended complaint pending the Company’s production of certain documents to CCAR Investments, Inc. The Company’s production was completed on January 29, 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 2, 2022, the Court entered a stipulation that the case will be dismissed without prejudice upon the Company providing notice to stockholders through the filing of a Current Report on Form 8-K and subsequent notification to the Court of such filing. On May 6, 2022, the Company provided notice to stockholders through the filing of a Current Report on Form 8-K that the case would be dismissed and gave notice to the Court of the Form 8-K filing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2021, Lebanon County Employees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Retirement Fund and Teamsters Local 443 Health Services &amp; Insurance Plan filed a complaint for a purported derivative action in the Delaware Court of Chancery against the Company and certain of its current officers and directors. The complaint alleges claims for breach of fiduciary duty allegedly arising from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Board’s and certain officers’ oversight of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company’s controlled substance diversion control programs. The defendants moved to dismiss the complaint on March 29, 2022. The motion is pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subpoenas, Ongoing Investigations, and Other Contingencies</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company receives subpoenas or requests for information from various government agencies relating to the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s business or to the business of a customer, supplier, or other industry participant. The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s responses often require time and effort and can result in considerable costs being incurred. Most of these matters are resolved without incident; however, such subpoenas or requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the healthcare industry, as well as to substantial settlements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, U.S. Bioservices Corporation (“U.S. Bio”), a former subsidiary of the Company, received a subpoena for information from the USAO-EDNY relating to its activities in connection with billing for products and making returns of potential overpayments to government payers. A filed qui tam complaint related to the investigation was unsealed in April 2019 and the relator filed an amended complaint under seal in the U.S. District Court for the Eastern District of New York. In December 2019, the government filed a notice that it was declining to intervene. The court ordered that the relator</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s complaint against the Company and other defendants, including AmerisourceBergen Specialty Group, LLC, be unsealed. The relator’s complaint alleged violations of the federal False Claims Act and the false claims acts of various states. The relator filed a second amended complaint, removing one state false claims act count. The Company filed a motion to dismiss the second amended complaint and all briefing on the motion was filed with the court on October 9, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Reliable Pharmacy, together with other retail pharmacies and North Sunflower Medical Center, filed a civil antitrust complaint against multiple generic drug manufacturers, and also included claims against ABDC and H.D. Smith (collectively, the “Company” for this matter description), and other drug distributors and industry participants. The case is filed as a putative class action and plaintiffs purport to represent a class of drug purchasers including other retail pharmacies and healthcare providers. The case has been consolidated for multidistrict litigation proceedings before the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that the Company and others in the industry participated in a conspiracy to fix prices, allocate markets and rig bids regarding generic drugs. In March 2020, the plaintiffs filed a further amended complaint. On July 15, 2020, the Company and other industry participants filed a motion to dismiss the complaint. On May 25, 2022, the Court granted the motion to dismiss without prejudice. On July 1, 2022, the plaintiffs filed an amended complaint, again including claims against the Company and other drug distributors and industry participants. On August 21, 2022, the Company and other industry participants filed a motion to dismiss the amended complaint.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2022, the United States Attorney’s Office for the Western District of Virginia notified the Company of the existence of a criminal investigation into MWI Veterinary Supply Co., the Company’s animal health subsidiary, in connection with grand jury subpoenas to which MWI previously responded relating to compliance with state and federal regulatory requirements governing wholesale shipments of animal health products to customers in certain states. The Company is cooperating with the investigation.</span></div> 4 4 48 0.99 6400000000 P18Y 36600000 147700000 6600000000 6000000000 6700000000 528700000 5500000000 Litigation Settlements<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Antitrust Settlements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous lawsuits have been filed against certain brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. These lawsuits are generally brought as class actions. The Company has not been a named a plaintiff in any of these lawsuits, but has been a member of the direct purchasers’ class (i.e., those purchasers who purchase directly from these pharmaceutical manufacturers). None of the lawsuits has gone to trial, but some have settled in the past with the Company receiving proceeds from the settlement funds. During the fiscal years ended September 30, 2022, 2021, and 2020, the Company recognized gains relating to these lawsuits of $1.8 million, $168.8 million, and $9.1 million, respectively. These gains, which are net of attorney fees and estimated payments due to other parties, were recorded as reductions to cost of goods sold in the Company’s Consolidated Statements of Operations.</span></div> 1800000 168800000 9100000 Business Segment Information<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is organized geographically based upon the products and services it provides to its customers. The Company’s reporting structure is comprised of two reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions. U.S. Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable segment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. International Healthcare Solutions consists of Alliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty (until it was divested in June 2022). Profarma had previously been included in the Pharmaceutical Distribution Services reportable segment. The Company's previously reported segment results have been revised to conform to its realigned reporting structure.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The chief operating decision maker ("CODM") of the Company is the Chairman, President &amp; Chief Executive Officer of the Company, whose function is to allocate resources to, and assess the performance of, the Company's operating segments. The CODM does not review assets by operating segment for the purpose of assessing performance or allocating resources.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Healthcare Solutions reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The U.S. Healthcare Solutions reportable segment also provides pharmaceutical distribution (including plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. Additionally, the U.S. Healthcare Solutions reportable segment provides data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The U.S. Healthcare Solutions reportable segment also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of retail and institutional healthcare providers. It also provides a full suite of integrated manufacturer services that ranges from clinical trial support to product post-approval and commercialization support. Additionally, it delivers packaging solutions to institutional and retail healthcare providers. Through its animal health business, the U.S. Healthcare Solutions reportable segment sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. It also offers demand-creating sales force services to manufacturers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International Healthcare Solutions reportable segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. The International Healthcare Solutions reportable segment distributes pharmaceuticals, other healthcare products, and related services to healthcare providers, including pharmacies, doctors, health centers and hospitals primarily in Europe. It also is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. In Canada, the business drives innovative partnerships with manufacturers, providers, and pharmacies to improve product access and efficiency throughout the healthcare supply chain.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following illustrates reportable and operating segment disaggregated revenue as required by ASC 606, "Revenue from Contracts with Customers," for the periods indicated:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Healthcare Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Human Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,284,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,777,128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,171,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,815,758 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,684,417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,216,462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. Healthcare Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,100,202 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,461,545 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,387,949 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Healthcare Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,890,402 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Healthcare Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,601,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,156,264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,508,106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total International Healthcare Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,491,673 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,529,629 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,508,106 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment eliminations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,869)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,587,006 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,988,843 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,893,926 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following illustrates reportable segment operating income information for the periods indicated:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Healthcare Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,456,972 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,257,918 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,020,067 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Healthcare Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706,458 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment operating income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,163,430 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648,204 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204,447 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following reconciles total segment operating income to income (loss) before income taxes for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment operating income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,163,430 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648,204 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204,447 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains from antitrust litigation settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,835 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,794 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIFO (expense) credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,028 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey highly inflationary impact</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,033)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related intangibles amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304,551)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176,221)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,478)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and opioid-related expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272,623)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,722,346)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition, integration, and restructuring expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183,059)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199,288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,961)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,936)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,373)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,946)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(361,652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharMEDium remediation costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharMEDium shutdown costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York State Opioid Stewardship Act</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366,378 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,354,197 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,135,354)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,352)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,736)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,581)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,074 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early retirement of debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,183,057 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221,859 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,293,831)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating income is evaluated by the CODM of the Company and excludes gains from antitrust litigation settlements; LIFO (expense) credit; Turkey highly inflationary impact; acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses; goodwill impairment; impairment of assets; </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PharMEDium remediation costs; PharMEDium shutdown costs; New York State Opioid Stewardship Act; and contingent consideration adjustment. All corporate office expenses are allocated to the operating segment level.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company recognized a net gain of $56.2 million from sale of non-core businesses, an expense related to the impact of Turkey highly inflationary accounting of $11.9 million, a foreign currency loss of $14.4 million on the remeasurement of deferred tax assets relating to Swiss tax reform, and a $4.8 million gain on the remeasurement of an equity investment in Other Income in the Consolidated Statements of Operations in the fiscal year ended September 30, 2022. The Company recorded a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note receivable related to a start-up venture, and a foreign currency loss of $3.4 million on the remeasurement of deferred tax assets relating to Swiss tax reform in Other Income in the Consolidated Statements of Operations in the fiscal year ended September 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following illustrates depreciation and amortization by reportable segment for the periods indicated:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Healthcare Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,554 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,575 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,687 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Healthcare Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,376 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related intangibles amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,551 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693,895 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505,172 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,062 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization includes depreciation and amortization of property and equipment and intangible assets, but excludes amortization of deferred financing costs and other debt-related items, which are included in interest expense, net.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following illustrates capital expenditures by reportable segment for the periods indicated:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Healthcare Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,406 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,525 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,249 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Healthcare Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,318 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,217 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,677 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Healthcare Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Human Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,284,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,777,128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,171,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,815,758 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,684,417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,216,462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. Healthcare Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,100,202 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,461,545 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,387,949 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Healthcare Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,890,402 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Healthcare Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,601,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,156,264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,508,106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total International Healthcare Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,491,673 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,529,629 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,508,106 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment eliminations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,869)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,587,006 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,988,843 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,893,926 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 207284444000 197777128000 182171487000 4815758000 4684417000 4216462000 212100202000 202461545000 186387949000 21890402000 7373365000 0 4601271000 4156264000 3508106000 26491673000 11529629000 3508106000 -4869000 -2331000 -2129000 238587006000 213988843000 189893926000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following illustrates reportable segment operating income information for the periods indicated:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Healthcare Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,456,972 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,257,918 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,020,067 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Healthcare Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706,458 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment operating income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,163,430 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648,204 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204,447 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The following illustrates depreciation and amortization by reportable segment for the periods indicated:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Healthcare Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,554 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,575 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,687 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Healthcare Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,376 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related intangibles amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,551 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693,895 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505,172 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,062 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                </span><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following illustrates capital expenditures by reportable segment for the periods indicated:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Healthcare Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,406 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,525 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,249 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Healthcare Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,318 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,217 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,677 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2456972000 2257918000 2020067000 706458000 390286000 184380000 3163430000 2648204000 2204447000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following reconciles total segment operating income to income (loss) before income taxes for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment operating income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,163,430 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648,204 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204,447 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains from antitrust litigation settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,835 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,794 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIFO (expense) credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,028 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey highly inflationary impact</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,033)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related intangibles amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304,551)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176,221)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,478)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and opioid-related expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272,623)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,722,346)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition, integration, and restructuring expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183,059)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199,288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,961)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,936)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,373)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,946)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(361,652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharMEDium remediation costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharMEDium shutdown costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York State Opioid Stewardship Act</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366,378 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,354,197 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,135,354)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,352)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,736)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,581)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,074 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early retirement of debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,183,057 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221,859 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,293,831)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 3163430000 2648204000 2204447000 1835000 168794000 9076000 67171000 -203028000 7422000 -40033000 0 0 304551000 176221000 110478000 123191000 272623000 6722346000 183059000 199288000 84961000 75936000 6373000 0 4946000 11324000 361652000 0 0 16165000 0 0 43206000 0 0 14800000 0 0 -12153000 2366378000 2354197000 -5135354000 27352000 41736000 1581000 -210673000 -174074000 -137883000 0 0 -22175000 2183057000 2221859000 -5293831000 56200000 11900000 -14400000 4800000 64700000 14000000 -3400000 274554000 266575000 253687000 114790000 62376000 26897000 304551000 176221000 110478000 693895000 505172000 391062000 295406000 310525000 316249000 200912000 127692000 53428000 496318000 438217000 369677000 Fair Value of Financial Instruments<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recorded amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable as of September 30, 2022 and 2021 approximate fair value based upon the relatively short-term nature of these financial instruments. Within Cash and Cash Equivalents, the Company had $1,602.0 million and $671.0 million of investments in money market accounts as of September 30, 2022 and 2021, respectively. The fair value of the money market accounts was determined based upon unadjusted quoted prices in active markets for identical assets, otherwise known as Level 1 inputs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recorded amount of long-term debt (see Note 6) and the corresponding fair value as of September 30, 2022 were $4,632.4 million and $4,130.3 million, respectively. The recorded amount of long-term debt and the corresponding fair value as of September 30, 2021 were $6,383.8 million and $6,761.6 million, respectively. The fair value of long-term debt was determined based upon inputs other than quoted prices, otherwise known as Level 2 inputs.</span></div> 1602000000 671000000 4632400000 4130300000 6383800000 6761600000 Subsequent EventIn November 2022, the Company's board of directors increased the quarterly dividend paid on common stock by 5% and declared a regular quarterly cash dividend of $0.485 per share, payable on November 28, 2022 to shareholders of record on November 14, 2022. 0.05 0.485 <div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:501.75pt"><tr><td style="width:1.0pt"/><td style="width:241.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.75pt"/><td style="width:1.0pt"/></tr><tr style="height:29pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning<br/>of Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged to<br/>Costs and<br/>Expenses (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions (2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>End of<br/>Period</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for returns and credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,124,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,854,036)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,626,729 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for returns and credit losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,967,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356,684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for returns and credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223,887 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,019,830 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,826,409)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417,308 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents the provision for returns and credit losses.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents reductions to the returns allowance and accounts receivable written off during year, net of recoveries.</span></div> <div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:501.75pt"><tr><td style="width:1.0pt"/><td style="width:241.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.75pt"/><td style="width:1.0pt"/></tr><tr style="height:29pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning<br/>of Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged to<br/>Costs and<br/>Expenses (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions (2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>End of<br/>Period</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for returns and credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,124,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,854,036)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,626,729 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for returns and credit losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,967,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356,684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for returns and credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223,887 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,019,830 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,826,409)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417,308 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents the provision for returns and credit losses.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents reductions to the returns allowance and accounts receivable written off during year, net of recoveries.</span></div> 1356684000 5124081000 4854036000 1626729000 1417308000 3906776000 3967400000 1356684000 1223887000 4019830000 3826409000 1417308000 EXCEL 107 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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

Q47'F=KRBQ<&49^V'-F5S7)]WG K4NJ;[OZ/UK1]*W?_XARYUH%:%HT/?MFRZ._D8=Y^S4E"F+X753[-/K\YOMC;/81KWQWOG6SC MG3?OX5D'>.>/#T>?/\'S3MI'[:/7N/W7;/ET.-[9;1_N_/&6MSY]Z.P=O>?M M-Y\[<#W__$=^CV.Z1UNT]>8]^<_%]MR^$XJ%$1Q[))E)B'MJD<'*(LP22 @W MDK.XL26E:AI&5]35^C:FXRE[.-0@^#) <-S\M!;F6IB?OS#7%OV%6?2=&8MN M&>>2\=SF.6K$F;1(Q^20$BK)H BF^=3@VJ+7(%B#(, +H8PXH[TCWG E%U91+Z1!UL _W!.!C,8":2,P MD8[#+R2CH&X2,E\H7J-@C8+/'P5KOZ86YA]&F&N3_N),^OOK)CVH%(30!L7$ M)>(*!P2V'1R;J*D(C >=GI])?PEM*-]-9==>W2FEMNS9(/4]ZGO4]WCX>ZSR M*!"QN>XG@?P^&L##8]&H.EOT>X/#SNF3UP9,SR7;I.+I"E)NQ^ 6[O334@BK MJ2686QY"LBD2K5/0G@?X5X_;Y@!E0U?<[3I;NWEO9E7#FDM8KS$T> __*HR* MO/V[YF1+<++W\X<+NFB9B10QDS#BV@ EBR(BJEG 0,>HDVYCBX@)&QNO_5:Y MY?YA->C'[+M_FS9V/&%IJ F"&^Z4-D+12*VW,J: J5HVN_.-/<]E&63M]:Q2 MPV;K,U+> I%0V!5?UN>//3*%O,KU?$9*XJ%4%CFY$0R'JQH/M.3<8I"D)A8)87%<6/+,-(T M]2DYSTFYUTNWVW%8Z_$J]7BV\D(9XD7B'B509,25$\AJ)I$17%IBI%'1;&RQ M)C6\*>[?BK96Y_559Q>E%3YA9W#BX-@::K54SEBSE81 MF$B$$%8A+' "C8Z@T2DDY"GW1#MG26XNS9N::6#?JTHZU!J]CNS[$52Z9M^/ MHN3;UY6<6D:L< 0!^Z*(@[>-M*<,@>AI;+BAC*6-+45T4XGY$XMJ^KVVVKU> MREW3[Y4K\DR! .*+9Q2""QS;E_GX*=$@(X3Z378<9J8R]::$--49IVL]8JJ M ,IGJZJ5^#HGU':O=MB6C4'+]GKK4AB0YY!O,O6L\VF*!V%H5.!S8J"MR04A MN0J>>^^%TZ+.IZT!A'VV"%EA M/FU9#?H615B@03\>1? L 3<@.C'O.#72 5' V0\D5G/.ECX6JG;I'U/#9O-I M03C/E%"(62(0+"<'MJ" (U@LB69<>QLVM@2G3;:R4_;6Z*B\'UR=;^///X(^ MU_[\8VCXC VE>9NCX1@%"0X CRZ?I$D<8BEHQT)4*>::%$6;A,[GRY=WYVOE M?M&VNG;G5ZS'L]DT8[EAE%'$@K"@QQ(L=20*^]?[E\K M\_HJLZ3<18HY3MCRB*U6A%#ME7#"!^%YG4M;1W6>RZ5A9W-?B8B<=@1QBAUR MP,21X3XHXYQD)&_?P::)%X39:WU>;WV^#?-^!(6NF?>CJ/A,)HWC&#@!;]HR MFS?=!XDT!8VW2GJ2.(W$)*#>'#9<"@( M$A"7*H#5C@$9%8**V@J:SS;E$FPU7B?NO:)]:>N=/.L/;?>F$ZG695/:$_:D M'9^!Q4"$0G^4IV:R)G4KB)5-T ]CKK@P28,#XGE47*3DF!-*&8*#Y9J8I2-% M"SW*ND/$ YJMO?G<3E \,8T1-X(C+HA'F@2!?&X3H;G@T:B-+='D3#8U%:MM M$;$"K7H>G71J?'WQ^'JK36LK MC:V7]BL)U)L_GD<9#4(!FM1)SY7':'*2*1 M1<%HC$3D4I4FP;R)M;Y_W6R-LS7.OC"<70,>VX[#FL4^*+#.YCT33T0;!;15 M2X)R' U9[!QRUBF)!0_:RES%S!AM*K:J'?\UNM;H6J/KC9WRH]9!>O HD^*8 M4QN824I+R8QR0K#E.TK648+'QM?Y1+1FR4G'D5=.(ZZL098EAK3@7H"YA$4& MYBJ;A(BF(O/,M0;8&F!K@%UQF&!5"%N'"9X:;6=J DC@.GB2D'(R(.X-0RXQ MC(10DCEBF;)X8TL+W01OI8X2U#!;P^SSX[%UE.#A<76F1"/B$%G0,>_?M,!B MI4':,@=5W_J]$+L#5\Q68+T(ZLY+>L^ M#F/6R2+: =RTTVL,X0\'V8%LV/)8YT&CGQK73C*>*P]I##H]'QM_Q=-A/'&Q M:##<;&25;YS%(C9."]#- H;>"*/8&/:S!L,0>@T_*HK8\^?Y;.3>H&J"O'DI M.^4B_!B3/$T,&_'K:>P-8IZ%[\WKF1TT_OL60$QY[NM)HTJ,^$Z:Q>?EL%@^4RS^_)]#[$_^[ME/9K1S GAZ M\9JTCSZ*UL7VV=[%AVYK]T.G=?+YJ'WR]FMK]_B\M>MY:_>W0\!5UGZ_+YWE M@@B)! XYX.H$TEXFY#%-."@E+,L;3;#:9',HV@ 9[,(/S5NMOM9.XF2X3LH" M3">G-+.&,\59$()6N_/Q9/7G[7&]^BM:_9WW^R$)Q;R,**5>"23W) M88YLPEV\E6#>,8\X)X_?BL-,O=G;ZL7:\/S=L]C]$ELPF,-:7F^0UX/SUOM] M+K2*R2H49?3 _!-'AGJ*6&83)H3$L-[8HDILSI>X3 MZ-3N6;\6C1M$XV+G]3Y5E&I-$F)$@V@ =(%H.()@58PA03"&318-_@UC=ETT M^+,1C<,BQEHX;A . CR7!8TCX1AAZ4 X D_(&0K@$9E@PE)FER M(9^-;,!W:]FX038X>$@^6&LL8TA9G5LF&9UKD1Q(B5:8$'!<<<8-R3?GCY.? MR$;%?4% 8!75[=VEIY&.UVD8BUI$OBTBQV>MLWT>C);$1Q22Q(A[ZI'#5B"< M-WU* _^G XA($YCIYGQ7K>M"DC>V19NG?B;"F"_+4M'ICZ/ YQ6!.QKW"68;DZL.B\D[G-J#B!PL MQ#$JU^*5[9[9\\'&+]FIGY;T[:4@'>E!YLSJHP,RAMORA%Z-4(!E3D M;\%P[-J,I0%<%F#OO[Z_>&IC:S>G0G+H__>,F#D-\#^_V*U%DG&_$/V#"[E: M*.3M_C!6P" W&]]J>7JGD/IU\_ FNN$;8##=_F!4Q%VX]6_=OC]^Q^_O3NI'7A:>LBC^$MVSN?P?0C< &.WO.= MW?;1WI$_W\MCAF?M_/%W%\9PT;Z __T!]]@-1_^Y>'O6.O)?]S&A@7#A$"'9 M85!,(1<"01%SJ3 /*GE6&6J Y!A>9]LHA N.>WK1K3P?QU>2'7T-G<-JUYZ\ZO7*\Y46_7G]>-O,S.?KR>=7'8P9@ MS*;"*I. <3^&\8/'_&"SY DK6KA[W0_S2[WZ!T39\$4-GV.B!H_80[8=6-J-+USG#K9Y9D?,J:IB? M[JUOT]C9*!NB]H&#'Y>L,TIC"ZZ78$Y8+..RVYS_W>\=[,;B)#/PZY'=U/D: M [J(17^-:I3OYII5-'XY;NW]W]BX\WOGTKZ.]DVV1@[F?WWR\ MV#MYSSY_VONZ,UNC?/+W8>NB?=3^X_W7-ES3OG@O]D[:G;VC8[JW^^ZXO=ON M?'X3NO \\9^+[;G33$SNP\,21Y0:AG@TN5"!TKSE3JJ$7:"89'JF*:&_KK9 M>97UQY5BU)!60]J#0!K&)C%*F PA\2BC#EI9);QRB5+GZ+)[,FI(>P!(FVTQ MYKSSU@2+@HX8\20CTOF<9Y:$%EQ('S!]7I"VHJ/GUIJKMOJ]>-XXL<5Q'#:2 M]9UN9WC^/$_+>A:01L&\:\,B:$'>4T^MP,XR:U,DA#-M:I;V9)#6FF-I,K)@ M#=4H*@60QCE&-B;@:TX2RD0PEL>50=J]>OW>@8C5^KJ,OA+XCY;>AL0(MXP9 MY_+)*\QA1XG5I*8@3ZBOLQ2$6.:)UQ:1E+54"U8>#XF\"8$H)F3(I7IKIJ\O MH3'WA^ACYTO.EPT:@^A'1>=R_\:$&LQS/ ='>SS$0H!PN1H$1"P$8B -8LX%*) 33 M6A,64I ;6TS@)@C9DY[:O?I04*VT55PW6>&,*TT;#R(YSZ61 M,D)&?6W9^! MU$I[/Z6=I2$^21TPN W&2(XX%2H?SQ<1_-EC18(@+JR=TGZ'ADQJ7V"D\=MZ MOG[?? EQG*S9C6X?'IQYU+]&O9),L3J2\W">(?>$&0_NAB<\2*VCA?]H;G $ M$QWK2,[30?+>'(^*+*F@>4 BA @\RA'D$O,#%31&-;.,ZSU=97Z:IC! MEE))G74\8@QO2H),CGIJ\[;/FD<]M=+.\BC-@@"M=4C&:$%I34(.>XF85-IK M!P#LU,86Y:8I^=,>B_J$X9RR_ODI5&\'1A0*FX9S(1S>^"E//OOU1NT\<*=S MQY([KC6-PEC/57*&FA@!G)5*@L""+[:FV^UW<^H) ]U)OY>%5^_& VO9KYV3 MT M^>-S9^]3N]NB;S'<-[_S1>O3N^.]W=?G[:.W,!$(PNV&CGGL00)(3Z9C2VRV(GZ>6:35QV66'E8XDX*6]/?QU'%V3 B,RER M2Y&/F"*>3#ZO%',4J=/140F6;W6)D3J,N([Z:IT@4BG-B<:<2*<#U0S<59F8 MM]Z&.I'YA/HZRWPI84[G%D71&(\XQ0%9+R7\JB)51*9H[-KIZTL(L[5&W6$' M7?9\+68K_6>IL*H#< ^&:$)184 !*.6)<^*- !4AD5&/ _-2U SDR1#M8(Z! M!.9H@-5!/(A\;+KTR&G'4 8?AZDDRJZN.K0.P*VCOLHD6&*&I$@%ITGH2#QG MVG)/8P35K1G($^KK7"D5I49C(I&BG"/NP/LV^>AH17127"FGTNH8R"/%WM8O M,_F .P93&)<^:,I"HIX3830@2X@!.T>(B80M'3:\WGID M.V^RC8/A!SN,?PUSO^ _8Y&WWMJ#> DMB-;8L@2VO#W[]\PQ<_]F'[KQ?S^< M?_X43AWELOWF(VZ_>?WU\]'KK_ Y:;]YCUOTW6&;MKZV_X#_[>;G_'WR^4TMGCB>3P@B;\KDYB>>6E@XCJXA DGJ&L;;>2+ZQ M)54^:W>^%*,*1DVMDA3$-VD=+Z=]0L)'CX9O[U5;U_,H]>) M!"WR#EJJ'09765O,O;("TSNRVW?6Q]?EN5BU+JY0%[]^C^?"F 5P6O)Y][78 MV3T&SGN,6T?')!^(!V."]WUW"'-R]OGH84XC$ZY"PA* 4C M+7$T">4VMM@F7R!?_UCH2,VV7:ZCJ*NF9'?3TYJ2/::2SCA2P25+-;=(" N4 M+$0^:JV]K];..E(&:T\4!?KE@7[E(QRL"PR!O63$R>0,B5EK=5,1OBY: M^V+2!+=QHW([/*Q%LDQX#C]9+)@B6H(S;!5SI':CUDD3S[]'?MW0,!8V([N]OL\QMXC]UV%^Z9W2B%+?'::V2TR.2M=J-6E<)RVZ4M98J0I&+$B0L"H^TY<#OHHR8$,.) M\MF-HF)9-TK4^:@')F1WT].:D#VFDL[FH[ (4CJ%F 3GB8-J(0>$&B4CHI0J M!N-D1<@ X]($",P=45EK55/*^0,TZVS4^KA1PGK&8Z0Z.,R# MM)H0+%SBE&$,["?5;M0Z:>+%=ZNN=@_HWD6WT]K]R#^?O*?M-_GYW:/R7$OX M!,9&6I_>BM9)F8WRT6I%I4766 %N%.BQ#3I',DTR3#!,9-K84CLJ8>!&)<*EUTDA9\O3SJ1&CAF%M' B>,-H>= RV^1+NU&JSD8]]!Z< M.^EI3<@>4TEGW"B2D#HC#:B'+(D/!AY L<:IL*:BX:$HZ?VIUG8WZ M ;16N^2T)E@JFKBCS%#N-?PW*@&N58RU&_7T6COC1FEPE;R, 46FP3@J+9"F MTB.MHK2&A*!RT;OBO*DT61>MK;-1"Y0O.DHY=2):QGC*)M-:*O+IO%QXDW#M M1JV3)N+OD=S/)V_YYS_>=5I_[,'\[!$@N?SS[O'%YS^V2?LB=.#=.-S_J/7I M[^Q&$14)-]H@X$P*]%@2(+F@S$0(0%P5.3%XA45]1-" -14L.L!W;RC1VA#+ MK" &E6Q$,:"D=J-^B$D++M1R<7 I4%>,)?Y741&"0[F0AF?;* .!M;=%,O M6]3'<)V->F!"=C>;4!.RQU32&3?*$VIAP2)BF'O$F8G(!F-0D+DPF^3CR72. M:XLFXWI=XMJUUJXT^*%))-XP"?X4CT8[2X14BHIYKMVHI]?:&3?*IJ"- M9@D96*@<8V1(.\P0MI$DPEC2N;$2-^!&L;71VCH;M?!L2!N5(TF)Q+G5TEIP M@XT0)EA,A%N^86CM1CV")I+OY@J./ARU/[T%0KM]]GFW?=)^\_FP=70(X_H M<_*OXU;YWL>B]:9THZ)D#NAL!%9+]RQ"MRI!Y( MVI9SI'@M8X\N8^!(<:4Y5N"J2^M5E?$$6\'!FTH:4"(:X.K9D5(+':F%GA2I M$U(/?F3P712UYF2/J:4SGI3U'BMOFW:O-=:N]*$5!"8.VE"4IR':'5*AK#$G"%.6H=K3^KIM7;&DR("$V.Q0(:F MLCL,!9_*:*22\B&JP)2*H+7:-)F\=W>8.B'U@)X4(]3DH+ .-G#OH@V8">X- M=A)[/.[+6'M2:Z*)]+LL-Z<(/FWGXQ3.=F"\[3=[^/,?[PYW_O@HVKMOSUL7 MVU_W+CZ> >O-GI2F"4M%%*(T LN5@2 8H:4QHIA#]97NM4EI!Y(UNJ$U+I* M6-EE0@APG@RB.E>."I PXX1#S&.> N=4>/#5^?+;HWB]/>K!-UK<24]K0O:8 M2CKC1K$@&# P@US"/)_Q@9'#!-3,!NJIHY:'5"6DB+QW75^=D%I'K97$16\D MUJ"]/(((4!)5#$00*AG!J7:CGEYK9]PHDP@+4EH49 J(DQ"0)>!5\20CDR1: M&UR5D#)\;9ILU@FI1>?!)D:X$L%%# R%&JN3=L3RR**FD=3-^M9*$]GWJZ[> M'7]^TSUNOWG/6_1#M_T&WO?-\5<@N*Q]=,Q@WLY;;PX/=W:[V8VR(1^Q%1BR M.F]S9)*"&\4#BE@:C44$\QM7YT8]D*S5;M2Z2ABX4=X$DZS R%/-$%@$<-2C MEH@(GFOX'?R2+<4F6[:NC]?;HQ[\C/ [Z6E-R!Y326>[3 /TXP0I!FSB LF MD!8IHJQB,G MM"CWJ[,FU?>N$*JS4>NHM=P[C9-Q$D?%B=5&>$X +[$C(G)= M=YE8 ZV=W1[%H@HX"80Q(Z"UDN1V7QY%3W+D0SLJ9*6UL'+KHK6/G8UZ"K5[ MW>UV;,_'QO]&VQT>>EM$T!DWO-.YB'44:*DHD(S,)NZ#B9XK171T.EK'8=J! M?810DXXGAB\^WR$8& 9-(2+,7FMG.P1'(0)-&$7IY"-VE=::N>B,E8RP9A1 M@8-O;+&U"2>X+TU2^!4<=N?VB[ M:Q'>HV?H3()W PC54)$YTH& M:ARRFD=$@F*24.F]UQM;LBDU:QIZ[[.5'D7C7T)8Y=]Q,&B\/H&+!_U1X>-O ML3B(O<;O_>*T7]A24?VH*&)OV( _Y-_KP,O#X1[X;I&R@+FCW,M@B.$A!F>E MD0E$_BY,Y_=J]6KX6R'\+3@.D@"SD2RB%*/)A;X!61DRX0F.YI-7HS ?XHV M 0[7Q9.KE7>5RNL,]HPQ"3Z)XBP0"WY*LE9:GS!EXDZ%^@N5-W6^QH N8M&O M]?;6>CM#6Y2AX(SHB%PD$7''"= 6KQ#!,3+CE5P33UP-&2J/\RM/#$RY8U MU7NU1[DHR9>-PB9O<6*+@TYO,E@-ZC/^2QZ=OHYM1Z/!L)/.JS]U>@$$^!71 M)?H^D!:7=WS5 2K>\=?T6LWJ-/)YX] .&K9QFZYL0E%A M**&4\L0Y\49X*4EDU./ O+PA#KB@4]:_86 [J9KOR72W[-?.R>CDMWY1],]@ M.7ZWI_#)\'PY]#//%/T^_^<0^Y._>_:3&>T<'9#VT7N^L]L^VCORYWMYS/"L MG3_^[L(8+MJ C^T_X!Z[X>@_%V^_M@[VN>56>TY02I0BKK5&CDF#9"1:PS+9 M%$T^5F6^[K/A.MUN7N^34AW\1!W&O:U&O4&$O\70*"[UPU?ZD<8+UOAI8UE5 MVOBY<=89'H*X#MHI8J/3:[3[7V)NW=8 9.;C>U>8\.[,0>QX8'=+4P.']H>P>@H_DF*44_A/<< M%J"EG?(6J>B?E+?]]_9O.Q_@;:J^<(TBSX*#B3L$^#C.5V?3W_AKY]V'_(;C M;\$-W$0E!K L,&%3;_;]J6]8[XL1C,Z"#3D%K4F=O*@VMRYS=@ _CT[S>UY- MX#\'Y:Z;_)U\O_S&1?6"Y9O"(('X$6:Z\"5Y%HQ'W#$A 3X1Y#]-YD9 M >$BZ$Y=]GZS@\[@K],BVK#3^]L6G6S1?OQ0T:N7WY_ _]\>/>AV^,9/MY,.\)"\ MXS$"9\#2' "W"8?>0A1U]+Q(-(A\G'6D@HM/4:Z;(ML04Z,EASAO!0^ MRJ2D!>G 9#GI* 6BM&J7,O*;[1V#26^\!C?G=%C6$/XUM">GV9*\BS%+#AC^ MO^"STIY7OA/#S=*._UP:FSM8&:42(]99 ]+"HQ0N*&M5"%JPG.6L >=!1,JS M]L&^4&!G/,9(&0K>LZPMTA9P2 7-E0/O>3[Z>$\3(SS(+3',.)%KK8(& M_\,$DXOLN$L8URO^("O.P>? L+(D^6Q8\A%S.E*D=7"YTY9E)J^Y EZQK(7) MQ--V@>SV2CH,C+0BQAD)?K<]&SK@)9\6X 27?Y^Q/9N-:8_VU)X/KMR3%"M. M?@(3IY:.^V$[7NNH;=V'3-[%HD-C.\!IS;I:T.=_D#HA&L:7"669QI/ED M96!O-#I#=8B<14YO+]^+?&Z8N)/.L.R,'N./=%KJ/=SJL]91:S]Z88-4,3>$ MS@?26XI,;A!!? !*Q;4U!FB46C6J,9]\\%XQJBGGENHDJJ.T)4O"$ENO^@.N M^O&^HR(Y[A6B)$JP9=HCJUE$ 2P:B=Y*1<&6+:BVN+;L %&]WLAVN^?-S'4R MO S+7A;^-_QAOS_(PM,H(IBV M1K^ '\((*'6V-%?2=+>PT+"1GS,$PUH]>>DKLV2".QVRUG!]X ?(?A(0RN M+:Z,?1RA3#,\&#D!AW@#44G MA[V 1]C!((+=!B'.L<8\JBK@.!TUS,''R=B'WUZJS<;=4P/CQ W*&> R+;(@ M6; VF9(," #>>G^M*OO3\NU/J[<'X8E%=.>@A:6: M5O'=3%!!4\O_[PP&H]@8'/:+(1KFF"Y<>0)_[!?GXT,C@(W"*]J#@R(>E&RW M/)0FR]SH--_F-ED9)PPX84XPZ1P'=]XZ( TD4.F#",;J.BOSF :#MG<_[JN$ M W.1(99/H^*86F2"SJ9#)6Z9Y#0;C&^F9<;XW._%,497YQ8-)AY,-TZA_D0R MLSBZ.$X8Q- L#4@:#:GRQ!3 : M-ZJD'CYHQ*]@^,*$XXX3QS/""9R%>D5<9E;6$:U)2C@Q+&Q4-"Z._W_+,<\Y MDFO"!PKO7X51$>SYRY,VGFFKC1J'R!RBRO"\:RDB8(L8<2L=50'\!NX-JB?="+BA'P>EP '-*&(.$5Q/5UTFR!I^#$_9 M@ ,\ _=*(R#BC5R& 9(*H'W]RF5)3SG BA-_N<6V&RCT116P8AD.1%81^YM M"EA9(R1V87%AT )L_BL;DRS[ET@\^&YS OSB]&'[*]QK7VF!.0L8>>P%XI+S M'.]FR!@9&:=)&V)OUV%B51:V7L7E5Q&4)@8K&8K@XL(J*H^T9 PI8A/)GJ_% ML(J]_IP)76!3KQ+H_=%P, 1KF'7\RG[>B#S?] -*JYKU=W/F["]X?I:?3F]D MJQ%-4>0QZ>2TVMT 3DY9)?"JB%WX\I?XZUDG# \G)8A3%XY)-;ZZQ#I V-'P MYDNFV';VY6/Q1-Q:S9XQ/?7O83$9S2EXAL@!OA\CFV"PKVSW#.S3QB_770SP M)F;F\)NOOY1GD=*#O7WEWP JC+MZO2JE+G\+AF/79BR-PR)#W7]UX#I).+=) MRL@Q(![&VAN% Q6!.QKW%?A*)?T$Q?@]HV0FI?_SB]U:M,8SFE AF7+<<<&I MDKE:-@"B4E!TPF)P,E#N*O2%:V)XG7&1.B-3XDP0I;AR0"%]4C)B)2( L=$; M/[ +_B'ZV/F2YWL ,.1+=GY1S65=IW@CZY)11B,(L5F4'0@75D8X:W&RA*H; MVKD]BDRN*?YV^X'6^4?9S MR\_(KS_?7)H(XE8&D0#-\N_ 77*PX#S[:->K%D4Y^,GWFG.#O'PF./9A85GC M3YV?RZCJL#,$OG%5IUB.H2IK+)7TJIHQ4R/P"^$!G<%AIE,>IKBH[C:.:]M& M#\#BZA)P)Z]N[,!(93P9]2[C'4T8!HP#[O6E \/,C\YO4L3AJ.AE:Q1!(WNQ M/QKD1' 9&"]]5%B?9O;\3D<%O-*@+#B%.\&M1J>ERUO><5"&F',XKE@8QP8T M\U48NHPH@WU")_"T\T;7EE8T7].U9X,JUO)3Y\O/.83=C>6\3J9T'+>._K"7 MR_(KL2E'>CWZ7T+>99P'IJPS+)?:@^4.Y=K''*F)EZ'("8D=IY?&P9ME)'$< M,IIXUJ6/?/L8Y+T1USJ_$&U?3U[Y7?7&V^-Q_COG!6K(O0%R:?OH[;[ 0HKD M(V*"EJ6 '!D,7A2'/PMAL @B!R&_ ;C-K/1'N: 9Q*$JULZU%Z N>==S5L ! MK$4)/;T80SX+N=2#+'MO0/9*],SJT+*@>HW_&]D">/U@JKJYJJ#([>4NJRA. MBY@E/]\GPT*& _ M0%J*7!(RRN-(N51M>--8IC.\2Q:8+*&*]TDKK2^3 \L#2-&+%8244+KD?#07 MM$=^4XP.KO5(+L&X*LFQ79CQT!D,BXX;E1]>)@+SMH9NMH_PW:O]#%5R=H+- M&5S+ /L5R\B+.S6&:X-^=YG5G!H." 9 B!'XX%EVU.F,V$QRC>K MR$<6F6R[\N!*,;W,N3?RY<7@L'-Z%6(="]@T"8+Q7657.[W*/E\:J3D5@84( MHYP['IS"=_I%A?:+[["YS.QW!N600#2^='S6P:K<8=%4WE(57@^J\/'TVY9= M*&%R099R;F.*^$Q_:VS0RJLK0S8L,QLE:Y\DVA8E4=)TK/>*4'8&5SEL$)HO M$98N7S>$CR_F8LJ9N%B D&RQ8.;Y;Q,'/-J4#[>"S+$(S+2NI^;Q'8_ M%T_N?(E%*&R:GM320)=4ME79N!<56,BTMF+.):A<[7O+UY9=7:KYFZ7C@.@Y M2U92(SN_22YGS4I?=,$R;/P\T9X%'T[\F\%U"9_8S0FS*(N"_F^4]7B*%'UC MUUZW#[.VJ%:A5_(CX/^=T](C*?$Q)]M*Q[-,\-[&$_!& 0[I93RI*+I'SCB/NB4*.:8(LMI&:O%U(V"I(?X,? M\"UQ'9M;F.NQ_YC=P=I4'&@>ZS;*:$H"DS^M-+TL.MW2?I;Z^J._' T+CPK;7,5'LJ6MO5IN_&ZET5KW!^[X4:#3JX^*P,M[Z(K1IESYM30 M]3!1%<@9QXGFQYY2I;.18[_>J*8'[G1631TQX 4R MCX/GR46GK-0ALN2Q5U:9<6*:,%*KZ8.KZ<>+]AN_3Y4R-&J*:-ZPQZ7SR&DA MD4B,U3Z(-@E&+,,M'.BD;<^;;(4*3,=9Y2WV.E=\L" N"B:NA.57$:>(H%;@O&O'ID@(9]K4=._4V)ALD%3AO52/X>ZJT M6'0?D/J\$"^UC-3^.ZOJ#^YK_G-P*U1)3) (@*(YM1R@1#.3@B>6,.J3HQ6J M8(*_R\ZNU\Z"Y,:JC+A&D)L,\,Z;[7UJDDW<>D2T] ;N1E85!P!96;8*@Z3 M[S>V^#=@8RK]2G3C4LRK NL82EZ?HU95?7:V2E/Y6GP/]5]?;?B.9U1&)?-, ME$3C-LJB9:)"2!GSUC@;F(ZNK/)DWF"LA'I"!OOR]C]D$]S:I]SK$%A$U-&0 M=ST(9)PG2,<@I6'E449@=S<7M048*]"7\9Y[5$;'2[J7.5WCIW'1Q#59NM*P M2=G$='W'-4Z;#79ASWJ3'+GO]@>9-TZ*WZO\Q?^-.N/N3?"G!:=AE8[^:S#9 MW06R/''8K^_2F\HTW##V6V_\,3$((Y.*SG%GA%$19E=9'1+AGI"QX/.:>SZ& MX+/6Q=M]&I)+S.7M/C27GA./C+8$>0?N-0L\.@N60WR3<()D_6L$3MF\8%UN MW[D=ES!,Q& L]I(;CS608@:L6(DD=.*3+0CRE@TR:B[Q?8EH7[S>5]YAY20% M[YTZQ+UDR($W@J3'Q%O.I.\Z3"*C_@5L9:)44HDX%3P6,(%CN2%+?",$D!N:K] M8-A4^\'F6^;*6:G\$"=#V4FW/W;\Y4GE]M>=W>/,\?N^[&U&N\^C6."7.GL$166$ A R@$_\N$C##)K:1:D<6U8-^!)?!<+C/M M%<"4%3D'N:(&_EL5?I6;92[;&&0\*JE<664L?LX(8$F@5 M',&B#HX\(*R\9:W=XWVP$ 'FW@";\0QQ3@%6=) HD*B#HS8&Q[Y-=S-_N%TO MG =:_DE):N[Q]M1C%$A:(R,59#%>[(C;*'TLHG*2.KOY2[<">["Q_ M9,G)1>HS4C/>*O]GT?%URZ1Y@>&M-SD+8Q0P_H12V0U#>>"6&'N$DU.,68=3 M/JC&F$TUWT'I'Q,/9BYGEWG&H?V2.P6.VV[GZLGS3@31>"10X2]I'?#]$8\/\B8EI+Q"V04\=)1)@$S(52,6E+GUX'3 ZY7:@ M,OPWB"<=-"G=+U/!11%MW@]4EDI7Q;;]JYU?%=6MT(GB.2@JI7RJ>IXIR&O>Y.IE9L*E92;ZFS1S6';8:>H*AG&F',;5@I@X8DB^5Q-S1D@B"66NTBD MCA%3*VM6^AC.+H//]G, /#*>&^"DB("4>F0IV!N7E,624\=,7#4K?:#EKUGI M,HN^\Z:U+T0PN5X-6G6QS08ACAI5688E,,S,_ MK>(055BCW!Y[N^2D\LP8K7&01''.B=-*&TR-2\"3(ZGZ5(-<5+&P.0%!8E8^ M_KR,A&5)>?LU=QH>=0:'^8^_]P?#08T32X@,;UV R&"6PY% -'SBB!MP89UU M.5)O(Y,>2Y? >Z5D49NV"5"<%I/89/[QI#,ZR1(SO^,-6,BLE:F[QGRG:XRL MN\;476,NN\:LN O,^M+9[:FP.;EWM#2:Y%FTB0NL.$VP*,%J^!6[Y**FD_0O MJWGIJ@]<(>TW'_=]DBP&:9&6,@$750D!(V1 2#5- HR/-R+W/1'TYNTWMV>C M#[3H-1N]<:EWW^Y[%8/%0B(5N$ \Z( L-PQ1IWD$.4A1\HTMO*G8_+D!"P.C M&0/&P0=V&1J%'V="HY._W"F^!N4-H] 7*"=SG_;YBR5*3!(+)92 GCB"C M3$"4I!0%)=)FV@G$9'.!AWIC/'11#.Q2,NX0 [O*ZHY%D)2522NT3 G$S"=F M! -G'5PC"VZ2"\Y;3H.*5-26Z:'$D.WLOM\GFC*K&$;"6( KK"0RP*D0N*A2 M$:]%M#Q;)KS2.,D#+7IMF6Y8:@[CV\=&*\H-05@YD\_HPODD2(Q@WGFT-F*A MRE-BU4+ ^:9E8N0J:4?FDG;D_I;IW@)36Z:EY"3'T*B,U'K !J]1)P0L$P6 M$P0$5A"8N6C-?/N8YINH:2^>U MKKWUS 2OIBKX1TP;;E?"F#I9NZN^F55SABOQFG0-FMFK=%45754TWFK3!M/6 M).=(,F!\/;,8*VJ\2Y'JW)KC.T=YU<6Q*]PDO/LQ'YFL/">!Q%QYP!U8/6\ MW( BZ60$#92!W?,;6WI!XNAZ*2PHU90JCG-'E_[2 U:R/G'J_3H_!&T:#3)8 M6=?_4AWC6;9N@4F"H1?ESNA)J\3R&^6)F ,#7"9+4BR*2M5LU2)@ MHYS>S8TYH[+0GBPP)YL MX/+%/\"?CH _>A>'EERV:5LEM>4:%L" XRR7P#, MER1GAN%,=5,[@,C6O-,,>3,YZ1/$6;C3*QEWNTCHIJD^3" MGHJ3'A(W:7J8CXJ;/=EMNIO?]'ENOU[KZ%@NQF#8 M]\>'L%BQ@(^KEHB3WK[E\6_Y\TM3>&*/RXA&&IOXR0#AG2>X^>NUF3N]%+KR M1K_FCA)V8C4GS2*[G=C+#Y]NFU>U"9X]>ZYZJDT)C'I>WU^K69GT6!XW4\S6 M-O=E'.66?8/&2>ZW6,5D>B"6G5#-TQ5CR&?938ZZ&^9FQ*60V_(8O4',[81? M7YO2R2J4730Z1;SJE[?D.7W7VU:E@,&\!SMV\?<6^.W&L8Y._EW@)D@XZ M?M0O.,6Q-'_(R=?9+B82'V>V$F[\].#\=-GX:8]+@EFXHL93+D' D#',/ M?$[3:&/B@7K,H[[A1" ZR]U:G5XY\(DMVYET?;UR/G\[_Q/F,@'GV?-4&/^Y*9LU@9Q&G@R]KA58-[&?]8OCL== M]S+\5^W.7XH=:_=[100R7 Q6;[^>R%Q5A&3^W^E776B^IKJ/91GJ@L-=_59^ MV\7\AY(95T[#;X6]Z'3G66'GLO4+T+OLZ5Q&2Y&Z6^,6?&X,FUL%JN>:#^5SY_X'*7[TN_]G$SJW"FY_W:O"L0 ,OV( MS.^OR\V[:53NW%W<)* 2U^)V1?5VUX_.Y9['Z)+1C+85U0>X,%/V;Y8*? @HU22A19 M2@9&/ [$Y5M9O7PG&3 M<.R\.=A/ED1&E$8LYB-H+(B)@W5 .D@)SI-BBH-P""HWV9*BP9^+:!R"8:Z% MXP;AX*W<[SC*J%/42&">/3>N03@(!^:O)3,F&*F [VO%-NF2PB&>B7"\ X)9 MR\:-LG&TM\^CT-X3C(2*$7&& ](1< 0<04PL4];J7)Q$-^=W@RX6#?E<1*/S MI8:-&T4C5U1'3EATC"'*7 []V("L(S07KR5J<7+1T+(684G)4)7?LN;2\3KO M;:D%Y+L"'D(%LMBHW$>?(,LP12IY$;1C0AC #M:D@F[.EZM<-=// MGG&YI>A'/9AM' (HPQ#]Z93L= )N^DR_J5*)P6RMQ/443W-<(CR.L^$R8W2K MONJYL@C3J/+A!]P2@X4QN2&9QDE:RK]7)C&G:Y/7_1/>MAWKZHB;5 C&T-I7 ME')/@P*CBQDX=8XBS0A#*BHPO2IBR\J=D>8;+MWM#*[63N)DN$[*W7T]@;Q":\T&6MT^^792'9!.42 ,@ M#5IKG4@(EH.GH RXR@H4EGP3HY_4)M?2L!II@+'L4W!T,:P*HBF!- 0OD'8: MI"'BY*D2$?1S8\M\$[R?W K$J@>#[5G :'4XH S4"%P]I\*D<2P^NJL#,K6[_WUR%0D,'.5;'< M+HSAMRY<_N0ZM#?6H=.CUN[KK^V+=N?S[M_=G3_@^MU_G>SM?CAIT[<$].&P M=>1!&^#YO\_HT$D+[O.6M>B_NNU/'_EG&&OKY/-A^X\]MK<+OW]Z>P[W/6J_ M>7WVGXOWN,Q(@*I@20UB1A.@Q,$A*XU"P4:A$I72,5]!(D@P3&:&(BL #@,( M;?*6:R-S 1H)FI!H*!<:(#2"+IWFQC+%")RHZ>7Y9Z-:H%)[)DO4&*]1HUJD M1K5*C:EEFBCP6'IF6J@L;)[R_5%>?RM-6&!,689UWED7M+3$)AX"-D;9%'Z8 M9BNYJMF.AH= UG,9_+5BETD!RZ3J.1=C=P85S;[1:@[*Y5I)P'C!KN>QXN;1 M57+Q^G+LRYE'_.)4^^U%^VR?:&V=C SQQ"G\D]L5!V(1TY,[5 CEF*P,MU)N5= MSR*GF9="A9E]0VL##-?%H\:&>4D@K6P@HO#@>"!F74(\8H,L4"4D.7!"!X+@ ME\>&&4G8^/G'#(S"JXYY[ Q1^N?@FHDL YTPV,YP?,++C=KP!5RDU48D9_J M3!G)O_NY<^J'_$(#^'E*$:;P$N;&9\P\ZQ=A$'LO6$G@YR._GV"BK07?R(*; MA#C.M1?$1T0C#1[,)V=4;VSU>W%>2?+:3FG*95.0LO_V5]\=#?*>V2*O1Y:1 M\NN3<(3KVZ*LO@^=(OIA?]P3(G^ MNRXUDB1;HZ\B8_9\WXP90BJIKH&_F!Q!8% ; F*@J<_ M'IF2T(V+0 (!.;-W#2 I%1GIL6*YA_MR>[E6^_/"'<$G^VGYQ=<49GNK!4_ M^= [[[1N&&$L;L7F$MZKHK9UZ,:=[39[A9Z S#(TS!<*#I:[9HK1&WW<+4_ M!KAAN#6XV$VMVZ"E='>H'W7+=H8:4$_.WF1?]-R!NE\F$ _*:M)!V\PRU3]_ M>RZ(&9^LLC2T?=9L-W,[^?/F0>EXYL.0"]L:*@EOGA;5PC7"BJ;TN>MZKQ@B M_QA_G@UT%9IP97\^]DB&FL%GU87!]%5"NO<(Z:I*2+<2TAW$@NZ-[8S%@J26 MA@/O] +G,DAA-!=1.V\]5MX%/:BSG'GW-E:\2H:MF>5FNGL=@>FX6)U<[M MS]C],!=2/]@82KV/P6;3 61 60O%GG7CA_X/_X*]]*QEKSXT3XN[+C[TK]'O MRY#\ QA"+M+K?4GQ?>7+/;3.&FY89< ^[\#_A_X7][!\K<#R7\[#Y&M2KQ&L M;WT9KY%'OB88>]0G[QHL86M"TM926\?S'8OBF$G>PEGIW?L=-X7Q+*U/>:AYR_^5Z>YX9 MT ^:@)'J])%Y> U/^6'W^(]"U*A] 9<(W7_.XV'?O+6'E1E;X;VU(B^JUK^C M5V4)F?\\8&X>=,/O;>+(+"O'67]\T&D#_4:]$7H?(S#_QT[)"Z+J! ,J9N2/ MS%ZR#P[N-3BLYT.]S6S(;*W(%WR(L=TV5;<9VMRF&-<>.-%PJ1>:Y?\9G\#Y MW?SP31?1JN6YZW_,HO$.ER".6.P/1WN?/E_N MPGI_Y[^^'[B2TMD^^\.W-7;Q[_8UN[WBZO?FUF?M?[7YO M'.\>_0IC^$+K1S"NDV_LO]>?S^M-_/,_.UOGVYO9X_RRKT,(GA*,&),:<:4H MLAJ(FOK(M5-45X;,D ;F;6FXK_O"IB^['=@5]/^YJ05Z4$:VM476D6M!^;@UO] M)CK;/$X%]U>," M4V0(58ASGJ5XG$1".$(L/$U*3=9ITA2O4C.IN/)PK)N.*HOC:]4*?E@C2&<$ M54)1JBBWAFMO&(LJ>B,#QZ9B*LNV@L>9"H:%F@!O$1'!(\Y80,Y8@ZC#BEDJ MM"!Z99TSLRJ78OT^-@CWFNA(<6*XB##:@U!KRH2]-=2RC#,93(3_.@Y.E9%4 M*TVSDHO"DM.*=RP5:GV9X!W*8!T#MTA;2A&W1"/-$T;4$""40@<=L\S JN1S M\*^6)4;TEE?O+-%?);6G420REFD2M/-%5]#_\S=-"?W7+0V1GGW5 MSBGP47RQ*I,:EYET]"1)AA*7RMQA/Y*XU&IW'W? =X\_==_G>C&N7C82@VD- M[8NH*#4$S0BN$MUY;Q M;8+A ;FSBD7P2SW0/*YH[GL/SBFC@@9,I8TEP],,KQKU%)8W]S7TDG&I"DKM=<@MD!)2VC*@WB$B MIRU&1'LFF,#6"+^RSKE8Y7P.\;T71M&"L_]2)+ /%VX-RYJ\G6*$YFEN(MDM M.L*>/YB]EV5ZZ8X3S]QK!2:B6;1*;=E>O^>BC>?0FR9J&ZNT#SKV))>IEL4HPR6;N8ZQ_\:+L_SK+&)LBMA%N^D?G5G/#S2MO MTYSIWI0SGY1=X\$TRF:OW;7:YE3%[EN:FQ,SVMR\;P:SRID8Z9S(JG-84:Y4 M,@EV,<) MP>LSR40^JL:D0()&RO+<>2<0Y"+QR"BJ MK$O$4*E6U@73=XC*UHHR9@"19K>_WXWU^IY1971>9I(5/QYB(G_&\_-6J:!< M6[UQN]J]#;2CS4_O\&. MTRU;5Q8-)+O%(RD4(X;XF)EQ;\MRI//8VW0TD28&+@\UW"FP0DV-UE)JV-?A MSS/KWE9[V^P6*.I'L+J>\G0DP2600T48>RBP\7!'L;B>0.][V_U?D/I&[I*78-XCHL91Q(.-R!(9D&#:DZ0M"5[#0IPB&SS!'UX@ M\#LO)@&[E+*)"T&#XP(G XL+8&CC8-^FH*DFP")2UGFP M@&5:<(-TXIBX&%,09F6=ROMHZ*P@1.<#0IQH3$C6%C&"!YQ<8-)8+;5//,0D M9FY<5X'0TVR*U2_WM0.WAAJ*J M 5"VFR&E"P,?17FKBJ3?@V;#G!*'%VDD% M0H\W&%X_V ])166%0E0E "&L$M(8?LJUYU0H2:EF*^M$X?QYM"09X;V&:XS<_96T,)S^%^0W _"?R9?9SWE\PRO"2/+QN7 M^\Q%S8F42*;<=-1YA5QNG)-[)B6:%'$:3\]K*1?DRR:WS(M>X >G@I!J.1X M\L%*V#T,4]0Y[8W0%;UX1M.\JF]^$=M?]ET0(7+3M?+L$:LHB%J(X0L[:=IS#/S8&@Z+4B1 !CFKN M<-Y4J++W$RD.AITLFXDN7?# SOJ]?8I^^ET^H]IFF-4^SQJB:M3T_WF$L.A MGFJGI64Y[X\*!WAJ"0LT@-?N5=DIA [@<#RSO2)9<^F*N+US?%D_JE\UCK[! M]^WN:VU8-)&CJ*1 L$UAY+Q5*!&N&-FLUP<[&"22(PZ MQEPER81S1@.L1BNYYM$FU[,FTKJX=(HG#;N>) MRQ(D"G$3I&32&.(R05^;+(1\..SDZKKOOV[,C#^+M9@*?QYO.FQ[Y]N^U%I0 MG!F[DAP8.U$('E#*Q0):12V3":$XEI]6C-4'H(7%@XE>9#RXN.*'W,*^Z>]N MG%%$B,M^J+42I&K;-\&YMQ@._]5VF[X6;2=3W>Y02\YF 0QG%^=ES\RBKV1F MP[GI5Z_CESTONW(63;K.V[6-7*+<;<.6$W^-G8-X"MM0YZS7UZ_?>+,<38ZG M_X@=>Q!KL&KS?@9@-#WV.1(>#3>!3AAJLQV*GJ3=W'PEK-4VFZUBO*_E=E9K M9ZV+LO]:R$//-R5UPA0CK(E%7&:)=0W_)"H53]H*R?C3 M.Q&^/,#,TG8P]-;OQ*+J+Z6;I?/X1H//WE:0Y$VU5 F]'',%MH^U%^ M[EU"W'?ZND/AHR+4\B[4 @_W/GT$!_CWD_K.YY][G[9PX^@;?.X+.,9ULGOM M66,GM(JQ_S:N%OCQ>!>'M>O_SIJ7'O2H-]P MX]/'XVF-&;V60FN54)#<(4ZS4YVT0I3QQ*VW2BJ2@4RO3-V^S[; M0\_A1D\D7E>WQE>$O7/WWSYG'>J<_VU;Y=%_+SUIZ#AXIUW\[=><2?6'OL6OK+M?3'O34FA5 ,%KSB1?<'(A$0;(^DU][:O/AS M%QVZ*OAMF=;5TG\;2W_N'M>\E_[;:[?X?*M^;,-GS,2@G46.4ECU7JC\4T3! M>494E(%Q.[=VBW-<]^^AM_/L1UZ]I*XE.?1:5.>PUXZOSW4JUDO1G0AL53QJ M?H@ZV6\:GB:VT@=D8Q:R,L(B;8A'5B? 6>$8PPQX%"&KP)KG&]-ZUE9:RQ(6 MKU#F94_6*I1Y#I09]]84%R1*0H"MV8BXI1H9GSPR6;\!0(6EA7*-! JU)GIBJ?OK]\^C,I6RS))*@WR#B; '0H M!VKC<%$^S:V,\%CUUB:4L)%*(Q"1"NAN!,-P7H-33820+HNO.)M% M8,C$)G1["XJLNC"FXMB]5<:Q@*YL&L4/S\N1*N-[UI+AZ^W-XWTN+-B7=RA) M7\A_1.28\$@ A#B>L4+E7NA3Y#_Z]C7)$:99W*V- V\7@.AMV)R6Z3UG[6XA M3?JA:, -%G%3"OOWT>R@'B'!-Q^Q#M@3\.I;/S)1)/-"O$3IL8R?H7_S< L; MA8]* CM^DC)RS*3#6'NC<* BY,ZS^X#K*_U/'79NDJ8.X.%VHCU&-L$M?K"M M2WO57?EEE-0!?QN;^3LG[4%<+J6%S5G)*&$Y]T04/A3R1?E=,!R[-&.I'78R M1O[M_H>G@&46M>3M5/LMPVLN9/_W+W9]FF4\C8T_?Q%N8>0-(-"ESZ37:@N6 MC_B:P2(?M7;.KW8Z,.@2O;J; $VM=O>BLT2B$"XL?/M:N][_;K^:?=R M>V<#[])=LGOR[7+[^]?CO9.OS;VCOYJ[1_[G[I_C.\ 7TMCY';Z[?KEWM"'J MFU^/\GOW=C;$WJ>O)WN??C]I?/^]V;C^>/A?&//VQK[U!*S.:$1<4H@S@A%, M,T7@$A.?^U&8V)-E GR/82/OHUIH8F&O)T)[;FG0T44J*$X,'@:C;EQCHO<0 M:L53J T_ADF'S>(Q[[UYV@8>=O4Y[Y+@XFY? MGL9.][!Y!JPK;YVPR?QZU6B?YF_OM($AG!Z4;QE0+43?W4K[)O:=C[C(,U1Y ML?&80TP"*%=6-]/"!)-RRX4I)V5_SQO!:%.!8?6B$1V@S-F;W4*N#[8;,)75 M; 7=)NQ"1;>!3F\AGN6%N%;;&5+U:Y_%4D*EE/_[83O-]D6W9@\ZL4Q-*2YN MAW)5:I?-\\.LZ[;:4V7.P[&U,Z#>)];'BR+P5 O-;IG]DFUT<+4L(MB]L*>% M^'RI[#PL,3CX$(QG['IGG7:X\.?%@L@KI!C5\)6+ N\ZP?<=7>T<.%??NT?0*;T!E 47$S<.V#>%IL3#??>]AI7QP$XU!X/*-'SD MQNZ%*<"."X88QET@00I#[ GMZD@05P\\. M\Q ?:L8'9IJ^?'>.Y\;K@\OM+_N8:B&,] M"T"!0Z[IU(PA9XQ!L/R82(CLP[+9+@3VG#B M-08&KE*(FM+[8F?5LW_RL[^J?]D/1FL?J$&&YW:.L *123@BQ86B@:G@,(%G MS^Y8\[5":NCN<&OI_=YT%BB;A/9"K_!7(-9GT><@5VN4I@'YZT0?FS\*PM(7 MUETM)">S].YIIN#P,>" L^XZG 1BE2W="B8,+P- M[W/8M?MU,,[*_A[DC5^#-ZX8RPWS/"+*$<13\ @<-XT<]K#C&\)A3[KC3&A* M3^/($I6 *BH*<#^\TX$* 9R21JLQ%\53?G'^0\,*A.Z\D;"CF;A M8<<_P-&#^=TX#=O9%_^C#1Y;/&^6U2&_@N>5FN?+&(/<^3Q8'WN;N[QQ?=C: MV_F]63\ZQGN?=J]V86W43[Z(^LE?8.-_'34^?6QM3ZR/K\>-HP.V_>FO5OWD M\]7V#JRG([@FC&UO\QC6W"Z!=0?C^2;^>PUCV/'[/O-=K"F2(K#90Q9EGX\",EB"()1;0';>!+1&J#E(E*N+9!F/R4(V9__8G44SZ76>Q2U M/UKV4<'(>P?Q5CS@X5!1]ZQ]VLV=+/M>\(UIUUQO0L_RA)8^,>PK*79R "HK M\\+"*.6?DY'!*>U&#V&G"+$5#XK(7Q$#"R?-TV8A MF=SK4G0^QC!'5DJ[6"FC#_:\7;1YZ"/9S: RBP4:>AX[IT!^_PH?.B]OHYV7U6YL,WVW7_BAUW?.-K0Y'VLYBIR U.4K7 MFZ2A:]KP VZG4QIY8C!6^WQC M,7E>7AC7Q\ZY M!9?S$+Z]=34,GUM]2,W1_J9OPK!AV9S8JYNO*'H2%!K_^0L*=W*V8Z4GYB . MG2_EUHJ;Y13\-C0#>:+JL*I.+DXV3F'K;0V_F#-]^A/=.WY:HE.F9^=2QSEZ M936+FB6!A.,I-X6B0*5(0MZ%1*W!S"J]LCX9OOA[-H67>OA]VGR; =B?E0$\ MR "VO^P+2PW7DB CA6X]:&QV8#L]N ",&25L MKCA1K)W;G_V]N(^%-WAR5\AIJ@TYI03#*?HH&$]*..JUDA(\3TDYTW)N-M0S MDT[=GOM#0-&1UTO3V4[%BP,+PN_.@+9^-H[J^Y[S0"UE".;?YH,/APR1$446 M(W:!!,]4T8I\2ENG3+ZBA3WM?_+K/;Y4]LU3]J0;/,GU3OE/X!+>#RU@5"6Z%%[9X(.O MUY3>-<)<-S8W]CU)6@&S09KG_"E%*'+&1603DR(8Q3F.*^N3:>H%PI1XLE;; M&#&'T.SZ'.N 7SI7(WY7SF@J;*>H(*B=MHNDFOC3QUX(I=4\R3$(,$#K6LWN MX8T9?N['/OHY([^U0X[A?/[Z6W;XLOL%YM$&-@4_PRLA L,J4JGV]^O" MD7WR,>=:SH$:^X*BK5Y_8=OS7AN[',H:BE3U?=P\A/9IK,&@B[3(='$:NM.N MFJ]7:YZ7A:F_"+'BW)*_:*. M%>YPCOO@L3E\#\-O^@M&">;U1]'%;^28#G6C_Q N.I?M3NC&T_<'+"+O3H3" M4U X(&X=L%V=LL( X8C2R'22&L.B7UE/N4BS,/+Q4X*B&6,'3*NH]"SS_]YV M[+K$G5Z0MX>E[J(+[^]F$.E%Q@:G \7!<><*Y92&9H)5,11?+H*NBXN4ON!D MY8;"Q1&M=6TPG5N/2/PAW%'>5=I]&'Y0P=[=T%J6$\^2_3'W8N);X"I/R]?! MSO-*:O.>'9D^\\;FEWTN@7%2'U"B'I")YM;;,E(,Z]>K@R@B<:P<$^/&DP ^]S*!?GW)&(G.()"<9E#%KF\_&5=4G7)IWK M&R.8-1MQ[I6\E2$\S1!V=O>99IX;H"@4W$^P!B>0U<:C%%)D7 CB/%U9YV)M MLL7(C2&,)!:^Q6UW."Q=^%GWG-,-M]_NGU]^!<;<_UNVTASL;N;#X^Q@Q-YA M[Z#"Q/4/I&$'[\96+!0_CN,5> ZGMJP%&"Z0*8(9$T?N@U-N> DH4NQT>U\Z M^EUQZI%>46B0O=7B?*3OM,;_S;^\X*%.SVDI4C^&,QB&]&Z_P\@_GQ:-TV&P MY?G.YE!URS(5C3W_LA]6A[BJ;V[M"C+RU#(F4BZMG?B.O%W&2 M\3#)GZ4[7U+8?,)M_UG[!U'_+/_0&^KGK[^]DPR*_AH9S0O*P//6 7H&; :2 M06JWS]14B+:Y0_P0:/:A=?4F.ZJD1J-H?9-#D5="D;R6RQK;G:$85+,SS=S+ M4]$>_@ZRWG+(S\5B--X.!:P'82SX0%$Y6>X>O2\YN3C/E^_%M$9=[U:S7\98 M:F' IWL)67>DVCTL87CVL@%ADO9!>1X5%RDYYH12P V#Y9H8>TO9P#2&^/"= M(G/&#CSG__0GHJ*.MZ77UJ\W]HU)05L7D*:*(*X]1T8(CZA4)E(6/%%I99V1 M-76[BM#,!4U1ZP"N O%)<#:[\/M<%]L21+(K/])T!ACM_+UL+[Y:[/^_2-\_Q:&30#7FQ/U:'CW^O"DOAF:VSN'K<;.%UJ__MC< M^[1U6?_T^>?N]X\G,![8!+Y<_??Z&VUDF4$L&5.*(V4# +_W&C#?FBS@3Z,F M0-V4'J^W24EXYK"AQEMNF++$ZB25,XX1;3P=K[HL%:BX*1$^@0WZ"R7GK+X%JMR4>:LK]4V[G(D>MHSC]&S#0"0!$=XGLYQ[K63 MQFH;M/ A!1OU0SV)F^5^"V?\]6JR!].E[831#KD;/VRSE9'Z8[OS"3[[6H0D MGQU2AN-4.5?G>!^<#8N]!W_#Y%"U"1@\#PL@3IP2 AXQ,3E71ZQ-AJH&_D:O M^8_M/X7LX8(7?9"?!%AUD1_;T/#S[YW5]^+P@P/ZPAAS]&58 M>J%OC3G\WDS-.&Y)A?+4_UZ A0X:7*51%:^<"C (0=GS''P"ZXU%&EHK2U85 M^F]%AH!M=FHPTX0\^M%C5(_,PNNF+^QN,YPDM1DL6)_8),%BFLWM5*C$U4( M5!4JZT6B%6Q6@ -716I>>;91!MI@N>;"*)BENZBF4H%+GHPUFG'&B2&):8D% M_.2MHM/3Q>>TKQ3_?(4Q-\%?C7^6*4)E/A99ZH2L%R"GU_5]:[TRFFHDP2] MP 0<"1.9BL8,-#"6\V&/Y-Q5SWCR&7LLK&68(IG*MCX>648=DM$) MIH.W6N6D.V"L**<_3>U+,9R#U\N[Z^%5 6'QYUFSR"9]%EQP]YN*&S>5K3Q" MV\OR7O;DS&>W$]RXW$^$ V/$8"%2%/\0,!/P4UW4DDHO \T]YKHYTWIZI@^CV-]69]_3^Z\40UVJ->V^Q.X\-%6.?F-0,'+3$!14N M2E@XC#!8ODR&5&'L2V+L]N:7?1*PISCD"KZBT;67R&21?_"L'::,Z"38W?OH MBS_CBC0]]&&G+! *VR;*8H% FB)%.LOH8*(T%EYKX<3*^OEA)\8%[ZCS,IIJ M1YVSH1Q?-C;V&>R;L&L&Y#F1.87((RTSS8Z:T."I]UR#G=R^G[[5"$#>34Z* M](QB Q[LO -OM!=X:G;[>?I%+58^@NK8?"V4KUL#D\RI4C]ZP:).'\#&UE.W MOVG;;+9]\>#8UW$<&DR[DV+S_*(S7G/??TOWAC048^[>#+H<<[=VT2V5N5TS MRUO#/M]G.CV9ZY-VB"UPPW^>E="]R66>WUCS)XM1AP'D&EQR]X8M<6S+TU?%G[/AF MM^! =K5V;H_SO31/@6#U-<][Z6QPD?*.8^S^WYH]**,J9= B$ZC5(N+2F\_B M[64@)'._&VWRXVJ&5NAYB\Z/PH CBG! /J4$49^$X=YNTOT1AT^ M%+&P\@D6B63C)/PF?C9:$CG(%ZUUX%\'8#8A$+Q*UP2',=$/8A>"/@%9&E?.2: MG,S/6?C!^Y_^,(:+5NP=ETT\\^+8H/?@\^,L;:7;O3@I_U8D0;SK<_CKXWV: M]048]4@*9H"UAX2TS5+CUFD-S-W+@,W,QUH8#S_Z5DPOU2Q\XA"TR(N;WN+Y MCINZM17[@^Z_-/WGF0']H G(!&'D]N]YN/?VJE^NISZ]1?S7 8UO]KI=%7S^ M 69P[^T_P#[NZQS^H,;@+V55#YSAV6K3GDAH^=P([8"C#A&:;"P?P5;ZC=&^ M@J4L4_G:XQC.[O??NWL[[9_0#;X?6=SWAWYXO8_K[7W/[TL5D_:K0: MFQML>W/C&JY-@?>>-W[#/_^SLW6^O9E[V7[9#YXJ@:5'QF7M**8\GH97J?C/J\*K002GJ(< ?[(,&SP*K\9N_U%X=?\45I"T M2$CJV\-FSQPJ2)H=DNH3D(1Y$E*"'QZHHXB+")!$M451FVBQP48QGR%)SQV2 M7B&%^FLD0#P<$GYI%E6AT@NCTHUI5+@T.RY]F< E$V7@RG,DN>4YZYH 2\K% M?28$IXC E!IPY/0:F2SS?,=A[8E_Q[>-?(6]1=1[(;^QJ# '@O*@\X=#Q4 MJ)B6PZI*K&XY#\QK;C\0X;E*#NG(8)$1IY'UL,BH,I)'+C$1"3;XM4D1Y"61 M ZP>^HP/_6AKGVK#+&4,\#1K/DFID(5_D2*!,X!7CSE>6>=KD\[FHZ4[YJ[^ M5SWW69_[P3XFQ/O<>L/:7"%!M4+.4-A6N516<2D ?5?6"9O2-/06;8[:1*7U M,Z<'#/.WX?2 C3Q"< .KE("C72!1*E +T$Y)UNI1-")#O$, KT%('PQA8OR( M_XWPH(T:\/23+,$^D4LXPF%LSUX*8.N40@^UYFF))OD-.7$OJV&-5'1,456^ M6U0YIWJ>P0J*1=*6BZWVY8?Y)C8\;X*",6M"DL2H/R]+X1]&4HWT!EPC=U7Z;BT&F=%E&7G2-S$+, M@*.%1&SLG/SS':>VC$L;O+\9Z*?B_MMU?EGOY>,6/V_U+*?XY8]L/=4L3<[2 MUWABF[EI<_';;S=+J_@]AQK?\:QM'!QTBM[3Q61\SOKOI]VF+WXKHK-S.1)] M;$K4TAU+;-^4DHPKMO8+ LA"3T[I'"<;UZ9,>2??[5+-^6PR58\4-F7SKJ88 MLI1&[PSX(?$4]DK]ZM[A!JL?_=K<._G,MG=^;^X='>#&SJ_-[4^_GS0VO[#= MZ[W#!H5QT+K(^JBCAQO^J@[OVSWRHG[R^\GVYA<"/CC?/=G%CWB>F%8L-/SP95:EKCX9-1Y3D?4X[)A?4?TD=(Q58?4)7\'U7GT!UG-CQOB! M:)1")H(=91$PQGZP4-'B\LJXG5?!>.C?J#2W3N^+!5##D4V9>@;S1MX?E6Z=C.KFA6;)88, M3SDWQHFB[ 5, " JIYPG;!%65 AAL93>K*S#\U]5:C+[8TG=CSEEF1;?KJ6$12D4 M/IS*,'C(%1[.#P\_3P1C L-)I""0D"$@GAA#EE")<$J>4XP9+_!PE>C)9I@3 M1UV/P9M%A5K>;1+Y8Z(I3USFLX=5NO>PH_[JOTWCIHJN/ 4$QJ,K-,6D*1$H M:0,@H&P"$) &<6N$TQ9^3FQE?4H57E7>,),8*/-Y*5GP<5WYTC!HSS M76]Y<%38[/1ZQ(7VR J2.Z00%@5/)-#,=R<]WI<^37Q=:_,)?/=YYFSY&,OL M?+=?TP!F&N^>H>J=CWWG>U!Q>$"Z)'WI>/NM!RFOT3F9S3?APB3M@_(\JJ(1 M*W-"*4-PL%P38V]IZ5GE2KXFIO)MPEOQ6D6:$D'>$8UXA)_ >4E(4.T54TXD MYG)XWK G'U;.M,:JZ/T2^3./PX8J%_*58,*$.A7QW 5#40C&('!9#'(JESD; MG[@(PBB?P'MA5;1^8>F.\RCKK](=7]U"'-NQ?CD?)6E\TH>GM$X[19?J0,PF;2XA.R_2EI<'-",)RTJ*PUF M)*'(N$<\&(*XBN4Y>UQVT)_9*YQ MD\64F;*SW*CK(H_VW=29+@MZ#IE*%3N9-VKN3L1.)*%68J.0 Q(-]$P$Y)PF MB,#SMX(+[03)L1-!)YM^/3G1^YYU5IT'5_&3.^"ABI_,$1022\A)2APU1!@$5#H#,:5B&5AS!/I!F/JP1)B" D( .. N*>"OA),V2\"EQ[ M)8V+P 3(*ECLG%R$)2KW7&J$VAKJ"_\CMXNT"0C.$N:D5-&3>T#2.O]A>ZQG M2$&U*OB:";[\9.VF8,8Q+A$515=S(I'%BB(J@[>&R!2-6UGG>#*7_>5"PM6Q M\_(%,&Y=H5488HZK=Z+HDFC*I"0H49QR\T."#&8*21V$!*HH%5% /B8U\*HT MCK++B]C4/E&FNWL',9:L[\>:C_R@LAI(,.-=KJ#SA&A M%N[L43@9X!CO3EB[M-T7[C@XGX/.FV+7G?:Y;3T&4MYA2S,*X]E/W'*.,P9( M#YX_)@X5G>VP U9":5(J%[%+O#8)"(.69B4RO&P7P\J07M20_#ZFTDON@=I: MV%8XH0SEBB,DK9,N6L\ XE;6A5Z;C"'=],9[^:Z(E1V]I!WM?-N/%K A$FVQ8/<8?>;@Q7+]1\SMK= M9G[/AZ*A'5RMU[6MQ\N'/MAC&_CF(]9UVZV+\]L_,JWYW$N0#HW')FCHW\/. M37^;@XA<)]IC5)R??+"M2WO57?EEE'L!S1J;PSMO_T&4*Z6%W7U)_&#IM3N% M,7P AL[^5TP'+LT8ZD==C+<_:T)G\NZV#9)6"*828>Q]D;A0$7@CL9]!22R M2" &VIC#.EDRI/;O7^SZM&<\MA)*O,'")9PB^ 9*%"XDD3X!@#O+I:>L%S"& MSX!_ER',.J<4]L#_ N-2$B."2\(I^* G,:;%Q\T&74T;[=,?A>-90'35P;3? MP?1Z:Q]+:GWT!"7)8B4'W%E?LW?4R55@]II>IPFM<+*:7Z<.Z3<[8Q)+IQ73< M7,Q@S<,&]-8[;AX AS^O!7L.2]0V.V5XI>JQ6?78G-(]\E-A*YO]#HD?L[U4 MC1$GYF] N*JVB"]]%K3XMHA/.)H>V$E9K+:=_NR-]AT<]EPUCN#Z)]^N=W>^ M'C\3G]OU:_A>W:V?C:N_57C:ORPYS-M9!J_TSAL?/H"W_7U M<'>GSK=W#JYWX7IP3Z2^L\4:UY_9M.:(3-*$G12(&AD0E\0C$W,-F^2:T42X M>GFB/, D+$4EF*?SMMTWJ%[P=6WD4SV;+ QGDQ& MN"8J2H(LL19Q)3&RQDG$@M#64T:EQ5-5C9]&C>XX+GX%TNIEOD.50/XZ==6? MG'0W3FLJYC(#!$UV$N*,6V$31P!#N:Q6>F1UHH@Q+:)6'#8AL;(NGZ2L7B6B M+S?Q6(BR^I,7>D4_YKWV)P35I7"<.XVD-4Z35WO>!T;+(F-QZ8%01FQF@[,MDG;]TV"L* M/I6(*@LBY9I$B9%* &N6,9F"65GG9,XM(.:PW*K@S!*1HWG*'%:G0LL('.,< M*#%/G14.*:DLXA%;9+$,B!I&HU 8C( ^D .]AT*^S8=5YHWF@XZ7YZT6GS_/ M!21#&6L%L>HGJ/;8UF7LQ"4HY'MR>+4?P!BLVP>JEKW#6AG>V#G8%U8DV,T] MBM[F% ]P3QPQ$25FB+,D*$%E5G-?F]0?FZO&9L<"RG!HDUL?2U>I7M/*?M7&_L&VV< W@!LV$,<7BF MR$;,D/#!6AH\YXJLK%-R5\'P:'U>;:#0ERYR'!O,YN9QUN+/_'.LE25X>5-M M%_OBLSBV<[>Y)V5"OD.3$XW-K7V*-<76692,-(@+F8!\!H:L8X%9X"M:VY5U MO,9OM;B2:$T6^+1O;U4Z6:LS"]C-R]ZV3LY:[:L8_XR='TT?IQ\6#8RJL+1N M47(\_/IO[>YYHWV^&V%POGUP"D0V_)DU)7I&65G?;=:WO;F[SRRESEB-@DZP M6<*#199(A;3EV&-FA?;Q;NM;K5T>-OUA[1)^K;D,9?VG $C6:5\<'-8:[1]E MH!3,@JW-I0ILFDM$]")=HN**'YI@?4U_=_5%X21]!9L%GR^OQ\(::]]@/747 M=N\OZ X.W6FIY9*1HUM6),'?SH!_=/*^UO,5,W4NI6J;I[ G@M&4DK5W%=*Z MA$GRT2;J&=>* R_7P>/ O7/>>/Q0 ;K'G$07_V0V!3!:DJGI$G*7;4"G>/KN M<*3^L[%3WY>.4<.)1TZPB'CP!'8QSE%PDGF7I$J.KJP#(,385WX;C8VLU;(^ MT(D]:G>:YX-JUL[=MN4B+)$L\E?8TI!]9?H.G^_$TK8*<^O8')N!2_^ O]B[ M[(ZX8 M;%DI*-C770HAQWFP[]D;RO8V(3]X5DQM:75YLF%Z,TU5\]*S3#A?^O&_HIP5C+O2P"LX\,/&>)==\ MJ]W-ACY4Z D[Q'$\SP#KXV3!-_@9)^W3 *4\K67!B([-N(_R M'E #)P#>42RFU+.DR Q58Y MS(K WK+QL,;.MWU#@\-9'IAK 4!@-8:-)R:D/<66NL58FKW!$I!1=GCA)65O!4*SC>3X)26(($!>XPXI$Z\)\M1991 M'8@@*7!PHH58FSS#>7S,3W*BK3FYC%_C,>@&OKB#'L4HAZ<24=Y"")4XD#]V.$M M7'#!6D%@ZI584"465(D%56)!+S)--YMHH8@S+6#[_B:ET@^J](/>QC7'-P%II3BAC(CHU=N)OV@QT1ZM_[W DCZYU/ GHO\Q^YV#EGO )&: M?I[^+A2%R.Z.A_=\_KFWV3B$GW']4_UZ>W/CY_;.EMBE6V(;.#[P>MYHCB>! M_G78 %]@]^CC<9U^A)^_7.Y>UWE]8Z4H5"D*/0%3YG=X]'!(>3=9Y<\& M*.-9Y=:HQ)S4*(0H$(\B(LLE1<)2J2V-S!BSLFZ>I[+NM13[?RJ/O5ZZDN[- MDY^GGF4](PLJ3.+-E?\_$RQ-Z@]I2;TT2J"4<,[X4/$1,M=9T-,BB/NG *(H D981P2,G*% M#6&L4 BA\Y9)?-TZ14^02:Q$BMXF=1DMPJFHRTRX-*EL9=[H,*'M'!R37DJ@*0 , M0%0<,M)JY**1PJ>8T_.J>,M./*8 M4<1I],CQQ)#T').D6'"^4'Z=C+I4JL\5=7ENZC(DNUKQEGE#P\0Y$?',,FF0 MV8F"<8JY^9U0=^W"58D5)0^*H>(%0!],1=K$"H0R54U M+'+G#2ER;J: WY-R;EZ!9F,5%9J!6CT.5ZJ\F[< *N-\RI&@ E<>&:$Q\*GD MD:;8(1EC#-3%P)G)?*J2.<=;2HH>J^XX]RKLYXH %\I%0\N\JN*<5K3W MY3*+8MF0O NP?",&=E"<]#CL/5 $HQ@U"9ZK6%D7>HTL:U5W957+9E7?]@U. MP(>,1-)0!K84&5A5!$\[1JX=I41)O;+.R)U6]>)5XI5E+9EE[=3WN3/<.>N0 MT4(B[I1&UFJ. *FB-)(J1]G*.I5WZJ@]NV[D([WQ9[3(1WGC[] (?]:/ONS' MK'SDO4!<1HXXSITEA6?@37.=P$)IM)GXWJ%\5B_[X\6W$ F])W8DQ\9DR(M(93% M^T0G![;2V\4*B:?:Q5E66/2'S?BC>$Z%$"3P_V8"*QG^U$$;&-!:[=>;3Q7V M]3/;:;;[>R.2)O:H5ME%+G?;)[=[#:8]]C]6Z M6IVUXL,)Q0^X)Q'UN?)R;_ORP^7[-8-$%(\Y'&T 7!B0- MT7=GME]8X_IX/]+H/541)1>R5JH"OU2!4H M"E(DZHQR!+N5=8JG645//JP$F)K-\URS)^V+T_-29W947?;LEOUQJBKN(]5M M?YL6&['=;MLW"\79R^;YX9#(V1U#&G<_[I*V+9A#<1MGL>!%M1XL^9+M8.-H]T"Z_!O[<5]"]53/X_!#X1N%(7;3* MMP)O 9\J4Y<8%JVU.SFKC]39?101JG0U%\9]KNM'?E]*P9FU#G8-28'[X-PU MW$BDA(Z1&.L9SMVXS-ID4>#C3F0$P3+KKEM' T^).RZUET83'Y('IE'I[#ZW M%5QO[3OJ.=/$($.]0IP %S;11628\)0%2W'N%LWTFIGG"8HB1AJ?I.>:JWQ& MQWR(T<$WLXBUK71VG]T2CO>QD$D0 \Z/M0EQSAC2/#>.X03LPQNN MQ /??,2Z;KMU<7[[1Z:IB;Y$X$.3L0D:^O>P!"1ZT1[C(K6%Q]LZ])> M=5=^&8W_-$_1V!S>>?L/"ONDM+"[+X-/L/3:G<(8/A0AG/PN&(Y=FK'4P/,' MP/I;$SXG">I*L_KMUL\EQ;6G M*4A.+*=4Z<2#]HH'[HWS1BRA9O7;*)'C>R>[8N_[U^;VI]W+O:,#W/CTA>U^ MWVO5KSUKG'SA]:.]X[WOOY_L_3E>S7)XLG?4:NU]^@S?^>O)]N87O+<9#O=. MOETWKCW=VSRX:IQ\;>V>[+6FRE*K*"/S' F;$N(B:60=5BAR(00F(<@$/@(U MU/U;^]H783=//?BM1*E?!RQ-BE(;'!7C(B+M>$29ERIQ6<#YS) M%-WZ2I3ZI8,VKY"YS"CN^(JHR]L4I7XF7)HB2DU9LIY:I**BB#.BD57:Y")@ M2IW/V5(*<(E/NE25*'7%6BI1ZK>%#A-B1#81S3Q#2@N%>(@<:6TH(E3[2 S5 MUJ25=3UOTO*ZXRV5*'7%6]Z1*/4S@=.D*+5(42?/.0K!"L05"\@8E9"7@DNJ M. DXK*P_I9M&%6ZIB$LE2;WTP##.6D1R/K(04531(4YB0H;)A*A2."K.A=-9 M>H$\3P.PI>8JE23UTE&@&=MR.*VS8)>2).56?X!_I:&(B.$R1--%)A#5IKVB ?&D,%8(>6$!MM@BIGX4,+T'C2G_QP2+.C1IX'<0J61 M]%HKW!K7N_L,RRB\PLC;%!&WTB"KA$!*4VZD"E[GS74VC:2QG+)?PO?/\6;WSZ>KS]J=&L_SFV4(Y@BSG:H+OT"V\<[1(8:Q,6 M!=^#!;:W"8MKYP#O??K"=^GGG_^]WL7U+_L<$\IP)(6 !@(L,\AHJE$$_]HY M\+$9]R7A /N$K3MCC.*$6RJ]8L'R%(G+FNB>4">"4"2+E8Y6COXG H9U)[:0 MD54PM;CX_B\:'5@"RTB!I!"3X\Q0&[0V)E!+=%9QI6^FB'5G2/KF$!S^5OOT M &41HUJKF.N\']22]5G6IPF_YEK4K!YTEHU_K?:YU K #/UWF+;*3A0I;UI>"2>W,]WJ?6*O]UE,\[%VA M>>I;%R$6%M$J'ZUOV8OBK1,6L,"U7]A@UD!=KOKOYU_TUXW+_9!$4%039"CA MB$N2?W(FJPA&YSG7F-KQM86MX#Y:%5PRW'MJJ3 ^>4VPQHI+_4;+Q0LAL7:K MU;[,!=S-5@N&UP&?I5NLH"R&WCXM5!-@^10F#W_KGA?KKU#7*IC#4"'WA]=< MH TK; V7L:U9*[2Y7B/J<>7)]Q0]4SG_HF,IPI5LP/"/;P/?*1C@W7' 1YZZ+52=8NFG]GX55 MC\]P@K541\B3ZI2/\I'O.D@>V/+ =7XE38@?Z5/WSVX:UW\=UNG'UM[1WE'C M^S<81^-D-Y_A''T\R>L\7WK>O?[7R>-DSK9V_G: MK-.]YO;F%UK_OLOKUUL4OOLGC)U/JSV,PGMA/4?8&X8XEQX9&2(BBL= 1'"* M*,!57@WAG=:.XF3X3HIRTE(3FEF#6>*LR!$3^+_#EWF M"N^>&>_&SZJ9=]HY)Y'%/"!N@LEX1Q#3-IH49"*.KJP325:QF&Q76.'=_0[$ M>P.[-XIT.:_ <)GA+@&^"8>U3-3B&'50THO[=,-3;\? MN2)6.86"MC1W:>)(6P%F'7-/ ::UY"YGY>A5PA>.='.!N3D5@BTU+OUYV.Z< M#QVJ/MZ9?]^58"_IPQ;/< <>885T"T"ZR2)TQ6%'HHDC$W+I.8O@PU)#D'$Z M16LLC\9FI%NEXLE9S4M_3J>N^M1K>,%K^,QUX/0$!)E$5&?U:H8>!V. M18,4=3P(8JQS9&6=KTHV65[]I6:;6.W_(Z MGKMO4:WCQ:[C,=?"D?3 H^I2TX,DQ(F =JU5-YG6HL41' M%\NG83<]1W.G?6Y;"S[ N.]S"U9^63K7[N$GVO.?H#>S/H>Y M0M*%(.FXHTQT2HS+B *7!O$(S\<( %9LJ9%4I62]!X*MR2J1K$+2.2+I.\VO MG.?4O!GTG'N8HD+/Q:#G6'B"&QZ#] $%23#P4,J1)@JCF'PB0$LIB1D].5X5 MYEEXZ'.D9-ZMV;88A17K_(>-;C>>=S=.PW^:UO5$9_X3X8_QWA7Q*]^($1@X?[]:<;172:MW#&,]KS=,2 M"C,6=V++]C34VJ/EM-U7+9YB])IFC]).D72-R<>J>-RIG<(>IQMRI\*'7!-X M$4(OS"Q CB0/]F'Z,<\H1V)>IQK)N],>6:W%GQYNNE![*D/L1;E 5EL#U/# M$,YK62RJ$BFI1$H6(U+RCA0WIL_(U_QS%E^[@-5G"QJZT#2Z>0 M[Z'F:^1+LY R:OY$A\T -/K#J_-:>AXX>-J[]U']^NMA@];Y[LY><_=['6]_ M_\+KG\ 3W]QE13'0>(%W3"ZQ)+,'3K(';I!V22-&L;1198%Z6TWY7*=<.1$- M(PRY)&'*%09/TWB-$E-!8ZPGG@XVQ- G8 *./A*,DF$*<,8<3DIUFJ>582H J-:Z.=ARC=K?SG1^\VNQ/^ MLRCJ-R-%TA*9NV!R9 Q.B&@7.%6><8>K*9_KE$MO$DY!(2-%0#R"VV&CL\AA MIXCS,5 ,4[[A?>*+^X5MV#Z;=XIMQ#Q83N>AG M'5W]=M'IQ-/*/Y@O?(R%+B@/QEE,D8DZ(1YT ,2F$AGAC>".$1P-^ ="KQ*] M3)5_%395V/3\H8L*FQ:)3>.Q"\.LEB(R9"T#:D.U0593()><$.DLI2*F7)0L M5IEXLN+1\E4E+S7,5!S^T8;N)SA\LDG+A#D*A@G$#6'(>)*0#EA3$J1FQE=3 M/M\I=YXQ[S%2/)JLB2B1I0:>@!;.:ZZ(-J%_TCO4D'5*X&AA)[X/4A=Y%\J% M"W8T&NU37^WG"UAS8[Y&$EQQ&S#R+G>J312#UR$M8AH';N")8LI6UK7DJU0_ M62UH^8Y)J_7\3.2\6L^+6<_C_%PG:QRU D4)W(7[Q)&F/K>?QBGZ7$C)5$Y[ MD*M$+.')XE./-99/-6CZPAQ6#7KJR5?5VJMJ[;54W*U"^/DA_,&D_H\(V$JE MD5;<(>Z,0T;9!$Z32@SCZ#CS1?8(I:M.+ M8Y*>YXAH!3(/ 9F?$SLU,4Q[HSDJ&K1QRR32-,'&+1)A*7)MJ5A99VMT,DCV M]VI%+6Y%/2X@4ZVH%UA1X]LVC=1:8Q#E6?X"'A(R+#$4!2 MLZ(>(*:9?\]FTSR]*'0+1^0(>];':7G4=];N-O-[/A3:ALT?L2<)V+/.H0_V M! 7QS4>LZ[9;%^>W?V2:LN%+2#WJ&S&O=C'!_:\+G).'<)BDCQTPZC&$K4CA0$;BC<5^MK!?*K5E9Z[<,CJ?GW=J_ M?['KTY[QV$HHP2M1SE,@*43@R\P BF95@T MT1@30U=N^1RV@OMH57#)<.\I M;(+&)Z\)UECQW!KLC4BCEHF"WG8/:ZG5OGRH!FJMV:W9;D]4=4Z*J+V9>79) M5%C-:Q@_2A.5\S7]0.7.6351;__2)\B,4J,6H8FJ^;L?+,-TV01\"4X6=7MRWS:/ 4B!KFBDZEJW5FK_)J6(B(SY,K-)9N"BM1N\7T(AV- M#?_1L\GWD*IW=MS8_'(-[[G:WOGUI+%SC/?@N[7>YL%58Z=UM+?9.-P] M^D9VQZ/#<.W&9IWO;7X6]4^[9'OGZS'<)\_CV][\3+:_-X[K]&.SL?/7T33% M32QEDF"XR&C+$;>.( M%3@M'IS&\X@I42''NY$()O?Z) Z9("F*#"<:.>,JJZ 1KE>97J:ZN J<*G!Z MUNZ9%3@] S@U!ZTT;&^LUL=W#U,^G6SU$_=CNO.-:V^>BH9.ZLQ9; M[T/ "/P&AK@* 6DF).+..QH]QRIDW5EE5BFI=&+#(%_*)$A$1,YCGYE79)5I=O-ICS?_ZF M*:'_JHX0*ZNKK*ZRNC=M=;,XY40SHQ-S+BANN##>:,5CY SSD)(HBL +I[SJ M8[L47-6/<%7XW'[T,EKE*0J"8,0S336<4L29P)$+"PZ+6ED75*Y239;MV'JR M^'RTV/P.W:%'1<1'K?8_$WY10?^MR@0WH&O_?7_9^_=F^)&EKSA MKZ)@]WEV)J*+H[I(JIK9QQ&,L6>9=X 9&X\/_.,HU04$33?;%V/X]&]F2>I6 M=X,!TT #VCCK ;HEE:HR?WG/[/;-R3,ETH-_'\7F])^>_JS&N\<'W>WC#;;/ M_A8[Q_L4UEH<;/X-!/@;_!<,H+W#^.#WO\4^V_H&QM'E[M]?K+6I$2(FL3>6 M")TXHK)4DQA(3FM!\\2[M<@!)Y_!]HX&8_=BZI??CX$,7'1:](K3\6F$O?-U M=Y)?'X6J\PAHU.B><=UN64T^7\Q\[@9NZ>7,DS8(SZ::6<;K6?:C=;5/4LVL MEEES^PR*1.M,LVAS[*+\(FJ6RCYD >FS*N#;&**#X;_SP;_>S!0.1POUHZ\A MM0%>FK<3$]H>XL]H8L)W];X: @$!=^#)>^>N^]5MPS*.7D7^;3_9__R);U]^ M2K8W/V#_*C!D_BAV?W]_O'_ZZ=OVZ?O3[NPM8^^7.9K?8N?S0_??ENX7$!PIV:.I%3BB5"1&) M,43E>4J8%C%+7:Q8GJR]H8IU8GYO0^:16XR_D!S-:R6 :,?\O23@0WUO[[S? MXMWR\&YK >\RI546@Q6=I0Z,:B$RHEV6DTSZW">I2%69Z)5V4KY*Q5"O1*E- M'K1KQ/<@[;9Y(BVDW172C@;.M:"V/%!;+#^7-LF5SRD1WN D4RZ($EX0S[F/ M>9K%>9X#J"5I)\E6*??KE>AI::NGO310>]\?#UI,6QZF_;V :6FJ,ZU<3E)A M8R(R;4DNJ22",Y]XIC)CL6J=IYULI:8SOQ)%+6L5M1>':<775D];(J9]6L T MQ9UU&9?$6,P:X*%-D(D)$R(77N+RLZ:6MGG;+L=1';N!"V_A6 M6WM)R+:!1]K"V_+A;;&(,O%:Q3Q3)(\-*&J2)D3ERA*>^,3E.#(C]FMO!)BA M+%NI9L0X6_5ON%?ORB6J=?<+,+?(> =D;,%P M>6!H%L#0TS0UE$FBL\02X>&GG&8YD9(['2MO$BIP>C/CLI/2N VMKERUTW#X M2U0E(DXR#R<-;X;1Z$B/HB/]U46]_BBZ<"/8CU/XE@%,K8]MJ0M/UY-;K/R* M@5!(#82O7Y%HF,.;E).$Z,/5;+UPW?>G1X1XG9NKX1W_V>F/]MWH;4V$GQI" M?B/T<&\!?WF ?[@ ^,Q;P823)%,L(T)[3A3UGE!A>>8EB *;829-AXK%1)J% MS,Y6[UTFC&^=GHU'H7<9&(-N.'IJ+;>%N?MKLDU\>_?-P%=;E%LVRITLY@O& M>29\9@A3,27"N9A(DQJ2Q);3+)62Q1Q1+NTHE=T#YE;/>QF>G94#(U<#\;YG MZ3]*5\:;KGNUV>)W?O_5QOXG@/Y7W('ET9+!SQ?&AN?,9#2EEDAG&:![RHC* MXH10:F.?J20WU*#3 HZP([)[AZCNRB9ML^8K/3T$;8N;^4=>=#"MZO!-]H[%0#WH=\/TMG)P\P66RY8-GG_% M/P\A,*-\ZDIR];N627\ M0#1^LP88JJ=W^B-7(C'%#7S8O;SO&G^]/]HNY>O[3@Y/]XW<@TG^#-6Z?'VS^S7_QP=?-[I;G_^ M4/S[5FSK^&DS&0.W)4S*ZQ+M)3P79'FB5=QYOW:0W>=^&B. MG!UWW:Z_AF#?]H>CX:NFT,V3+]A8(I$Z)H*9G(@T3@F<$RB!<2J88_!/9E]H MRPF4LF6G"&2-HMN%Y0'K! 'K0+"6K()34,># "7/P1'@R1 M);PAV#U%W^*#+*@B0)C/NF^%4NM9G/U(VXJ$K6?T=M/7[]JV@B^_;05?3])V ML0^UV&29#4'NT!CCVJ_2Y'DVT6AV%GG70R5]1N6^2QN-E0@"W>ZM2UWX(3NI MW,6#L=H4LM!-I=V;YM[0=F^NW9MX*5UX[NP,#/K=//HTE4JBKG#M/*4[O:$? MDMJ=8AW@,JJ'Q51?7*D&/R\Z7G.WEW\QP9JESS?Z;3R$]0R'8!7E12\0<8/8 MFY;V[#.\IGNTNWF2X#7;>_"C.,L M8X;E),UQ&$B<)D3[Q!&:)(Q3*G3L,?F4JDZ2/GA7G^=?L7SD5#!\O"U(BV#OU9V;X?ZW,+"$=;B%L>Q$T[:6SO;5SL M;&[%7T!)%\K2A'#', \="RVM28E(91X+F2O%0BN-3KI2\S=:-EYU&ZYEXP=D MX]I0F[!QFDGG=2*)]481P;'+E]:2Q"J5<1HKESDL)^&=+%ZE;JPM&Z^Z+=*R M\4.R\;PTEMH9SX0BTL78HL^G1#&;$YKG)A%6&L'HVALN.B)>)6G\&@I@:Z,\ M&@$[#$LN0&:$]^@/GK[?R\N&M:49&5CX7Y_DWLQ!OBO/L06XAS W:H^*U33C M-F?$7%?(:M_R\=&NCY>I-%E&1.XX2YY2S ^AO#"\%/+UT_!U_/= M[U.6RSBS)*&8.G)T=6)NHT-%:(?2$!MU=XI6(X M7XN^*X&^\_:XRG.;.2V)$8(385T*]GCN2 Q';JC.-646.UJK#KO_H-$6?5OT M;='W*:*R+?JN!OK.Z;ZY3D62QCE)/+-8J^8)'+8A1CG 9"YL9@%]I5ABY/;I MP?<6#6Q?1E/%VW:Z:?97#%T0?=FH[ (;E;G91F7EH=<-@J.S ?#A );>[$QL MT-V)'8O[I@A_.R]&1^'&S8?V?;31[1:A#?'_P*I&1T8/W/J5T[NN]<0]PZU\ MD&;6MWR-A1;/=#6W^TJRPNW\8]QSY;KU]$2N(Z6EM.Y<,9Y>+%2]!=-.&GIC M ]7N&#\K>?3*?9[-%M&35M*!C>%A=0?TO)+M4V+_M/YQO7$ T<=^=XP'A'W+ MS_J#JOFI.\1I?NO1O5Z%WN]5IM^N7JH/=%6_4-".ZK6@CC(H-1=8TN.\7'RK MEZN;Z4>N6YQ6RA4N9CCNAEZX?M _G>L!CWK3$"_!RQWH53U8+-S5?8,7QJ_^ M=:0'V^\VB_$ISE,\0PC 6]4[L[Z2:%'*I,5_YYK77]F4OGJ'ZGZ"E9&4Q3D% M53_44IEN7%AA2#R]1.=#I(SK+[FJ+_!30(GDJ,KVPJ?XLF\0\K0I\< M1VXHUKH"P(>KI-/-JN:EE"R;GC?;@Z[4CI=S2^Y@1 Q\5E:/;>Z / M5_CQ(&2[!J(+'U;?+4\1OE' '0T08Q_,O.%_13WG[' ]3'@YUK!YAY>---P'U53??)#OR$G^4[Z;$7=]&H:PMN^'+V%J_/X3[ MPD&7,W4ZN)0SA[JAZUYTYJ^?*D]][^'HH_[9"-2MBJC.NKJW'BWOC1J:GX[^ M\Q&]=LE\%M/O0*Y_]H?#W=Y'C8,[_AKT06,<7?P%;SQZ![;7&2JZMW//I<_4 M/7>/@1YLY_+O+YEB3F2,$2VRE B5*:+BW)%4>=:Q$P7A?/ M_% 'ZR00$-!M$/!GU5FLWT;#O>78):"'ES)VB3_XV*4_W:'N;NL1Z,/#C9Y] M&S;]T/4,V)8K,\7F@WB^?;Q3[!]OT>V]$[9]^2D^^/T3$#H0\^](\._@ M[Y_.#_;PZ7-$?[QQLQ,.(*I.( #[S!G\P$REFUK5J7 D5&#U##&0^& 890G:H] YT9;2P'8^8T"+ZO M_>[7,/H[ZNKSX;A >:LMF(M%&/ #XA'1S( F!H<'GQWVO[I!#T5+-!SG9WW7 MT[-_A5N"G"T.2W='!W8#6.VHWP63">39*8Z7*)7>?A#**._!&)]1QD" %4!& MPU$'G1Q (:!A=CNX#@OB>S)^[Z(3/+O=+N@&8Z"V&G5113@<@Y+0'\#/+CAZ MPM)P(O9@XHIIKN*T)-3UZ",<< %JA,:OZU.PK4&O&$1G\)K=X)@ZU;A[T; _ MAA-8<.'@/@YA9^L;EL]H_B7<8.! /H/B6IHH]6RCAJH,J@J>R_K,=,-R="!P M$WX,>JZKKQQ.[WY^Y'HXU;" DX=7PSW)@]D9YB#JZ=Z%@8BYPV_7,YMPJ;@. M'0:%5YIVU 4=(X+]P+<>.#WL]^!^%Q&>\2GJ80^H&\MUEJR>>OP^;'J_L>EX M#.4\R>8QX@;7$Q^!J"Z#RMB@W>9W87_QJV=P#(4I/7W]\0AYM#J&8A 5\%7X M;'9N)(Z&'/1@^ ME^@4K/K:CL=?D/>C;E =&TI'24)=79QB@ 1%>(Y^'=?MGW?@4+KH$9SN,L $ M E13D('IKT'S#)892+,"Y2&*-52 :HR>$VSPE2!\X=@KV=?KHS]B7(:* BB% M54\ K%,2U[A4+29,T(!Q#&'!WT_[@X9^,-5ZIL0PQ-NB5(%=JE[35A&R *WY M$/0'Y+LRL(4?E',12YS&%SK20.4:[^<0U4&E P4-=L=Y[Q:$2 N3U\%D&:P+ M4@UURUK( +;IX5'DX6AJ]0WHH3H#//KYVT*\78 :!-T#MPW$\E0]IBX0[ M_@("MUN86YC]NV=%O[#1GY5Q$7AY:\9$>(E9 !LSJDQO'%R(0;8"(!4H*4_' MO<(49[H<(]ZT1::V%)"+0U.H*%V4>L8+'F+YPU&8P8H7_S4&); ??2A,OX-: MX3D81OC?'IK8_?&P^=T10B@\U!==0-+:\,-G?-5 P_!E[RS*SDYY56-U:%WB M,:+;:P@T?Z0'I]JX<4CG B'.=T2U MPA;P>%Q84!]A\1OH'@!;:V#<;VX CW:'(P/X0:EBH(:RT^(("S^=>.WS;?A M1_KKS^'._[.^"?8.NU+0M^L;_86279B9>_T0Q2J-_T<%K9[5/2CG_#CZFGAFLGS MX+PVG2D# 2RF&>B'O6CC; T [_*6G/%QQ2@(P1;.@IIDJ#ZNI) =*TAAE@7 M$-1)K;-.(@IE[*,(3I?3?AF_J"BO$YP7B P7G9J%03^.FND^P/#GI>EV#-K" M$"W)2IGMP5M_G2Q?A1O\ 2R [B*,-C1?H,2$C^/#0\3H(.Y\]"$X;J9Y@G\ M,P=Q]I?NN2[*NVO/+XC& JD1X!!#L=?%3(*&-QS-N@5.X$>)Z)E #1 M&XR6G*/#Q?4F@9+XU?F,X3N;YML7EV?>YQDEJ=*<"$HET91SHF*J4Q9GG.9F M[8T'"EJ,E)1<7])5+3>:8@ Y\ZR/&1%(465L'RAUXEL#SH]0%PPQY%(NU6(( MR/XMH!_79,'36:X, M#ABPJ(-_9UM?5+G#J!CV:[$(G_PQ[I8?K4>[U6^B3J,IF1I%5TC6@PN.Q_:P MBD5$7G_M#VI?MG4>:'@^]Z.!1:7#_:R+SM3"^PEJ@?)]=N;*K(3)\RK3M9&U M"?_;&!^"'A:5Z3VLO%\-2V$3\,D-9]7D64$M"DL!"=X_<:"I5&$*_*!R7-F) MYTHW7 ]3N;QPK4:%O]6?38>#,=H"U5Z,J+PP!VYWA"5G<:K+#AX\!D:X+=R %TE0(*S M(\0R@"A/00,KB28$0 +=O2[O6LTAF%U6YIC-&ETU.92:V6CBRT>>+8V\23KU MG-DT8]0=:3OQD8;8QK5G.O4>XR.!M'QYHK4KI,*:(3QUB#HBT$Y_W+65]Z6& ME*E[+009@L6(>5Q%L.>FAG%E94VLVI*%\XN&*=OMX]M<:6A?F4']:,B[DFZP MO>_QZ_1LZ@\C/BM_L1&:B2#Z6!/+&:*=4+4LH;\:_6=<(9S^HY-C;"> MLS2),^%I*KFW>29E+JDPU+L;FH'K7*S?;&[=TCA_O > M)VQG;^M+YK1),^^(HR(E(F)KG.$O1[]=5OU M; KW".9U*N[DKU5H=N[^LPI(F78 JO[X#!\'BO6@_RWDDH#.\I18<)=TWAB3 MRE(J,B.UT%DJ4QM+FVF1R"Q+';VI 96\0>1LEKE'&^=Z /+P']T=N]NE\JI7 MQ^DGR?;E-O\B>>83IRW(GSPGP@H+0L@8XGU"-4VXYWFV]B9=%]?4R>=5/F]_ M)7D=--7OYLS^$#TVA G&W#].V/PO'1+F]MS@=-'#8\<#S%M[=70V(U$NMS>^ MY+F(LSC)20HBG0BO!E;5N%:F5Y4: M&,"TZ:1P0RQ@+89'918.&D"F"_>!SX[ZXV&5DA"PM>%WB> ?77I2T>(:'0%. M3ZV[ICE7>BK<-TPQ.RN/O\Z?"#>U[LSU@@NA+)CM1A@_ZR^F, !)NE*0E.Z# M2J\:Z1,75;B*?MS^P)DN^I/FS;7\8E9D_>36#]<[X?,HUX.0!G'#-3^OSWF9 M0A. 4&_7%IQ^K^!4M 6G;<'I)./^Q@SZN8S[.!=I#M(DI303CCJ9:.VX9$!YB[H_K^'QT_R9KA@""J5%V&M$Y:,]UBGZ(6\.^3=/FX-+# M 1@[F/KBT'6,5LBIJV1$$,GH[2Y3;L[*H%?E/"SC#)48JUW1NCR%W,FR O+M9#MP$TM?:K\^@*2.61"-8/9.BT*?U;-+=O>TO.:CW,Q94A5 @NUQ37_5 MEAX>PM.]O7GXA:/299@B(CB8)D"7'(RU5P():34*?69YY+B__GLI@+RFSQ./T84K\_=-$<4QW]_R;R@ M/$T\ =W8 &5X0V1J,^)-)F/I8Y=P@YZGZS"B]CQ=W[[DJG#9;/<0O+B1=(=_ M+C.OR8=*4+UK-+Y#/>=M,SLC*$^E#HG9D)-4]YD"Q$F^0Q"";D;B3>L*Y]HS M7*?ESM9[3LH))VE:"^K<3T&Y/3^:*[B<5MF5:K&^4I/^>28ENJK,*/>G7F_C M9:;U?,5H3N=>O/4PW'J:MJ#S_E=79C_2)T7'BD*6O&V==L_1UT>X[H[^T3*=6VL1GB:!@4*O$6<%!2\@T MR[(DD,>B)M"2Q]+)(]D^_Q+'268ECXD%;9 (HSR1TC#B;6P<"&?N78KD<9T2 M< -YT-FZ[_FBU^!.16_O(^#++57)&?)Y6ZZWU2JOIZ*3"P 99WU*N>+$Q2(G M CMR: 94E*D,!(GFQF-K_83)FY3)27GVF<;RDD'1#WZ'!;KBDXJ#X=2B!75@ MHY+G$Q4AJ ^ED)RI9)MH #/*PV^Z&XHB/QXY-RI)MRQ#1]G>[?<."9:&-U2$ M.YK'2Q.-$PG_H>R?L-/OF;O0ZNM#O#EE]_+P2Y)F2GJ6DYSSA C%-5%6 ?DJ MPVV:)9RE'HAV_;K!\#7TK:3CZQJ^:"C6?TZ)N"VAO54)[?>@XO-1457!-]7Y MVKQ *V729J0!'ZB>+_C<.E77DW&O;'?2GYH4(7GTR@+P*WN@US78,XTGBD8R M^FS==^T27(]^X>2<[%,?5HP(#X<_:1X2 M2GW+C0FM'"PL K:Y?,JTP0P6C84S"GN&;11LX7W9D"<4KL,*)G5 =:^1BCSP MN>&63\E[G^"4NV6Y:NAEH9NM".KL]RORG^K(&;[%I'-$J"T=8%RGLH/+TOU> M>->OQ6$?ZWAA1\HR!MQCU_4A3-'MSK1V6=&XPL>B[)W0;%B$[PJ,&C(, MD# MTRQT IDR]14=*8+SYI$3K)#S AG;QN.N.^81./LLBRYT98!/G5 M#?"VP[J!2=$['O=*%AJX;N%\B09(H+KLH-!B_RVPO]]P)+W$$%&I(T_(K.RW M5"?"_$@I>*.4I2Y;^&6F?>V9ONA7N4/# MXH="HM*Q=^C8[ZPS-LS-#XL8H# M_UK-P?C4=E'-MT-%6 M==N"\I;XC- GJ.'SPT*S?FAR5U42-7>@YPZ!O+ .K0-OGW<+$_7&Q5#WZC+0 M<0\I#[9Z *]WLF59#U!?0UU +0!H WM>C$J::-8% MSV=]S2A?HQ0>!44)F:G\ \/%OTYSIFJ6: M-#)AKLX5#-E9Y"_05C!3#0D23O]M5:1?+F4A>#R<:Q65:Q65W= Z M?(;?,44(2XD'%_-[.ZHGZ;3[>KM]G03UFBU7\!E_8$^RB^BGI]Y %J_F!G[Z MN+%+=OZ8:6O44M^/4M\[/1S--_[!9^WW!R\@*A[E.6/3JLF)@E*( M/3VQ)^RDJ>>$1IK&8= -7>\0#*.JK:L9#TN]?^*%K5<^ W63^-,5\AHO*J>_ M16]1P<4'_CYM2_Y^H,=MJEM MN,I>2E6_^(_.C =E_\-I#.95&0"[O6C7C/H8Q*6AG0=5G6C/ 4L& M[^F?H9&%$+PF_8_U_*/_JT_/?HVV>G7'6AP+TXD^CM:CO_2X&[W#IOF#8.PB M&8>Y.$B_?V&B%O[W=E__#*(3U_%Q?'966N'8$ZYQC^@G6+*(<'1TE6'VM&/HWT?GR*QL8TV$,WC(L=%%]+QU<5DZZLW$VPUL\14LH&>5A/F5N(:IULZ$8?33LW32Z*\SN<;A<;ZO@!)5@1GW3A@37X1>5UT*]6D M'SHGNVGSN'*.+7RI<3+!S:SK)K ._ MF/76F+EN;=M;6S5@_%SJFG4[NVID3#G7H 0/&\+?];3>VN59U48#SWLR3.UU.>\#7 M!)T6CB=TAVRT.*QVO+3D?NOC,!S8ZPO^.)I M <:8*P>@AA$J:+K-S+P*G2O![*PEV[2;9+69);Q,L*;LJC!IT$SCYJ*_0R=U M#6O0E+^SUHG1/-TN>,^+<%TC/GZU1S&U]SX(6D;/[2-'R:-'QZ\ MD<-S<+N$H"N&7$LP?OMVXT,UN*2J^@J:]CW<"K>:5M",54QDP?*]#O74 WS) MV]K6MM)'<:FE15TJQ0UC^J+3F"9VCN&7J[-I&@KWC'8[$=LXW3GXIK&CPZS4 MGDB"*S.$KG=IEWE#=8Y168=3G@\5/^F?ZZ1Y4<5%V6*YZ M)83>D6O-KZW]'*1GI0'2&7UD;K-A/=5)>QPQR<]KJL\]+.N MTV6"1-3P&3+5T#GK:67UW8 5)_T#SS!_=Q0,G6LH'9LV%2%;>?*^TT7B!@[J M41R-61/ET\.2)MKVS"9\;TTC.,Q),AV\';)I>/,@=*)_%P;^.M?:S=?9S8WX2XB-(-W]:$QI-0(K5^LUU\4$;J&X7*>1 M/"5-3;2A:2.&F1TIMZ!V,LSH2RM)ATM0XLH3GH[UN,:ET-13MO4 #KP2P-6 MCDJONM9A\&)C[=,)[G4"]];<^/9I*?"TZKMPCSJT\+#BVF906\TH]FW&_^=\;@AW0NW>>1Z=:EI M50H)R.$\3C$NY93N-0:Z8(_B B-OZ*@R?>23W)5AMB#3+1;,#!NU?,UZP4E$ MK#8XX*(P81#KGLXQ\[V:('HU0^)*T%JN:06+: <3ZZ_4#:;#XL)XJCKD5XXT MQ_F_=?+8%=.JKU%=2FH[#=KK)/1P%%0L4]8'EW0X4[V"9D=CSDTCCOBZ-/^M M9I4+>N5"9MUO17]8*Z=7S82MOU0[LF!KKXBCS_J3.M.:"CTAH*M!?#:(VX3M MLOP95-[BNJAPZ(. 6B4./RP]!J4^=ZI/\.\#-QH/RM*WZ6Q$%!95 #J01D-Z MP)]#H=%&I9 #(T8C?=K0?>8:<\W&K-!3,>YA9*9J?5 /-U637,9P?7_0&(FV MX&1IQ'=J)V=(@+S:M_F]?.RK K2AZFOZQK7A41O+U32K\]"-RW0GJ<58CS3X MZGJN-@>"K8'-6>L96(VW:['^.JQOF%'?!;BK9^PM#G*NHGM@:OV.):I@QO_Y MMH/^D)H,ZTXRX5P:!L*<%WJN3C3X8ZJZ"Y*CG(P3G+8U*?OP09U/82;))1?93UW#E&7YU8F0.5#XX;"P"2LA?U?!OP)G^8=G$8F8L M0W-">%'E_819TM''<<]W0>\83#*RW@;_:6?J&PEJ \KPT0 # 8N\=(I91F>P MC% &79C(8M+XW)CR\M2'_6DWDKFAB)C./S?[?#ZC%&EA,N-Z8GN#<*Q@N1A6 MJE;5TC"4J__<+-@.*YN9!%C5OBYHT;4#I@K&5[L1NE]?56)>IE)-9V]6'J0R M(1ZKYX.55%V"M22X$/B2.8('#(8-M/G>F34TKLK'.VBN$VL;0C7[PH3RTYD) MU\W,B7M,([]*!O[E>KWA1?>K[A7ZQK36!0">#'E:/)&J[EJ'=SLK!CCJ/@1- MOF'3L'*\?1=G(XY0WQZ2V>WSM>J(1[(8\FBFTRS>9R&TT5AR\UY7CHY=E!:! M89LM&*X?;OJ#C#>-.C)Z57SC?ENZ>((OLKU'3=6\N8.S?'U-:=*$P7$0S3R# M3^;2E*$J-SL>H![E]@VN0-NSLW@Y;WX^V/V]%_V +)O@"G&,HQKB M^ZW/''G#:XQ=[2H@;!A"G:OLE"O+H"?#??#)9]@BJBSR+_T!2!A-8ZB1-!]N M.9W#.I=\VQ]"#:H5I-@>N32#[?@)9>GT"&2XWI!7=F+E$.5]KT\Y>0]K9 M4N< +9_(KXZ6[/1'KFQB2<7Z=Z?Q,<%@OYC+/&>P9U3%B5*YR*2,/78Q__#$WT!A.WGRQJ3;56/2LV+[\I_CWY_.=_?^@+^9B_WCG>.=S>UD^_<_3@_>SC4F/=VZW/F\+7;W M/EWN'.-U?].=O8UD^W1;[%S^46RS[7C[\N1\__3@!)OH[FR^^\*%3V!O$Y+S M)"/8#IM([05QE-J,J91+P>>G5!GILCBW2>Z8%=)[9;7 7M^!QU*KUR*P>_09 MXL1@#,S8R#Z>#D@D OTJ25T7Q'MUK'KW62/"A8E9'JQF4#JAG#OS3ZRN2URNIK M?M[!4L2JKU(Y>:HL0!@U_!?8M*K?/XF*4]"1SM $*YNZED-9?^X (%H=$RLJ+(T MOM$#;=I]#IL^3HQU7<55:N6Y3 %I. ?JK(AR+3\5ZVZ]4V+Y*#2S:+@10-6< M_%K=J-&%%+_[G;/Z>3W:00]@M8X&%: VVRLCR-C'JWR!(:BH)864D9U)?]DS M/1Q-=='92#.>0^5S:'0D:C1"\R"_8:,WQY,C^]Y,D7(;KALLLA#J[A_V@!\P M40W(>#Y6W:2'.W;Y_B&9^;U.];_# K%;?34 9:\_1?(I"#V7)O6/+5\-W]WX M GO/'66>9%([(HQF)!?,$DI9$BM&CP7",=." M6I]GDFLE>":X31*6!!*(:Q*XQ=RK6Y+ ZSUEL7WX)065A,!)BIGB1(I'KB'$T[R6*:>Z=@Y:;/4)#>-LVK9 M?:F$D "[,R^8RF-%I$QS(F+CB4Z-)!;(P&6Y=M: DJK6Z7?( #U =;"AUA"" MI*C;Q8:>GJZ<8%VYSB+O*M_\M-O[),IMRUZRI:NRJA: >[F0!E(/940Y5.7< ME\Z?*G7DL-\'$3GL=R=R];N#+*Z=@G4;[\]M71SIVDLQ@I,'-X(_NE#C4N;2 M@Y:QBI;O?CV2X]O!GCT]V+1'.YL[Q_M[6_'!WON3W=_WP5+MGNQ__OL;/+V[ MSV =\ZQZ_+Z[PPY.=MB[>)OM'&T??^AN?_Y;'!QOQ+N?X?N;[X\/3O\Y/OC] M/;#J_N7NWM87ES)'8PG,Z90'T2P=D53G),^I2J1.C#;)PGSFE,7:RY3IW L7 M,PV8[M,X3KCEDC,V;_G^5N?05<<0;4T38'[ _KWY\;/+S92!#YSB2L6".98# ME22I5J"3>)5;\>!5B$\Q:+; U+-#7:G8#K.7W]IY M/X\$0&=@JNSZ$@K0SU@1Y7!&I,,1&!3KYR 8AJXWD>CQJX.)>G+/W\GVWE:R ML[?]A:L!AL /]=+*1]:_-1*E M?AJ':2-UDAOFG%:=L,S@5'R?P&JH$+"!T"B NH]")CS"&]XPC'!DQCD(B$ MPW+$S@EHO3^MO=W=W%[[>2Y1%4$Z_'JD"SC#'A*0&X8\Z*I2ZVVX[[MOSHQ# MLDT9FAXL)+R>!Q>8#Q-/RC(8G%I?9X)@MC7F[>%?JQRD,'6H%$)N$."WC%// M.(O^:]AXI1HV*L*!]XELW]6C6W'$4+CK*#1?6[AL$DT/*4'#,B0>%A%\84+#-,&9/X+!(2'<$\$OVABT%YIO,*6>N174M_QY?F)(\XS/CBZ&!5S?*YWRU7"1Z=R%7?[>*Z'FU,EEQG M5=[I>"8G8_4(-QQN/PJT4@VU"K4U#I./.M?N4*A?+;#U\%$OO&)T4R1I671T M@;?5A]6P%=AT/VE_UE@H*D)5\[QZS=78G#)!:7J/:-CWHU )'#B[<; 5UY6) M;H"^HW%U\ZO3.+?F%XQ)AV'X25%.$\=B@,-!0)/FSC3(+K3):56-(PC!4%"G.$SJ\96H6QH4!)K:0%7E\W3#:ARUG5#>6MTILV) M#F&^Z;B_4+[0?.T2#L.>7)?(.NW^/9L=59?$_0"U#EVW.P\B,QQ_I@<:&:9YJ7J#K>P9:Z@ MA:9Y4Y-4S3>^;_ P>V7-S>366[0K@W9L:5:D8YYND*CJK.J\2T'WN7 MID*TJ,=<(2=L//0HZ-7N6^7N51C(1/F<#(.@!G#^RP;LQ M!N^G5(TCM:*J[\]D'M9$XHX Q8;AE2?)]2 DBL"5D^5--&L0)'/'5.<%A^SN MMX#5:!C/U-;:02A[+L" K?H[H(,>U$+,T:P:G9@GUB? T%U:8V.@T%<:F5FB3"/$(+0+OSR?L=LURGK(B%"6;[W>[_?-0 M&M_MCL/0D%F77+"V%CPF(-KTX2$6[(R"-^VKPZF8E!.0MSX^#9*X[03 MK7VHOA!47B2A02B+#!#^ME;%.FM31PR\$,96<>0A>HGL+TO1DB:0^+!QQ0]8 M5VF*;A$X *,*X>VQST<=5MCK-T/#KSKXNE?#U)V\4^U&*36]WV7X'$2C(#0D;@^W]K?&VJ-874 M[%_8V;>(S@(<9FO/TW))QH^?SQ&730E8GREM2N^2I/;;$") M\(^S!?)6._"^S(W==WH0O9M-C<4F@S-;\QP._G9O_5,( /;'< L[_'D9YS_] M:H7U*-_ANU&0HE']1L^*-E"!N,7>W.J%7]O&T7;C?FSCXKM SF)+#6.< X/U M1[?D"274@A$4=N1:3_5MZ.NZW;D+;=UKA^_S@':1UR[RSEQ1-9J9(_P(_YN5 M+JM5YH'_&<,M*B;X(;*?>_WYP[K+ML713_>.#[L'Q=KQ_^>%H?^^3V-[;C[?W_NCN;IK+[;WW MQ7Y17?/O/X[R4]O=/?X-UO!'L7/<+79._SG=OOQPO//[^Z.=O<-O.\=_?]L^ M_21V+K>_;7_^H_CWY?9HNXB__;GW;K2[">]TN?TEMH+F22)(GGE.A!$I4=(Z MPFDJ4QLSZ;U 72'K,"DZ0HB%G,VK[;H?@<<[,$,+22TDW0A)W#"?&!$+:HW( M$YYS03.>9MISG?F4E?[;&I(6J_Q:2'H42-IY.PM)7KE<>,5)K'))!!.:Y":C MQ'L7JU10SI59>T-5ULFRK$/98K%@"TDM)*TF)+DTRY,X ZPQ $9YID0B:>)I MGILXE]+>5'O>0M+C0-*TTU)SFP(D2=:A M&>T(3'E8&4CZ4;?.,S5@9^IL'M1QP^ZVAU?B]+,&L]AXQC0SL;-":)O)!(P) MYHU.,L[CS+8FWPJ V=\+)I\R,4]I+(D2WA$!(HEH(7/"I,K!.IVSMC>B M8.J X7Y?*/L.G#R4=M5R\&TYF(LXU2ZV.8M!P)G<"!/K+&4TM2K5MK605H*# MYRTD)B4UF;:$Y@;4$0['H_(<.=@P9K6/52*0@U-TV=![*R,M!Z\N!QM'L]3Z MV#A& M4I$FR,$ Q!V1LA7BX"7%PVZR(4X+:[ONB?AOKS\"$V*YX> ;/#ZW0K3J'M<& M,5\XUN5)SJP!$QRL#.$2+HV2J4RHSIG1)HY;>V,%L.[3C+VQNWGX16DAO&0I ML3J."=@)7'O#*.L 173@Y);D/+D=FSRQI[?E^YOY/F5, M*&F5X5X*KJQ.I8L3D66)8ERDKK525H+OFU8*\KU63&4Q]G?,+>@X0*(D=PE8 M*9IFN*Y4:9S*5)S+U MK6VS&GP_)^\3FR;!=\O M,XQ"5S^,%OFW]_\=QQPQ6HYMQ8(N)$$:5R2F+#,I8P*Z5( MT"3O2!5WQ-(L\F>J?[]L%N99$B=.^,0H)C2-<]30;$9UFG/%](VS$%H6?F3K MNF3AW&2.B501SG-'1.XRM*X]D8DP)HZMM]2NO 4Y.,\4 M=<))ZYT2/J7:,Z^4X/ C\X;1FR97_81"Z9-]9P5B)A M1*=>$^$H)9+B=+D#@>:-"@NW'07,DE@G@8)IJ(KED1&8I5TZRV)1I231).RR]=RUHR\&KR\&9 MR 1G.N:@C@JCO:*)\$X2RPZ-TQ7BX$=*+'Q2_BL3"Q\HMO88&06; ]TEC;/.,IH1DF&3*N2*ZU),J; MV"=2IU+RM3@5,#_7269M(H#I19;17,>:<8.TQ02/ M96NVK 3SSYLM<::DSRD&/R0G0J66:&8%D),0G.>)RAR8+91V$J8Z*7OPA*.6 M^9\C\Z?*2H>1STPJ076FE<=YU)2ZC#KK;QP4WC+_XS#_G.1/4D%-J@WA/LZ) M< 8DOW0I&$!Q[ V3@-QNB1;/8_'^DD(M*VT.!4.HGB/@NL5I45I%;7CE[GOY MTUW4G#3-I; JS9P3+/,R]CEGFO/8Q)E);IJ:C$@WA!>&GUK(>WC(.UPP=JSP M+A,,C!W.$B)R%I..VV- MX%KFGK',TDRSQ&0VR6]AJ;0L_(@L/&^R6.FMDYDA%GXB LZ1Y+G@1">@?,I4 M:R7-VAO6X7PQ3MJR\(M@8>YLQJT4N1).*)]J.'D;)\IF2C!F["WLC9:%'Y.% MYZ1P[G*620HLG"H#AH=G1#MK"$T2&F=,B40'%J97.!R>A(5?63%(Q05/T<6\ ML@ZKJ5(<]LSVQSBCJG[K^[E95FZK[]S==1&:=>-D>J"6PT(HW.V[! MM 73.X.IE'D:>S"E?*8%M3[/)-=*\$QPFR2LK6I:#3!=2$",+><^CDF6Y9H( MRG,B72J(8BGWC&%C^%"8R#M*RHX42X[CMV#:@FD+I@M@JG*6*)$BHGJ T"2/ M9>J9CIV3-DM-&QE=$3"=K\>PPB74.D*="R6BE&AO-$EM:J3/$R]4Z%JO.E(! MH+*7HYD&3\>_PH3G-_5+52.^WTR'TS_BW.]02?81%EIX6'1O-/F\=[@UP&8@FH?(8J MY:T43HC8YIE5U!B>Y2(1%D]K;H#X#PZ1/QX/1X6_*/]4]"RSB(P=XVNWVSX&LHJ+;A>4-@(:&T<"=]0?5E/0JW-X_<_!9^&+/]$\=_*?$ M8I0%\%,$%!O!=XJ^'<)G%L@6J/&7"18$)KK?OL$VM9/;VV'HSVVQ[>3VFUZJ MG=R^X@??3FYO)[>OPL:UD]O;R>W/;G+[TG;UI7G0[OS^+\9!MO1.Q;NU=;85 MC+,_^\/7X2MC!\>?V,'GO^GN[Q^Z.WO;\<'OVQ?[>R>7^\<[Q>YG>/;>P='^ MY=;ESL=Y7]G!Z<[>0?=@\Y,X^/T3W;[\<+)_^4P!])1+'0XKRG++4^&IQV(<8"5_YP!K"WD/#'GSL5;'.3Y2FUL[QX&;2'OH2%O3LNC>6SW+.0L@VGUXG390W.7+U:T6?8.F?UF^8\PW*5I^R+TX+?@X+?]J*)FRB? MQ-J06%%.1,P!!F-+B3?P,TVU=*E>>Y/%*1BY]];VVG[A*\S*R^YRT[+R [/R M0IJLLUIQYHA-,$TV2Q*BTMS /S+)\XQJIOG:&Z[B#I/+RNIJ67D%67GI/6M: M5GYH5IZ3RD9PDPF?D03G\0B9>Z*HR0D%5I9@FU!JL7>5%!TNXQ5BY59 MC=*9%6E"4D9!SZ9"$@E'2K1P"3>I3S*1H^L_%;+#XF6-MF@QM,70%D-+#!7> M*BHTXXE)19X"0QJ5VB27"6/2<-?Z*E8.0^?U4$FQ C(GVJ6,")'E1$J-?2>- MSTTFA,AER!B)10<^?0$8.EM(&FK>YLM)EU\[^,BEJ347_37H^V*$7-16HUY= MC7KR)8EY*J43Q&F9$F%I2A3G0+$BUK&18'QIME!=^O2UH(/JS.'^H^\ZLN#C M^J>?ND )/T>Y T1UDX_U-[C'S>6A;5UG6RKYW!;;UG6V=9UM76=;U]G6=;9U MG6U=YTIX%U8VZMJF_;^BM/\V?KH[I^^ M/]H^_3LYV-O_=H -TC;?L8.%1FC8-&V;'FS^=KISN15O7WXXW=W<*?8_O[LX MV.QV=X[?G^Z<_G.RO7=P>E5QIZ=@%'-.B4NU)()22K12DN0N@V/T>:92^6#Q MT[;2:;4XOX6\-MSY\B!O822FY-P(88A7VA)AM0#(HS&QQB6Q9[EBUC]8N+.% MO-7B_!;RVNCD"X2\.2U/&,6]%)SD.55$,"J(]%03E5.-7>#SS.0/%IULBSOO MPZ>_ZZ(WC/R@?QKIWJ@8#<;#4=0M1L5AV8]TZ$:CK@OQR+;*\R%1,&9:4^=3 M $$GW[W*$T\6H>^#ZX;XVZ5K6?G36GK?R.,^S6&2")!JGB,865![)&&%.N41I ME61. 6NGLI.I>]MX+7.O+G,[Z;W.)*5&<&&[T4_NVYGK#=W/D1DX6XP>(AIY*X!['=.2EVZ9;/6^ H3U!Q=XFA\'K@6WY8';WPM&B7),L32C!'11383GGN16IR2)50;62B*,!@/R.6?ER#Y)KYYRUK/R9KSQLEH*DPKT5.?.8R'(B;$&4-)YIE H?; MITFHM(MY)V;+ZBK:,O@JRNRE6R4M8S\J8\_);*:,\XP;0DV2$^'0(#$J)4YP MY6SJXMC8M3=91[#%_NA/(K)?0^AD;SPX<1?1$?RI>X%#W+IEC\P!_')Z!KO? M!DQ6W2ZY1HO9.(7=#),B#WNP>+O5*R/)FV.WU]]J'/2&,?A-V.06_Y:'?],V M+-M[&Y<[>^_.OX#-0F.;26(-YA$J18FTWA&3"RLL=2E-0;,1<2?FBX.I;X^ MK:/U11LM2^9R7WQSEERZ0;]E\#LR>&VY3!B<9S+A-DX)T\P10:TG*F6*"+!: MN*298-9BW9QDE/VZ0D[7ELU7/9[2LOD3LOF\'*=Q#B?)8B)U8D&.,T^TI98P M9Q(34_B$IZO(YJ\AMK)A_G=<# O<:3(H@X]@U8QT[[#(L7^!/NW#8B\#N[0A MEU4W;>928D=';K#IS@;PG7" &SV[T3C/UGQY"/-E,OR$R3Q+:$ZTMPDH-XAZ MPC P8;2@+K8^2;*U-SP6G21I8RXOE*>7;K^T//T4%LNDLC'E2L>Q)R:VC @F M+=&9,<0*[IAS+A4I77M#L[3#6,O3+Y2GEVZLM#S]%.;)).\K9Y;!,1('8IF( M1"4DIYX3ZI3+XC3F*N? TS3NB&PQ?MH&6AXJZ6M:CJ)[-NJ?%?W"3DR4*AFL M+4]Y9B;)!S<<#<9F-![ KI5!Y+9,;XGPMK]@AB1I'BO+Q39CL01X8[P#,JN-HKQ,/EZZ&=+R\4/S\;SID2B7<.%2@@Q-1.YR4%-, M3H0VUEK#4B&QPT#&.BEKHZ$OE(^7;GJT?/S@?#PGCS7+O1+&DD0:+#-)<28" MTR015HK4:TN=6'N3=C+&.EPLEIH\"2>_LDA(!T,@[G"@RU_0_A@T&>5^YD?K M:;DMW/U0^_6KX$[GYI??QD-8S'#XMG^:%^5DZ\:1;TT/?*-G9V#Q7778+2XN M#Q?-U$[9VXBW]]Y],9E-8A]GQ&>9(L(D*9$TX00,EH3'!DP8A7:*Y!T@@M5P MP[0,OVR&ES)/8Q"/$AO(4.OS#&Q5)7@FN$T2EMS:3FD9?N48?F+05 SOXP0@ M/!&$&Y\0D0I+\I0+DDO%4L.9T<'OJE2'R17QN[8,OVR&5SE+E$B1ZSVP>9+' M,O4,YR]*FZ7F]@.56X9?/8:?D_"2@?G*:49<(@416*2 T_*9-29BSSW&%Q7M*!,UT-'T[+R"L?56D9^1'-D#K] M0YLD=VE&A. Q:"5>$ZE *TFM=1I.SSF.G3$Z/&NC*L^(CY^TF=4E3\.&4Q:(^C[2PZ'[P9;" MK4OER*E8]KA@GFA#1,Y !M)8R=!-?$)-A'&SC[2>CC/+$-? MB>BH>T6(6]?H"O/Q\DO?6SY^<#Y>R-IB<&3.Y,0P+!A)K"&*24X2X3,5.VH3 MAE%-VN%LL6%PR\@O@I&77]S>,O+#,_)\E8@TC#/'".4F(7",.=$\2XEV.HME MPE.:L[4W\)].FK3MN!Z-#_\"VM]^MUF,3Z.!.W6VK)^"UQVVHTN>R>@2C-Q^ MF)[=6SRZUE>R%!@[6; K+&59EL:&P(E8(K@58%*DDH ](5C&A->,KJ*OI&7? M56VLU;+O [+OO#F1*I7E-E=$R!3,"2I3(H5V8$XD3A@E)P"E"'9HN3@AKRS\> MWI(8'HU'MG]^'S/B=7M'GLJ,J!- /U8'V"HCR\.Q=^=_[FV-MC\BEAU>;N]M MQ%^$I\+:5!.C?$Q$G F2"P R.#:F?**L$,O31EH7Y^HR\5*-B9:)'Y:)_YYC M8F5=EBM*G.-9V=(JSQRVBTB-$!+PV;&6B9\K$S^927$++F[MBONR\OZ\/-8Y MHU80:[TG0L<9439+B=*YM+FR7GE@9<$[+%Z1K('7$*+ V^SW!R?1QY$>N6@W M-+*"7]RY'MCA47$6;;130YZ1D0'+Q^,,IUD>9N,LX2BK8K)68UD.S'U;-#MR MKV@"N!8[G1/A%<"LX0B0&0;99G MQ"B*(TJU)%)02KABG,D\H9S+EJV?*UL_F2'R0WS=FB;W9>XYTR3/LMP+Q0D3 MG!,AI"42SI5D3*HX3A*7)/':&RHZ,H[;F,=C,>7;?IA\@]49P(##PKI!U7'7 M'H^'HQ^N!7_=/I>GK-6XH@7&])#?-L]X8S#0\%<\X^';(_QQJU=.3=KUUUSR M9Z'SHEN,+FBK!2T'*"\6C9M,6I8S.&^/-:DT3G'F84:HE>)<;EIW["N MAJ67?[30\-R@8=,26VA876A8 M@GUTS0SD)\&(UMBZ+U#,&5O.<$]%GI \8SD1B-RA$H*.L M8JP03BPI&!2>G:UGR8H;7[MG@2]ZAU$11I-&/W7[P^&"K?O8OJ6\/P"&):/^ MV2^XF<-^M[ 1[L8+!]6E]1J>3'6JS[>N1WQ-995 MBP4/C@5S5E FK4\S)PE+8[""4JO 'C*>6&6-!)@P&0Y,2CJ4)X@']X\Z/2P, MO(9X5!B$6IE#;>#I>8Q6J0%NI]_KSV)<&UE?/LS%"T9/YCBU4ELBG4V)D+DC MN8%3XT:EU,0N]3K#N7" <2O2EZ1EYI4=F](R\R,S\YS]8K70*<\H4:E,B&#& M$9WJC*2I5YQ[KV.8F9)]MXHPARZ M(T') F9.*#&&&<70,VG5VAO:260[[N3Q&A(#I^$LQWJ$8R?JN;;Z9M4C*]K#G$&U)MSMN%$+/E>4PR;Z37:99G.8 < MZ)R=](H!"FW6_HOA\B78("V7KPR7S]DEAJ7,Q-BCB**3@8J4R-108K7UPH+% M(M')0#/1B;-%3VK+Y2^&RQ\N0-)R^>-S^9S!DL@XUUQX(J011+!8DERQA'AE M9,IJR*=7E;I[/J)LS< MB"A=](9XIFZXVWOW#?%M7 R/\$1W_2:<9YM&OQR48PL6"V6YB*6F)(5_09=A MG&B%.2*Q43[/J97&MVGTKX"IEQXU:9GZ\9AZSD!15'/-I",=6BVV#:YK6IYM/A*HY8ERAVPA*L+7$;ZFWN0J2RWS,PK-^87 M#KMI^^.\ZZ)Z/ZY-W;M5SNO*'<)__F#JXC(VZ,5(DJ7;?-/,W_>#_FE9)#F& M?:M2@_N]X6^!744%0Q1:8M4)XS_N&XI11:DB3+L=X=S ,M$X^5[P9L@X1ZCBG0'<9H M1R:JA><6GEMX?@9IK-=&BEN@?B9 /5^2)ZPQWAGBE7)$2.M(+N ?F@A@@IQ; M1@V6Y#'%.Y+?)RMV93 ZN'_^-=+PT#?U^^R,3X'_#/QNBZ]O_AO^J5_D5 \. MBUZ]7@E,6?T%%RAG<1,[-!;^HOQ3T;.N-_J%IP'9'QD;&&+#1W=8QJ/GVYH4 MP\A]U=VQ'CD;Y1?1Z,A%;W^C8C2 EXVZQ:@X+!M4#MUHU"V[#_T:_;GU?C?ZJ4KH_3DR V>+T:_1WGAP MXBZB(UAD]P)6X[OA6D" J(!'&OB*-O\[+H8%_ID,7#B-=.^P@ ,;1OJT M#V=[&:[[M?E\7&P_=).=7%<]?SASUP[>SAV6N-0)ER'.#,9F-![@)DVO.NSW M[7G1[8;%E9.]?VW\C-NE MS9D^!/@9.'U"M(?%_J*[Y_IBN/:O68X$YIO;P^^^_JT8T?L'>_L2#D!B]4N: M^P5 T0WP6[ 1Q+H[+8LL2*G+DOH+GO M(7HB_:.L1Y8'!M!OKCKC.4XHQ33-P )(A*<@:X2)C4Y386QJA3:)$+%>NR\$ M/Q&9?V_V^:_1M?,,?XUN-9'DUP!6YN8.P>O1!H 6G/$9'C.>DR^,FP!;I _R^N\,.3G;8NWB;[1QM'W_H;G_^6QP<;\2[G^'[F^^/#T[_.3[X_?W)OR\_ MQ;M[AN[L'<*Z3L3VWU]<3CEU*2.PYY((4&A)GDM).%5249YQZSGHM^GZ8B5V M22- CET\]:#X#'6)>O U4&N!B_+J/-P0-8F:PZ): :E8J]1M\,+O*$#:&.S5 MB QX1ZH3W'G'7:9,9@4U6CMC&4]2K5)%F79WIKJR:^2'"4=L]4K#;7/L]OI; MC45O3-;<$N2-!+EW*';.OSC-$Y5DC*2:8LM8)H@4GA.;\-1;;U1NP."B=/TZ MIUA%D$!ON.4 V6MW> ""\7$\-:Z57 M8$]_:\GG&O(!TOGT)5:2"9DZ@LTCL,VP)MK(F'@6)S&EG"7:X:B&]>L*/6H0 M@_\A'J%NHH?C9KJR=W!(%O,!*I.FQ#!$(P"QC^<%$!9^., 3.RW-)OTTLA%' MB+P#D:V_$^G4-&FOZ*G6F:X@,Y6,X-I![];G! MCU'98JC*4BEZE0>B%QP_08H&G3@X%O V4Y]B_65?X%%&%TX/(@?V#%SASN"* M'&[+XTZ$Y+0>S2M[ ^ON2L+W#7"U)+PL$GYW#B1,M_?>L1U8X\[E]A=IO!9@ M41)/K09%3R=$.XIZ7YR T6J596SM32K6K\L%^&$:[CPE%;TO>KIG *9!6W/% M5S3+MR8.JK=@U2 M=+TED%ZKZST6.1Y^R95@<28]L;'!$D#A -,2#A9L[M)4Q)1E=NT-?S2U[[&D M-7W)3J>K/:+ CX8JY2T8C\=+NP&^@-',*QGP'Z%-.PR?_?WI_[WI-4(4?=:DW9Y[J*&)R0;< !G&S[2ZHEM8)L#&P!=IQ??U>W M)!"CP0:;H7>=X]B@H8>UGE[SROI4N#\H8EWX0&!3:@N$[1>[!]L9=GR^F7XH MS(*L<)QC M2[.XOR*)1$]>G+@RCH4K8\*I&G]GX&,+X;E?:\?HF=\9NOZL.Q<-%NG'ABD' MNZG!&DL]]HF$AR=3F%:X%!E3U\X(,(I]D:\32&-/H+4U,X[F+#Z5KOBI5)P^ ME<:B')9N"]]P]<=9\ZIQ]7!]DR<\9K;\Q\-7N(S_^5/JET,> M]UKL5POEW^7"MY^>QA"B9J#B@'>FL4RB.E2C*C4MPR"@1FJB-Y5%F@0$B8 2 5=#0-?5$&"@PTR&B&E8KJ^;)$ !09Z)"0E6SNZ2"/C:"%@Y M'4= 3 +=9,127<]#*K%U0Z6:IZG$L S;11JV3 29FJF?8 MIDH\'ZMV *H92"[!6P2]S1,*6*! M:7@F(VZ@N1Y"NHM SG%T,PA65U=$&&P6_"3F;0SSODVI*LR%S6, =X&+7)4@ MW5=MC?)>2-30/>II&C./3G2-N^ZF:];(VN)[P]>&AY$-H@O5?9,8Q'1MT_)U MP[$M/2"8D)55%.%#R]?[R-;.#@%HV0A[1B<<<&IA8,TQ&8>Z^XSHKZRF2KU^5KR=-B[8. M_YFVZF@,J\2V+94ZGJLB9'DH0!8+L# M:CEBS M =ODBS^T:J=OV2M 6KI>]Q2YG-+Z#->GH+SK*B.\L35UN*7+PJI/#9NZV#,T MIAV=F+Q2J?/B<*6M*5S M5E^TF;@WT'8%95F^%\C)WE2EBBGN(/^J!?! MY*.&A8R"M!Q:7%@[;@H@*A;YS.V/G/"\WTA.>6B&7E-4PTY&S=\LV@/PC@!I M-=\<+P<]49%H9DV:)6K,[ <%S"\MY-%NR&V(8NG\D!_7A6]:&5_^KGS^ALMWEP^5TTD+VZ?F=>-6 MJWRNA)7/WYOE/[7;\H^O_/?;2N';G^M&$9YU]7C=R&NSBOOHFN=:?L!4SS69 MRLLHJZZ%7-6C-M9]W_8"DP$@.T:.:"_.>)*E+20.[C8.(M-FIHT]VW,9,3"Q M-6*:OD60A4 ;):NG?$H50'K3-7&MJ,&FA\8ED^I M9FA')SK2<@:6)7XD#AXX#E+?T9%#7,OT'(("UV:. 7Q"-#NPJ6U9*_M:)0Z^ M$0Y.R(,V8I2Y5%<-CV@J[VZK.AKV5)]BRS(MW\!FP''0S&$RK_/>UN&@+/0C M"_UL/'-6UPGS'82(Z1$&D.@S IJR[?C,8;IG2@UY)Q!QNMP/=37'XB4#* (< M)" *JFY =#6 HT]W38TYU.$F2RWGH'7%H&Q1J)[D\&%-$ OYNA7X)N'M@T'\ M<4'< 9ZW ^1[@46E[K8PP-3]UT4((U:<(;;MNUXGL88,K!'D.%H4JO9%0Z?.,,Q:#44 MD4#5$&\,K;FV2K5 4VT3VSZQ+(<$[.C$T',$OSBM=OMJ_^Q66NVLT+@W]'+* M'(176*"].4'6GDTK3Y"W.$&F*RGYF@[JGD-4'^F62@C&*@B+5+48.HL+6^ MZI@,J=1$6N!9O.JR"U"KVSF,UMQK0$*MA%H)M9O/K)50^T90.UDIQO(TU\.& MBIC%5.('GLH3\U1>9PQ15POL@!Z=Z*:3,ZW]@=JQ_-HX>6Y&)NK4)SS!3E 9 M\).)N&O<-!G1=-/5--MS+,W'AD]M 2N$/:_5Z7P->\*G5\6[?G+%OAXQ= M:>3_7/VYTBKXV^_*G[)6^?']IMKPP_*-]UAMW.+KFS*I_/E^5WETM.M_FIIW M][U-?SB#ZDT1E0$,*C??].M"42__^8:N?\"[<.FQ\J=D5!O7=^4_O_3*CRO] MGS^WC]7\3]WT7(<9ENKI'N=+-P 1R"*JHUNNSZCAZ]2.,1K(D_EY#H^^"?QK M@VQ$?4PH[\Y$"?P@/B]0@@Q8=@9HV86%[T<#=G3"EUT1Z\XS@\_BA&#:4DKM M'EP@X#GE^&3G3Y;([7UR%/N4VQLQCV.52-D>P'KQA>2INJ>=.QC1XW]XGF^O M*9*KQ2\\>?L>#JPV3]2FGA??!$]A\#&@42[._TZ_Z-)'&J=V\P4RAW6[4^0WG8I\I =_<>[&Y+NW!" ?=3EN,3:1VA_>L]:CTFIVH MK_99= <VLR?A[+,T/!W((1^1PK/P(^\VPK9RFLQ*_%+.SRDQ?:5)?^9]5 M^L;YB)C8!?1@/M$U1AFAEF>:GFWHFFE[/TLS;6;&)*#P48$,P?_)C&T&S"PG M7)@'AT'EQ_*OG\35>2R+I^J6;JI$#S30P$B@NH[)FU_Z#-3LHQ.4,S5\/-WF M2 &6:Z45#58A MUW0*0, A,'%(X1@VI&$/@.PZ9-30>9@@BFM7E)!.LG@NJW MGRXHW,0)+!5;%*D$!XYJ&]A6 ^3XE&+?]Y!^=&)::!$) *J$[7O6ZPL4X:4C M[CIM]J@ UM^R_@COEL.Y'$!8K\N\&,2.%5%D801W"03/?L,#Y?4V..(!GOM9 M:!RTJ<]/&/C[WT&'_].%$X^)T5+QKN1A/5&0(>3'#Q6CSR9PS&&$B1L%SN@. T+74;-C^HY!O0ZO3_A6?+KRFB/*NQY@R$BS-]V)' M^5[!G7Q+.VTNV6?W:0KAWKN 8 =]PRT3' MT]G*BV!E7(*<0)3Y8F,LU26ET_I-D+W&I,?Y8J&"9TN$+S([$OP.ARVQ+U8*I82/NLUJX;I9_G/YI]( CH'[KFYJMU7#Y7/95PN%']?3?+179%4[HIP7QE5[LJ/UXU:6/D,_X<[K^Z M[QIY#?CSH=PXN_GG#UQ7*/_4/$ MS_148E@ZZ'4Z/YH#7=5MZH.^[VK4-B<- MC)X+QW:@!1H%>M,-D^JZ9VC8IZYG.P9V)PV,HS57Q*(OMB;NARHTVRCZY,J= ME-J@&MW'];8X#> M:Z< 032$6]JPBW>@#<-* +GS&H-S3SHX;.#]DWE-@+BV;6B!HQ-B6Y9C. R! MD&.:6 M<)CH,8%Q MY.]J(?_31X:!;.2HILZ/-C/P5(J0#0QJN[9E!KYA>T4@60$0+A1W8E'J3^ MO)#,9T@7VN&1Q6/Y3_FGH=O,9SI2?8]W6E'XGOJS9:?DL$MI1K&:-78Y(?/GQ+&_IYJ'\ MY+]N]$&^2;YIV39#MQ-W&/Z8>L"22K1)-$SFQF1LVN@6ZO9X%O7\ M6V85U'T+^<-V)M2)S,]5% ECJ$@THU'QRU],=>'@O@4(@BE^I*T'^M@[^C"^ MO["5$RN_<-&6DMF"8&-K%A.7S^%.8-G' 0PHXE?!<.C6C$5I1OP8_C]/;YYU M=-*(H3X 1)HD3L^_ON!GLRBC&G&Y&SH;%,L2JE1+"O.\5.UY#5.FTV0Q?V++P9"^P<_#)6]M' MP/E=H>!JI5&KGM<%.5[4JJ?% M!@?9U$^$;[4.3FO6$KA%$ @$#)J-.*NR!< M1!V/^6-)AWO$=XU,>,X=Y>TCPG8/=,/A6GC9M>@.UX+;-OM)!P@X4;C_!90& MUA;WB._"=FRWYLL;,1'4*ZYQ6?KXN&O$N%TC[G?04WH#]R[L<\.I./+$577F M#2*0O^#MQ=]>D[9_,27O"8\/ B4TQVVIH%"*P;SC-QQE+SMZGU/"WM!=E(LG MT^OQ7WN#.]@Q6#8_CKB*1P&/>8CCF_C#^K#LPYX+W%H(UXK,> M!G[5BZ?"G-R;OY"@#7?6LI"]@=<X&X0]^T0$6>@7H->+UI%\/N! M=D" $RTEX"_*NU*(27*3$,!C82_;/CJ$7'L;_3"B"!/FR$+@-Z M]D301S4(0@\(4D2[B>]&D9+)=SE!-G&/#LK#CL/N$&5BQ\"=4*!GA >.]B2G M-"F\CL48E1CU6!#$7HHV$.[TW4NP[3O:BPE%.#-"[L8(A \#"*C&:3BQP.LT M/9%LC/!?"C+>L3A QG^K*]&;)IENO@6,1,84=(J1E#URB,7;MCA J1=4,)H MQ#?=000*&DOCAL2"Q?:M4;L4>/P]XU3L/L*G80HX:R7D-SK.3L6JBP"EI/97 M*SW)%#[I#*'6Q*2!J_>4?X%2!+FT.XJ7K H0$4Q1:86W M''@%+$_1.97J]V(MHP+%5X)JM*=DFSV2 ;7RW"W6ZPPBCWUBT2_6!BH$A(M- ]]$17, Z;K,=37<)>DQ,I1]E4\!-_^W#.\XCQ MY>F<+CA%5#@=@N'!D?SU+)'N>'H]5N)&<=;U8.-CZ0=.%NYB&/&@Z)@VB. ^ MEI%ZD@CYD+IA*^P_\H'-7((DQ*@+']%H>-J/+H4E[[,XW%5LP>]DV,,S2X25 M. A><@U+#G7(PPW0ZHA"&; M*>N_H+E8DJ*E\EQ0P6%/<2%ZC2"$V5SX+GS/)07.#9Q*1.0P%1*&V)>A(R1> ME!S?M@P%^0QN;(E4C@'OZ]:*>_3Q6)(6[^46M #/8VT""*T7NV7BY>9]U!+K M\E!ZB4.))^2\OPYE(_A.+&+26(P<6\;-%0<:^XWOJMB["[CS[D#"%8Z;7C+C''0 ;!JE'1P M% _)G!DQ':7Q !-DP[\]&-)YBG9& _TP&-1!#E$(_VWS[R41 ;M=-'%?H,6 M'+-I3AGP'I=P5X9WIY6RA(D%-0"MM!)UB X%O42I49)\K%D4N9=Z]B?F45C! M.!N$R^Q P:T0>#2F[=P*Y]@=?019OY]NIM@3L87*7=C++*.2;_4ZPO)SP[PA M!W'V8V.VP'$]&\ C&(ATN-3\PYFU-W!O!)IW%)!*;M,-3I17/B(7H.B."U)# MFCTA.YBP$N$0]]MFOB,47 S6!##)$ 2%JI(<68)@%@:!XWJ]>2:3ETF1"S-0CD'QAH'>#NR 2W>C$.A?#XJ+E?P!8=S+>SU MA8&K.P =S\L**$$8W>648M3N]1,:H'?=OY0K^/Y7_,'Y^45.;!H0T4"8C14* M1-CKI]9GO@_I0;5>SN)*S- 8EB'H\T/ZY !&ELQEE<+ MT-A^.LW&/IR5:N4E 5P, MX@VL\'/,>+'10$2QIN&3J77H4QJT7<@J:0O-?'/78&O<#M5NV!9B\_K=#MNU MLS]8HKD-0%J'PW&Q>9;O.:@(O= /:11RBRC(6]9?SQ7'94@??S[V!7/I='A<-\+01E63NG$Q)-;<3&3 M9\8Z]ONA_9J[5KC-I-4:*==)9A>H5B.Y<:U[,#6[907/K:-N$8F0)?'<+ L4 MGR]06]NGW J:$,)%+&RFQJS\2.BLPM+V^'L2]'MWV1;<4^=:>0^HX^(T7_WT M/LYO$1XWC]-<*_0%F>=I,F,6R.!SS$]?X9K*^O)>A:_QP$\ M2M@?4W/3:())C6=E3\LP7HASE9@8_[(\G--PFK6AJC5UJ%;G'*K'2E4P0;(B ML;\J%.:KA/0YX7=&QW5_QO(N/Z,A '+6$X!QK' 0B;AM<[;RF55/AU@B^#^N M%WR)T$\]88P M"HV^3?8UM@$],*7;HO%R=5G$P]OBG1!O@JWMN,(!-]-T3]W. ![19"*2ZCE, MSHU((Y%AKL2PH_M7S6Q9@CGQ0V,O'TTN2U+\82+4 M+8ZYRX9<\F@R(6>$O@"CD:,P@6!A'.!2YST?>&+X12Y]$.\DW><5[]EG(3?UI M//'^1IF\:(66CS11WJ&MC<'P4F?Z.[Q-T0F;"$SP-AV8X&4"$Y1W^EM[["=I M^S7]]MN%A%G'O*"WG7;.CTLJ.^"@/_FOJ$0^\E*)ZN>P^2W:[;&/Z2]_<1IN MT<>/85MLH;CIKW&ZXKZ\.?GZ6)O54&+H(DKO MG?U]]N:D>]V$WPXEKY[9[F)F5XO9S\'Z$L_9A0X5'WH?8F_LI*2 @63)@0/U:&]IR8%/.Y*Q76U\*=:44N6L6BOG&Z5J91\CH5Y4 M, !;HF*59FG.PLXL6TJ(ISM"B*.2%3S8(U\KB,B.:JU8^EQ1OE[62O5"Z903 M:%UI?,DWE(M:\3N/#"E5ZA?%^(O])-U^QNGP_*H7!EF-=-\T!N@B7X.-+95F MJ#N+2CU&IGIV53HNUN S( M:;5V4:WE&T7E,T_1Y/F9>UF5II0IO0 T!;2IFQ M?N)3F0K_NH@ZOQ_CH =A$4O2U[GVH#]U?US+0EPY\1A1TT)85N-QS1IMG&QY M-#F +S#-%I]J+W?$\T7C8!NF?.9VG-C0RL==8W$!B3*/ X[XM?S3H[QP?HQB MA9*OC[@E' :4/LU7N.D(ULL5EE=N1O*8<*<\A*V6$H0M-EJ%R1$.#2E+.%Z[ M@Z@WH'$EB]K0=9MDH9)\6L<#=C7^S >E01$:1&S[XT4T4D-@DA[^".NWES'D M6:*>]*E/U;F8#K81A"7,8A;)%HC=N0Q[HAW>V&?Y90'N+#)+WRKDVCVDL==@CK1 M,1V%![HB//#8Z]QM>*P+1P9KSIF!IZ8G%72$:?B!AL(,'G7NKZ0:&H[I]\@M"."TD@Z.JV6+XJ5^MYJV]DS@[M0AI$S\T[O MI>62926/1/ 8X24_D%B[-PH0GKIA\?"6$%2>SW3Z[C$=WA&FJP//U4J-*Z7Z MHP+ZR)?2!4\L =6DD2]5E$_%2A$4%5XM)OY>Z"NC>C/BSUKQ''27@E)O5$__ M_E(]+Q1K<$FC 9=+YEV%>3^Q-@/A1$@I#VU@NF;8C6V^HL. T&)2QOUWP"-; MQKB6-_=6,J-[4Y8U=X]E]1UAV90Y!=]QJQXP;7V,$QNU/)R>L5$K54Y+%W!8CJI0*V?% M8LR<]6+M>^ETO:5^]Y_KYIO&UL]"AQQE@-<296!A&64@HPRVR$/V?3,.,LN8 M=8K"4#T5IL\;!'V,BV _;MM9:NS(65K\YTOI4ZE1GVC;4&^ @"LTS_KIEV+A M\GPO2N>_H^]%F+X(W<;ODW#$L"=2)4>FZ_HH:IU?6?>:S.SG9.XIF3#+N22C!58F;RX!-@3UYLE G7TEC M#NZ];N2Q@? Q?F;D,3&<]-ZG(X]7>[)SK"U[[YR09K)SH6U45YZ4LDB4\'B+(SN9DB5\YDAP4V.LT 9BH!W M):7JY[+_\U0P251K("H#S=E^"1M[L,,F.3HYS0IAGVA+6$KK3<;ZO85%)@5= M[-5*[.&4A.J!M?V;&)Z'2^L5/.7)\V8[;!!Y\NSQ#EL3)T]]K,19-2Z)PO.@ MTVCA3&AJ;V'?HCT#.VO_#B:8TI[N%-J_*>VG",&Y2I,BQ'X?,(:QD@BQSBH* M4H38^ Y;VD(1@D?;1:S)VCT>,5MJBW(GRP@3RE[*$7RU]G!*>[I3>R9'Q#NU MCX*$8"LI2.SY,6.84I#8XQW6%PL2HV)HV=3D_RA)6/^!&RCXZNWAE/9TI_9- ML-#W5K#0I6"Q_\>.84DGQQ[OL+-8L*"]IG+6ZCP3FE/=VK?9 AG M;V4(1\H0^W_"&+:4(?9WAVTLBB;&M9/&A(E9&1:2U_>;$@SGC0V1;YY&9>B M2+J*T1C7>_UHD+;5B<0M<"AD!M'V),65(+9@O(DMO7\\B3Z\D5$5GNP:6RH[HFUPI#GF-K0 HM. MLEUIQ]-5"B.\9@D1>ZD*(@GYBE.M,N">Z25L8R]8@=>K#+/<_ NLYT5AEP/> M>HV"^B)K[7,+:\RFGXT::;O$Q6IY'HYAG,>_.O4/&\P'%<(=>,^YB[K/W"KS _:XM^U M>\JG3@>DA7PK[C_,"]MXQ^+2_*AIQB?1-&/8/43TPHX]:'%YBZ^T/>"=R$T1 MKH&4=V/%2+-52.,N,6(+%*#CM,-R7$$GHNW^?WK*Z2"*XK(Z<36>MG+6B>X4 M6_U;M/P172[2-]KQ&]\?/\LVO 2BD&7Z"^\ :.A+@8;$A3QH7R@/I2';9CK;CWASG.G+%,83 M>W (YT*DY?@W-'D/<+UH_#3^AORPY4WV46?,C3@[)Z4(+?$XE%O^ 9FQ" Q" M1,QSM?L5T8X96%B;PSC\S(*#VX=Q6&+<(6 <%I2D6Q^HZR5X ^P>):CF+@"\3X\M^M!["MKR M@U^PLPK2A72AK0,09@LU\3UCDDWZ[EBRT3;']?J>2#9$2C9[SO5"X<&ZYF@F ML;']P7.P@TWV^YX\),)-2=B9!]SSG.7C2N<^$_>/',Y2&OQ,M:!Q+A5(<7E< M/U8^T?:M4A'CAY,YW^MUO#!1>^#!_0@(@+%54(&\%!7&9X+U>"82')X&!RD2 M[#HA&D8?,#141%.K:LGXC])CZ. >*L,XCZ3:4^Z'9;PB("?#T' M-,HTT4-PK ^0->%%;AA-$W<9'J& ?@R+];]IV]9B(D!K@P5.;;^T^!HE>A+9V&P)*Z,FV:Q2)U&QBN!"S;F@(OQJLK7 M[#60LM'38&-(L)%@,Q*-UL//L6CT0@1[:P!;0CK:,=3:'Q')E*AUP*B5*'3U M\/?VBTAD+L*0%46D%ZIB4D1Z+MA8$FPDV*0BTKKX68A(+T6PMP:PS1N0I(CT M7-2R)6H=!&I9FH4 NP"U+!5;R,!CFEV=W0-E+H;%O0'B8$'KM>S3\S2P ME<+\7JR,#6=O;#J8;W\D(T=BC,28K&-M+:P#ZP6YFOM M%%@A3:+5(:-5HL@5^1BV6" BQ_HHE!:)G8(P,=)88DS46K8>7 MA43T N!Z:]S:O)WH%06B9U:UW$*PDH'7!P%66--,W=:T#_T[GJ^$#-U'/P&M MTI3T2KBLHE6FCTJ-+*A?DY$UUO'TV(,D\M(,^K=*0HM92P8IO8$,"+7_"'IV:H]'R-B1\ MZ,<*EL?*S 79KF-ECY0@F7$HCY6L[W0NB*^B!&W'*;6*+W5RVJD>Q.MM+]*# MY($E#ZP=.+">V[A\"P\LF6RZ[P=6W+G"X6,GP\X5!!'5T7G7*'-]R/?B!M3B6@^A$M]EN?G-Z7\5-8WC;FD2OIG>=]J^I5C=I M\[_XIM-.TN\O:0$8=P2,O_M\YWY9)8":4^U+HXR'LTGJ\>@2+)8 BX/)MK*V M'2P6#O!E/7"2II^&;7S@$*$N:NTW;4H3S4&;G1:,I316,,L] MT4]T.4-BBAY;(BB]_D9NI4GM]9=AV1ZPG%:QC"=8^HR067/;;P2%H7QBR)G^'<6=$ I!,#35HMWW5;GD3&E$$;,ZW>BWG^4>K_CW2K5V-9_T:+M ML=[2L[H[QLT=5ZJ2R^5-:R943!L\L[V;ES+X)>U@M7A8$C.6QPP9I'\8F&%C MHA/323##61HS"IRA(]Z]OG/7!6&!S@$)$"C2EM S$0.+^D6:O2ID.*\"&;:$ MC.4A8P.1TL-4+HD:6X(:J;4# H4"S M38 "C)&E6^@/^ZTB[2<0P5B$*^@8H,VWPB#DAVU6L<@_T,@?63,$ Z?*B!AG M:@]9%5-6,'AKRTL3JP0;I, Q*ZU?(L=,Y)!AAGL.&TF(BLW'CK61>12IU/4H M'/O=[C)2Q$S[Z! W8H"Y@'N;M/>4A)$ZO&.;*5I9%5G)SCE41IXP=B8Q^K&\ M(]60%1!$=JS8=P1)=1#;-N CKH-@P["M59203ZS-@K OH"/];!D])"U"G+!Q M?,"_;G#.^! VKISL2PK#""!DEX@#00BB<3&# $(0U;*PO@I 5._:H3OH/4NE MV$ 8'HIU"2+Y? 4^E[&[!\'G&&L$60CSC$",-&QJ/OXY$9JWT)V!\8O8_65V MQFPFHHQJ6(6]#R;:]K#9>]XQKH\;&+DD'X5>?VA>O&SSM/BL67%FG,/2-L:U M2 3ZDC@1;(%$L(>0L8'@2^F7V"G4(!.%-X"#-NR;>*EH,3,E=BG1(K8AS@:* MMV!$1:+44BBU@7A-B5([A5+&#)1:0L!Y=6PR-H)-$AX6PL,&0C,E/.P4/)@S MX.&"15QI$,G#(D]D*X074P+$ZP.$#,0\ (#(5/K0[%$8A<7#*#@0=(*V4&NF MH,+98GUG:">9G1'R@N2Q8??8M8=4R 9'"\@_;G!D3"RS;'"TS9 E&QS)!D=S M[Y4-CF2#HXTT.-I#.5QF06S/H?;:Q<;0DG;PDG,DMBU["DMP28 MC$ D6XH*";HRLKE6,9A@#6M".IG$$ZQMG7 R)\J2DS2R_EJG;1!K$DF61Q(L MLREV#4E>4-!.,[,H\B_B0E=2Q(_SHA$%D18 M7L*6&=,'(6%/.Q"1%H1MVO9"V@+QN#-8JL3:67H+0#6_1\C;%YU6Z#V^K+3B M!FSVF_3^/1<(EF*7)#H1/ASV4OT5BWZDB&=WA3TFH),#*>6( MNJ#G;G%XY=S^NFDSD5AU=$8]=CGO\X9&M!UW3:SWV3U\_.48/N6C6$^HVE)] M52?&N'V>Y#U!%G-3R"*CZ[**GH<73]39$E5QUE HM!NMP4;S5/=@CV,^QSW2%%C*8^$]\.X"Z:&67@.S MK%/@\CDR1-7K=[AO"YEQ/DI.H7>=]J_8+%$79HFQ9XT\=1DSA6AEX@X>6903 MHYBV:12BP:^I]N_Y>D&I=QE_6O]1^<+@GR;ORY13SL]/Q3,[40A'+^4]HE^C M0/IP,9Q-)^?L$Q;)_+[]QB+-,32$=7@\(4BW/WBBI3/[?>\X#VA)"!KV1YL# M0Z(U0=*F63 ?>@$2]5BKQ:'H:1A*+H_NN"H,*=_K=6!LPW=0_RYL"S#B <,K MY#0[SLM;NSQF^S=)4%L&U'29:G@8H(8 U @'-6028@.H(2T%M;,PZO7C[H^I M5VVM.&?'#:;?".=&^$9_B7)I?$[##]\*[M;1R2J!.Q(O[^;@SMB3J$T.=S(A MZE#@SL&V@SYX6+>Q$\-=TMVF#B^,=;#%'?;\Q+*]MCS7(,P_I $5:Q96GF>'/.1C.,U@U[EOL*TA+"6] MM4IZXXN,8_?!!OL:[A/V;: [F<2^+<0^7=-TS2&B<[F.L#$.?6> )/WFFK$O M\>>-09^^.]#';TOAK]&Y?>RHY;#?&[AAKQDJEV=?<_'$SOO^<4[L_U4GNE4^ M 7AYS5=#Q#D]&\>7WMITO_9] L0--$*3@+B5@&CHR#($( *78/,G'D/$,%@_ M( [:;$P_DVCX*O+AUT$K@4)]S4@H^[ L8."X#\MDK*OLP[+-H"O[L,@^+'/O ME7U89!^6C?1A,?=(?]A IU2I/VRE_F 9".E"?^#U@B8L*O7P]]KUAS$7C[5+ M&D291K>LK]3[,*^^<@;; .2?: Q)A"?M]8">._#\B\JI4#46&9O%Q8RMIILT M"MNGFXSM:=)Y5EIJED+:#;2+9,@GT5)9J_BXCNHUD]NY.9#<)W.ES-G<=Y",:T68@IA( M)G\<>,343)P$_3Y?0]XU@D*Q+\DQLEA(*EX+"UT@UE5"X=5!H"]K*- K!#R$PWV^: M"*(/K+7^T-MAZXX$$"T)B,^L][C&_BF6Q,EE<%*FIQX0,)),7U^=:GB4FMIG M&Q 4TT)G:4>CW8'%\N79YXQ"K;P+/MQ^H$NBY?N7H.,JB?IS!$5ST_VC]J@" M$]E BJJLD[V=$"@JVNHX X%JP%-3!?313*[J)K"PSKK],2'1V5DT7#.\K:0- MCY8QL0QNL-SW/L'N M,K"U1]@FDV+V'=A$* Y&FFG:NO&A?X<1,A&Q??23Q^*HY(E8G!B;RO1104)H MX%YCK].&;>P/^MPA^RY\+QCV.;4X)\N>9P!OS;7)IZJ>KU(R7=S[+DPFRA.( MUH7_4Q/>?X07/IT=ZA.X.9[C>R$7 A:BMDL],#>W#*G (Q<#%F-)J4\<3"0^ MF*0VNXS$)Y/S]E#B&ZFP8SR&=,,T-,%C.G(,DO*8GDW0VX0N.Q[RB]%!2CKZ M?DHZSZ.UK$XOUR1>DWT\ZI^W$JNZZ>PUG_BR7-@"\HC+A4UVL)3EPK99N)#E MPF2YL+GWRG)ALES81LJ%[5-PWP8*-TBO[Q8(J#.D4\R;[B"=2Z<8VZ:-?!Q+ MI]GB#9MT^<:I>!@?I)J,]E--?@:=[;>._(P%V4<%^1G+L&($!(Z-;AOLLZ+O MT3F_@6(D\IS?-CZ;$]VEJ[CMTZC+HJ 33??8FSS:+\1U,$$XPR[YL/I4Y*0O M'=#%?C-OD!R'TR?UY"'=S;SNUX!RU^#K1,/+)NO/ 1)9L.,@4&0Z%!ZIXL5- MX-!?T9QR;QD<$7\_+])]/EQP/G<[4=1YX(#4&[B]T ]I%+(IZ9U?V>+@-ENP M_WI1[D2_@*!.A>*2E/L]SA]/5A""E8K5A=>K:O&: >Q[9,HP9*?T74.FWIJ# M:O29_=(7Q7@FG'H:,3^<"U=E"N-*H0IEZZD)+(E2P6D;P&TQL-%Q8!/%*T\+AZ/+^@\,SJ=Q MR!('Q2DO+L?@0$BSW"]8N]U[;-W3=DA7+-8^H_#1?^97^$AORY3Y&*_OD9E) M4D]@@YTL]@DL9(6/PP +HADVUO6XDP6!WR:Z,$_G-IW#>T50S#ST$+6&8YXC MP\KLKX,>LRN;KX >,XL$C9JDZMJFJYWOD5W0D(W<#P)#YL>X)B RTZ6P6+]> M(HQ^MXV!.Z;I;88P=ES]W QY#C9L)(7'TBI M9_@@(.JI]<.67 98AKFAB[LMFKPH*NS?K^U,&HF=D-C(SV)4C/;J NBJ-O#G\-/G3J7 M='JY\0\S;^R-'+\7E--2V*6BU%%]X (=A3WA]GT'[_99 ,OAQR=3V'Z_N2/F M0W[563)BP-!%80L#!]Q5-$U;$RB2KU)(\YQW66K5YA#1(E;JJ; MLE#(%5?^H"W^;&[/[W3Z()"V6J$(Y/W2:7$ZZ_$B9:\AD8X:SFB;A@RT)S82 M+$,$=@DODO$(.0(#L]\FS)[5+8&IQ[E',L%33"#=5KO(!+KJP,D'C! SP2E( MJOR$ /HO1NU>XB+^O_2N^Y=RU1FT?R6]M7GWQ!(\L\M$58V$4> HXGF@;BOT ME+SGP?5"##X+HSO)/T_PCXZ.Y3&R@QRD(S3.0K5!*PE[0#I5$7E'WW] AA__ MIISR_0E@AX3DQ^-!FB$#9A.)7MST6 T"GF@M^>5I?I'!5CO)+W@-_#(J;"#Y M94E^D=RRB]PRP2QUYO'K4WXQM'$&&2HNP%=S@C__%C&K"^U:$]&ACXRFH:'#S*YL?"BWFXG\ M]3XW;H5M4##XD(&*^ZS="WDMN$^#'GS2ZR6#XLK%.6W_&O"N[>_"?S[5SM]_ MY T&XL<*1@"FX&6WA,'L$VT)FUJ]R5B_EQ,E^N=<6A\M" ]CZ+)X3O%-2]YU MVKGK1JS)!P\L6&I[G3O&[[]?\O8F3 TV&U:BWN]XM\U.BSNW_Z,4_QV$_4=X MTK(/HKVF-Q>./6%$&J-G':^W^->^G*Q(VUB U%M, MY[0#0U$N.$N5^$+#ZP'U3!5QG_O'T9H7^_SMZNO@ILNRCI[=X%2%Y3=LW5=91;%^I M42PKR#R>MW_I,FQH;.*)'\,^+(6WQ&C/JK6R(@2/^F6YG*]=S66IN0M\(BIX MKG[?Z_/5[ V!HUJAW2ZL%P?#:3)=:I:O6:%Z:XI1VQ.*S401XB79VT9#]MY@ M">L=JE;]YF/9?&'J#'@[L^30-\+N>NES)=^XK!7K3TD6"=ORD^?)@VB%2ND; MG=W%(.H-:)PXR0_OB('*$XTTF@DS"#_$D?'.?Y\>]O#]( *,@A$5?WM"CU+R MGG!K(4IE[;3XJ5C[7*PHI]7:1;66;Y2J ME;&)[@M5%D A_#@,BHMWE!LJN;GR@&AU!V?TZ?'C/DUGLQNT?H/:BQUU'WH? MXCG7&\7O@#1?C@%LSL]+=67%_^:HR:^-G?4^[YXGI@$27-C;DF&=-FG(:P;G ME(N(]4(_+3XZQX,XPT&XN"'6JVL4BTPJ&[9HO4BG65)O&2DF7&EQ>71YHINX MK-5YF(A('S^P4H4E *,$RJ[H+@(MW$[U6FFS:6<&L*X!HU'N]2+QP=;RIW. MB_2:.5L_QS[UVFJ/XQS;AOXLK<<\MBQK(UJ/LWY-PCQV\*8UB==LV;0LW,(( M:'\0L9<=F5LXLW5( ELXK4;8;[%5=(@$(;C9Y,7=M?95KMOJ&>WM!JY7^E#,"5!946/ATN:[BRAL<_=^:_J"][-X=\);BJTE M8I7&HE8V<^D!(LO7?+E85\Z 3<^+^=K52D$V;X,L7RE_&!]QB]'H40++C@#+ M"!F^ R[,1)>IJ.E)=)FZ0*++5J/+>?XZ7[NL*W_72G]7:Z5\9=**1MB2X[@BYUU@X[T7QHR23,SL&6Z2L.%URVV6VA5&N5XOEY7OF4 MK]7R.R"P5*,V:[6H\HD'V$I V86D@T(2\WRP + 3TD7A6"GG:W\KA* M95JO*+WZ*P]0SOZ:KQ25XK'RI5BI%*]R2OFX<+SEDO97RHL>P9!9N\T>XR%+ M:7L7I.US1OVQLKA2%]\%C/@[W_AR#GHX-W9]N3HO;KTN_C?M-UL\\X,/^#%S M>$ETV&)TD&"PW6"@G%=KQ^'@/75198O[>&UX2_B[CJYO\0_5S MV:C\^71;OOE^6_E<>KS^;O^N%K[=7[>_-J__=&^O&WF]TH#O;OQ6^<^55O[C M/5S]^'YS=?--A_?B2L%O5@HE=!4ZVO4_3H2K% MU%#M@+H:,4V*&"PPZWFTRXDO&G!^D_NW)?OWZR?@"=8,9*FN3AGLGX54%WNN M&C#+T#WB,QS0J?W;0CBIGWXI%B[/BTJIE-82MS'"?RG?\^>7(TSY=ID_+YU= ME2J?E?SI:?6RTGBRLO!;%:PU-"3.U?D1-&."WWBL"QG>.R^BY=E?;N:YABT' M+ ?\[ '/T<2=Y_7>6:C_KA7=)ANRS%82WY5X8;K. ![A]]ZO8%C9A';XE@N1 MMK:B?9$U_(D!J+9A].(O$(0OX*D=_X 7Z+0)!PTO[=X12W+:Z8%6 %0C_BK^ MYFUGX%WOT"$340$D1"_N(_@.'_)"3'!3L>V#,BE^G<%'<[J;&8NB!:EW^RL" M>=M7DQEY'F.@6*^S)-J;!E5>\69_Q47-_I8I$#=OF5:)DESW4D=\EEM566+Y M@GMR/>5ZRO7O[1N*75)<@-J(%,W3<(#;"C&=2U--]G ;%=S_A9XI;6V,#J,R^\HZW>_SM2 M]=3<.NBIORCM?AP96H=4FF_[-08SN&>]1,8\2GH>PWM_]S^V!W>JWQ$N$/Y8 M($Y8/B;(="=ML%<_OO:N&]U6^SL%HX M"Z\_%U&E<(M@;G_*=]];__PI]Q7"^7?Y<*WGY[F!KYAV2H-D*<2 MA#25.KJE8BNP-0\SQT3HZ 3E=,/,F3;Y[X=Q*IES=*V(H,J*["%!2H+4TR"% M3,_5'-CY:)>:31H<;3N#SQ&(BT6N=Z%4Y M'4 M;2]\C2R;$K'6BE@3\I9I(3_03%?U+=-0B8=-U?$ MJA- A6T =?#%%2 M']P /E4G)*K 9(Y%0!]T3#A9B$:1ZEC45(FIVQX)/$9]D^N#)C9S%G:V2*): MIY=I'>;4-9MD=5@6OS/@843/J)HA1[F_H]Q_T_8S/:AH$T;M-:WF]IWW+W!" MR2632R:7;->\F1.GUG9!_AMX,Y\XQ5=9QWW37F=-<;N99@7MU;8.AGW? M(8$>.+9MZXZ/=(ITYAN!T%XUJ;UNG?9Z.>7-M!$+=-TU5=,S;97HV%!MIOFJ MC5WF&H[K&U1HKP19.5VS7ZJ]SD;0C9K8)$@=)DB9+B&^CVQ,79,$V+0!L"@. MD.4XQ-$L+-P!6NH.>''LA?1FO@)Z37HS+=T;D.@ET6M+O9FO#%_2F[DAQ)J0MYCA>Q1AIB(@7Y68 MKJ/:A@_REF9[6J#[-OQ?()9IY0BO//%L;Z8$*PE6,KI5XM-B?)KT9E+;L1 U M&.B#1%>)Q1S5#6Q=-1W=138%8L4$/G!SEOHQR M_TW;S_1F:F^='[;K3A.Y9'+)Y))MX9+M?P#+[N5F)B=W4G5JP>&]C^KML]9@ MN]ENI6A>9AD:MBS;0H0%CJ-[%"$K\'6$J(-=KO\B1^J_6Z?__IKRA^HZ"9"M M455SD*L2WW!55V<\Q=.F!G$+@[Y# M;$(-"[O((9864 \C@BSDF::)+,_B/@ODI#Z+%P>(2)?K*P#DI,N5NI[N6IJE M&EI@J 2[GFJ[)E9UV[1LQ]8]#Q.>C@4;G;/U:0>&!$@)D/L%D*MX=5\9(:57 M=T.@."$UN@'#CFWP]"_35PD)-!5D2*)BW;"X/X78@<:]NC8V1G=V,9E&3I<7_S:V\GUF+FT&O'P:/"6Z.(G#SIKVP[&I5?]/J8)-8M4X3Y]5__U]A2F<M08]T( (IWDNDWF=*- M.O=AC^/E0LOV\9[L!][F_8A&1:O[';$[P_U(SQ>Q,S1I< )?>RR\%QTK'J*P MWV=MI1,$BC^(X#7*(Z-13FFS/F\?!)=V &W"J:W\,-:H9?KO%[#L4OQ\F+V] MT,0F9'^Z'?\1_FGV[UHG_Q]02P,$% @ O7YV5'-D[5UM<^*XLOZ^OT*7K=J[IVJ9).1E)K,[>XKA M9<*]!+) 9LY^.B5L ;YC+%:VDW!^_57+-AC\(MN81.>8K=H)8'6WI*,+U^N^"J$57:V;,%PYJ MG#<:^T_9Q]MK?'6#KV_J5Q?OW]>O;AO3.KZYF-6GY/IV=G[SX>;RXOJ7^4>B MZ].KVZE>O[EI7-2O;J97]=O+JP_\Z_G%^VM->Z]K#<'TQ?YH:PNRQ(@WS+(_ MOMB?:@O'67T\.WM^?G[W?/F.LOE9X_S\XNP?]_VQ*%KSRYJ&]7VG],N4F4'Y MRS-X/,4V"8KCJ;93&B\),VSJ,HU,"9L3ZYU&EV?0[//;R_. "G@:*5(,RW:P MI6VDZ ZK.^L5L>-I^.,S> QRSNOG%_7&15B2[FS(PF*NS[R'-80=AQE3UR%= MRI9M,L.NR4E+PX<85<>611U!#[_XOZU6AC6CW@_\)P#L8X#:B,R" M>2PR+\<,#?'G(V8:HZ9D')VM&%T1YAC$#L_I@L&"D=FG&I_9Z\$D]4\33]_Q MB@0E(OQW-0\>GW$28O:W#0EH ?Q/-9OWOTF\KE&XW2M&\K:;D]A\I1 P_[LW M7\-FWN9S$LTU_R-:KY-9WM9S$L,R"C0>J"?\.3+T3[46Y<9H#<%OCZ->!F-" MR/:H K8!XVV-?C\7_UV@^M: K2-!]=O9?MD]+JY-]*'UN_B\K^ ^L5\DA7!/ M-3+3[79J+)G_8]"+*7W;='7#Z?$9ERU%37)W2&/V0F: MR?@!,]ZJ!7$,7L_R<-IE*P7M*CMHZ.<=WG^K*(CC"?_WOC.8C(?=X4-GU)ST M^-.# $Q@*07O.@V\+5,T[*(MVQ-LW=;P_F'4N>L,QKVOG=Z ?^V4AE\<;RF0 M-]F!W.&// $G2+NMN^;@2V?<&XPGP];_W@W[[?"A-#T[K<12FYOBNVQ]^*P_W@*$4 MU]LPY@_4-#2#V+EQR\A6 MAM[%.>PE#5LSJ>TR E!ZC!&=H1!KM.6- N85 K&I_>4:MN"&+;UIV\2Q^8>^ M@:>&:8#_YXZ8.M^ C[%)\GL .JAZVYP;70FRQRHR!E*(7F M:A^:@*68N 13M.7J3VH5@JQ-IDYN6 21M.NO][L>R"K4M6.':M\7U-0)LSM\ M[7367.6^$3AQ0_3F$V%X3EITN:36>,%W(O;0=2 R#^=[\AMR!\B2 GD3L>Y" MTOAV2L@3XRF0B'R1R).)/*$H)+5">C B)AS'XKM-9SUAV+*Q!ISSSX:)C*0( MOM]'T&>%!"\49E8I8!R#B0UGL+Y\)A87X#SP!:<(/*GLI"!]B((4, PM5CY/ M))A6""PQA7S&G)K/*2O"];50G#2!C12[VNS_RB.'[3\>F_U>]\_>X$NSU1H^#@J<1,S,6(I7Q'D0L$:]WD\_ M7MR<__K3CQ\:%XU?T482XJ+05A8*A%4)V$RAU2-';C-'"T*8RDV(8\:$DQ?&KB%,H*%\0G"@'*2(1UT@XN%]%%&1!^8+09&0KQ2OB M,LD2\:\BCA".+XA5B%2*1\13 L15[.\#8O1%SSU?I/+P/5EV(5(4(XZ5 M(D'1*F*>')TIB*^4H13+B",E+>A31]O-H@OSH[Q78JA'[VJW32JWU((66<[IJ$ MSL0L:FB\(UO87AQ7D612I9H35@!!#4ZJD@A:BUHPX+R5UZ:S M%B.ZX8P,^_MQE44N5ZHN$7]4+G79K0#0>%5 4(>3PB0"UZ6,[U^MELL8L;3U M<;4D09A4-2*NKURJX4M%@=B3-B0")/-5'E<]LDJ7ZDO$-9=+7[+Y54\ZE(#B M/6': AQ>-NE9<.R%,O[K<34G7:947Z+.OCSZ$A*.0M)/*I)\?,-+# A>6W"D MKF #<%P%29,H58^8@UTYU",0+::3C?"3=F38>+R^GF23+=68Z-&RHEN?D_;D M=L+P&=@E(Z+1N2?ZV/Z6)'E2+3GD;!JX5H1@%))\4HOD@;TP(/7SG ^C._X_ M9S-O4?O8%JU,JE1%#CGB!@$N3[R8/((*(%JI*KM-I35WW2IHAYW=1=2E/ MLDQEKLLY+X##6=E.5W*EB_5H8@'MZ .A6XR#6;H3C@!3;XQGF-D%172I'JE1[(I[@Q&/GN]ON!&WQ-N2B"B== MV:!6JJ5<0(14"R+^W10M.)F]<=<2VOR##?F$+=T/IWD/NXPNO00*+M]:#E?$ M#\!^)KSK2)A!074X1AVD^A)Q^.YAG@2I!6R2'NZ<#V:W":$?WLR_A;U5$%EZ2E\453 M5(G..K,9T1SC:3L81]@I;(86%B3%/.*0W<-\5QQ8 QN!87T F557@5)M@JQ\ MI0!'W*E[ )\6_S@L0XYFN"9!+3BO26=M,B.,$9V7"=G(A_DLRI$JTX.;B(]T M3P_"KO6ME#*5X1?RY/EZGM;>,)!ZE@GVL>DAU)'IDMX2$'R<5*T?%P@Z@IJ:Y2U>\ MYD,LC?",D06Q;..)]*E=_$CG*]=/JI+1\\&EJ.2N0RM47=_4V*DP@AJ?U+6X M.K0-T^4$>X01DC=6VIRUE*IN]-SR$537KW2415SJI0IJ<-)[E8KJFHR?3"O> M1]SNR:]KJBA@:6]:*@Y;%JY2\"+N(NA3::N" 9VHV0$[S) &PS38F1\&@= M<%3A %%2X+/G,@T#'\JCY0UT(?2D!U%P'@@3=HVED:,K0JHLJ29$_999-"$D ML_*JX*6?%?_"U>BB*">PD0(8\?+YZ7#]#^*Z=H5QV5RT_XQ-,406A(1SG/HN M!(=ZQ0]#KZ P*<81=]@&X]!]?E\F$D)W-E:!F\2AFUS)E=4'/PQ_\!XZG9L, MT0\)+_$-Q>NKO2_VNJ/K.KQW[CG;I;L<06O,![P6L?%'2R>,+T@:Z+P)E['\ MFS+6O(R17(9DJ1)$7&(;)?#$(U\^\BJ @AH@406T4P>TJ<1IC)< 7H$#0&7* M/JG.JZM.OC3W)=R!SR%%J@YIJ1-R9-.O(.QI[P4HAC;[B.OW5X]5$ MSXAY?7AAV-*82?&*N$GC7TE>29B27S%1:ERKH!@IM!$W:>K[+4[QK4S(^[_X M:0C+ASR>OQ3KB&=4@G7P:Y!.\01R# @; ].[$GCO*UI=QZ2;4KXJ&5:%?THFBBOCDT0]Z0*BKE)A\= MG74-OK_2#%CZ#[[UD9&M5"4B#MU0SCJ.]X9WY6^#C-VI3?YR>0,Z3X< E\1' MAM1MS/NK D[(8U5-7%IWG?9CO]/K?6WV'YN3WG#0'+3_>&SV>]T_>X,OS59K M^#B8C OCE9._%,?HVZ1\":C7^^G'BYOS7W_Z\4/CHO$KV@A$7"+:BD2!S/]T MP'\[>[$_8LC\/*/PB_?=LJA7=_$3_X5X.UJA#GBJ_?.>6F1]C]EWXG0Q+%_. M^IXL.; UA*=\%L.:\ZG&)S-20Q9'_E,MA<""BY13DP0$+U-F&A_YDF90'2KZ MJ::[WO)60S8?D([AN/#M"Z/NZE/-*VXX9%E#CE?<877X9'_4Z1(;5H\_ T:U MLZ3FM(TG0R>6SM=7!E[1!\+@#5%X3L+MF6'3WC0HC>2(+5IY8N1-XFI AOZ[ MM8(>A\S?3.>"N@2#XSBH>]]8&DYB2PMPDG> 8<%Q>R=X-/7BF9]JFA"3L5N\ M7Y9)M2FQ=.E&>9NV-19U,CS84Q\0R*!M0A]AMES3.+R_2AV)R>06&8I#H:>>$ M/6.0R07*?3.<1<_28<%PL0F&"2,^7M[M(ZZ#':PMNJYIBA^2%YW2!>68J7/H M@2VD9>^X"7[Q,A7TO45DDRI+VA,IE,47H:,J_K [ZG#C^/-PU&H/1Z/N2*+X MB>454/S=M[V*."3'!-P3H9AD(H89J=7$,2&#&#>$3%??^)7XDP=B81,T$H.Q MZ*40YM,T;XH^( Z==8E. ]!HF==31YBMIJ^Q-^XWV^!6);7H%QXIWTY$K> M->ESTZ]_4DL2"I?>#'^J=N!<0!;3Q+/PV\3[V[-\I>IP24LX7ON73Z!Z(8W.V^!"#9!_A'3 ML3V/- M'T1=TQQN97!_\[V-<#59^F&>JWQ,%-VUQK\ 9?= 4JLYZHR;FB.+L!3BI4+$ M9<2_ZG[](/J5XJS<+Z@HK*"*\#\8VT_8A"W6GI[N*VZHI#=,H]X9W\G8>=%$ M?GH UX.<,]M9'S9%0ZO$9I%('4_*UEE1G"-KT67.M>M2H;4K."7)[>RI86T. M;GKN[I[.BQHS\18^/_V^/]7NOL!89!CB-DE,[NU$S3N^8#4MGS+;W7(9XP2A M!^,%9<*9"4Z05^E[:1T4W8,5N)(*K"?[B]U5SNCAE4K1PWN\ MYLMU0WB91F3E,F[0V.2!T3G#2TG$)0NI DV,'.<8D.T5#7 H\,F"/_,.(8H7 M(\TH>\9,SW%") =+-=?LF!-[<#83".U$Q4ZE>>.8\A?&NY#H#UP#')>?/*1D"K01.EF<.OFW#$J?0LG MF^.T"%]%[:+(6,X@+F]>&R5(V>QZP\$ZAGCI7*+U^"ENC.Q\4:G(+N5*Q]Q=:KIFD:T'/; MD"X,5\GZ$H-P4Z(LL)A]3]30X& M"F]X\FYV%$(P:L=MD"#V UZ'M]59KB 6YJ?NI!WLO:03]GY!!>#E:R*#/9?& MC)6X%Y?>B,3B"C0E8=L,[B%M0>SFBY'H[\]$6L[\HAM+>.^G9^85FU\"2ZXY M9T0\"6TTLMF :90*(+F;]%D<&J>S1SN(GTMN F:E?N,PSC=L @J6_9E27BU_ M#>!#*KH<1'_IS-U4'G\%-"+&!\S-GR?#-O8REO8@G0\V0QD=8'59F<0A M3?W_7-L!MI$@9Q[?<[ER%5W5^KS-9"_YNOAG0)T_B0,7.PBOA"XN.8@F$[VY MA+\I=S>+L_PW">E<7><\+W&MT! +C!.NG) 1 RZ?P8T5_WKIA(;>I@7.+/^$ M>O+9YH+L%!T0,1-!?*+Z9D*B^CQ33%[.BO99#H=SG\+%Q=(#Q+%L%9U,]@R5 MX=3!8),:5N PYVO-?KH6F2ET&,\W-I#$P4=L=BG;I#=H\864[Q79&)O$]AU" MB7J2F5Y1A6B:GE-=O-@.O!Y\ FAA"^O<5GM@?!L!O[5TRN"OS,-0@)4":](# M7QK@ HF[W)JF=_Y*(MVK9B16H)FY$E1Y\=_ %RC"*^5DOHIEK$(8^%,6)KAO(2-#&9=39:Q56#TB-_AR;M(;*FW21^2) MFD^0=%98GE!+6:J11 (%FN-%Z?OXV78-QTN]!]DO_/15LN10V8@5:&8HS8.( M:VT]@G;3\:PMJ*%#'W"&F'@Q9@IT@R3*TA9L"H9H F(%FAEXOL)5W;[O:O), M_>EQ../;4#[+2R)N!;DIT!%-EU>3AE_^*_-7I%&\L54ALO!Y/B1MO3>K9DSF MGX.# NA-%MP@[XL;E\[ /]JWV1Q2)IFN 4FA8WG@@_].EG8P]2 M9*6=.4RG4W0X1EP15SE=%U<*@;&0XV7VE'O"]448MS)%[;&C1=%EJ**ZO 0N$?]-])K^>=/A8W MQ>1K178&K[U*3I+"N*!$&< M+\*_"%_"P_U?_^5'^2?QXP\X*_,ZG7WXRX__\?X7"#_^ MSW_[EW_YU_\/X'_]_/;U#R_FY>P49ZL?GB\PK;#^\/MT]?&'?U1<_O.'MIB? M_O"/^>*?T\\)X-_6?_1\_NG+8OKAX^H')92Z^=O%GZ--QB7KP$COP425(3G9 M(*.-3;C@M+3__X<_8ZW9Q%S!.27!N&P@:A/H1R&]+<77HM8?>C*=_?//_4M. M2_R!!C=;KG_\RX\?5ZM/?_[II]]___U/?^3%R9_FBP\_*2'T3Y?O_O'B[7_< M>O_O>OUN&6/\:?W;J[]D3Y6_O2__O;Z7?F(IPFFL^4JS4I_P'+ZY^7Z MQ=?SDE;K.7\4UP_WOJ/_!)=O@_X22 5:_NF/9?WQW_[EAQ_.IV,Q/\&WV'[H M__['VU?7'IE.<3%=SL\6!3,N/N#L3V5^^E-_YT_/W_SZ[LWK5R^>O7_YXN=G MKY_]^OSENW]_^?+].QK'^G-77S[A7WY<3D\_G>#E:Q\7V/[R8\H%NKQ%U**# M^1_W?]9/7W&6=%+.3M;3\II^OOC$CH49,OZQPEG%\SFZ?/K)O%Q[TTF7T'QQ M^9/)^M7)V1(^I/1I\FRYQ-5R8K2Q$86$U@5@JH\0/%%5R4ADE4$D%Z]/ M3Q_,DD:SEF9+R[P6Z<7'_M0G[B<\62TO7UE/Y7H:KS_Y?.X.Q?_\;+&@!3U! MCP%U=!"][,N1OB23$)PW$FL3,8DZR# N %P?S087GBW*#_-%Q07M3S_^\#OV MW>1BJSI'DQ;E%DFN+Y2+=_RT/#L]77\F3%=X>OGW?=\Z6+*K.=?DGHN/(!\J MW]\6\T^X6'WY[23-5L]F]>5_GDT_]2NB MJR4'HYG%_1">;:2OOAWILTT]&QG^.I_7WZQMA*R_'2'O-:5L GVS^HB+\U'\.I^5BXU&FB)5:P:4S<2M M*CP$2X,24<3FM?"M<2_K.X%L(VKS[8CZ\,EFD_NK&1F3'Z;Y!"_PX.KE'^7D MK)OL5XPL0>HJ-.TI6I.]'(V"$!V"K0I+D_3%.V8:;(-K&U;8;X<5[*)@(\D+ M;$@I^5'LJ7Z M/]V>^IQ.Z$.7SU;/TV+QA9;!3#B0_G2!@HB_..32ET KD M'N56P,;GW^S#BYN,YY<)'_E+F9\1F+=8D(#1+DWK\'+,U;J65":%C3G2KMPT M1&<\.!VJ)2>M6,>]"SZ$9WSN#P\]PXQA#_R4IO7E'Y]PMD3:G#:,]\L1 M%IU%4,J H\T(C)!KHTP#6>PE^FISLY8]^O$HK/$Y31R,X)8'&U&>SV>K12JK M?TQ7'Y^?+5=DLIW#^NMBOKR"EHTP4O2-25II9$[O+L5 ML/'Y4BSV!+M,&'7'A5&/&PIMHJ2WIC4%)2*IL1 U)&G)O6N8;=2>MCO!KD3N M #(^3XI'FQPZY\R^U)OV8KK\-%^F$R+DV2?"=^[NTZN%J#N=G6%]\PD7ZVFZ MG(&0F\G9-5"A5#")OHN9OO.D_F+%BD8.<[2R#]IMB.2_.2(=27IL;'NWFI=_ M?IR?T'0ONV.U^C))/DJ1M(.02NZ;7H9448!W3OJJ16@E,;/H-HK#=>[IZ7RV M_MQSUU!+$6K1$9JL HPD_S#D)$!;3Y8C#= 4;B/\)H8Q>>8'ROVV.CU@NOFV MSEJG?>SIY#84P2@5:A.-F32W M4>SHZL.W1(P#YWQ @_O*._AMOEA/]FJUF.:S57=!W\][&D"/5AEK$BXSD^4FAG&;^T>GRD$B8B/*ZVG*TQ/R57#Y;%;O MH&]&B444":4HTA8F9HA!6&A!8,Q62",5,W$>P\0XYLL@E.]SC#WT%#6I6$2$ ME&(#99N/I#"-+-Q.SVT48]I+67EQD_H'"H"/_//9A_>X.'V!>;61=QB\=MZ+ M"DK5CH6LI(@Q@/6:ECL:G;%PD^%.)&/:,8W".0QA3^&)0LG*+AO4^P">0K?T5$480E*]+5 M0(8?%DA1>JBN29>USU9SFUCWHQE3WL.@+&$2"*,EOII^6,_*6USBXC-N (H. M51;"@(N1?,CD"5HDE9B**=UJ0IVYTRD?@#.F7(B![50>D3"F5)V>3E>GZQS@ M67V^/E/_@+-"HY]8C])KJX!,:2*MI*TM]RLSL:*WF*M$-\1)[SUPQI3F,"A' MN$0RMDAK(F)# P"8 P6Y*N+.=Z5DKPR$$S. M8*+4$(TW4,C%0.>$:NQVVL;C1QHQXI#YOI,\A%+;*Q-6Q%::#Q'\.GE0J3YX M*Z VXX3)05?DOE5^(.21AI0XV'1,8=Y@X+_^=',Z7]//K 6GWKVGKW][^>O[ M=V]^>?/;R[?/WK^BWU['LW/EJ7L^=+ 25-L,@JD6U:^X^II%-9%5VA94@AJ% MZX4I'$2;-53C>NTAJ3-[JO@U R5B]ITM1Y*">B+\PU,*[XG_4M:'=E!]E)% MJ[QSFCLOX.O3QV2-[B_A.XH3[3.[;&KHVDBV;"JSY"J!4+, ;2P133I,$=NP_ .&&/:K2G/71UF.Z!F438S]AKRD+ZX.%(FTDC9@0(NH Y#98W72+20U0'^U1 M7&,*?HR5;NSRY2NQF::S99\P\LAG-!>$Y6RZ_-B/WLA#Q[R:^-:<:JI"HW4! MQJKS>CIM@>2ZE7^SCW4R=95UU;*>"UZ8$J&EMVRH%LIOJBK*_L M]_8V'C\FH_)0>=^B]9ZSS)<*@.LU^E>OH)3FA0N!'$ON[*+MD(W*Y^=FQP#"83RO^K3 ,EU/"^WW MGQ;S>E;Z#Q/CE"V9'<^[;H@>/"/A. MM$][2LE_K>&\:3 #. MJ*Y[G7Y*TT6'LQYCE47[8#QX*35AJ32\4B)8;T5P0NKBN"_< MW8UDQV3F;XL-#)//5_UA!C1CAG,WQ8Q&(5Q,$%2+I.?SY;3&2Z7S^>G>3H[G^;RGV?3Y;J* M4@\R?#B/4)"=_!;)1B9;Z&Q!\W&QMRTGHLA<7'-0-2(8&Q,$Y0QHU-8EQ%9N MUA&]E:H/@,(+PMD23M8R1 M._/NOER'<9W BES)9U">%(!(I ]:A*P+0D@B*%E*(+Y\JR>P3QM2VI-]=]=I M?7KA\Q?[O=@BH\<7T]!7(KO1F!8D\DZP=T(-;Z#G:R)Y0=V\,>O>1O,7/ M.#LC!2>1/"E,!:2D562$;)!4+!!="]ZYU*+GMF$OGSVF36]?R=ZNC+C'O#+> MM5RNWK3N0:WO;N'B\[3@\MW\I))Y+#"%UFVF7K*XR@BITJ(1NN14BN\96LQR MOA_-J#8J+M$S3?[3)E8_?_.WW]Z^_/>7O[Y[]?>7KWZE'U\R9EC?]>E'2;5^ M=%A,.==WU+#\6K]22D5**?0>G]U!+0Y"M@5LDRW9$I1F3S!Y [#M>[[/GJO M*YU-QZ!*LI"<:V!05$@Q"@@6+>I0T;&W)V0>PIC4&11(\_C0\U![/^ADE6]5^_ST M;.,=^R_S!9'TXN9Q^?)^D6;+5"Z.8M8_71"[_I^SY;I4T=5L%:5L:-) T[WG M4\@&HM4>4+:"Y,*I;+A;9PTSDC%I"':>[K)$CT2&P1?U^O4K:-;;:$NN@*57 MTK+60L1>E@^E0%U0:,-^ VX;8&-2(D]&N_U%]<3QN6?O_OV7UV_^P1F4N_S( MXT3B[AP 7\F#WG:<3,S/4_JTG[_\Q[*75+U**7A&F\KG=7V,B0I)N=Y]N&C: M+DSM5Y*%]Y!R4R:H+#)[ \;MT3'Z0+5JYZ(+((,@K[;X!%%&!XI\VQS)L:V6 M.U%^G#[00-QXP+W99>H'28.?>&DPM%2 ]@#=B\EXYA;_Y M_#%IFB.)?^_I9^RL>&DDD5FUF74]:284&8( M';=49O&%8T&EZ*T.I.7);G9 M<"^8,5UK/1(U> 3#F63V>;JDQQ.:%_.SO&IG)Y?U""=&61JE$N0A5]GO+A*' M;74T3B^2*Z*8-D")G7OQC.E"ZO'T"(]XANL><",CAZ!$5[,"XFPO\J(#A&(* M*3X;2@_IB<8=;7T$TICJPA]-__ )B>].Y\>TP)\3#;A[8@3G?-M+,?3_&KET ME1 (IR'KW*#1=]5;%6WCSFV]&\F8BL,?B2<,(F%,K/Q,2G&^^/+ZU2]O+JK6 M_T:.Y;R>Y_9/WH,%6#]N*#_([V0Z&$<$1RW>% M(*KPMI$G+C)Y4=(3=7. 2EYXSCX*5-PQ-9;R7?*8=6>/I5#X1,5[5-PS7F@* MKE="%*8)0;XWN! )CA869D_/"N39(TL==8+9BS-'*TAR),3RBX;Q> MN*!]#U_@^;^O9I?AOK=8.OF[L/TJUX=K2R.4_&,W:A'D$#7O1'FP29 MCY>5$"_)_V4B:!?5Z"N45"NI8D<(?56 -@IEC';> M^KTVJ"T>OE4"WW<5FQY:0L,:2S?ZATX0L=>:1\"<53_.#Y L =6I]L1$VC@S M]VW0;7!M1:OO+"^875Z2AN1, MR1FS%X6;3]NC8TB(+(AU7:[LU7)Y1I^/%Z'C:%NNR5B(SM6N*DSO-^Y)+DX7 MS*4%]@24^]%\ TGUAW+GCF1(#M&P+9FWY$)_Z4<+RS?MW%:=SSZ\Q\7I&E(B M%8!&:6A:IGXG+4-22H$-,AF?I<+$?2;T(*!157\X$F/X),29<'U%XM<]V>%- M>[[ .EU-7+8F"6&@WW,#8VN!F'HM.Q605$[U+7+7YKH7S#>0F#_D[K*_8 ;9 M7*[#T2FZH&H"+44!XUL?'S;P4M108RE&0L#^DDCI<4.Q[$%GCTS[^65UN'(>P^#C-AY\Q9/>ECM_?Q]^N,?T]7'C_.3 M7CB(MLE[;JCT/@X>'?E[A;X8$R6$$"*$W)2J9+>;RKX=[8EU5&T5CLRU0>4Z MB/;;T-!KA_&NF)?@NZ#< M@$(<0D]B7EW/3^V%HY>3))51RGL0:$F'IU @H)=0Y Q^KR MKB^?T2N?<+'Z\MM)FJV>S6J_D?*I+_>)"[XYU E5(5+21T M@Q[\/ +O&S@).I1=#[K!C,)C5_3OY^M.8PN\'U])3C5#.TO6*??BYX$V )^! MUG^JDC2,3D,%YQY']RT<&K&3:QC9#<>MRUNS>%XLL<_1Q6_J1"3CFBP1A"D" MC%2JN_6D8U+**MFFO&I#L^L!?*-JA/U4_.*2WQ!'"IL[[=J7NFLV:O12UA3! MYVX)5XR]K[<&977HG1G)S&$_N=P-XK=P3C44SX:0XG";V?D]X+_AZN.\?KT- MO)R48JW1@@QP87IU-"$ANDP+0<=HI->^5O86F%MB^Q9.L@;?Q#CD-HB7_&*Z M'OGJ;+%18**G\5FG@T@6O)6M%QFPD$TM],77HC"T[+EKPVP!ZQLXTQK2F.<0 M%E]7%AI\_W^G]F?R,M8![>5J,2TKK&LM?=$O^.J%C7>>UT2ZG>]YT1/AY1_E M8YI]P+=IA2];P[*:R+AN.U?!U][ZP"8!R:@**BBI1<%H/+>7>=P1'I(U_V*Z M_#1?II._+N9GGZZ>0:^6\Y:R6*\ZRAY9;#;Z:JI$XGH_<'7.0HBB0E!%.&S> MM;)-<9C1#G!,X841K\C-"P2CE>5.9&6Y[7+<\=&'/3KW5U,_:>B+=,I DMJ2 M::+(X"VHH0EKF@LY!Q1;K-P1#W%,I;>_D;4[8FGN1-CO?O6J7H2EA]V2B309 MF&@7RX)FQ#7R.(Q7+FVC=T<\Q",>];CFR9#& *FY D8)#;%&!UIM/'_@SP^E"=L/#Z?CS=M'.8!;$[FURD^G_+;SL9R8I,-3?4F M6CH(,/V2:5:B011"8+$JU\H=8WCZ48_A,M/WO.Z>7L([\7IHO737G?'8JG'% MT'SV\B6F=GS"D"$O\/@;BR7%:$+[K@EM\F;=W MTP^S:9N6G@-Q5;#YM_G)M!#P=^4CUK,3G+?K GJ!JS0]65Z'O%6?0I[GLC8S M'& JF#H>'K1R)M[4%JWUQ+)>;CO:"BFE +J%8IN6W@3NRQ0' 3[\:NWF!Y-/ MHQ1FBQ!*ZIG@U4#TL8#S0GNK2\V"VV>XCF ,_NWQF73[6NW>4F$]\:,!WAC6 M,]J^%XLOM,;_GD[.J3' XJ@>U4[0:.DH;;@JDLZ%">XTUVV C8&__+I M><0OPW$JVLNLQ+21D'@\=?O0TY]4Z6X]+4RJ]][D4++Z)L%J3$5:D*Y?,@JM M9XJBA9"B,E5Z)]F;?S^$Y^ N2Z6=P)"K1IZ:(UO7%16D="*SWR;GPKZCLAXVV8N-?+>:-SV%I#G3O^Z& M0X[>S:K_?7QFR/9E7%PTP(DQZ^ M3!9\/C_-T]EZF&^QS,EF^"^LKRKQC(R'=6'AG:LB>-A6KMBF[/33.,3GH3\SSS5294=&#S7C@'-7SL\6" M_N#\G5^+3O>+Q4['&"HXERL8# :")Q_4F4:(?#7&?%Y_GYZ<3+PHIE1:KA4-34_S 5)L K2N5-KE&**J/BCK,<96!C.)D=*:W'1ZQ1 MKIFK]H:;*F,28_15.@'8UN6R58(DA8&86_6*E 5F[@:"@P]JQUN8_[U6GHI0 MHUPG%Z=&FX=0 EOS+17P2M+:;SI#:%Y ":G13A!,:MSGPL..:$QW2[_C%7(@ ME<:Y/#97^T7OP+M[!J+':@-YZC)*!S0V#ZGF"*4X8KL/WEKNYB!/,M =2\C^ M]V(:$_%&N<8N6[]^F129?6RJ%X:C*3?:*TBF6YU9:MI(//V2VY$>9" [EK[] M[S5R3.*,<@U<]J-]G_ZXF.3DDK"R%V8UOO1ZYH8FV6>HN4GC9145N3.G!QW0 MF$KS?L=KXC BC7)M;+:(2TC.EO2>M%M,8$RK$'N/9D73[).K6J(:\:JXMPO@ MTYU/7A@:&[]X]W&^6%TUBQ)>9^=T E]C!I-3@X!9@E4E8$35$&_HY,&/*A^! M_+V>6NZ[#H8ZNN1DSB@WGHV]='/N?335Q^"@>A'[5B\AAUYPP9ED'?I2TYB# M[G>/ZGL]P3QTT8R45Z-<+U^CHQN_6[NJD^BL%,(Y"%9),D)2;UX>*[B,IAE3 MFXO<1>>.,[+O]0!VC.N&B5\L%6*&5:27?;?/ S[+RXC/1!HEDF\-LH@>C/<. MDA (O1ZS"T&TAMO4?GD2\-_KF>[XS3(.-HU2X=PYU'Y#9OE;^M(_8R)KT$[T M!K=.D_,K;(1H:)SH0RR8,-E1I[(^.L#O]?!WC.J'EVU#+JCG\]ER6B^N\+]? MI-GRW."4$Y4C2I4BZNN9HA0$8Q.D&C 9A=H'[@20QS"-/%S!PZ4=>@'L+JBG6$IK#2HGUF@I MM+10O*RMM=:*:MUCJVN?8%#%3.JF5V;I!\&!L/O>0U*9('0.MAS!Q]X7_L@=Z2=G M*:OX1VG-KR]:.H*I3 MAQ)E]H 84!2;8IV=2YECCFH^3MSX^_Q5.=75D_I(>S!U]&N9-L>H_5 MYU().=3D/!@=>\7+IB$(ZTG3ZRSZ!/:ESFBOYM_[ZZ/> MTG\4Q5-?V-]MFICN[F\>8[1=FF><1Z(FK:0D:J_AV]N7&;1D>F*Q@,3/:K). MY#(S[VT'0CY42^SPQ(NH]P;@RVE3+GH7LH#ZRU5XW9UOA=MHY M<(_) CHF'NH])^"M.M(VNUCDDG$XAJY#B!J+Y^$E99=GS65J]'52J\R M=]6'PU&/*2#UC="60_XLV1D[8+Z6L_AUOF066I WHF0%4ZV%H*LBOR37JK7. M7I9'C&0&&&/*F'@*!AY;DD^Q95[F K[%STB_N(2M,>JD@P,K>T_BI!VD2E]* M[QAJLA%2<=_!/1CTF'(1OI$-DT'ZQ]XO7\]G'VXNLFRK:[VHL C5])YS'G*3 M'F*,O15=K8&[%>@=*,9TR_L;V"T/E2/;9GD>?]EKFJJ)J91J(?F6:7./-$W6 M9"@QYN1]4(&]N\C^:(^H5.XN!3Y!:V7(I8$W@<1KLH4L8X80R8&P(9(3P1TN M.ACTF((>1V+J ?J$0?#\^N37^>H^)_>RUO+K^7+YUS2=O9G]8T$R>#'_?3:) MKN36&H(SJ1?&)1LNZYRA>EE-D+5)L;-2V0_*F (81^;@4PCS*<-M-+QU@O3K M>9IM5!CL)U0N*"RR5\.J9)F9X@M$J7ME3M>2]MDEY$X=9!W F.(9X]])F0GQ MU-&XBY/]FDJR&A49DJ0#2!%H\H8#V7O"]C1J4634XPC$;9_T<:P(R/@Y>Z# MGX*C]U8@O)JZ4I0T/D Q2%,G@H2HK0856U UHXWJ"1G[&/PQA43&SU]6,CP% MFV\6\OYZV.AME+)!"8XT18X18G:T**NJS:2@I.2^=7$XZC'%4\;/70[1/\T& MO"XM=KVFV"7X8FJ6R=E^09#\1J)I-]Z(*V%7T7,8JE4D0HNC1\[CNGN @>)VE2]T5?4+6WH0[IEIQXV?J0<)^ M"G9>5J&_Q(NIVM(\]JZ+71\8 ]'$ LK'E,B$D=(_H3U[ ^V8:K:-GYN'B/HX MZ<-_3XMU'O3E+:*7-(35EZ\]).]*A5UWEFQI<9KV3QCF>2YKBO 4\&4%'SA MN3?90JPZ0ZU?6A%_.,>4APD?+:I'[ZM<:=G*B8E2?24NE=^"[Y"5F1O MYY153$UYZ[EKQF_?:GP,$?\#R< T]?Q=]W*VSJ8>_;>V@;&-C TR\Z&16X6B M6F5]8Q;\+EWWCAL:/TC(>TTIFT#7V\O-\'FG5R]^&K2K4$32-*0J(&FMH*AF M@@M-H>2^N7T?EO&%DP\2.,N4\Q+@ L-5A<]))*,QYYXBE+&W-=%D4ZY+02%: MU('^B]S+^TX@XXO/'B[Z@R:;3>Z;-X0,T:Q(GR XU_/#?(-@LX!JBS7HG+2& M.RS*4(O_IE=T_;H>J;02>'2:M8!HDV9_"WL)G:O2":U,=$H;1+W MQK<5L#%%,ABIPBP1-K);Y8S'^?SCXL)TXB66+1@)8R]Z*(E@SN?C(; MLO>BQ-LIT0=3XPX88PIV<31IA5M M3&@M,8];*VX\?TR!#2Y![SV_?(?'%W?^7LW*_!2O]X#H-KA5PF$/G0L4ZW+' MI)I"R/1C%JHI)4-D3U]X&-*88AI%W+-E:Y M)KL!YX5V@O!)=E;_ M_(5FZOEYC@)ILZLDA>7/V.AMFQ^P]['^$"A8#_D'GR:F(__SQ_1[4UO#>?G' M:I%HJ4UG:?'E%:V0-6'I+VG@])@/EWD-D]";GS2M0?<3.=-$IHVL$9=#1%M, M+2IS%[L:<#B''QKN#.V2.9/LLVPA&;("6^@^HX*0I %EK/3%TY[#WIWV +AC M\NS'PN_;YYS'80/CF??.@"]VNXDM.BE)[DNC[9N4F*P0LHZ@=2.\+KLLN2N' M[8]V3+&&[XB\^W#AZ ;-U;<7)] _XPS;=,5BICSRV4,9'[L,B=6DN/7(";I0 MHL\.1,H:C(LD>B$"2)M#K:EX8X#0GD:J'8TT!Z^ M"SGV$$Y$HTN0[)V?'D8T/H5\&#MNI0[RR6.X6,L-4+&T6F62()JF_3>8#!F# M!>NS$=WK:YX[;>P12./3?+PLX90(&TT>H6Y+H9;6!*"HNL>"/"2%1%U34LLZ MN**YZ^;LLI7L/=Y?L/<9.;D]8&VS-:IH0+(%P(BL2 A-@<=@K'$E!/8N88] M&M/FR_90%L%PKXX+X_&. =-Z1RO)ZHJV]N0!":D)T"$J[4G#5IA>G9?ICVC26A&N8*NE5B&6CP/(QN3QCX*A_CD MQ,ZA:UKA7H2Q"O+Y,F!HA%":!D&I!M:8?A,DU%;9>ZCL@&],>OP8?&*7V='# MOKUCUZQ,3Z;K3Y^WEZUA64T_?XU?OZ4ALD2!=WO44$'A P;,%".^^XEWG21, M,-=J=2F@@RE@M.Z5H0U"55BBJ9CX?;SMT1U2J?;NIUR7S?-G;U^^>U96OR%) M=+::6.EU,B[V$J9(N[/IO:EU _1>Z.@+;=WV$3;N^>@QF5H#L6>S\NS0PF%3 MG=L O7N+QMYN4U:I906=B2:FUU\/+1%VJ;R/V(IB+W%X"-XQF6H#<_#HXCTJ M(>G%=[A:G>#INGB#R5IK96U/<._)L&1]IN@C5)/(7BA.2?:+M+NC')-=-R+R M'2#*HU+NIMNSMG"F](<]&C5-)Q.=!)$D-I"(_6BI&$BF=ELXAFJ43\IQ7^WG MP#VF3/D1T9)5W$G?_&.^6'T\P>7RW6I>_GEI!HM< MM6K60+5"@ F9,#?R^FV_.VQK=?1$)A_E821CNBLP$I>%471'W13/[X[7_W.V M7)W;&0V-P&H3^%03(9427>MOTI=L&;.,=4O6%$V]Y!XCPJ\9Y_ M3+,/](:7L]3+SEWNRQE%\5X7B.AI7U8>(6=RM!P&EZ7$2K[^$]#O;K1CJB,Q M(A(RB/;HH>IW9--.6[]+M'H^/_TTG_75,V^7L?CKEPG/:VVPQ*T/>.Y006RN MJ6"*:&\\]VM1&V="\U5G$*+6'H#I7=ZUAFR0]CGIY "-F^[ P74\=_69?T\G M9^<[R,G)_/GA6[3_X01+A6UD1([Z,3O? !$A9K(IJT&( MO"PR!RCD5(/Q*4..BEQL$40HT?EFN?--'\(STJV/FQ0'BV)H71BT%TYH"S)* M3WJ9W-[@0P";O4FU9>7"4+1X2!?N%BV\:PE>>'"S#_U^Z+-9_]US>LMT]3PM M%E_:?/%[6M1EKVPA,[8*)))^$;0W!LY)08HM">5DQ'K#%KB[Q^[>",:4T,# MD6MM=7.3BX+ M\$V\5UHH,F]B$:HW7JF0>U&6K(*,WLB:D+WO'?LH1KI7'TK1D8C]J>E[JP#@ MQ+9<*ZDA"$+ICMY!%(:TG\@Q"QJ8DH/[T'MB'U-VQ'BH>IB(CTG0'D*C?\]% M-JL7>;O+EZ>?3N9?\#*/=SG1.NN 4H$,DO2#E83?8X6$10=1L&3S!!3=$OV8 MAJ1#B'D$-'WW,2WPY[3$NOF&Y_-EOXDH+'E^9#K*WBK=:-((4@APF%LA M32$Q#G5;@',<8\J?&!5UF40_'(G79YV3FINTNCG0U:Z+"Q3()40P @69)56I MQ%U/]6XD8TJ*. :1=I_^)[8+S\]"/^"L='LAV>IK21)QI%'V?%:Y7 MZLE #GJ1I($%UAOQS>WB>S+$6LH[-7?=X0XQG#PD7C$([:!N=7-77*8GRT6/5'[_*) 32X56P24 MVB\*:)4)7D%H06=3BT]9#U5&Z%%P8XS1'HE/AXKJ.(GTE\9?NNBT=M,"O//% M_?/G#WH<:]H\W\#9:H3?Z@#[\H]R1^F"^\(#-(:?)N MK?4V^(;L/L@-K2)&!RI7(?D'Q/^S(# MOP[>F7<1X3%VYO,# Y-M:#E+T!(E&%L#I&9SKY[M3;187.!>8H]A&O/N/ "1 M6$5T+)7NI55)B (HK".'J]]WD6E#[!06A6-EF@ YWJ? MY)@\&5950DS%Y)B;;Y7['AG'0CG6CLO(EYT7R"ZB.<8">5;*V6D7!=9GI_/% M:OI?ZQF@GR(T)7UI)H5HA_9J MAHDU;64JY6 %EJ2@N=#-8-6K-LH*/@:CT*M(&_D(?+IQ^2\'\^BV]\(NK*?4 MK-+&B&@TT"0$,-E8"+%:P&HQZL5M03/IO-?SV8?WN#CMCR015N^C-^"R<+T$3/=5=02G MFUD'T<+K.N6?IR?T#0O>_;*Z@NY'/]8SS5IL,^X2!_Z ME;'3^6Q]0VSYYFRU)(W75>FU.M/]E-8*J9U.*- M9_]Z=DIC?7.)[!:422;*NY 5E'7Y9="3$)4[I/DPU&/274/RO\&E;/U-_?*KCG@UC5 M]C9@N=S-RX=, A99,A9H 16Q(_;4=)]!A%R2S.0H>.[\W*N''[K'?"V1=36< MXB*VF!TH(Q*8*B29O+*W]!+]/CEJ:;AUVVT48])5^TGZYCYPX$RS:95W'^>+ M57=WON)(02O3I#XO^FU,[MHM*G"(F$SPI;"7:[R-8DSZ@4?B!\XTF\3_GA;3 M;N1\A>&4J*HI!UG5TIN9BQY.=Q!BJ;YH E.XXPFW0(SI1A./O ^;YV-J\W=] M7A9?YNWG=-++RKW[B+AZ-6OSQ?ETO<5U4'PU/W_[H3I_S\<-8!EP#)S)?KBN M#R[OE7R9"">LJKZ"4ZXK!5LA-B5!IF)"=-9)Q9W?@(PQM<[#C80OD('FPZ:9[,&V$84-!&Y/T MY\7@#48#N9'>S+87AA>I97:_]E%08[)5CLB4/:5R3,WVR]GJ;(%_F\ZFIV>G M;]]"'TC?^D*^KKPSQ8S7$\>P"=QSXE; [T12($1A&]2 M02T3BGN[*5]L8Y)K0["N5OGB<<0*M^1 M\Y9H_S>FQ?O?YY.20S"R%="M]5!X\9!EJN0F$4KTJ)WG3G':$>*8M/.H"+>/ M")^&9T0]-9."!U:G*8DL(['VZ=L4XIMHMH^/:SD(\.M6> MM14NUE"GGW%2C4_1]_H@,M&J*+01YT3K0Z4LFB[&NO)4!MPUH&,J\#(JTNTO MSJ?9Y#K*%J/*N55PND@PRDA(K1;(JDFIUT%XWSZ.,,O UT2VYK>P8<6&AK:TOJI920++O5*:5%Y8V-,QB%_@L.P 9A> M:_C.9_0OO\Y7_QM[AV5Z2L%*8IHNU\V6UO=$Z-^)5SKDV.L/]S0@$[!G" M7Z]I'W6RULE':'L8@F\RJ+(+CS:+0A])4,?1RYL@7_Y1Z*T74'6EC5W9 &CZ M^4LA%ZF7XP G27\(+:MG[XZX%]!O,KRR#_6.)\ZAC],F11=EL9_/D L$IO:Z M("$A^*IB\1E3\I;[!?X"MDQ-(R+2LX'G);M]QQ6TXQAJ <:85VO_7RVG,Z(@Z3 \G1VO@KN M!/;L'F 3S-8);1IM+2KT.TH&$D8-+8DB6K68:MG"#CD8R,%)B=BSHTF'KXN! MRPD-29EH>O*!HW$926O-6@'>%BN;30DU]UW'&Q#&8& =GR.W4A@/D N;4GMX M"BY2MLZKR%M56NE=)KVSNO?PRY"2LA!*R-E+@5)R'TYMCVX,AM/34VH@:;*T M^+G$]IXXO[Q*"GS9Z-M>W+F$)%7JU:.= 4-N1<]Y*604)'(L;)3^9I[_@YOM MG0\9@WGT=!SAE0&?5=T+^%P;Y47/"F%TT%&"5JZG]TI+QERLT(22P:=,0^6. MX=\#90Q'0T^_M7#(:4M3^^+U_B636?]O__)_ 5!+ P04 " "]?G959Q:> M#0.8 "JKP8 % &%B8RTR,#(R,#DS,%]D968N>&UL[+U;=ULYDB[XWK\B M)^=UHA+W2ZVN/LMI.ZL\XTQ[;%?5F2(*+VA1EG)-?_U_L_8\Y1^9C!&,%!F:C 2^7H6\:M3LGF)!8/ M'0W'__YS_2>&&?Y @QO/%M_^Y<!!B.9_,P M3C'%3U>?^2F, M1H1X\83YYX_XEQ]GPXN/(US][,,4R[WH5T.NH'2%\W_6I_VT-Z8/!&2:+B," M_13'E> -,6YZ^OZ8KY\%&4NX',T;(K[[[*9X)Q=AV%+ =Q[= .WB07"!%Q&G M+:%^\=Q;.%<@UQ'61X8+G YGD\MI0OJK]SC^4YI<_+3 ^?35;V]?O7SQ[,F[ MY\_>OJ-_?WW^V[NWKWYY^K/ZKH\N2;2 M*$0<+7XZN)S!^Q ^#M[.:8NLNR6)"%_0E[.!D,X*9P/$;&C3DU[0?B<9N")X MHIU,A,3OTG"VHG4)L[@@XM4K?JHJ_0E'\]GJ)PLE+Q1\/XJE'G]AF@?>J8S6,2B>T>Z= M3 3G: LWGLLH@]!.;YA[>PUZ2XA?2N2&VT^F*]E<+2([KC+5-&K*C?GD<"I9 MTH+&]^,/DRD][B\_LGT9=!<<#6!T6;[T2 M9')T[=[E*-^7HZ^GDS*%R2 .W(B7A"G&^,6/NPW+>+&FB@;O,4$UL MG1>SV27F9Y?3N@>23S3)_PBC2US\[M7'JH39\S]PFH8SS -K79+S0A=A M]#H,\XOQT_!Q. ^CMQ_"%&O\+]>UE!;215CQ#9+D9L,YOL7IIV'"Y4C?8)J\ M7VIT,>A!=!'1E0(Q8B!CC'F(4B?(R?E)<$_K6&;S7W'^89('R7 EO'8@>:!9&2Q"8*8 JLQ8BH5V M -.8M5UPG3?SFFOF+GMLGYOR;_C[XC>S@4Z%>\V1G!'E0#FR'+RFE5TX9[AW M,A5LO>AU G;>_&FOF[L$'[Q<33YC$ANQS^'\P]5"(1R]@9']4CT MW>0-SN;38:*O%POL/^A;^OU E'@O:[ MO_T\*7,@;=SEC^]S 5HLE[.%>F8#H8UAFFQ*YJP"A3*!MRH#R\K+Y%UBZI#. MP&ULY\FI7C6T(4ZY=S!]<_AT):I?2(AO+^-LF(=A^ODJ'$NCJAD) Y5%Y-%* MX(8E4(K\8^]3 B.*MDEA22DT)M?N:,^;;@?2X@8"[ATIWPQ]);0*G;ZFF3(9 M#?/"PQAP8[6+D8'1+(/R3$%0FH$70F",@:?F0;&M07Z+=&NELPTLVSL^?U<6 MB[CP($D3LY+D1!@F:/G-"GP6 40IS.3,HA*J]T/ !93S9DP+^6_@Q=Z1]T:G MC3+R8*.(X%DAT4CIB=GU"$I)](H&(FW_--K_+'F'T&%*D\MQM8G?SL,X$TUF M?_](_7)( M(Z.:&< 72>S!QI%#@E&+B,$26+VK2/ ':#]M5G M;_2A@AY.Q*]'_:[R<2 55YYK!"$4 \5%@XLT/:;W /^;/1XL7_N7'&;ZO7S1C MPG+9JM'CR;B&FI_\,9P-B(D6I=" AM&(,DH(N@A(P7M#*ZO6F?5%C$V &O+D M@:SB!WBS@Z+OX\S> N]A75C#]&RQAG8"-5C+8"<%Z75KGZQV0"E^DP!^?"=L(NP<& MW,K"^'5A30V0]D74-3A1L@?E$CF0SF6(DG&5HN-*MK:P[X XO*G80#F3EI+M M(9OWGM/E*W \%V.X]8 ZT% YC=>3PTA[G[)69A&E;&TF/@CH'"C03N(]S/PW M.*?Q87X>IN-Z$G.%*BFFR&L^.?)D20Q*LJ-(ZB78SDG,@0 ,9 M]Y!"2W[LY<7EXMSMOIS-*Z Z,A%=C!"D":!B0?"2:6#(,406,K/-%X6NX,Z! M'_UHHH>\V2^21:X@Q1)LR85#5!9!Z<(@)I_!H2FH MTF$W!S&OL(DB/69GP>IZ)[Q&8D,D/UF':!UCTB6N&VO^(3SG0(%F\FZ8M3J; MS@=/E^L3+4?/2\$T7YZNORI/\F216[OPBEA)-976@:WY_$I$ 5'+ .0/L4# M2U"=S@GIA;>X0-_=\* KEJ\XB-2+N!N:#UWPK69"!X3;!)7V),8Q(DO]:',+ MJNRABH;>QA9(N0I2('G&G#-"ZG6$B,5!EAB=8IB"E%\Y6>Z)/9T*5[;1P($Y MLQ FZ\%+K454@2,["![SAJNP]DB?>EUF]UH'Z7< M&^'ZSY_69/>2OMV[7,?;RXN+,/T\*6^'[\?#,DQA/+\YT'T]&0W3$&=O,-%H M1I\7(\1\ZP/3R9B^3(L]?O:L^O6CV9=#Z53/HQ<8+0M^]"^GM8H@"HV+5J*V MR2EO0M2:&XV6"12<&3GH!=&>WA'^?M\+7DV??@CC]^2]W_[$<)R&'VMZP.ID M.J=82@B:)B*O,T619^>=K!8^B]SGE)1K[4+M"_I$4H""K N6DN0*AWJ%N"@@ M_CA 2:0QQJ!@W\M)'(.G/168V$;?/1R;+,-P[\(?RSUP]F2T^!O,SX93^G[T M^=WD*ARPMEN^*@](>,!X)#$H\MSYFZV;MVF_F4R?6#\"V\:%;DJSEEP.= (?1'@8BJ0DXU<\R*3;UTE9BN MQXIE'I W]]^&;ZR_'I;,=_2Y&U]XE>/1 5-/Z72;\!PGFZY'-:Z?G+72P:'X M89+00M:,Y(CU+D;RX"P6$$$RF94.LGEERV\/",8- MEU<@5;7\8O"@40;:[VOA#LD$>3Q!1Z5X4:6U6] )V.&M_/UUV/7ZQLX*.,D0 M9BUGGB]'."DW5^IK@:V^8Y:/O??P0^F%0A4C3YBDM3$: M*4SH&I5\#,*^*7RWG_EDO/A/=3X_A5%=1Q>,[GLR?ANGT,VEE61$)H_?9^0PTU1VM(0XAA.)J MU=*(,L= L[QU@G,78(=?8GODSYULZ.:JZ2'4]Z4\:"L(Y,($"=DL"MAH1FCJ MD:MAZ (9(%:V3G#[$L%9,V(/8?=Q#X(PK(WUCBR^_,&M3PZ\BRI6.T0FQT$Q MJPB\=,!]C(KQ7$HH/2PI.P,^:V(=3I4]Y&:O#(97Y3&)+:,M&+CQ63*PG$M0 M6"+XF"18QXJU1K+H6S-O2XB'BK4>D&%]*NE40JD_AU&M6O/V ^+\Y55OHX5? M;G+)HEYG%][I6E"REK&I"W5FQAN=BK:M3Z[OPW*T9,\^]3_I00\];)B;<%VE M&W5!UE,,]'Y4QXF$MM%>!TKL(?K#DB,Q9C&R",Y*VE\="G#:,4!)%J!$FXQK M?:7HT*1X) QZ:$YL(_%>&G3@QS#,S_^HE8MQ1FOD\JK3Y71**^23V0SGJWMQ M/L3(5;$@7"8?()+MY:V+$$/1GF<396QMS'1'=WB;N95.[_3RZ$4A/?CC"UPU M*V@#-*&#DS6GU5@E@# &B$)E,MNC%B5JIIK7C'X SMF0HY7([UU(CAD:?TKC MHD%-%\*:3;A_,UP]N^^@^./O_GPX?$MI;$6( ^Q$@N3*5XJ4KUG27/Z M?\0#,FA=UP#YXR#VK6]QZ_GUL3<>()/2.>\])*,2*.YJCD(US9WFA:-3*;>^ MZ7X_FOWK>*P]^36Y,_2#\![YH$1;5-$(5AE:$+)6X)A#&FFTCEQ=ZTJGFS7[ MC/06GL,OEHU8<+?$1R.A][!WWL&V=$4-ULIG+$% 94&I;,#GS"!8CMR$[+1N M?75W,Y)#A84.I?KMQ7LJD9X[0_GY3T*A>&'(E. ,G+,1M,PI M)I>YDJTK #\ YUCQGA;*?HP_.PJ]EY)0ZZ.E/[PR+;M ZRFT\P"LX\1VFJGP MT:5E/_D?F"(Q1R;J01X7-"&4Y0FBMAQ"-DIXQZS UH[9P:GQ2(3G&,S81NQ] M,.)R-I]FR$GP( S:6K^&O%-O$5A.9 \974)JW1_C$4@G8(7N MJKYU6C24_2$LT9\__XSC](&\PW\OID2,+FLOZY1(C/917U/NE(3$?-$):[^^ MUB'AQS"=MZ6QN_A[./&^BV^%;C4U.N [E,VQANUD#(\]-/HH71JHXQ FR#I. M5Z*0@N:,KMT/5 MPNZCZNTRY+RH#S'\5'?35?G5(&/42%81C9AP$?>=1UE+.6<>#8\EM+7*J&7%B)6'1@K--=C]/2^0-EY ZB\FVDVE#5M8WL M/\/H_11)$#]/)HO:&\.:!?%BG%:Q#BN+$RZ KF7RE'""%C-%:YOF3+K G&=K M1YT;N_<^\IK#5GEKI(A)/U)L:+,M^@3_\7&*L]G;-!U^G,]N(.F0-%9=>6=K MS73O(>KD@3NF2@5+2#LH]I['?^T*;2&UDTS9^64R1?K],CDM?>X[3^>>UQT^ M.:?+N-<+Z64K2NTJ0E-5%6^CB\B"TX%FK<(<.V;DW//F8Q?,$V@P2EW DH4* M2CL/0; ,L6 JR)%\RM9]#8]>,._)17TTN5$3TM?_8'XQ7A:?>G:)[R8OQF6T ML.1)I3<@!LEJE;-.8+0T]0JE X_6@7 632G!Q.9933O _!J+AFW#P#LN<<^: M["%PLE\5((F:=A=1T]@S!^710*PE/&)$&96.GGD\D>GZE54$VX>&A]/IJ20W M+:?936O0V_1\*-HU:+:U/+L;Z7"0OSSGG!9,F<1%:6P[=X>V[.Z[DO7SE_['5<^( M%?0!CX*C3P84&MKGT4KPQBM(K'C/5*C=DWN9&QT!GB][^M-3'Z[9+;!K@GDW M^1F?#6XI\TE%V?NF2QA*08!_)=1W#M8M:>73V(6/C%'1X3\"W-Q5N M([+&^8:O/P0R4?+P\N)O&$;S#RE,\6^34;5S;Z59<87!"D&V2?0<5,B"MBS! MH201HTC,J_6N'ANC?)U>=CB#<#\]3/H4XDEV7G@]G="N-O\E1??.OQ-[:K3BJR:#@P+A:V:P'R6SR(I+0+4F6%K;,)'D>U?_'&>]Y ME:Y M'+T<%C*V) :NA ;.':T*P1I:[%G-7A72"'JFB*V=G0ZP#N\W-^;(W;*-;571 M0QCOQE"_%^S2/E?6.Q%0@$U*D56@) 1I""RM )C0J5):!URZ8CN46]PS6WI1 MQ;&=X$=E=ZO.BL$@K9 )6)$,E&3U0IMUD%P.FA5N6&I?2_916,=WH5O2H>L* MM:-:>BE&?-_H;TJQ=('84W97!WC'R?%JKMJNU-E3+T>B$+23[ZQ28LXTZ^JB&?SE<^+J$;O7EBXN/T\FG99;M M*M.%V1!US)!3TJ T%@C)>' IL^@,R!*>?;PM@U0539(_%6Y!.V[I)6XA1*@B<)6V0)I%H?0#^ )SS(T@KV?=1 MT&92YK^'*1*RU9?/\!..)@N,-2=RQ=_D2_*80JW@(4%%J<$;HZ $)E-4B#JW M)DEG<.='F7[TTO PN]X[?E,O1. M%9 >J8MP_<*S]'MV%VD?>ETE07> T;#:R:U7'[Z^R8["7U??'I)K7,CD-APR M.)(TS$-Q:.IJ),#5(IX<(^,^YBASI]+;QU;@ \5*VNIO&X&UKBY%DKJXO+@" M$C@M&E8+2+59BE+*@1-"@,XB9YVYC;E3NX7'"DO=?NEA"UCL+/9)"YDUM+:7 M)7/^N 5$:B\,O1I0U)9'V43: [B%XA&5X9(+VT1YMU_Z%2IO9YF=Y"6-FS;M MQSC#[?;VPY_F[B"5M7/=;!A#)X721:G E>?%9A6-3LF@UEVO9W0#TOL);^91 M8!2N]B1GM9(E0G"T4&G#%4TCK14_6%3O9>\GO'^=UHL!7G.7G?200Z!U.=6. M[%9%,,(PFYPIPK>NV_XPHA-R'7=C1N< YO8*Z*=\ZN7%Y2C,,3_#CU-,P^5U M/Z3%;R'V<7YR,9G.A_^S^/F]@QEDEZ73PH(,5M X:H%)YCR8:+WV#%7)K1L/ MM<)^=I0[BE(/>13S&\X'9,M8E;D!9ZM%F4A4+O( 3+*HHPADF+0N&/40GK,C M43/A]WICXY&P#^/1JZ 3>*UJF>-2:RSE#%(%YS(37'>K#WK>B2C[T*0757Q- MB2A>)Z*^$9!-L:!8MB2\5*OM&Q,8TR:9@ZU#7U$BRE9TV"$191NU'"F+H O$ M[XDH>ZIVAW2"7?1R) I%GTU"Q\&4&M]Q*=4FI!Y\8IR[%&+[BXA?KD%TT@CD,"J*I5VJ+HX4V!@[2AA1\+"&7UN[8S=M/R!;>53F3 M)I+MP6'OEMPBM40NB.BRQ%S#[1RB2!R8QJ(DUYJ7[\E&39C17A\]+ P/);PH M*;GU3('-@EPY;@H$GC4X;4HMO..D:AWU_.J2C?8A2"O9W^M&'_5@Y(QRF;".)M6,4YDJ1GDBFN5=<"R<++S:))&7( MY(1W/49Y!,+NMV0W//DF>B $C83P@R>T9%0%!%>S>[/EC'ZNF?3J$:4_]HZ] MXT4XJL_[*](\#*,:_LP71(K9HE?2)WS^QT!IAZ89&M42TO:Y 6" M#R9K99Q/V/I.23=DAUL5FVK[3JRHO1H:UWG<,/1EN,)K]%+47#[/:@*+C^"9 MHV$'YT4*.G#VV,KVT//[#@;VHM9F CN5<-]O87XYQ5?EBHC+S"7CI:IW++W. MB<@H23"&>^ EI:)8X3H]5(1EIT+W=V$<.IS73K7K%>KW%'$O)9[GM/=?O*9_ M)GFQ8?XVF3\9U3^DT:ZJC'3 V%M)\,?Q'2=8M[TDQ.T M?P4%*F(&K[($HS"+$A4:UCJ[XGAL>20^=Q2R;*. /FYS7"VA3VZ6T"O/SR.+ MY/P[X$K3?FL4[;Q(WPH5$K=*6:LZ9?]N8VK>!^881:9;ZV[=TFPB^ -7H7F2 M_OMR.%L\CS O2Y_1%R^'(0Y']&-<%$(KDVDMBOXDY^4G1R_&]*.+JPR/7=WN M=N]NZ7KW))$U]UMK$:VWPFGOE"S&"X;1"9=R2E*9-&@'8]_8[XP,]MGL%IX; M"][+9&+B!FJ3.%!%.@B1)XBN6*.50+?NH30(^=Z/9^_3K_!Y$4!]-UD\?8JK ME^%LF3C'-/-!)EH42O583#"T4-1D%":*D%8YZUHW>7\,T^$7TF:,N'/:U5+\ MO1R#+.$\G5S$X7@QQYY.R!"AIR^^>3<-XUG!Z1070=?YY\66@[33O)C-+K&6 MDZQ?+*M)%IL2.3603(W".OK'^1IYH"'$S W'V/ZPI!G\,R+=L93:A^4WGZ1_ M+U$]NYS6(.W"UGG[(1#>6X*;#;@NS#CM(/G:U8272!-)%B"(5C/:H9V.K2W! MKN#.B%O]**2/W,:*Z/5TF' 0>,E:2P$YR@#*6P1O"H.4([/,,&]M\WCT]=O/ M2?>[B?2N0#.&1&DE=#O\L'L7O6H>WTY31_"#&^2)9_D?UW.Y@O;?,"U],9GLK/XXNY]JEG9]811\VRT M<-JZUIM7)V!G0)O^%+&!+GMU@-E [M?3R:?A;/T,[T550AC=CS[A>J<>; ML?QS,OUWS;L-'X?S,!HH'ATKS($4G(,2OMYW-!9,U,+SP$K48;>%IQG&,R#; M2:EQ S]WC@FW']@S7 :OWH4_EN?8 R=X"DQ&L)*DKB3Y'8[14&G_EH9<#H&E M2_IVSS"_L[2Y,C<0=>?X=ONQ+:*K5Z/*TO+@R'R(N;8P-M+6H+V"6KVL%&5H M&J:#4_06P._D;*C #;3<.TC^2U4(CFI'R?6VQJM(#!^0D\R1[%;PKK:R8RAI MD1<(1LB4A/=1-D^@Z8+K#,C5FQHV<&7O:/B&T:^,U\41XC)-L?YX9=O6C-8: MV*-E^!GFRS1?#.NBSHU!B='$H.OE%55[_#@!ONB:YNIX\HH,6]\ZS[/I ,Z( M?<=3[ ::[ARD?R!FAM:X12DO201*1-@$Q MN.2:MRCLCNX,F=18)1O8L]>9PF^753ZORMO+.!OF89@.<39@WD1F+8)$ZVK9 M!P:QU-ADSE8F9,R7V,'OW/3L,]!P$[%M2*#C?\Y)=_DV>3W\<#EI(V. JS/F7CH M#41&M PI6S3>VQ)8![4W@'(F+#FT4C:0:N^$[DYCV 2#JFL#S_9.__X"^(MQ&EW6DE(;X7]Q\CI(&9,6 M!B%Z*4!YE< ;B9!J1!BU]RZTKD.Z*]9SY5E?ZMK L[TST3M-D#HYZB1Y-5Y] M?)"2DJQH!S9X)-RB0$!KP!4OE8Q,DU]YC.7L+M1S95E/RMI LKWC[COB?CLG M*V!QAE 6)POXO%[8G=7HV\OA;#[0FM?^G ;R\F8X=Q!%X> 3E]P)C&02G 8' M'QG)=XJV5/4&!N]]&G!3SWJ#Y&8_?[[UW;(X3D"N0P@%(F<$6"&M\(P)\,HQ M[XPTEK>.=%7=NP:E./7F.]#_8]'0K=60P_WBS?!6D9A5^53N@#LJ6+5H^".4ZZJ MB2H[T&-_/1R%,!)3LM(5\)G5&_,T&4.*#K07GAP2;3AO;=D?B2B/5*HZ#D^V M$7]#?M3XW#_#Z#T!H;5S,IG/GHQ&PS!.2/;8ZLN_81C-/Z0P7?65C"&R(!*" MT;)&29B!X# #LRS4RVLNNBX7P+9^\4D8S/LH;G(HJ3?[^\\=5 MR6NO@RO:6IH_(0)MQ:66D?0@C'0\D97/T;5ESH-X#EM9MV>5[T:N=OKJ8=OZ MPJU\.@JSV:+\]?6:;)D646<-S%?_T#(.T3@)1O)2]>;=)OE]'"V6+. MB((TUFB QA] $5;P4EO(O*01#0-V'+M%-)#P7#KK!<39 N8'JR M6KX _G8PN%RO51:.VRYYQ=W>]K6JN =9]K%(7\;9[37))Z432Z'V>*P7L$6& MH)V'DD4HR&(6NK7!OP;AV[#9]A![#T4X;\%9L;X#H+XLM74P1[+6]E'1_>K> M0[[]3O\K8.2D9A>SAJ(C[3[&"'"NWF31)B<7$ZWAK0/2!U+X8[9:K_K>1JR- M+;1[SV:$$)RG$D#H>A[,!(=@::,.I03+N-:B4W&?TSGKW%/LD\8R.^GV.\NJ M!5_\^E#==QYX]?&:[W25QUKO'5Y0*)F=1"7)!(C.,^9J]T_+O.>^;-E[YP$4 M/;;>04D^A2RV1BMM3;,FCX,'"5(H%E74A?O65WR.VGHG13+C4Y)0HG,T7G3@ MD@R@BRJ"5@KE;>M8Q%?6>F<;1FS=>F<;\9]XZYT4HW1&*W#2U10#X<';&(!I M3T,JA4R(UMG2Y]MZ9Q_2'4NI/68Z=F_A@)Z9DAA"(.,&5"#SQ-$&!"8+)TAN M.C6_.O>U]]@X$-=V4% /Z21; .;59.:180'DM7Y5"0*\"Q$P&%/K1'+=6WY^ M%WS?)H^V4\MA&O^\P31Y/Q[^#^87F?;[81F&.^70OC1EZ7>7%YA_P_F3.)M/ M0YH/1!8\^:1!>N-J9;T(H19/<]88)1 5DZU/C'L:RGD3\^#*[B'*V7)8BR88 MXX4M\8D>XOL^/DV3080SHG3^_44/X9AKA5JQS.DS]\NMYV4RE%*0QX. M(U^':PU>!U8K*NM@$R:-!ZAMV/] OT^)"TNHA5:UGZD#'J)V/SCO1N@'S00;V?>*<)H=Z:.ZZJF4^ MT*%8E86 9)%PD*C LV)!DY<4"QF!UK?NY+IZ]W>Z[:R)QNU=6\KE%6T&ZVT< M!IZ[I)4B TMJLK=R".!DUF!0.EL=)<7K<:=A.N(\! M7K?BLRKD4B Z+FK(U4(4S($PRM6]T>=TRD'[[_0_&7;TT2"YAZ#1[5\L.P/. M7H?/BXPP$8J3/B&PJ NH9 7-;MK_0M'2Y>)S2*U]SX,.\/LT.6U.':!G=-N1 M3B]Q%7>=K0*O Z<3Y]S3B'-M@5&8!%>+$$8TSAEAG8F']JT[@_^V9\C7P9D# M=*YN..*W'R;3^3N<7CS#.!\4(TSBI(;L:LYQD('V4TZ#C<<6640%B+Y63Q(&@E<>&+U;<] M2TZ4/7VTZ&XJ]NOHPJW?+?=#V@Z%%:)&I:,'98L"5Z0'[S37R6C'V"D';N\? MV?>)8MAWEX$@E&.6<\!8Y"@L- B@-X#.INEL4S:U-=%UL9#^3X= M3H4G!VI^OH^L!YGE(!V-0D13+P=I#]$)"5Y$CED*J=DI)\S1$+[S_=B\Z+-C M>KL>\(EEST0I($QDH&*MOU$KR\?"G,@ARYP.<$:WWR#.^Z;8 17<,-WL'G]^ MUSODU_$KX5BRF8RL+%@F2RLF6@AJSQ6)W!?O70IYM[C.OM#.@(6GH+3&"6Y7 M-\3>$,#I,,VOKHQ=K?._D$AO"6\@4 BGK( L:P6ZS,F,UY:6]U)(7HQCD5WJ M,&[SSC-A36]B[B$3[(%Z*K3'ORJWH0^D947%*" (LCE4S &B]0%8=-:CB24U MK]^X#;XSH$_O:NDA=^KM?)+^O5SOGEU.:=^ES7@XR6\_A"E^4>9R0(/.-5Y6 ML[TC+7T2(:CL22+.D*"*E[9U*9'.X,Z(//THI&%B45TD.ZZ.S)!-AA)XQMIF M/B(XC_4PVQFD)3(PWZ4AUK>T^[07;!\I-EL7Q-721LV=!.9KX>H4(\2<&-"/ M10S<:I2L]=KQ-;8.WFOAZ%,II]XZV'N/MM;*%UJG:HC5>[#< V-,H%/9!NPK M#6L-RE=3I'HK]7=L';R-&H[2";8+P.^M@[=6Y=8M87?1PU$(HPRG'=5S,"Z2 M>6XT!X?2 LO,1,4"+[W=DSTP479L'=PO3[81_]%;!R_A^5=9O'!ZH_'8'!$>KPKVM M=-:*<4>,7&?.L%BA8E(>BQ-<2*%16!/$=L6X.X#9;U_ZI4H67PX_U8(O7[[@ MQEFH04:IR$^0N5Z_%Q9K^QD/L7A,*?"4Y7QC_ MQ.'[#W/,3S[A-+S'O\^P7(Y>#@L.%%?&L$AR<8OT0#)E?$D*D@J<&5ND7=^U M]Z;2/GC/D&('4U\?;7*NW>X'T"\=;JD+QXHO.59%Q#7-#YZ!2\G0*LS)-F^@ MU1G=H<)?O9.I)X6<>@",5ZLZ%P_:ZIJWICR$[ 7$'$5*TBG=6_;+R07 VBJ^ M8^AK&P4<)9+1!>#WT-?6JMPZI+&+'HY"&*>]=6350:VO2K-$6?!9T"5#9GI5H&/Y#!B M\ 4E9\&&ULTCMX!WYC9+7XKJH9[V U!O@/X6+E:3K0OQ\;I3?7= M*=9,;SU80=O"=M%CR%9""C7G*M*6[P)C-"F=,#87F7L_GD J=O<+3(.)]]&'Y<=7I?.SH\"VF^9(2^2%L"W\S!?A*-_#J/J4+[]@%A+NC_) M>0EV]&PXJ]'LRRG2QDW??)S,PNBOT\GEQQD]8G29A^/W]3.3\7PXOL3\ZN/5 M9:I;T?OLF32J:"C.T>3T-)](,AZ*=LJJ1//6MZ[6HBR;@']JE76ESVR5L.0V3A=. =AR^( PH$/I?;$ M\)I%53V(UM5E&D'_3NL&M&[&C1[Z$VXUC'LZ7*V&$G/.*F<)P<102\TJLK 4 MAV1$0)%U$LXNZXG*O,N%!2!AU;VH1'!2 M".#%,EF8E$H=T9]<0_N=S W(O \#>FCDMY4A]65T>#4";E@QA3P!$X('I90% M%VP&\G]E* 6]5ZT;)N^/^CN7FYC6^S.B8:6F'4:PL)V^:$\[J)?]H^(12( $ M'KT$+X4%4Z(,/'IMRA&C('7(Y( M"?GE9#;[*VGNU?B?T^$ M#:!\)^BFC,-#Z[B'^E7+B?*J;!-&O]HAT 1N5H,(+)$0K8=4BXG0!A)K M;40./!?DJB0OTG%)O1GW=UZWX74#5K1NBK?% +[HS;3"SJ3S-HL(F7$%*BG" M'JP&SQA-3Z5DR6%;.WA[&-\)^J@-W+-N6[>AVP+[R\GX_3KTE'/(D3/(A>:5 M"@S!1?(SF13,9)3&"MF6EAM0?&?EGJS<5[-]](3; OZJ:=<;_(3TB]4(1"F) ME2+ 82'!8:(1\&B@7FD+C L;XA&/W#:#_D[E!A9 S[TT<1MQSC>%WWHG#T+^3N?[Z'Q(+O31.*U_.2_O80MK,WFB M&;RH,@Y!0V\81FF M90BG7O)E7//":6>+(C-0FDO:XYP$'4N.F265L-=\C+N0CE7BX219]) ILZU7W0+@![J@+Q*+CCU'UHJM+N=-E#'T^JJ^1S&L[\ M\ZKBTZ1LNO<]*:^GDQ*F%V'WV_IMWMOR?GX/DEB[D9^TB(EIE6AA4J8:]:W!V7JCS=OWFA7Y9RPCK1K.T_HA:D0AD8%+\BB!):,U;UU_ M!Y&)@T67! M=.O;BAN!G!=1]I=U#Q;=]87;BL4SY8(A8S7+5.^*AP2Q2#(7N%'*:2F,;A^R MNWG_>:E[9\GV<(WYZO[I\S\^DI>#7UY#'81(!F8.'!RO=>:BUN!KNWCZ80Y> MVBQC;*SUA_"<%PN:2;Z'F[_W7M6LC+5D(1HN$W@?775*#-0<=;"T7VE)9 [- MC8J'\)P;*QI)OH<+LJL[CX,B$RIM%,AKH\NEI[U:X"5<5+[(GBTM<,I[4Z#-/NXX;?Q MJ@M9%[=H5PNUUN*;Q#B6KT+-S&E KD-@SM?P8$^>_0.PSHP-C?70PX6ZN[=' M5I[)[:P[(9"AI:V)IUH\6"BD3 MZ+K.>+QU<6+@D@M1TKAR$+1\,9]IDPL(VCOT44N;8FNEWW[_>6E[9\FVO"!U M?91\=:%@F8CU+OQQ:_VI/HNPD1B'%DR25XUUR&2E/8M6($2;DPFM"^X_ NF\ MR-!2_GW<55K?DVZ9,T9FQIT14*2NWHR3X)R*8'267)C" VL=*KH?S7FQHI'4 M^[CJ<]L^22*5J+P"KC@9M,%(B,75)$LMC+%)E3\6PR&N9:,VDUDD46I?"""ZX@U2B9*4TX]W2XNDE MMZA$W]W0Z*'W'[_-84,]3QK+NV$6PGV8KA(CNZ#:)EM]!S8<(S6]G:8>4?T> M8CX<";CRR(V)P'SU?NO59K*" W#',$F!V99.MN6)*?^>-/-#ZWX;Z?:0?K1Y MTWP]'5Z$Z>>?<4S"3D/Z\BJ+.6&I-?,4L,)) "J0(<24@!!XB=F+&'/K8@?; M(3R<(=I2KY.#*>4D4LMO[I*]&)?)].*JG$+;//('7])_TGCW,:YEB"LFR:\( MHH0B%(O&V<0=*FZ+]BR%< \['GQ?O^G@,03)M2A@B(>@8E'@:KZ,(3BXO)^.U\DOX]X-S6S$$.BM=# M)+8HC> 3R(3&.V,S+[E]=M;#H$[/"=^&&1M2M!KJH(?4[=KS\%590'E-'@9Y M8N$]_>#5[V.-92%4/ ZZY4N1K0O$Z@[*$-<9(THF^2&,Q M&MWZ#M_6(,^+1/WJJ =[[#' 3PH)Z3;>XDW2B+3;LUK- J,#Q[4&C4$)EX0+ MS1L;;8OQVZ+47AKJ(?6\:TA#2N6+,PYL=@J4R0P\)]1:,9H*P2:)K7?QKRR MN!=K>M#"L0.(&8>#E_@^C*XLT.HA9Q%"B1AI)[:"?!%;9105Y!09BEAX4 ^E M,,XP_>G]Y--/].@E@>B+&]YL>.&I!PJWTN>DC5P;;DL5RA+%E5O;!4>'B.#C M>K[]UL-&__86_Z2A[/K4I?-2)(,9N+%D1#/ZQ\G:GI0,9U,PRY(>RD4\!1W> M$\3K387;B*RAZFJAU>LKWL-ZE35>#O-D&C+2C_/E?#+[I?XNX>5\F":SMW]Z M\J>KX)#7K+"4(Q29??64&,3$(GB;N%?<)N'7#G(VEL[=[>V'L_SVT]3DH&)N MZ(L^&*U. 6V1/$&.-M7;;<1]U+)>:TI9U\X1N5-*P)F>X>VR-3>3=T-#_Y% M=!=4W]H9WE::ZG:.LXN8#W>&I[W&E+@%G>H1@1 >HF=U2731">6RZ!:N/#'E M[W*&UX/NMY'N\<_P3#+&9B;)_'$2E T&8N0:7$QHDW$QYM85#[_2,[RM]+K? M&=XV2FEL/]Q$KA;ETRR/*CH$ICW69MBU.W#@8(*TAD499>I4@N*1E>*+EYZK MI;"[9!L6&_@"R*KJ80N04B"71YD$:*VF MS4T9@H0%@J@_()?'->>92]LK#U\@J -*I'K&4@8 M0+N6--9CY&XMVOI5.O=[*VM__WX;23?'3AQ<>: M@%JLN[H/W6Z9A$QWV$(3K@OV7R12'[\=?;CA# M^L-ZFW081@,;O<>2!7FS+I/P&,F-L0BN6C&ZQ,*:%_EO@?M;YF-3G?:0_M5E M#/3#MSB?+]."9@,R+*1.@2!B8/7*:XUXUN-RJU@B)\@$TSI O#W*;YES>^BK MARJF71 __1#&[^D#S\>A%N%>V0P1E9<^95JI&:]-KRR$(@.DPF164J))K9-7 M=T?[+3.N@?X:5DKM*I]GF"\7.;C_G$SG'T8XF]U.VZ7'")YB<*!9C>DP)\!; MFC=%YOWV2YBNXR68;%,N N=00 M(:I:5GIQ,5RCP"Q,$(WHM/;J;Y4_^VB@AZ*N72 OBY'F?UW.YLO-6UF9=+T8 M*I?=\+P'CS$"9SD+:UW4\1C&UCK.T-K'M97SL>S\KGE\/ZLGE_,-DNDJT M5R%[9T."7.K=7",RN%@,6*.R830>J5K7B-B,Y-!I13UJ?&/#Y[TDWTLKHW54 M5V>Z77#UU/3V/DS'Z77;0F^/4F$/H1^2%$4FFBK2@'2*^)\+&5%..O+NB/O, M>9[6,QB^,C(\TL?VD%S81M8]<. J1OZT5F6_SGC53#$4C+Q[4>J-F5* [&8R MHBUGRG@MC&N]36S"@C%/9VVP 3:EE& /9 M4D4*P.2TWJ(TEM@ M3 E!5G9U>GI?]E=HOB4+<2<-]' @N1G9RFCI@.U@EN(-KE.Q%G?382=J[*& M@RT@J])ZP:I:(@UX4O4ZAB@0.$T\%6P0S'.IFU]@.CPYMK8>^^?&-G+O@1-_ MP^FOX5^TV7V>O<%/.+ZL:4!/+V?SR<7L;[^^>7JU];GL=:Z'D(S7X*QU]4PR M&4C),&84SZEYEX1NR$[!X-A5FY/>5=%'@;;?A[/95=)B%4*^((G/YLO8ZR_O MGJRN[H>$6C-?VSZ3(+*K,5B=('D=0D8;N&_=9:D;LC,B3 ^J.%Z^?N/RI5V? MW%,V_LZ%2@TWT4:R2C62E\**3T;&:*Q7W.4LS:#K2_;LBK(\31F_?SF9S9Z& MZ?0SO>#W,,VSF_A]*DDK'0IH*22H6@#&"94A^B)\ 8"Y!5\8I6X<":'P%V G;XU:TU4^[K']1. M'SULBC=>YY>I.,/9Q\ELH8!7976+:H"9:Q%HVW;<:U"$$T(%3 YI9EQ&[4QO M1SD=\)T?A7K33@_V.(%*RS-MS-='V@1]&>!X53;^?I"Y\YFL/[ Y6Y(.(@3/ M+61/HS&9^Y2:-S';!>CY<:M_?36,%M5(V?5DN%HZEU4SYJNLKT&RJ ,Q'9"G M3(ZN% 1-1A!DD(:L)*KUEE<;\Q(>>'_.H[6/\11I?+N\FCT>3WVB!B(%-D7C@'E@<#RA8'WIIJN!#GLPR, M9=\W@>["^@9XLZDB37HQ\8="^QW'ZO&CS'D:OIY-/PWK$,F I\^)0@=:F M9G$G!L[0,BES8IZC*4DT[YCZ,*3SHTE+'33,?UYG\3U6\2 &],&*>JF2D35< M[6)/PP8IM5;6JLA$ZZ.!1R"='T5:ZN N1?S>3;?O'?[ 9%&DMQG,HK%'$9$L M9*PU17T@>\N07=6Z:L3]:,Z/&(TDOR'RM5W[)&Z'\?P8U*N6-M#J(.4T MWGX(4_PYS# _G5Q4:VGQT^=_))S-Z ^N3*>K ?&4K);534?.:;/4A6QL$\ ( MVC>3\;7(=6/:M1[#^='RJ%K>0-N=@[8;(LFOPS#_AO.!53R5ZO +(0E2B@BQ M<)I362(FYHH.K;VGNRC.CSI[2GJ#\O>.\?Y]G*_*Z=8B^F$ZIM'/7I6K2REO M+^-LF(=A.L39 'WQW$5"Z61MVHH18FW?6EB.02AN0VY=XJP[NO,C2T^:V4"B MG<.[U078"'.R">9K<@G"&,?ST>EU[PC@?^AQ:)QOXM'/\=XE]2EOI^_'P?Q9VWM56.:.E>]7.:#$ VK=I,BU3HE>Q3LUTCMZ0$6>UIS%Y04MP M]*"59(&1GZMPHZW\#EO4\A'CB37:0(YV),":D *S4UPW %OG@)6:@H>$XJZ$Z-YIKD M/ARD:N#QTQZVE_QI50I<(E$DR)Y8II)S85E?+U09:,# MA[Y'=JP&J4VYN/$8XZ0XT<\EN>Z ;UVV[P*[IT(X.T(^9HV)$O@9+ @+?-2H8A,MZ[2XQZ!\4X&YN;IO;Y66'=WD.HK9)GS+OL^S!W7I9TF>IZM6XK$G+*I@,7I#3E97T*EFM M+;:^,G0Z%0D/9^GM+?M#UR+L@NU[+<(M=;A-O;E=%'#H6H39&M,TIHP5D*3Q97[E>I!<6 M;+;.6GX1DK&04@G9Y8*$GB>[]L<1EF2TL:E=0EDG642K6D]:*8AB-P2N>8 \:L M.DUD>ORM24S?W4S@S6\^IUV_@6P;UKNZB^8=_<45E;M@VF9GWTKO-S@.NY^W MT,^]JMY3N W7Z >Q96.LLE("+7$%5%21?"',H(NGA8@92R[U5Z?P>_;I0^E[ M&YDVWHM??1Q.AOEE^'UV.9PO4\CK_9@KG+-5=-Q%5"8*LC^*H1&S"%&X N@S M*[P898/IL#EW>MGA=NMV.IGT*="#'#_JZSU-+B$Z(4#S$(W4 MRHK<6R'+H[;&/,XQP]8R[Z'\X;U-O[K@^I:;8FZEMZZ-$'<1^B&;8C*N;'2E MNANT=BDIR0^-/A)2$4O1)D;W+3;%[(4+V\BZCX#-QL9].7K&DI @:1LD4('V MK=K+R0;IF8PEDO'3.EYSXMT1M])3I^Z(VPBYC[Y$->GGR3B_I$^._N_+Z7"6 MAZD*=Q5XB,I[2?9N0$<#%H9!L#H"9N>M%H4%V[I$PB.0SH0-+05_J#:YRB8E M&)$SJ&H19F5DL<7QJ%-B MM?TK=Z'V2J,UB5PDX)C4-/R$.NM_H)%6%32=C+) MCJW !V)P;?6WC< :Z^U7DM3%Y?4)3A21<^; A%H3S1D$C\I!"I,?AR#;";WR&^F0TQ^DX MU.)'5\8*@;W:\HPV$F618(VVM.5Q,E@],BC6"QV3T"C6BFIO/#E]X!6'#WTT M5<6DO1SOM?OZ:;V]:DD5QOG5_ -.U_M2+0MOS(;CA;AH@ZUI?S@IJ[_;O35W MJS>W;-W=BS366GOGVG3%QFAB,4J1,1FTSEXFP8Q,-N*@%8C]]HO5TUY>%][( MF)BMQ?=BTA)421:"1_)CN-&*[.DH7>OCDSL@]MT%5P]\,QF-?EG._0&S7!?O M"VA5?!U7(,->)"B>&9\M+?>RM?V\ <;A5\+]-+R^Q>TKV1[.@E:0!DDGSR4B MH#:UA3,MYU$$!,UD- 6MLKGUO8_5NX^GUIT5<8]BMY)B#P;L=?/$]-^70]K! MGUU.:>V[ZL-)VVE"Y0QXOFA5))",,_I'LN X=\KJV-IZ?0C/^6A];VGW<+-X MA:W6[AQ.:X6'ZO4/1))*<<4A&:352R"M7IF&R[S)B$E'X5JW#-N,Y'RTOX>$ M>[BGM4+U;AK&LX+3V4![&VQ0BGQ_2T3D08)CQ8#TKHC,M?"Q=6'=.R#.1]N[ MR;5ATOXZH'].AW.RG5^5\@9'88[YW>1M&.&K\O,EF;\XF_V=1#W((7&TW$.* MJ8#2.D! H4!H@3ZRE*)N7<)Q*X#G0Y#V^N@A*70%]C4Y>!]JUGM*-2.!=J\G M^5^7LWE=S68#GS)'$QDHM:@!J0M$*S2$6)POK&AN6V<+=P)V/F1I)_\>VEVO M0*YR5A9U;]/GQ0HX6B2[_Y5DM]CT7,Q.>J;!\%IOTM8,EAH?TDX+0=X[(K;N M+-<=W?G0I;$F>CANN7:$A%#.)69 I-I8.:M(W#4*B+A.>55X?U;'WNF1Z0/F MR[ID7V_ZB_.Q)'6(BNRYDJMEIUDF#88$.><@"VKO?>O8SCU0#E5JMFWTHX5< M3Z6@[$W=O*M=_>WRN+<1..;CI;_@+(<4Z2&RIJG0)[2[EWU4>>>?&< M@P^<['O:X2$(7TTWCC755V#S:.H!5/[(N?"A-+Z-3T>7M M*Y\LY:@*(Y-.IZO\16^M@YQ"PE*$0M7E#NT#KSB\);N'X"?MI=;P_*/"6C26 M&8=EG=O[$=92";70(&QPLG._=.9ZJ->NWVMJ]5Q3W(\MZI M>YQ3_HT_[.]H_\'7'?(\O_NXUP[Q0Q',(G,%I2('$(.2&+7'D),('.6CA_@/ MOGG?"[!7C,+O554,YIF@YBC4U68!"0YN79PB: M.XE*DEO$1>--?1><^U\.?O"=S_^X*NA\[>MSXVM++@1?UW'EC08OE $F;4!) MFG>I]<'BMAB/<7VL9X;=O6?&UH MC(Y#L28S';DND1]O)SB-D$][LFRWX.VEM%YJ;CP(]P;L[0KD'2#W5J-E:[C' M*M_2(PVVHUPS'9X*_0BW25R#5)*\-1T(>G$". W)F^A"TJWO_I\,[1XM%'/B MK-M"=7W[7<=P:!TD_:-VCH NN M'L?^&\Z?Q-HA(,T'VEFK$QGF7M5C5))$O3$;(4AK6;'(0VSMUG1#=OC9TIPM M=XJOM%?)02?-WV=8+D9+&G"]]]_B>D\'VZ^ MM2@*NIE%%0RP=Z^^THH\@68;B99DJNA?/Y&291M9LE])^>ID+HHRME$^&?%D M9D1F',AN#A;0&1(#RX@BBF!DZ_"*+KA.BC0[Z[0S;7942!^EFS:+X=\G\[!D M(S%;LC]\K2.N6.* '!$,TSYGK8P,!]QEYYB>&5EV4$0/>0&/X'L1X_77ZWG, MZHNOX\EL^#_SYYR!-5PSIR(8J3PHM *"- YBB=843-K[UF&@VZ-\;F1JH:P> MT@\>%\H@!&0J2 3K8TV.T E!WC M;O^123VXI1$N,^9C@!@2[9ZU(4\@_QDTK1G'?*UO<#BS^@3O]-L2I/NVM9>B M#FMNK[W4Z0*WIWO\+:$>YPZ_-]5WIU@SO9T W53)3">OP=&: Q5S@9"5!,_H M)*"CP)(/^+._E19MHVZ>F#7R^OI;/PU3^;YBC56[\OPVVV\7M:2D4<* M*0E>PP$=^*P9&)&%+0&M$ZU#GAZ!CA\91LG>/"B]NXO265>Q= M":782$9F[4_GL8 KC(%T5@J>3=1L)0AB;5SLIL^_3&4WD^B!HV-_SV%6_WLS M(@?U>A[5OWOLZR,?UC*RM2OFE;A5(6Q*P64G4U),!Q>D1%I]*A;2:XJ#1SYW MWQZJ]S_TSKM+J#F/W -YY@[(=T_@E7$@E<@Z>W0AMLXFV0!EW[.F?M"[LB@N M]QKC\&HX^W%30O:W\60R_FLX^OP2O]%/9C\&0=!R<)F65M&U(.F\A H/P**W MWBGNA6R=1K<-OF-T'=V?'ZNG3F\:Z>%I[.?Y$]K\XFO-FQ]D:R5FH)]O#J=!_+ MHCC&;!!M)H=="I!1AVI+)S+3?08=BP\Y1L9%ZTYV:V!MY:JJ>2N_7S/.:7]Z64H%QV MH$W@H'+-7R_DL\A 3JK@DJ6>[TN.^5J[MUX?Y<]=5^=/4J!/05^2$(DGDQA6I";B;0_\N3!66U >%.4SD$8USIT\;!$>.+% M\U \V$;.C2OR?,C?QU??ZR7E_ KSS_'LMJ59]$I::6F7*P1*TDQ]8@P,,YYE M'H59=?/7OD]M'.#8YMZN\A^W%E[C!\<_QJ/\XP^<_"O?74@O^V9G)HHO$%.] M?#360[!H:AFY'+3!@%QUT.C& 2Y HVV$UWR-QCS\7BV1Z<=,3N1P&:Z\"I'E M:%!Q*"[,JR)+\/-T"C3>,N*<8Z[3BNTTW 5HNP_!-KQ]G3]VDP/Y=HRCWZ_S M_[X>95*6O $5F36)$PK!I*=)RPA(% 4>?$F(R8O41=L;![@ _;817L,;UPKJ MW?<\21,LJQN,-()EZ3*$I E2$@Q\L0*2X=8Q;:,TOH,^-WS\!6BSA> :7J7. MCPLRS(?+>M(KUL *RNR4944QL*)6(S=)0' F@D8KGYM,R%R+4&<\K\["$P.4J1 PS@7W&J/MTMMPT^=? M@(*;B*[AE>E:3&IY9BA"Q(R!I#6=_=)Q<#(C,"3;T)7(R!G<19WJW7K(&9DFO[,;2J2_SEIL^_1'7N(KJ'ZG1- MU6EO_3-;>.$,&%/U8B8RJ!7*M5,"\PID#I*XYIW77K<271K;BKVNGQZ (K?;AG% MB: B9%_?O)-3X#V=!>A95,S%8E9+_G73)[]XBNC7ZW.OJ:1646AX!65C' M#5$K!$ZS5"D!6FV!%=K[B8&11;:#/M7EGIX[B6Z-/O>Z3GH :GD&>%\,QIR! M"T\&MXOUBLMSX#Y'%4.VF,4N^KSC*]CRC9;&6M?Y@3JZEL]2! 1NZQC3PHFT*(7>SY,BB3TDEDX&F$^D&D\WM5:?D M4!KDWLLZ_>WN5?VQ\<\]P*:9;!N^V&S"=$/J+JBV";#90?/'"*MIIZDG5+^' MF!L^V3Z!3B$70I.]E]B\+2DBF?-)T1Y'P+ATF9E.I>1.3/D;0FD.K?MMI-M8 MY^^Q1G>_''_]AJ/ELX0(/BVSO;NCG\EYSL$ M)9U+$I%SQ6)QRA:DE6PRF<\ZVL&3G]Y/YC>SDB&W#HIEAKA7$GAI.&AM4C8" MO=>MZV^<0N8W$UY[2>M"\/D36M: C-AE0C#&R8!,-L_0.\O,[VWXL5?F]S8: MZ3WS^S><#JC?^)D6&WPFG;*!T%GFKL38)7S9(@S"7Y>]MQGEI.( M*&2_>2&;L5T&:WK11 \QX>O836?QU^%LGM&>\_WD9$T'L98:',9Y%YH*-0A( MVC-69M4X5WP+>9?"F+WWTD"R^)@..Y\R\4!),J>$VVT"VEFX/Z>,?OXPG5;^.8QW4[T8L8Z:-KX'3&V?4DOQE%.M.F^>V0-JA! M]C:'6K)"Q?I H@)Y;3Q'\";J8"(/'KM<66\]\'FKOW]9]YY;?J_PC2XJ1Y\T M6%X8*,RJ1H YX+6<=G+&FMBZIN;IEQAJ=P[L*.D>LLT_Y&_X8U[4[5WYJ.1:;:[1/-M-$XK',%Y71Z79_DWT^&\;YC M0Q:/]=$A9*4+G7"U>II",G133$4$PZ3NDI+::;#SUGX_,FT8_/DT/5^5DN-L M^/T^6%5X8(;\&^,=G6W!6?"U#!H&3B>>)<2IWX3T)P">-VGZUTG+<-,EVO>W MAV#%_>KO&3E(U\/IEZ_SUZ/I;#H(17&G> 'K9(UO%AQ"UAJ8$VA9P5;_NC^MKS9^W[9C<=IJ,X M_%9?-/_,?\\^_96OON<_QJ/9%Y(22SFP>F.?:KW7'"4X$1+MD%I(GH0LS;M( M[ 7X,OAU.)VU#.7="?U_99Q\^FL\\&2O:285[:DQTC)1"#X5!)ZM1:9UT)8? MDV@W.)\AOW;14,LHXMU!$T_R +//V9D:=,M8#6PGRT[(!(@)';F$,HG6KS:[ M(7VNU-I:2RUCFW>&_7I\/1E(%97B(4":>PV9I.4L>0U.FH#%>T^PC\VM"O29 M4FMK':UAUMY7R=NC)L]T8+DJR6L/0=; ":33W/M<34>EK0K2,M4\&F$7H,^5 M6=OJ: VS]KZBW@+UBT*.RBUP*8,7*1@P/$A0.EMPCF6.]9C6+T!1R*[F M0'MA;>:1G,YH"F^]?VP%\#(XTI].UH3+-0[.O6D$S"S+AN9LF"-,7M0N>5&! M-S6:(XB(K-^'CI.HS]XP3FYKJ9YP?79!M/2Y&."J]@ZI53[0& 4F%.1*6.5Y MOZ_FIY8^NI5>GZ[/OHU\#UF.NPNNYUJ??2N==:W+O8O #TD('QGG3C#RFQS9 MN$$(\('PR2)UM7_1QSZLB5.NS]X+#[:1<^/:SUN4P*3CL6@A))#-2RBE\>"2 M$9"0I]IT4&BWTK;C'E*XJB%+I^00K][CM]N6QY8;[9DH M0-#(0N+"@9-H0& TEBPD(7/KQDUK@9PY%=H)^4BEWSFWP:=48SS#O(-@O?_G M9 99V@NY9%*L-IJ_D-+ONR[\/@3;N/3[YNX29'%XG6P!7:UN?0FF-W_;80WH%*O[MHYUG @(G0*)06@@\/0Y]1!GZ=? M^GU7;;807.O2[QL[A41> EIF(<_KP24NP3FFP(803+&2Y=(EW>DAV%SI%UJ9SXZ" 7I.+]A=BXZ/OFQB]&HM+.%Q N!U#%>CH['('B@=A8 MDC>YB^ET#EUS&FAU#^'U7/?]MMHU-\(K0WY9*$:#4IP,=$?SS8FID.I,2Y>F M9F=0*'Q7?3817<]UWV\W#3+G/&T0CHB5.2B1,Z"B[2/ZDA3GW@4E=U#G!6VZ M3437=]WWVRTCN6Q220Q2\:'>G=#I+FG+D-Z&G.@/W>EBX@QZX#33YRZBZ[ON M^VTQ>L^RKGL#.)HAU%;U@%$DT()[&4O2.G1)P3R#.O[-MMM=1-='.LO]^E+S MMQ*RSBS+CH%D/M?G=3+0!&FK>&80"^\FVAQI,]_'<\+D+ MHIY>CQ^B.D3E>XBXA_?B-<@4,Z9X%\$JGXC;2H/GG@.+/A8KI2JK M;X-GH_0GWHC[UODVDFW\./3QW>L/K_[QX>=C*1NI7* M>:*2^.V YVZ9[2Z]AH]^MR!NF-0%1L,&$/>&/GS'AQV%OZJ^/237QUIMA?#SF(?MY!90]-H#F1147WY M.JR##8@&;,R1@! )G9 T'5Y3 :P57'5R8YY2WOU!SU!Y.\NLCT+BX]'GV4T" MWR?Z-_,=1:L2BR+/RX?@:Q\/!2$P1Z=Z%L)8$47J(T=W%<>YVSC-9-PP-F83 MIAN[O0NJGFZAUB,ZSDW4_AI[@@)[B/L F\ -.F:UU2XSX"9+4(@<@K86"@H? M<](.8^LLMT.2X(F;J4-Q8!LI]Z#[^4O(>_Q1=[E/X]]P]*_I[0.7-XDG!TH; M!31IFFN*!F)24CC,.F+K"ED;P1S^4J.%ML9]B+JQ!7=;X6W.[Y(3+X%&+F24 M$+^K*1F8A.*=,S$EFVR+[G<_#7KNQ_Q^4FP8)?D3D!N^=H'2\$IC9?C#7VOL MH8AUZMQ#BHW=Y%5(UA3&E5*06+35^Y#@T'G@JK:R$MX&WZD5U"DH])%KCG[T MN8WP&K\*_2=>U8C;T?2W\7@V77:W?C.*#QM=/_S.J\\_OBV;)IN"Y#?R:H H MFH-V'!QS#+0BCU+KHERG%X96> [KA^^ET/&1M7'@UIS'SA*_YF'G[_,/1QR\TJ^F[Z]ET1K\R''UNW#&S+R0M M&VT>1%HK_3F5XYQIXF_$HE(LZ*WR+.DP JT6V+\FZ?N9" MX"^N9U_&D^'_Y#3@T7MO40"Z9$ 9^LJC*)"EX19S#HRU+F?^")S#.TZM6;$N M";B%['M* K^!]AXG[R:+%A[_Q*OK6I%_CG: #M$(0I>LKZW!M .4Y/GI;#U: ME;*+?:2$/P'KHFG21!<]7+V\)_7FR22G]61V5AFC1()$0$!94PLPPF@G:](H$KYB'P#)BYBHJW?J> MKANR2^=+$XTTSF&_M^W]39?<)K?3\:?)_CU;DM;-"'D@RRC MSHHQH"E+.OF2)G(R!"V+$]PAE[YUP'%':)=#F3YUTD-OT)]F?G,41A(-[7:# M$G)!1M,/O!100C)PD>QJICROU<>C-*$Q71Z!39;5&&=#E26Y&H1RBAJRKJS9"DYER%':7E0R6L>.I@B6PY[.;SH6^8-RP0\ M?AQ^R%6.];[R]ER\^YWE"'5=>V,NZ\GEZ:N_X]5URNDU29)L^V_7L_GE^+OR"B=U M0M.E57_3NCM;)7Q-V<_%U#<>C#2)(L!+3,$SS X[!4=L0;\FP"^/B8?79Q^M M4=?)9Q&&DAQC7$@ZLD.1M?2'@>""AYRYLTE'0S!;7Q)O G.H*O.]7P@WD?:I MU)V?\_BA4[F(4:RWDQG!&I=J82<.+A&M4] %I=(TT];&^&8TQPKN:J3MU1.P MC=1[>$M8C^PVS/AI;#U%=3^&ZSBQW:UTV(D:>RC@T"2QQ'S#Z#3D+&E0@D6@ MP[& 2<777CU)LDX!92=-CB=BOH_!C6WDWC@6[5[)Q_40EYE.Z(K+TI'U+@0H MZ1AXS+7HLBGU BH@ZQ)JUG&XPYNK[?0S[E>XC0L;_(&U("1[%)Y$Y[D0"I+2 M'I1%!T%D 48BB]98S*5+1<8.0UV(WEL+M77'BCD\\3B\4HS.TH/4%NO[)<%3 M)H$QD14G$[K5[J^/Z/S1H2Y*Y^V$VD,PPW\>4'3E(.(-&7RM0S*8IAN?:FQ 2 M=+*_=%>245@(ME)-$H&5Y288'G,J+"%1/'"_3S+*3F#W?/I[;)@W(U+!?+"[ M-P9>? F&96"^!H5[%^IRY""L4\[G3$NT=<;*MAB;/,'_I,%!$3FFK")(42)M M9O5E128!&K5QH5B>5"]/ZS^A./SNWBL[UKZ?[R[V'A)6.DY_X0UQ'Q0/S(,O M/,.\,X%'SH$;S0QR9-H?:6$<])WRH)3I34$G\XY9P^?K!]T\_]X>$',+.YB4 MLK &XNU@(YT9]%.<>.^I'XP2LAH:H:6!%H(Y$5ME!$_U:O;]72>?T6Q[1%[/W5SB:ODC_]WHZ^WIW*Z.8U,)Q M6^M\ZEJ;#@A/TFW:1=6;"=5:3_UN1)\FA.]J'GSZ M &54&+S% I+95 O(10A&<"@RQ22]D#YU*G"\&YL>0?8,6-1*+PW?Y>9-#U;D M<(=M^F(VFPS#]:P:]K/Q>YS< 4X^)"P9P26L)[E3@$HJ,$QEJ9AVTG0)S-AI M\$OCRF&TL#'5NY\K^P]Y/AF"._LQ9S[&^ME[7+$_]8DMK\2W0K]RA6V==MK0 M<4T'01@\]>'[G00;/OWN1H@V%D^0+#"IL#XC8=16@\6_(?\/8^N@89X.3.:8BA508NU9'FJI9J3]6!@IC!'T MAVN=J;X1S(6QI8W0^[&\:S[7]$..>?A]WHGJ9WQ,UD;*0I-GD,BV"Y;P21?H MI.:%%9%4^YI;3V&Z,&XT54$?86_Q2T[75_E=V73T__;CIY_,;])11EESZ8%G M9\F41 T8T(%(ADM/_PG7N@+73D /]?35*X7Z5]&QW[QJX=J7=9GDR;'$IZ[)$[R4P)+]%!57KC+$,:+3Q@2FMO&/M:+U@&T/6XH]=:]RNX2 MY&OYX4JJ58C+=Y8.(%NVI.L*[/"5W??7X?A0"C@:6XQ0Q49-9ZN@I:$P<_"9 M,7#2<2>D$V@[.9:GS9)'RL4?B23;R/UX]>1O[\EM=E&2[86AEJAS$;SC$JP7 MDLPQGF1<"?7:MW#\43JU]:.\W6K'[R#Y7KSF+B?M?,E$CF2W<0M%UP0UYCA@ M"0%XY(DL^,)D\WCO[N@NWV;I66,].%CW\=RLJRZ(>@K,>8CF.%$Y?>GO$9KL M(?P>KF;6(-,.BT_(P 3:9)45KMX$9'!&.&>ME9*E,Z7#$Y$YQV/#-C+O@05O M1M_SE'YE^4+'4&HO(^V(6H J04"H%2UM45[65SH96]_1_HS@N)=ON^ADW$R@ MO;:/DR7SD"P",X9HFYT@(UO.Y\1,D4D(UVEMGT/[N,/>8.PNYX8%QM=U7NH" MY7(;S&VEB$<:DNTBQ9X;S/D@!0OSAN(U(,:IVMY:D[.2/5>A&*.[I?V>@D([ M-YAKI<]MA-?X0N#%74S%;_.8BIM#@CO)33#HG:(-Z'6F-/5J-!O>6(*%9:5JQ1#&!8)*I)/: M+!8*2];[@)&[QTI!3G/\7Y_'W_^-/GJQ"NF+NP6X9L#+/T[WE7+#M@T5R@+% MLM%H!QP=3M.GM7Y_U,,>HGN+?]Q0=@WWW@=XO%$F9Z] B]HS*/D"3M?<3L:9 M<\8DKA^+]#T%'6XX-WM3X38B._H]NF"HH?Q MOEY_ M?3$:7>/5_1_6"NBOB(KC'SG?Q'@.LK:!1UK$3)#9K$*V@,)+,!A8+6T:_&H! MN+7;6 ,HA[^6:\^<^[O>H;73PY/AIBG@W]VGP&L)O10#\'F9+!<](+])D#T_>NT]@D%-1V9/(9*WZ M2W:T VKEU0/KN:'^1;V?=-6[N^@3J*J1)KM_%R8_[O_3//*WM M2FD&PW$:8+:T-A*"B(F$)P.)S&4'T26,F%1QJ_V"MS'XM@-S2=PZCH9Z:"*[ M81*UF]R'',>?1_/FV"'5>M@Z ;(00#%3(%B>P)82B>9)C)V 71*E^M-( MPP:R-[R?]\6N:=EY-%VDV$\F./H\]_W_B&B%Q"9QBJ=6DR5>"]][5>94\35#K.;-J6]<%P2>0ZNEQZZSVZ%ORX%&C>] M'6(87M7RBCFR%(K(($(-N$VF=N.6C":CI(K22UEZL/7W0'Q)_#N"#AMWL]T* M^4]G^Z+R;76?,7YY?7UUM>@.;QF30I#<1*9I*%8TB3$6X(@V1)$\K;+6NUP' M7)?$NJ/KK8^6N;=OXVOJ(-T)[J;^HU$B*ALU?YWMO[TE!.L"?[6Y1HOQ6ES1J[)4XD)4I'9 M.I%5P;2[+WE_J./'I337\=-^X\ZR;OPX_@2\92)5!X#K@U=V(<4Q8E=Z455W M&NPAYZ,0PBOG=&8<")!;M+8+/"+PI'W614;L:NXQ_I>O M0O<1OAY.IK-/I,=\>T__$:_(J%I6V/,)ZPY(($VDDS;.JP TZ43\<\,Y'_^W' MW:^\QQ_U6R_^PDFZ<]R<=V)>:A-=K;PILB:*2@Z:A>S(CFESOQ?J)AV\ M=T'PYW5=U[3*YQ<<+[Z3#JO#\GH\^7?ZM[.!1Z%UC3-2*&B9>U[CC+@';E12 MQ:!]/,W@H-)\8BY'ZBE[.#:O;2]^;%+T$'RV\[SF?WS(_WT]G YG^6.>?!_& MO'A;Y0.1;7%6<'HN M874NK_[^-IS@3835//I%&\L"(K L;$W]R$#.B(=:RML%H9S)O;"X!?CG2>&# MJ[UA7-W>8IF]N9K/2#G7^P]]QEE_C$=<*I$]M-N\SK^5'X MU,C20TSCSB;3S1RKW9_3;UYWA>ZBZOW%4.;&:%DT"!>V] %>D -?F]M==VM"Y* MK5I']O8TE5]4/P(E>@C27+ZTWMPOKA?R+?;YA*;ST^G^SVM&QY_CV7_E>WD= M]\RZZ<"H8CFYRL!,)L._AN+[DLF8;@F_-Z= MF:[FOT.@UDYOZ:%P;YR)N1# N1RCK172:TYYB%+;F MT>1X+X.+KM=O1M/9Y'K>VG->DN;3%QRMM:/F"^[NPL49=$S5.H "1;UUT> # M=Q!L1IAQ#! M"_JK,U(X$:/0LG7-[X--[M=J.0G:K%D@>[]J]F:E#:(HCDND@S/YVJU>)))_ M;3T39!+111^:!USU-IEGMP!.@Q9K"+_W,VAO,[NYF!I/;KY5?X\/E!56,5V@ MV!K6G&OU'F89!&F$#UI@,JVO<0X[PU]+XW0(M&:][/\(NNMEUOT0G@_UI7=Z MUW1[('QM7^\5,"G);?>"U: TA,1+P$VAT^_O&@'PJS50CDH6%^*12[DJ0<+ULGD@Z&?-*?K3P".G_1^ M4 ZL7D;NK(MC!&IO%,3=-$:IQN7<:SW:94X]M4CL8S[':;*X!TVVO=/@]SPM5+Y*3F?;"R1A!TR%"/E_1$*(TP&-0G.R;K&270@)/ M#'."ODOO>ASWHX0><@-OKQGN7KMO@#D6G)2B@$%E:]23 B<5)U,XR<*2Y-JW MMMDV@GG&'&JKJ,8[S)_C94G>9;\95$)Q3EMO,+JF ;H,:!,A0B9S8L4_R']> MNZ<\^.!GS(#]!=U+G_):W33.;N)D_D':F'[X^(\E.,FE2)Y#\EK78AS MCC&XNNJ6@_4'/ M4'D[RZR'2^CY,5Z3V.=;B#T]#"V N6(;UJ[*6>3FO>0;)\[P;)Y>RA>D!<'ML0: MXN)J[(*/(!U3OJ!@'%NG5AQ$T5T>@7K1\S8";7R[.B]50MO59#B>?!J_'DXC M7I'T^C6X;>U5Z^.C'/[>8R\%C'N1 M7N-:SC?(WHQN08FE61'J2>08\!!T[8^2 5&*VDX#.=:(??94Q=U'!SA[;>XI MLY,HL7P;M+ON2K9UJ>5.@_5?EG<8]>@EF(WGD&6D'8BI5;R*"=YY!C*B$8]*KJ!L?VONC/H.N20GSV6R$]!#D4$6:Y@)K'DQU /-[==".LI"VH-@ MIU0U^\EYDA9*'OXT54S9.(ET^&*M/!08^)0%Q. B#Y)EG4^FX<_VT_NUG(ZR MG/:C61]5M0]FS%KMC6#2@"%?%A2/!APZ^D-$E+4KBG<7XB^=I!:>K.]^?_$P MC=QGP\''1/92X P1_+>;37,Q]U3?>07?-DD%X#"@$SR!$#2C5];(I!@N: M&\4#:E?DK]J*1[[3.XJR3[.V(LJ:1^H32)O([A'R2436H60,UI&^M9H@K)9.I]-Y((3 Y[*)7MTX*,GDRD9A2K> K.N@)(I M@6M&R(]NV2RF*+PRA1 M )4X1XP< /)&QY8<4ZI\PFAO)AD MLFV8?^1DLFT(=-;)9,P)GP)*X$XXLAEK7+6HS;AJ^@]MN5C$&4;Z/)-DLJU8 M>K1DLFTH=L8A.8-"DXD6:79%U4('*8 WF@&7,A@I8S'\?')@GEDRV6FNI#T( M=L;A, /!4S UAH_X7AV]V@PU88 LC"E)&$L>P=DLI&>63'::"VD/@IUC*,J] MJ<9@O Q9D0)DHL-7!PB:T5\#3SX7FP66LUE+SR^9[#27TWXT.\_ D-O*"#IS MQP04&6TMH9[,2OB7JCX%GYOEL$S.7$;? AT= M6C^?PK MF>PB%G.?'#['&[QNZ3C&%(!LE!2=8D$:1*^GP2N\\QF8P6D8S9&1#" M5048M8B9+L&%X%.)EC4O#O8,D\GVNM,[BK)/,YG,"6%3R;4PLU;U^4$ >E_W MBZ!M<$64;KW@GF\RV58<>#29;!M=G$LR3IYT/_N1W,KS=*IGLY&B[C6I[H.NF[NI9 M2^F]S^ P(%DV6H++TH%QM;^Z]FA*:P-R Y03=(I[U_.XO9(.G#KV-G_&JS]P M-LN3*8Y(D*/9D*0WBL.\1XI8ET]MF0JV]2Q64KY4(4U$Z7@*J&(J7D@5D4&\BKPH+X1LG:*\ M&W<7":?"B%VD(6C,R#DFI:+M+> M&I23/#!K7<\468/J4BFRKP(:][U]#!V=P)$.^0$!,MP5XBT3!,H9!UXC ZN$ MIU/7)K&:Y;JV4VJ'HZ7V(M(<'[!6(O^-7_)RG\+[/C36HSIX?/2F@X;/HG,'50%LPMEKY-\;^ISSY.IAW M]5:L6M\F !U=@;8JI0'1J%P2II1,E[U@XPAGK^*& NSAI6R%>"]BG%SCU?O) M^/NP7BP,HM=%1T$'D#61/+9D:F57";*X)&-BUL76 25/0#I[0O0A^H?,T/TP MX\7L)4XF/^B;BUW),S)5A"8_WHE<>W=Y< 4S1!2I&&MR[[;B>F 7SI)]U/"0 M*Z8?KOP$\>7U9%(MG:1#5LQGD"[0?H>& QI&HC%*8G&>R="ZPF=W=!?.FKT5 M\I Z=F_JD( _S^\6/^1IGGS/?XY'\09:%%YD[@(83+YV]_* /!;007G/A8RT M,[;FRF8XET..1B)_R ;7=B.A&2\>=IV)V:"*8%*N;=Z2@Y!KN*_PM/,)@ZB: M$V$MDD.%91QD6]A)O,>.G9A.9O<(_!*GBRGF :D+IFUB&+92 M]QV.P\8>M-#/1E7O*=Q#*1Y9+#+F!%B*(2M%1PA"6S#*^L*5<=RU7]]]*WS# MH_VA]+V-3!M?,_]!%!JFX:(DZ!W %Z,T#SS]D*]P7BF4_GPYOI[<^Y6;5]_ MG)':9O#*5NQ&$78N Z=]<1S.)FRGR?&1U-#P,:MB?_=M M.!ZFM_C7]'HXJ^_&;^81RC?XEM$!WDI>4LF0K3*U;G($GQT#J0VWLF 0R7?@ M2:?!SIP,[07:<--(>;BX17U%)L_LQWQ#3!A"=-*#98DLX8B*/%?'(97D"@JI MO7DL/&>:X__Z//[^;_31BR.!OK@[#=8,> &FWKYB;/CV5*$L4-SPM@N.#K;= MTVJ]/^IA+;F]Q3]N*+O&J_,G/#+:8&)A($22H%)-8:IY3#9@L"%+AEF>N XW M&&>]J7 ;D36VQCZ1"O);G'RF[?[/^6Z/5[_/K8)P3?]JN?4G91WGFH,HBA!* M)6B:"<%&%0FN8U:Y#F=IM]$.=YCNIXEQKV+L(P#HUFZH=MWU=,[@D T/&A/D M6!/H#6> UEI(40=,QEFSJMJ&-ZUW."[@A&TFYAY2FU$D/6(SI. M:L?^&GN" GN(NX>@]PWH7')!AIJFZG.@S2];\-:1"^%=EEI''D3K+(M#DN") M/(E#<6 ;*?>2\#"/2WW@SI?(331:@S?S,#1R[$.2$526!FU,'$7K%,0-4([P MV-9 4P]2%O872]D[J MM6,1<9A'IFDA/(^6)\->\QHWRG! M:CV4B]!^"S%O7/O])*S\=CT=CO)T^G'Q1O=F-,^XF4L^I>'"HKWWS=US6'8< MJ&5:2XNYKF2Z:.<".FFY%ZB2=5 OW MW@!O;U^5;=3HI;9TLC$BNI UB3\:.N-,(CS) MP\^C1;QE_/%I@J,IQ@ISN2)^RR2E_ G_'B@6A2ED$1:/KMXDN_IVYX%KBPRE MT\ZT#K?? MX%\JDOY33.P%G6YZH/L@N!?,TXO9[,8^J62 <\(P]2&1!:L;J1 M%G A"'"TC7+N@G*!/6&8=Q[L@KC0CX ;)NM4@*^'(QQ%FC;M?7GXO=I3;[Y^ MP^&D GSY9?[J,+#::ADP K-&@S(.P;%")VDR F/P(<30@0!=QKHP_3<7;P\9 M.?<*96T6Q6\_;GZX>,(PRB=> AUV(B*H%!!"+ 58=N2:*E^L:MX#*CAU]O9SGPNB:!X;5CWM;_T'55[TNUXG5)^\(*1D/"K.&($F2C&NA MA?#,E-8VS"-P3J"J73],&/>CD1X81LIL9N]-A# M!P.39H' M(B_051/\SSR[?41C$I6FU3KQ"/??[A[=N&*A@W MEM^!ZZ9M?B:Y/4N_Y]%U[N/]:?T(AWEXZC"[E14-.0GMG:YEF.?J%.^C<97#Z:=Q-I'T,0.]CR+ M.DIC3=VI+2C:40&#X\"T0"\"6?/FE_/=CBI]J^C8SG?-^GDY'DW'5\,TG\M< M9'/3CSS'*(O7(*,GT\^Q")Y, M ^1:]X1BDZ)<@_D1ZY?O1SXJ=P; MI\H^1'1C*7;!U#!'>A..P^=(M]#1HRK?0\"'4G[B6A95R):WF:SZ'!SXG!!$ M(&)[R15+G4I6GY32'\F3/I3.MY%K#S9!T2V;2@\5U- M#Z1Y(T?"9&N')$RN_4/W"H1G8[;M(?D>\O/OP;DA?A= ?1EKJV".9+#MHZ+- MZMY#OOWN $O_5W%U-:Q=(N_LO66GR)*Y$EB 9F-K!QU-6XD+4+@J5@=1 MY]I%=QL^_ZPUV$)F#:^N;B/7-AOM7'"':"1M!(889FLY7&XE:*4,4ZR85+JL MQ,='.6>=-I3?1EOW2/%_MR\U-\F?_<4!;ACIH/& 76:[$A=H33%!"M*O<4H; MY;05Q@@M&&V]DNFGXP(W#'J(^,!BK#3D?N<4:,LQM;K 'RU5OG MCQPB/G!%H/-\0L6Y(A45D+F^+-9>#DXIA(119^TM5_T]W][!.-6HP2UXL/$I M=T=A]_",^WO^-LEQ>%/8A;:FN8A'Z<77*H/_F7]_D&*A$S=[FFDB8XG7I^92 M(D34'K5TBMO6W.^"ZP(9TEP=?41]U!/\/M!5?%I*D;()1.E$E%;!0Y V0O:< MN6B#TK%U#9NG,%T@59JJH8?WW9MVDM-/XQ?QOZ^'D_Q^,J;];_;C_16.9@2V M)K=_J[\RB$$P)ZT!DPPCH\\R")P$(FNA%1GHF[%UG=?NZ"Z0.CVIIH^[YQVN MWLDES%ZF#+K4EK0\UE;FIFZ/DI=8>+:A]?9S]O'M>Y"I;Q6=<'P[STYRZ>GX MC5* $JDF?T0'T1O,R6OTNM.^=?'Q[5OI^^GX]FWD?J@0YRZ8GE-\^U8ZZA+K MO(N #Z7\R&T)Q2HHTA"_:QD>%PM97LI(SF3Q+O23Z'):\>W-=;Z-7 \8W^Z# MTT;+FNM<-"@I-02=R!_SL:@H0D[-XUE/.[Y]*SUUC&_?1L@]7(S\@;,\&>)5 M+>HWBL.K>K[5&=^^_]FBG""J2T10*"SA)-N)!2EX+9@=1>N&T8\CN@ F-!3Y MP4/<.3/";/%0].,B6:![%>2HC[+M9A>ZWT'N+>!0]QS4MX[D8%E6D8J&#*,"NV*MK;J2"[8+)O'39UXB'L[ MC6\CW .&N-= !!.%!)ND!U6X@5"[*BCG$Q8KBDA=RIZ><(C[5H+O&.*^C=2. M$^*>!:^U'P(Q59.34\-[D24-DKM$QH^UQG?I-W<>(>Z[JK@'69Y,TY%;\W3^ MM_'2T%EYW)V-%_]_31)>-'&[II_=_!))H(_HD+;(#A--TJ,T'U:E\E9HY 7) M&\G8!HE:A)SD'5.H$S@X&VR9*:%7&PI#'WK M_.MC1:ND(KDQ,D 0M0)3D!F"R@Q20N=R23GFUI[X^42K;,.#+M$JVPB[QQXI M-RW@/XWO-1Q>3<*4Q(SH!NT". MM%=(+P53'VS>OWWW(TSSYGM_3435.BQ+J@Q(SRU$C9&=#S>9 H%,W MDY5C@PJA^%3:5ZMX'-,%8EF>#-A"I10ZQB"*Z,@;,A$\TP58T-;95&H_QE]Q M']HR+@7MA8R.3/*6?0'GR%LF.M?G M%6<!&S*J"'QN/TU_#JZJZ#T,*ETR95OPT<-V2<"TR T32P@!Z.9[.:'>*@IE2$+B71,HL"@03$PCA"U,^AZ*Z=&E; M_=P+4N;>8GNH0M_"5/CXY7J6QG_= ")O.66T"G3R"E0M-XN>\5J:*)>$-F;1 MY7UJ[8=?F#+W%^":VZJ]WB#_S'_]UWCRK_G3^;MOP_$P?9SEOW"2IE^&WU[$ MV8TM,5!,2$<>*RA=*NMX 62JVA."YLRDEM)W4'+'X2Y,[7T(>0T1]KZW7&-Q M+IZ5/MN>!IG9!Q#UE4JPA_]ZWL7^.1^.?'Z"6 MRY)%EX3#V@03RR+]U;F2@7,T$8VPV+P;]48P%TBP-H)?0XF]+U#G027D6?^$ MZC[C5WQ76]7#Z91Z]47[/83:0W'!O6(*D>16!)'./.;+^6.&V5O$T MV/KQ[TE0%\B6MHI80Y6]&UG?A3EL"N#Y+9-0\N+W/N'?>4KSF" !&-:7IKF, MB/\U_Y1$?S67XF*)#)S!@M+3,DA<@E+HP3MC0&OKDQ626]LZ2*7'Z5P@/4]% M^6N(O??%[RXY&3Z3$+/DY/I&@A ^T-S<.(#OS)/I]Z->W MBDXXB=X&@5:G "X;FD:4$GRB68E4"R;;$@+OIS?4N:5);:7OIY/HMY'[H?*H MNV!Z3DGT6^FH2T+U+@(^6 4%JR/CM'4F5DNF1^' 29X!B\I!*DZ'9Z?WIY-2 M^O9)],UUOHU<#YA$KX056&.'O7:U/%6-QF*!CDO/?2&#B";P?Y#:]J*>Z/7W*>_?MD?/V-B'4[[&VJ[TO\ M-G>6[[PBXXQ%;2+P5"*H( *$D .8Q# ';VT,K=O&[(MYWUUOG39NOS>/!)FN M0S9]$>C7,#N:7./WR8I3J_VJMQ^]X-9_!4J2_#Z?U5N!ZD@8.OUVQG<$4AW4+V/#Z&T'DS^M^/1YT]Y\K5>Z]_"&PBM MK"Q<@?11U/N+"#Y("U9EZ0.Z9%3KM+RU0)X9:_971@^Y5G>;]X]U,U]<>-FH M K=201"),'*/X(4G%DNNI*9=6^7^3(?-N YUZ7S< ZZU@HY] [UF8G]DK+OE MO$0-3H>+ZY=0&":%"%(I:HO7&KNT#MJ;;7%C"/4_FKJ9I7*YGWK*,>:+4&8-VN M%Y%YRQL@SXV75AI@3*2:@"; %^-J^U##R:CS$EO7,.^"ZRAUQ/KD3W-E''D? M*LE:9:RD([_&Z04F 4M0X$*F73EEK4/K8*8C[3];7A(TT^\>&] VRNG%YY], M?M#!O7AJSFDAA,UP.49MA2\0K" GLB+U!3T4D32B93KKUGO0EA /SZ?>U/W MU>]/5SUL4:^FL^'7FDU1.L@%:RD_*PQ$,A)!2:$A%,Y "4YHK?0J=@KXV()7 MV^"[7%+UIJ5^+PANO_R/89[0(%]^O,W?\]7\[*<=FT12*\Z77&.NHH/: M'RMHJVA9M#[ONB%[#DY;*\7T29][%N/T(=X; Z +V)Z\MZV 'MU_:Z;Q3:3J M35U].G*=0$O)4W*Y0)(U>L\I!ZAB N:Y=4%[VM-[VZF.QZWNKMUI4&L;+?5) MJ3>C;]>SZ5P"?-F[O-[,&TZ >.V'04XOH T&."NH3 T.$*V?3QZ! PC-HR)'%DOS(O./P'EN!-E% M"WWL( ^?&N=;J"&C/87BJ_U.T_72 Z9L0487K,P*F-D(,9%)$)1AG)K+4V@!; MC^3PMM?QM+L:_KZ_:C::[?V$O7^\#M/\W]M&M>)FU<=J(NW'CJM^'WX>)%MR;49R0ZUN+ZD?" MA)_S( LEC#,((LVK$]:2^H[._EB"GA.[C%YSDWW.\HO^E@?',,NX*6)EL+=0E #V==#K*8 NYK4*U M;D'0!=>9$Z,W%?319O3GB2]N,J((B<[<#,&C)%O=,)JT]^ P%J%-+%RWOBY> MA^-@%3KZ4/[>@CV5H.?5B= _FSMTTC#!+=?@8JZWV5Z!8]Z0NES].TCYT+=3+__CU>__ M>/OJS9M_OGC[CQ>?WKS[\\6?O_^??[QX^^;U?[WY\]]?O'SY[A]_?OJXQZW5 MEB,TOMY9R9BP)%)+I;->O'LB2X9HR(NW(@31I C;UL#VOZG_ MGA>]?.^&OKH:_U6??Z>+1CVU#>'TP_CJZO5X4HO #XJ0/BIRY#27!12+!5!* M YBB5E44HOFYMP/,PY:JZ9=1#R_Q^]5:#X$YCP.]"3@8!!53",Q"S(R$DG6! MX$3=\F6P7O.H7>N;YT[ #G^\]J[B<=_ZZ<$&>QSDHFE0^C2N;4KH^\NR[,XF MRTVNCV0BD+>:!;A"4J(CR'M6:HW(UJ$].P%][B1KH;\>;@\?!_U[3M=Q7E=@ M(+W/W IWLSAL88 BJ]K%N61:&"*DUC>*7;$]=VKMJ*4>HLVZ[;,Y0Y;PJ>U'@?-T/D_=_7 6-/#R1=\!WGK:0/_6YG\NRNG&,1*6NC(HL6' 9'>[D5 MX%/B4+(/B0PS6_# !O3QWE9.A3_;Z*0A;VK3R9W+P7>AN!S?8].FDQ'))N -ND,VK" 19.M(%7!@W0[TH7M]UR5SY\W^X)LR]YLOC(VEUJP/ M#M":^1O'.3B7 MGM;:*J^>%-*V._K-M^L? :?Y_____A]02P,$% @ O7YV552B/(?H-P M!3@ !, !A8F,M,C R,C Y,S!?9S$N9VEF17=E5!3>%^V(BK0P- C2-?30 M"$A*2PT-DD-("T@I0P_=,91T# W2C31#,W1W(R (J,S[_=_[\,ZWL\Y:=^^S M][GKWO-.14E,W#+WZ1.LWX#_%V H ( % " 8 ! 8 (("0 @ " 4 M80 0 "!D"@ @" $$!(!@ # " @0$P* "& ,!0 !@&@ 0 D& $@I (@!( M% ") : ! #08@(8"T @ &@5 8_X[&X ! S!0 8!P* F/^2_[#!8 4#$" M :C_:F 0 P"@T%0, @!!J' ( P8 @!#P& (% Q!@"$H, 0#A@' ,# 8!@7# M$& 8"@S#@)$ ,!(,1D+!2 08B0(C,6 T (P&@]%0,!H!1J/ : P8 P!CP& , M%(Q!@#$H,.8_'O^U#88"H% @I _4<+"@) 06 H" H%(: @%!2$@4( 4 @8 M"H%"(0@H! 6%8* P !0&AL*@4!@""D-!81@H$@!%@J%(*!2)@")14"0&B@9 MT6 H&@I%(Z!H%!2-@6( 4 P8BH%",0@H!@7%_"?!?XJ#$0 H H! %#_*8( M 1 @, ($18 0"! * <(@( $!(R 0!$0! *"0D P"!@ 0,C8% $#(& H1 P M# ()0"#!""04@40@D"@$$H- Q!H, (-1: 1"#0*@<8@, $!HS 0!$8! *# M0F#^4_\_L\$H !0%0* J/_,0($ *! 8!8*B0 @4"(4"85 0 H"1D&@* @" M!4&A(!@4#(""@5$P* J&0,%0*!@&A02@D& 4$HI"(E!(% J)0:$!*#08A8:B MT @4&H5"8U 8 H#1F&@* P"A4&A,)C_#<)_;OPGR7^\_BO^-PH@ 8$QH"@ M&! " T)A0!@,!("!@#$0* :"P$!0& @& P-@8& ,#(J!(3 P% :&P2 !&"08 M@X1BD @,$H5!8C!H 8-QJ"A�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�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end

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դ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�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�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end XML 108 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 109 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 110 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 298 531 1 false 108 0 false 10 false false R1.htm 0000001 - Document - Cover Sheet http://www.amerisourcebergen.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.amerisourcebergen.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 3 false false R4.htm 0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS CONSOLIDATED STATEMENTS OF OPERATIONS Statements 5 false false R6.htm 0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 6 false false R7.htm 0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Sheet http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Statements 7 false false R8.htm 0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) Statements 8 false false R9.htm 0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOW Sheet http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW CONSOLIDATED STATEMENTS OF CASH FLOW Statements 9 false false R10.htm 0000010 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 0000011 - Disclosure - Acquisition and Assets and Liabilities Held for Sale Sheet http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSale Acquisition and Assets and Liabilities Held for Sale Notes 11 false false R12.htm 0000012 - Disclosure - Variable Interest Entity Sheet http://www.amerisourcebergen.com/role/VariableInterestEntity Variable Interest Entity Notes 12 false false R13.htm 0000013 - Disclosure - Income Taxes Sheet http://www.amerisourcebergen.com/role/IncomeTaxes Income Taxes Notes 13 false false R14.htm 0000014 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 14 false false R15.htm 0000015 - Disclosure - Debt Sheet http://www.amerisourcebergen.com/role/Debt Debt Notes 15 false false R16.htm 0000016 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding Sheet http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstanding Stockholders' Equity and Weighted Average Common Shares Outstanding Notes 16 false false R17.htm 0000017 - Disclosure - Related Party Transactions Sheet http://www.amerisourcebergen.com/role/RelatedPartyTransactions Related Party Transactions Notes 17 false false R18.htm 0000018 - Disclosure - Retirement and Other Benefit Plans Sheet http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlans Retirement and Other Benefit Plans Notes 18 false false R19.htm 0000019 - Disclosure - Share-Based Compensation Sheet http://www.amerisourcebergen.com/role/ShareBasedCompensation Share-Based Compensation Notes 19 false false R20.htm 0000020 - Disclosure - Leases Sheet http://www.amerisourcebergen.com/role/Leases Leases Notes 20 false false R21.htm 0000021 - Disclosure - Acquisition, Integration, and Restructuring Expenses Sheet http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpenses Acquisition, Integration, and Restructuring Expenses Notes 21 false false R22.htm 0000022 - Disclosure - Legal Matters and Contingencies Sheet http://www.amerisourcebergen.com/role/LegalMattersandContingencies Legal Matters and Contingencies Notes 22 false false R23.htm 0000023 - Disclosure - Litigation Settlements Sheet http://www.amerisourcebergen.com/role/LitigationSettlements Litigation Settlements Notes 23 false false R24.htm 0000024 - Disclosure - Business Segment Information Sheet http://www.amerisourcebergen.com/role/BusinessSegmentInformation Business Segment Information Notes 24 false false R25.htm 0000025 - Disclosure - Fair Value of Financial Instruments Sheet http://www.amerisourcebergen.com/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 25 false false R26.htm 0000026 - Disclosure - Subsequent Events Sheet http://www.amerisourcebergen.com/role/SubsequentEvents Subsequent Events Notes 26 false false R27.htm 0000027 - Disclosure - SCHEDULE II????? VALUATION AND QUALIFYING ACCOUNTS Sheet http://www.amerisourcebergen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS SCHEDULE II????? VALUATION AND QUALIFYING ACCOUNTS Notes 27 false false R28.htm 0000028 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPolicies 28 false false R29.htm 0000029 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPolicies 29 false false R30.htm 0000030 - Disclosure - Acquisition and Assets and Liabilities Held for Sale (Tables) Sheet http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleTables Acquisition and Assets and Liabilities Held for Sale (Tables) Tables http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSale 30 false false R31.htm 0000031 - Disclosure - Variable Interest Entity (Tables) Sheet http://www.amerisourcebergen.com/role/VariableInterestEntityTables Variable Interest Entity (Tables) Tables http://www.amerisourcebergen.com/role/VariableInterestEntity 31 false false R32.htm 0000032 - Disclosure - Income Taxes (Tables) Sheet http://www.amerisourcebergen.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.amerisourcebergen.com/role/IncomeTaxes 32 false false R33.htm 0000033 - Disclosure - Goodwill and Other Intangible Assets (Tables) Sheet http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsTables Goodwill and Other Intangible Assets (Tables) Tables http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssets 33 false false R34.htm 0000034 - Disclosure - Debt (Tables) Sheet http://www.amerisourcebergen.com/role/DebtTables Debt (Tables) Tables http://www.amerisourcebergen.com/role/Debt 34 false false R35.htm 0000035 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding (Tables) Sheet http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingTables Stockholders' Equity and Weighted Average Common Shares Outstanding (Tables) Tables http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstanding 35 false false R36.htm 0000036 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.amerisourcebergen.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.amerisourcebergen.com/role/ShareBasedCompensation 36 false false R37.htm 0000037 - Disclosure - Leases (Tables) Sheet http://www.amerisourcebergen.com/role/LeasesTables Leases (Tables) Tables http://www.amerisourcebergen.com/role/Leases 37 false false R38.htm 0000038 - Disclosure - Acquisition, Integration, and Restructuring Expenses (Tables) Sheet http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpensesTables Acquisition, Integration, and Restructuring Expenses (Tables) Tables http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpenses 38 false false R39.htm 0000039 - Disclosure - Business Segment Information (Tables) Sheet http://www.amerisourcebergen.com/role/BusinessSegmentInformationTables Business Segment Information (Tables) Tables http://www.amerisourcebergen.com/role/BusinessSegmentInformation 39 false false R40.htm 0000040 - Disclosure - Summary of Significant Accounting Policies - Recently Adopted Accounting Pronouncements (Details) Sheet http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails Summary of Significant Accounting Policies - Recently Adopted Accounting Pronouncements (Details) Details 40 false false R41.htm 0000041 - Disclosure - Summary of Significant Accounting Policies - Schedule of Restricted Cash (Details) Sheet http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails Summary of Significant Accounting Policies - Schedule of Restricted Cash (Details) Details 41 false false R42.htm 0000042 - Disclosure - Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details) Sheet http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details) Details 42 false false R43.htm 0000043 - Disclosure - Summary of Significant Accounting Policies - Foreign Currency (Details) Sheet http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesForeignCurrencyDetails Summary of Significant Accounting Policies - Foreign Currency (Details) Details 43 false false R44.htm 0000044 - Disclosure - Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets (Details) Sheet http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangibleAssetsDetails Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets (Details) Details 44 false false R45.htm 0000045 - Disclosure - Summary of Significant Accounting Policies - Merchandise Inventories (Details) Sheet http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesMerchandiseInventoriesDetails Summary of Significant Accounting Policies - Merchandise Inventories (Details) Details 45 false false R46.htm 0000046 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) Sheet http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails Summary of Significant Accounting Policies - Property and Equipment (Details) Details 46 false false R47.htm 0000047 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details) Sheet http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details) Details 47 false false R48.htm 0000048 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details) Sheet http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails Summary of Significant Accounting Policies - Revenue Recognition (Details) Details 48 false false R49.htm 0000049 - Disclosure - Summary of Significant Accounting Policies - Shipping and Handling Costs (Details) Sheet http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsDetails Summary of Significant Accounting Policies - Shipping and Handling Costs (Details) Details 49 false false R50.htm 0000050 - Disclosure - Acquisition and Assets and Liabilities Held for Sale - Additional Information (Details) Sheet http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails Acquisition and Assets and Liabilities Held for Sale - Additional Information (Details) Details 50 false false R51.htm 0000051 - Disclosure - Acquisition and Assets and Liabilities Held for Sale - Assets And Liabilities (Details) Sheet http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails Acquisition and Assets and Liabilities Held for Sale - Assets And Liabilities (Details) Details 51 false false R52.htm 0000052 - Disclosure - Acquisition and Assets and Liabilities Held for Sale - Fair Value Of Intangible Assets (Details) Sheet http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleFairValueOfIntangibleAssetsDetails Acquisition and Assets and Liabilities Held for Sale - Fair Value Of Intangible Assets (Details) Details 52 false false R53.htm 0000053 - Disclosure - Acquisition and Assets and Liabilities Held for Sale - Assets and Liabilities Held for Sale (Details) Sheet http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails Acquisition and Assets and Liabilities Held for Sale - Assets and Liabilities Held for Sale (Details) Details 53 false false R54.htm 0000054 - Disclosure - Variable Interest Entity - Schedule of Assets and Liabilities of Profarma (Details) Sheet http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails Variable Interest Entity - Schedule of Assets and Liabilities of Profarma (Details) Details 54 false false R55.htm 0000055 - Disclosure - Variable Interest Entity - Additional Information (Details) Sheet http://www.amerisourcebergen.com/role/VariableInterestEntityAdditionalInformationDetails Variable Interest Entity - Additional Information (Details) Details 55 false false R56.htm 0000056 - Disclosure - Income Taxes - Domestic and Foreign Income From Continuing Operations Before Income Taxes (Details) Sheet http://www.amerisourcebergen.com/role/IncomeTaxesDomesticandForeignIncomeFromContinuingOperationsBeforeIncomeTaxesDetails Income Taxes - Domestic and Foreign Income From Continuing Operations Before Income Taxes (Details) Details 56 false false R57.htm 0000057 - Disclosure - Income Taxes - Income Tax Expense (Benefit) (Details) Sheet http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails Income Taxes - Income Tax Expense (Benefit) (Details) Details 57 false false R58.htm 0000058 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details) Sheet http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails Income Taxes - Reconciliation of Effective Income Tax Rate (Details) Details 58 false false R59.htm 0000059 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 59 false false R60.htm 0000060 - Disclosure - Income Taxes - Significant Components of Deferred Tax Liabilities (Assets) (Details) Sheet http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails Income Taxes - Significant Components of Deferred Tax Liabilities (Assets) (Details) Details 60 false false R61.htm 0000061 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) Sheet http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) Details 61 false false R62.htm 0000062 - Disclosure - Goodwill and Other Intangible Assets - Changes in Carrying Value of Goodwill (Details) Sheet http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingValueofGoodwillDetails Goodwill and Other Intangible Assets - Changes in Carrying Value of Goodwill (Details) Details 62 false false R63.htm 0000063 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Details) Sheet http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails Goodwill and Other Intangible Assets - Additional Information (Details) Details 63 false false R64.htm 0000064 - Disclosure - Goodwill and Other Intangible Assets - Other Intangible Assets (Details) Sheet http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails Goodwill and Other Intangible Assets - Other Intangible Assets (Details) Details 64 false false R65.htm 0000065 - Disclosure - Debt - Debt Instruments (Details) Sheet http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails Debt - Debt Instruments (Details) Details 65 false false R66.htm 0000066 - Disclosure - Debt - Additional Information (Details) Sheet http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails Debt - Additional Information (Details) Details 66 false false R67.htm 0000067 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding - Additional Information (Details) Sheet http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails Stockholders' Equity and Weighted Average Common Shares Outstanding - Additional Information (Details) Details 67 false false R68.htm 0000068 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Accumulated Other Comprehensive Loss (Details) Sheet http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingComponentsofAccumulatedOtherComprehensiveLossDetails Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Accumulated Other Comprehensive Loss (Details) Details 68 false false R69.htm 0000069 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Diluted Weighted Average Shares Outstanding (Details) Sheet http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingComponentsofDilutedWeightedAverageSharesOutstandingDetails Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Diluted Weighted Average Shares Outstanding (Details) Details 69 false false R70.htm 0000070 - Disclosure - Related Party Transactions (Details) Sheet http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.amerisourcebergen.com/role/RelatedPartyTransactions 70 false false R71.htm 0000071 - Disclosure - Retirement and Other Benefit Plans (Details) Sheet http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlansDetails Retirement and Other Benefit Plans (Details) Details http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlans 71 false false R72.htm 0000072 - Disclosure - Share-Based Compensation - Additional Information (Details) Sheet http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails Share-Based Compensation - Additional Information (Details) Details 72 false false R73.htm 0000073 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details) Sheet http://www.amerisourcebergen.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails Share-Based Compensation - Weighted Average Assumptions (Details) Details 73 false false R74.htm 0000074 - Disclosure - Share-Based Compensation - Stock Options (Details) Sheet http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails Share-Based Compensation - Stock Options (Details) Details 74 false false R75.htm 0000075 - Disclosure - Share-Based Compensation - Nonvested Options (Details) Sheet http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails Share-Based Compensation - Nonvested Options (Details) Details 75 false false R76.htm 0000076 - Disclosure - Share-Based Compensation - Nonvested Restricted Stock Units (Details) Sheet http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails Share-Based Compensation - Nonvested Restricted Stock Units (Details) Details 76 false false R77.htm 0000077 - Disclosure - Share-Based Compensation - Nonvested Performance Stock Units (Details) Sheet http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails Share-Based Compensation - Nonvested Performance Stock Units (Details) Details 77 false false R78.htm 0000078 - Disclosure - Leases - Lease Cost (Details) Sheet http://www.amerisourcebergen.com/role/LeasesLeaseCostDetails Leases - Lease Cost (Details) Details 78 false false R79.htm 0000079 - Disclosure - Leases - Summary of Balance Sheet Information Related to Leases (Details) Sheet http://www.amerisourcebergen.com/role/LeasesSummaryofBalanceSheetInformationRelatedtoLeasesDetails Leases - Summary of Balance Sheet Information Related to Leases (Details) Details 79 false false R80.htm 0000080 - Disclosure - Leases - Other Information (Details) Sheet http://www.amerisourcebergen.com/role/LeasesOtherInformationDetails Leases - Other Information (Details) Details 80 false false R81.htm 0000081 - Disclosure - Leases - Future Minimum Rental Payments Under Noncancelable Operating Leases (Details) Sheet http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails Leases - Future Minimum Rental Payments Under Noncancelable Operating Leases (Details) Details 81 false false R82.htm 0000082 - Disclosure - Acquisition, Integration, and Restructuring Expenses (Details) Sheet http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpensesDetails Acquisition, Integration, and Restructuring Expenses (Details) Details http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpensesTables 82 false false R83.htm 0000083 - Disclosure - Legal Matters and Contingencies (Details) Sheet http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails Legal Matters and Contingencies (Details) Details http://www.amerisourcebergen.com/role/LegalMattersandContingencies 83 false false R84.htm 0000084 - Disclosure - Litigation Settlements (Details) Sheet http://www.amerisourcebergen.com/role/LitigationSettlementsDetails Litigation Settlements (Details) Details http://www.amerisourcebergen.com/role/LitigationSettlements 84 false false R85.htm 0000085 - Disclosure - Business Segment Information - Additional Information (Details) Sheet http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails Business Segment Information - Additional Information (Details) Details 85 false false R86.htm 0000086 - Disclosure - Business Segment Information - Segment Revenue (Details) Sheet http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentRevenueDetails Business Segment Information - Segment Revenue (Details) Details 86 false false R87.htm 0000087 - Disclosure - Business Segment Information - Segment Operating Income (Details) Sheet http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentOperatingIncomeDetails Business Segment Information - Segment Operating Income (Details) Details 87 false false R88.htm 0000088 - Disclosure - Business Segment Information - Reconciliation of Segment Operating Income to Income From Continuing Operations (Details) Sheet http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails Business Segment Information - Reconciliation of Segment Operating Income to Income From Continuing Operations (Details) Details 88 false false R89.htm 0000089 - Disclosure - Fair Value of Financial Instruments (Details) Sheet http://www.amerisourcebergen.com/role/FairValueofFinancialInstrumentsDetails Fair Value of Financial Instruments (Details) Details http://www.amerisourcebergen.com/role/FairValueofFinancialInstruments 89 false false R90.htm 0000090 - Disclosure - Subsequent Events (Details) Sheet http://www.amerisourcebergen.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.amerisourcebergen.com/role/SubsequentEvents 90 false false R91.htm 0000091 - Disclosure - SCHEDULE II????? VALUATION AND QUALIFYING ACCOUNTS (Details) Sheet http://www.amerisourcebergen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails SCHEDULE II????? VALUATION AND QUALIFYING ACCOUNTS (Details) Details http://www.amerisourcebergen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS 91 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: abc:DeferredCompensationArrangementWithIndividualDiscretionarySharesPerEachFullShare - abc-20220930.htm 4 abc-20220930.htm abc-20220930.xsd abc-20220930_cal.xml abc-20220930_def.xml abc-20220930_lab.xml abc-20220930_pre.xml exhibit1023-rsuawardtoempl.htm exhibit1024-psuawardtoempl.htm exhibit21202210-k.htm exhibit23-9302022.htm exhibit311-9302022.htm exhibit312-9302022.htm exhibit32-9302022.htm abc-20220930_g1.gif http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 113 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "abc-20220930.htm": { "axisCustom": 1, "axisStandard": 41, "contextCount": 298, "dts": { "calculationLink": { "local": [ "abc-20220930_cal.xml" ] }, "definitionLink": { "local": [ "abc-20220930_def.xml" ] }, "inline": { "local": [ "abc-20220930.htm" ] }, "labelLink": { "local": [ "abc-20220930_lab.xml" ] }, "presentationLink": { "local": [ "abc-20220930_pre.xml" ] }, "schema": { "local": [ "abc-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 833, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 10, "http://www.amerisourcebergen.com/20220930": 1, "http://xbrl.sec.gov/dei/2022": 4, "total": 15 }, "keyCustom": 56, "keyStandard": 475, "memberCustom": 53, "memberStandard": 50, "nsprefix": "abc", "nsuri": "http://www.amerisourcebergen.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "role": "http://www.amerisourcebergen.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Acquisition and Assets and Liabilities Held for Sale", "role": "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSale", "shortName": "Acquisition and Assets and Liabilities Held for Sale", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Variable Interest Entity", "role": "http://www.amerisourcebergen.com/role/VariableInterestEntity", "shortName": "Variable Interest Entity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Income Taxes", "role": "http://www.amerisourcebergen.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Goodwill and Other Intangible Assets", "role": "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssets", "shortName": "Goodwill and Other Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Debt", "role": "http://www.amerisourcebergen.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "abc:StockholdersEquityandWeightedAverageCommonSharesOutstandingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding", "role": "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstanding", "shortName": "Stockholders' Equity and Weighted Average Common Shares Outstanding", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "abc:StockholdersEquityandWeightedAverageCommonSharesOutstandingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Related Party Transactions", "role": "http://www.amerisourcebergen.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Retirement and Other Benefit Plans", "role": "http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlans", "shortName": "Retirement and Other Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Share-Based Compensation", "role": "http://www.amerisourcebergen.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "0000002 - Document - Audit Information", "role": "http://www.amerisourcebergen.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Leases", "role": "http://www.amerisourcebergen.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Acquisition, Integration, and Restructuring Expenses", "role": "http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpenses", "shortName": "Acquisition, Integration, and Restructuring Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Legal Matters and Contingencies", "role": "http://www.amerisourcebergen.com/role/LegalMattersandContingencies", "shortName": "Legal Matters and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Litigation Settlements", "role": "http://www.amerisourcebergen.com/role/LitigationSettlements", "shortName": "Litigation Settlements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Business Segment Information", "role": "http://www.amerisourcebergen.com/role/BusinessSegmentInformation", "shortName": "Business Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Fair Value of Financial Instruments", "role": "http://www.amerisourcebergen.com/role/FairValueofFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Subsequent Events", "role": "http://www.amerisourcebergen.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - SCHEDULE II\u00a0\u2014 VALUATION AND QUALIFYING ACCOUNTS", "role": "http://www.amerisourcebergen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS", "shortName": "SCHEDULE II\u00a0\u2014 VALUATION AND QUALIFYING ACCOUNTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Acquisition and Assets and Liabilities Held for Sale (Tables)", "role": "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleTables", "shortName": "Acquisition and Assets and Liabilities Held for Sale (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Variable Interest Entity (Tables)", "role": "http://www.amerisourcebergen.com/role/VariableInterestEntityTables", "shortName": "Variable Interest Entity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Income Taxes (Tables)", "role": "http://www.amerisourcebergen.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Goodwill and Other Intangible Assets (Tables)", "role": "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsTables", "shortName": "Goodwill and Other Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Debt (Tables)", "role": "http://www.amerisourcebergen.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding (Tables)", "role": "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingTables", "shortName": "Stockholders' Equity and Weighted Average Common Shares Outstanding (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Share-Based Compensation (Tables)", "role": "http://www.amerisourcebergen.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Leases (Tables)", "role": "http://www.amerisourcebergen.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Acquisition, Integration, and Restructuring Expenses (Tables)", "role": "http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpensesTables", "shortName": "Acquisition, Integration, and Restructuring Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Business Segment Information (Tables)", "role": "http://www.amerisourcebergen.com/role/BusinessSegmentInformationTables", "shortName": "Business Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Summary of Significant Accounting Policies - Recently Adopted Accounting Pronouncements (Details)", "role": "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails", "shortName": "Summary of Significant Accounting Policies - Recently Adopted Accounting Pronouncements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i30202022f7304c5bb22c7aa75e82f41d_I20201001", "decimals": "-5", "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Summary of Significant Accounting Policies - Schedule of Restricted Cash (Details)", "role": "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails", "shortName": "Summary of Significant Accounting Policies - Schedule of Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "ibe292c05886d45deb4c377709cd7cfd7_I20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ReceivablesPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i7ef1710ae8464669bf8a0a04969ac01b_D20211001-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)", "role": "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails", "shortName": "Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ReceivablesPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i7ef1710ae8464669bf8a0a04969ac01b_D20211001-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i96bc9c48857545f9a5b285f3c87dd3f9_D20211001-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmountRecognizedInIncomeDueToInflationaryAccounting", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Summary of Significant Accounting Policies - Foreign Currency (Details)", "role": "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesForeignCurrencyDetails", "shortName": "Summary of Significant Accounting Policies - Foreign Currency (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i96bc9c48857545f9a5b285f3c87dd3f9_D20211001-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmountRecognizedInIncomeDueToInflationaryAccounting", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i7037f7499c044e1c91df1582e871575b_D20210701-20210701", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets (Details)", "role": "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangibleAssetsDetails", "shortName": "Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "us-gaap:PercentageOfLIFOInventory", "span", "div", "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:PercentageOfLIFOInventory", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Summary of Significant Accounting Policies - Merchandise Inventories (Details)", "role": "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesMerchandiseInventoriesDetails", "shortName": "Summary of Significant Accounting Policies - Merchandise Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:PercentageOfLIFOInventory", "span", "div", "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:PercentageOfLIFOInventory", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "id07311e8e30b4878b132107d5be226bc_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)", "role": "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails", "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "id07311e8e30b4878b132107d5be226bc_D20211001-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)", "role": "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails", "shortName": "Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "abc:AccrualForEstimatedCustomerSalesReturns", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)", "role": "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails", "shortName": "Summary of Significant Accounting Policies - Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "abc:AccrualForEstimatedCustomerSalesReturns", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Summary of Significant Accounting Policies - Shipping and Handling Costs (Details)", "role": "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsDetails", "shortName": "Summary of Significant Accounting Policies - Shipping and Handling Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i734d044f7d5c49b78347e11e90a25823_D20211001-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Acquisition and Assets and Liabilities Held for Sale - Additional Information (Details)", "role": "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "shortName": "Acquisition and Assets and Liabilities Held for Sale - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "ia60e405f474f4c8dbf37601b7f639090_D20210701-20210930", "decimals": "INF", "lang": "en-US", "name": "abc:NumberOfSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "subsidiary", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Acquisition and Assets and Liabilities Held for Sale - Assets And Liabilities (Details)", "role": "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails", "shortName": "Acquisition and Assets and Liabilities Held for Sale - Assets And Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "idb0907b6e89e4b9ea10497ba6281cdd7_D20210601-20210601", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "idb0907b6e89e4b9ea10497ba6281cdd7_D20210601-20210601", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Acquisition and Assets and Liabilities Held for Sale - Fair Value Of Intangible Assets (Details)", "role": "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleFairValueOfIntangibleAssetsDetails", "shortName": "Acquisition and Assets and Liabilities Held for Sale - Fair Value Of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "iee9c4da9a482417d8e91a9b98feeb512_D20210601-20210601", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Acquisition and Assets and Liabilities Held for Sale - Assets and Liabilities Held for Sale (Details)", "role": "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails", "shortName": "Acquisition and Assets and Liabilities Held for Sale - Assets and Liabilities Held for Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i5d8a067658bf4df482fdacb1288ed0e6_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Variable Interest Entity - Schedule of Assets and Liabilities of Profarma (Details)", "role": "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails", "shortName": "Variable Interest Entity - Schedule of Assets and Liabilities of Profarma (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i6b32762c71a5489381e246c0889ce0a0_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Variable Interest Entity - Additional Information (Details)", "role": "http://www.amerisourcebergen.com/role/VariableInterestEntityAdditionalInformationDetails", "shortName": "Variable Interest Entity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "ib3cb734bc00f4b6e9962287bc79db3af_D20200801-20200831", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Income Taxes - Domestic and Foreign Income From Continuing Operations Before Income Taxes (Details)", "role": "http://www.amerisourcebergen.com/role/IncomeTaxesDomesticandForeignIncomeFromContinuingOperationsBeforeIncomeTaxesDetails", "shortName": "Income Taxes - Domestic and Foreign Income From Continuing Operations Before Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Income Taxes - Income Tax Expense (Benefit) (Details)", "role": "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails", "shortName": "Income Taxes - Income Tax Expense (Benefit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)", "role": "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails", "shortName": "Income Taxes - Reconciliation of Effective Income Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i7e88d6c51cf74042ad39f7866397b553_I20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxLiabilitiesDeferredExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i9b25946b60ff4375b086f2a0ee8d76c5_D20191001-20200930", "decimals": "-5", "lang": "en-US", "name": "abc:IncomeTaxExpenseBenefitCARESAct", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "role": "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Income Taxes - Significant Components of Deferred Tax Liabilities (Assets) (Details)", "role": "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails", "shortName": "Income Taxes - Significant Components of Deferred Tax Liabilities (Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i7e88d6c51cf74042ad39f7866397b553_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)", "role": "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i18414caa083a4c10a4a26516e2630bd7_I20190930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i7e88d6c51cf74042ad39f7866397b553_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Goodwill and Other Intangible Assets - Changes in Carrying Value of Goodwill (Details)", "role": "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingValueofGoodwillDetails", "shortName": "Goodwill and Other Intangible Assets - Changes in Carrying Value of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i7037f7499c044e1c91df1582e871575b_D20210701-20210701", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Details)", "role": "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails", "shortName": "Goodwill and Other Intangible Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i7e88d6c51cf74042ad39f7866397b553_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - Goodwill and Other Intangible Assets - Other Intangible Assets (Details)", "role": "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails", "shortName": "Goodwill and Other Intangible Assets - Other Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i7e88d6c51cf74042ad39f7866397b553_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - Debt - Debt Instruments (Details)", "role": "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails", "shortName": "Debt - Debt Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "ic97ade8cd4f74fab9780a21153b5a06e_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsOfDebtExtinguishmentCosts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - Debt - Additional Information (Details)", "role": "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "shortName": "Debt - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000067 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding - Additional Information (Details)", "role": "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails", "shortName": "Stockholders' Equity and Weighted Average Common Shares Outstanding - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000068 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Accumulated Other Comprehensive Loss (Details)", "role": "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingComponentsofAccumulatedOtherComprehensiveLossDetails", "shortName": "Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Accumulated Other Comprehensive Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i603b9b08d37d408991869ec10d573522_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000069 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Diluted Weighted Average Shares Outstanding (Details)", "role": "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingComponentsofDilutedWeightedAverageSharesOutstandingDetails", "shortName": "Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Diluted Weighted Average Shares Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i18414caa083a4c10a4a26516e2630bd7_I20190930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "role": "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i64bc0694f9e3405593c0e5bfc636ba01_I20190930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "icab3f099e52845f18d6fe338115e6817_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000070 - Disclosure - Related Party Transactions (Details)", "role": "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "icab3f099e52845f18d6fe338115e6817_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "abc:DefinedContributionPlanMinimumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000071 - Disclosure - Retirement and Other Benefit Plans (Details)", "role": "http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlansDetails", "shortName": "Retirement and Other Benefit Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "abc:DefinedContributionPlanMinimumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i9b25946b60ff4375b086f2a0ee8d76c5_D20191001-20200930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000072 - Disclosure - Share-Based Compensation - Additional Information (Details)", "role": "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "shortName": "Share-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i9b25946b60ff4375b086f2a0ee8d76c5_D20191001-20200930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i9b25946b60ff4375b086f2a0ee8d76c5_D20191001-20200930", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000073 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details)", "role": "http://www.amerisourcebergen.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails", "shortName": "Share-Based Compensation - Weighted Average Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i9b25946b60ff4375b086f2a0ee8d76c5_D20191001-20200930", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i7e88d6c51cf74042ad39f7866397b553_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000074 - Disclosure - Share-Based Compensation - Stock Options (Details)", "role": "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails", "shortName": "Share-Based Compensation - Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i7e88d6c51cf74042ad39f7866397b553_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000075 - Disclosure - Share-Based Compensation - Nonvested Options (Details)", "role": "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails", "shortName": "Share-Based Compensation - Nonvested Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i5e6362add38948449e3777492396ec7b_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000076 - Disclosure - Share-Based Compensation - Nonvested Restricted Stock Units (Details)", "role": "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails", "shortName": "Share-Based Compensation - Nonvested Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i45e1d0153c5f402096857885d2509333_D20211001-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "if748c2fd641a42278f4d8c74d4c9bc95_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000077 - Disclosure - Share-Based Compensation - Nonvested Performance Stock Units (Details)", "role": "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "shortName": "Share-Based Compensation - Nonvested Performance Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "ic9ad204ee8064e48b63b79b25268369a_D20211001-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000078 - Disclosure - Leases - Lease Cost (Details)", "role": "http://www.amerisourcebergen.com/role/LeasesLeaseCostDetails", "shortName": "Leases - Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "abc:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000079 - Disclosure - Leases - Summary of Balance Sheet Information Related to Leases (Details)", "role": "http://www.amerisourcebergen.com/role/LeasesSummaryofBalanceSheetInformationRelatedtoLeasesDetails", "shortName": "Leases - Summary of Balance Sheet Information Related to Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "abc:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)", "role": "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000080 - Disclosure - Leases - Other Information (Details)", "role": "http://www.amerisourcebergen.com/role/LeasesOtherInformationDetails", "shortName": "Leases - Other Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000081 - Disclosure - Leases - Future Minimum Rental Payments Under Noncancelable Operating Leases (Details)", "role": "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails", "shortName": "Leases - Future Minimum Rental Payments Under Noncancelable Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i459f8cd7c4e745ffb3b577910da4819a_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000082 - Disclosure - Acquisition, Integration, and Restructuring Expenses (Details)", "role": "http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpensesDetails", "shortName": "Acquisition, Integration, and Restructuring Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i7e88d6c51cf74042ad39f7866397b553_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LitigationReserveNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000083 - Disclosure - Legal Matters and Contingencies (Details)", "role": "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails", "shortName": "Legal Matters and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i0274d6147c8a4a7686d08d7a458776e1_D20211001-20220930", "decimals": "-8", "lang": "en-US", "name": "us-gaap:LossContingencyDamagesAwardedValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:GainLossRelatedToLitigationSettlement", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000084 - Disclosure - Litigation Settlements (Details)", "role": "http://www.amerisourcebergen.com/role/LitigationSettlementsDetails", "shortName": "Litigation Settlements (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R85": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000085 - Disclosure - Business Segment Information - Additional Information (Details)", "role": "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "shortName": "Business Segment Information - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000086 - Disclosure - Business Segment Information - Segment Revenue (Details)", "role": "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentRevenueDetails", "shortName": "Business Segment Information - Segment Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "ib5b2dc6834124e538c986851ab2cac00_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000087 - Disclosure - Business Segment Information - Segment Operating Income (Details)", "role": "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentOperatingIncomeDetails", "shortName": "Business Segment Information - Segment Operating Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000088 - Disclosure - Business Segment Information - Reconciliation of Segment Operating Income to Income From Continuing Operations (Details)", "role": "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails", "shortName": "Business Segment Information - Reconciliation of Segment Operating Income to Income From Continuing Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i02aa1ef65c6e4bf0bc113b1a57936ff1_D20211001-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GainLossRelatedToLitigationSettlement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "if85753f1381e4fed80543ed36df6d725_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000089 - Disclosure - Fair Value of Financial Instruments (Details)", "role": "http://www.amerisourcebergen.com/role/FairValueofFinancialInstrumentsDetails", "shortName": "Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "if85753f1381e4fed80543ed36df6d725_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOW", "role": "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOW", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2424002e7f3244a190599b47880f6a24_D20211001-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000090 - Disclosure - Subsequent Events (Details)", "role": "http://www.amerisourcebergen.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i04738850f9344877959e157a6620fbe9_D20221101-20221122", "decimals": "2", "lang": "en-US", "name": "abc:DividendIncreasePercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "ib41bfa5163d54af2905ab70ddef48bc5_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000091 - Disclosure - SCHEDULE II\u00a0\u2014 VALUATION AND QUALIFYING ACCOUNTS (Details)", "role": "http://www.amerisourcebergen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails", "shortName": "SCHEDULE II\u00a0\u2014 VALUATION AND QUALIFYING ACCOUNTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "abc-20220930.htm", "contextRef": "i2de7502778714ef993ca117fd311a92b_I20190930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 108, "tag": { "abc_A2022OmnibusIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 Omnibus Incentive Plan", "label": "2022 Omnibus Incentive Plan [Member]", "terseLabel": "2022 Omnibus" } } }, "localname": "A2022OmnibusIncentivePlanMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_AccrualForEstimatedCustomerSalesReturns": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Accrual for Estimated Customer Sales Returns", "terseLabel": "Accrual for estimated customer sales returns" } } }, "localname": "AccrualForEstimatedCustomerSalesReturns", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "abc_AccumulatedOtherAdjustmentsAttributabletoParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accumulated Other Adjustments Attributable to Parent [Member]", "label": "Accumulated Other Adjustments Attributable to Parent [Member]", "terseLabel": "Other" } } }, "localname": "AccumulatedOtherAdjustmentsAttributabletoParentMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingComponentsofAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "abc_AggregateIntrinsicValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available", "label": "Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "AggregateIntrinsicValue", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "abc_AllianceHealthcareDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alliance Healthcare Debt", "label": "Alliance Healthcare Debt [Member]", "terseLabel": "Alliance Healthcare debt" } } }, "localname": "AllianceHealthcareDebtMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_AllianceHealthcareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alliance Healthcare", "label": "Alliance Healthcare [Member]", "terseLabel": "Alliance Healthcare" } } }, "localname": "AllianceHealthcareMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentRevenueDetails" ], "xbrltype": "domainItemType" }, "abc_AllowanceForReturnsAndDoubtfulAccountsCurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allowance For Returns And Doubtful Accounts, Current", "label": "Allowance For Returns And Doubtful Accounts, Current [Member]", "terseLabel": "Allowances for returns and doubtful accounts" } } }, "localname": "AllowanceForReturnsAndDoubtfulAccountsCurrentMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" ], "xbrltype": "domainItemType" }, "abc_AlternateBaseRateAndCanadianPrimeRateCdorRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alternate base rate and Canadian prime rate.", "label": "Alternate Base Rate And Canadian Prime Rate Cdor Rate [Member]", "terseLabel": "Alternate base rate and Canadian prime rate" } } }, "localname": "AlternateBaseRateAndCanadianPrimeRateCdorRateMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_AlternativeMinimumTaxMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to alternative minimum tax.", "label": "Alternative Minimum Tax [Member]", "terseLabel": "Alternative minimum tax credit carryforwards" } } }, "localname": "AlternativeMinimumTaxMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_AmerisourceBergenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AmerisourceBergen [Member]", "label": "AmerisourceBergen [Member]", "terseLabel": "AmerisourceBergen" } } }, "localname": "AmerisourceBergenMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "abc_AnimalHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MWI Animal Health [Member]", "label": "Animal Health [Member]", "terseLabel": "Animal Health" } } }, "localname": "AnimalHealthMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentRevenueDetails" ], "xbrltype": "domainItemType" }, "abc_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets And Liabilities, Lessee", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Schedule of Summarized Balance Sheet Information" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "abc_AuditorInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Auditor Information", "label": "Auditor Information [Abstract]" } } }, "localname": "AuditorInformationAbstract", "nsuri": "http://www.amerisourcebergen.com/20220930", "xbrltype": "stringItemType" }, "abc_BusinessCombinationAcquisitionIntegrationAndRestructuringExpenses": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 8.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Acquisition, Integration, And Restructuring Expenses", "label": "Business Combination, Acquisition, Integration, And Restructuring Expenses", "negatedTerseLabel": "Acquisition, integration, and restructuring expenses", "terseLabel": "Acquisition, integration, and restructuring expenses", "totalLabel": "Total" } } }, "localname": "BusinessCombinationAcquisitionIntegrationAndRestructuringExpenses", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpensesDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "abc_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableAndOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable and Other", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable and Other", "negatedTerseLabel": "Equity consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableAndOther", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abc_BusinessCombinationContingentConsiderationPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Payment", "label": "Business Combination, Contingent Consideration, Payment", "terseLabel": "Settled" } } }, "localname": "BusinessCombinationContingentConsiderationPayment", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abc_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Assets", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Assets", "terseLabel": "Increased in the deferred tax assets" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxAssets", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abc_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Assets", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Assets", "negatedTerseLabel": "Decreased other assets" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherAssets", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abc_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentWorkingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Working Capital", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Working Capital", "negatedTerseLabel": "Working capital adjustments" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentWorkingCapital", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOther": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Expenses And Other", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Expenses And Other", "negatedTerseLabel": "Accrued expenses and other" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOther", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Short Term Debt", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Short Term Debt", "negatedTerseLabel": "Short-term debt" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermDebt", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOherIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Oher Intangible Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Oher Intangible Assets", "terseLabel": "Other intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOherIntangibleAssets", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abc_BusinessShutdownCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Shutdown Costs", "label": "Business Shutdown Costs", "negatedTerseLabel": "PharMEDium shutdown costs" } } }, "localname": "BusinessShutdownCosts", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "abc_BusinessTransformationEfforts": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpensesDetails": { "order": 3.0, "parentTag": "abc_BusinessCombinationAcquisitionIntegrationAndRestructuringExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Transformation Efforts", "label": "Business Transformation Efforts", "terseLabel": "Business transformation efforts" } } }, "localname": "BusinessTransformationEfforts", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpensesDetails" ], "xbrltype": "monetaryItemType" }, "abc_CashAndRestrictedCashAcquiredFromAcquisition": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash And Restricted Cash Acquired From Acquisition", "label": "Cash And Restricted Cash Acquired From Acquisition", "negatedTerseLabel": "Cash acquired, including restricted cash of $143,308 included in Prepaid Expenses and Other" } } }, "localname": "CashAndRestrictedCashAcquiredFromAcquisition", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAndDisposalGroupIncludingDiscontinueOperation": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect And Disposal Group, Including Discontinue Operation", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect And Disposal Group, Including Discontinue Operation", "totalLabel": "INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, INCLUDING CASH CLASSIFIED WITHIN ASSETS HELD FOR SALE" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAndDisposalGroupIncludingDiscontinueOperation", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "abc_CommonStockVotingRightsVotePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Voting Rights, Vote Per Share", "label": "Common Stock, Voting Rights, Vote Per Share", "terseLabel": "Number of votes per share" } } }, "localname": "CommonStockVotingRightsVotePerShare", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "abc_DebtInstrumentIssuancePricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Issuance Price, Percentage", "label": "Debt Instrument, Issuance Price, Percentage", "terseLabel": "Percentage of principal amount" } } }, "localname": "DebtInstrumentIssuancePricePercentage", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "abc_DeferredCompensationArrangementWithIndividualAnnualDistributions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of the annual amount of the participant's base salary and bonus incentive by which the compensation exceeds the annual compensation limit established by the provisions of the Internal Revenue Code.", "label": "Deferred Compensation Arrangement with Individual, Annual Distributions", "terseLabel": "Deferred compensation, annual benefit, percent of compensation, Benefit Restoration Plan" } } }, "localname": "DeferredCompensationArrangementWithIndividualAnnualDistributions", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "abc_DeferredCompensationArrangementWithIndividualDiscretionarySharesPerEachFullShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Compensation Arrangement with Individual, Discretionary Shares Per Each Full Share", "label": "Deferred Compensation Arrangement with Individual, Discretionary Shares Per Each Full Share", "terseLabel": "Stock purchased with the participant's compensation allocated to stock credits (in shares)" } } }, "localname": "DeferredCompensationArrangementWithIndividualDiscretionarySharesPerEachFullShare", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlansDetails" ], "xbrltype": "sharesItemType" }, "abc_DeferredTaxAssetsLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Lease Liabilities", "label": "Deferred Tax Assets, Lease Liabilities", "negatedLabel": "Lease liabilities" } } }, "localname": "DeferredTaxAssetsLeaseLiabilities", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "abc_DeferredTaxAssetsNetOperatingLossAndTaxCreditCarryforwards": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards and net operating loss.", "label": "Deferred Tax Assets, Net Operating Loss and Tax Credit Carryforwards", "negatedTerseLabel": "Net operating loss and tax credit carryforwards" } } }, "localname": "DeferredTaxAssetsNetOperatingLossAndTaxCreditCarryforwards", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "abc_DefinedContributionPlanEmployerDiscretionaryContributionVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Contribution Plan, Employer Discretionary Contribution, Vesting Period", "label": "Defined Contribution Plan, Employer Discretionary Contribution, Vesting Period", "terseLabel": "Discretionary contributions, vesting period (in years)" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionVestingPeriod", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlansDetails" ], "xbrltype": "durationItemType" }, "abc_DefinedContributionPlanMinimumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Contribution Plan, Minimum Annual Contributions Per Employee, Percent", "label": "Defined Contribution Plan, Minimum Annual Contributions Per Employee, Percent", "terseLabel": "Minimum allowed employee contributions, percent of salary" } } }, "localname": "DefinedContributionPlanMinimumAnnualContributionsPerEmployeePercent", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "abc_DefinedContributionPlanTranchesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Contribution Plan Tranches [Axis]", "label": "Defined Contribution Plan Tranches [Axis]", "terseLabel": "Defined Contribution Plan Tranches [Axis]" } } }, "localname": "DefinedContributionPlanTranchesAxis", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlansDetails" ], "xbrltype": "stringItemType" }, "abc_DefinedContributionPlanTranchesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Defined Contribution Plan Tranches [Axis]", "label": "Defined Contribution Plan Tranches [Domain]", "terseLabel": "Defined Contribution Plan Tranches [Domain]" } } }, "localname": "DefinedContributionPlanTranchesDomain", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlansDetails" ], "xbrltype": "domainItemType" }, "abc_DisposalGroupIncludingDiscontinuedOperationCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "label": "Disposal Group, Including Discontinued Operation, Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "verboseLabel": "LESS: INCREASE IN CASH CLASSIFIED WITHIN ASSETS HELD FOR SALE" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "abc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Long-term Debt, Current", "label": "Disposal Group, Including Discontinued Operation, Long-term Debt, Current", "terseLabel": "Long-term debt" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "abc_DisposalGroupIncludingDiscontinuedOperationShortTermDebtCurrent": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Short-term Debt, Current", "label": "Disposal Group, Including Discontinued Operation, Short-term Debt, Current", "terseLabel": "Short-term debt" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationShortTermDebtCurrent", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "abc_DisposalGroupNotDiscontinuedOperationAccumulatedLossGainOnWriteDown": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Not Discontinued Operation, Accumulated Loss (Gain) on Write-down", "label": "Disposal Group, Not Discontinued Operation, Accumulated Loss (Gain) on Write-down", "terseLabel": "Accumulated loss on the remeasurement" } } }, "localname": "DisposalGroupNotDiscontinuedOperationAccumulatedLossGainOnWriteDown", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "abc_DividendIncreasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dividend increase percentage.", "label": "Dividend Increase Percentage", "terseLabel": "Dividend increase percentage" } } }, "localname": "DividendIncreasePercentage", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "abc_EffectiveIncomeTaxRateReconciliationCARESActPercent": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, CARES Act, Percent", "label": "Effective Income Tax Rate Reconciliation, CARES Act, Percent", "terseLabel": "CARES Act" } } }, "localname": "EffectiveIncomeTaxRateReconciliationCARESActPercent", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "abc_EffectiveIncomeTaxRateReconciliationDeductionWorthlessStockPercent": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Deduction, Worthless Stock, Percent", "label": "Effective Income Tax Rate Reconciliation, Deduction, Worthless Stock, Percent", "terseLabel": "PharMEDium worthless stock deduction" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeductionWorthlessStockPercent", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "abc_EffectiveIncomeTaxRateReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation [Line Items]", "label": "Effective Income Tax Rate Reconciliation [Line Items]", "terseLabel": "Effective Income Tax Rate Reconciliation [Line Items]" } } }, "localname": "EffectiveIncomeTaxRateReconciliationLineItems", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" ], "xbrltype": "stringItemType" }, "abc_EffectiveIncomeTaxRateReconciliationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation [Table]", "label": "Effective Income Tax Rate Reconciliation [Table]", "terseLabel": "Effective Income Tax Rate Reconciliation [Table]" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTable", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" ], "xbrltype": "stringItemType" }, "abc_EmployeeContributionAdditionalTwoPercentOfSalaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the employee contribution by additional two percentage of the salary.", "label": "Employee Contribution Additional Two Percent Of Salary [Member]", "terseLabel": "Employee contribution, additional 2% of salary" } } }, "localname": "EmployeeContributionAdditionalTwoPercentOfSalaryMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlansDetails" ], "xbrltype": "domainItemType" }, "abc_EmployeeContributionFirstThreePercentOfSalaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the employee contribution up to the first three percent of the salary.", "label": "Employee Contribution First Three Percent Of Salary [Member]", "terseLabel": "Employee contribution, first 3% of salary" } } }, "localname": "EmployeeContributionFirstThreePercentOfSalaryMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlansDetails" ], "xbrltype": "domainItemType" }, "abc_EmployeeTaxWithholdingsRelatedToRestrictedShareVesting": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Withholdings Related to Restricted Share Vesting", "label": "Employee Tax Withholdings Related to Restricted Share Vesting", "negatedLabel": "Employee tax withholdings related to restricted share vesting" } } }, "localname": "EmployeeTaxWithholdingsRelatedToRestrictedShareVesting", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "abc_EquityInvestmentRemeasurementGainLoss": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity Investment, Remeasurement Gain (Loss)", "label": "Equity Investment, Remeasurement Gain (Loss)", "negatedTerseLabel": "Gain on remeasurement of equity investment", "terseLabel": "Gain on revaluation of equity investment" } } }, "localname": "EquityInvestmentRemeasurementGainLoss", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "abc_ExpressScriptsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Express Scripts,\u00a0Inc.", "label": "Express Scripts,\u00a0Inc. [Member]", "terseLabel": "Express Scripts,\u00a0Inc." } } }, "localname": "ExpressScriptsIncMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "abc_FinancingReceivableImpairmentCharges": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Impairment Charges", "label": "Financing Receivable, Impairment Charges", "terseLabel": "Turkey highly inflationary impact" } } }, "localname": "FinancingReceivableImpairmentCharges", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abc_GrantedInFiscal2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Granted In Fiscal 2022", "label": "Granted In Fiscal 2022 [Member]", "terseLabel": "Granted beginning in fiscal 2022" } } }, "localname": "GrantedInFiscal2022Member", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_GrantedPriorToFiscal2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Granted Prior to Fiscal 2021", "label": "Granted Prior to Fiscal 2021 [Member]", "terseLabel": "Granted prior to fiscal 2021" } } }, "localname": "GrantedPriorToFiscal2021Member", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_HumanHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Human Health", "label": "Human Health [Member]", "terseLabel": "Human Health" } } }, "localname": "HumanHealthMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentRevenueDetails" ], "xbrltype": "domainItemType" }, "abc_IncomeTaxExpenseBenefitCARESAct": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income Tax Expense (Benefit), CARES Act", "label": "Income Tax Expense (Benefit), CARES Act", "negatedTerseLabel": "Cares act, tax benefit" } } }, "localname": "IncomeTaxExpenseBenefitCARESAct", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abc_IncreaseDecreaseInAccruedEstimatedLitigationLiability": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) in Accrued Estimated Litigation Liability", "label": "Increase (Decrease) in Accrued Estimated Litigation Liability", "terseLabel": "Long-term accrued litigation liability" } } }, "localname": "IncreaseDecreaseInAccruedEstimatedLitigationLiability", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "abc_IncreaseDecreaseInIncomeTaxesPayableAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) in Income Taxes Payable And Other Liabilities", "label": "Increase (Decrease) in Income Taxes Payable And Other Liabilities", "terseLabel": "Income taxes payable and other liabilities" } } }, "localname": "IncreaseDecreaseInIncomeTaxesPayableAndOtherLiabilities", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "abc_InflationaryAccountingImpact": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inflationary Accounting Impact", "label": "Inflationary Accounting Impact", "terseLabel": "Turkey highly inflationary impact" } } }, "localname": "InflationaryAccountingImpact", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "abc_InternationalHealthcareSolutionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "International Healthcare Solutions", "label": "International Healthcare Solutions [Member]", "terseLabel": "International Healthcare Solutions" } } }, "localname": "InternationalHealthcareSolutionsMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentOperatingIncomeDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentRevenueDetails", "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingValueofGoodwillDetails" ], "xbrltype": "domainItemType" }, "abc_LeaseCashFlowAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Cash Flow [Abstract]", "label": "Lease Cash Flow [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities" } } }, "localname": "LeaseCashFlowAbstract", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesOtherInformationDetails" ], "xbrltype": "stringItemType" }, "abc_LegalSettlementPaymentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legal Settlement Payment Term", "label": "Legal Settlement Payment Term", "terseLabel": "Legal settlement term (in years)" } } }, "localname": "LegalSettlementPaymentTerm", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails" ], "xbrltype": "durationItemType" }, "abc_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount", "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount", "negatedTerseLabel": "Less: Future payments for leases that have not yet commenced" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "abc_LineOfCreditFacilityAccordionFeatureIncreaseLimit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Line of Credit Facility, Accordion Feature, Increase Limit", "label": "Line of Credit Facility, Accordion Feature, Increase Limit", "terseLabel": "Potential increase in receivables securitization facility" } } }, "localname": "LineOfCreditFacilityAccordionFeatureIncreaseLimit", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abc_LossContingencyClaimsSettledPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Claims Settled, Percent", "label": "Loss Contingency, Claims Settled, Percent", "terseLabel": "Settlement percent of population" } } }, "localname": "LossContingencyClaimsSettledPercent", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails" ], "xbrltype": "percentItemType" }, "abc_May2020ShareRepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "May 2020 Share Repurchase Program [Member]", "label": "May 2020 Share Repurchase Program [Member]", "terseLabel": "May 2020 Share Repurchase Program" } } }, "localname": "May2020ShareRepurchaseProgramMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_May2022ShareRepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "May 2022 Share Repurchase Program", "label": "May 2022 Share Repurchase Program [Member]", "terseLabel": "May 2022 Share Repurchase Program" } } }, "localname": "May2022ShareRepurchaseProgramMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_MoneyMarketFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Money Market Facility", "label": "Money Market Facility [Member]", "terseLabel": "Money market facility" } } }, "localname": "MoneyMarketFacilityMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_MultiCurrencyRevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Multi Currency Revolving Credit Facility [Member]", "terseLabel": "Multi-currency revolving credit facility due 2027" } } }, "localname": "MultiCurrencyRevolvingCreditFacilityMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_MultidistrictLitigationAndOtherRelatedStateCourtLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Multidistrict Litigation and Other Related State Court Litigation", "label": "Multidistrict Litigation and Other Related State Court Litigation [Member]", "terseLabel": "Multidistrict Litigation and Other Related State Court Litigation" } } }, "localname": "MultidistrictLitigationAndOtherRelatedStateCourtLitigationMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails" ], "xbrltype": "domainItemType" }, "abc_NewYorkStateOpioidStewardshipActExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "New York State Opioid Stewardship Act Expense", "label": "New York State Opioid Stewardship Act Expense", "negatedTerseLabel": "New York State Opioid Stewardship Act" } } }, "localname": "NewYorkStateOpioidStewardshipActExpense", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "abc_NonEmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to compensation granted to Non-employee director.", "label": "Non Employee [Member]", "terseLabel": "Non-employee options" } } }, "localname": "NonEmployeeMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_NonrecourseDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-recourse Debt [Member]", "label": "Non-recourse Debt [Member]", "terseLabel": "Nonrecourse debt" } } }, "localname": "NonrecourseDebtMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_NumberOfSubsidiaries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Subsidiaries", "label": "Number Of Subsidiaries", "terseLabel": "Number Of Subsidiaries" } } }, "localname": "NumberOfSubsidiaries", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "abc_October2018ShareRepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "October 2018 Share Repurchase Program [Member]", "label": "October 2018 Share Repurchase Program [Member]", "terseLabel": "October 2018 Share Repurchase Program" } } }, "localname": "October2018ShareRepurchaseProgramMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_OperatingLeaseRightofUseAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Right-of-Use Assets [Abstract]", "label": "Operating Lease, Right-of-Use Assets [Abstract]", "terseLabel": "Right of use assets" } } }, "localname": "OperatingLeaseRightofUseAssetsAbstract", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesSummaryofBalanceSheetInformationRelatedtoLeasesDetails" ], "xbrltype": "stringItemType" }, "abc_OperatingLossCarryforwardsTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term operating loss carryforwards.", "label": "Operating Loss Carryforwards, Term", "terseLabel": "Net operating loss carryforwards, term (in years)" } } }, "localname": "OperatingLossCarryforwardsTerm", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "abc_OpioidLawsuitsandInvestigationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Opioid Lawsuits and Investigations [Member]", "label": "Opioid Lawsuits and Investigations [Member]", "terseLabel": "Opioid Lawsuits and Investigations" } } }, "localname": "OpioidLawsuitsandInvestigationsMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails" ], "xbrltype": "domainItemType" }, "abc_OptionsExpectedToVest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Options Expected to Vest", "terseLabel": "Expected to vest after end of period (shares)" } } }, "localname": "OptionsExpectedToVest", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "abc_OptionsExpectedToVestWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Options Expected to Vest Weighted Average Exercise Price", "terseLabel": "Expected to vest after end of period (usd per share)" } } }, "localname": "OptionsExpectedToVestWeightedAverageExercisePrice", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "abc_OtherHealthcareSolutionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Healthcare Solutions", "label": "Other Healthcare Solutions [Member]", "terseLabel": "Other Healthcare Solutions" } } }, "localname": "OtherHealthcareSolutionsMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentRevenueDetails" ], "xbrltype": "domainItemType" }, "abc_OtherIncomeLossNetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other (Income) Loss, Net", "label": "Other (Income) Loss, Net [Member]", "terseLabel": "Other (Income) Loss, Net" } } }, "localname": "OtherIncomeLossNetMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesForeignCurrencyDetails" ], "xbrltype": "domainItemType" }, "abc_OverdraftFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to overdraft facility.", "label": "Overdraft Facility [Member]", "terseLabel": "Overdraft facility due 2024 (\u00a310,000)" } } }, "localname": "OverdraftFacilityMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_PharmediumHealthcareHoldingsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to PharMEDium Healthcare Holdings, Inc.", "label": "Pharmedium Healthcare Holdings Inc [Member]", "terseLabel": "PharMEDium Healthcare Holdings, Inc" } } }, "localname": "PharmediumHealthcareHoldingsIncMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "abc_ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Profarma Distribuidora de Produtos Farmaceuticos S.A.", "label": "Profarma Distribuidora de Produtos Farmaceuticos S.A. [Member]", "terseLabel": "Profarma Distribuidora de Produtos Farmaceuticos S.A." } } }, "localname": "ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_ReceivablesSecuritizationFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables Securitization Facility [Member]", "terseLabel": "Receivables securitization facility due 2025" } } }, "localname": "ReceivablesSecuritizationFacilityMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_ReducedTaxRatePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reduced Tax Rate, Period", "label": "Reduced Tax Rate, Period", "terseLabel": "Reduced tax rate for a period (in years)" } } }, "localname": "ReducedTaxRatePeriod", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "abc_RemediationCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Remediation Costs", "label": "Remediation Costs", "negatedTerseLabel": "PharMEDium remediation costs" } } }, "localname": "RemediationCosts", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "abc_RestrictedCashAcquiredFromAcquisition": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restricted Cash Acquired from Acquisition", "label": "Restricted Cash Acquired from Acquisition", "terseLabel": "Restricted cash acquired" } } }, "localname": "RestrictedCashAcquiredFromAcquisition", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abc_RetailBusinessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Retail Business", "label": "Retail Business [Member]", "terseLabel": "Retail Business" } } }, "localname": "RetailBusinessMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_RevolvingCreditNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revolving Credit Note [Member]", "terseLabel": "Revolving credit note" } } }, "localname": "RevolvingCreditNoteMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_RightofUseAssetObtainedinExchangeforLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right-of-Use Asset Obtained in Exchange for Lease Liabilities [Abstract]", "label": "Right-of-Use Asset Obtained in Exchange for Lease Liabilities [Abstract]", "terseLabel": "Right-of-use assets obtained in exchange for lease liabilities" } } }, "localname": "RightofUseAssetObtainedinExchangeforLeaseLiabilitiesAbstract", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesOtherInformationDetails" ], "xbrltype": "stringItemType" }, "abc_SOFREURIBORCDORRFRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SOFR/EURIBOR/CDOR/RFR", "label": "SOFR/EURIBOR/CDOR/RFR [Member]", "terseLabel": "SOFR / EURIBOR / CDOR / RFR" } } }, "localname": "SOFREURIBORCDORRFRMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_SeniorNotesDue2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Notes Due 2021 [Member]", "terseLabel": "$500,000, 3.5% senior notes due 2021" } } }, "localname": "SeniorNotesDue2021Member", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_SeniorNotesDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes Due 2023", "label": "Senior Notes Due 2023 [Member]", "terseLabel": "0.737% senior notes due 2023" } } }, "localname": "SeniorNotesDue2023Member", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_SeniorNotesDue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Notes Due 2024 [Member]", "terseLabel": "$500,000, 3.400% senior notes due 2024" } } }, "localname": "SeniorNotesDue2024Member", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_SeniorNotesDue2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 3.25% senior notes due March 1, 2025.", "label": "Senior Notes Due 2025 [Member]", "terseLabel": "$500,000, 3.250% senior notes due 2025" } } }, "localname": "SeniorNotesDue2025Member", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_SeniorNotesDue2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes Due2027 [Member]", "label": "Senior Notes Due 2027 [Member]", "terseLabel": "$750,000, 3.450% senior notes due 2027" } } }, "localname": "SeniorNotesDue2027Member", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_SeniorNotesDue2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes Due 2030", "label": "Senior Notes Due 2030 [Member]", "terseLabel": "$500,000, 2.800% senior notes due 2030" } } }, "localname": "SeniorNotesDue2030Member", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_SeniorNotesDue2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes Due 2031", "label": "Senior Notes Due 2031 [Member]", "terseLabel": "$1,000,000, 2.700% senior notes due 2031" } } }, "localname": "SeniorNotesDue2031Member", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_SeniorNotesDue2045Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 4.25% senior notes due March 1, 2045.", "label": "Senior Notes Due2045 [Member]", "terseLabel": "$500,000, 4.250% senior notes due 2045" } } }, "localname": "SeniorNotesDue2045Member", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_SeniorNotesDue2047Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes Due2047 [Member]", "label": "Senior Notes Due2047 [Member]", "terseLabel": "$500,000, 4.300% senior notes due 2047" } } }, "localname": "SeniorNotesDue2047Member", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_ShippingandHandlingCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shipping and Handling Costs [Policy Text Block]", "label": "Shipping and Handling Costs [Policy Text Block]", "terseLabel": "Shipping and Handling Costs" } } }, "localname": "ShippingandHandlingCostsPolicyTextBlock", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "abc_ShippingandHandlingLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Shipping and Handling [Table]", "label": "Shipping and Handling [Line Items]", "terseLabel": "Shipping and Handling [Line Items]" } } }, "localname": "ShippingandHandlingLineItems", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsDetails" ], "xbrltype": "stringItemType" }, "abc_ShippingandHandlingTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shipping and Handling [Table]", "label": "Shipping and Handling [Table]", "terseLabel": "Shipping and Handling [Table]" } } }, "localname": "ShippingandHandlingTable", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsDetails" ], "xbrltype": "stringItemType" }, "abc_StockholdersEquityandWeightedAverageCommonSharesOutstandingTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stockholders' Equity and Weighted Average Common Shares Outstanding", "label": "Stockholders' Equity and Weighted Average Common Shares Outstanding [Text Block]", "verboseLabel": "Stockholders' Equity and Weighted Average Common Shares Outstanding" } } }, "localname": "StockholdersEquityandWeightedAverageCommonSharesOutstandingTextBlock", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstanding" ], "xbrltype": "textBlockItemType" }, "abc_SupplierReservesPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplier Reserves Policy", "label": "Supplier Reserves Policy [Policy Text Block]", "terseLabel": "Supplier Reserves" } } }, "localname": "SupplierReservesPolicyPolicyTextBlock", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "abc_SwissTaxReformMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Swiss Tax Reform", "label": "Swiss Tax Reform [Member]", "terseLabel": "Swiss federal tax reforms" } } }, "localname": "SwissTaxReformMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_TermLoanAgreementOctober2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan Agreement October 2018 [Member]", "label": "Term Loan Agreement October 2018 [Member]", "terseLabel": "Term Loan Agreement October 2018" } } }, "localname": "TermLoanAgreementOctober2018Member", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_TermLoanDueFebruary2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan Due February 2021", "label": "Term Loan Due February 2021 [Member]", "terseLabel": "Term Loan Due February 2021" } } }, "localname": "TermLoanDueFebruary2021Member", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_TermLoanDueJune2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan Due June 2023", "label": "Term Loan Due June 2023 [Member]", "terseLabel": "Term loan due June 2023" } } }, "localname": "TermLoanDueJune2023Member", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_ThreeLargestNationalDistributorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Largest National Distributors", "label": "Three Largest National Distributors [Member]", "terseLabel": "Three Largest National Distributors" } } }, "localname": "ThreeLargestNationalDistributorsMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails" ], "xbrltype": "domainItemType" }, "abc_TradeNamesAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents trade names and other.", "label": "Trade Names And Other [Member]", "terseLabel": "Trade names and other" } } }, "localname": "TradeNamesAndOtherMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "abc_TreasuryStockValueAcquiredCostMethodSettlements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Treasury Stock, Value, Acquired, Cost Method, Settlements", "label": "Treasury Stock, Value, Acquired, Cost Method, Settlements", "verboseLabel": "Shares repurchased, cash settled" } } }, "localname": "TreasuryStockValueAcquiredCostMethodSettlements", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abc_USHealthcareSolutionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. Healthcare Solutions", "label": "U.S. Healthcare Solutions [Member]", "terseLabel": "U.S. Healthcare Solutions" } } }, "localname": "USHealthcareSolutionsMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentOperatingIncomeDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentRevenueDetails", "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingValueofGoodwillDetails" ], "xbrltype": "domainItemType" }, "abc_UndistributedEarningsofForeignSubsidiariesPermanentlyReinvested": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Undistributed Earnings of Foreign Subsidiaries Permanently Reinvested", "label": "Undistributed Earnings of Foreign Subsidiaries Permanently Reinvested", "terseLabel": "Permanently reinvested cumulative undistributed earnings" } } }, "localname": "UndistributedEarningsofForeignSubsidiariesPermanentlyReinvested", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abc_UnrecognizedTaxBenefitsIncludingIncomeTaxPenaltiesandInterestAccrued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued", "label": "Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized tax benefits, including interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncludingIncomeTaxPenaltiesandInterestAccrued", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abc_UnrecognizedTaxBenefitsIncludingIncomeTaxPenaltiesandInterestAccruedNetofFederalBenefit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued, Net of Federal Benefit", "label": "Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued, Net of Federal Benefit", "terseLabel": "Unrecognized tax benefits, including interest and penalties, net of federal benefit" } } }, "localname": "UnrecognizedTaxBenefitsIncludingIncomeTaxPenaltiesandInterestAccruedNetofFederalBenefit", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abc_WalgreensBootsAllianceIncAllianceHealthcareAllianceHealthcareEgyptMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Walgreens Boots Alliance, Inc. Alliance Healthcare, Alliance Healthcare Egypt", "label": "Walgreens Boots Alliance, Inc. Alliance Healthcare, Alliance Healthcare Egypt [Member]", "terseLabel": "Alliance Healthcare Egypt" } } }, "localname": "WalgreensBootsAllianceIncAllianceHealthcareAllianceHealthcareEgyptMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_WalgreensBootsAllianceIncAllianceHealthcareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Walgreens Boots Alliance, Inc. Alliance Healthcare", "label": "Walgreens Boots Alliance, Inc. Alliance Healthcare [Member]", "terseLabel": "WBA Alliance Healthcare" } } }, "localname": "WalgreensBootsAllianceIncAllianceHealthcareMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleFairValueOfIntangibleAssetsDetails", "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "abc_WalgreensBootsAllianceIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Walgreens Boots Alliance Inc.", "label": "Walgreens Boots Alliance Inc. [Member]", "terseLabel": "WBA" } } }, "localname": "WalgreensBootsAllianceIncMember", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "abc_WeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available", "label": "Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term" } } }, "localname": "WeightedAverageRemainingContractualTerm", "nsuri": "http://www.amerisourcebergen.com/20220930", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r867", "r868", "r869" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r867", "r868", "r869" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r867", "r868", "r869" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r867", "r868", "r869" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r870" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r865" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r864" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails", "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangibleAssetsDetails", "http://www.amerisourcebergen.com/role/VariableInterestEntityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r864" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r864" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r878" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r864" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r864" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r864" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r864" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r893" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r867", "r868", "r869" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails", "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangibleAssetsDetails", "http://www.amerisourcebergen.com/role/VariableInterestEntityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r863" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r866" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r154", "r368", "r373", "r381", "r610", "r611", "r619", "r620", "r726", "r860", "r879", "r881", "r890", "r891" ], "lang": { "en-us": { "role": { "documentation": "Information by consolidated entity or group of entities.", "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails", "http://www.amerisourcebergen.com/role/VariableInterestEntityAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r154", "r368", "r373", "r381", "r610", "r611", "r619", "r620", "r726", "r860", "r879", "r881", "r890", "r891" ], "lang": { "en-us": { "role": { "documentation": "Entity or group of entities consolidated into reporting entity.", "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails", "http://www.amerisourcebergen.com/role/VariableInterestEntityAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r154", "r215", "r228", "r229", "r230", "r231", "r233", "r235", "r239", "r368", "r369", "r370", "r371", "r372", "r373", "r375", "r376", "r378", "r380", "r381", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891" ], "lang": { "en-us": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentOperatingIncomeDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r154", "r215", "r228", "r229", "r230", "r231", "r233", "r235", "r239", "r368", "r369", "r370", "r371", "r372", "r373", "r375", "r376", "r378", "r380", "r381", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891" ], "lang": { "en-us": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentOperatingIncomeDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r76", "r78", "r151", "r152", "r387", "r422", "r892" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r166", "r174", "r180", "r267", "r516", "r517", "r518", "r559", "r560", "r643", "r646", "r648", "r649", "r715" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Adoption ASC" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r166", "r174", "r180", "r267", "r516", "r517", "r518", "r559", "r560", "r643", "r646", "r648", "r649", "r715" ], "lang": { "en-us": { "role": { "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r166", "r174", "r180", "r267", "r516", "r517", "r518", "r559", "r560", "r643", "r646", "r648", "r649", "r715" ], "lang": { "en-us": { "role": { "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.", "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.", "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r244", "r437", "r439", "r837" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r356", "r358", "r359", "r360", "r386", "r421", "r467", "r469", "r739", "r740", "r741", "r742", "r743", "r744", "r766", "r836", "r838", "r861", "r862" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r356", "r358", "r359", "r360", "r386", "r421", "r467", "r469", "r739", "r740", "r741", "r742", "r743", "r744", "r766", "r836", "r838", "r861", "r862" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r244", "r437", "r439", "r837" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails", "http://www.amerisourcebergen.com/role/VariableInterestEntityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails", "http://www.amerisourcebergen.com/role/VariableInterestEntityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ParentCompanyMember": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "The registrant that controls, directly or indirectly, another entity (or entities). The usual condition for control is ownership of a majority (over 50 percent) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.", "label": "Parent Company [Member]", "terseLabel": "Parent Company" } } }, "localname": "ParentCompanyMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r335", "r356", "r358", "r359", "r360", "r386", "r421", "r442", "r467", "r469", "r505", "r506", "r507", "r739", "r740", "r741", "r742", "r743", "r744", "r766", "r836", "r838", "r861", "r862" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r335", "r356", "r358", "r359", "r360", "r386", "r421", "r442", "r467", "r469", "r505", "r506", "r507", "r739", "r740", "r741", "r742", "r743", "r744", "r766", "r836", "r838", "r861", "r862" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r77", "r78", "r151", "r152", "r387", "r422" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r161", "r880" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "terseLabel": "SCHEDULE II\u00a0\u2014 VALUATION AND QUALIFYING ACCOUNTS" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" ], "xbrltype": "textBlockItemType" }, "srt_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/srt/2022", "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r155", "r156", "r157", "r159", "r160", "r880" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201613Member": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.", "label": "Accounting Standards Update 2016-13 [Member]", "terseLabel": "ASU 2016-13" } } }, "localname": "AccountingStandardsUpdate201613Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r167", "r168", "r169", "r170", "r254", "r255", "r264", "r265", "r266", "r267", "r268", "r269", "r516", "r517", "r518", "r559", "r560", "r590", "r591", "r592", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r687", "r688", "r693", "r694", "r695", "r712", "r713", "r714", "r715", "r716", "r717", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]", "terseLabel": "Accounting Standards Update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r63", "r729" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "auth_ref": [ "r797", "r825" ], "calculation": { "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r855" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts receivables" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r812", "r854" ], "calculation": { "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, after Allowance for Credit Loss", "terseLabel": "Accounts receivables, net" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r246", "r247" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "verboseLabel": "Accounts receivable, less allowances for returns and credit losses: 2022\u00a0\u2014 $1,626,729; 2021\u00a0\u2014 $1,356,684" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedParties": { "auth_ref": [ "r51", "r150", "r721", "r723", "r822" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.", "label": "Accounts Receivable, Related Parties", "terseLabel": "Receivable from related party" } } }, "localname": "AccountsReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "auth_ref": [ "r45", "r791", "r814" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.", "label": "Accrued Income Taxes, Noncurrent", "terseLabel": "Accrued income taxes" } } }, "localname": "AccruedIncomeTaxesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities and Other Liabilities", "terseLabel": "Accrued expenses and other" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r67" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "verboseLabel": "Accrued expenses and other" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r81", "r85", "r93", "r94", "r95", "r616" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Pension and postretirement adjustments" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingComponentsofAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r35", "r324" ], "calculation": { "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingComponentsofAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r54", "r83", "r84", "r85", "r818", "r846", "r850" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r93", "r94", "r677", "r678", "r679", "r680", "r681", "r683" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingComponentsofAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r82", "r85", "r93", "r94", "r95", "r163", "r164", "r165", "r616", "r717", "r841", "r842" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss", "verboseLabel": "Total accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingComponentsofAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r80", "r85", "r93", "r94", "r95", "r616", "r678", "r679", "r680", "r681", "r683" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingComponentsofAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Weighted-Average Useful Life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleFairValueOfIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r52" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r163", "r164", "r165", "r516", "r517", "r518", "r648" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r133", "r310" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "verboseLabel": "Amortization, including amounts charged to interest expense" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r167", "r168", "r169", "r170", "r180", "r254", "r255", "r264", "r265", "r266", "r267", "r268", "r269", "r516", "r517", "r518", "r557", "r558", "r559", "r560", "r590", "r591", "r592", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r687", "r688", "r693", "r694", "r695", "r696", "r712", "r713", "r714", "r715", "r716", "r717", "r770", "r771", "r772", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r472", "r520", "r521" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r509" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r58", "r249", "r270" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowances for returns and credit losses" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r133", "r300", "r310" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense", "verboseLabel": "Amortization" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmountRecognizedInIncomeDueToInflationaryAccounting": { "auth_ref": [ "r685" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount that will be recognized through the income statement (as well as the impact on the other financial statements) as part of highly inflationary accounting.", "label": "Amount Recognized in Income Due to Inflationary Accounting", "terseLabel": "Turkey highly inflationary impact" } } }, "localname": "AmountRecognizedInIncomeDueToInflationaryAccounting", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesForeignCurrencyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of diluted earnings per share (shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r133", "r319" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "negatedLabel": "Impairment of assets", "terseLabel": "Impairment of assets, including goodwill" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r39", "r145", "r223", "r230", "r237", "r262", "r368", "r369", "r370", "r372", "r373", "r374", "r375", "r377", "r379", "r381", "r382", "r610", "r619", "r663", "r727", "r729", "r789", "r813" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r30", "r62", "r145", "r262", "r368", "r369", "r370", "r372", "r373", "r374", "r375", "r377", "r379", "r381", "r382", "r610", "r619", "r663", "r727", "r729" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r5", "r6", "r21", "r23", "r27", "r321", "r330" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Assets held for sale", "totalLabel": "Total assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails", "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r476", "r477", "r478", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r490", "r491", "r492", "r493", "r494", "r495", "r497", "r498", "r500", "r501", "r504", "r505", "r506", "r507", "r508" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]", "terseLabel": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r476", "r477", "r478", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r490", "r491", "r492", "r493", "r494", "r495", "r497", "r498", "r500", "r501", "r504", "r505", "r506", "r507", "r508" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted.", "label": "Award Date [Domain]", "terseLabel": "Award Date [Domain]" } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r476", "r477", "r478", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r490", "r491", "r492", "r493", "r494", "r495", "r497", "r498", "r500", "r501", "r504", "r505", "r506", "r507", "r508" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r636", "r637" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Buildings and improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r466", "r468", "r586" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleFairValueOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r466", "r468", "r580", "r581", "r586" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleFairValueOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r579" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Ownership percentage" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "auth_ref": [ "r601" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.", "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "terseLabel": "Goodwill expected to be deductible" } } }, "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": { "auth_ref": [ "r584" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.", "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value", "negatedTerseLabel": "Noncontrolling interest", "terseLabel": "Noncontrolling interest" } } }, "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r578" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpensesDetails": { "order": 2.0, "parentTag": "abc_BusinessCombinationAcquisitionIntegrationAndRestructuringExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Acquisition-related deal and integration", "verboseLabel": "Acquisition related costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpensesDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r594", "r595", "r597" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "totalLabel": "Fair value of total consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r594", "r595" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Equity (2 million shares of AmerisourceBergen Corporation common stock)", "verboseLabel": "Equity issued" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredOther1": { "auth_ref": [ "r599" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.", "label": "Business Combination, Consideration Transferred, Other", "terseLabel": "Other equity consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredOther1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r132", "r602" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "negatedTerseLabel": "Contingent consideration adjustment" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r593", "r596", "r600" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Accrued consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r587", "r603" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisition and Assets and Liabilities Held for Sale" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSale" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r583" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r583" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r583" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r583" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r583" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedTerseLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": { "auth_ref": [ "r583" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "terseLabel": "Deferred income taxes" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r583" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedTerseLabel": "Deferred income taxes" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r582", "r583" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r583" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedTotalLabel": "Total liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r582", "r583" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "auth_ref": [ "r583" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "negatedTerseLabel": "Other liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r583" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r582", "r583" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r658", "r659" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying amount" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r113" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash Acquired from Acquisition", "terseLabel": "Acquired cash and cash equivalents" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r28", "r33", "r135" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r136", "r787" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents, and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r129", "r135", "r138" ], "calculation": { "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT END OF YEAR", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of year", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails", "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r129", "r676" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r431", "r432", "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r72", "r798", "r824" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note\u00a013)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r350", "r351", "r352", "r361", "r856" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Litigation Settlements" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LitigationSettlements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r364", "r857" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments Disclosure [Text Block]", "terseLabel": "Leases" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Cash dividends (usd per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "verboseLabel": "Quarterly cash dividend declared (usd per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r163", "r164", "r648" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r49", "r424" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding (shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r49", "r729" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.01 par value\u00a0\u2014 authorized, issued, and outstanding: 2022\u00a0\u2014 600,000,000 shares, 292,700,490 shares and 206,203,817 shares; 2021\u00a0\u2014 600,000,000 shares, 290,722,533 shares and 208,089,298 shares" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets and Liabilities [Abstract]", "terseLabel": "Components of Deferred Tax Assets and Liabilities [Abstract]" } } }, "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r88", "r90", "r91", "r103", "r804", "r831" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss) income attributable to AmerisourceBergen Corporation" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r88", "r90", "r102", "r607", "r608", "r630", "r803", "r830" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "negatedTerseLabel": "Comprehensive loss (income) attributable to noncontrolling interests" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r88", "r90", "r101", "r606", "r630", "r802", "r829" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r204", "r205", "r244", "r660", "r661", "r855" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r204", "r205", "r244", "r660", "r661", "r852", "r855" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r204", "r205", "r244", "r660", "r661", "r852", "r855" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r204", "r205", "r244", "r660", "r661" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r202", "r204", "r205", "r206", "r660", "r662", "r855" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r204", "r205", "r244", "r660", "r661", "r855" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "auth_ref": [ "r618", "r622", "r624" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "ConsolidationVariableInterestEntityPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetGrossCurrent": { "auth_ref": [ "r435", "r436" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract with Customer, Asset, before Allowance for Credit Loss, Current", "terseLabel": "Right to recover assets" } } }, "localname": "ContractWithCustomerAssetGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r108", "r768" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of Sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesForeignCurrencyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Manufacturer Incentives" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r146", "r554", "r563" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r146", "r554" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r146", "r554", "r563", "r565" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current provision (benefit)" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "verboseLabel": "Current provision (benefit):" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r146", "r554", "r563" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State and local" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r203", "r244" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r589" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleFairValueOfIntangibleAssetsDetails", "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of debt and lease obligation, classified as current.", "label": "Debt, Current", "terseLabel": "Short-term debt" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r143", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r400", "r407", "r408", "r410", "r419" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r41", "r42", "r44", "r144", "r154", "r383", "r384", "r385", "r386", "r387", "r388", "r390", "r396", "r397", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r413", "r414", "r415", "r416", "r691", "r790", "r793", "r811" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable rate spread" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r383", "r413", "r414", "r690", "r691", "r692" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r69", "r412", "r690", "r691" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective yield percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r69", "r384" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r70", "r144", "r154", "r383", "r384", "r385", "r386", "r387", "r388", "r390", "r396", "r397", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r413", "r414", "r415", "r416", "r691" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r70", "r144", "r154", "r383", "r384", "r385", "r386", "r387", "r388", "r390", "r396", "r397", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r409", "r413", "r414", "r415", "r416", "r425", "r426", "r427", "r428", "r689", "r690", "r691", "r692", "r808" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": { "auth_ref": [ "r112" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses.", "label": "Debt Related Commitment Fees and Debt Issuance Costs", "verboseLabel": "Amortization of financing fees and accretion of original issue discounts" } } }, "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability": { "auth_ref": [ "r441" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of the liability as of the balance sheet date to an individual under a deferred compensation arrangement. This amount may be the result of periodic accruals made over the period of active employment, or reflect termination benefits resulting contractual terms or a death benefit.", "label": "Deferred Compensation Arrangement with Individual, Recorded Liability", "terseLabel": "Deferred compensation liability" } } }, "localname": "DeferredCompensationArrangementWithIndividualRecordedLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r146", "r555", "r563" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r146", "r555", "r563" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r528", "r529" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r133", "r146", "r555", "r563", "r564", "r565" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "negatedLabel": "Deferred tax benefit", "totalLabel": "Total deferred provision (benefit)", "verboseLabel": "Provision (benefit) for deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW", "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred provision (benefit):" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r46", "r47", "r544", "r792", "r810" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "totalLabel": "Gross deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r528", "r529" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r146", "r555", "r563" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State and local" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetDomain": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.", "label": "Deferred Tax Asset [Domain]", "terseLabel": "Deferred Tax Asset [Domain]" } } }, "localname": "DeferredTaxAssetDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "negatedLabel": "Goodwill and other intangible assets", "terseLabel": "Deferred tax asset" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r545" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "negatedTotalLabel": "Gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r547" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "negatedTotalLabel": "Deferred tax assets, net of valuation allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r552", "r553" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "negatedLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": { "auth_ref": [ "r552", "r553" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits", "negatedLabel": "Employee and retiree benefits" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r552", "r553" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "negatedLabel": "Share-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r552", "r553" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "negatedLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "auth_ref": [ "r552", "r553" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.", "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss", "negatedLabel": "Allowance for credit losses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": { "auth_ref": [ "r552", "r553" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies", "negatedLabel": "Accrued litigation liability" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r546" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "terseLabel": "Valuation allowance for deferred tax assets" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r529", "r547" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "totalLabel": "Net deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesDeferredExpense": { "auth_ref": [ "r552", "r553" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs.", "label": "Deferred Tax Liabilities, Deferred Expense", "terseLabel": "Deferred tax expense" } } }, "localname": "DeferredTaxLiabilitiesDeferredExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts": { "auth_ref": [ "r552", "r553" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.", "label": "Deferred Tax Liabilities, Inventory", "terseLabel": "Inventories" } } }, "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": { "auth_ref": [ "r552", "r553" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets", "terseLabel": "Goodwill and other intangible assets" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "auth_ref": [ "r552", "r553" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.", "label": "Deferred Tax Liabilities, Leasing Arrangements", "terseLabel": "Right-of-use assets" } } }, "localname": "DeferredTaxLiabilitiesLeasingArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r552", "r553" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r552", "r553" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsofDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r465" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Defined contribution plans expense" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Employer matching contribution, percent of salary" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Employer matching contribution, percent of match" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Maximum allowed employee contributions, percent of salary" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r133", "r322" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation, including amounts charged to cost of goods sold" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r133", "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Total depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationNonproduction": { "auth_ref": [ "r133", "r322" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.", "label": "Depreciation, Nonproduction", "verboseLabel": "Depreciation" } } }, "localname": "DepreciationNonproduction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r153", "r632", "r633", "r634", "r635", "r638" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r475", "r476", "r510", "r511", "r513", "r523" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "auth_ref": [ "r9", "r10", "r11", "r12", "r20", "r24", "r530", "r562", "r571" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "negatedTerseLabel": "Tax benefit" } } }, "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationsHeldforsaleMember": { "auth_ref": [ "r7", "r8", "r23" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.", "label": "Discontinued Operations, Held-for-sale [Member]", "terseLabel": "Held for sale" } } }, "localname": "DiscontinuedOperationsHeldforsaleMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "auth_ref": [ "r5", "r6", "r21", "r330" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "terseLabel": "Accounts receivable, less allowance for credit losses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": { "auth_ref": [ "r5", "r6", "r21", "r321", "r330" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": { "auth_ref": [ "r5", "r6", "r21", "r321", "r330" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "auth_ref": [ "r5", "r6", "r21", "r330" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Total proceeds" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent": { "auth_ref": [ "r5", "r6", "r21", "r321", "r330" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as deferred revenue attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Deferred Revenue, Current", "terseLabel": "Deferred income taxes" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent": { "auth_ref": [ "r5", "r6", "r21", "r321", "r330" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails": { "order": 9.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Goodwill, Current", "terseLabel": "Goodwill" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent": { "auth_ref": [ "r5", "r6", "r21", "r321", "r330" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails": { "order": 6.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Current", "terseLabel": "Other intangible assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "auth_ref": [ "r5", "r6", "r21", "r321", "r330" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails": { "order": 8.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Inventory, Current", "terseLabel": "Inventories" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": { "auth_ref": [ "r5", "r6", "r21", "r321", "r330" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current", "terseLabel": "Other assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": { "auth_ref": [ "r5", "r6", "r21", "r321", "r330" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current", "terseLabel": "Other liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r6", "r21", "r321", "r330" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails": { "order": 7.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current", "terseLabel": "Prepaid expenses and other" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": { "auth_ref": [ "r5", "r6", "r21", "r321", "r330" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails": { "order": 5.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current", "terseLabel": "Property and equipment" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "auth_ref": [ "r133", "r320", "r328" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "terseLabel": "Net gain" } } }, "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of income that includes gain (loss) recognized on sale or disposal of disposal group. Excludes discontinued operation.", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]" } } }, "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": { "auth_ref": [ "r133", "r320", "r328" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down", "verboseLabel": "Loss on write-down" } } }, "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r466", "r468" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r429" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Cash dividends" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "U.S.", "verboseLabel": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r104", "r172", "r173", "r174", "r175", "r176", "r181", "r183", "r188", "r189", "r190", "r193", "r194", "r649", "r650", "r805", "r832" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r104", "r172", "r173", "r174", "r175", "r176", "r183", "r188", "r189", "r190", "r193", "r194", "r649", "r650", "r805", "r832" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "perShareItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r676" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 3.0, "parentTag": "abc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAndDisposalGroupIncludingDiscontinueOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r531" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r148", "r531", "r567" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory U.S. federal income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r531", "r567" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "Tax law changes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r531", "r567" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Tax effect of foreign operations" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r531", "r567" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other, net" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "auth_ref": [ "r522", "r531" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount", "negatedLabel": "Excess tax benefit from the exercise of stock options and lapses of restricted stock units" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r531", "r567" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State and local income tax rate, net of federal tax benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": { "auth_ref": [ "r531", "r567" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.", "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent", "terseLabel": "Litigation settlements and accruals (see Note 13)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r512" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Expected future compensation expense relating to restricted shares outstanding" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average period over which expected future compensation expense relating to restricted shares outstanding will be recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r512" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Expected future compensation expense relating to nonvested options outstanding" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Employee options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r93", "r94", "r95", "r163", "r164", "r165", "r168", "r177", "r179", "r197", "r267", "r424", "r429", "r516", "r517", "r518", "r559", "r560", "r648", "r677", "r678", "r679", "r680", "r681", "r683", "r717", "r841", "r842", "r843" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingComponentsofAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r128", "r261", "r663" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "Equity Securities" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r398", "r413", "r414", "r657" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessOfReplacementOrCurrentCostsOverStatedLIFOValue": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The excess of replacement or current cost over the stated LIFO (last in first out) inventory value when the LIFO inventory method is utilized.", "label": "Excess of Replacement or Current Costs over Stated LIFO Value", "terseLabel": "Excess cost of inventories over LIFO, if used FIFO" } } }, "localname": "ExcessOfReplacementOrCurrentCostsOverStatedLIFOValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesMerchandiseInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r652", "r658", "r659" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r398", "r413", "r414", "r443", "r445", "r446", "r447", "r448", "r449", "r450", "r462", "r653", "r736", "r737", "r738" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r398", "r413", "r414", "r652", "r655" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r398", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueofFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r398", "r443", "r445", "r450", "r462", "r653", "r736" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r398", "r413", "r414", "r443", "r445", "r450", "r462", "r653", "r737" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r398", "r413", "r414", "r443", "r445", "r446", "r447", "r448", "r449", "r450", "r462", "r736", "r737", "r738" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r256", "r257", "r258", "r259", "r260", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r409", "r423", "r639", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r871", "r872", "r873", "r874", "r875", "r876", "r877" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]", "terseLabel": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]" } } }, "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Weighted Average Remaining Useful Life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r37", "r309" ], "calculation": { "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 }, "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails_1": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r311" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r311" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r311" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r311" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r311" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r301", "r305", "r309", "r313", "r769", "r773" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleFairValueOfIntangibleAssetsDetails", "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r309", "r773" ], "calculation": { "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleFairValueOfIntangibleAssetsDetails", "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r301", "r308" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleFairValueOfIntangibleAssetsDetails", "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r309", "r769" ], "calculation": { "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]", "terseLabel": "Finite-Lived" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r302" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-Lived Intangible Assets Acquired", "terseLabel": "Fair Value" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleFairValueOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r672", "r673", "r674", "r675" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Foreign currency loss" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r686" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnSaleOfBusiness": { "auth_ref": [ "r133", "r617" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.", "label": "Gain (Loss) on Disposition of Business", "negatedTerseLabel": "Gain on sale of businesses", "terseLabel": "Gain (loss) on disposition of business" } } }, "localname": "GainLossOnSaleOfBusiness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r133" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "terseLabel": "Gain on the sale of a facility" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r353" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (Loss) Related to Litigation Settlement", "verboseLabel": "Gains from antitrust litigation settlements" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/LitigationSettlementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossRelatedToLitigationSettlementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Settlement [Abstract]", "terseLabel": "Litigation Settlement [Abstract]" } } }, "localname": "GainLossRelatedToLitigationSettlementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r133", "r417", "r418" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on early retirement of debt", "negatedTerseLabel": "Loss on early retirement of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r36", "r285", "r287", "r294", "r298", "r729", "r788" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails", "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingValueofGoodwillDetails", "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r288", "r298" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "verboseLabel": "Goodwill recognized in connection with acquisition" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingValueofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "verboseLabel": "Goodwill and Other Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r295", "r306" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Other Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r292" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "verboseLabel": "Foreign currency translation" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingValueofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r133", "r286", "r291", "r297", "r298" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "negatedLabel": "Goodwill impairment", "terseLabel": "Goodwill impairment", "verboseLabel": "Goodwill impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingValueofGoodwillDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingValueofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r293", "r577" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Purchase accounting adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingValueofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingValueofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillTransfers": { "auth_ref": [ "r293" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers into (out of) an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Transfers", "terseLabel": "Goodwill reclassified to assets held for sale" } } }, "localname": "GoodwillTransfers", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingValueofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "auth_ref": [ "r290", "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Written off Related to Sale of Business Unit", "negatedTerseLabel": "Goodwill derecognized in connection with disposal" } } }, "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingValueofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r107", "r145", "r223", "r229", "r233", "r236", "r239", "r262", "r368", "r369", "r370", "r373", "r374", "r375", "r377", "r379", "r381", "r382", "r663" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_HerMajestysRevenueAndCustomsHMRCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of United Kingdom.", "label": "Her Majesty's Revenue and Customs (HMRC) [Member]", "terseLabel": "UK" } } }, "localname": "HerMajestysRevenueAndCustomsHMRCMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Impaired Long-Lived Assets Held and Used [Line Items]", "terseLabel": "Assets Held and Used [Line Items]" } } }, "localname": "ImpairedLongLivedAssetsHeldAndUsedLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r133", "r314" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Impairment loss" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r133", "r318" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Impairment of assets, including goodwill" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r317", "r334" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Held for Sale" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r147", "r566" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesDomesticandForeignIncomeFromContinuingOperationsBeforeIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesDomesticandForeignIncomeFromContinuingOperationsBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r98", "r223", "r229", "r233", "r236", "r239", "r786", "r799", "r806", "r833" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/IncomeTaxesDomesticandForeignIncomeFromContinuingOperationsBeforeIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.amerisourcebergen.com/role/IncomeTaxesDomesticandForeignIncomeFromContinuingOperationsBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r147", "r566" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesDomesticandForeignIncomeFromContinuingOperationsBeforeIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesDomesticandForeignIncomeFromContinuingOperationsBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r466", "r468" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r6", "r14", "r15", "r16", "r17", "r18", "r19", "r22", "r25", "r26", "r27", "r332", "r333" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r329", "r339" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesForeignCurrencyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesForeignCurrencyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r148", "r532", "r542", "r549", "r561", "r568", "r572", "r573", "r575" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityCumulativeEffectOfChangeInAccountingPrinciple": { "auth_ref": [ "r562", "r569" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative tax effect on beginning retained earnings from change in accounting principle.", "label": "Income Tax Effects Allocated Directly to Equity, Cumulative Effect of Change in Accounting Principle", "terseLabel": "Cumulative adjustment to retained earnings, tax" } } }, "localname": "IncomeTaxEffectsAllocatedDirectlyToEquityCumulativeEffectOfChangeInAccountingPrinciple", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r149", "r178", "r179", "r221", "r530", "r562", "r570", "r834" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "totalLabel": "Provision (benefit) for income taxes", "verboseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r92", "r526", "r527", "r542", "r543", "r548", "r556" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationDispositionOfBusiness": { "auth_ref": [ "r531" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation.", "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Amount", "terseLabel": "Worthless stock ordinary income tax deduction" } } }, "localname": "IncomeTaxReconciliationDispositionOfBusiness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r137" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income tax payments, net of refunds" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r50", "r796", "r826" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Current", "terseLabel": "Income tax receivable", "verboseLabel": "Net current income tax receivable" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r132" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r132" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r132" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": { "auth_ref": [ "r132" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.", "label": "Increase (Decrease) in Income Taxes Receivable", "negatedTerseLabel": "Income tax receivable" } } }, "localname": "IncreaseDecreaseInIncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r132" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r132" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (decrease) in stockholders' equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r184", "r185", "r186", "r190", "r474" ], "calculation": { "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingComponentsofDilutedWeightedAverageSharesOutstandingDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Effect of dilutive securities\u00a0- stock options and restricted stock units (shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingComponentsofDilutedWeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r304", "r312" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-Lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r312" ], "calculation": { "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangibles" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r304", "r312" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [ "r36" ], "calculation": { "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails_1": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "totalLabel": "Gross Carrying Amount" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r299", "r307" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Other intangible assets", "totalLabel": "Net Carrying Amount" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "negatedLabel": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r126", "r130", "r137" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterimPeriodCostsNotAllocableDomain": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred.", "label": "Interim Period, Costs Not Allocable [Domain]", "terseLabel": "Interim Period, Costs Not Allocable [Domain]" } } }, "localname": "InterimPeriodCostsNotAllocableDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r215", "r228", "r229", "r230", "r231", "r233", "r235", "r239" ], "lang": { "en-us": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations [Member]", "terseLabel": "Intersegment eliminations" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryLIFOReservePeriodCharge": { "auth_ref": [ "r283" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.", "label": "Inventory, LIFO Reserve, Period Charge", "negatedLabel": "LIFO (expense) credit", "terseLabel": "LIFO expense (credit)" } } }, "localname": "InventoryLIFOReservePeriodCharge", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesMerchandiseInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r29", "r61", "r729" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r32", "r59", "r140", "r195", "r281", "r282", "r284", "r767" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestorMember": { "auth_ref": [ "r720", "r721" ], "lang": { "en-us": { "role": { "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.", "label": "Investor [Member]", "terseLabel": "Investor" } } }, "localname": "InvestorMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r709", "r711" ], "calculation": { "http://www.amerisourcebergen.com/role/LeasesLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r709" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Legal Matters and Contingencies" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r701" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r710" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Renal Payments, Operating Leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r710" ], "calculation": { "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total future undiscounted lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r710" ], "calculation": { "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r710" ], "calculation": { "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r710" ], "calculation": { "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r710" ], "calculation": { "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r710" ], "calculation": { "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r710" ], "calculation": { "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r710" ], "calculation": { "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r66", "r145", "r231", "r262", "r368", "r369", "r370", "r373", "r374", "r375", "r377", "r379", "r381", "r382", "r611", "r619", "r620", "r663", "r727", "r728" ], "calculation": { "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r57", "r145", "r262", "r663", "r729", "r795", "r821" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r31", "r68", "r145", "r262", "r368", "r369", "r370", "r373", "r374", "r375", "r377", "r379", "r381", "r382", "r611", "r619", "r620", "r663", "r727", "r728", "r729" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r5", "r6", "r21", "r23", "r27", "r321", "r330" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "terseLabel": "Liabilities held for sale", "totalLabel": "Total liabilities held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsandLiabilitiesHeldforSaleDetails", "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Facility fee" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationReserveNoncurrent": { "auth_ref": [ "r72", "r353" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.", "label": "Estimated Litigation Liability, Noncurrent", "terseLabel": "Accrued litigation liability" } } }, "localname": "LitigationReserveNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation Settlement, Expense", "terseLabel": "Litigation and opioid-related expenses" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r44", "r397", "r411", "r413", "r414", "r793", "r816" ], "calculation": { "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "terseLabel": "Long-term debt", "totalLabel": "Total debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails", "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r65" ], "calculation": { "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Less nonrecourse current portion" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-Term Debt, Fair Value", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r154", "r366", "r402" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "terseLabel": "Scheduled future principal payments, thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r154", "r366", "r402" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "Scheduled future principal payments, in fiscal 2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r154", "r366", "r402" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "Scheduled future principal payments, in fiscal 2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r154", "r366", "r402" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "Scheduled future principal payments, in fiscal 2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r154", "r366", "r402" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "Scheduled future principal payments, in fiscal 2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r154", "r366", "r402" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "Scheduled future principal payments, in fiscal 2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "verboseLabel": "Total, net of current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r70", "r367" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r353", "r355", "r356", "r357", "r358", "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r353", "r354" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Total liability accrual" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualCarryingValueCurrent": { "auth_ref": [ "r353" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.", "label": "Loss Contingency, Accrual, Current", "terseLabel": "Current estimate recorded in accrued expenses and other" } } }, "localname": "LossContingencyAccrualCarryingValueCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualProvision": { "auth_ref": [ "r353" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.", "label": "Loss Contingency Accrual, Provision", "terseLabel": "Recorded charge", "verboseLabel": "Legal accrual" } } }, "localname": "LossContingencyAccrualProvision", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyClaimsSettledNumber": { "auth_ref": [ "r355", "r357" ], "lang": { "en-us": { "role": { "documentation": "Number of claims settled.", "label": "Loss Contingency, Claims Settled, Number", "terseLabel": "Settling States" } } }, "localname": "LossContingencyClaimsSettledNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyDamagesAwardedValue": { "auth_ref": [ "r353", "r355", "r357" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of damages awarded to the plaintiff in the legal matter.", "label": "Loss Contingency, Damages Awarded, Value", "terseLabel": "Loss contingency, damages awarded, value" } } }, "localname": "LossContingencyDamagesAwardedValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyPendingClaimsNumber": { "auth_ref": [ "r355", "r357" ], "lang": { "en-us": { "role": { "documentation": "Number of pending claims pertaining to a loss contingency.", "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Number of pending claims" } } }, "localname": "LossContingencyPendingClaimsNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery, equipment, and other" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Segment reconciling items" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentOperatingIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r75", "r145", "r262", "r368", "r373", "r374", "r375", "r381", "r382", "r663", "r794", "r820" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Ownership percentage (more than)" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Ownership percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market accounts" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NatureOfExpenseAxis": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cost or expense.", "label": "Nature of Expense [Axis]", "terseLabel": "Nature of Expense [Axis]" } } }, "localname": "NatureOfExpenseAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r129" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 2.0, "parentTag": "abc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAndDisposalGroupIncludingDiscontinueOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r129" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 1.0, "parentTag": "abc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAndDisposalGroupIncludingDiscontinueOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r129", "r131", "r134" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 4.0, "parentTag": "abc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAndDisposalGroupIncludingDiscontinueOperation", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "NET CASH PROVIDED BY OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r27", "r86", "r89", "r95", "r99", "r134", "r145", "r167", "r172", "r173", "r174", "r175", "r178", "r179", "r187", "r223", "r229", "r233", "r236", "r239", "r262", "r368", "r369", "r370", "r373", "r374", "r375", "r377", "r379", "r381", "r382", "r650", "r663", "r800", "r827" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income (loss) attributable to AmerisourceBergen Corporation" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r86", "r89", "r95", "r178", "r179", "r613", "r629" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net loss (income) attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesForeignCurrencyDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r166", "r167", "r168", "r169", "r170", "r171", "r174", "r180", "r193", "r254", "r255", "r264", "r265", "r266", "r267", "r268", "r269", "r516", "r517", "r518", "r557", "r558", "r559", "r560", "r590", "r591", "r592", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r687", "r688", "r693", "r694", "r695", "r696", "r712", "r713", "r714", "r715", "r716", "r717", "r770", "r771", "r772", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesForeignCurrencyDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": { "auth_ref": [ "r430", "r615" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.", "label": "Noncontrolling Interest, Decrease from Deconsolidation", "negatedTerseLabel": "Sale of business" } } }, "localname": "NoncontrollingInterestDecreaseFromDeconsolidation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "auth_ref": [ "r430", "r609", "r615" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "terseLabel": "Acquisition of Alliance Healthcare (Note 2)" } } }, "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r163", "r164", "r165", "r429", "r604" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-controlling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r111" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedLabel": "Other income", "negatedTerseLabel": "Other income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableToBanksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a bank.", "label": "Notes Payable to Banks [Member]", "terseLabel": "Notes Payable to Banks" } } }, "localname": "NotesPayableToBanksMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/SubsequentEventsDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r223", "r229", "r233", "r236", "r239" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating income", "totalLabel": "Operating income (loss)", "verboseLabel": "Total segment operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentOperatingIncomeDetails", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r702", "r711" ], "calculation": { "http://www.amerisourcebergen.com/role/LeasesLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r698" ], "calculation": { "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/LeasesSummaryofBalanceSheetInformationRelatedtoLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesFutureMinimumRentalPaymentsUnderNoncancelableOperatingLeasesDetails", "http://www.amerisourcebergen.com/role/LeasesSummaryofBalanceSheetInformationRelatedtoLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability [Abstract]", "terseLabel": "Lease liabilities" } } }, "localname": "OperatingLeaseLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesSummaryofBalanceSheetInformationRelatedtoLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r698" ], "calculation": { "http://www.amerisourcebergen.com/role/LeasesSummaryofBalanceSheetInformationRelatedtoLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Accrued expenses and other" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesSummaryofBalanceSheetInformationRelatedtoLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r699" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesSummaryofBalanceSheetInformationRelatedtoLeasesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r698" ], "calculation": { "http://www.amerisourcebergen.com/role/LeasesSummaryofBalanceSheetInformationRelatedtoLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesSummaryofBalanceSheetInformationRelatedtoLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r699" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesSummaryofBalanceSheetInformationRelatedtoLeasesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r700", "r705" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating lease cash payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r697" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Other assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesOtherInformationDetails", "http://www.amerisourcebergen.com/role/LeasesSummaryofBalanceSheetInformationRelatedtoLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r699" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesSummaryofBalanceSheetInformationRelatedtoLeasesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r708", "r711" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesSummaryofBalanceSheetInformationRelatedtoLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r707", "r711" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesSummaryofBalanceSheetInformationRelatedtoLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r550" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Potential tax benefits from net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r228", "r229", "r230", "r231", "r233", "r239" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentOperatingIncomeDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets", "verboseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r79" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r87", "r90", "r93", "r94", "r96", "r100", "r424", "r677", "r682", "r683", "r801", "r828" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive (loss) income", "totalLabel": "Total other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeOtherNetOfTax": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in other comprehensive income, after tax, from changes classified as other.", "label": "Other Comprehensive Income, Other, Net of Tax", "terseLabel": "Other, net" } } }, "localname": "OtherComprehensiveIncomeOtherNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDepreciationAndAmortization": { "auth_ref": [ "r109", "r133", "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.", "label": "Other Depreciation and Amortization", "negatedLabel": "Acquisition-related intangibles amortization", "terseLabel": "Acquisition-related intangibles amortization" } } }, "localname": "OtherDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIntangibleAssetsNet": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.", "label": "Other Intangible Assets, Net", "terseLabel": "Other intangible assets" } } }, "localname": "OtherIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r71" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "verboseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r134" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherRestructuringCosts": { "auth_ref": [ "r133" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpensesDetails": { "order": 4.0, "parentTag": "abc_BusinessCombinationAcquisitionIntegrationAndRestructuringExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.", "label": "Other Restructuring Costs", "terseLabel": "Other restructuring initiatives" } } }, "localname": "OtherRestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r115", "r118" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other, net" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r122" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "auth_ref": [ "r124" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "negatedTerseLabel": "Payment of premium on early retirement of debt", "terseLabel": "Payment of premium on early retirement of debt" } } }, "localname": "PaymentsOfDebtExtinguishmentCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW", "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r122" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Cash dividends on common stock" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r122" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedTerseLabel": "Tax withholdings related to restricted share vesting" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r116", "r598" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash", "verboseLabel": "Purchase price in cash" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r116" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Cost of acquired companies, net of cash acquired", "terseLabel": "Net cash paid" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r116" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments to Acquire Equity Method Investments", "negatedLabel": "Cost of equity investments" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r117" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Capital expenditures", "terseLabel": "Total capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentOperatingIncomeDetails", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_PendingLitigationMember": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.", "label": "Pending Litigation [Member]", "terseLabel": "Pending Litigation" } } }, "localname": "PendingLitigationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r442", "r444", "r450", "r451", "r453", "r454", "r455", "r456", "r457", "r462", "r463", "r464", "r465", "r470" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "Retirement and Other Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PercentageOfLIFOInventory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of LIFO (last in first out) inventory to total inventory as of the balance sheet date if other than 100 percent.", "label": "Percentage of LIFO Inventory", "terseLabel": "Percentage of inventories, cost determined using LIFO" } } }, "localname": "PercentageOfLIFOInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesMerchandiseInventoriesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance stock units" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r656" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r48", "r420" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r62" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r113" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from sale of businesses" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r119" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Profarma retail equity offering" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW", "http://www.amerisourcebergen.com/role/VariableInterestEntityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r120" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Senior notes and other loan borrowings" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r120", "r144" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "verboseLabel": "Borrowings under revolving and securitization credit facilities" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r121", "r125" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "verboseLabel": "Other, net" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r114" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of property and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r119", "r515" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Exercises of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r27", "r86", "r89", "r95", "r127", "r145", "r167", "r178", "r179", "r223", "r229", "r233", "r236", "r239", "r262", "r368", "r369", "r370", "r373", "r374", "r375", "r377", "r379", "r381", "r382", "r606", "r612", "r614", "r629", "r630", "r650", "r663", "r806" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r34", "r323" ], "calculation": { "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, at cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r325", "r729", "r807", "r823" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails", "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r325", "r858", "r859" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r105", "r272" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "verboseLabel": "Provision for credit losses" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r248", "r251", "r252", "r253" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk and Allowance for Credit Losses" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r229", "r233" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Schedule of Reconciliation of Total Segment Operating Income to Income from Continuing Operations before Income Taxes" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r231", "r233" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of each significant reconciling item, other than profit (loss), revenues, or assets, in the reconciliation of totals of such items in reportable segments to the entity's corresponding consolidated amount.", "label": "Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]", "terseLabel": "Schedule of Operating Income" } } }, "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r228", "r233" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "terseLabel": "Schedule of Segments Revenue" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r452", "r720", "r721" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r452", "r720", "r723", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r718", "r719", "r721", "r724", "r725" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r123", "r144" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedLabel": "Repayments under revolving and securitization credit facilities" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r123" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "terseLabel": "Repayments of debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "auth_ref": [ "r123" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.", "label": "Repayments of Other Long-Term Debt", "negatedLabel": "Senior notes and other loan repayments" } } }, "localname": "RepaymentsOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r33", "r138", "r787", "r817" ], "calculation": { "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restricted Cash and Cash Equivalents Items [Line Items]", "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]" } } }, "localname": "RestrictedCashAndCashEquivalentsItemsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]", "terseLabel": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r337", "r338", "r341", "r348", "r349" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Acquisition, Integration, and Restructuring Expenses" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r133", "r336", "r344", "r346" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "negatedLabel": "Litigation and opioid-related expenses" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r53", "r429", "r729", "r819", "r845", "r850" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r163", "r164", "r165", "r168", "r177", "r179", "r267", "r516", "r517", "r518", "r559", "r560", "r648", "r841", "r843" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r106", "r371", "r373", "r374", "r380", "r381", "r382", "r853" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Revenue from related party" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r141", "r142" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r97", "r145", "r214", "r215", "r228", "r234", "r235", "r241", "r242", "r244", "r262", "r368", "r369", "r370", "r373", "r374", "r375", "r377", "r379", "r381", "r382", "r663", "r806" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentRevenueDetails", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r706", "r711" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "New operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.", "label": "Sale of Stock, Percentage of Ownership after Transaction", "terseLabel": "Ownership percentage after equity offering" } } }, "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.", "label": "Sale of Stock, Percentage of Ownership before Transaction", "terseLabel": "Ownership percentage before equity offering" } } }, "localname": "SaleOfStockPercentageOfOwnershipBeforeTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r204", "r244" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesConcentrationsofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r85", "r682", "r683" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Components of Accumulated Other Comprehensive Loss" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "terseLabel": "Schedule of Fair Value of the Intangible Assets Acquired" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r580", "r581", "r586" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash and Cash Equivalents" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Income Tax Expense (Benefit)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r70", "r154", "r413", "r415", "r425", "r426", "r427", "r428", "r689", "r690", "r692", "r808" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "verboseLabel": "Schedule of Debt Instruments" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Significant Components Of Deferred Tax Liabilities (Assets)" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r458", "r459", "r460", "r461", "r462" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementandOtherBenefitPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r6", "r14", "r15", "r16", "r17", "r18", "r19", "r22", "r25", "r26", "r27", "r332", "r333" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedule of Assets and Liabilities Held for Sale" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Reconciliation of Effective Income Tax Rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r301", "r308", "r769" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleFairValueOfIntangibleAssetsDetails", "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r301", "r308" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Other Intangible Assets - Finite-lived" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingValueofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "verboseLabel": "Schedule of Changes in the Carrying Value of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "For a long-lived asset to be held and used by an entity, the table may include a description of the impaired long-lived asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired long-lived asset is reported.", "label": "Schedule of Impaired Long-Lived Assets Held and Used [Table]", "terseLabel": "Schedule of Assets [Table]" } } }, "localname": "ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Domestic and Foreign Income from Continuing Operations before Income Taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r312", "r315" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r312", "r315" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Other Intangible Assets - Indefinite-lived" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.", "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]", "terseLabel": "Schedule of Nonvested Performance Stock Units" } } }, "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.", "label": "Schedule of Nonvested Share Activity [Table Text Block]", "terseLabel": "Schedule of Nonvested Options" } } }, "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r585" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r722", "r723" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": { "auth_ref": [ "r138", "r787", "r817" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table]", "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r138", "r787", "r817" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Restrictions on Cash and Cash Equivalents" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r342", "r343", "r345" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Schedule of Employee Severance, Litigation, and Other Charges" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r223", "r226", "r232", "r295" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentOperatingIncomeDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r471", "r473", "r476", "r477", "r478", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r490", "r491", "r492", "r493", "r494", "r495", "r497", "r498", "r500", "r501", "r504", "r505", "r506", "r507", "r508" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r480", "r496", "r499" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Options" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Weighted Average Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Nonvested Restricted Shares" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "auth_ref": [ "r610", "r611", "r619", "r620", "r621", "r623", "r625", "r626", "r627", "r747", "r748", "r749" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule of Variable Interest Entities [Table]", "terseLabel": "Schedule of Variable Interest Entities [Table]" } } }, "localname": "ScheduleOfVariableInterestEntitiesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": { "auth_ref": [ "r621", "r623", "r625", "r626", "r627" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule of Variable Interest Entities [Table Text Block]", "terseLabel": "Schedule of Assets and Liabilities of Profarma" } } }, "localname": "ScheduleOfVariableInterestEntitiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Schedule of Components of Diluted Weighted Average Shares Outstanding" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r210", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r228", "r229", "r230", "r231", "r233", "r234", "r235", "r236", "r237", "r239", "r244", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r298", "r340", "r347", "r835" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentOperatingIncomeDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentRevenueDetails", "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingValueofGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r210", "r212", "r213", "r223", "r227", "r233", "r237", "r238", "r239", "r240", "r241", "r243", "r244", "r245" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Business Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationofSegmentOperatingIncometoIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentOperatingIncomeDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r110" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "verboseLabel": "Distribution, selling, and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SettledLitigationMember": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.", "label": "Settled Litigation [Member]", "terseLabel": "Settled Litigation" } } }, "localname": "SettledLitigationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r133" ], "calculation": { "http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpensesDetails": { "order": 1.0, "parentTag": "abc_BusinessCombinationAcquisitionIntegrationAndRestructuringExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Employee severance" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionIntegrationandRestructuringExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r132" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "verboseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "terseLabel": "Service period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r495" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r495" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested, end of period (shares)", "periodStartLabel": "Nonvested, beginning of period (shares)", "terseLabel": "Nonvested shares outstanding (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted Stock Units", "verboseLabel": "Performance Stock Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested, end of period (usd per share)", "periodStartLabel": "Nonvested, beginning of period (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r498" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Total fair values of restricted shares vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility of common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable, end of period (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable, end of period (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r498" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of stock option exercises" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair values of options granted (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r514" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, end of period (shares)", "periodStartLabel": "Outstanding, beginning of period (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, end of period (usd per share)", "periodStartLabel": "Outstanding, beginning of period (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r501" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Expected to vest after end of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r476", "r477", "r478", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r490", "r491", "r492", "r493", "r494", "r495", "r497", "r498", "r500", "r501", "r504", "r505", "r506", "r507", "r508" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r479", "r502", "r503", "r504", "r505", "r508", "r519", "r523" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (in usd per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Expiration period (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life of the options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r514" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "periodEndLabel": "Nonvested, end of period (shares)", "periodStartLabel": "Nonvested, beginning of period (shares)", "terseLabel": "Nonvested options outstanding (shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options forfeited.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (usd per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Nonvested, end of period (usd per share)", "periodStartLabel": "Nonvested, beginning of period (usd per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Expected to vest after end of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r498" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Total fair values of options vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "negatedLabel": "Vested (shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (usd per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShippingAndHandlingMember": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Packing and transport of product.", "label": "Shipping and Handling [Member]", "terseLabel": "Shipping and Handling" } } }, "localname": "ShippingAndHandlingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesShippingandHandlingCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r40", "r729", "r790", "r815" ], "calculation": { "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-Term Debt", "terseLabel": "Short-term debt", "verboseLabel": "Amount outstanding" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r703", "r711" ], "calculation": { "http://www.amerisourcebergen.com/role/LeasesLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-Term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r139", "r162" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": { "auth_ref": [ "r534" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.", "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit", "terseLabel": "Reduction of unrecognized tax benefits reasonably possible" } } }, "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Software development costs" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r13", "r210", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r228", "r229", "r230", "r231", "r233", "r234", "r235", "r236", "r237", "r239", "r244", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r298", "r331", "r340", "r347", "r835" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentOperatingIncomeDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentRevenueDetails", "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingValueofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r74", "r93", "r94", "r95", "r163", "r164", "r165", "r168", "r177", "r179", "r197", "r267", "r424", "r429", "r516", "r517", "r518", "r559", "r560", "r648", "r677", "r678", "r679", "r680", "r681", "r683", "r717", "r841", "r842", "r843" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingComponentsofAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r163", "r164", "r165", "r197", "r768" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r48", "r49", "r429" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Equity issued (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAssetsAndLiabilitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r48", "r49", "r424", "r429", "r486" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r74", "r424", "r429" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Equity consideration issued for acquisition of Alliance Healthcare (Note 2)" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r48", "r49", "r424", "r429" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Profarma retail equity offering" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r74", "r424", "r429" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercises of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": { "auth_ref": [ "r48", "r49", "r424", "r429", "r431" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.", "label": "Stock Issued During Period, Value, Treasury Stock Reissued", "terseLabel": "Treasury stock reissued" } } }, "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionPlanExpense": { "auth_ref": [ "r133" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "Stock or Unit Option Plan Expense", "terseLabel": "Stock option expense" } } }, "localname": "StockOptionPlanExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Authorized amount under share repurchase program" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Availability remaining under program" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r49", "r55", "r56", "r145", "r250", "r262", "r663", "r729" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total AmerisourceBergen Corporation stockholders' (deficit) equity", "verboseLabel": "Total accumulated other comprehensive loss" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingComponentsofAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r2", "r3", "r94", "r145", "r163", "r164", "r165", "r168", "r177", "r262", "r267", "r429", "r516", "r517", "r518", "r559", "r560", "r604", "r605", "r628", "r648", "r663", "r677", "r678", "r683", "r717", "r842", "r843" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance, end of period", "periodStartLabel": "Balance, beginning of period", "totalLabel": "Total stockholders' equity", "verboseLabel": "Cumulative adjustment to retained earnings" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedTerseLabel": "Other, net" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]", "terseLabel": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]", "terseLabel": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationSegmentRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r684", "r731" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r684", "r731" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r684", "r731" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r684", "r731" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r730", "r732" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "auth_ref": [ "r534", "r541", "r543" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Summary of Income Tax Contingencies [Table Text Block]", "terseLabel": "Schedule of Reconciliation Amount Of Unrecognized Tax Benefits, Excluding Interest and Penalties" } } }, "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SwissFederalTaxAdministrationFTAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Switzerland.", "label": "Swiss Federal Tax Administration (FTA) [Member]", "terseLabel": "Swiss" } } }, "localname": "SwissFederalTaxAdministrationFTAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TangibleAssetImpairmentCharges": { "auth_ref": [ "r12", "r326" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.", "label": "Tangible Asset Impairment Charges", "verboseLabel": "Impairment of assets" } } }, "localname": "TangibleAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r550" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforwards" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade names", "verboseLabel": "Trade name" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionandAssetsandLiabilitiesHeldforSaleFairValueOfIntangibleAssetsDetails", "http://www.amerisourcebergen.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r256", "r257", "r258", "r259", "r260", "r409", "r423", "r639", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r871", "r872", "r873", "r874", "r875", "r876", "r877" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instrument [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r73", "r431" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r73", "r431" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "verboseLabel": "Treasury stock (shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r49", "r424", "r429" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Repurchase of common stock (shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r73", "r431", "r434" ], "calculation": { "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost: 2022\u00a0\u2014 86,496,673 shares; 2021\u00a0\u2014 82,633,235 shares" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r424", "r429", "r431" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Purchases of common stock", "terseLabel": "Repurchase of common stock" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r167", "r168", "r169", "r170", "r180", "r254", "r255", "r264", "r265", "r266", "r267", "r268", "r269", "r516", "r517", "r518", "r557", "r558", "r559", "r560", "r590", "r591", "r592", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r687", "r688", "r693", "r694", "r695", "r696", "r712", "r713", "r714", "r715", "r716", "r717", "r770", "r771", "r772", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Accounting Standards Update [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UndistributedEarningsOfForeignSubsidiaries": { "auth_ref": [ "r524", "r574", "r809", "r851" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.", "label": "Undistributed Earnings of Foreign Subsidiaries", "terseLabel": "Undistributed earnings of international subsidiaries" } } }, "localname": "UndistributedEarningsOfForeignSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r525", "r536" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized tax benefits at end of period", "periodStartLabel": "Unrecognized tax benefits at beginning of period" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r537" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedLabel": "Reductions of tax positions of the prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r533" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized tax benefits, interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r538" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions of tax positions of the current year", "verboseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r537" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Additions to tax positions of the prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r539" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedLabel": "Expiration of statutes of limitations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r540" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r198", "r199", "r200", "r201", "r207", "r208", "r209" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.", "label": "Valuation Allowance by Deferred Tax Asset [Axis]", "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]" } } }, "localname": "ValuationAllowanceByDeferredTaxAssetAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r547" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "verboseLabel": "Valuation allowance - increase (decrease)" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r155", "r160" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "terseLabel": "Allowance for doubtful accounts for long-term accounts receivable" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r158" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "Charged to costs and expenses" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r159" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedLabel": "Deductions" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r155", "r156", "r157", "r159", "r160" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r155", "r156", "r157", "r159", "r160" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityDisclosureTextBlock": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.", "label": "Variable Interest Entity Disclosure [Text Block]", "terseLabel": "Variable Interest Entity" } } }, "localname": "VariableInterestEntityDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntity" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableInterestEntityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Variable Interest Entity [Line Items]", "terseLabel": "Variable Interest Entity [Line Items]" } } }, "localname": "VariableInterestEntityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "auth_ref": [ "r610", "r611", "r619", "r620", "r621" ], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "terseLabel": "Profarma" } } }, "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/VariableInterestEntityScheduleofAssetsandLiabilitiesofProfarmaDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r704", "r711" ], "calculation": { "http://www.amerisourcebergen.com/role/LeasesLeaseCostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r182", "r190" ], "calculation": { "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingComponentsofDilutedWeightedAverageSharesOutstandingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (shares)", "totalLabel": "Weighted average common shares outstanding\u00a0- diluted (shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingComponentsofDilutedWeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "verboseLabel": "Weighted average common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r181", "r190" ], "calculation": { "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingComponentsofDilutedWeightedAverageSharesOutstandingDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (shares)", "verboseLabel": "Weighted average common shares outstanding\u00a0- basic (shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.amerisourcebergen.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.amerisourcebergen.com/role/StockholdersEquityandWeightedAverageCommonSharesOutstandingComponentsofDilutedWeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e639-108305" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r245": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.L)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e99989-122729" }, "r284": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r316": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r349": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "https://asc.fasb.org/topic&trid=2175745" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r352": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r361": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r419": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(21))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "https://asc.fasb.org/topic&trid=2122478" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944" }, "r523": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126928070&loc=d3e28200-109314" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r575": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479" }, "r603": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2AA", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r631": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521" }, "r686": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r725": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r732": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6479915&loc=d3e66715-112838" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r823": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r825": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r845": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r846": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r849": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r850": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6487024&loc=d3e29054-158556" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r857": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r863": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r864": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r865": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r866": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r867": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r868": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r869": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r870": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r871": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r872": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r873": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r874": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r875": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r876": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r877": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r878": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r879": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r880": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09" }, "r881": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "01" }, "r882": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "02" }, "r883": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(ii)", "Subsection": "01" }, "r884": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)", "Subsection": "01" }, "r885": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(A)", "Subsection": "01" }, "r886": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(A)", "Subsection": "02" }, "r887": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(B)", "Subsection": "01" }, "r888": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(B)", "Subsection": "02" }, "r889": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(C)", "Subsection": "02" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r890": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "01" }, "r891": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "02" }, "r892": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r893": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" } }, "version": "2.1" } ZIP 114 0001140859-22-000098-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140859-22-000098-xbrl.zip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